AU2013203064A1 - Compounds and methods for modulating gene expression - Google Patents

Abstract

The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.

Description

WO 2007/146511 PCT/US2007/068401 -1 5 COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION 10 SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled CORE0061WO7SEQ.txt, created on May 7, 2007 which is 700 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by 15 reference in its entirety. BACKGROUND Targeting disease-causing gene sequences was first suggested nearly 40 years ago (Belikova et al., Tet. Lett., 1967, 37, 3557-3562), and antisense activity was demonstrated in cell culture a decade 20 later (Zamecnik et al., Proc. Nat]. Acad. Sci. U.S.A., 1978, 75, 280-284). One advantage of antisense technology in the treatment of a disease or condition that stems from a disease-causing gene is that it is a direct genetic approach that has the ability to modulate expression of specific disease-causing genes. Generally, the principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and effects modulation of gene expression activity or function, such as transcription, 25 translation or splicing. The modulation of gene expression can be achieved by, for example, target degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound. Another example of modulation of gene expression by target degradation is RNA interference (RNAi). RNAi is a form of antisense-mediated gene silencing involving the introduction of 30 dsRNA leading to the sequence-specific reduction of targeted endogenous mRNA levels. Sequence specificity makes antisense compounds extremely attractive as tools for target validation and gene functionalization, as well as research tools for identifying and characterizing nucleases and as therapeutics to selectively modulate the expression of genes involved in the pathogenesis of any one of a variety of diseases. 35 Antisense technology is an effective means for reducing the expression of one or more specific gene products and can therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications. Chemically modified nucleosides are routinely used for incorporation into WO 2007/146511 PCT/US2007/068401 -2 antisense compounds to enhance one or more properties, such as nuclease resistance, pharmacokinetics or affinity for a target RNA. Despite the expansion of knowledge since the discovery of antisense technology, there remains an unmet need for antisense compounds with greater efficacy, reduced toxicity and lower cost. Until the 5 present disclosure, high-affinity modifications have not been employed in the design of short antisense compounds for reducing target RNA in vivo. This is because of concerns regarding the degree of target specificity that a sequence 15 nucleotides or shorter would have when employed to reduce target in a living system. Previous studies have described that greater specificity, and therefore greater potential for potency, is achieved by antisense compounds between 16 and 20 nucleobases in length. 10 The present disclosure describes incorporation of chemically-modified high-affinity nucleotides into antisense compounds allows for short antisense compounds about 8-16 nucleobases in length useful in the reduction of target RNAs in animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than 15 previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. SUMMARY Disclosed herein are short antisense compounds and methods of using said compounds to reduce target RNA expression in cells or tissues. In certain embodiments, provided herein is a method of reducing expression of a target in an animal, comprising administering to the animal a short antisense 20 compound targeted to a nucleic acid of such target. In certain embodiments, shorts antisense compounds are oligonucleotide compounds. In certain embodiments short antisense oligonucleotides are about 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length and comprises a gap region flanked on each side by a wing, wherein each wing independently consists of 1 to 3 nucleotides. Preferred motifs include but are not limited to wing - deoxy gap -wing motifs selected 25 from 3-10-3, 2-10-3, 2-10-2, 1-10-1, 2-8-2, 1-8-1, 3-6-3 or 1-6-1. In a preferred embodiment, the short antisense oligonucleotide comprise at least one high-affinity modification. In a further embodiment, the high-affinity modification includes chemically-modified high-affinity nucleotides. In a preferred embodiment, each wing independently consists of 1 to 3 high-affinity modified nucleotides. In one embodiment the high affinity modified nucleotides are sugar-modified nucleotides. 30 In certain embodiments short antisense compounds exhibit greater uptake in the gut as compared to antisense compounds of greater length. Thus, also provided herein are methods of reducing a target in an animal, comprising orally administering the short antisense compounds of the present invention. In certain embodiments, short antisense compounds are targeted to a nucleic acid encoding a protein selected from ApoB, SGLT2, PCSK9, SOD 1, CR.P, GCCR, GCGR, DGAT2, PTP1B and PTEN. 35 Further provided are methods of treating a metabolic disorder in an animal, comprising administering to an animal in need of such therapy a short antisense compound targeted to a nucleic acid involved in regulating glucose metabolism or clearance, lipid metabolism, cholesterol metabolism, or WO 2007/146511 PCT/US2007/068401 -3 insulin signaling. Also provided are methods of increasing insulin sensitivity, decreasing blood glucose or decreasing HbAc in an animal, comprising administering to said animal a short antisense compound targeted to a nucleic acid encoding a target involved in regulating glucose metabolism or clearance, lipid 5 metabolism, cholesterol metabolism, or insulin signaling. Further provided are methods of decreasing total serum cholesterol, serum LDL, serum VLDL, serum HDL, serum triglycerides, serum apolipoprotein(a) or free fatty acids in an animal, comprising administering to said animal a short antisense compound targeted to a nucleic acid encoding a target that is involved in regulating glucose metabolism or clearance, lipid metabolism, cholesterol metabolism, or 10 insulin signaling, wherein said short antisense compound is 8 to 16 nucleotides in length and comprises a gap region flanked on each side by a wing, wherein each wing independently consists of 1 to 3 high affinity modified nucleotides. Certain targets involved in regulating glucose metabolism or clearance, lipid metabolism, cholesterol metabolism, or insulin signaling include, but are not limited to, GCGR and ApoB-100. Thus, 15 provided are short antisense compounds targeting nucleic acids encoding GCGR and ApoB-100 and methods of reducing expression of said targets and/or target nucleic acids in animal. In addition, provided is the use of short antisense compounds targeting nucleic acids encoding GCGR, and ApoB- 100 for the treatment of a metabolic or cardiovascular disease or condition. In certain embodiments, short antisense compounds further comprise a conjugate group. 20 Conjugate groups include, but are not limited to, C 16 and cholesterol. In certain embodiments short antisense compounds comprise at least one modified nucleobase, internucleoside linkage or sugar moiety. In certain embodiments, such modified internucleoside linkage is a phosphorothioate internucleoside linkage. In certain embodiments, each internucleoside linkage is a phosphorothioate internucleoside linkage. 25 In certain embodiments, short antisense compounds comprise at least one high affinity modification. In certain such embodiments, the high-affinity modification is a chemically-modified high affinity nucleotide. In certain embodiments, chemically-modified high affinity nucleotides are sugar modified nucleotides. In certain embodiments, at least one of the sugar-modified nucleotides comprises a bridge between the 4' and the 2' position of the sugar. Each of the sugar-modified nucleotides is, 30 independently, in the -D or a-L sugar conformation. In certain embodiments, each of said high-affinity modified nucleotides confers a Tm of at least 1 to 4 degrees per nucleotide. In certain embodiments, each of said sugar-modified nucleotides comprises a 2'-substituent group that is other than H or OH. Such sugar-modified nucleotides include those having a 4' to 2' bridged bicyclic sugar moiety. In certain embodiments, each of the 2'-substituent groups is, independently, alkoxy, substituted alkoxy, or 35 halogen. In certain embodiments, each of the 2'-substituent groups is OCH 2

CH

2

OCH

3 (2'-MOE). In certain embodiments, short antisense compounds have one or more sugar-modified nucleotides comprising a bridge between the 4' and 2' position of the sugar, wherein each of said bridges WO 2007/146511 PCT/US2007/068401 -4 independently comprises from 2 to 4 linked groups independently selected from -[C(R)(R 2 )]n-,

-C(R

1

)=C(R

2 )-, -C(R 1 )=N-, -C(=NRI)-, -C(=0)-, -C(=S)-, -0-, -Si(Ri) 2 -, -S(=O).- and -N(Ri)-; wherein x is 0, 1, or 2; 5 nis1,2,3,or4; each R 1 and R2 is, independently, H, a protecting group, hydroxyl, CI-C 12 alkyl, substituted CI-C 12 alkyl, C 2

-C

1 2 alkenyl, substituted C 2

-C

1 2 alkenyl, C 2 The-C12 alkynyl, substituted C 2

-C

1 2 alkynyl, C 5

-C

20 aryl, substituted C 5

-C

2 0 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5

-C

7 alicyclic radical, 10 substituted C 5

-C

7 alicyclic radical, halogen, OJI, NJIJ 2 , SJI, N 3 , COOJ, acyl (C(=0)-H), substituted acyl, CN, sulfonyl (S(=0) 2 -JI), or sulfoxyl (S(=O)-JI); and each J, and J 2 is, independently, H, C 1

-C

12 alkyl, substituted C 1

-C

12 alkyl, C 2 -Ci 2 alkenyl, substituted C 2

-C

1 2 alkenyl, C 2

-C

1 2 alkynyl, substituted C 2

-C

1 2 alkynyl, C 5

-C

20 aryl, substituted C 5

-C

20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a 15 substituted heterocycle radical, CI-C 12 aminoalkyl, substituted C 1

-C

1 2 aminoalkyl or a protecting group. In one aspect, each of said bridges is, independently, -[C(R)(R 2 )]n-, -[C(R 1

)(R

2 )]n-O-, -C(RiR 2

)

N(Ri)-O- or -C(RIR 2

)-O-N(R

1 )-. In another aspect, each of said bridges is, independently, 4'-(CH 2

)

3 -2', 4'-(CH 2

)

2 -2', 4'-CH 2 -O-2', 4'-(CH 2

)

2 -O-2', 4'-CH 2 -O-N(Ri)-2' and 4'-CH 2 -N(Ri)-O-2'- wherein each R, is, 20 independently, H, a protecting group or C 1

-C

1 2 alkyl. In certain embodiments, provided herein are short antisense compounds useful in the reduction of targets and/or target RNAs associated with disease states in animals. In certain embodiments, provided are methods of using the short antisense compounds for reducing expression of a target RNA in an animal. In certain embodiments, provided herein is the use of a short antisense compound in the 25 preparation of a medicament for the treatment of a metabolic disorder in an animal. In certain embodiments, provided herein is the use of a short antisense compound in the preparation of a medicament for increasing insulin sensitivity, decreasing blood glucose or decreasing HbAic in an animal. Also provided is the use of a short antisense compound in the preparation of a medicament for decreasing total serum cholesterol, serum LDL, serum VLDL, serum HDL, serum triglycerides, serum 30 apolipoprotein(a) or free fatty acids in an animal. In certain embodiments, short antisense compounds provided herein exhibit equal or increased potency with regard to target RNA knockdown as compared to longer parent antisense oligonucleotide at least 20 nucleotides in length. In certain embodiments, short antisense compounds exhibit a faster onset of action (target RNA reduction) as compared to the parent antisense oligonucleotide. In certain 35 embodiments, increased potency is in the kidney. In certain embodiments, target RNA is predominately expressed in the kidney. In certain embodiments, increased potency is in the liver. In certain embodiments, target RNA is predominately expressed in the liver.

WO 2007/146511 PCT/US2007/068401 -5 DETAILED DESCRIPTION It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. 5 Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise. 10 The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose. US patent application serial nos 10/712,795 and 10/200,710 are hereby expressly incorporated by reference in their entirety for any 15 purpose. A. Definitions Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard 20 techniques may be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of subjects. Certain such techniques and procedures may be found for example in "Carbohydrate Modifications in Antisense Research" Edited by Sangvi and Cook, American Chemical Society , Washington D.C., 1994; and "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., 18th edition, 1990; and which is hereby incorporated by reference for 25 any purpose. Where permitted, all patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to throughout in the disclosure herein are incorporated by reference in their entirety. Unless otherwise indicated, the following terms have the following meanings: As used herein, the term "nucleoside" means a glycosylamine comprising a nucleobase and a 30 sugar. Nucleosides includes, but are not limited to, naturally occurring nucleosides, abasic nucleosides, modified nucleosides, and nucleosides having mimetic bases and/or sugar groups. As used herein, the term "nucleotide" refers to a glycosomine comprising a nucleobase and a sugur having a phosphate group covalently linked to the sugar. Nucleotides may be modified with any of a variety of substituents. 35 As used herein, the term "nucleobase" refers to the base portion of a nucleoside or nucleotide. A nucleobase may comprise any atom or group of atoms capable of hydrogen bonding to a base of another nucleic acid.

WO 2007/146511 PCT/US2007/068401 -6 As used herein, the term "heterocyclic base moiety" refers to a nucleobase comprising a heterocycle. As used herein, the term "deoxyribonucleotide" means a nucleotide having a hydrogen at the 2' position of the sugar portion of the nucleotide. Deoxyribonucleotides may be modified with any of a 5 variety of substituents. As used herein, the term "ribonucleotide" means a nucleotide having a hydroxy at the 2' position of the sugar portion of the nucleotide. Ribonucleotides may be modified with any of a variety of substituents. As used herein, the term "oligomeric compound" refers to a polymeric structure comprising two 10 or more sub-structures and capable of hybridizing to a region of a nucleic acid molecule. In certain embodiments, oligomeric compounds are oligonucleosides. In certain embodiments, oligomeric compounds are oligonucleotides. In certain embodiments, oligomeric compounds are antisense compounds. In certain embodiments, oligomeric compounds are antisense oligonucleotides. In certain embodiments, oligomeric compounds are short antisense compounds. In certain embodiments, 15 oligomeric compounds are short antisense oligonucleotides. In certain embodiments, oligomeric compounds are chimeric oligonucleotides. As used herein, the term "monomer" refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occuring or modified. As used herein "oligonucleoside" refers to an oligonucleotide in which the internucleoside 20 linkages do not contain a phosphorus atom. As used herein, the term "oligonucleotide" refers to an oligomeric compound comprising a plurality of linked nucleotides. In certain embodiment, one or more nucleotides of an oligonucleotide is modified. In certain embodiments, an oligonucleotide comprises ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). In certain embodiments, oligonucleotides are composed of naturally 25 and/or non-naturally-occurring nucleobases, sugars and covalent internucleotide linkages, and may further include non-nucleic acid conjugates. As used herein "intemucleotide linkage" refers to a covalent linkage between adjacent nucleotides. As used herein, the term "monomeric linkage" refers to a covalent linkage between two 30 monmers. Monomeric linkages include, but are not limited to internucleotide linkages and internucleoside linkages. As used herein "naturally occuring intemucleotide linkage" refers to a 3' to 5' phosphodiester linkage. As used herein, the term "antisense compound" refers to an oligomeric compound that is at least 35 partially complementary to a target nucleic acid molecule to which it hybridizes. In certain embodiments, an antisense compound modulates (increases or decreases) expression of a target nucleic acid. Antisense compounds include, but are not limited to, compounds that are oligonucleotides, oligonucleosides, WO 2007/146511 PCT/US2007/068401 -7 oligonucleotide analogs, oligonucleotide mimetics, and chimeric combinations of these. Consequently, while all antisense compounds are oligomeric compounds, not all oligomeric compounds are antisense compounds. As used herein, the term "antisense oligonucleotide" refers to an antisense compound that is an 5 oligonucleotide. As used herein, the term "parent antisense oligonucleotide" refers to an oligonucleotide 20 nucleotides in length having a deoxy gap region having ten 2'-deoxyribonucleotides, flanked by a first and a second wing region each having five 2'-O-(2-methoxyethyl) ribonucleotides (a 5-10-5 MOE gapmer) and comprising the sequence of the corresponding short antisense compound to which it is a 10 parent. As used herein, the term "short antisense compound" refers to an antisense compound about 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers in length. In certain embodiments, a short antisense compound has at least one high-affinity modification. As used herein, the term "short antisense oligonucleotide" or refers to an antisense 15 oligonucleotide about 8, 9, 10, 11, 12, 13, 14, 15 or 16 nucleotides in length. In certain embodiments, a short antisense oligonucleotide has at least one high-affinity modification. As used herein, the term "short gapmer" refers to a short antisense oligonucleotide having a first and a second wing region each independently 1 to 3 nucleotides in length and a gap region 2 to 14 nucleobase in length. 20 As used herein, the term "motif' refers to the pattern of unmodified and modified nucleotides in a short antisense compound As used herein, the term "chimeric antisense oligomer" refers to an antisense oligomeric compound, having at least one sugar, nucleobase or internucleoside linkage that is differentially modified as compared to at least on other sugar, nucleobase or internucleoside linkage within the same antisense 25 oligomeric compound. The remainder of the sugars, nucleobases and internucleoside linkages can be independently modified or unmodified, the same or different. As used herein, the term "chimeric antisense oligonucleotide" refers to an antisense oligonucleotide, having at least one sugar, nucleobase or internucleoside linkage that is differentially modified as compared to at least on other sugar, nucleobase or internucleoside linkage within the same 30 antisense oligonucleotide. The remainder of the sugars, nucleobases and internucleoside linkages can be independently modified or unmodified, the same or different. As used herein, the term "mixed-backbone antisense oligonucleotide" refers to an antisense oligonucleotide wherein at least one internucleoside linkage of the antisense oligonucleotide is different from at least one other internucleotide linkage of the antisense oligonucleotide. 35 As used herein, the term "target" refers to a protein, the modulation of which is desired. As used herein, the term "target gene" refers to a gene encoding a target. As used herein, the terms "target nucleic acid" and "nucleic acid molecule encoding a target" WO 2007/146511 PCT/US2007/068401 -8 refer to any nucleic acid molecule the expression or activity of which is capable of being modulated by an antisense compound. Target nucleic acids include, but are not limited to, RNA (including, but not limited to pre-mRNA and mRNA or portions thereof) transcribed from DNA encoding a target, and also cDNA derived from such RNA, and miRNA. For example, the target nucleic acid can be a cellular gene (or 5 mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. As used herein, the term "targeting" or "targeted to" refers to the association of an antisense compound to a particular target nucleic acid molecule or a particular region of nucleotides within a target nucleic acid molecule. 10 As used herein, the term "5' target site" refers to the nucleotide of a target nucleic acid which is complementary to the 5'-most nucleotide of a particular antisense compound. As used herein, the term "3' target site" refers to the nucleotide of a target nucleic acid which is complementary to the 3'-most nucleotide of a particular antisense compound. As used herein, the term "target region," refers to a portion of a target nucleic acid to which one 15 or more antisense compounds is complementary. As used herein, the term "target segment" refers to a smaller or sub-portions of a region within a target nucleic acid. As used herein, the term "nucleobase complementarity" refers to a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine 20 (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic 25 acid is considered to be complementary at that nucleobase pair. As used herein, the term "non-complementary nucleobase" refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization. As used herein, the term "complementary" refers to the capacity of an oligomeric compound to hybridize to another oligomeric compound or nucleic acid through nucleobase complementarity. In 30 certain embodiments, an antisense compound and its target are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleobases that can bond with each other to allow stable association between the antisense compound and the target. One skilled in the art recognizes that the inclusion of mismatches is possible without eliminating the ability of the oligomeric compounds to remain in association. Therefore, described herein are antisense compounds 35 that may comprise up to about 20% nucleotides that are mismatched (i.e., are not nucleobase complementary to the corresponding nucleotides of the target). Preferably the antisense compounds contain no more than about 15%, more preferably not more than about 10%, most preferably not more WO 2007/146511 PCT/US2007/068401 -9 than 5% or no mismatches. The remaining nucleotides are nucleobase complementary or otherwise do not disrupt hybridization (e.g., universal bases). One of ordinary skill in the art would recognize the compounds provided herein are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to a target nucleic acid. 5 As used herein, the term "mismatch" refers to a non-complementary nucleobase within a complementary oligomeric compound. As used herein, "hybridization" means the pairing of complementary oligomeric compounds (e.g., an antisense compound and its target nucleic acid). While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or 10 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases). For example, the natural base adenine is nucleobase complementary to the natural nucleobases thymidine and uracil which pair through the formation of hydrogen bonds. The natural base guanine is nucleobase complementary to the natural bases cytosine and 5-methyl cytosine. Hybridization can occur under varying circumstances. 15 As used herein, the term "specifically hybridizes" refers to the ability of an oligomeric compound to hybridize to one nucleic acid site with greater affinity than it hybridizes to another nucleic acid site. In certain embodiments, an antisense oligonucleotide specifically hybridizes to more than one target site. As used herein, "designing" or "designed to" refer to the process of designing an oligomeric compound that specifically hybridizes with a selected nucleic acid molecule. 20 As used herein, the term "modulation" refers to a perturbation of function or activity when compared to the level of the function or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression. As further example, modulation of expression can include perturbing splice site selection of pre-mRNA processing. 25 As used herein, the term "expression" refers to all the functions and steps by which a gene's coded information is converted into structures present and operating in a cell. Such structures include, but are not limited to the products of transcription and translation. As used herein, "variant" refers to an alternative RNA transcript that can be produced from the same genomic region of DNA. Variants include, but are not limited to "pre-mRNA variants" which are 30 transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence. Variants also include, but are not limited to, those with alternate splice junctions, or alternate initiation and termination codons. As used herein, "high-affinity modified monomer" refers to a monomer having at least one 35 modified nucleobase, internucleoside linkage or sugar moiety, when compared to naturally occurring monomers, such that the modification increases the affinity of an antisense compound comprising the high-affinity modified monomer to its target nucleic acid. High-affinity modifications include, but are WO 2007/146511 PCT/US2007/068401 -10 not limited to, monomers (e.g., nucleosides and nucleotides) comprising 2'-modifed sugars. As used herein, the term "2'-modified" or "2'-substituted" means a sugar comprising substituent at the 2' position other than H or OH. 2'-modified monomers, include, but are not limited to, BNA's and monomers (e.g., nucleosides and nucleotides) with 2'- substituents, such as allyl, amino, azido, thio, 0 5 allyl, O-C 1

-C

0 alkyl, -OCF 3 , 0-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -0-N(Rm)(R), or O-CH 2 C(=O)-N(Rmn)(R.), where each Rm and Rn is, independently, H or substituted or unsubstituted C 1 -Clo alkyl. In certain embodiments, short antisense compounds comprise a 2'modified monomer that does not have the formula 2'-O(CH 2 )nH, wherein n is one to six. In certain embodiments, short antisense compounds comprise a 2'modified monomer that does not have the formula 2'-OCH 3 . In certain 10 embodiments, short antisense compounds comprise a 2'modified monomer that does not have the formula or, in the alternative, 2'-O(CH 2

)

2 0CH 3 . As used herein, the term "bicyclic nucleic acid" or "BNA" or "bicyclic nucleoside" or "bicyclic nucleotide" refers to a nucleoside or nucleotide wherein the furanose portion of the nucleoside includes a bridge connecting two carbon atoms on the furanose ring, thereby forming a bicyclic ring system. 15 As used herein, unless otherwise indicated, the term "methyleneoxy BNA" alone refers to 1-D methyleneoxy BNA. As used herein, the term "MOE" refers to a 2'-methoxyethyl substituent. As used herein, the term "gapmer" refers to a chimeric oligomeric compound comprising a central region (a "gap") and a region on either side of the central region (the "wings"), wherein the gap 20 comprises at least one modification that is different from that of each wing. Such modifications include nucleobase, monomeric linkage, and sugar modifications as well as the absence of modification (unmodified). Thus, in certain embodiments, the nucleotide linkages in each of the wings are different than the nucleotide linkages in the gap. In certain embodiments, each wing comprises nucleotides with high affinity modifications and the gap comprises nucleotides that do not comprise that modification. In 25 certain embodiments the nucleotides in the gap and the nucleotides in the wings all comprise high affinity modifications, but the high affinity modifications in the gap are different than the high affinity modifications in the wings. In certain embodiments, the modifications in the wings are the same as one another. In certain embodiments, the modifications in the wings are different from each other. In certain embodiments, nucleotides in the gap are unmodified and nucleotides in the wings are modified. In certain 30 embodiments, the modification(s) in each wing are the same. In certain embodiments, the modification(s) in one wing are different from the modification(s) in the other wing. In certain embodiments, short antisense compounds are gapmers having 2'-deoxynucleotides in the gap and nucleotides with high affinity modifications in the wing. As used herein, the term "prodrug" refers to a therapeutic agent that is prepared in an inactive 35 form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. As used herein, the term "pharmaceutically acceptable salts" refers to salts of active compounds WO 2007/146511 PCT/US2007/068401 -11 that retain the desired biological activity of the active compound and do not impart undesired toxicological effects thereto. As used herein, the term "cap structure" or "terminal cap moiety" refers to chemical modifications, which have been incorporated at either terminus of an antisense compound. 5 As used herein, the term "prevention" refers to delaying or forestalling the onset or development of a condition or disease for a period of time from hours to days, preferably weeks to months. As used herein, the term "amelioration" refers to a lessening of at least one indicator of the severity of a condition or disease. The severity of indicators may be determined by subjective or objective measures which are known to those skilled in the art. 10 As used herein, the term "treatment" refers to administering a composition of the invention to effect an alteration or improvement of the disease or condition. Prevention, amelioration, and/or treatment may require administration of multiple doses at regular intervals, or prior to onset of the disease or condition to alter the course of the disease or condition. Moreover, a single agent may be used in a single individual for each prevention, amelioration, and treatment of a condition or disease sequentially, or 15 concurrently. As used herein, the term "pharmaceutical agent" refers to a substance provides a therapeutic benefit when administered to a subject. As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that provides a therapeutic benefit to an animal. 20 As used herein, "administering" means providing a pharmaceutical agent to an animal, and includes, but is not limited to administering by a medical professional and self-administering. As used herein, the term "co-administration" refers to administration of two or more pharmaceutical agents to an animal. The two or more pharmaceutical agents may be in a single pharmaceutical composition, or may be in separate pharmaceutical compositions. Each of the two or 25 more pharmaceutical agents may be administered through the same or different routes of administration. Co-administration encompasses administration in parallel or sequentially. As used herein, the term "pharmaceutical composition" refers to a mixture of substances suitable for administering to an individual. For example, a pharmaceutical composition may comprise an antisense oligonucleotide and a sterile aqueous solution. 30 As used herein, the term "individual" refers to a human or non-human animal selected for treatment or therapy. As used herein, the term "animal" refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees. 35 As used herein, the term "subject" refers to an animal, including, but not limited to a human, to whom a pharmaceutical composition is administered. As used herein, the term "duration" refers to the period of time during which an activity or WO 2007/146511 PCT/US2007/068401 -12 event continues. In certain embodiments, the duration of treatment is the period of time during which doses of a pharmaceutical agent are administered. As used herein, the term "parenteral administration," refers to administration through injection or infusion. Parenteral administration includes, but is not limited to, subcutaneous administration, 5 intravenous administration, or intramuscular administration. As used herein, the term "subcutaneous administration" refers to administration just below the skin. "Intravenous administration" means administration into a vein. As used herein, the term "dose" refers to a specified quantity of a pharmaceutical agent provided in a single administration. In certain embodiments, a dose may be administered in two or more 10 boluses, tablets, or injections. For example, in certain embodiments, where subcutaneous administration is desired, the desired dose requires a volume not easily accommodated by a single injection. In such embodiments, two or more injections may be used to achieve the desired dose. In certain embodiments, a dose may be administered in two or more injections to minimize injection site reaction in an individual. As used herein, the term "dosage unit" refers to a form in which a pharmaceutical agent is 15 provided. In certain embodiments, a dosage unit is a vial comprising lyophilized antisense oligonucleotide. In certain embodiments, a dosage unit is a vial comprising reconstituted antisense oligonucleotide. As used herein, the term "pharmaceutical agent" refers to a substance provides a therapeutic benefit when administered to an individual. For example, in certain embodiments, an antisense 20 oligonucleotide is a pharmaceutical agent. As used herein, the term "active pharmaceutical ingredient" refers to the substance in a pharmaceutical composition that provides a desired effect. As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that provides a therapeutic benefit to an individual. In certain embodiments, a 25 therapeutically effective amount of an antisense compound is the amount that needs to be administered to result in an observable benefit. As used herein, the term "hypercholesterolemia" refers to a condition characterized by elevated serum cholesterol. As used herein, the term "hyperlipidemia" refers to a condition characterized by elevated serum 30 lipids. As used herein, the term "hypertriglyceridemia" refers to a condition characterized by elevated triglyceride levels. As used herein, the term "non-familial hypercholesterolemia" refers to a condition characterized by elevated cholesterol that is not the result of a single inherited gene mutation. 35 As used herein, the term "polygenic hypercholesterolemia" refers to a condition characterized by elevated cholesterol that results from the influence of a variety of genetic factors. In certain embodiments, polygenic hypercholesterolemia may be exacerbated by dietary intake of lipids.

WO 2007/146511 PCT/US2007/068401 -13 As used herein, the term "familial hypercholesterolemia (FH)" refers to an autosomal dominant metabolic disorder characterized by a mutation in the LDL-receptor (LDL-R) gene, markedly elevated LDL-C and premature onset of atherosclerosis. A diagnosis of familial hypercholesterolemia is made when a individual meets one or more of the following criteria: genetic testing confirming 2 mutated LDL 5 receptor genes; genetic testing confirming one mutated LDL-receptor gene; document history of untreated serum LDL-cholesterol greater than 500 mg/dL; tendinous and/or cutaneous xanthoma prior to age 10 years; or, both parents have documented elevated serum LDL-cholesterol prior to lipid-lowering therapy consistent with heterozygous familial hypercholesterolemia. As used herein, the term "homozygous familial hypercholesterolemia" or "HoFH" refers to a 10 condition characterized by a mutation in both maternal and paternal LDL-R genes. As used herein, the term "heterozygous familial hypercholesterolemia" or "HeFH" refers to a condition characterized by a mutation in either the maternal or paternal LDL-R gene. As used herein, the term "mixed dyslipidemia" refers to a condition characterized by elevated serum cholesterol and elevated serum triglycerides. 15 As used herein, the term "diabetic dyslipidemia" or "Type II diabetes with dyslipidemia" refers to a condition characterized by Type II diabetes, reduced HDL-C, elevated serum triglycerides, and elevated small, dense LDL particles. As used herein, the term "CHD risk equivalents," refers to indicators of clinical atherosclerotic disease that confer a high risk for coronary heart disease. For example, in certain embodiments, CHD risk 20 equivalents include, without limitation, clinical coronary heart disease, symptomatic carotid artery disease, peripheral arterial disease, and/or abdominal aortic aneurysm. As used herein, the term "non-alcoholic fatty liver disease (NAFLD)" refers to a condition characterized by fatty inflammation of the liver that is not due to excessive alcohol use (for example, alcohol consumption of over 20 g/day). In certain embodiments, NAFLD is related to insulin resistance 25 and the metabolic syndrome. As used herein, the term "non-alcoholic steatohepatitis (NASH)" refers to a condition characterized by inflammation and the accumulation of fat and fibrous tissue in the liver, that is not due to excessive alcohol use. NASH is an extreme form of NAFLD. As used herein, the term "major risk factors" refers to factors that contribute to a high risk for a 30 particular disease or condition. In certain embodiments, major risk factors for coronary heart disease include, without limitation, cigarette smoking, hypertension, low HDL-C, family history of coronary heart disease, and age. As used herein, the term "CHD risk factors" refers to CHD risk equivalents and major risk factors. 35 As used herein, the term "coronary heart disease (CHD)" refers to a narrowing of the small blood vessels that supply blood and oxygen to the heart, which is often a result of atherosclerosis. As used herein, the term "reduced coronary heart disease risk" refers to a reduction in the WO 2007/146511 PCT/US2007/068401 -14 likelihood that a individual will develop coronary heart disease. In certain embodiments, a reduction in coronary heart disease risk is measured by an improvement in one or more CHD risk factors, for example, a decrease in LDL-C levels. As used herein, the term "atherosclerosis" refers to a hardening of the arteries affecting large 5 and medium-sized arteries and is characterized by the presence of fatty deposits. The fatty deposits are called "atheromas" or "plaques," which consist mainly of cholesterol and other fats, calcium and scar tissue, and damage the lining of arteries. As used herein, the term "history of coronary heart disease" refers to the occurrence of clinically evident coronary heart disease in the medical history of a individual or a individual's family member. 10 As used herein, the term "Early onset coronary heart disease" refers to a diagnosis of coronary heart disease prior to age 50. As used herein, the term "statin intolerant individual" refers to a individual who as a result of statin therapy experiences one or more of creatine kinase increases, liver function test abnormalities, muscle aches, or central nervous system side effects. 15 As used herein, the term "efficacy" refers to the ability to produce a desired effect. For example, efficacy of a lipid-lowering therapy may be reduction in the concentration of one or more of LDL-C, VLDL-C, IDL-C, non-HDL-C, ApoB, lipoprotein(a), or triglycerides. As used herein, the term "acceptable safety profile" refers to a pattern of side effects that is within clinically acceptable limits. 20 As used herein, the term "side effects" refers to physiological responses attributable to a treatment other than desired effects. In certain embodiments, side effects include, without limitation, injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system abnormalities, and myopathies. For example, increased aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin 25 may indicate liver toxicity or liver flmction abnormality. As used herein, the term "injection site reaction" refers to inflammation or abnormal redness of skin at a site of injection in an individual. As used herein, the term "individual compliance" refers to adherence to a recommended or prescribed therapy by an individual. 30 As used herein, the term "lipid-lowering therapy" refers to a therapeutic regimen provided to a individual to reduce one or more lipids in a individual. In certain embodiments, a lipid-lowering therapy is provide to reduce one or more of ApoB, total cholesterol, LDL-C, VLDL-C, IDL-C, non-HDL-C, triglycerides, small dense LDL particles, and Lp(a) in an individual. As used herein, the term "lipid-lowering agent" refers to a pharmaceutical agent provided to a 35 individual to achieve a lowering of lipids in the individual. For example, in certain embodiments, a lipid lowering agent is provided to an individual to reduce one or more of ApoB, LDL-C, total cholesterol, and triglycerides.

WO 2007/146511 PCT/US2007/068401 -15 As used herein, the term "LDL-C target" refers to an LDL-C level that is desired following lipid-lowering therapy. As used herein, the term "comply" refers to the adherence with a recommended therapy by an individual. 5 As used herein, the term "recommended therapy" refers to a therapeutic regimen recommended by a medical professional for the treatment, amelioration, or prevention of a disease. As used herein, the term "low LDL-receptor activity" refers to LDL-receptor activity that is not sufficiently high to maintain clinically acceptable levels of LDL-C in the bloodstream. As used herein, the term "cardiovascular outcome" refers to the occurrence of major adverse 10 cardiovascular events. As used herein, the term "improved cardiovascular outcome" refers to a reduction in the occurrence of major adverse cardiovascular events, or the risk thereof. Examples of major adverse cardiovascular events include, without limitation, death, reinfarction, stroke, cardiogenic shock, pulmonary edema, cardiac arrest, and atrial dysrhythmia. 15 As used herein, the term "surrogate markers of cardiovascular outcome" refers to indirect indicators of cardiovascular events, or the risk thereof. For example, surrogate markers of cardiovascular outcome include carotid intimal media thickness (CIMT). Another example of a surrogate marker of cardiovascular outcome includes atheroma size. Atheroma size may be determined by intravascular ultrasound (IVUS). 20 As used herein, the term "increased HDL-C" refers to an increase in serum HDL-C in an individual over time. As used herein, the term "lipid-lowering" refers to a reduction in one or more serum lipids in an individual over time. As used herein, the term "metabolic disorder" refers to a condition characterized by an alteration 25 or disturbance in metabolic function. "Metabolic" and "metabolism" are terms well know in the art and generally include the whole range of biochemical processes that occur within a living organism. Metabolic disorders include, but are not limited to, hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance and metabolic syndrome. As used herein, the term "metabolic syndrome" refers to a clustering of lipid and non-lipid 30 cardiovascular risk factors of metabolic origin. It has been closely linked to the generalized metabolic disorder known as insulin resistance. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) established criteria for diagnosis of metabolic syndrome when three or more of five risk determinants are present. The five risk determinants are abdominal obesity defined as waist circumference of greater than 102 cm for men or greater than 88cm for women, triglyceride levels greater 35 than or equal to 150 mg/dL, HDL cholesterol levels of less than 40 mg/dL for men and less than 50 mg/dL for women, blood pressure greater than or equal to 130/85 mm Hg and fasting glucose levels greater than or equal to 110 mg/dL. These determinants can be readily measured in clinical practice WO 2007/146511 PCT/US2007/068401 -16 (JAMA, 2001, 285: 2486-2497). The term "alkyl," as used herein, refers to a saturated straight or branched hydrocarbon radical containing up to twenty four carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like. Alkyl groups typically 5 include from 1 to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms (C 1

-CI

2 alkyl) with from 1 to about 6 carbon atoms being more preferred. The term "lower alkyl" as used herein includes from 1 to about 6 carbon atoms. Alkyl groups as used herein may optionally include one or more further substituent groups. The term "alkenyl," as used herein, refers to a straight or branched hydrocarbon chain radical 10 containing up to twenty four carbon atoms and having at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, 1 -methyl-2-buten l-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon atoms with from 2 to about 6 carbon atoms being more preferred. Alkenyl groups as used herein may optionally include one or more further substituent 15 groups. The term "alkynyl," as used herein, refers to a straight or branched hydrocarbon radical containing up to twenty four carbon atoms and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and the like. Alkynyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon 20 atoms with from 2 to about 6 carbon atoms being more preferred. Alkynyl groups as used herein may optionally include one or more further substitutent groups. The term "aminoalkyl" as used herein, refers to an amino substituted alkyl radical. This term is meant to include CI-CI 2 alkyl groups having an amino substituent at any position and wherein the alkyl group attaches the aminoalkyl group to the parent molecule. The alkyl and/or amino portions of the 25 aminoalkyl group can be further substituted with substituent groups. The term "aliphatic," as used herein, refers to a straight or branched hydrocarbon radical containing up to twenty four carbon atoms wherein the saturation between any two carbon atoms is a single, double or triple bond. An aliphatic group preferably contains from I to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms with from 1 to about 6 carbon atoms being more 30 preferred. The straight or branched chain of an aliphatic group may be interrupted with one or more heteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groups interrupted by heteroatoms include without limitation polyalkoxys, such as polyalkylene glycols, polyamines, and polyimines. Aliphatic groups as used herein may optionally include further substitutent groups. The term "alicyclic" or "alicyclyl" refers to a cyclic ring system wherein the ring is aliphatic. 35 The ring system can comprise one or more rings wherein at least one ring is aliphatic. Preferred alicyclics include rings having from about 5 to about 9 carbon atoms in the ring. Alicyclic as used herein may optionally include further substitutent groups.

WO 2007/146511 PCT/US2007/068401 -17 The term "alkoxy," as used herein, refers to a radical formed between an alkyl group and an oxygen atom wherein the oxygen atom is used to attach the alkoxy group to a parent molecule. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used 5 herein may optionally include further substitutent groups. The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine. The terms "aryl" and "aromatic," as used herein, refer to a mono- or polycyclic carbocyclic ring system radicals having one or more aromatic rings. Examples of aryl groups include, but are not limited 10 to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like. Preferred aryl ring systems have from about 5 to about 20 carbon atoms in one or more rings. Aryl groups as used herein may optionally include further substitutent groups. The terms "aralkyl" and "arylalkyl," as used herein, refer to a radical formed between an alkyl group and an aryl group wherein the alkyl group is used to attach the aralkyl group to a parent molecule. 15 Examples include, but are not limited to, benzyl, phenethyl and the like. Aralkyl groups as used herein may optionally include further substitutent groups attached to the alkyl, the aryl or both groups that form the radical group. The term "heterocyclic radical" as used herein, refers to a radical mono-, or poly-cyclic ring system that includes at least one heteroatom and is unsaturated, partially saturated or fully saturated, 20 thereby including heteroaryl groups. Heterocyclic is also meant to include fused ring systems wherein one or more of the fused rings contain at least one heteroatom and the other rings can contain one or more heteroatoms or optionally contain no heteroatoms. A heterocyclic group typically includes at least one atom selected from sulfur, nitrogen or oxygen. Examples of heterocyclic groups include, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, 25 oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofiryl and the like. Heterocyclic groups as used herein may optionally include further substitutent groups. The terms "heteroaryl," and "heteroaromatic," as used herein, refer to a radical comprising a mono- or poly-cyclic aromatic ring, ring system or fused ring system wherein at least one of the rings is 30 aromatic and includes one or more heteroatom. Heteroaryl is also meant to include fused ring systems including systems where one or more of the fused rings contain no heteroatoms. Heteroaryl groups typically include one ring atom selected from sulfur, nitrogen or oxygen. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, 35 benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like. Heteroaryl radicals can be attached to a parent molecule directly or through a linking moiety such as an aliphatic group or hetero atom. Heteroaryl groups as used herein may optionally include further substitutent groups.

WO 2007/146511 PCT/US2007/068401 -18 The term "heteroarylalkyl," as used herein, refers to a heteroaryl group as previously defined having an alky radical that can attach the heteroarylalkyl group to a parent molecule. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl, napthyridinylpropyl and the like. Heteroarylalkyl groups as used herein may optionally include further substitutent groups on one or both 5 of the heteroaryl or alkyl portions. The term "mono or poly cyclic structure" as used in the present invention includes all ring systems that are single or polycyclic having rings that are fused or linked and is meant to be inclusive of single and mixed ring systems individually selected from aliphatic, alicyclic, aryl, heteroaryl, aralkyl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, heteroarylalkyl. Such mono and poly cyclic 10 structures can contain rings that are uniform or have varying degrees of saturation including fully saturated, partially saturated or fully unsaturated. Each ring can comprise ring atoms selected from C, N, 0 and S to give rise to heterocyclic rings as well as rings comprising only C ring atoms which can be present in a mixed motif such as for example benzimidazole wherein one ring has only carbon ring atoms and the fused ring has two nitrogen atoms. The mono or poly cyclic structures can be further substituted 15 with substituent groups such as for example phthalimide which has two =0 groups attached to one of the rings. In another aspect, mono or poly cyclic structures can be attached to a parent molecule directly through a ring atom, through a substituent group or a bifunctional linking moiety. The term "acyl," as used herein, refers to a radical formed by removal of a hydroxyl group from an organic acid an d has the general formula -C(O)-X where X is typically aliphatic, alicyclic or aromatic. 20 Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphatic phosphates and the like. Acyl groups as used herein may optionally include further substitutent groups. The term "hydrocarbyl" includes groups comprising C, 0 and H. Included are straight, branched and cyclic groups having any degree of saturation. Such hydrocarbyl groups can include one or more 25 heteroatoms selected from N, 0 and S and can be further mono or poly substituted with one or more substituent groups. The terms "substituent" and "substituent group," as used herein, include groups that are typically added to other groups or parent compounds to enhance desired properties or give desired effects. Substituent groups can be protected or unprotected and can be added to one available site or to many 30 available sites in a parent compound. Substituent groups may also be further substituted with other substituent groups and may be attached directly or via a linking group such as an alkyl or hydrocarbyl group to a parent compound. Such groups include without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (-C(O)Raa), carboxyl (-C(O)O-Raa), aliphatic groups, alicyclic groups, alkoxy, substituted oxo (-O-Raa), aryl, aralkyl, heterocyclic, heteroaryl, heteroarylalkyl, amino (-NRbbRec), imino(=NRbb), 35 amido (-C(O)NRbbRcor -N(Rbb)C(O)Raa), azido (-N 3 ), nitro (-NO 2 ), cyano (-CN), carbamido (-OC(O)NRbbRcc or -N(Rbb)C(O)ORaa), ureido (-N(Rbb)C(O)NRbbRc), thioureido (-N(Rbb)C(S)NRbbRc), guanidinyl (-N(Rbb)C(=NRbb)NRbbRec), amidinyl (-C(=NRbb)NRbbRc or -N(Rbb)C(NRbb)Raa), thiol (-SRbb), WO 2007/146511 PCT/US2007/068401 -19 sulfinyl (-S(O)Rbb), sulfonyl (-S(O)2Rbb), sulfonamidyl (-S(O) 2 NRbbRc or -N(Rbb)S(O)2Rbb) and conjugate groups. Wherein each Raa, Rbb and Rc, is, independently, H, an optionally linked chemical functional group or a further substituent group with a preferred list including without limitation H, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. 5 B. Certain Oligomeric Compounds In certain embodiments, it is desirable to chemically modify oligomeric compounds, compared to naturally occuring oligomers, such as DNA or RNA. Certain such modifications alter the activity of the oligomeric compound. Certain such chemical modifications can alter activity by, for example: 10 increasing affinity of an antisense compound for its target nucleic acid, increasing its resistance to one or more nucleases, and/or altering the pharmacokinetics or tissue distribution of the oligomeric compound. In certain instances, the use of chemistries that increase the affinity of an oligomeric compound for its target can allow for the use of shorter oligomeric compounds. 1. Certain monomers 15 In certain embodiment, oligomeric compounds comprise one or more modified monomer. In certain such embodiments, oligomeric compounds comprise one or more high affinity monomer. In certain embodiments, such high-affinity monomer is selected from monomers (e.g., nucleosides and nucleotides) comprising 2'-modifed sugars, including, but not limited to: BNA's and monomers (e.g., nucleosides and nucleotides) with 2'- substituents such as allyl, amino, azido, thio, O-allyl, 0-C-C 10 20 alkyl, -OCF 3 , 0-(CH 2

)

2

-O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -O-N(Rm.)(R.), or O-CHrC(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted CI-C 10 alkyl. In certain embodiments, the oligomeric compounds including, but no limited to short antisense compounds of the present invention, comprise one or more high affinity monomers provided that the oligomeric compound does not comprise a nucleotide comprising a 2'-O(CH 2 ).H, wherein n is one to six. 25 In certain embodiments, the oligomeric compounds including, but no limited to short antisense compounds of the present invention, comprise one or more high affinity monomer provided that the oligomeric compound does not comprise a nucleotide comprising a 2'-OCH 3 or a 2'-O(CH 2

)

2 0CH 3 . In certain embodiments, the oligomeric compounds including, but no limited to short antisense compounds of the present invention, comprise one or more high affinity monomer provided that the 30 oligomeric compound does not comprise a a-L-Methyleneoxy (4'-CH 2 -O-2') BNA. In certain embodiments, the oligomeric compounds including, but no limited to short antisense compounds of the present invention, comprise one or more high affinity monomer provided that the oligomeric compound does not comprise a p-D-Methyleneoxy (4'-CH 2 -O-2') BNA. In certain embodiments, the oligomeric compounds including, but no limited to short antisense 35 compounds of the present invention, comprise one or more high affinity monomer provided that the oligomeric compound does not comprise a a-L-Methyleneoxy (4'-CH 2 -O-2') BNA or a p-D Methyleneoxy (4'-CH 2 -O-2') BNA.

WO 2007/146511 PCT/US2007/068401 -20 a. Certain Nucleobases The naturally occurring base portion of a nucleoside is typically a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. For those 5 nucleosides that include a pentofuranosyl sugar, a phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, those phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleotide backbone of the oligonucleotide. The naturally occurring linkage or backbone of RNA and of DNA is a 3' to 5' 10 phosphodiester linkage. In addition to "unmodified" or "natural" nucleobases such as the purine nucleobases adenine (A) and guanine (G), and the pyrimidine nucleobases thymine (T), cytosine (C) and uracil (U), many modified nucleobases or nucleobase mimetics known to those skilled in the art are amenable with the compounds described herein. In certain embodiments, a modified nucleobase is a nucleobase that is 15 fairly similar in structure to the parent nucleobase, such as for example a 7-deaza purine, a 5-methyl cytosine, or a G-clamp. In certain embodiments, nucleobase mimetic include more complicated structures, such as for example a tricyclic phenoxazine nucleobase mimetic. Methods for preparation of the above noted modified nucleobases are well known to those skilled in the art. b. Certain sugars 20 Oligomeric compounds provided herein may comprise one or more monomer, including a nucleoside or nucleotide, having a modified sugar moiety. For example, the furanosyl sugar ring of a nucleoside can be modified in a number of ways including, but not limited to, addition of a substituent group, bridging of two non-geminal ring atoms to form a bicyclic nucleic acid (BNA). In certain embodiments, oligomeric compounds comprise one or more monomers that is a 25 BNA. In certain such embodiments, BNA s include, but are not limited to, (A) a-L-Methyleneoxy (4'

CH

2 -0-2') BNA, (B) p-D-Methyleneoxy (4'-CH 2 -0-2') BNA, (C) Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA, (D) Aminooxy (4'-CH 2 -O-N(R)-2') BNA and (E) Oxyamino (4'-CH 2 -N(R)-O-2') BNA, as depicted in Figure 1. 0B 0 Bx 0 Bx 0 Bx 01Bx 0 BxN O 0--N-. -0 O'N R O 30 (A) (B) (C) (D) (E) Figure 1. Certain BNA Structures In certain embodimnents, BNA compounds include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the sugar wherein each of the bridges independently WO 2007/146511 PCT/US2007/068401 -21 comprises 1 or from 2 to 4 linked groups independently selected from -[C(R)(R 2 )]n-, -C(Ri)=C(R 2 )-,

-C(R

1 )=N-, -C(=NRI)-, -C(=0)-, -C(=S)-, -0-, -Si(R 1

)

2 -, -S(=O),- and -N(R 1 )-; wherein: x is 0, 1, or 2; 5 nis1,2,3,or4; each R, and R 2 is, independently, H, a protecting group, hydroxyl, Cl-C 1 2 alkyl, substituted C 1 C 12 alkyl, C 2

-C,

2 alkenyl, substituted C 2

-C

12 alkenyl, C 2

-C

12 alkynyl, substituted C 2

-C

12 alkynyl, C 5

-C

20 aryl, substituted C 5

-C

20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5

-C

7 alicyclic radical, substituted CS-C 7 alicyclic radical, halogen, OJi, NJiJ 2 , SJi, N 3 , COOJi, 10 acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O) 2 -JI), or sulfoxyl (S(=0)-J); and each J, and J 2 is, independently, H, C 1

-C

12 alkyl, substituted CI-C 1 2 alkyl, C 2

-C

1 2 alkenyl, substituted C 2

-C

12 alkenyl, C 2 -Ci 2 alkynyl, substituted C 2

-C

12 alkynyl, C 5

-C

20 aryl, substituted C 5

-C

20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, CI-C 1 2 aminoalkyl, substituted C 1

-C

12 aminoalkyl or a protecting group. 15 In one embodiment, each of the bridges of the BNA compounds is, independently, -[C(R 1

)(R

2 )]n

-[C(R)(R

2 )]-O-, -C(RiR 2

)-N(R

1 )-O- or -C(RjR 2 )-O-N(R)-. In another embodiment, each of said bridges is, independently, 4'-CH 2 -2', 4'-(CH 2

)

2 -2', 4'-(CH 2

)

3 -2', 4'-CH 2 -O-2', 4'-(CH 2

)

2 -O-2', 4'-CH 2

-O

N(R

1 )-2' and 4'-CH 2

-N(R

1 )-O-2'- wherein each R, is, independently, H, a protecting group or CI-C 12 alkyl. 20 Certain BNA's have been prepared and disclosed in the patent literature as well as in scientific literature (Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607 3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; WO 94/14226; WO 2005/021570; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Examples of issued US patents and published applications that disclose BNA s 25 include, for example, U.S. Patent Nos. 7,053,207; 6,268,490; 6,770,748; 6,794,499; 7,034,133; and 6,525,191; and U.S. Pre-Grant Publication Nos. 2004-0171570; 2004-0219565; 2004-0014959; 2003 0207841; 2004-0143114; and 20030082807. Also provided herein are BNAs in which the 2'-hydroxyl group of the ribosyl sugar ring is linked to the 4' carbon atom of the sugar ring thereby forming a methyleneoxy (4'-CH 2 -O-2') linkage to 30 form the bicyclic sugar moiety (reviewed in Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2, 558 561; Braasch et al., Chem. Biol., 2001, 8 1-7; and Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239 243; see also U.S. Patents: 6,268,490 and 6,670,461). The linkage can be a methylene (-CH 2 -) group bridging the 2' oxygen atom and the 4' carbon atom, for which the term methyleneoxy (4'-CH 2 -O-2') BNA is used for the bicyclic moiety; in the case of an ethylene group in this position, the term 35 ethyleneoxy (4'-CH 2

CH

2 -O-2') BNA is used (Singh et al., Chem. Commun., 1998, 4, 455-456: Morita et al., Bioorganic Medicinal Chemistry, 2003, 11, 2211-2226). Methyleneoxy (4'-CH 2 -O-2') BNA and other bicyclic sugar analogs display very high duplex thermal stabilities with complementary DNA and WO 2007/146511 PCT/US2007/068401 -22 RNA (Tm = +3 to +100 C), stability towards 3'-exonucleolytic degradation and good solubility properties. Potent and nontoxic antisense oligonucleotides compriseing BNAs have been described (Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638). An isomer of methyleneoxy (4'-CH 2 -O-2') BNA that has also been discussed is alpha-L 5 methyleneoxy (4'-CH 2 -O-2') BNA which has been shown to have superior stability against a 3' exonuclease. The alpha-L- methyleneoxy (4'-CH 2 -O-2') BNA's were incorporated into antisense gapmers and chimeras that showed potent antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372). The synthesis and preparation of the methyleneoxy (4'-CH 2 -O-2') BNA monomers adenine, 10 cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). BNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226. Analogs of methyleneoxy (4'-CH 2 -O-2') BNA, phosphorothioate- methyleneoxy (4'-CH 2 -0-2') BNA and 2'-thio-BNAs, have also been prepared (Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 15 2219-2222). Preparation of locked nucleoside analogs compriseing oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (Wengel et al., WO 99/14226 ). Furthermore, synthesis of 2'-amino-BNA, a novel comformationally restricted high-affinity oligonucleotide analog has been described in the art (Singh et al., J. Org. Chem., 1998, 63, 10035 10039). In addition, 2'-Amino- and 2'-methylamino-BNA's have been prepared and the thermal stability 20 of their duplexes with complementary RNA and DNA strands has been previously reported. Modified sugar moieties are well known and can be used to alter, typically increase, the affinity of the antisense compound for its target and/or increase nuclease resistance. A representative list of preferred modified sugars includes but is not limited to bicyclic modified sugars (BNA's), including methyleneoxy (4'-CH 2 -O-2') BNA and ethyleneoxy (4'-(CH 2

)

2 -O-2' bridge) BNA ; substituted sugars, 25 especially 2'-substituted sugars having a 2'-F, 2'-OCH 3 or a 2'-O(CH 2

)

2

-OCH

3 substituent group; and 4' thio modified sugars. Sugars can also be replaced with sugar mimetic groups among others. Methods for the preparations of modified sugars are well known to those skilled in the art. Some representative patents and publications that teach the preparation of such modified sugars include, but are not limited to, U.S. Patents: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 30 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; 5,700,920; 6,531,584; and 6,600,032; and WO 2005/121371. In certain embodiments, BNA's include bicyclic nucleoside having the formula: TI-0 Bx T2 wherein: WO 2007/146511 PCT/US2007/068401 -23 Bx is a heterocyclic base moiety; T, is H or a hydroxyl protecting group;

T

2 is H, a hydroxyl protecting group or a reactive phosphorus group; Z is C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, substituted C 1

-C

6 alkyl, substituted C 2

-C

6 alkenyl, 5 substituted C 2

-C

6 alkynyl, acyl, substituted acyl, or substituted amide. In one embodiment, each of the substituted groups, is, independently, mono or poly substituted with optionally protected substituent groups independently selected from halogen, oxo, hydroxyl, OJI,

NJIJ

2 , SJi, N 3 , OC(=X)JI, OC(=X)NJlJ 2 , NJ 3

C(=X)NJJ

2 and CN, wherein each J 1 , J 2 and J 3 is, independently, H or CI-C 6 alkyl, and X is 0, S or NJi. 10 In certain such embodiments, each of the substituted groups, is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, OJI, NJiJ 2 , SJI,

N

3 , OC(=X)JI, and NJ 3 C(=X)NJiJ 2 , wherein each J 1 , J 2 and J 3 is, independently, H, CI-C 6 alkyl, or substituted Cl-C 6 alkyl and X is 0 or NJ,. In certain embodiments, the Z group is C 1

-C

6 alkyl substituted with one or more X, wherein each 15 XX is independently OJI, NJIJ 2 , SJi, N 3 , OC(=X)Ji, OC(=X)NJIJ 2 , NJ 3 C(=X)NJiJ 2 or CN; wherein each JI,

J

2 and J 3 is, independently, H or C 1

-C

6 alkyl, and X is 0, S or NJ,. In another embodiment, the Z group is

C

1

-C

6 alkyl substituted with one or more X, wherein each X is independently halo (e.g., fluoro), hydroxyl, alkoxy (e.g., CH 3 0-), substituted alkoxy or azido. In certain embodiments, the Z group is -CH 2 X, wherein Xx is OJI, NJIJ 2 , SJI, N 3 , OC(=X)Ji, 20 OC(=X)NJIJ 2 , NJ 3 C(=X)NJiJ 2 or CN; wherein each J 1 , J 2 and J 3 is, independently, H or C-C 6 alkyl, and X is 0, S or NJ,. In another embodiment, the Z group is -CH 2 X, wherein X' is halo (e.g., fluoro), hydroxyl, alkoxy (e.g., CH 3 0-) or azido. In certain such embodiments, the Z group is in the (R)-configuration: TI-O - Bx Z% T2 25 In certain such embodiments, the Z group is in the (S)-configuration: TI-0 Bx Z T2 In certain embodiments, each Ti and T 2 is a hydroxyl protecting group. A preferred list of hydroxyl protecting groups includes benzyl, benzoyl, 2,6-dichlorobenzyl, t-butyldimethylsilyl, t-butyl diphenylsilyl, mesylate, tosylate, dimethoxytrityl (DMT), 9-phenylxanthine-9-yl (Pixyl) and 9-(p 30 methoxyphenyl)xanthine-9-yl (MOX). In certain embodiments, T, is a hydroxyl protecting group selected from acetyl, benzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl and dimethoxytrityl wherein a WO 2007/146511 PCT/US2007/068401 -24 more preferred hydroxyl protecting group is T, is 4,4'-dimethoxytrityl. In certain embodiments, T 2 is a reactive phosphorus group wherein preferred reactive phosphorus groups include diisopropylcyanoethoxy phosphoramidite and H-phosphonate. In certain embodiments T is 4,4'-dimethoxytrityl and T 2 is diisopropylcyanoethoxy phosphoramidite. 5 In certain embodiments, oligomeric compounds have at least one monomer of the formula: .0 Bx Z O z * or of the formula: -O Bx 60 or of the formula: 10 T3-0 O Bx z 60 T4 wherein Bx is a heterocyclic base moiety;

T

3 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group 15 attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound;

T

4 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; 20 wherein at least one of T 3 and T 4 is an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; and Z is C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, substituted C 1

-C

6 alkyl, substituted C 2

-C

6 alkenyl, substituted C 2

-C

6 alkynyl, acyl, substituted acyl, or substituted amide. In one embodiment, each of the substituted groups, is, independently, mono or poly substituted 25 with optionally protected substituent groups independently selected from halogen, oxo, hydroxyl, OJI,

NJIJ

2 , SJ 1 , N 3 , OC(=X)Ji, OC(=X)NJiJ 2 , NJ 3 C(=X)NJiJ 2 and CN, wherein each J 1 , J 2 and J 3 is, independently, H or C1-C 6 alkyl, and X is 0, S or NJ,. In one embodiment, each of the substituted groups, is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, OJI, NJIJ 2 , SJ 1 , N 3

,

WO 2007/146511 PCT/US2007/068401 -25 OC(=X)Ji, and NJ 3

C(=X)NJIJ

2 , wherein each J 1 , J 2 and J 3 is, independently, H or C 1

-C

6 alkyl, and X is 0 or NJ,. In certain such embodiments, at least one Z is C 1

-C

6 alkyl or substituted C 1

-C

6 alkyl. In certain embodiments, each Z is, independently, C 1

-C

6 alkyl or substituted Ci-C 6 alkyl. In certain embodiments, at 5 least one Z is C 1

-C

6 alkyl. In certain embodiments, each Z is, independently, C 1

-C

6 alkyl. In certain embodiments, at least one Z is methyl. In certain embodiments, each Z is methyl. In certain embodiments, at least one Z is ethyl. In certain embodiments, each Z is ethyl. In certain embodiments, at least one Z is substituted C 1

-C

6 alkyl. In certain embodiments, each Z is, independently, substituted C

C

6 alkyl. In certain embodiments, at least one Z is substituted methyl. In certain embodiments, each Z is 10 substituted methyl. In certain embodiments, at least one Z is substituted ethyl. In certain embodiments, each Z is substituted ethyl. In certain embodiments, at least one substituent group is C-C 6 alkoxy (e.g., at least one Z is C 1 C 6 alkyl substituted with one or more CrC6 alkoxy). In another embodiment, each substituent group is, independently, C 1

-C

6 alkoxy (e.g., each Z is, independently, CrC 6 alkyl substituted with one or more Cr 15 C 6 alkoxy). In certain embodiments, at least one C 1

-C

6 alkoxy substituent group is CH 3 0- (e.g., at least one Z is CH 3 0CH 2 -). In another embodiment, each C 1

-C

6 alkoxy substituent group is CH 3 0- (e.g., each Z is

CH

3 0CH 2 -). In certain embodiments, at least one substituent group is halogen (e.g., at least one Z is C 1

-C

6 20 alkyl substituted with one or more halogen). In certain embodiments, each substituent group is, independently, halogen (e.g., each Z is, independently, C 1

-C

6 alkyl substituted with one or more halogen). In certain embodiments, at least one halogen substituent group is fluoro (e.g., at least one Z is CH 2

FCH

2 -,

CHF

2

CH

2 - or CF 3

CH

2 -). In certain embodiments, each halo substituent group is fluoro (e.g., each Z is, independently, CH 2

FCH

2 -, CHF 2

CH

2 - or CF 3

CH

2 -). 25 In certain embodiments, at least one substituent group is hydroxyl (e.g., at least one Z is C 1

-C

6 alkyl substituted with one or more hydroxyl). In certain embodiments, each substituent group is, independently, hydroxyl (e.g., each Z is, independently, C 1

-C

6 alkyl substituted with one or more hydroxyl). In certain embodiments, at least one Z is HOCH 2 -. In another embodiment, each Z is HOCH2-. 30 In certain embodiments, at least one Z is CHr, CH 3

CH

2 -, CH 2 0CH 3 -, CH 2 F- or HOCH 2 -. In certain embodiments, each Z is, independently, CH 3 -, CH 3

CH

2 -, CH 2

OCH

3 -, CH 2 F- or HOCH 2 -. In certain embodiments, at least one Z group is Ci-C 6 alkyl substituted with one or more X', wherein each X is, independently, OJi, NJiJ 2 , SJi, N 3 , OC(=X)JI, OC(=X)NJIJ 2 , NJ 3 C(=X)NJiJ 2 or CN; wherein each J 1 , J 2 and J 3 is, independently, H or C 1

-C

6 alkyl, and X is 0, S or NJi. In another 35 embodiment, at least one Z group is C 1

-C

6 alkyl substituted with one or more X, wherein each X is, independently, halo (e.g., fluoro), hydroxyl, alkoxy (e.g., CH 3 0-) or azido. In certain embodiments, each Z group is, independently, C 1

-C

6 alkyl substituted with one or more WO 2007/146511 PCT/US2007/068401 -26 X', wherein each X is independently OJI, NJiJ 2 , SJi, N 3 , OC(=X)Ji, OC(=X)NJiJ 2 , NJ 3

C(=X)NJIJ

2 or CN; wherein each J 1 , J 2 and J 3 is, independently, H or C 1

-C

6 alkyl, and X is 0, S or NJ,. In another embodiment, each Z group is, independently, Ci-C 6 alkyl substituted with one or more X", wherein each X' is independently halo (e.g., fluoro), hydroxyl, alkoxy (e.g., CH 3 0-) or azido. 5 In certain embodiments, at least one Z group is -CH 2 X, wherein X is OJi, NJ 1

J

2 , SJi, N 3 , OC(=X)Jj, OC(=X)NJIJ 2 , NJ 3

C(=X)NJIJ

2 or CN; wherein each J 1 , J 2 and J 3 is, independently, H or C 1

-C

6 alkyl, and X is 0, S or NJ, In certain embodiments, at least one Z group is -CH 2 XX, wherein X" is halo (e.g., fluoro), hydroxyl, alkoxy (e.g., CH 3 0-) or azido. In certain embodiments, each Z group is, independently, -CH 2 X, wherein each X" is, 10 independently, OJI, NJIJ 2 , SJi, N 3 , OC(=X)JI, OC(=X)NJIJ 2 , NJ 3

C(=X)NJIJ

2 or CN; wherein each J 1 , J 2 and J 3 is, independently, H or CI-C 6 alkyl, and X is 0, S or NJ,. In another embodiment, each Z group is, independently, -CH 2 XX, wherein each X is, independently, halo (e.g., fluoro), hydroxyl, alkoxy (e.g.,

CH

3 0-) or azido. In certain embodiments, at least one Z is CH3-. In another embodiment, each Z is, CHr. 15 In certain embodiments, the Z group of at least one monomer is in the (R)- configuration represented by the formula: Z , Bx or the formula: ZO Bx Z 6 20 or the formula:

T

3 -0 Bx O O IT4 In certain embodiments, the Z group of each monomer of the formula is in the (R)- configuration. 25 In certain embodiments, the Z group of at least one monomer is in the (S)- configuration represented by the formula: WO 2007/146511 PCT/US2007/068401 -27 Bx or the formula: -0 . Bx z or the formula: 5 T3-0 Bx T4 In certain embodiments, the Z group of each monomer of the formula is in the (S)- configuration. In certain embodiments, T 3 is H or a hydroxyl protecting group. In certain embodiments, T 4 is H or a hydroxyl protecting group. In a further embodiment T 3 is an internucleoside linking group attached 10 to a nucleoside, a nucleotide or a monomeric subunit. In certain embodiments, T 4 is an internucleoside linking group attached to a nucleoside, a nucleotide or a monomeric subunit. In certain embodiments,T 3 is an internucleoside linking group attached to an oligonucleoside or an oligonucleotide. In certain embodiments, T 4 is an intemucleoside linking group attached to an oligonucleoside or an oligonucleotide. In certain embodiments, T 3 is an internucleoside linking group attached to an oligomeric compound. In 15 certain embodiments, T 4 is an internucleoside linking group attached to an oligomeric compound. In In certain embodiments, at least one of T 3 and T 4 comprises an internucleoside linking group selected from phosphodiester or phosphorothioate. In certain embodiments, oligomeric compounds have at least one region of at least two contiguous monomers of the formula: Bx 20 or of the formula: -O . Bx z 0 0 or of the formula: WO 2007/146511 PCT/US2007/068401 -28

T

3 -0 ",o Bx Z to 4 In certain embodiments, the oligomeric compound comprises at least two regions of at least two contiguous monomers of the above formula. In certain embodiments, the oligomeric compound comprises a gapped oligomeric compound. In certain embodiments, the oligmeric compound comprises 5 at least one region of from about 8 to about 14 contiguous p-D-2'-deoxyribofuranosyl nucleosides. In certain embodiments, the oligomeric compound comprises at least one region of from about 9 to about 12 contiguous p-D-2'-deoxyribofuranosyl nucleosides. In certain embodiments, monmers include sugar mimetics. In certain such embodiments, a mimetic is used in place of the sugar or sugar-internucleoside linkage combination, and the nucleobase is 10 maintained for hybridization to a selected target. Representative examples of a sugar mimetics include, but are not limited to, cyclohexenyl or morpholino. Representative examples of a mimetic for a sugar internucleoside linkage combination include, but are not limited to, peptide nucleic acids (PNA) and morpholino groups linked by uncharged achiral linkages. In some instances a mimetic is used in place of the nucleobase. Representative nucleobase mimetics are well known in the art and include, but are not 15 limited to, tricyclic phenoxazine analogs and universal bases (Berger et al., Nuc Acid Res. 2000, 28:2911-14, incorporated herein by reference). Methods of synthesis of sugar, nucleoside and nucleobase mimetics are well known to those skilled in the art. 3. Monomeric Linkages 20 Described herein are linking groups that link monomers (including, but not limited to, modified and unmodified nucleosides and nucleotides) together, thereby forming an oligomeric compound. The two main classes of linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus containing linkages include, but are not limited to, phosphodiesters (P=O), phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates (P=S). Representative 25 non-phosphorus containing linking groups include, but are not limited to, methylenemethylimino (-CH 2 N(CH 3 )-O-CHr), thiodiester (-O-C(O)-S-), thionocarbamate (-O-C(O)(NH)-S-); siloxane (-O-Si(H)2-0 ); and N,N'-dimethylhydrazine (-CH 2

-N(CH

3

)-N(CH

3 )-). Oligomeric compounds having non-phosphorus linking groups are referred to as oligonucleosides. Modified linkages, compared to natural phosphodiester linkages, can be used to alter, typically increase, nuclease resistance of the oligomeric 30 compound. In certain embodiments, linkages having a chiral atom can be prepared a racemic mixtures, as separate enantomers. Representative chiral linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous containing linkages are well known to those skilled in the art. The oligomeric compounds described herein contain one or more asymmetric centers and thus WO 2007/146511 PCT/US2007/068401 -29 give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), a or P such as for sugar anomers, or as (D) or (L) such as for amino acids et al. Included in the antisense compounds provided herein are all such possible isomers, as well as their racemic and optically pure forms. 5 4. Oligomeric Compounds In certain embodiments, provided herein are oligomeric compounds having reactive phosphorus groups useful for forming linkages including for example phosphodiester and phosphorothioate internucleoside linkages. Methods of preparation and/or purification of precursors or oligomeric compounds are not a limitation of the compositions or methods provided herein. Methods for synthesis 10 and purification of oligomeric compounds including DNA, RNA, oligonucleotides, oligonucleosides, and antisense compounds are well known to those skilled in the art. Generally, oligomeric compounds comprise a plurality of monomeric subunits linked together by linking groups. Nonlimiting examples of oligomeric compounds include primers, probes, antisense compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate 15 splicers, and siRNAs. As such, these compounds can be introduced in the form of single-stranded, double-stranded, circular, branched or hairpins and can contain structural elements such as internal or terminal bulges or loops. Oligomeric double-stranded compounds can be two strands hybridized to form double-stranded compounds or a single strand with sufficient self complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. 20 In certain embodiments, the present invention provides chimeric oligomeric compounds. In certain such embodiments, chimeric oligomeric compounds are chimeric oligonucleotides. In certain such embodiments, the chimeric oligonucleotides comprise differently modified nucleotides. In certain embodiments, chimeric oligonucleotides are mixed-backbone antisense oligonucleotides. In general a chimeric oligomeric compound will have modified nucleosides that can be in 25 isolated positions or grouped together in regions that will define a particular motif. Any combination of modifications and/or mimetic groups can comprise a chimeric oligomeric compound as described herein. In certain embodiments, chimeric oligomeric compounds typically comprise at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. In certain embodiments, an additional region of the 30 oligomeric compound may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA: DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligomeric compounds when chimeras are used, compared to 35 for example phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

WO 2007/146511 PCT/US2007/068401 -30 In certain embodiments, chimeric oligomeric compounds are gapmers. In certain embodiments, chimeric compounds are short antisense compounds. In certain embodiments, short antisense compounds are gapmers. In certain such embodiments, a mixed-backbone antisense oligomer has one type of internucleotide linkages in one or both wings and a different type of internucleotide linkages in the gap. 5 In certain such embodiments, the mixed-backbone antisense oligonucleotide has phosphodiester linkages in the wings and phosphorothioate linkages in the gap. In certain embodiments in which the internucleotide linkages in a wing is different from the internucleotide linkages in the gap, the internucleotide linkage bridging that wing and the gap is the same as the internucleotide linkage in the wing. In certain embodiments in which the internucleotide linkages in a wing is different from the 10 intemucleotide linkages in the gap, the internucleotide linkage bridging that wing and the gap is the same as the internucleotide linkage in the gap. C. Certain Short Antisense Compounds Disclosed herein are short antisense compounds 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds 15 are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds comprise one or more chemical modifications. In certain such embodiments, short antisense compounds comprise at least one modified 20 nucleotide. In certain embodiments short antisense compounds comprise at least two or more modified nucleotides. In certain embodiments, short antisense compounds comprise at least one modified intermucleotide linkage. In certain embodiments, short antisense compounds are mixed-backbone oligonucleotides. In certain embodiments, short antisense compounds are chimeric oligonucleotides. In certain embodiments, short antisense oligonucleotides are uniformly modified. In certain embodiments, 25 short antisense oligonucleotides comprise modifications independently selected at each nucleobase and at each linkage. In certain embodiments, short antisense compounds are short gapmers. In certain such embodiments, short gapmers comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds comprise 1 to 3 high-affinity 30 modifications in each wing. In certain embodiments, high affinity modifications of the short antisense compounds allow for a target affinity similar to, or even greater than, the target affinity of longer antisense compounds. In certain embodiments, the high-affinity modified nucleotides are sugar modified nucleotides. Such sugar modified nucleotides include those comprising a bridge between the 4' and 2' position of the sugar. Exemplary high affinity sugar modifications include, but are not limited to, BNA s 35 and other 2'-modifications such as 2'-MOE. In an alternate embodiment of the invention, the high affinity modification is not a 2'-O-(CH 2 )nH (n= 1-6) sugar-modified nucleotide. In an additional alternate embodiment, the high affinity modified nucleotide is not a 2'-OCH 3 or a 2'-OCH 2

CH

2

OCH

3 nucleotide.

WO 2007/146511 PCT/US2007/068401 -31 In certain embodiments, the high-affinity modified nucleotides confer a Tm of at least 1, at least 1.5, at least 2, at least 2.5, at least 3.0, at least 3.5 or at least 4.0 degrees per nucleotide. Some high-affinity nucleotide modifications are known in the art to increase toxicity. As shown herein, short antisense compounds having a limited number (generally 2 to 6) of high affinity modifications exhibit little to no 5 increase in toxicity but retain or increase affinity for the target RNA, while also significantly reducing expression of the RNA target. Short antisense compounds of the invention may optionally comprise a conjugate group, such as, for example, cholesterol or C 16 . 1. Certain Wings 10 In certain embodiments, the short antisense compounds comprise a 5' wing and/or a 3' wing. In such embodiments, the features of the 3' wing and the features of the 5' wing are selected independently. Thus, in such embodiments, the number of monomers in the 5' wing and the number of monomers (length) in the 3' wing may be the same or may be different; the modifications, if any, in the 5' wing may be the same as the modifications, if any, in the 3' wing or such modifications, if any, may be different; 15 and the monomeric linkages in the 5' wing and the monomeric linkages in the 3' wing may be the same or they may be different. In certain embodiments a wing comprises one, two or three monomers (i.e. has a length of 1, 2, or 3). In certain embodiments, the monomers of a wing are modified. In certain such embodiments, the monomers of the wing are modified to increase affinity of the antisense compound for its target nucleic 20 acid. In certain embodiments, the monomers of a wing are nucleosides or nucleotides. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers (nucleosides or nucleotides) of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -O-2') BNA, p-D Methyleneoxy (4'-CH 2 -O-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -O-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

25 2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, O-allyl, 0-C-Cio alkyl, OCF 3 , O-(CH 2

)

2

-O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2 )rO-N(Rm)(R), and O-CHrC(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted CI-Co alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. 30 In certain embodiments, the monomeric linkages in a wing are naturally occurring internucleotide linkages. In certain embodiments, the monomeric linkages in a wing are non-naturally occurring internucleotide or internucleoside linkages. In certain such embodiments, the monomeric linkages in the wing are more resistant to one or more nucleases than naturally occurring internucleotide linkages. In certain such embodiments, the monomeric linkages in the wing are phosphorothioate linkages (P=S). In 35 certain embodiments where a wing has more than one monomeric linkage, the monomeric linkages are the same as one another. In certain embodiments where a wing has more than one monomers linkage, the monomers linkages are different from each other.

WO 2007/146511 PCT/US2007/068401 -32 One of ordinary skill in the art will recognize that the features and modifications discussed above may be used in any combination to prepare a wing. The table below provides non-limiting examples showing how one might prepare a wing by selecting a certain number of monomers, monomeric modifications (if any), and monomeric linkages both within the wing. 5 Length Monomer type/ monomeric linkages within modifications wing I 2' MOE None I BNA None 1 Methyleneoxy None BNA 1 ENA None 2 2'MOE P=S 2 BNA P=S 2 Methyleneoxy P=S BNA 2 ENA P=S 2 2'MOE P=O 2 BNA P=O 2 Methyleneoxy P=O BNA 2 ENA P=O 3 2'MOE P=S 3 BNA P=S 3 Methyleneoxy P=S BNA 3 ENA P=S 3 2'MOE P=O 3 BNA P=O 3 Methyleneoxy P=O BNA 3 ENA P=O In certain embodiments in which a wing comprises two, three or four monomers, those two, three or four monomers all comprise the same modifications, if any. In certain embodiments in which a wing comprises two, three or four monomers, one or more of those two, three or four nucleobases comprises 10 one or more modifications that is different from one or more of the modifications of one or more of the WO 2007/146511 PCT/US2007/068401 -33 remaining monomers. 2. Certain Gaps In certain embodiments, the short antisense compounds comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, 5 thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, the monomeric linkages in the gap are naturally occurring 10 internucleotide linkages. In certain embodiments, the monomeric linkages in the gap are non-naturally occurring linkages. In certain such embodiments, the monomeric linkages in the gap are more resistant to one or more nuclease than naturally occurring intemucleotide linkages. In certain such embodiments, the monomeric linkages in the gap are phosphorothioate linkages (P=S). In certain embodiments, the monomeric linkages in the gap are all the same as one another. In certain embodiments, the monomeric 15 linkages within the gap are not all the same. One of ordinary skill in the art will recognize that the features and modifications discussed above may be used in any combination to prepare a gap. The table below provides non-limiting examples showing how one might prepare a gap by selecting a certain number of monomers, monomeric modifications (if any), and monomeric linkages within the gap region. 20 Length Monomer type/ Monomeric linkages within modifications gap 5 DNA P=S 6 DNA P=S 7 DNA P=S 8 DNA P=S 9 DNA P=S 10 DNA P=S 11 DNA P=S 12 DNA P=S 13 DNA P=S 14 DNA P=S 6 DNA P=O 7 DNA P=O 8 DNA P=O 9 DNA P=O 10 DNA P=O WO 2007/146511 PCT/US2007/068401 -34 11 DNA P=O 12 DNA P=O 8 RNA P=S 9 RNA P=S 10 RNA P=S 11 RNA P=S 12 RNA P=S 3. Certain Gapped Antisense Oligomeric Compounds One of ordinary skill in the art will recognize that the wings and the gaps discussed above may be selected and then combined in a variety of combinations to generate gapped oligomeric compounds, 5 including, but not limited to, gapped antisense oligomeric compounds, and gapped antisense oligonucleotides. The features (length, modifications, linkages) of the 5' wing and the 3' wing may be selected independently of one another. The features of the gap include at least one difference in modification compared to the features of the 5' wing and at least one difference compared to the features of the 3' wing (i.e., there must be at least one difference in modification between neighboring regions to 10 distinguish those neighboring regions from one another). The features of the gap may otherwise be selected independently. In certain embodiments, the monomeric linkages within a wing and the monomeric linkages within the gap are the same. In certain embodiments, the monomeric linkages within a wing and the monomeric linkages within the gap are different. In certain such embodiments, the monomeric linkage 15 bridging the wing and the gap are the same as the monomeric linkages in the wing. In certain embodiments, the monomeric linkage bridging the wing and the gap are the same as the monomeric linkages in the gap. In certain embodiments, short antisense compounds have uniform linkages throughout the compound. In certain such embodiments, all of the linkages are phosphorothioate (P=S) linkages. 20 One of ordinary skill in the art will recognize that the 3' wings, 5' wings, gaps, and linkages discussed above may be used in any combination to prepare a gapmer. The table below provides non limiting examples showing how one might prepare a gapmer by selecting a certain 5' wing, a gap, a 3' wing and certain linkages bridging the gap and each wing. 5' Wing 5'Bridge Gap 3' 3' Wing Bridge Length Monomer Link Link Length Monomer Link Link Length Monomer Link 2 MOE P=S P=S 6 DNA P=S P=S 2 MOE P=S 2 BNA P=S P=O 8 DNA P=O P=S 3 BNA P=S 1 MOE None P=S 10 DNA P=S P=S 1 MOE P=S WO 2007/146511 PCT/US2007/068401 -35 2 MOE P=S P=S 8 RNA P=S P=S 2 MOE P=S 3 Methyleneoxy P=S P=S 8 RNA P=S P=S 3 MOE P=S BNA 3 DNA P=O P=O 10 RNA P=S P=O 3 2'OH P=O 2 2-F P=S P=S 5 RNA P=S P=S 2 2'-F P=S I MOE P=O P=S 5 DNA P=O P=S 4 MOE P=S In certain embodiments, the oligomeric compounds disclosed herein may comprise from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this 5 comprehends antisense compounds of 8, 9, 10, 11, 12, 13, 14, 15 or 16 nucleobases. In certain embodiments, oligomeric compounds are antisense compounds. In certain embodiments, short antisense compounds are 8 nucleobases in length. In certain embodiments, short antisense compounds are 9 nucleobases in length. In certain embodiments, short antisense compounds are 10 nucleobases in length. 10 In certain embodiments, short antisense compounds are 11 nucleobases in length. In certain embodiments, short antisense compounds are 12 nucleobases in length. In certain embodiments, short antisense compounds are 13 nucleobases in length. In certain embodiments, short antisense compounds are 14 nucleobases in length. In certain embodiments, short antisense compounds are 15 nucleobases in length. 15 In certain embodiments, short antisense compounds are 16 nucleobases in length. In certain embodiments, short antisense compounds are 8 monomers in length. In certain embodiments, short antisense compounds are 9 monomers in length. In certain embodiments, short antisense compounds are 10 monomers in length. In certain embodiments, short antisense compounds are 11 monomers in length. In certain embodiments, short antisense compounds are monomers in length. In 20 certain embodiments, short antisense compounds are 13 monomers in length. In certain embodiments, short antisense compounds are 14 monomers in length. In certain embodiments, short antisense compounds are 15 monomers in length. In certain embodiments, short antisense compounds are 16 monomers in length. In certain embodiments, short antisense compounds comprise 9 to 15 monomers. In certain embodiments, short antisense compounds comprise 10 to 15 monomers. In certain embodiments, 25 short antisense compounds comprise 12 to 14 monomers. In certain embodiments, short antisense compounds comprise 12 to 14 nucleotides or nucleosides. One having skill in the art and informed by the short antisense compounds illustrated herein will be able, without undue experimentation, to identify further short antisense compounds. In certain embodiments, short antisense compounds comprise a gap flanked by more than one 30 wing on either or both sides. Thus, in certain embodiments, a short antisense compound comprises two or more 5' wings and two or more 3' wings. In certain embodiments, a short antisense compound comprises WO 2007/146511 PCT/US2007/068401 -36 one 5' wing and two or more 3' wings. In certain embodiments, a short antisense compound comprises one 3' wing and two or more 5' wings. Certain such embodiments comprise, for example, the following regions: a first 5' wing - a bridge - a second 5' wing - a bridge - a gap - a bridge - a second 3' wing a bridge - a first 3'wing. In such embodiments, each region has at least one difference in modification 5 when compared to its neighboring region. Thus, in such embodiments, the second 5' wing and the second 3' wing each independently comprises one or more differences in modification compared to the gap and compared to the first 5' wing and the first 3' wing. In such embodiments, the modifications of the first 3' wing and first 5' wing may either or both be the same or different from the modifications of the gap, if any. 10 4. Certain Conjugate Groups In one aspect, oligomeric compounds are modified by covalent attachment of one or more conjugate groups. In general, conjugate groups modify one or more properties of the attached oligomeric compound including but not limited to pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and clearance. Conjugate groups are routinely used in the chemical 15 arts and are linked directly or via an optional linking moiety or linking group to a parent compound such as an oligomeric compound. A preferred list of conjugate groups includes without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes. 20 Preferred conjugate groups amenable to the present invention include lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553); cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053); a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765); a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533); an aliphatic chain, 25 e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 111; Kabanov et al., FEBS Lett., 1990, 259, 327; Svinarchuk et al., Biochimie, 1993, 75, 49); a phospholipid, e.g., di hexadecyl-rac-glycerol or triethylammonium-1,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651; Shea et al., Nucl. Acids Res., 1990, 18, 3777); a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969); 30 adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651); a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229); or an octadecylamine or hexylamino-carbonyl oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923). Linking groups or bifunctional linking moieties such as those known in the art are amenable to the compounds provided herein. Linking groups are useful for attachment of chemical functional groups, 35 conjugate groups, reporter groups and other groups to selective sites in a parent compound such as for example an oligomeric compound. In general a bifunctional linking moiety comprises a hydrocarbyl moiety having two functional groups. One of the functional groups is selected to bind to a parent WO 2007/146511 PCT/US2007/068401 -37 molecule or compound of interest and the other is selected to bind essentially any selected group such as chemical functional group or a conjugate group. In some embodiments, the linker comprises a chain structure or an oligomer of repeating units such as ethylene glycol or amino acid units. Examples of functional groups that are routinely used in a bifunctional linking moiety include, but are not limited to, 5 electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In some embodiments, bifunctional linking moieties include amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), and the like. Some nonlimiting examples of bifunctional linking moieties include 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). 10 Other linking groups include, but are not limited to, substituted C 1

-C

10 alkyl, substituted or unsubstituted

C

2

-C

10 alkenyl or substituted or unsubstituted C 2 -Clo alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl. 5. Synthesis, Purification and Analysis 15 Oligomerization of modified and unmodified nucleosides and nucleotides can be routinely performed according to literature procedures for DNA (Protocols for Oligonucleotides and Analogs, Ed. Agrawal (1993), Humana Press) and/or RNA (Scaringe, Methods (2001), 23, 206-217. Gait et al., Applications of Chemically synthesized RNA in RNA: Protein Interactions, Ed. Smith (1998), 1-36. Gallo et al., Tetrahedron (2001), 57, 5707-5713). 20 Oligomeric compounds provided herein can be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives. The 25 invention is not limited by the method of antisense compound synthesis. Methods of purification and analysis of oligomeric compounds are known to those skilled in the art. Analysis methods include capillary electrophoresis (CE) and electrospray-mass spectroscopy. Such synthesis and analysis methods can be performed in multi-well plates. The method of the invention is not limited by the method of oligomer purification. 30 D. Antisense Antisense mechanisms are all those involving the hybridization of a compound with target nucleic acid, wherein the outcome or effect of the hybridization is either target degradation or target occupancy with concomitant stalling of the cellular machinery involving, for example, transcription or splicing. 35 One type of antisense mechanism involving target degradation includes an RNase H. RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNAse H activity in mammalian WO 2007/146511 PCT/US2007/068401 -38 cells. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of DNA-like oligonucleotide-mediated inhibition of gene expression. In certain embodiments, chemically-modified antisense compounds have a higher affinity for target RNAs than does non-modified DNA. In certain such embodiments, that higher affinity in turn 5 provides increased potency allowing for the administration of lower doses of such compounds, reduced potential for toxicity and improvement in therapeutic index and decreased overall cost of therapy. The present disclosure demonstrates that the incorporation of chemically-modified high-affinity nucleotides and nucleosides into antisense compounds allows for the design of short antisense compounds 8-16 nucleobases in length useful for the reduction of target RNAs and/or target proteins in cells, tissues, 10 and animals, including, but not limited to, humans with increased potency and improved therapeutic index. Thus, in certain embodiments, provided herein are short antisense compounds comprising high affinity nucleotide modifications useful for reducing a target RNA in vivo. Certain such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, certain short antisense compounds have greater 15 potential for oral dosing. To address the need for more potent antisense compounds, provided herein are short antisense compounds (8-16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length) with increased activity in vivo relative to longer compounds. Certain short antisense compounds are gapmer compounds comprising high-affinity chemically-modified nucleotides on the 3' and 5' ends 20 (wings) of the compound. In certain embodiments, the addition of high-affinity modified nucleotides allows antisense compounds to be active against, and specific for, their intended target RNA in vivo despite being shorter in length. Contemplated herein are short antisense compounds wherein each of the wings independently comprises 1 to 3 high-affinity modified nucleotides. In certain embodiments, the high-affinity modifications are sugar modifications. High-affinity modified nucleotides include, but are 25 not limited to, BNA s or other 2'-modified nucleotides, such as 2'-MOE nucleotides. Also contemplated are short antisense compounds having at least one modified internucleotide linkage, such as a phosphorothioate internucleotide linkage. In certain embodiments, the short antisense compounds of the present invention can have all phosphorothioate internucleoside linkages. The short antisense compounds optionally comprise a conjugate group. As shown herein, short antisense compounds have greater affinity 30 for target RNA than they have for DNA and are significantly more potent in vivo as shown by reduction of target mRNA as well as by amelioration of a variety of disease indications. As used herein, an RNA which is involved in regulating glucose metabolism or clearance, lipid metabolism, cholesterol metabolism or insulin metabolism is any RNA involved in the biochemical pathways that regulate these processes. Such RNAs are well known in the art. Examples of target genes 35 include, but are not limited to, ApoB-100 (also known as APOB; Ag(x) antigen; apoB-48; apolipoprotein B; apolipoprotein B-100; apolipoprotein B-48) and GCGR (also known as glucagon receptor; GR), CRP, DGAT2, GCCR, PCSK9, PTEN, PTPlB, SGLT2, and SODL.

WO 2007/146511 PCT/US2007/068401 -39 1. Modulation of Target Expression In certain embodiments, a target is identified and antisense oligonucleotides are designed to modulate that target or its expression. In certain embodiments, designing an oligomeric compound to a target nucleic acid molecule can be a multistep process. Typically the process begins with the 5 identification of a target protein, the activity of which is to be modulated, and then identifying the nucleic acid the expression of which yields the target protein. In certain embodiments, designing of an antisense compound results in an antisense compound that is hybridizable to the targeted nucleic acid molecule. In certain embodiments, the antisense compound is an antisense oligonucleotide or antisense oligonucleoside. In certain embodiments, an antisense compound and a target nucleic acid are 10 complementary to one another. In certain such embodiments, an antisense compound is perfectly complementary to a target nucleic acid. In certain embodiments, an antisense compound includes one mismatch. In certain embodiments, an antisense compound includes two mismatches. In certain embodiments, an antisense compound includes three or more mismatches. Modulation of expression of a target nucleic acid can be achieved through alteration of any 15 number of nucleic acid functions. In certain embodiments, the functions of RNA to be modulated include, but are not limited to, translocation functions, which include, but are not limited to, translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, and translation of protein from the RNA. RNA processing functions that can be modulated include, but are not limited to, splicing of the RNA to yield one or more 20 RNA species, capping of the RNA, 3' maturation of the RNA and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. Modulation of expression can result in the increased level of one or more nucleic acid species or the decreased level of one or more nucleic acid species, either temporally or by net steady state level. Thus, in one embodiment modulation of expression can mean increase or decrease in target RNA or protein levels. In another embodiment 25 modulation of expression can mean an increase or decrease of one or more RNA splice products, or a change in the ratio of two or more splice products. In certain embodiments, expression of a target gene is modulated using an oligomeric compound comprising from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will 30 appreciate that this comprehends methods of modulating expression of a target gene using one or more antisense compounds of 8, 9, 10, 11, 12, 13, 14, 15 or 16 nucleobases. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 8 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 9 nucleobases in length. In certain embodiments, 35 methods of modulating a target gene comprises use of a short antisense compound that is 8 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 10 nucleobases in length. In certain embodiments, methods of modulating a target gene WO 2007/146511 PCT/US2007/068401 -40 comprises use of a short antisense compound that is 10 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 11 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 12 nucleobases in length. In certain embodiments, methods of modulating a 5 target gene comprises use of a short antisense compound that is 13 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 14 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 15 nucleobases in length. In certain embodiments, methods of modulating a target gene comprises use of a short antisense compound that is 16 nucleobases in length. 10 In certain embodiments, methods of modulating expression of a target gene comprises use of a short antisense compound comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of a target gene comprises use of a short antisense compound comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of a target gene comprises use of a short antisense compound comprising 12 to 14 monomers. In certain embodiments, methods of 15 modulating expression of a target gene comprises use of a short antisense compound comprising 12 or 14 nucleotides or nucleosides. 2. Hybridization In certain embodiments, antisense compounds specifically hybridize when there is a sufficient 20 degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays. As used herein, "stringent hybridization conditions" or "stringent conditions" refers to conditions 25 under which an antisense compound will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances, and "stringent conditions" under which antisense compounds hybridize to a target sequence are determined by the nature and composition of the antisense compounds and the assays in which they are being investigated. 30 3. Complementarity It is understood in the art that incorporation of nucleotide affinity modifications may allow for a greater number of mismatches compared to an unmodified compound. Similarly, certain oligonucleotide sequences may be more tolerant to mismatches than other oligonucleotide sequences. One of ordinary skill in the art is capable of determining an appropriate number of mismatches between oligonucleotides, 35 or between an oligonucleotide and a target nucleic acid, such as by determining melting temperature (Tm). Tm or Tm can be calculated by techniques that are familiar to one of ordinary skill in the art. For example, techniques described in Freier et al. (Nucleic Acids Research, 1997, 25, 22: 4429-4443) allow WO 2007/146511 PCT/US2007/068401 -41 one of ordinary skill in the art to evaluate nucleotide modifications for their ability to increase the melting temperature of an RNA:DNA duplex. 4. Identity Antisense compounds, or a portion thereof, may have a defined percent identity to a SEQ ID NO, 5 or a compound having a specific Isis number. As used herein, a sequence is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, an RNA which contains uracil in place of thymidine in the disclosed sequences of the compounds described herein would be considered identical as they both pair with adenine. This identity may be over the entire length of the oligomeric compound, or in a portion of the antisense compound (e.g., nucleobases 1-20 of a 27-mer may 10 be compared to a 20-mer to determine percent identity of the oligomeric compound to the SEQ ID NO. It is understood by those skilled in the art that an antisense compound need not have an identical sequence to those described herein to function similarly to the antisense compound described herein. Shortened versions of antisense compounds taught herein, or non-identical versions of the antisense compounds taught herein, are also provided herein. Non-identical versions are those wherein each base does not have 15 the same pairing activity as the antisense compounds disclosed herein. Bases do not have the same pairing activity by being shorter or having at least one abasic site. Alternatively, a non-identical version can include at least one base replaced with a different base with different pairing activity (e.g., G can be replaced by C, A, or T). Percent identity is calculated according to the number of bases that have identical base pairing corresponding to the SEQ ID NO or antisense compound to which it is being 20 compared. The non-identical bases may be adjacent to each other, dispersed through out the oligonucleotide, or both. For example, a 16-mer having the same sequence as nucleobases 2-17 of a 20-mer is 80% identical to the 20-mer. Alternatively, a 20-mer containing four nucleobases not identical to the 20-mer is also 80% identical to the 20-mer. A 14-mer having the same sequence as nucleobases 1-14 of an 18-mer 25 is 78% identical to the 18-mer. Such calculations are well within the ability of those skilled in the art. The percent identity is based on the percent of nucleobases in the original sequence present in a portion of the modified sequence. Therefore, a 30 nucleobase antisense compound comprising the full sequence of the complement of a 20 nucleobase active target segment would have a portion of 100% identity with the complement of the 20 nucleobase active target segment, while further comprising an 30 additional 10 nucleobase portion. In the context of the instant description, the complement of an active target segment may constitute a single portion. In preferred embodiments, the oligonucleotides provided herein are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to at least a portion of the complement of the active target segments presented herein. 35 E. Target Nucleic Acids, Regions and Segments In certain embodiments, short antisense compounds may be designed to target any target nucleic WO 2007/146511 PCT/US2007/068401 -42 acid. In certain embodiments, the target nucleic acid encodes a target that is clinically relevant. In such embodiments, modulation of the target nucleic acid results in clinical benefit. Certain target nucleic acids include, but are not limited to, the target nucleic acids illustrated in Table 1. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding ApoB. 5 Nucleic acid molecules that encode ApoB include, without limitation, SEQ ID NO: 1 and SEQ ID NO: 2. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding SGLT2. Nucleic acid molecules that encode SGLT2 include, without limitation, SEQ ID NO: 3. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding PCSK9. Nucleic acid molecules that encode PCSK9 include, without limitation, SEQ ID NO: 4. 10 In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding SOD 1. Nucleic acid molecules that encode SODI include, without limitation, SEQ ID NO: 5. In certain embodiments, a target nucleic acid-is a nucleic acid molecule encoding CRP. Nucleic acid molecules that encode CRP include, without limitation, SEQ ID NO: 6. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding GCCR. 15 Nucleic acid molecules that encode GCCR include, without limitation, SEQ ID NO: 7 and SEQ ID NO: 8. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding GCGR. Nucleic acid molecules that encode GCGR include, without limitation, SEQ ID NO: 9. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding DGAT2. 20 Nucleic acid molecules that encode DGAT2 include, without limitation, SEQ ID NO: 10. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding PTPIB. Nucleic acid molecules that encode PTP1B include, without limitation, SEQ ID NO: 11 and SEQ ID NO: 12. In certain embodiments, a target nucleic acid is a nucleic acid molecule encoding PTEN. 25 Nucleic acid molecules that encode PTEN include, without limitation, SEQ ID NO: 14 or SEQ ID NO: 15. Table 1: Certain Target Nucleic Acids Target Species GENBANK@ Accession Number S NO ApoB Human NM_000384.1 1 ApoB Mouse XM_137955.5 2 SGLT2 Human NM_003041.1 3 PCSK9 Human NM 174936.2 4 SODI Human X02317.1 5 CRP Human NM_000567.1 6 GCCR Mouse BC031885.1 7 GCCR Human Nucleotides 1 to 10600 of AC012634 8 GCGR Human NM 000160.1 9 DGAT2 Human NM 032564.2 10 WO 2007/146511 PCT/US2007/068401 -43 PTPlB Human NM_002827.2 11 PTPlB Human Nucleotides 1417800 to 1425600 of 12 NT 011362.9 PTEN Mouse U92437.1 13 PTEN Human NM 000314.4 14 PTEN Human Nucleotides 8063255 to 8167140 of 15 PTEN Hua NT 033890.3 15 The targeting process usually includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect will result. In certain embodiments, the 5'-most nucleotide of a target region is the 5' target site of a short 5 antisense compound and the 3'-most nucleotide of a target region is the 3' target site of the same short antisense compound. In certain embodiments, the 5'-most nucleotide of a target region is the 5' target site of a short antisense compound and the 3'-most nucleotide of a target region is the 3' target site of a different short antisense compound. In certain embodiments, a target region comprises a nucleotide sequence within 10, 15, or 20 nucleotides of a 5' target site or a 3' target site. 10 In certain embodiments, a target region is a structurally defined region of the nucleic acid. For example, in certain such embodiments, a target region may encompass a 3' UTR, a 5' UTR, an exon, an intron, a coding region, a translation initiation region, translation termination region, or other defined nucleic acid region. The locations on the target nucleic acid defined by having one or more active short antisense 15 compounds targeted thereto are referred to as "active target segments." In certain embodiments, the target nucleic acid having one or more active short antisense compounds targeted thereto is a target RNA. When an active target segment is defined by multiple short antisense compounds, the compounds are preferably separated by no more than about 10 nucleotides on the target sequence, more preferably no more than about 5 nucleotides on the target sequence, even more preferably the short antisense 20 compounds are contiguous, most preferably the short antisense compounds are overlapping. There may be substantial variation in activity (e.g., as defined by percent inhibition) of the short antisense compounds within an active target segment. Active short antisense compounds are those that modulate the expression of their target nucleic acid, including but not limited to a target RNA. Active short antisense compounds inhibit expression of their target RNA at least 10%, preferably 20%. In a preferred 25 embodiment, at least about 50%, preferably about 70% of the short antisense compounds targeted to the active target segment modulate expression of their target RNA at least 40%. In a more preferred embodiment, the level of inhibition required to define an active short antisense compound is defined based on the results from the screen used to define the active target segments. A suitable target segment is at least about an 8-nucleobase portion of a target region to which an 30 active short antisense compound is targeted. Target segments can include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative target segments (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning WO 2007/146511 PCT/US2007/068401 -44 immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA comprises about 8 to about 16 nucleobases). Target segments are also represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative target segments (the remaining nucleobases being a consecutive stretch of the same DNA or 5 RNA beginning immediately downstream of the 3'-terminus of the target segment and continuing until the DNA or RNA comprises about 8 to about 16 nucleobases). It is also understood that antisense target segments may be represented by DNA or RNA sequences that comprise at least 8 consecutive nucleobases from an internal portion of the sequence of an illustrative target segment, and may extend in either or both directions until the short antisense compound comprises about 8 to about 16 nucleobases. 10 One having skill in the art armed with the target segments illustrated herein will be able, without undue experimentation, to identify further target segments. Once one or more target regions, segments or sites have been identified, short antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect. 15 The short antisense compounds may also be targeted to regions of the target nucleobase sequence comprising any consecutive nucleobases 8 to 16 nucleobases in length along the target nucleic acid molecule. Target segments 8-16 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative target segments are considered to be suitable 20 for targeting as well. Thus, the short antisense compounds may also encompass 8-16 nucleobases within those segments identified herein as beginning at a particular 5' target site. Any segment of 8, 9, 10, 11, or more preferably 12, 13, 14, 15 or 16 contiguous nucleobases in a 50, preferably 25, more preferably 16 nucleobase perimeter around these regions are also considered to be suitable for targeting. In a further embodiment, the "suitable target segments" identified herein may be employed in a 25 screen for additional short antisense compounds that modulate the expression of a target nucleic acid. "Modulators" are those compounds that decrease or increase the expression of a target nucleic acid and which comprise at least an 8-nucleobase portion which is complementary to a target segment. The screening method comprises the steps of contacting a target segment of a nucleic acid with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the 30 expression of a target nucleic acid. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a target nucleic acid, the modulator may then be employed in further investigative studies of the function of the target, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention. For all short antisense compounds discussed herein, sequence, monomer, monomeric 35 modification, and monomeric linkage may each be selected independently. In certain embodiments, short antisense compounds are described by a motif. In such embodiments, any motif may be used with any sequence, whether or not the sequence and/or the motif is specifically disclosed herein. In certain WO 2007/146511 PCT/US2007/068401 -45 embodiments, short antisense compounds comprise modifications that are not amenable to description by motif (for example, short antisense compounds comprising several different modifications and/or linkages at various positions throughout the compound). Such combinations may be incorporated for any sequence, whether or not it is disclosed herein. The sequence listing accompanying this filing provides 5 certain nucleic acid sequences independent of chemical modification. Though that listing identifies each sequence as either "RNA" or "DNA" as required, in reality, those sequences may be modified with any combination of chemical modifications and/or motifs. In certain embodiments, short antisense compounds comprise at least one high-affinity modified monomer. In certain embodiments, provided are short antisense compounds targeted to nucleic acid 10 molecules encoding targets including, but not limited to, ApoB-100 (also known as APOB; Ag(x) antigen; apoB-48; apolipoprotein B; apolipoprotein B- 100; apolipoprotein B-48), GCGR (also known as glucagon receptor; GR), CRP, DGAT2, GCCR, PCSK9, PTEN, PTPlB, SGLT2, and SOD1. In certain such embodiments, such short antisense compounds are targeted to a nucleic acid molecule encoding any of those targets. 15 F. Certain Targets In certain embodiments, short antisense compounds may be designed to modulate any target. In certain embodiments, the target is clinically relevant. In such embodiments, modulation of the target results in clinical benefit. Certain targets are preferentially expressed in the kidney. Certain targets are preferentially expressed in the liver. Certain targets are associated with a metabolic disorder. Certain 20 targets are associated to a cardiovascular disorder. In certain embodiments, a target is selected from: ApoB, SGLT2, PCSK9, SODI, CRP, GCCR, GCGR, DGAT2, PTPlB, and PTEN. In certain embodiments, a target is selected from: ApoB, SGLT2, PCSK9, SOD1, CRP, GCCR, GCGR, DGAT2, and PTP lB. In certain embodiments, a target is any protein other than SGLT2. In certain embodiments, short antisense compounds exhibit liver and kidney-specific target 25 RNA reduction in vivo. Such property renders those short antisense compounds particularly useful for inhibition of many target RNAs involved in metabolic and cardiovascular diseases. Thus, provided herein are methods of treating cardiovascular or metabolic disorders by contacting said kidney or liver tissues with short antisense compounds targeted to RNAs associated with said disorders. Thus, also provided are methods for ameliorating any of a variety of metabolic or cardiovascular disease indications 30 with the short antisense compounds of the present invention. I1. ApoB ApoB (also known as apolipoprotein B-100; ApoB-100, apolipoprotein B-48; ApoB-48 and Ag(x) antigen), is a large glycoprotein that serves an indispensable role in the assembly and secretion of 35 lipids and in the transport and receptor-mediated uptake and delivery of distinct classes of lipoproteins. ApoB performs a variety of activities, from the absorption and processing of dietary lipids to the regulation of circulating lipoprotein levels (Davidson and Shelness, Annu. Rev. Nutr., 2000, 20, 169-193).

WO 2007/146511 PCT/US2007/068401 -46 This latter property underlies its relevance in terms of atherosclerosis susceptibility, which is highly correlated with the ambient concentration of ApoB-containing lipoproteins (Davidson and Shelness, Annu. Rev. Nutr., 2000, 20, 169-193). ApoB-100 is the major protein component of LDL-C and contains the domain required for interaction of this lipoprotein species with the LDL receptor. Elevated levels of 5 LDL-C are a risk factor for cardiovascular disease, including atherosclerosis. Definitions "ApoB" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. 10 "ApoB nucleic acid" means any nucleic acid encoding ApoB. For example, in certain embodiments, a ApoB nucleic acid includes, without limitation, a DNA sequence encoding ApoB, an RNA sequence transcribed from DNA encoding ApoB, and an mRNA sequence encoding ApoB. "ApoB mRNA" means an mRNA encoding ApoB. 15 ApoB Therapeutic Indications In certain embodiments, the invention provides methods of modulating the expression of ApoB in an individual comprising administering a short antisense compound targeted to an ApoB nucleic acid. In certain embodiments, the invention provides methods of treating an individual comprising administering one or more pharmaceutical compositions comprising a short antisense compound targeted 20 to an ApoB nucleic acid. In certain embodiments, the individual has hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with 25 dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. Guidelines for lipid-lowering therapy were established in 2001 by Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., Circulation, 2004, 110, 227-239). The guidelines include obtaining a complete lipoprotein profile, 30 typically after a 9 to 12 hour fast, for determination of LDL-C, total cholesterol, and HDL-C levels. According to the most recently established guidelines, LDL-C levels of 130-159 mg/dL, 160-189 mg/dL, and greater than or equal to 190 mg/dL are considered borderline high, high, and very high, respectively. Total cholesterol levels of 200-239 and greater than or equal to 240 mg/dL are considered borderline high and high, respectively. HDL-C levels of less than 40 mg/dL are considered low. 35 In certain embodiments, the individual has been identified as in need of lipid-lowering therapy. In certain such embodiments, the individual has been identified as in need of lipid-lowering therapy according to the guidelines established in 2001 by Adult Treatment Panel III (ATP III) of the National WO 2007/146511 PCT/US2007/068401 -47 Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., Circulation, 2004, 110, 227 239). In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 190 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 160 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C 5 above 130 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy has LDL C above 100 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 160 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 130 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 100 mg/dL. In certain such embodiments the 10 individual should maintain LDL-C below 70 mg/dL. In certain embodiments the invention provides methods for reducing ApoB in an individual. In certain embodiments the invention provides methods for reducing ApoB-containing lipoprotein in an individual. In certain embodiments the invention provides methods for reducing LDL-C in an individual. In certain embodiments the invention provides methods for reducing VLDL-C in an individual. In certain 15 embodiments the invention provides methods for reducing IDL-C in an individual. In certain embodiments the invention provides methods for reducing non-HDL-C in an individual. In certain embodiments the invention provides methods for reducing Lp(a) in an individual. In certain embodiments the invention provides methods for reducing serum triglyceride in an individual. In certain embodiments the invention provides methods for reducing liver triglyceride in an individual. In certain embodiments 20 the invention provides methods for reducing Ox-LDL-C in an individual. In certain embodiments the invention provides methods for reducing small LDL particles in an individual. In certain embodiments the invention provides methods for reducing small VLDL particles in an individual. In certain embodiments the invention provides methods for reducing phospholipids in an individual. In certain embodiments the invention provides methods for reducing oxidized phospholipids in an individual. 25 In certain embodiments the invention provides methods for reducing Ox-LDL-C concentration in a subject. In certain such embodiments, the reduction in ApoB, LDL-C, VLDL-C, IDL-C, total cholesterol, non-HDL-C, Lp(a), triglyerides, or Ox-LDL-C is, independently, selected from at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at 30 least 90%, at least 95%, and at least 100%. In certain such embodiments, the reduction in ApoB, LDL-C, VLDL-C, IDL-C, total cholesterol, non-HDL-C, Lp(a), triglyerides, or Ox-LDL-C is, independently, selected from at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, and at least 70%. In certain such embodiments, the reduction in ApoB, LDL-C, VLDL-C, IDL-C, total cholesterol, non-HDL C, Lp(a), triglyerides, or Ox-LDL-C is, independently, selected from at least 40%, at least 50%, at least 35 60%, and at least 70%. In certain embodiments, the invention provides method for raising HDL-C concentration in a subject.

WO 2007/146511 PCT/US2007/068401 -48 In certain embodiments, the methods provided by the present invention do not lower HDL-C. In certain embodiments, the methods provided by the present invention do not result in accumulation of lipids in the liver. In certain embodiments, the methods provided by the present invention do not cause hepatic steatosis. 5 In certain embodiments, the invention provides methods for lowering ApoB concentration in a subject while reducing side effects associated with treatment. In certain such embodiments, a side effect is liver toxicity. In certain such embodiments, a side effect is abnormal liver function. In certain such embodiments, a side effect is elevated alanine aminotransferase (ALT). In certain such embodiments, a side effect is elevated aspartate aminotransferase (AST). 10 In certain embodiments, the invention provides methods for lowering ApoB concentration in a subject who is not reaching target LDL-C levels as a result of lipid-lowering therapy. In certain such embodiments, a short antisense compound targeted to an ApoB nucleic acid is the only lipid-lowering agent administered to the subject. In certain such embodiments, the subject has not complied with recommended lipid-lowering therapy. In certain such embodiments, a pharmaceutical composition of the 15 invention is co-administered with an additional different lipid-lowering therapy. In certain such embodiments, an additional lipid-lowering therapy is LDL-apheresis. In certain such embodiments, an additional lipid-lowering therapy is a statin. In certain such embodiments, an additional lipid-lowering therapy is ezetimibe. In certain embodiments, the invention provides methods for lowering ApoB concentration in a 20 statin-intolerant subject. In certain such embodiments, the subject has creatine kinase concentration increases as a result of statin administration. In certain such embodiments, the subject has liver function abnormalities as a result of statin administration. In certain such embodiments the subject has muscle aches as a result of statin administration. In certain such embodiments the subject has central nervous system side effects as a result of statin administration. In certain embodiments, the subject has not 25 complied with recommended statin administration. In certain embodiments, the invention provides methods for lowering liver triglycerides in a subject. In certain such embodiments, the subject has elevated liver triglycerides. In certain such embodiments, the subject has steatohepatitis. In certain such embodiments, the subject has steatosis. In certain such embodiments, liver triglyceride levels are measured by magnetic resonance imaging. 30 In certain embodiments, the invention provides methods for reducing coronary heart disease risk in a subject. In certain embodiments the invention provides methods for slowing the progression of atherosclerosis in a subject. In certain such embodiments the invention provides methods for stopping the progression of atherosclerosis in a subject. In certain such embodiments the invention provides methods for reducing the size and/or prevalence of atherosclerotic plaques in a subject. In certain embodiments the 35 methods provided reduce a subject's risk of developing atherosclerosis. In certain embodiments the methods provided improve the cardiovascular outcome in a subject. In certain such embodiments improved cardiovascular outcome is the reduction of the risk of developing WO 2007/146511 PCT/US2007/068401 -49 coronary heart disease. In certain such embodiments, improved cardiovascular outcome is a reduction in the occurrence of one or more major cardiovascular events, which include, but are not limited to, death, myocardial infarction, reinfarction, stroke, cardiogenic shock, pulmonary edema, cardiac arrest, and atrial dysrhythmia. In certain such embodiments, the improved cardiovascular outcome is evidenced by 5 improved carotid intimal media thickness. In certain such embodiments, improved carotid intimal media thickness is a decrease in thickness. In certain such embodiments, improved carotid intimal media thickness is a prevention an increase of intimal media thickness. In certain embodiments a pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid is for use in therapy. In certain embodiments, the therapy is the 10 reduction of LDL-C, ApoB, VLDL-C, IDL-C, non-HDL-C, Lp(a) , serum triglyceride, liver triglyceride, Ox-LDL-C, small LDL particles, small VLDL, phospholipids, or oxidized phospholipids in an individual. In certain embodiments, the therapy is the treatment of hypercholesterolemia; non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing 15 atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. In additional embodiments, the therapy is the reduction of CHD risk. In certain the therapy is prevention of atherosclerosis. In certain 20 embodiments, the therapy is the prevention of coronary heart disease. In certain embodiments a pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid is used for the preparation of a medicament for reducing LDL-C, ApoB, VLDL-C, IDL-C, non-HDL-C, Lp(a) , serum triglyceride, liver triglyceride, Ox-LDL-C, small LDL particles, small VLDL, phospholipids, or oxidized phospholipids in an individual. In certain embodiments 25 pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid is used for the preparation of a medicament for reducing coronary heart disease risk. In certain embodiments a short antisense compound targeted to an ApoB nucleic acid is used for the preparation of a medicament for the treatment of hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial 30 hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. 35 ApoB Combination Therapies In certain embodiments, one or more pharmaceutical compositions comprising a short antisense WO 2007/146511 PCT/US2007/068401 -50 compound targeted to an ApoB nucleic acid are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain such embodiments, the one or more pharmaceutical agents are lipid-lowering agents. In certain 5 embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical 10 agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more 15 other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately. In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid 20 include lipid-lowering agents. In certain such embodiments, pharmaceutical agents that may be co administered with a pharmaceutical composition of the present invention include, but are not limited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. In certain such embodiments, the lipid-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the lipid-lowering agent is administered following administration of a 25 pharmaceutical composition of the present invention. In certain such embodiments the lipid-lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co-administered lipid-lowering agent is the same as the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is lower than the dose that would be administered if 30 the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co administered lipid-lowering agent is greater than the dose that would be administered if the lipid-lowering agent was administered alone. In certain embodiments, a co-administered lipid-lowering agent is a HMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoA reductase inhibitor is a statin. In certain such 35 embodiments the statin is selected from atorvastatin, simvastatin, pravastatin, fluvastatin, and rosuvastatin. In certain embodiments, a co-administered lipid-lowering agent is a cholesterol absorption WO 2007/146511 PCT/US2007/068401 -51 inhibitor. In certain such embodiments, cholesterol absorption inhibitor is ezetimibe. In certain embodiments, a co-administered lipid-lowering agent is a co-formulated HMG-CoA reductase inhibitor and cholesterol absorption inhibitor. In certain such embodiments the co-formulated lipid-lowering agent is ezetimibe/simvastatin. 5 In certain embodiments, a co-administered lipid-lowering agent is a microsomal triglyceride transfer protein inhibitor (MTP inhibitor). In certain embodiments, a co-administered pharmaceutical agent is a bile acid sequestrant. In certain such embodiments, the bile acid sequestrant is selected from cholestyramine, colestipol, and colesevelam. 10 In certain embodiments, a co-administered pharmaceutical agent is a nicotinic acid. In certain such embodiments, the nicotinic acid is selected from immediate release nicotinic acid, extended release nicotinic acid, and sustained release nicotinic acid. In certain embodiments, a co-administered pharmaceutical agent is a fibric acid. In certain such embodiments, a fibric acid is selected from gemfibrozil, fenofibrate, clofibrate, bezafibrate, and 15 ciprofibrate. Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid include, but are not limited to, corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory 20 agents, including, but not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen, COX-1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; 25 osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines. In certain embodiments, a pharmaceutical composition comprising a short antisense compound targeted to an ApoB nucleic acid may be administered in conjunction with a lipid-lowering therapy. In 30 certain such embodiments, a lipid-lowering therapy is therapeutic lifestyle change. In certain such embodiments, a lipid-lowering therapy is LDL apheresis. In one embodiment, the antisense compounds provided herein can be used to lower the level of apolipoprotein B-containing lipoproteins in a human subject. As used herein, "apolipoprotein B containing lipoprotein" refers to any lipoprotein that has apolipoprotein B as its protein component, and is 35 understood to include LDL, VLDL, IDL, and lipoprotein(a). LDL, VLDL, IDL and lipoprotein(a) each contain one molecule of apolipoprotein B, thus a serum apolipoprotein B measurement reflects the total number of these lipoproteins. As is known in the art, each of the aforementioned lipoproteins is WO 2007/146511 PCT/US2007/068401 -52 atherogenic. Thus, lowering one or more apolipoprotein B-containing lipoproteins in serum may provide a therapeutic benefit to a human subject. Small LDL particles are considered to be particularly atherogenic relative to large LDL particles, thus lowering small LDL particles can provide a therapeutic benefit to a human subject. Additional lipid parameters can also be determined in a subject. Reduction of 5 total cholesterol:HDL ratio or LDL:HDL ratio is a clinically desirable improvement in cholesterol ratio. Similarly, it is clinically desirable to reduce serum triglycerides in humans who exhibit elevated lipid levels. Other indications of cardiovascular disease that can be measured in a subject include serum LDL particle size; serum LDL cholesteryl ester concentration; serum LDL cholesteryl ester composition; 10 the extent of polyunsaturation of serum LDL cholesteryl esters; and serum HDL cholesterol levels. As used herein, "serum LDL particle size" refers to the classification of serum LDL particle size, which may be very small, small, medium, or large, and is typically expressed in g/pmol. In the context of the present invention, "serum LDL cholesteryl ester concentration" means the amount of cholesteryl ester present in LDL particles, and is typically measured as mg/dL. In the context of the present invention, "serum LDL 15 cholesteryl ester composition" is a measurement of the percentage of saturated, monounsaturated and polyunsaturated cholesteryl ester fatty acids present in serum LDL particles. "Polyunsaturation of serum LDL cholesteryl esters" means the percentage of polyunsaturated cholesteryl ester fatty acids in serum LDL particles. Methods of obtaining serum or plasma samples for analysis and methods of preparation of the 20 serum samples to allow for analysis are well known to those skilled in the art. With regard to measurements of lipoproteins, cholesterol, triglyceride and cholesteryl esters, the terms "serum" and "plasma" are herein used interchangeably. In another embodiment, the antisense compounds provided herein can be used to treat metabolic disorders. A variety of biomarkers can be used for evaluating metabolic disease. For example, blood 25 glucose levels can be determined by a physician or even by the patient using a commonly available test kit or glucometer (for example, the Ascensia ELITETM kit, Ascensia (Bayer), Tarrytown NY, or Accucheck, Roche Diagnostics). Glycated hemoglobin (HbAIc) can also be measured. HbAic is a stable minor hemoglobin variant formed in vivo via posttranslational modification by glucose, and it contains predominantly glycated NH 2 -terminal B-chains. There is a strong correlation between levels of HbAc 30 and the average blood glucose levels over the previous 3 months. Thus HbAc is often viewed as the "gold standard" for measuring sustained blood glucose control (Bunn, H.F. et al., 1978, Science. 200, 21-7). HbA can be measured by ion-exchange HPLC or immunoassay; home blood collection and mailing kits for lbA 1 measurement are now widely available. Serum fructosamine is another measure of stable glucose control and can be measured by a colorimetric method (Cobas Integra, Roche 35 Diagnostics). Certain Short Antisense Compounds Targeted to an ApoB Nucleic Acid WO 2007/146511 PCT/US2007/068401 -53 In certain embodiments, short antisense compounds are targeted to an ApoB nucleic acid having the sequence of GENBANK@ Accession No. NM_000384.1, incorporated herein as SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 1 is at least 90% complementary to SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to 5 SEQ ID NO: 1 is at least 95% complementary to SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 1 is 100% complementary to SEQ ID NO: 1. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 1 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Table 2 and Table 3. The nucleotide sequence set forth in each SEQ ID NO in Tables 2 and 3 is independent of any 10 modification to a sugar moiety, a monomeric linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. 15 Tables 2 and 3 illustrate examples of short antisense compounds targeted to SEQ ID NO: 1. Table 2 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 1. Table 3 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 1. The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment 20 comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is 25 listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. Table 2: Short Antisense Compounds targeted to SEQ ID NO: 1 5' 3' ISIS Target Target SEQ No Site Site Sequence (5'-3') Gapmer Motif ID NO 372816 263 278 CCGGAGGTGCTTGAAT 3-10-3 MOE 16 372894 264 277 CGGAGGTGCTTGAA 2-10-2 MOE 17 372817 428 443 GAAGCCATACACCTCT 3-10-3 MOE 18 372895 429 442 AAGCCATACACCTC 2-10-2 MOE 19 372818 431 446 GTTGAAGCCATACACC 3-10-3 MOE 20 372896 432 445 TTGAAGCCATACAC 2-10-2 MOE 21 372819 438 453 CCTCAGGGTTGAAGCC 3-10-3 MOE 22 372897 439 452 CTCAGGGTTGAAGC 2-10-2 MOE 23 372820 443 458 TTTGCCCTCAGGGTTG 3-10-3 MOE 24 WO 2007/146511 PCT/US2007/068401 -54 372898 444 457 TTGCCCTCAGGGTT 2-10-2 MOE 25 372821 468 483 AGTTCTTGGTTTTCTT 3-10-3 MOE 26 372899 469 482 GTTCTTGGTTTTCT 2-10-2 MOE 27 372822 587 602 CCTCTTGATGTTCAGG 3-10-3 MOE 28 372900 588 601 CTCTTGATGTTCAG 2-10-2 MOE 29 372823 592 607 ATGCCCCTCTTGATGT 3-10-3 MOE 30 372901 593 606 TGCCCCTCTTGATG 2-10-2 MOE 31 346583 715 728 TGCCACATTGCCCT 3-8-3 MOE 32 346584 716 729 TTGCCACATTGCCC 3-8-3 MOE 33 346585 717 730 GTTGCCACATTGCC 3-8-3 MOE 34 346586 718 731 TGTTGCCACATTGC 3-8-3 MOE 35 346587 719 732 CTGTTGCCACATTG 3-8-3 MOE 36 346588 720 733 TCTGTTGCCACATT 3-8-3 MOE 37 346589 721 734 TTCTGTTGCCACAT 3-8-3 MOE 38 346590 722 735 TTTCTGTTGCCACA 3-8-3 MOE 39 346591 723 736 ATTTCTGTTGCCAC 3-8-3 MOE 40 372824 929 944 GTAGGAGAAAGGCAGG- 3-10-3 MOE 41 372902 930 943 TAGGAGAAAGGCAG 2-10-2 MOE 42 372825 1256 1271 GGCTTGTAAAGTGATG 3-10-3 MOE 43 372903 1257 1270 GCTTGTAAAGTGAT 2-10-2 MOE 44 372826 1304 1319 CCACTGGAGGATGTGA 3-10-3 MOE 45 372904 1305 1318 CACTGGAGGATGTG 2-10-2 MOE 46 372829 2135 2150 TTTCAGCATGCTTTCT 3-10-3 MOE 47 372907 2136 2149 TTCAGCATGCTTTC 2-10-2 MOE 48 372832 2774 2789 CATATTTGTCACAAAC 3-10-3 MOE 49 372910 2775 2788 ATATTTGTCACAAA 2-10-2 MOE 50 372833 2779 2794 ATGCCCATATTTGTCA 3-10-3 MOE 51 372911 2780 2793 TGCCCATATTTGTC 2-10-2 MOE 52 372835 2961 2976 TTTTGGTGGTAGAGAC 3-10-3 MOE 53 372913 2962 2975 TTTGGTGGTAGAGA 2-10-2 MOE 54 346592 3248 3261 TCTGCTTCGCACCT 3-8-3 MOE 55 346593 3249 3262 GTCTGCTTCGCACC 3-8-3 MOE 56 346594 3250 3263 AGTCTGCTTCGCAC 3-8-3 MOE 57 346595 3251 3264 CAGTCTGCTTCGCA 3-8-3 MOE 58 346596 3252 3265 TCAGTCTGCTTCGC 3-8-3 MOE 59 346597 3253 3266 CTCAGTCTGCTTCG 3-8-3 MOE 60 346598 3254 3267 CCTCAGTCTGCTTC 3-8-3 MOE 61 346599 3255 3268 GCCTCAGTCTGCTT 3-8-3 MOE 62 346600 3256 3269 AGCCTCAGTCTGCT 3-8-3 MOE 63 372836 3350 3365 AACTCTGAGGATTGTT 3-10-3 MOE 64 372914 3351 3364 ACTCTGAGGATTGT 2-10-2 MOE 65 372837 3355 3370 TCATTAACTCTGAGGA 3-10-3 MOE 66 372915 3356 3369 CATTAACTCTGAGG 2-10-2 MOE 67 372838 3360 3375 ATTCATCATTAACTCT 3-10-3 MOE 68 372916 3361 3374 TTCATCATTAACTC 2-10-2 MOE 69 372839 3409 3424 TTGTTCTGAATGTCCA 3-10-3 MOE 70 3-10-3 Methyleneoxy BNA Unmodified 387461 3409 3424 TTGTTCTGAATGTCCA cytosines in gap 70 3-10-3 Methyleneoxy 380147 3409 3424 TTGTTCTGAATGTCCA BNA 70 372917 3410 3423 TGTTCTGAATGTCC 2-10-2 MOE 73 372840 3573 3588 CAGATGAGTCCATTTG 3-10-3 MOE 74 WO 2007/146511 PCT/US2007/068401 -55 372918 3574 3587 AGATGAGTCCATTT 2-10-2 MOE 75 372841 3701 3716 ATCCACAGGGAAATTG 3-10-3 MOE 76 372919 3702 3715 TCCACAGGGAAATT 2-10-2 MOE 77 372843 4219 4234 CAGTTGTACAAGTTGC 3-10-3 MOE 78 372921 4220 4233 AGTTGTACAAGTTG 2-10-2 MOE 79 372844 4301 4316 CACAGAGTCAGCCTTC 3-10-3 MOE 80 372922 4302 4315 ACAGAGTCAGCCTT 2-10-2 MOE 81 372845 4308 4323 GGTCAACCACAGAGTC 3-10-3 MOE 82 372923 4309 4322 GTCAACCACAGAGT 2-10-2 MOE 83 346601 5588 5601 CAGCCACATGCAGC 3-8-3 MOE 84 346602 5589 5602 CCAGCCACATGCAG 3-8-3 MOE 85 346603 5590 5603 ACCAGCCACATGCA 3-8-3 MOE 86 346604 5591 5604 TACCAGCCACATGC 3-8-3 MOE 87 346605 5592 5605 TTACCAGCCACATG 3-8-3 MOE 88 346606 5593 5606 GTTACCAGCCACAT 3-8-3 MOE 89 346607 5594 5607 GGTTACCAGCCACA 3-8-3 MOE 90 346608 5595 5608 AGGTTACCAGCCAC 3-8-3 MOE 91 346609 5596 5609 TAGGTTACCAGCCA 3-8-3 MOE 92 372851 5924 5939 AGGTTCTGCTTTCAAC 3-10-3 MOE 93 372929 5925 5938 GGTTCTGCTTTCAA 2-10-2 MOE 94 372854 6664 6679 TACTGATCAAATTGTA 3-10-3 MOE 95 372932 6665 6678 ACTGATCAAATTGT 2-10-2 MOE 96 372855 6908 6923 TTTTTCTTGTATCTGG 3-10-3 MOE 97 372933 6909 6922 TTTTCTTGTATCTG 2-10-2 MOE 98 372856 7190 7205 ATCCATTAAAACCTGG 3-10-3 MOE 99 372934 7191 7204 TCCATTAAAACCTG 2-10-2 MOE 100 372858 7817 7832 ATATTGCTCTGCAAAG 3-10-3 MOE 101 372936 7818 7831 TATTGCTCTGCAAA 2-10-2 MOE 102 346610 7818 7831 TATTGCTCTGCAAA 3-8-3 MOE 102 346611 7819 7832 ATATTGCTCTGCAA 3-8-3 MOE 104 346612 7820 7833 AATATTGCTCTGCA 3-8-3 MOE 105 346613 7821 7834 GAATATTGCTCTGC 3-8-3 MOE 106 346614 7822 7835 AGAATATTGCTCTG 3-8-3 MOE 107 346615 7823 7836 TAGAATATTGCTCT 3-8-3 MOE 108 346616 7824 7837 ATAGAATATTGCTC 3-8-3 MOE 109 346617 7825 7838 GATAGAATATTGCT 3-8-3 MOE 110 346618 7826 7839 GGATAGAATATTGC 3-8-3 MOE 111 372859 7995 8010 ATGGAATCCTCAAATC 3-10-3 MOE 112 372937 7996 8009 TGGAATCCTCAAAT 2-10-2 MOE 113 372861 8336 8351 GAATTCTGGTATGTGA 3-10-3 MOE 114 372939 8337 8350 AATTCTGGTATGTG 2-10-2 MOE 115 372862 8341 8356 AGCTGGAATTCTGGTA 3-10-3 MOE 116 372940 8342 8355 GCTGGAATTCTGGT 2-10-2 MOE 117 372863 8539 8554 TGAAAATCAAAATTGA 3-10-3 MOE 118 372941 8540 8553 GAAAATCAAAATTG 2-10-2 MOE 119 372871 9344 9359 AAACAGTGCATAGTTA 3-10-3 MOE 120 372949 9345 9358 AACAGTGCATAGTT 2-10-2 MOE 121 372872 9515 9530 TTCAGGAATTGTTAAA 3-10-3 MOE 122 372950 9516 9529 TCAGGAATTGTTAA 2-10-2 MOE 123 372875 9794 9809 TTTTGTTTCATTATAG 3-10-3 MOE 124 372953 9795 9808 TTTGTTTCATTATA 2-10-2 MOE 125 372877 10157 10172 GATGACACTTGATTTA 3-10-3 MOE 126 372955 10158 10171 ATGACACTTGATTT 2-10-2 MOE 127 WO 2007/146511 PCT/US2007/068401 -56 372878 10161 10176 GTGTGATGACACTTGA 3-10-3 MOE 128 372956 10162 10175 TGTGATGACACTTG 2-10-2 MOE 129 372879 10167 10182 TATTCAGTGTGATGAC 3-10-3 MOE 130 372957 10168 10181 ATTCAGTGTGATGA 2-10-2 MOE 131 372880 10172 10187 ATTGGTATTCAGTGTG 3-10-3 MOE 132 372958 10173 10186 TTGGTATTCAGTGT 2-10-2 MOE 133 346619 10838 10851 CCTCTAGCTGTAAG 3-8-3 MOE 134 346620 10839 10852 CCCTCTAGCTGTAA 3-8-3 MOE 135 346621 10840 10853 GCCCTCTAGCTGTA 3-8-3 MOE 136 346622 10841 10854 GGCCCTCTAGCTGT 3-8-3 MOE 137 346623 10842 10855 AGGCCCTCTAGCTG 3-8-3 MOE 138 346624 10843 10856 GAGGCCCTCTAGCT 3-8-3 MOE 139 346625 10844 10857 AGAGGCCCTCTAGC 3-8-3 MOE 140 346626 10845 10858 AAGAGGCCCTCTAG 3-8-3 MOE 141 346627 10846 10859 AAAGAGGCCCTCTA 3-8-3 MOE 142 372890 13689 13704 GAATGGACAGGTCAAT 3-10-3 MOE 143 372968 13690 13703- AATGGACAGGTCAA 2-10-2 MOE 144 372891 13694 13709 GTTTTGAATGGACAGG 3-10-3 MOE 145 372969 13695 13708 TTTTGAATGGACAG 2-10-2 MOE 146 372892 13699 13714 TGGTAGTTTTGAATGG 3-10-3 MOE 147 372970 13700 13713 GGTAGTTTTGAATG 2-10-2 MOE 148 346628 13907 13920 TCACTGTATGGTTT 3-8-3 MOE 149 346629 13908 13921 CTCACTGTATGGTT 3-8-3 MOE 150 346630 13909 13922 GCTCACTGTATGGT 3-8-3 MOE 151 346631 13910 13923 GGCTCACTGTATGG 3-8-3 MOE 152 346632 13911 13924 TGGCTCACTGTATG 3-8-3 MOE 153 346633 13912 13925 CTGGCTCACTGTAT 3-8-3 MOE 154 346634 13913 13926 GCTGGCTCACTGTA 3-8-3 MOE 155 346635 13914 13927 GGCTGGCTCACTGT 3-8-3 MOE 156 346636 13915 13928 AGGCTGGCTCACTG 3-8-3 MOE 157 346637 13963 13976 CAGGTCCAGTTCAT 3-8-3 MOE 158 346638 13964 13977 GCAGGTCCAGTTCA 3-8-3 MOE 159 346639 13965 13978 TGCAGGTCCAGTTC 3-8-3 MOE 160 346640 13966 13979 GTGCAGGTCCAGTT 3-8-3 MOE 161 346641 13967 13980 GGTGCAGGTCCAGT 3-8-3 MOE 162 346642 13968 13981 TGGTGCAGGTCCAG 3-8-3 MOE 163 346643 13969 13982 TTGGTGCAGGTCCA 3-8-3 MOE 164 346644 13970 13983 TTTGGTGCAGGTCC 3-8-3 MOE 165 346645 13971 13984 CTTTGGTGCAGGTC 3-8-3 MOE 166 346646 14051 14064 TAACTCAGATCCTG 3-8-3 MOE 167 346647 14052 14065 ATAACTCAGATCCT 3-8-3 MOE 168 346648 14053 14066 AATAACTCAGATCC 3-8-3 MOE 169 346649 14054 14067 AAATAACTCAGATC 3-8-3 MOE 170 346650 14055 14068 AAAATAACTCAGAT 3-8-3 MOE 171 346651 14056 14069 CAAAATAACTCAGA 3-8-3 MOE 172 346652 14057 14070 GCAAAATAACTCAG 3-8-3 MOE 173 346653 14058 14071 AGCAAAATAACTCA 3-8-3 MOE 174 346654 14059 14072 TAGCAAAATAACTC 3-8-3 MOE 175 Table 3: Short antisense compounds targeted to SEQ ID NO: 1 and having 1 or 2 mismatches 5' 3' SEQ Isis Target Target ID NO. Site Site Sequence (5'-3') Gapmer Motif NO WO 2007/146511 PCT/US2007/068401 -57 372894 771 784 CGGAGGTGCTTGAA 2-10-2 MOE 17 372905 1111 1124 CAGGGCCTGGAGAG 2-10-2 MOE 176 346628 1493 1506 TCACTGTATGGTTT 3-8-3 MOE 149 372828 2006 2021 TCTGAAGTCCATGATC 3-10-3 MOE 177 372906 2007 2020 CTGAAGTCCATGAT 2-10-2 MOE 178 372830 2382 2397 TGGGCATGATTCCATT 3-10-3 MOE 179 372908 2383 2396 GGGCATGATTCCAT 2-10-2 MOE 180 346616 3162 3175 ATAGAATATTGCTC 3-8-3 MOE 109 346617 3163 3176 GATAGAATATTGCT 3-8-3 MOE 110 372929 3513 3526 GGTTCTGCTTTCAA 2-10-2 MOE 94 372946 3800 3813 TGGAGCCCACGTGC 2-10-2 MOE 181 372904 4040 4053 CACTGGAGGATGTG 2-10-2 MOE 46 372842 4084 4099 TTGAAGTTGAGGGCTG 3-10-3 MOE 182 372920 4085 4098 TGAAGTTGAGGGCT 2-10-2 MOE 183 346586 4778 4791 TGTTGCCACATTGC 3-8-3 MOE 35 372847 5030 5045 ACCAGTATTAATTTTG 3-10-3 MOE 184 372925 5031 5044 CCAGTATTAATTTT 2-10-2 MOE 185 372848 5192 5207 GTGTTCTTTGAAGCGG 3-10-3 MOE 186 372926 5193 5206 TGTTCTTTGAAGCG 2-10-2 MOE 187 372953 5625 5638 TTTGTTTCATTATA 2-10-2 MOE 125 372935 7585 7598 AGTTACTTTGGTGT 2-10-2 MOE 188 372860 8255 8270 TGGTACATGGAAGTCT 3-10-3 MOE 189 372938 8256 8269 GGTACATGGAAGTC 2-10-2 MOE 190 391260 8256 8269 GGTACATGGAAGTC 2-10-2 MOE 190 392068 8256 8269 GGTACATGGAAGTC 2-10-2 MOE 190 2-10-2 Methyleneoxy 387462 8256 8269 GGTACATGGAAGTC BNA 190 1-1-10-2 2' (butylacetomido) palmitamide Methyleneoxy BNA/Methyleneoxy BNA Unmodified cytosines in 391872 8256 8269 GGTACATGGAAGTC gap 190 2-10-2 Methyleneoxy 380148 8256 8269 GGTACATGGAAGTC BNA 190 1-1-10-2 2' (butylacetomido) palmitamide/MOE/MOE Unmodified cytosines in 391871 8256 8269 GGTACATGGAAGTC gap 190 2-10-2 ENA 391755 8256 8269 GGTACATGGAAGTC mC in wing only 190 2-10-2 (6'S)-6'-methyl Methyleneoxy BNA 398296 8256 8269 GGTACATGGAAGTC Unmodified Cytosines 190 372942 8455 8468 TCCATGCCATATGT 2-10-2 MOE 200 372865 8888 8903 CCCTGAAGAAGTCCAT 3-10-3 MOE 201 372943 8889 8902 CCTGAAGAAGTCCA 2-10-2 MOE 202 372866 8908 8923 GCCCAGTTCCATGACC 3-10-3 MOE 203 372944 8909 8922 CCCAGTTCCATGAC 2-10-2 MOE 204 372867 9058 9073 TTGAGGAAGCCAGATT 3-10-3 MOE 205 372945 9059 9072 TGAGGAAGCCAGAT 2-10-2 MOE 206 WO 2007/146511 PCT/US2007/068401 -58 372870 9261 9276 TGGATGCAGTAATCTC 3-10-3 MOE 207 372948 9262 9275 GGATGCAGTAATCT 2-10-2 MOE 208 372881 10185 10200 TATAAAGTCCAGCATT 3-10-3 MOE 209 372959 10186 10199 ATAAAGTCCAGCAT 2-10-2 MOE 210 372882 10445 10460 AAGTTCCTGCTTGAAG 3-10-3 MOE 211 372960 10446 10459 AGTTCCTGCTTGAA 2-10-2 MOE 212 372964 11451 11464 AATGGTGAAGTACT 2-10-2 MOE 213 346612 13459 13472 AATATTGCTCTGCA 3-8-3 MOE 105 346613 13460 13473 GAATATTGCTCTGC 3-8-3 MOE 106 In certain embodiments, a target region is nucleotides 263-278 of SEQ ID NO: 1. In certain such embodiments, short antisense compounds targeted to nucleotides 263-278 of SEQ ID NO: 1 comprise a nucleotide sequence selected from SEQ ID NO: 16 or 17. In certain such embodiments, a short antisense 5 compound targeted to nucleotides 263-278 of SEQ ID NO: 1 is selected from Isis NO. 372816 or 372894. In certain embodiments, a target region is nucleotides 428-483 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 428-483 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27. In certain such embodiments, a short antisense compound targeted to nucleotides 428-483 of SEQ ID NO: I is selected 10 from Isis NO. 372817, 372895, 372818, 372896, 372819, 372897, 372820, 372898, 372821, or 372899. In certain embodiments, a target region is nucleotides 428-458 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 428-458 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 18, 19, 20, 21, 22, 23, 24, or 25. In certain such embodiments, a short antisense compound targeted to nucleotides 428-458 of SEQ ID NO: 1 is selected 15 from Isis NO. 372817, 372895, 372818, 372896, 372819, 372897, 372820, or 372898. In certain embodiments, a target region is nucleotides 468-483 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 468-483 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 26 or 27. In certain such embodiments, a short antisense compound targeted to nucleotides 468-483 of SEQ ID NO: 1 is selected from Isis NO. 372821 or 372899. 20 In certain embodiments, a target region is nucleotides 587-607 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 587-607 of SEQ ID NO: I comprises a nucleotide sequence selected from SEQ ID NO 28, 29, 30, or 31. In certain such embodiments, a short antisense compound targeted to nucleotides 587-607 of SEQ ID NO: 1 is selected from ISIS NO. 372822, 372900, 372823, or 372901. 25 In certain embodiments, a target region is nucleotides 715-736 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 715-736 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 32, 33, 34, 35, 36, 37, 38, 39, or 40. In certain such embodiments, a short antisense compound targeted to nucleotides 715-736 of SEQ ID NO: 1 is selected from Isis NO. 346583, 346584, 346585, 346586, 346587, 346588, 346589, 346590, or 346591. 30 In certain embodiments, a target region is nucleotides 929-944 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 929-944 of SEQ ID NO: 1 comprises a WO 2007/146511 PCT/US2007/068401 -59 nucleotide sequence selected from SEQ ID NO 41 or 42. In certain such embodiments, a short antisense compound targeted to nucleotides 929-944 of SEQ ID NO: 1 is selected from Isis NO. 372824 or 372902. In certain embodiments, a target region is nucleotides 1256-1319 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 1256-1319 of SEQ ID NO: 1 5 comprises a nucleotide sequence selected from SEQ ID NO 43, 44, 45, or 46. In certain such embodiments, a short antisense compound targeted to nucleotides 1256-1319 of SEQ ID NO: 1 is selected from Isis NO. 372825, 372903, 372826, or 372904. In certain embodiments, a target region is nucleotides 1256-1271 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 1256-1271 of SEQ ID NO: I 10 comprises a nucleotide sequence selected from SEQ ID NO 43 or 44. In certain such embodiments, a short antisense compound targeted to nucleotides 1256-1271 of SEQ ID NO: 1 is selected from Isis NO. 372825 or 372903. In certain embodiments, a target region is nucleotides 1304-1319 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 1304-1319 of SEQ ID NO: 1 15 comprises a nucleotide sequence selected from SEQ ID NO 45 or 46. In certain such embodiments, a short antisense compound targeted to nucleotides 1304-1319 of SEQ ID NO: 1 is selected from Isis NO. 372826 or 372904. In certain embodiments, a target region is nucleotides 2135-2150 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 2135-2150 of SEQ ID NO: 1 20 comprises a nucleotide sequence selected from SEQ ID NO 47 or 48. In certain such embodiments, a short antisense compound targeted to nucleotides 2135-2150 of SEQ ID NO: 1 is selected from ISIS NO. 372829 or 372907. In certain embodiments, a target region is nucleotides 2774-2794 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 2774-2794 of SEQ ID NO: 1 25 comprises a nucleotide sequence selected from SEQ ID NO 49, 50, 51, or 52. In certain such embodiments, a short antisense compound targeted to nucleotides 2774-2794 of SEQ ID NO: 1 is selected from ISIS NO. 372832, 372910, 372833, or 372911. In certain embodiments, a target region is nucleotides 2961-2976 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 2961-2976 of SEQ ID NO: 1 30 comprises a nucleotide sequence selected from SEQ ID NO 53 or 54. In certain such embodiments, a short antisense compound targeted to nucleotides 2961-2976 of SEQ ID NO: 1 is selected from ISIS NO. 372835 or 372913. In certain embodiments, a target region is nucleotides 3248-3269 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 3248-3269 of SEQ ID NO: 1 35 comprises a nucleotide sequence selected from SEQ ID NO 55, 56, 57, 58, 59, 60, 61, 62, or 63. In certain such embodiments, a short antisense compound targeted to nucleotides 3248-3269 of SEQ ID NO: 1 is selected from ISIS NO. 346592, 346593, 346594, 346595, 346596, 346597, 346598, 346599, or 346600.

WO 2007/146511 PCT/US2007/068401 -60 In certain embodiments, a target region is nucleotides 3350-3375 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 3350-3375 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 64, 65, 66, 67, 68, or 69. In certain such embodiments, a short antisense compound targeted to nucleotides 3350-3375 of SEQ ID NO: 1 is selected 5 from ISIS NO. 372836, 372914, 372837, 372915, 372838, or 372916. In certain embodiments, a target region is nucleotides 3409-3424 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 3409-3424 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 70 or 73. In certain such embodiments, a short antisense compound targeted to nucleotides 3409-3424 of SEQ ID NO: 1 is selected from ISIS NO. 10 372839,387461,380147,or372917. In certain embodiments, a target region is nucleotides 3573-3588 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 3573-3588 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 74 or 75. In certain such embodiments, a short antisense compound targeted to nucleotides 3573-3588 of SEQ ID NO: 1 is selected from ISIS NO. 15 372840 or 372918. In certain embodiments, a target region is nucleotides 3701-3716 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 3701-3716 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 76 or 77. In certain such embodiments, a short antisense compound targeted to nucleotides 3701-3716 of SEQ ID NO: 1 is selected from ISIS NO. 20 372841 or 372919. In certain embodiments, a target region is nucleotides 4219-4234 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 4219-4234 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 78 or 79. In certain such embodiments, a short antisense compound targeted to nucleotides 4219-4234 of SEQ ID NO: 1 is selected from ISIS NO. 25 372843 or 372921. In certain embodiments, a target region is nucleotides 4301-4323 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 4301-4323 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 80, 81, 82, or 83. In certain embodiments, a short antisense compound targeted to nucleotides 4301-4323 of SEQ ID NO: 1 is selected from ISIS NO. 30 372844,372922,372845,or372923. In certain embodiments, a target region is nucleotides 5588-5609 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 5588-5609 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 84, 85, 86, 87, 88, 89, 90, 91, or 92. In certain such embodiments, a short antisense compound targeted to nucleotides 5588-5609 of SEQ ID NO: 1 is 35 selected from ISIS NO. 346601, 346602, 346603, 346604, 346605, 346606, 346607, 346608, or 346609. In certain embodiments, a target region is nucleotides 5924-5939 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 5924-5939 of SEQ ID NO: 1 WO 2007/146511 PCT/US2007/068401 -61 comprises a nucleotide sequence selected from SEQ ID NO 93 or 94. In certain such embodiments, a short antisense compound targeted to nucleotides 5924-5939 of SEQ ID NO: 1 is selected from ISIS NO. 372851 or 372929. In certain embodiments, a target region is nucleotides 6664-6679 of SEQ ID NO: 1. In certain 5 such embodiments, a short antisense compound targeted to nucleotides 6664-6679 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 95 or 96. In certain such embodiments, a short antisense compound targeted to nucleotides 6664-6679 of SEQ ID NO: 1 is selected from ISIS NO. 372854 or 372932. In certain embodiments, a target region is nucleotides 6908-6923 of SEQ ID NO: 1. In certain 10 such embodiments, a short antisense compound targeted to nucleotides 6908-6923 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 97 or 98. In certain such embodiments, a short antisense compound targeted to nucleotides 6908-6923 of SEQ ID NO: 1 is selected from ISIS NO. 372855 or 372933. In certain embodiments, a target region is nucleotides 7190-7205 of SEQ ID NO: 1. In certain 15 such embodiments, a short antisense compound targeted to nucleotides 7190-7205 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 99 or 100. In certain such embodiments, a short antisense compound targeted to nucleotides 7190-7205 of SEQ ID NO: 1 is selected from ISIS NO. 372856 or 372934. In certain embodiments, a target region is nucleotides 7817-7839 of SEQ ID NO: 1. In certain 20 such embodiments, a short antisense compound targeted to nucleotides 7817-7839 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 101, 102, 104, 105, 106, 107, 108, 109, 110, or 111. In certain such embodiments, a short antisense compound targeted to nucleotides 7817-7839 of SEQ ID NO: 1 is selected from ISIS NO. 372858, 372936, 346610, 346611, 346612, 346613, 346614, 346615, 346616, 346617, or 346618. 25 In certain embodiments, a target region is nucleotides 7995-8010 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 7995-8010 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 112 or 113. In certain such embodiments, a short antisense compound targeted to nucleotides 7995-8010 of SEQ ID NO: 1 is selected from ISIS NO. 372859 or 372937. 30 In certain embodiments, a target region is nucleotides 8336-8356 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 8336-8356 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 114, 115, 116, or 117. In certain such embodiments, a short antisense compound targeted to nucleotides 8336-8356 of SEQ ID NO: 1 is selected from ISIS NO. 372861, 372939, 372862, or 372940. 35 In certain embodiments, a target region is nucleotides 8539-8554 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 8539-8554 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 118 or 119. In certain such embodiments, a WO 2007/146511 PCT/US2007/068401 -62 short antisense compound targeted to nucleotides 8539-8554 of SEQ ID NO: 1 is selected from ISIS NO. 372863 or 372941. In certain embodiments, a target region is nucleotides 9344-9359 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 9344-9359 of SEQ ID NO: 1 5 comprises a nucleotide sequence selected from SEQ ID NO 120 or 121. In certain such embodiments, a short antisense compound targeted to nucleotides 9344-9359 of SEQ ID NO: 1 is selected from ISIS NO. 372871 or 372949. In certain embodiments, a target region is nucleotides 9515-9530 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 9515-9530 of SEQ ID NO: 1 10 comprises a nucleotide sequence selected from SEQ ID NO 122 or 123. In certain such embodiments, a short antisense compound targeted to nucleotides 9515-9530 of SEQ ID NO: 1 is selected from ISIS NO. 372872 or 372950. In certain embodiments, a target region is nucleotides 9794-9809 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 9794-9809 of SEQ ID NO: 1 15 comprises a nucleotide sequence selected from SEQ ID NO 124 or 125. In certain such embodiments, a short antisense compound targeted to nucleotides 9794-9809 of SEQ ID NO: 1 is selected from ISIS NO. 372875 or 372953. In certain embodiments, a target region is nucleotides 10157-10187 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 10157-10187 of SEQ ID NO: 1 20 comprises a nucleotide sequence selected from SEQ ID NO 126, 127, 128, 129, 130, 131, 132, or 133. In certain such embodiments, a short antisense compound targeted to nucleotides 10157-10187 of SEQ ID NO: 1 is selected from ISIS NO. 372877, 372955, 372878, 372956, 372879, 372957, 372880, or 372958. In certain embodiments, a target region is nucleotides 10838-10859 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 10838-10859 of SEQ ID NO: 1 25 comprises a nucleotide sequence selected from SEQ ID NO 134, 135, 136, 137, 138, 139, 140, 141, or 142. In certain such embodiments, a short antisense compound targeted to nucleotides 10838-10859 of SEQ ID NO: 1 is selected from ISIS NO. 346619, 346620, 346621, 346622, 346623, 346624, 346625, 346626, or 346627. In certain embodiments, a target region is nucleotides 13689-13714 of SEQ ID NO: 1. In certain 30 such embodiments, a short antisense compound targeted to nucleotides 13689-13714 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 143, 144, 145, 146, 147, or 148. In certain such embodiments, a short antisense compound targeted to nucleotides 13689-13714 of SEQ ID NO: 1 is selected from ISIS NO. 372890, 372968, 372891, 372969, 372892, or 372970. In certain embodiments, a target region is nucleotides 13907-13928 of SEQ ID NO: 1. In certain 35 such embodiments, a short antisense compound targeted to nucleotides 13907-13928 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 149, 150, 151, 152, 153, 154, 155, 156, or 157. In certain such embodiments, a short antisense compound targeted to nucleotides 13907-13928 of WO 2007/146511 PCT/US2007/068401 -63 SEQ ID NO: 1 is selected from ISIS NO. 346628, 346629, 346630, 346631, 346632, 346633, 346634, 346635, or 346636. In certain embodiments, a target region is nucleotides 13963-13984 of SEQ ID NO: 1. In certain such embodiments, a short antisense compound targeted to nucleotides 13963-13984 of SEQ ID NO: 1 5 comprises a nucleotide sequence selected from SEQ ID NO 158, 159, 160, 161, 162, 163, 164, 165, or 166. In certain such embodiments, a short antisense compound targeted to nucleotides 13963-13984 of SEQ ID NO: 1 is selected from ISIS NO. 346637, 346638, 346639, 346640, 346641, 346642, 346643, 346644, or 346645. In certain embodiments, a target region is nucleotides 14051-14072 of SEQ ID NO: 1. In certain 10 such embodiments, a short antisense compound targeted to nucleotides 14051-14072 of SEQ ID NO: 1 comprises a nucleotide sequence selected from SEQ ID NO 167, 168, 169, 170, 171, 172, 173, 174, or 175. In certain such embodiments, a short antisense compound targeted to nucleotides 14051-14072 of SEQ ID NO: 1 is selected from ISIS NO. 346646, 346647, 346648, 346649, 346650, 346651, 346652, 346653, or 346654. 15 In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense 20 oligonucleotides. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to an ApoB nucleic acid comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid comprise 1 to 3 high-affinity modifications in each 25 wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -O-2') BNA , p-D Methyleneoxy (4'-CH 2 -O-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing 30 comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, 0-C-C 10 alkyl, OCF 3 , O-(CH 2

)

2

O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , O-(CH 2

)

2 O-N(Rm)(R), and O-CH 2 C(=O)-N(Rm)(R), where each Rm and Rn is, independently, H or substituted or unsubstituted CI-Co alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid comprise a 35 gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are WO 2007/146511 PCT/US2007/068401 -64 unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid have 5 uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 8 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic 10 acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 13 monomers in length. In certain embodiments, short 15 antisense compounds targeted to an ApoB nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid 20 comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to an ApoB nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of ApoB. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to an 25 ApoB nucleic acid, wherein the short antisense compound targeted to an ApoB nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of ApoB using one or more short antisense compounds targeted to an ApoB nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. 30 In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 10 monomers in length. In certain 35 embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 12 monomers in WO 2007/146511 PCT/US2007/068401 -65 length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating ApoB comprise use 5 of a short antisense compound targeted to an ApoB nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid comprising 9 to 15 monomers. In certain 10 embodiments, methods of modulating expression of ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of ApoB comprise use of a short antisense compound targeted to an ApoB nucleic acid comprising 12 or 14 15 nucleotides or nucleosides. In certain embodiments, short antisense compounds targeting a ApoB nucleic acid may have any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a ApoB nucleic acid have a motif (wing deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8 20 3, 2-8-2, 1-8-1, 3-6-3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. 2. SGLT-2 Sodium dependent glucose transporter 2 (SGLT-2) is expressed in the kidney proximal tubule 25 epithelial cells, and functions to reabsorb glucose preventing glucose loss in the urine. For the human genome SGLT-2 is a member of an 11 -membered family of sodium substrate co-transporters. Many of these family members share sequence homology, for example SGLT-1 shares about 59% sequence identity with SGLT-2 and about 70% sequence identity with SGLT-3. SGLT-1 is a glucose transporter found in the heart and the CNS. SGLT-3 is a glucose sensing sodium channel in the small intestine. The 30 separate localization patterns for these SGLTs is one point of distinction between the homologous family members. (Handlon, A.L., Expert Opin. Ther. Patents (2005) 15(11):1532-1540; Kanai et al., J. Clin. Invest., 1994, 93, 397-404; Wells et al., Am. J. Physiol. Endocrinol. Metab., 1992, 263, F459-465). Studies of human SGLT2 injected into Xenopus oocytes demonstrated that this protein mediates sodium-dependent transport of D-glucose and .alpha.-methyl-D-glucopyranoside (.alpha.-MeGle; a 35 glucose analog) with a Km value of 1.6 mM for .alpha.-MeGlc and a sodium to glucose coupling ratio of 1:1 (Kanai et al., J. Clin. Invest., 1994, 93, 397-404; You et al., J. Biol. Chem., 1995, 270, 29365-29371). This transport activity was suppressed by phlorizin, a plant glycoside that binds to the glucose site of the WO 2007/146511 PCT/US2007/068401 -66 SGLTs but is not transported and thus inhibits SGLT action (You et al., J. Biol. Chem., 1995, 270, 29365 29371). Diabetes is a disorder characterized by hyperglycemia due to deficient insulin action. Chronic hyperglycemia is a major risk factor for diabetes-associated complications, including heart disease, 5 retinopathy, nephropathy and neuropathy. As the kidneys play a major role in the regulation of plasma glucose levels, renal glucose transporters are becoming attractive drug targets (Wright, Am. J. Physiol. Renal Physiol., 2001, 280, F10-18). Diabetic nephropathy is the most common cause of end-stage renal disease that develops in many patients with diabetes. Glucotoxicity, which results from long-term hyperglycemia, induces tissue-dependent insulin resistance in diabetic patients (Nawano et al., Am. J. 10 Physiol. Endocrinol. Metab., 2000, 278, E535-543). Definitions "Sodium dependent glucose transporter 2" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. Sodium dependent glucose transporter 2 15 is generally referred to as SGLT2 but may also be referred to as SLC5A2; sodium-glucose transporter 2; sodium-glucose cotransporter, kidney low affinity; sodium-glucose cotransporter, renal; solute carrier family 5 (sodium/glucose cotransporter), member 2; SL52. "SGLT2 nucleic acid" means any nucleic acid encoding SGLT2. For example, in certain embodiments, a SGLT2 nucleic acid includes, without limitation, a DNA sequence encoding SGLT2, an 20 RNA sequence transcribed from DNA encoding SGLT2, and an mRNA sequence encoding SGLT2. "SGLT2 mRNA" means an mRNA encoding a SGLT2 protein. Therapeutic indications In certain embodiments, short antisense compounds are used to modulate expression of SGLT-2 and related proteins. In certain embodiments, such modulation is accomplished by providing short 25 antisense compounds that hybridize with one or more target nucleic acid molecules encoding SGLT-2, including, but is not limited to, SGLT2, SL52, SLC5A2, Sodium-Glucose Co-Transporter, Kidney Low Affinity Sodium-Glucose Co-Transporter, Renal Sodium-Glucose Co-Transporter 2 and Solute Carrier Family 5 Sodium/Glucose Co-Transporter Member 2. Also provided are methods of treating metabolic and/or cardiovascular disease and disorders as described herein. In particular embodiments, 30 short antisense compounds that inhibit the expression of SGLT2 are used in methods of lowering blood glucose levels in an animal and methods of delaying or preventing the onset of type 2 diabetes. Such methods comprise administering a therapeutically or prophylactically effective amount of one or more of the compounds of the invention to the animal, which may be in need of treatment. The one or more compounds can be a short antisense compound targeting a nucleic 35 acid encoding SGLT2. Provided herein are methods of enhancing inhibition of expression of SGLT2 in kidney cells or kidney tissues, comprising contacting the cells or tissues with one or more of the compounds of the invention, such as short antisense compounds targeting a nucleic WO 2007/146511 PCT/US2007/068401 -67 acid encoding SGLT2. While certain compounds, compositions and methods have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds of the invention and are not intended to limit the same. 5 In certain embodiments, short antisense compounds are chimeric oligomeric compounds having mixed phosphorothioate and phosphodiester backbones,. Certain mixed backbone short antisense compounds have a central gap comprising at least 5 contiguous 2'-deoxy nucleosides flanked by two wings each of which comprises at least one 2'-O-methoxyethyl nucleoside. In certain embodiments, the internucleoside linkages of the mixed backbone compounds are phosphorothioate linkages in the gap and 10 phosphodiester linkages in the two wings. In certain embodiments, mixed backbone compounds have phosphorothioate linkages in the wings, except for one phosphodiester linkage at one or both of the extreme 5' and 3' ends of the oligonucleotide. In certain embodiments short antisense compounds targeted to SGLT2 have a motif (wing - deoxy gap -wing) selected from 3-10-3, 2-10-3, 2-10-2, 1-10 1,1-10-2, 2-8-2, 1-9-2, 1-8-1, 3-6-3 or 1-6-1. In certain embodiments short antisense compounds targeted 15 to SGLT2 have a motif (wing - deoxy gap -wing) selected from 1-10-1, 1-10-2, 2-8-2, 1-9-2, 1-8-1, 3-6-3 or 1-6-1. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid and having a mixed backbone are efficiently delivered to the kidney. In certain embodiments, administration of short antisense compounds targeted to an SGLT2 nucleic acid and having a mixed backbone results in 20 modulation of target gene expression in the kidney. In certain such embodiments, there is little or no liver or kidney toxicity. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid and having a mixed backbone are more potent for reducing SGLT-2 mRNA and have a faster onset compared with a short antisense compound that does not have a mixed back-bone, but is otherwise identical. In certain such embodiments, such increase potency and/or reduced toxicity is in 25 mouse and/or rat. In certain such embodiments, such increase potency and/or reduced toxicity is in a human. By way of example, and only for illustrative purposes, ISIS 145733, which comprises uniform phosphorothioate linkages and ISIS 257016 which comprises phosphodiester linkage in the wings and phosphorothioate linkages in the gap, are otherwise identical. Both comprise the sequence 30 GAAGTAGCCACCAACTGTGC (SEQ ID NO. 1572). Both of the oligonucleotides further comprise a gap consisting of ten 2'-deoxynucleotides, flanked on each side by five-nucleotide "2'-methoxyethyl (2' MOE) nucleotides. All cytidine residues are 5-methylcytidines. The mixed back-bone compound, ISIS 257016, was about 50 times more potent for reducing SGLT-2 mRNA compared to the non-mixed parent compound, ISIS 145733 (see EXAMPLE 9). 35 Pharmacokinetic studies of certain mixed backbone compound ISIS 257016 indicate that in certain embodiments, the compound acts as a prodrug that is metabolized to a 12 nucleobase pharmacophore. Studies with ISIS 370717, a 12 nucleobase short antisense compound corresponding to WO 2007/146511 PCT/US2007/068401 -68 ISIS 257016, show that the compound has a similar pharmacological profile to ISIS 257016 but with a faster onset of action. ISIS 370717 is a 12 nucleobase antisense oligonucleotide targeted to SGLT-2 comprising the sequence TAGCCACCAACT (SEQ ID NO. 1554), further comprising a gap consisting of ten 2'-deoxynucleotides, flanked on both sides by one-nucleotide wings. The wings are composed of 5 2'-methoxyethyl (2'-MOE) nucleotides. All cytidine residues are 5-methylcytidines. The intermucleoside linkages are phosphorothioate (P=S) throughout the oligonucleotide. The similarity in pharmacological activity of ISIS 257016 and ISIS 370717 supports the pharmacokinetic studies indicating ISIS 257016 was a prodrug having a 12 nucleotide pharmacophore (see EXAMPLE 10). Further, studies with stabilized (end-capped) versions of ISIS 257016 show dramatic loss of activity. 10 In certain embodiments, short antisense compounds comprising 2' MOE monomers in the wings are efficiently delivered to the kidney and treatment with such compounds results in efficient modulation of target gene expression in the kidney without liver or kidney toxicity. It is further shown herein that in certain embodiments, short antisense compounds are more potent for reducing SGLT-2 mRNA and have a faster onset compared with parent oligonucleotides targeted to SGLT-2 mRNA in mouse and rat. 2' 15 MOE gap shortmers are shown herein to improve potency and bioavailability over parent compounds. By way of example, and only for illustrative purposes studies with ISIS 370717 reveal significantly higher accumulation of the short antisense compound in the kidney tissue (approximately 500 micro grams per gram of tissue) compared to the longer parent. Moreover, SGLT-2 mRNA was reduced by more than 80% over the controls (see EXAMPLE 11). ISIS 370717 1-10-1 gapmer was used 20 as a template to make sequence related oligos with varying motifs. Studies evaluating wing, gap and total length variations around the ISIS 370717 12 mer oligonucleotide can be seen in EXAMPLE 12. Certain motifs evaluated included 1-10-1, 2-8-2, 1-8-1, 3-6-3, and 1-6-1 (see Table 60 in EXAMPLE 12). The compounds were analyzed for their effect on SGLT2 mRNA levels. All the motifs inhibited the expression of SGLT2 in vivo in a dose-dependent manner. The 1-10-1, 2-8-2 and 1-8-1 gapmers were 25 found to be particularly potent. SGLT-2 mRNA was reduced by more than 80% over the controls using these motifs. In certain embodiments, the invention provides short antisense compounds targeted to an SGLT2 nucleic acid and having a motif selected from: 1-10-1 and 1-10-2 MOE gapmer. (see Table 62 in EXAMPLE 13). Certain such compounds were analyzed for their effect on rat SGLT2 mRNA. Results 30 in Table 63 illustrate that both the 1-10-1 and 1-10-2 MOE gapmers inhibit the expression of SGLT2 in vivo in a dose-dependent manner and over 80% reduction of SGLT-2 mRNA could be achieved. Certain additional 1-10-1 and 2-8-2 MOE gapmers were evaluated in both mouse and rat in vivo models (see, e.g., EXAMPLE 14 and 15). Greater than 80% reduction in SGLT-2 mRNA was achieved with many of the 1-10-1 and 2-8-2 MOE gapmers at relatively low concentrations of oligo and in the 35 absence of any toxicity effects. In another non-limiting example, the effect of ISIS 388625 on dog SGLT2 mRNA levels was also analyzed. Dog studies illustrate that greater than 80% inhibition of the expression of SGLT2 can be WO 2007/146511 PCT/US2007/068401 -69 achieved at a 1 mg/kg/wk dose. Even greater inhibition can be achieved at slightly higher doses. Administration of ISIS 388625 in dog was also shown to improved glucose tolerance. Peak plasma glucose levels were decreased by over 50% on average and the subsequent drop in glucose was lessened compared to saline controls in a standard glucose tolerance test (See EXAMPLE 17). Also, in a rat model 5 of diabetes, short antisense compounds were shown to significantly decrease plasma glucose levels and HbAlC over time compared to PBS and control treated animals (See Example 16). The animals in all studies were further evaluated for toxicity. For example, total body weight, liver, spleen and kidney weight were evaluated. Significant changes in spleen, liver or body weight can indicate that a particular compound causes toxic effects. All changes were found to be within the margin 10 of error. No significant changes in body weight were observed during the treatment or at study termination. No significant changes in liver or spleen weights were observed. Certain Short Antisense Compounds Targeted to an SGLT2 nucleic acid In certain embodiments, short antisense compounds are targeted to an SGLT2 nucleic acid 15 having the sequence of GENBANK@ Accession No. NM_003041.1, incorporated herein as SEQ ID NO: 2. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 3 is at least 90% complementary to SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 3 is at least 95% complementary to SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 3 is 100% complementary to SEQ ID NO: 1. In certain 20 embodiments, a short antisense compound targeted to SEQ ID NO: 3 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Table 4 and 5. The nucleotide sequence set forth in each SEQ ID NO set forth in Tables 4 and 5 is independent of any modification to a sugar moiety, a monomeric linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar 25 moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Tables 4 and 5 illustrate examples of short antisense compounds targeted to SEQ ID NO: 3. Table 4 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 3. Table 5 30 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 3. The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' 35 deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is WO 2007/146511 PCT/US2007/068401 -70 listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. 5 Table 4: Short Antisense Compounds Targeted to SEQ ID NO: 3 5' 3' ISIS Target Target SEQ ID No Site Site Sequence (5'-3') Gapmer Motif NO 379684 84 95 TGTCAGCAGGAT 1-10-1 MOE 214 405193 113 124 CAGCAGGAAATA 2-8-2 MOE 215 405194 114 125 CCAGCAGGAAAT 2-8-2 MOE 216 405195 115 126 ACCAGCAGGAAA 2-8-2 MOE 217 405196 116 127 GACCAGCAGGAA 2-8-2 MOE 218 405197 117 128 TGACCAGCAGGA 2-8-2 MOE 219 379685 117 128 TGACCAGCAGGA 1-10-1 MOE 219 405198 118 129 ATGACCAGCAGG 2-8-2 MOE 221 405199 119 130 AATGACCAGCAG 2-8-2 MOE 222 405200 120 131 CAATGACCAGCA 2-8-2 MOE 223 405201 121 132 CCAATGACCAGC 2-8-2 MOE 224 379686 135 146 ACCACAAGCCAA 1-10-1 MOE 225 379711 172 183 TAGCCGCCCACA 1-10-1 MOE 226 388628 172 183 TAGCCGCCCACA 2-8-2 MOE 226 405202 207 218 CCGGCCACCACA 2-8-2 MOE 228 405203 208 219 ACCGGCCACCAC 2-8-2 MOE 229 405204 236 247 GATGTTGCTGGC 2-8-2 MOE 230 379687 236 247 GATGTTGCTGGC 1-10-1 MOE 230 405205 237 248 CGATGTTGCTGG 2-8-2 MOE 232 405206 238 249 CCGATGTTGCTG 2-8-2 MOE 233 405207 239 250 GCCGATGTTGCT 2-8-2 MOE 234 405208 240 251 TGCCGATGTTGC 2-8-2 MOE 235 405209 241 252 CTGCCGATGTTG 2-8-2 MOE 236 405210 260 271 CAGGCCCACAAA 2-8-2 MOE 237 405211 261 272 CCAGGCCCACAA 2-8-2 MOE 238 405212 262 273 GCCAGGCCCACA 2-8-2 MOE 239 379688 288 299 CCAAGCCACTTG 1-10-1 MOE 240 379689 318 329 AGAGCGCATTCC 1-10-1 MOE 241 379690 435 446 ACAGGTAGAGGC 1-10-1 MOE 242 405248 474 485 AGATCTTGGTGA 2-8-2 MOE 243 379691 474 485 AGATCTTGGTGA 1-10-1 MOE 243 382676 527 539 TGTTCCAGCCCAG 1-10-2 MOE 245 388625 528 539 TGTTCCAGCCCA 2-8-2 MOE 246 389780 528 539 TGTTCCAGCCCA 1-9-2 MOE 246 379692 528 539 TGTTCCAGCCCA 1-10-1 MOE 246 1-10-1 246 Methyleneoxy 392170 528 539 TGTTCCAGCCCA BNA 2-8-2 246 Methyleneoxy 392173 528 539 TGTTCCAGCCCA BNA 405213 529 540 ATGTTCCAGCCC 2-8-2 MOE 251 405214 564 575 TGGTGATGCCCA 2-8-2 MOE 252 WO 2007/146511 PCT/US2007/068401 -71 405215 565 576 ATGGTGATGCCC 2-8-2 MOE 253 405216 566 577 CATGGTGATGCC 2-8-2 MOE 254 379693 566 577 CATGGTGATGCC 1-10-1 MOE 254 405217 567 578 TCATGGTGATGC 2-8-2 MOE 256 405218 568 579 ATCATGGTGATG 2-8-2 MOE 257 405219 587 598 CCCTCCTGTCAC 2-8-2 MOE 258 405220 588 599 GCCCTCCTGTCA 2-8-2 MOE 259 405221 589 600 AGCCCTCCTGTC 2-8-2 MOE 260 405222 590 601 CAGCCCTCCTGT 2-8-2 MOE 261 405223 591 602 CCAGCCCTCCTG 2-8-2 MOE 262 405224 592 603 GCCAGCCCTCCT 2-8-2 MOE 263 379694 629 640 GACGAAGGTCTG 1-10-1 MOE 264 405225 707 718 GTATTTGTCGAA 2-8-2 MOE 265 379695 737 748 GGACACCGTCAG 1-10-1 MOE 266 379696 974 985 CAGCTTCAGGTA 1-10-1 MOE 267 405226 998 1009 CATGACCATGAG 2-8-2 MOE 268 405227 999 1010 GCATGACCATGA 2-8-2 MOE 269 405228 1000 1011 GGCATGACCATG 2-8-2 MOE 270 405229 1001 1012 TGGCATGACCAT 2-8-2 MOE 271 405230 1002 1013 CTGGCATGACCA 2-8-2 MOE 272 379697 1002 1013 CTGGCATGACCA 1-10-1 MOE 272 405231 1003 1014 CCTGGCATGACC 2-8-2 MOE 274 379698 1091 1102 GCAGCCCACCTC 1-10-1 MOE 275 405232 1092 1103 AGCAGCCCACCT 2-8-2 MOE 276 405233 1093 1104 GAGCAGCCCACC 2-8-2 MOE 277 405234 1130 1141 CATGAGCTTCAC 2-8-2 MOE 278 405235 1131 1142 GCATGAGCTTCA 2-8-2 MOE 279 382677 1131 1143 GGCATGAGCTTCA 1-10-2 MOE 280 388626 1132 1143 GGCATGAGCTTC 2-8-2 MOE 281 379699 1132 1143 GGCATGAGCTTC 1-10-1 MOE 281 405236 1133 1144 GGGCATGAGCTT 2-8-2 MOE 283 405237 1157 1168 CAGCATGAGTCC 2-8-2 MOE 284 405238 1158 1169 CCAGCATGAGTC 2-8-2 MOE 285 379700 1158 1169 CCAGCATGAGTC 1-10-1 MOE 285 405239 1159 1170 GCCAGCATGAGT 2-8-2 MOE 287 379701 1230 1241 CCATGGTGAAGA 1-10-1 MOE 288 405240 1542 1553 CACAGCTGCCCG 2-8-2 MOE 289 405241 1543 1554 ACACAGCTGCCC 2-8-2 MOE 290 405242 1544 1555 CACACAGCTGCC 2-8-2 MOE 291 382678 1544 1556 GCACACAGCTGCC 1-10-2 MOE 292 388627 1545 1556 GCACACAGCTGC 2-8-2 MOE 293 379702 1545 1556 GCACACAGCTGC 1-10-1 MOE 293 379703 1701 1712 GCCGGAGACTGA 1-10-1 MOE 295 405243 1976 1987 ATTGAGGTTGAC 2-8-2 MOE 296 405244 1977 1988 CATTGAGGTTGA 2-8-2 MOE 297 405245 1978 1989 GCATTGAGGTTG 2-8-2 MOE 298 405246 1979 1990 GGCATTGAGGTT 2-8-2 MOE 299 405247 1980 1991 GGGCATTGAGGT 2-8-2 MOE 300 Table 5: Short antisense compounds targeted to SEQ ID NO: 3 and having 1 or 2 mismatches 5' 3' ISIS Target Target SEQ ID No Site Site Sequence (5'-3') Gapmer Motif NO WO 2007/146511 PCT/US2007/068401 -72 405200 96 107 CAATGACCAGCA 2-8-2 MOE 223 405215 382 393 ATGGTGATGCCC 2-8-2 MOE 253 405216 383 394 CATGGTGATGCC 2-8-2 MOE 254 379693 383 394 CATGGTGATGCC 1-10-1 MOE 254 379701 471 482 CCATGGTGAAGA 1-10-1 MOE 288 405218 472 483 ATCATGGTGATG 2-8-2 MOE 257 405246 536 547 GGCATTGAGGTT 2-8-2 MOE 299 405248 570 581 AGATCTTGGTGA 2-8-2 MOE 243 379691 570 581 AGATCTTGGTGA 1-10-1 MOE 243 379698 683 694 GCAGCCCACCTC 1-10-1 MOE 275 405232 684 695 AGCAGCCCACCT 2-8-2 MOE 276 379711 685 696 TAGCCGCCCACA 1-10-1 MOE 226 388628 685 696 TAGCCGCCCACA 2-8-2 MOE 226 379698 950 961 GCAGCCCACCTC 1-10-1 MOE 275 405232 951 962 AGCAGCCCACCT 2-8-2 MOE 276 405235 978 989 GCATGAGCTTCA 2-8-2 MOE 279 382677 978 990 GGCATGAGCTTCA 1-10-2 MOE 280 388626 979 990 GGCATGAGCTTC 2-8-2 MOE 281 379699 979 990 GGCATGAGCTTC 1-10-1 MOE 281 405236 980 991 GGGCATGAGCTT 2-8-2 MOE 283 379698 1043 1054 GCAGCCCACCTC 1-10-1 MOE 275 405239 1171 1182 GCCAGCATGAGT 2-8-2 MOE 287 405209 1213 1224 CTGCCGATGTTG 2-8-2 MOE 236 405233 1364 1375 GAGCAGCCCACC 2-8-2 MOE 277 405240 1366 1377 CACAGCTGCCCG 2-8-2 MOE 289 405211 1500 1511 CCAGGCCCACAA 2-8-2 MOE 238 405212 1501 1512 GCCAGGCCCACA 2-8-2 MOE 239 379695 1643 1654 GGACACCGTCAG 1-10-1 MOE 266 379698 1875 1886 GCAGCCCACCTC 1-10-1 MOE 275 405239 1993 2004 GCCAGCATGAGT 2-8-2 MOE 287 405211 2210 2221 CCAGGCCCACAA 2-8-2 MOE 238 405212 2211 2222 GCCAGGCCCACA 2-8-2 MOE 239 In certain embodiments, a target region is nucleotides 85-184 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 85-184 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 85-184 comprises a nucleotide 5 sequence selected from SEQ ID NO 214, 215, 216, 217, 218, 219, 221, 222, 223, 224, 225, or 227. In certain such embodiments, a short antisense compound targeted to nucleotides 85-184 of SEQ ID NO: 3 is selected from Isis No 379684, 405193, 405194, 405195, 405196, 405197, 379685, 405198, 405199, 405200,405201, 379686, 379711 or 388628. In certain embodiments, a target region is nucleotides 113-132 of SEQ ID NO: 3. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 113-132 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 113-132 comprises a nucleotide sequence selected from SEQ ID NO 215, 216, 217, 218, 219, 221, 222, 223, or 224. In certain such embodiments, a short antisense compound targeted to nucleotides 113-132 of SEQ ID NO: 3 is selected from Isis No 405193, 405194, 405195, 405196, 405197, 379685, 405198, 405199, 405200, or 405201. 15 In certain embodiments, a target region is nucleotides 207-329 of SEQ ID NO: 3. In certain WO 2007/146511 PCT/US2007/068401 -73 embodiments, a short antisense compound is targeted to nucleotides 207-329 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 207-329 comprises a nucleotide sequence selected from SEQ ID NO 228, 229, 230, 232, 233, 234, 235, 236, 237, 238, 239, 240, or 241. In certain such embodiments, a short antisense compound targeted to nucleotides 207-329 of SEQ ID NO: 5 3 is selected from Isis No 405202, 405203, 405204, 379687, 405205, 405206, 405207, 405208, 405209, 405210,405211,405212,379688,or379689. In certain embodiments, a target region is nucleotides 207-273 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 207-273 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 207-273 comprises a nucleotide 10 sequence selected from SEQ ID NO 228, 229, 230, 232, 233, 234, 235, 236, 237, 238, or 239. In certain such embodiments, a short antisense compound targeted to nucleotides 207-273 of SEQ ID NO: 3 is selected from Isis No 405202, 405203, 405204, 379687, 405205, 405206, 405207, 405208, 405209, 405210,405211, or 405212. In certain embodiments, a target region is nucleotides 207-219 of SEQ ID NO: 3. In certain 15 embodiments, a short antisense compound is targeted to nucleotides 207-219 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 207-219 comprises a nucleotide sequence selected from SEQ ID NO 228 or 229. In certain such embodiments, a short antisense compound targeted to nucleotides 207-219 of SEQ ID NO: 3 is selected from Isis NO.. 405202 or 405203. 20 In certain embodiments, a target region is nucleotides 236-252 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 236-252 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 236-252 comprises a nucleotide sequence selected from SEQ ID NO 230, 232, 233, 234, 235, or 236. In certain such embodiments, a short antisense compound targeted to nucleotides 236-252 of SEQ ID NO: 3 is selected from Isis NO. 405204, 25 379687, 405205, 405206, 405207, 405208, or 405209. In certain embodiments, a target region is nucleotides 260-273 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 260-273 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 260-273 comprises a nucleotide sequence selected from SEQ ID NO 237, 238, or 239. In certain such embodiments, a short antisense 30 compound targeted to nucleotides 260-273 of SEQ ID NO: 3 is selected from Isis NO. 405210, 405211, or 405212. In certain embodiments, a target region is nucleotides 435-640 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 435-640 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 435-640 comprises a nucleotide 35 sequence selected from SEQ ID NO 242, 243, 245, 246, 251, 252, 253, 254, 256,257, 258, 259, 260, 261, 262, 263, or 264. In certain such embodiments, a short antisense compound targeted to nucleotides 435 640 of SEQ ID NO: 3 is selected from Isis NO. 379690, 405248, 379691, 389780, 379692, 382676, WO 2007/146511 PCT/US2007/068401 -74 388625, 392170, 392173, 405213, 405214, 405215, 405216, 379693, 405217, 405218, 405219, 405220, 405221,405222,405223,405224,or379694. In certain embodiments, a target region is nucleotides 527-540 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 527-540 of SEQ ID NO: 3. In certain 5 such embodiments, a short antisense compound targeted to nucleotides 527-540 comprises a nucleotide sequence selected from SEQ ID NO 245, 246, or 251. In certain such embodiments, a short antisense compound targeted to nucleotides 527-540 of SEQ ID NO: 3 is selected from Isis NO. 389780, 379692, 382676,388626,392170,392173,or405213. In certain embodiments, a target region is nucleotides 564-603 of SEQ ID NO: 3. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 564-603 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 564-603 comprises a nucleotide sequence selected from SEQ ID NO 252, 253, 254, 256, 257, 258, 259, 260, 261, 262, or 263. In certain such embodiments, a short antisense compound targeted to nucleotides 564-603 of SEQ ID NO: 3 is selected from Isis NO. 405214, 405215, 405216, 379693, 405217, 405218, 405219, 405220, 405221, 15 405222, 405223, or 405224. In certain embodiments, a target region is nucleotides 564-579 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 564-579 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 564-579 comprises a nucleotide sequence selected from SEQ ID NO 252, 253, 254, 256, or 257. In certain such embodiments, a short 20 antisense compound targeted to nucleotides 564-579 of SEQ ID NO: 3 is selected from Isis NO. 405214, 405215,405216,379693,405217,or405218. In certain embodiments, a target region is nucleotides 587-603 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 587-603 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 587-603 comprises a nucleotide 25 sequence selected from SEQ ID NO 258, 259, 260, 261, 262, or 263. In certain such embodiments, a short antisense compound targeted to nucleotides 587-603 of SEQ ID NO: 3 is selected from Isis NO. 405219,405220,405221,405222,405223,or405224. In certain embodiments, a target region is nucleotides 974-1014 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 974-1014 of SEQ ID NO: 3. In 30 certain such embodiments, a short antisense compound targeted to nucleotides 974-1014 comprises a nucleotide sequence selected from SEQ ID NO 267, 268, 269, 270, 271, 272, or 274. In certain such embodiments, a short antisense compound targeted to nucleotides 974-1014 of SEQ ID NO: 3 is selected from Isis NO. 379696, 405226, 405227, 405228, 405229, 405230, 379697, or 405231. In certain embodiments, a target region is nucleotides 998-1014 of SEQ ID NO: 3. In certain 35 embodiments, a short antisense compound is targeted to nucleotides 998-1014 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 998-1014 comprises a nucleotide sequence selected from SEQ ID NO 268, 269, 270, 271, 272, or 274. In certain such WO 2007/146511 PCT/US2007/068401 -75 embodiments, a short antisense compound targeted to nucleotides 998-1014 of SEQ ID NO: 3 is selected from Isis NO. 405226, 405227, 405228, 405229, 405230, 379697, or 405231. In certain embodiments, a target region is nucleotides 1091-1170 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 1091-1170 of SEQ ID NO: 3. In 5 certain such embodiments, a short antisense compound targeted to nucleotides 1091-1170 comprises a nucleotide sequence selected from SEQ ID NO 275, 276, 277, 278, 279, 280, 281, 283, 284, 285, 286, or 287. In certain such embodiments, a short antisense compound targeted to nucleotides 1091-1170 of SEQ ID NO: 3 is selected from Isis NO. 379698, 405232, 405233, 405234, 405235, 388626, 379699, 382677, 405236,405237,405238,379700,or405239. 10 In certain embodiments, a target region is nucleotides 1091-1104 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 1091-1104 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 1091-1104 comprises a nucleotide sequence selected from SEQ ID NO 275, 276, or 277. In certain such embodiments, an short antisense compound targeted to nucleotides 1091-1104 of SEQ ID NO: 3 is selected from Isis NO. 15 379698,405232,or405233. In certain embodiments, a target region is nucleotides 1130-1144 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 1130-1144 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 1130-1144 comprises a nucleotide sequence selected from SEQ ID NO 278, 279, 280, 281, or 283. In certain such embodiments, 20 a short antisense compound targeted to nucleotides 1130-1144 of SEQ ID NO: 3 is selected from Isis NO. 405234,405235,388626,379699,382677,or405236. In certain embodiments, a target region is nucleotides 1157-1170 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 1157-1170 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 1157-1170 comprises a 25 nucleotide sequence selected from SEQ ID NO 284, 285, or 287. In certain such embodiments, a short antisense compound targeted to nucleotides 1157-1170 of SEQ ID NO: 3 is selected from Isis NO. 405237, 405238, 379700, or 405239. In certain embodiments, a target region is nucleotides 1542-1556 of SEQ ID NO: 3. In certain embodiments, a short antisense compound is targeted to nucleotides 1542-1556 of SEQ ID NO: 3. In 30 certain such embodiments, a short antisense compound targeted to nucleotides 1542-1556 comprises a nucleotide sequence selected from SEQ ID NO 289, 290, 291, 292, or 293. In certain such embodiments, a short antisense compound targeted to nucleotides 1542-1556 of SEQ ID NO: 3 is selected from Isis NO. 405240,405241,405242,388629,379702,or382678. In certain embodiments, a target region is nucleotides 1976-1991 of SEQ ID NO: 3. In certain 35 embodiments, a short antisense compound is targeted to nucleotides 1976-1991 of SEQ ID NO: 3. In certain such embodiments, a short antisense compound targeted to nucleotides 1976-1991 comprises a nucleotide sequence selected from SEQ ID NO 296, 297, 298, 299, or 300. In certain such embodiments, WO 2007/146511 PCT/US2007/068401 -76 a short antisense compound targeted to nucleotides 1976-1991 of SEQ ID NO: 3 is selected from Isis NO. 405243, 405244, 405245, 405246, or 405247. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain 5 embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are short 10 gapmers. In certain such embodiments, short gapmers targeted to an SGLT2 nucleic acid comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such 15 embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -O-2') BNA, -D Methyleneoxy (4'-CH 2 -0-2') BNA, Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, 0-C-Clo alkyl, OCF 3 , O-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -0-N(Rm)(Rn), and O-CH 2 -C(=O)-N(Rm)(Rn), where 20 each Rm and R. is, independently, H or substituted or unsubstituted C-Co alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers 25 of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid have 30 uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 8 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic 35 acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 11 monomers in length. In certain embodiments, short antisense WO 2007/146511 PCT/US2007/068401 -77 compounds targeted to an SGLT2 nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 15 monomers 5 in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to an SGLT2 nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense 10 compounds targeted to an SGLT2 nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of SGLT2. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to an SGLT2 nucleic acid, wherein the short antisense compound targeted to an SGLT2 nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. 15 from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of SGLT2 using one or more short antisense compounds targeted to an SGLT2 nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 8 monomers in length. In certain embodiments, 20 methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 11 monomers in length. In certain embodiments, methods of 25 modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating 30 SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid comprising 9 to 15 monomers. In certain 35 embodiments, methods of modulating expression of SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of SGLT2 comprise use of a short antisense compound targeted to an SGLT2 WO 2007/146511 PCT/US2007/068401 -78 nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of SGLT2 comprise use of a short antisense compound targeted to an SGLT2 nucleic acid comprising 12 or 14 nucleotides or nucleosides. 5 3. PCSK9 In individuals with autosomal dominant hypercholesterolemia (ADH), elevated LDL-C levels have been linked to mutations in the genes encoding LDL-receptor (LDL-R), apolipoprotein B (apoB), or proprotein convertase subtilisin/kexin type 9 (PCSK9) (Abifadel et al., Nat. Genet., 2003, 34:154-156). PCSK9 was identified as a third locus associated with ADH when gain-of-function mutations in PCSK9 10 were found to be linked to elevated LDL-C levels. ApoB participates in the intracellular assembly and secretion of triglyceride-rich lipoproteins and is a ligand for the LDL-R. PCSK9 is proposed to reduce LDL-R expression levels in the liver. Reduced LDL-R expression results in reduced hepatic uptake of circulating ApoB-containing lipoproteins, which in turn leads to elevated cholesterol. 15 Definitions "PCSK9" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. "PCSK9 nucleic acid" means any nucleic acid encoding PCSK9. For example, in certain embodiments, a PCSK9nucleic acid includes, without limitation, a DNA sequence encoding PCSK9, an 20 RNA sequence transcribed from DNA encoding PCSK9, and an mRNA sequence encoding PCSK9. "PCSK9 mRNA" means an mRNA encoding PCSK9. PCSK9 Therapeutic Indications In certain embodiments, the invention provides methods of modulating the expression of 25 PCSK9 in an individual comprising administering a short antisense compound targeted to a PCSK9 nucleic acid. In certain embodiments, the invention provides methods of treating an individual comprising administering one or more pharmaceutical compositions of the present invention. In certain embodiments, the individual has hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart 30 disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. Guidelines for lipid-lowering therapy were established in 2001 by Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., 35 Circulation, 2004, 110, 227-239). The guidelines include obtaining a complete lipoprotein profile, typically after a 9 to 12 hour fast, for determination of LDL-C, total cholesterol, and HDL-C levels. According to the most recently established guidelines, LDL-C levels of 130-159 mg/dL, 160-189 mg/dL, WO 2007/146511 PCT/US2007/068401 -79 and greater than or equal to 190 mg/dL are considered borderline high, high, and very high, respectively. Total cholesterol levels of 200-239 and greater than or equal to 240 mg/dL are considered borderline high and high, respectively. HDL-C levels of less than 40 mg/dL are considered low. In certain embodiments, the individual has been identified as in need of lipid-lowering therapy. In 5 certain such embodiments, the individual has been identified as in need of lipid-lowering therapy according to the guidelines established in 2001 by Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., Circulation, 2004, 110, 227 239). In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 190 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 10 160 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 130 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy has LDL C above 100 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 160 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 130 mg/dL. In certain such embodiments the individual in need of 15 lipid-lowering therapy should maintain LDL-C below 100 mg/dL. In certain such embodiments the individual should maintain LDL-C below 70 mg/dL. In certain embodiments the invention provides methods for reducing ApoB in an individual. In certain embodiments the invention provides methods for reducing ApoB-containing lipoprotein in an individual. In certain embodiments the invention provides methods for reducing LDL-C in an individual. 20 In certain embodiments the invention provides methods for reducing VLDL-C in an individual. In certain embodiments the invention provides methods for reducing IDL-C in an individual. In certain embodiments the invention provides methods for reducing non-HDL-C in an individual. In certain embodiments the invention provides methods for reducing Lp(a) in an individual. In certain embodiments the invention provides methods for reducing serum triglyceride in an individual. In certain embodiments 25 the invention provides methods for reducing liver triglyceride in an individual. In certain embodiments the invention provides methods for reducing Ox-LDL-C in an individual. In certain embodiments the invention provides methods for reducing small LDL particles in an individual. In certain embodiments the invention provides methods for reducing small VLDL particles in an individual. In certain embodiments the invention provides methods for reducing phospholipids in an individual. In certain embodiments the 30 invention provides methods for reducing oxidized phospholipids in an individual. In certain embodiments, the methods provided by the present invention do not lower HDL-C. In certain embodiments, the methods provided by the present invention do not result in accumulation of lipids in the liver. In certain embodiments a pharmaceutical composition comprising a short antisense compound 35 targeted to a PCSK9 nucleic acid is for use in therapy. In certain embodiments, the therapy is the reduction of LDL-C, ApoB, VLDL-C, IDL-C, non-HDL-C, Lp(a) , serum triglyceride, liver triglyceride, Ox-LDL-C, small LDL particles, small VLDL, phospholipids, or oxidized phospholipids in an individual.

WO 2007/146511 PCT/US2007/068401 -80 In certain embodiments, the therapy is the treatment of hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, 5 hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. In additional embodiments, the therapy is the reduction of CHD risk. In certain the therapy is prevention of atherosclerosis. In certain embodiments, the therapy is the prevention of coronary heart disease. In certain embodiments a pharmaceutical composition comprising a short antisense compound targeted to a PCSK9 nucleic acid is used for the preparation of a medicament for reducing LDL-C, ApoB, 10 VLDL-C, IDL-C, non-HDL-C, Lp(a) , serum triglyceride, liver triglyceride, Ox-LDL-C, small LDL particles, small VLDL, phospholipids, or oxidized phospholipids in an individual. In certain embodiments pharmaceutical composition comprising a short antisense compound targeted to PCKS9 is used for the preparation of a medicament for reducing coronary heart disease risk. In certain embodiments a short antisense compound targeted to a PCSK9 nucleic acid is used for the preparation of a medicament for the 15 treatment of hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hyperfattyacidemia, hepatic steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease. 20 PCSK9 Combination Therapies In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more 25 pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions 30 of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, 35 one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared WO 2007/146511 PCT/US2007/068401 -81 separately. In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include lipid-lowering agents. In certain such embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of 5 the present invention include, but are not limited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. In certain such embodiments, the lipid-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the lipid-lowering agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the lipid-lowering agent is administered at the same time as a 10 pharmaceutical composition of the present invention. In certain such embodiments the dose of a co administered lipid-lowering agent is the same as the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is lower than the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is greater than the 15 dose that would be administered if the lipid-lowering agent was administered alone. In certain embodiments, a co-administered lipid-lowering agent is a HMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoA reductase inhibitor is a statin. In certain such embodiments the statin is selected from atorvastatin, simvastatin, pravastatin, fluvastatin, and rosuvastatin. 20 In certain embodiments, a co-administered lipid-lowering agent is a cholesterol absorption inhibitor. In certain such embodiments, cholesterol absorption inhibitor is ezetimibe. In certain embodiments, a co-administered lipid-lowering agent is a co-formulated HMG-CoA reductase inhibitor and cholesterol absorption inhibitor. In certain such embodiments the co-formulated lipid-lowering agent is ezetimibe/simvastatin. 25 In certain embodiments, a co-administered lipid-lowering agent is a microsomal triglyceride transfer protein inhibitor (MTP inhibitor). In certain embodiments, a co-administered lipid-lowering agent is an oligonucleotide targeted to an ApoB nucleic acid. In certain embodiments, a co-administered pharmaceutical agent is a bile acid sequestrant. In 30 certain such embodiments, the bile acid sequestrant is selected from cholestyramine, colestipol, and colesevelam. In certain embodiments, a co-administered pharmaceutical agent is a nicotinic acid. In certain such embodiments, the nicotinic acid is selected from immediate release nicotinic acid, extended release nicotinic acid, and sustained release nicotinic acid. 35 In certain embodiments, a co-administered pharmaceutical agent is a fibric acid. In certain such embodiments, a fibric acid is selected from gemfibrozil, fenofibrate, clofibrate, bezafibrate, and ciprofibrate.

WO 2007/146511 PCT/US2007/068401 -82 Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include, but are not limited to, corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory agents, including, but not limited to non 5 steroidal anti-inflammatory drugs (e.g., ibuprofen, COX-1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, 10 calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines. In certain embodiments, the pharmaceutical compositions of the present invention may be administered in conjuction with a lipid-lowering therapy. In certain such embodiments, a lipid-lowering therapy is therapeutic lifestyle change. In certain such embodiments, a lipid-lowering therapy is LDL 15 apheresis. Certain Short Antisense Compounds Targeted to a PCSK9 Nucleic Acid In certain embodiments, short antisense compounds are targeted to a PCSK9 nucleic acid having the sequence of GENBANK@ Accession No. NM_174936.2, incorporated herein as SEQ ID NO: 20 4. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 4 is at least 90% complementary to SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 4 is at least 95% complementary to SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 4 is 100% complementary to SEQ ID NO: 4. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 4 comprises a nucleotide sequence 25 selected from the nucleotide sequences set forth in Table 6 or Table 7. The nucleotide sequence set forth in each SEQ ID NO in Tables 6 and 7 is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an intemucleoside linkage, or a nucleobase. Short antisense compounds described by Isis Number 30 (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an intemucleoside linkage, or a nucleobase. Tables 6 and 7 illustrate examples of short antisense compounds targeted to SEQ ID NO: 4. Table 6 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 4. Table 7 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 4. 35 The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif' WO 2007/146511 PCT/US2007/068401 -83 column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is 5 listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. Table 6: Short Antisense Compounds targeted to SEQ ID NO: 4 5' 3' SEQ ISIS Target Target ID NO. Site Site Sequence (5'-3') Gapmer Motif NO 400297 695 708 ATGGGGCAACTTCA 2-10-2 MOE 329 400298 696 709 CATGGGGCAACTTC 2-10-2 MOE 330 400299 697 710 ACATGGGGCAACTT 2-10-2 MOE 331 400300 742 755 GGGATGCTCTGGGC 2-10-2 MOE 332 400301 757 770 CGCTCCAGGTTCCA 2-10-2 MOE 333 400302 828 841 GATACACCTCCACC 2-10-2 MOE 334 400303 829 842 AGATACACCTCCAC 2-10-2 MOE 335 400304 830 843 GAGATACACCTCCA 2-10-2 MOE 336 400305 937 950 GCCTGTCTGTGGAA 2-10-2 MOE 337 400306 952 965 CTGTCACACTTGCT 2-10-2 MOE 338 400307 988 1001 CGGCCGCTGACCAC 2-10-2 MOE 339 400308 989 1002 CCGGCCGCTGACCA 2-10-2 MOE 340 400309 990 1003 CCCGGCCGCTGACC 2-10-2 MOE 341 400310 991 1004 TCCCGGCCGCTGAC 2-10-2 MOE 342 400311 992 1005 ATCCCGGCCGCTGA 2-10-2 MOE 343 400312 993 1006 CATCCCGGCCGCTG 2-10-2 MOE 344 400313 994 1007 GCATCCCGGCCGCT 2-10-2 MOE 345 400314 1057 1070 GTGCCCTTCCCTTG 2-10-2 MOE 346 400315 1075 1088 ATGAGGGTGCCGCT 2-10-2 MOE 347 400316 1076 1089 TATGAGGGTGCCGC 2-10-2 MOE 348 400317 1077 1090 CTATGAGGGTGCCG 2-10-2 MOE 349 400318 1078 1091 CCTATGAGGGTGCC 2-10-2 MOE 350 400319 1093 1106 CGAATAAACTCCAG 2-10-2 MOE 351 400320 1094 1107 CCGAATAAACTCCA 2-10-2 MOE 352 400321 1095 1108 TCCGAATAAACTCC 2-10-2 MOE 353 400322 1096 1109 TTCCGAATAAACTC 2-10-2 MOE 354 400323 1147 1160 GCCAGGGGCAGCAG 2-10-2 MOE 355 400324 1255 1268 GAGTAGAGGCAGGC 2-10-2 MOE 356 400325 1334 1347 CCCCAAAGTCCCCA 2-10-2 MOE 357 400326 1335 1348 TCCCCAAAGTCCCC 2-10-2 MOE 358 400327 1336 1349 GTCCCCAAAGTCCC 2-10-2 MOE 359 400328 1453 1466 ACGTGGGCAGCAGC 2-10-2 MOE 360 400329 1454 1467 CACGTGGGCAGCAG 2-10-2 MOE 361 400330 1455 1468 CCACGTGGGCAGCA 2-10-2 MOE 362 400331 1456 1469 GCCACGTGGGCAGC 2-10-2 MOE 363 400332 1569 1582 CAGGGAACCAGGCC 2-10-2 MOE 364 400333 1570 1583 TCAGGGAACCAGGC 2-10-2 MOE 365 WO 2007/146511 PCT/US2007/068401 -84 400334 1571 1584 CTCAGGGAACCAGG 2-10-2 MOE 366 400335 1572 1585 CCTCAGGGAACCAG 2-10-2 MOE 367 400336 1573 1586 TCCTCAGGGAACCA 2-10-2 MOE 368 400337 1574 1587 GTCCTCAGGGAACC 2-10-2 MOE 369 400338 1575 1588 GGTCCTCAGGGAAC 2-10-2 MOE 370 400339 1576 1589 TGGTCCTCAGGGAA 2-10-2 MOE 371 400340 1577 1590 CTGGTCCTCAGGGA 2-10-2 MOE 372 400341 1578 1591 GCTGGTCCTCAGGG 2-10-2 MOE 373 400342 1621 1634 GTGCTGGGGGGCAG 2-10-2 MOE 374 400343 1622 1635 GGTGCTGGGGGGCA 2-10-2 MOE 375 400344 1623 1636 GGGTGCTGGGGGGC 2-10-2 MOE 376 400345 1624 1637 TGGGTGCTGGGGGG 2-10-2 MOE 377 400346 1738 1751 GAGCAGCTCAGCAG 2-10-2 MOE 378 400347 1739 1752 GGAGCAGCTCAGCA 2-10-2 MOE 379 400348 1740 1753 TGGAGCAGCTCAGC 2-10-2 MOE 380 400349 1741 1754 CTGGAGCAGCTCAG 2-10-2 MOE 381 400350 1834 1847 CCCTCACCCCCAAA 2-10-2 MOE 382 400351 1835 1848 ACCCTCACCCCCAA 2-10-2 MOE 383 400352 1836 1849 CACCCTCACCCCCA 2-10-2 MOE 384 400353 1837 1850 ACACCCTCACCCCC 2-10-2 MOE 385 400354 1838 1851 GACACCCTCACCCC 2-10-2 MOE 386 400355 1839 1852 AGACACCCTCACCC 2-10-2 MOE 387 400356 1840 1853 TAGACACCCTCACC 2-10-2 MOE 388 400357 2083 2096 TGGCAGCAGGAAGC 2-10-2 MOE 389 400358 2084 2097 ATGGCAGCAGGAAG 2-10-2 MOE 390 400359 2085 2098 CATGGCAGCAGGAA 2-10-2 MOE 391 400360 2086 2099 GCATGGCAGCAGGA 2-10-2 MOE 392 400361 2316 2329 GGCAGCAGATGGCA 2-10-2 MOE 393 400362 2317 2330 CGGCAGCAGATGGC 2-10-2 MOE 394 400363 2318 2331 CCGGCAGCAGATGG 2-10-2 MOE 395 400364 2319 2332 TCCGGCAGCAGATG 2-10-2 MOE 396 400365 2320 2333 CTCCGGCAGCAGAT 2-10-2 MOE 397 400366 2321 2334 GCTCCGGCAGCAGA 2-10-2 MOE 398 400367 2322 2335 GGCTCCGGCAGCAG 2-10-2 MOE 399 400368 2323 2336 CGGCTCCGGCAGCA 2-10-2 MOE 400 400369 2324 2337 CCGGCTCCGGCAGC 2-10-2 MOE 401 400370 2325 2338 GCCGGCTCCGGCAG 2-10-2 MOE 402 400371 3543 3556 AGTTACAAAAGCAA 2-10-2 MOE 403 2-10-2 (6'S)-6'-methyl 403739 988 1001 CGGCCGCTGACCAC Methyleneoxy BNA 339 2-10-2 (6'S)-6'-methyl 403740 1455 1468 CCACGTGGGCAGCA Methyleneoxy BNA 362 Table 7: Short antisense compounds targeted to SEQ ID NO: 4 and having 1 or 2 mismatches 5' 3' SEQ ISIS Target Target ID NO. Site Site Sequence (5'-3') Gapmer Motif NO 400323 349 362 GCCAGGGGCAGCAG 2-10-2 MOE 355 400370 679 692 GCCGGCTCCGGCAG 2-10-2 MOE 402 400361 1860 1873 GGCAGCAGATGGCA 2-10-2 MOE 393 400323 1873 1886 GCCAGGGGCAGCAG 2-10-2 MOE 355 WO 2007/146511 PCT/US2007/068401 -85 400310 2257 2270 TCCCGGCCGCTGAC 2-10-2 MOE 342 400361 2653 2666 GGCAGCAGATGGCA 2-10-2 MOE 393 400350 2811 2824 CCCTCACCCCCAAA 2-10-2 MOE 382 400351 2812 2825 ACCCTCACCCCCAA 2-10-2 MOE 383 400352 2813 2826 CACCCTCACCCCCA 2-10-2 MOE 384 400353 2814 2827 ACACCCTCACCCCC 2-10-2 MOE 385 400334 2966 2979 CTCAGGGAACCAGG 2-10-2 MOE 366 400332 3379 3392 CAGGGAACCAGGCC 2-10-2 MOE 364 400340 3448 3461 CTGGTCCTCAGGGA 2-10-2 MOE 372 400341 3449 3462 GCTGGTCCTCAGGG 2-10-2 MOE 373 In certain embodiments, a target region is nucleotides 695-710 of SEQ ID NO: 4. In certain such embodiments, short antisense compounds targeted to nucleotides 695-710 of SEQ ID NO: 4 comprise a nucleotide sequence selected from SEQ ID NO: 329, 330, or 331. In certain such embodiments, a short 5 antisense compound targeted to nucleotides 695-710 of SEQ ID NO: 4 is selected from Isis NO. 400297, 400298, or 400299. In certain embodiments, a target region is nucleotides 742-770 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 742-770 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 332 or 333. In certain such embodiments, a short 10 antisense compound targeted to nucleotides 742-770 of SEQ ID NO: 4 is selected from Isis NO. 400300 or 400301. In certain embodiments, a target region is nucleotides 828-843 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 828-843 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 334, 335, or 336. In certain such embodiments, a short 15 antisense compound targeted to nucleotides 828-843 of SEQ ID NO: 4 is selected from ISIS No. 400302, 400303, or 400304. In certain embodiments, a target region is nucleotides 937-1007 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 937-1007 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 337, 338, 339, 340, 341, 342, 343, 344, or 345. In 20 certain such embodiments, a short antisense compound targeted to nucleotides 937-1007 of SEQ ID NO: 4 is selected from Isis NO. 400305, 400306, 400307, 400308, 400309, 400310, 400311, 400312, 400313, or 403739. In certain embodiments, a target region is nucleotides 937-965 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 937-965 of SEQ ID NO: 4 comprises a 25 nucleotide sequence selected from SEQ ID NO 337 or 338. In certain such embodiments, a short antisense compound targeted to nucleotides 937-965 of SEQ ID NO: 4 is selected from Isis NO. 400305 or 400306. In certain embodiments, a target region is nucleotides 988-1007 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 988-1007 of SEQ ID NO: 4 comprises 30 a nucleotide sequence selected from SEQ ID NO 339, 340, 341, 342, 343, 344, or 345. In certain such WO 2007/146511 PCT/US2007/068401 -86 embodiments, a short antisense compound targeted to nucleotides 937-1007 of SEQ ID NO: 4 is selected from Isis NO. 400307, 400308, 400309, 400310, 400311, 400312, 4003313, or 403739. In certain embodiments, a target region is nucleotides 1057-1160 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1160 of SEQ ID NO: 4 5 comprises a nucleotide sequence selected from SEQ ID NO 346, 347, 348, 349, 350, 351, 352, 353, 354, or 355. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1160 of SEQ ID NO: 4 is selected from ISIS NO. 400314, 400315, 400316, 400317, 400318, 400319, 400320, 400321, 400322, or 400323. In certain embodiments, a target region is nucleotides 1057-1109 of SEQ ID NO: 4. In certain 10 such embodiments, a short antisense compound targeted to nucleotides 1057-1109 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 346, 347, 348, 349, 350, 351, 352, 353, or 354. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1109 of SEQ ID NO: 4 is selected from ISIS NO. 400314, 400315, 400316, 400317, 400318, 400319, 400320, 400321, or 400322. 15 In certain embodiments, a target region is nucleotides 1057-1091 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1091 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 346, 347, 348, 349, or 350. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1091 of SEQ ID NO: 4 is selected from ISIS NO. 400314, 400315, 400316, 400317, or 400318. 20 In certain embodiments, a target region is nucleotides 1093-1109 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1093-1109 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 351, 352, 353, or 354. In certain such embodiments, a short antisense compound targeted to nucleotides 1057-1109 of SEQ ID NO: 4 is selected from ISIS NO. 400319, 400320, 400321, or 400322. 25 In certain embodiments, a target region is nucleotides 1334-1349 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1334-1349 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 357, 358, or 359. In certain such embodiments, a short antisense compound targeted to nucleotides 1334-1349 of SEQ ID NO: 4 is selected from ISIS NO 400325, 400326, or 400327. 30 In certain embodiments, a target region is nucleotides 1453-1469 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1453-1469 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 360, 361, 362, or 363. In certain such embodiments, a short antisense compound targeted to nucleotides 1453-1469 of SEQ ID NO: 4 is selected from ISIS NO 400328, 400329, 400330, 400331, or 403470. 35 In certain embodiments, a target region is nucleotides 1569-1591 of SEQ ID NO: 4. In certain such embodiments, a short antisense compound targeted to nucleotides 1569-1591 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 364, 365, 366, 367, 368, 369, 370, 371, 372, WO 2007/146511 PCT/US2007/068401 -87 or 373. In certain such embodiments, a short antisense compound targeted to nucleotides 1569-1591 of SEQ ID NO: 4 is selected from ISIS NO 400332, 400333, 400334, 400335, 400336, 400337, 400338, 400339, 400340, or 400341. In certain embodiments, a target region is nucleotides 1621-1637 of SEQ ID NO: 4. In certain 5 such embodiments, a short antisense compound targeted to nucleotides 1621-1637 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 374, 375, 376, or 377. In certain such embodiments, a short antisense compound targeted to nucleotides 1621-1637 of SEQ ID NO: 4 is selected from ISIS NO 400342, 400343, 400344, or 400345. In certain embodiments, a target region is nucleotides 1738-1754 of SEQ ID NO: 4. In certain 10 such embodiments, a short antisense compound targeted to nucleotides 1738-1754 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 378, 379, 380, or 381. In certain such embodiments, a short antisense compound targeted to nucleotides 1738-1754 of SEQ ID NO: 4 is selected from ISIS NO 400346, 400347, 400348, or 400349. In certain embodiments, a target region is nucleotides 1834-1853 of SEQ ID NO: 4. In certain 15 such embodiments, a short antisense compound targeted to nucleotides 1834-1853 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 382, 383, 384, 385, 386, 387, or 388. In certain embodiments, a short antisense compound targeted to nucleotides 1834-1853 of SEQ ID NO: 4 is selected from ISIS NO 400350, 400351, 400352, 400353, 400354, 400355, or 400356. In certain embodiments, a target region is nucleotides 2083-2099 of SEQ ID NO: 4. In certain 20 such embodiments, a short antisense compound targeted to nucleotides 2083-2099 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 389, 390, 391, or 392. In certain such embodiments, a short antisense compound targeted to nucleotides 2083-2099 of SEQ ID NO: 4 is selected from ISIS NO 400357,400358, 400359, or 400360. In certain embodiments, a target region is nucleotides 2316-2338 of SEQ ID NO: 4. In certain 25 such embodiments, a short antisense compound targeted to nucleotides 2316-2338 of SEQ ID NO: 4 comprises a nucleotide sequence selected from SEQ ID NO 393, 394, 395, 396, 397, 398, 399, 400, 401, or 402. In certain such embodiments, a short antisense compound targeted to nucleotides 2316-2338 of SEQ ID NO: 4 is selected from ISIS NO 400361, 400362, 400363, 400364, 400365, 400366, 400367, 400368, 400369, or 400370. 30 In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense 35 oligonucleotides. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a PCSK9 nucleic acid comprise at least WO 2007/146511 PCT/US2007/068401 -88 one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such 5 embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, P-D Methyleneoxy (4'-CH 2 -0-2') BNA, Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, O-C-Clo alkyl, OCF 3 , 0-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -0-N(Rm)(R), and O-CH 2 -C(=O)-N(Rm)(R), where 10 each Rm and R, is, independently, H or substituted or unsubstituted Ci-Clo alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers 15 of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeting a PCSK9 nucleic acid may have 20 any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a PCSK9 nucleic acid have a motif (wing deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8 3, 2-8-2,1-8-1, 3-6-3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid have 25 uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 8 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic 30 acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 13 monomers in length. In certain embodiments, short 35 antisense compounds targeted to a PCSK9 nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid are 16 monomers in WO 2007/146511 PCT/US2007/068401 -89 length. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a PCSK9 nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted 5 to a PCSK9 nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of PCSK9. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to a PCSK9 nucleic acid, wherein the short antisense compound targeted to a PCSK9 nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. 10 from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of PCSK9 using one or more short antisense compounds targeted to a PCSK9 nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 8 monomers in length. In certain embodiments, 15 methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating 20 PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating 25 PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid comprising 9 to 15 monomers. In certain 30 embodiments, methods of modulating expression of PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of PCSK9 comprise use of a short antisense compound targeted to a PCSK9 nucleic acid comprising 12 35 or 14 nucleotides or nucleosides. 4. Superoxide Dismutase 1 Enzyme (SOD 1) WO 2007/146511 PCT/US2007/068401 -90 The enzymes known as the superoxide dismutases (SODs) provide defense against oxidative damage of biomolecules by catalyzing the dismutation of superoxide to hydrogen peroxide (H 2 0 2 ) (Fridovich, Annu. Rev. Biochem., 1995, 64, 97-112). Two major classes of superoxide dismutases exist. One consists of a group of enzymes with active sites containing copper and zinc while the other class has 5 either manganese or iron at the active site (Fridovich, Annu. Rev. Biochem., 1995, 64, 97-112). Mutations in the superoxide dismutase 1 gene are associated with a dominantly-inherited form of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease) a disorder characterized by a selective degeneration of upper and lower motor neurons (Cleveland and Liu, Nat. Med., 2000, 6, 1320 1321). The deleterious effects of various mutations on superoxide dismutase 1 are most likely mediated 10 through a gain of toxic function rather than a loss of superoxide dismutase 1 activity, as the complete absence of superoxide dismutase I in mice neither diminishes life nor provokes overt disease (Al-Chalabi and Leigh, Curr. Opin. Neurol., 2000, 13, 397-405; Alisky and Davidson, Hum. Gene Ther., 2000, 11, 2315-2329). Over 100 mutations of the human SOD1 gene have been identified, and altogether account for 15 approximately 20% of familial amyotrophic lateral sclerosis (ALS) cases. Some mutations, such as the A4V mutation most commonly found in the United States, are highly lethal and result in survival only nine months from the onset of disease symptoms. Other mutations of SODI manifest in a slower disease course. 20 Definitions "SOD1" means the gene product or protein of which expression is to be modulated by administration of a short antisense compound. "SOD1 nucleic acid" means any nucleic acid encoding SOD1. For example, in certain embodiments, a SOD1 nucleic acid includes, without limitations, a DNA sequence encoding SOD1, an 25 RNA sequence transcribed from DNA encoding SOD1, and an mRNA sequence encoding SOD1. "SODI mRNA" means an mRNA encoding SOD1. SOD] Therapeutic Indications It has been discovered that antisense inhibition of superoxide dismutase I (SOD1) in an animal 30 model of familial ALS reduces both SOD 1 mRNA and protein, and further results in a slowing of disease progression and, importantly, increased survival time. Accordingly, in certain embodiments, the invention provides methods for the slowing of disease progression in an individual suffering from familial ALS by administering to such an individual a short antisense compound targeted to an SOD1 nucleic acid. In certain such embodiments, a short antisense compound targeted to SOD1 are delivered directly to the 35 cerebrospinal fluid of the individual. In certain such embodiments, methods further comprise increasing survival time of an individual suffering from familial ALS. Slowing of disease progression is indicated by an improvement in one or more indicators of ALS disease progression, including, without limitation, WO 2007/146511 PCT/US2007/068401 -91 the revised ALS functional rating scale, pulmonary function tests, and muscle strength measurements. SOD) Combination Therapies In certain embodiments, one or more pharmaceutical compositions comprising a short antisense 5 compound targeted to an SODi nucleic acid is co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain 10 embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are 15 administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents 20 are prepared separately. In certain embodiments, a co-administered pharmaceutical agent is a nicotinic acid. In certain such embodiments, the nicotinic acid is selected from immediate release nicotinic acid, extended release nicotinic acid, and sustained release nicotinic acid. In certain embodiments, a co-administered pharmaceutical agent is a fibric acid. In certain such 25 embodiments, a fibric acid is selected from gemfibrozil, fenofibrate, clofibrate, bezafibrate, and ciprofibrate. Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising a short antisense compound targeted to SOD 1 include, but are not limited to, corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to 30 intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory agents, including, but not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen, COX-I inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and 35 thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines.

WO 2007/146511 PCT/US2007/068401 -92 Certain Short Antisense Compounds Targeted to a SOD] Nucleic Acid In certain embodiments, short antisense compounds are targeted to a SODI nucleic acid having the sequence of GENBANK@ Accession No. NMX02317. 1, incorporated herein as SEQ ID NO: 5. In 5 certain such embodiments, a short antisense compound targeted to SEQ ID NO: 5 is at least 90% complementary to SEQ ID NO: 5. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 5 is at least 95% complementary to SEQ ID NO: 5. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 5 is 100% complementary to SEQ ID NO: 5. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 5 comprises a nucleotide sequence 10 selected from the nucleotide sequences set forth in Table 8 or Table 9. The nucleotide sequence set forth in each SEQ ID NO in Tables 8 and 9 is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Short antisense compounds described by Isis Number 15 (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Table 8 illustrates examples of short antisense compounds targeted to SEQ ID NO: 5. Table 8 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 5. The column labeled 'gapmer motif' indicates the wing-gap-wing motif of each short antisense compounds. The gap 20 segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2' modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2'-deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Intemucleoside linkages are phosphorothioate. The short antisense compounds comprise 5 25 methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. In certain embodiments, short antisense compounds targeting a SOD1 nucleic acid may have any 30 one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a SODI nucleic acid have a motif (wing deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8 3, 2-8-2, 1-8-1, 3-6-3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. 35 Table 8: Short Antisense Compounds targeted to SEQ ID NO: 5 WO 2007/146511 PCT/US2007/068401 -93 5' 3' ISIS Target Target Gapmer SEQ ID NO. Site Site Sequence (5'-3') Motif NO 387541 85 100 GTCGCCCTTCAGCACG 3-10-3 MOE 406 387540 86 99 TCGCCCTTCAGCAC 2-10-2 MOE 407 387539 87 98 CGCCCTTCAGCA 1-10-1 MOE 408 In certain embodiments, a target region is nucleotides 85-100 of SEQ ID NO: 5. In certain such embodiments, short antisense compounds targeted to nucleotides 85-100 of SEQ ID NO: 5 comprise a nucleotide sequence selected from SEQ ID NO: 406, 407, or 408. In certain such embodiments, a short 5 antisense compound targeted to nucleotides 85-100 of SEQ ID NO: 5 is selected from Isis No. 387541, 387540, or 387539. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 9 to 14 nucleotides in 10 length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to a SODI nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a SOD1 nucleic acid comprise at least 15 one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid comprise I to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, P-D 20 Methyleneoxy (4'-CH 2 -0-2') BNA, Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, O-allyl, O-C-Clo alkyl, OCF 3 , O-(CH 2

)

2

-O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , O-(CH 2

)

2 O-N(Rm)(R), and O-CH 2 -C(=O)-N(Rm)(R.), where each Rm and R, is, independently, H or substituted or unsubstituted CI-Clo alkyl. In certain embodiments, 25 the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to a SODI nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are 30 unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid have WO 2007/146511 PCT/US2007/068401 -94 uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a SODI nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 8 5 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD 1 nucleic acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a SODI nucleic acid are monomers in length. In certain embodiments, short antisense 10 compounds targeted to a SOD1 nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid comprise 9 15 to 15 monomers. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a SOD1 nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a SODI nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of SOD1. In 20 certain embodiments, such methods comprise use of one or more short antisense compound targeted to a SODI nucleic acid, wherein the short antisense compound targeted to a SODl nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of SOD1 using one or more short antisense compounds 25 targeted to a SODI nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating SODI comprise use of a short antisense compound targeted to a SODI nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating SOD1 comprise use of a short antisense compound targeted to a SOD1 nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating SOD 1 comprise use of 30 a short antisense compound targeted to a SODI nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating SODI comprise use of a short antisense compound targeted to a SOD 1 nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating SOD 1 comprise use of a short antisense compound targeted to a SODI nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating SOD1 comprise use of a short antisense 35 compound targeted to a SOD1 nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating SODI comprise use of a short antisense compound targeted to a SODI nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating SODI comprise use WO 2007/146511 PCT/US2007/068401 -95 of a short antisense compound targeted to a SOD 1 nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating SODI comprise use of a short antisense compound targeted to a SODI nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of SODI comprise use of a short 5 antisense compound targeted to a SODI nucleic acid comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of SOD1 comprise use of a short antisense compound targeted to a SOD 1 nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of SOD 1 comprise use of a short antisense compound targeted to a SODI nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of 10 SOD 1 comprise use of a short antisense compound targeted to a SOD 1 nucleic acid comprising 12 or 14 nucleotides or nucleosides. 5. CRP CRP (also known as C-reactive protein and PTX1) is an essential human acute-phase reactant 15 produced in the liver in response to a variety of inflammatory cytokines. The protein, first identified in 1930, is highly conserved and considered to be an early indicator of infectious or inflammatory conditions. Plasma CRP levels increase 1,000-fold in response to infection, ischemia, trauma, bums, and inflammatory conditions. In clinical trials where patients receive lipid-lowering therapy, such as statin therapy, it has been demonstrated that patients having reductions in both LDL-C and CRP have a reduced 20 risk of future coronary events relative to patients experiencing only reductions in LDL-C. Definitions "CRP" means the gene product or protein of which expression is to be modulated by a short antisense compound. 25 "CRP nucleic acid" means any nucleic acid encoding CRP. For example, in certain embodiments, a CRP nucleic acid includes, without limitations, a DNA sequence encoding CRP, an RNA sequence transcribed from DNA encoding CRP, and an mRNA sequence encoding CRP. "CRP mRNA" means an mRNA encoding CRP. 30 CRP Therapeutic Indications In certain embodiments, the invention provides methods of modulating CRP expression in an individual comprising administering to the individual a short antisense compound targeted to a CRP nucleic acid. In certain embodiments, the invention provides methods of treating an individual comprising administering one or more pharmaceutical compositions comprising a short antisense compound targeted 35 to a CRP nucleic acid. In certain embodiments, the individual has hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing WO 2007/146511 PCT/US2007/068401 -96 atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, one or more risk factors for coronary heart disease. In certain embodiments, the individual has acute coronary syndrome, vascular injury, arterial occlusion, unstable angina, post peripheral vascular disease, post myocardial infarction (MI), thrombosis, deep vein thrombus, end-stage renal disease 5 (ESRD), chronic renal failure, complement activation, congestive heart failure, or systemic vasculitis. In certain embodiments, the individual has had a stroke. In certain embodiments, the individual has undergone a procedure selected from elective stent placement, angioplasty, post percutaneous transluminal angioplasty (PTCA), cardiac transplantation, renal dialysis or cardiopulmonary bypass. 10 In certain embodiments, the individual has an inflammatory disease. In certain such embodiments, the inflammatory disease is selected from inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or osteoarthritis. Guidelines for lipid-lowering therapy were established in 2001 by Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., 15 Circulation, 2004, 110, 227-239). The guidelines include obtaining a complete lipoprotein profile, typically after a 9 to 12 hour fast, for determination of LDL-C, total cholesterol, and HDL-C levels. According to the most recently established guidelines, LDL-C levels of 130-159 mg/dL, 160-189 mg/dL, and greater than or equal to 190 mg/dL are considered borderline high, high, and very high, respectively. Total cholesterol levels of 200-239 and greater than or equal to 240 mg/dL are considered borderline high 20 and high, respectively. HDL-C levels of less than 40 mg/dL are considered low. In certain embodiments, the individual has been identified as in need of lipid-lowering therapy. In certain such embodiments, the individual has been identified as in need of lipid-lowering therapy according to the guidelines established in 2001 by Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP), and updated in 2004 (Grundy et al., Circulation, 2004, 110, 227 25 239). In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 190 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 160 mg/dL. In certain such embodiments, the individual in need of lipid-lowering therapy has LDL-C above 130 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy has LDL C above 100 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should 30 maintain LDL-C below 160 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 130 mg/dL. In certain such embodiments the individual in need of lipid-lowering therapy should maintain LDL-C below 100 mg/dL. In certain such embodiments the individual should maintain LDL-C below 70 mg/dL. In certain embodiments the invention provides methods for reducing CRP in an individual. In 35 certain such embodiments, the reduction in CRP is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, and at least 100%.

WO 2007/146511 PCT/US2007/068401 -97 In certain embodiments, the methods provided by the present invention do not lower HDL-C. In certain embodiments, the methods provided by the present invention do not result in accumulation of lipids in the liver. In certain embodiments, the methods provided by the present invention do not cause hepatic steatosis. 5 In certain embodiments, the invention provides methods for lowering CRP concentration in a subject while reducing side effects associated with treatment. In certain such embodiments, a side effect is liver toxicity. In certain such embodiments, a side effect is abnormal liver function. In certain such embodiments, a side effect is elevated alanine aminotransferase (ALT). In certain such embodiments, a side effect is elevated aspartate aminotransferase (AST). 10 In certain embodiments, the invention provides methods for lowering CRP concentration in a subject who is not reaching target LDL-C levels as a result of lipid-lowering therapy. In certain such embodiments, a short antisense compound targeted to a CRP nucleic acid is the only pharmaceutical agent administered to the subject. In certain such embodiments, the subject has not complied with recommended lipid-lowering therapy. In certain such embodiments, a pharmaceutical composition of the 15 invention is co-administered with an additional different lipid-lowering therapy. In certain such embodiments, an additional lipid-lowering therapy is LDL-apheresis. In certain such embodiments, an additional lipid-lowering therapy is a statin. In certain such embodiments, an additional lipid-lowering therapy is ezetimibe. In certain embodiments, the invention provides methods for lowering CRP concentration in a 20 statin-intolerant subject. In certain such embodiments, the subject has creatine kinase concentration increases as a result of statin administration. In certain such embodiments, the subject has liver function abnormalities as a result of statin administration. In certain such embodiments the subject has muscle aches as a result of statin administration. In certain such embodiments the subject has central nervous system side effects as a result of statin administration. In certain embodiments, the subject has not 25 complied with recommended statin administration. In certain embodiments, the invention provides methods for reducing coronary heart disease risk in a subject. In certain embodiments the invention provides methods for slowing the progression of atherosclerosis in a subject. In certain such embodiments the invention provides methods for stopping the progression of atherosclerosis in a subject. In certain such embodiments the invention provides methods 30 for reducing the size and/or prevalence of atherosclerotic plaques in a subject. In certain embodiments the methods provided reduce a subject's risk of developing atherosclerosis. In certain embodiments the methods provided improve the cardiovascular outcome in a subject. In certain such embodiments improved cardiovascular outcome is the reduction of the risk of developing coronary heart disease. In certain such embodiments, improved cardiovascular outcome is a reduction in 35 the occurance of one or more major cardiovascular events, which include, but are not limited to, death, myocardial infarction, reinfarction, stroke, cardiogenic shock, pulmonary edema, cardiac arrest, and atrial dysrhythmia. In certain such embodiments, the improved cardiovascular outcome is evidenced by WO 2007/146511 PCT/US2007/068401 -98 improved carotid intimal media thickness. In certain such embodiments, improved carotid intimal media thickness is a decrease in thickness. In certain such embodiments, improved carotid intimal media thickness is a prevention an increase of intimal media thickness. In certain embodiments a pharmaceutical composition comprising a short antisense compound 5 targeted to a CRP nucleic acid is for use in therapy. In certain embodiments, the therapy is the reduction of CRP in an individual. In certain embodiments, the therapy is the treatment of hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, or early 10 onset coronary heart disease. In additional embodiments, the therapy is the reduction of CHD risk. In certain the therapy is prevention of atherosclerosis. In certain embodiments, the therapy is the prevention of coronary heart disease. In certain embodiments, the therapy is the treatment of acute coronary syndrome, chronic renal failure, vascular injury, arterial occlusion, atherothrombosis, unstable angina, post peripheral vascular disease, post myocardial infarction (MI), thrombosis, deep vein thrombus, end 15 stage renal disease (ESRD), complement activation, congestive heart failure, or systemic vasculitis. In certain embodiments the therapy is the treatment of an individual who has undergone a procedure selected from elective stent placement, angioplasty, post percutaneous transluminal angioplasty (PTCA), cardiac transplantation, renal dialysis or cardiopulmonary bypass. In certain embodiments, the therapy is the treatment of an inflammatory disorder. 20 In certain embodiments a pharmaceutical composition comprising a short antisense compound targeted to a CRP nucleic acid is used for the preparation of a medicament for reducing CRP in an individual. In certain embodiments pharmaceutical composition comprising a short antisense compound targeted to a CRP nucleic acid is used for the preparation of a medicament for reducing coronary heart disease risk. In certain embodiments a short antisense compound targeted to a CRP nucleic acid is used 25 for the preparation of a medicament for the treatment of hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, a risk of developing atherosclerosis, coronary heart disease, a history of coronary heart disease, early onset coronary heart disease, or one or more risk factors for coronary heart disease. 30 In certain embodiments, a short antisense compound targeted to a CRP nucleic acid is used for the preparation of a medicament for the treatment of acute coronary syndrome, chronic renal failure, vascular injury, arterial occlusion, atherothrombosis, unstable angina, post peripheral vascular disease, post myocardial infarction (MI), thrombosis, deep vein thrombus, end-stage renal disease (ESRD), complement activation, congestive heart failure, or systemic vasculitis. In certain embodiments, a short 35 antisense compound targeted to a CRP nucleic acid is used for the preparation of a medicament for the treatment of an individual who has had a stroke. In certain embodiments, a short antisense compound targeted to a CRP nucleic acid is used for WO 2007/146511 PCT/US2007/068401 -99 the preparation of a medicament for the treatment in an individual who has undergone a procedure selected from elective stent placement, angioplasty, post percutaneous transluminal angioplasty (PTCA), cardiac transplantation, renal dialysis or cardiopulmonary bypass. In certain embodiments, a short antisense compound targeted to a CRP nucleic acid is used for 5 the preparation of a medicament for the treatment of an inflammatory disease. In certain such embodiments, a short antisense compound targeted to a CRP nucleic acid is used for the preparation of a medicament for the treatment of inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or osteoarthritis. 10 CRP Combination Therapies In certain embodiments, one or more pharmaceutical compositions comprising a short antisense compound -targeted to a CRP nucleic acid are co-administered with one or more other pharmaceutical agents. In certain embodiments, the one or more other pharmaceutical agents is a lipid-lowering agent. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease 15 or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more 20 pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other phannaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In 25 certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately. In certain embodiments, pharmaceutical agents that may be co-administered with a 30 pharmaceutical composition comprising a short antisense compound targeted to a CRP nucleic acid include lipid-lowering agents. In certain such embodiments, pharmaceutical agents that may be co administered with a pharmaceutical composition of the present invention include, but are not limited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. In certain such embodiments, the lipid-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In 35 certain such embodiments, the lipid-lowering agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the lipid-lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In WO 2007/146511 PCT/US2007/068401 -100 certain such embodiments the dose of a co-administered lipid-lowering agent is the same as the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is lower than the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co 5 administered lipid-lowering agent is greater than the dose that would be administered if the lipid-lowering agent was administered alone. In certain embodiments, a co-administered lipid-lowering agent is a HMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoA reductase inhibitor is a statin. In certain such embodiments the statin is selected from atorvastatin, simvastatin, pravastatin, fluvastatin, and 10 rosuvastatin. In certain embodiments, a co-administered lipid-lowering agent is ISIS 301012. In certain embodiments, a co-administered lipid-lowering agent is a cholesterol absorption inhibitor. In certain such embodiments, cholesterol absorption inhibitor is ezetimibe. In certain embodiments, a co-administered lipid-lowering agent is a co-formulated HMG-CoA 15 reductase inhibitor and cholesterol absorption inhibitor. In certain such embodiments the co-formulated lipid-lowering agent is ezetimibe/simvastatin. In certain embodiments, a co-administered lipid-lowering agent is a microsomal triglyceride transfer protein inhibitor (MTP inhibitor). In certain embodiments, a co-administered pharmaceutical agent is a bile acid sequestrant. In 20 certain such embodiments, the bile acid sequestrant is selected from cholestyramine, colestipol, and colesevelam. In certain embodiments, a co-administered pharmaceutical agent is a nicotinic acid. In certain such embodiments, the nicotinic acid is selected from immediate release nicotinic acid, extended release nicotinic acid, and sustained release nicotinic acid. 25 In certain embodiments, a co-administered pharmaceutical agent is a fibric acid. In certain such embodiments, a fibric acid is selected from gemfibrozil, fenofibrate, clofibrate, bezafibrate, and ciprofibrate. Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising a short antisense compound targeted to a CRP nucleic acid include, but are not 30 limited to, corticosteroids, including but not limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory agents, including, but not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen, COX- 1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins, sulfonylureas, and thiazolidenediones); 35 adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic WO 2007/146511 PCT/US2007/068401 -101 agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines. In certain embodiments, a pharmaceutical composition comprising a short antisense compound targeted to a CRP nucleic acid may be administered in conjuction with a lipid-lowering therapy. In certain 5 such embodiments, a lipid-lowering therapy is therapeutic lifestyle change. In certain such embodiments, a lipid-lowering therapy is LDL apheresis. Certain Short Antisense Compounds Targeted to a CRP nucleic acid In certain embodiments, short antisense compounds are targeted to a CRP nucleic acid having 10 the sequence of GENBANK@ Accession No. NM_000567.1, incorporated herein as SEQ ID NO: 6. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 6 is at least 90% complementary to SEQ ID NO: 6. In certain such embodiments, a short antisense-compound targeted to SEQ ID NO: 6 is at least 95% complementary to SEQ ID NO: 6. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 6 is 100% complementary to SEQ ID NO: 6. In certain 15 embodiments, a short antisense compound targeted to SEQ ID NO: 6 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Table 9. The nucleotide sequence set forth in each SEQ ID NO in Table 9 is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar 20 moiety, an intemucleoside linkage, or a nucleobase. Short antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Table 9 illustrates examples of short antisense compounds targeted to SEQ ID NO: 6. Table 9 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 6. The column 25 labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2' modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2'-deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE 30 nucleotides. Intemucleoside linkages are phosphorothioate. The short antisense compounds comprise 5 methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. 35 In certain embodiments, short antisense compounds targeting a CRP nucleic acid may have any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a CRP nucleic acid have a motif (wing - WO 2007/146511 PCT/US2007/068401 -102 deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8 3, 2-8-2, 1-8-1, 3-6-3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. 5 Table 9: Short Antisense Compounds targeted to SEQ ID NO: 6 5' 3' Seq ID ISIS Target Target NO NO. Site Site Sequence (5'-3') Gapmer Motif 353506 1257 1272 ACTCTGGACCCAAACC 3-10-3 MOE 409 353507 1258 1271 CTCTGGACCCAAAC 2-10-2 MOE 410 353484 1305 1320 CCATTTCAGGAGACCT 3-10-3 MOE 411 353485 1306 1319 CATTTCAGGAGACC 2-10-2 MOE 412 In certain embodiments, a target region is nucleotides 1305-1320 of NM_000567.1. In certain such embodiments, short antisense compounds targeted to nucleotides 1305-1320 of NM_000567.1 comprise a nucleotide sequence selected from SEQ ID NO: 1305 or 1306. In certain such embodiments, a 10 short antisense compound targeted to nucleotides 263-278 of NM_000567.1 is selected from Isis NO. 353484 or 353485. In certain embodiments, a target region is nucleotides 1257-1272 of NM_000567.1. In certain such embodiments, a short antisense compound targeted to nucleotides 1257-1272 of NM_000567.1 comprises a nucleotide sequence selected from SEQ ID NO 1257 or 1258. In certain such embodiments, a 15 short antisense compound targeted to nucleotides 428-483 of NM_000567.1 is selected from Isis NO. 353506 or 353507. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 9 to 14 nucleotides in length. 20 In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a CRP nucleic acid comprise at least 25 one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, p-D 30 Methyleneoxy (4'-CH 2 -0-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA, Aminooxy (4'-CH 2 -0-N(R) 2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, 0-C 1 -Clo alkyl, OCF 3 , 0-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -0-N(Rm)(R), and O-CH 2 -C(=0)-N(Rm)(R.), where WO 2007/146511 PCT/US2007/068401 -103 each Rm and R, is, independently, H or substituted or unsubstituted CI-Co alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, 5 eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. 10 In certain embodiments, short antisense compounds targeted to a CRP nucleic acid have uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 8 15 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted 20 to a CRP nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid comprise 9 to 15 monomers. In certain 25 embodiments, short antisense compounds targeted to a CRP nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a CRP nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of CRP. In 30 certain embodiments, such methods comprise use of one or more short antisense compound targeted to a CRP nucleic acid, wherein the short antisense compound targeted to a CRP nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of CRP using one or more short antisense compounds 35 targeted to a CRP nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 8 monomers in length. In certain embodiments, methods WO 2007/146511 PCT/US2007/068401 -104 of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a 5 CRP nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 14 10 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating CRP comprise use of a short antisense compound targeted to a CRP nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of CRP comprise use of a short 15 antisense compound targeted to a CRP nucleic acid comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of CRP comprise use of a short antisense compound targeted to a CRP nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of CRP comprise use of a short antisense compound targeted to a CRP nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of CRP 20 comprise use of a short antisense compound targeted to a CRP nucleic acid comprising 12 or 14 nucleotides or nucleosides. 6. Glucocorticoid Receptor (GCCR) Glucocorticoids were among the first steroid hormones to be identified and are responsible for a 25 multitude of physiological functions, including the stimulation of gluconeogenesis, decreased glucose uptake and utilization in peripheral tissues, increased glycogen deposition, suppression of immune and inflammatory responses, inhibition of cytokine synthesis and acceleration of various developmental events. Glucocorticoids are also especially important for combating stress. Stress-induced elevation of glucocorticoid synthesis and release leads to, among other responses, increased ventricular workload, 30 inhibition of inflammatory mediators, inhibition of cytokine synthesis and increased glucose production (Karin, Cell, 1998, 93, 487-490). Both natural glucocorticoids and their synthetic derivatives exert their action through the glucocorticoid receptor, a ubiquitously expressed cytoplasmic member of the nuclear hormone superfamily of receptors. Human glucocorticoid receptor is also known as nuclear receptor subfamily 3, 35 group C, member 1; NR3Cl; GCCR; GCR; GRL; Glucocorticoid receptor, lymphocyte. The gene is located on human chromosome 5ql 1-ql 3 and consists of 9 exons (Encio and Detera-Wadleigh, J Biol Chem, 1991, 266, 7182-7188; Gehring et al., Proc Natl Acad Sci U S A, 1985, 82, 3751-3755). Multiple WO 2007/146511 PCT/US2007/068401 -105 forms of human glucocorticoid receptor mRNA exist: a 5.5 kb human glucocorticoid receptor a cDNA containing exons 1-8 and exon 9a; a 4.3 kb human glucocorticoid receptor p cDNA containing exons 1-8 and exon 9p; and a 7.0 kb human glucocorticoid receptor a cDNA containing exons 1-8 and the entire exon 9, which includes exon 9a, exon 9P and the 'J region', which is flanked by exons 9a and 9P 5 (Hollenberg et al., Nature, 1985, 318, 635-641; Oakley et al., J Biol Chem, 1996, 271, 9550-9559). Human glucocorticoid receptor a is the predominant isoform of the receptor and the one that exhibits steroid binding activity (Hollenberg et al., Nature, 1985, 318, 635-641). Additionally, through usage of three different promoters three different exon 1 variants can be transcribed, and alternative splicing of one exon 1 variant can result in three different versions of this exon. Thus, human glucocorticoid receptor 10 mRNA may contain 5 different versions of exon 1 (Breslin et al., Mol Endocrinol, 2001, 15, 1381-1395). Examination of the expression patterns of the a and P isoforms of human glucocorticoid receptor mRNA reveals that the a isoform is more abundantly expressed. Both isoforms are expressed in similar tissues and cell types, including lung, kidney, heart, liver, skeletal muscle, macrophages, neutrophils and peripheral blood mononuclear cells. Only human glucocorticoid receptor a is expressed in colon. At the 15 level of protein, while the a isoform is detected in all tissues examined, the p isoform is undetectable, suggesting that under physiological conditions, the default splicing pathway is the one that produces the a isoform (Pujols et al., Am J Physiol Cell Physiol, 2002, 283, C1324-1331). The p isoform of glucocorticoid receptor binds neither a glucocorticoid agonist nor an antagonist. Furthermore, the P isoform is localized primarily in the nucleus in transfected cells, independent of hormone stimulation. 20 When both isoforms are expressed in the same cell, the glucocorticoid receptor p inhibits the hormone induced, glucocorticoid receptor a-mediated stimulation of gene expression, suggesting that the p isoform functions as an inhibitor of glucocorticoid receptor a activity (Oakley et al., J Biol Chem, 1996, 271, 9550-9559). Unless otherwise noted, the human glucocorticoid receptor described herein is defined as the ubiquitous product(s) of the gene located on chromosome 5ql I -ql3. 25 Cell lines transfected with a complementary glucocorticoid receptor antisense RNA strand exhibited a reduction in glucocorticoid receptor mRNA levels and a decreased response to the glucocorticoid receptor agonist dexamethasone (Pepin and Barden, Mol Cell Biol, 1991, 11, 1647-1653). Transgenic mice bearing an antisense glucocorticoid receptor gene construct were used to study the glucocorticoid feedback effect on the hypothalamus-pituitary-adrenal axis (Pepin et al., Nature, 1992, 30 355, 725-728). In another study of similarly genetically engineered mice, energy intake and expenditure, heart and vastus lateralis muscle lipoprotein lipase activity, and heart and brown adipose tissue norepinephrine were lower than in control animals. Conversely, fat content and total body energy were significantly higher than in control animals. These results suggest that a defective glucocorticoid receptor system may affect energy balance through increasing energetic efficiency, and they emphasize the 35 modulatory effects of hypothalamic-pituitary-adrenal axis changes on muscle lipoprotein lipase activity (Richard et al., Am JPhysiol, 1993, 265, R146-150). Behavorial effects of glucocorticoid receptor antagonists have been measured in animal models WO 2007/146511 PCT/US2007/068401 -106 designed to assess anxiety, learning and memory. Reduced expression of glucocorticoid receptor in rats long-term intracerebroventricularly infused with antisense oligodeoxynucleotides targeting glucocorticoid receptor mRNA did not interfere with spatial navigation in the Morris water maze test (Engelmann et al., Eur JPharmacol, 1998, 361, 17-26). Bilateral infusion of an antisense oligodeoxynucleotide targeting 5 the glucocorticoid receptor mRNA into the dentate gyrus of the rat hippocampus reduced the immobility of rats in the Porsolt forced swim test (Korte et al., Eur JPharmacol, 1996, 301, 19-25). Glucocorticoids are frequently used for their immunosuppressive, anti-inflammatory effects in the treatment of diseases such as allergies, athsma, rheumatoid arthritis, AIDS, systemic lupus erythematosus and degenerative osteoarthritis. Negative regulation of gene expression, such as that caused by the 10 interaction of glucocorticoid receptor with NF-kB, is proposed to be at least partly responsible for the anti-inflammatory action of glucocorticoids in vivo. Interleukin-6, tumor necrosis factor a and interleukin-1 are the three cytokines that account for most of the hypothalamic-pituitary-adrenal (HPA) axis stimulation during the stress of inflammation. The HPA axis and the systemic sympathetic and adrenomedullary system are the peripheral components of the stress system, responsible for maintaining 15 basal and stress-related homeostasis. Glucocorticoids, the end products of the HPA axis, inhibit the production of all three inflammatory cytokines and also inhibit their effects on target tissues, with the exception of interleukin-6, which acts synergistically with glucocorticoids to stimulate the production of acute-phase reactants. Glucocorticoid treatment decreases the activity of the HPA axis (Chrousos, N Engl J Med, 1995, 332, 1351-1362). 20 In some cases, patients are refractory to glucocorticoid treatment. One reason for this resistance to steroids lies with mutations or polymorphisms present in the glucocorticoid receptor gene. A total of 15 missense, three nonsense, three frameshift, one splice site, and two alternative spliced mutations, as well as 16 polymorphisms, have been reported in the NR3C1 gene in association with glucocorticoid resistance (Bray and Cotton, Hum Mutat, 2003, 21, 557-568). Additional studies in humans have 25 suggested a positive association between metabolic syndrome incidence and progression, with alleles at the glucocorticoid receptor (GR) gene (Rosmond, Obes Res, 2002, 10, 1078-1086). Other cases of glucocorticoid insensitivity are associated with altered expression of glucocorticoid receptor isoforms. A study of human glucocorticoid receptor p isoform mRNA expression in glucocorticoid-resistant ulcerative colitis patients revealed the presence of this mRNA was 30 significantly higher than in the glucocorticoid-sensitive patients, suggesting that the expression of human glucocorticoid receptor p mRNA in the peripheral blood mononuclear cells may serve as a predictor of glucocorticoid response in ulcerative colitis (Honda et al., Gastroenterology, 2000, 118, 859-866). Increased expression of glucocorticoid receptor p is also observed in a significantly high number of glucocorticoid-insensitive asthmatics. Additionally, cytokine-induced abnormalities in the DNA binding 35 capacity of the glucocorticoid receptor were found in peripheral blood mononuclear cells from glucocorticoid-insensitive patients transfection, and HepG2 cells with the glucocorticoid receptor P gene resulted in a significant reduction of glucocorticoid receptor ax DNA-binding capacity (Leung et al., J Exp WO 2007/146511 PCT/US2007/068401 -107 Med, 1997, 186, 1567-1574). Dexamethasone binding studies demonstrate that human glucocorticoid receptor 0 does not alter the affinity of glucocorticoid receptor a for hormonal ligands, but rather its ability to bind to the GRE (Bamberger et al., J Clin Invest, 1995, 95, 2435-2441). Taken together, these results illustrate that glucocorticoid receptor P, through competition with glucocorticoid receptor a for 5 GRE target sites, may function as a physiologically and pathophysiologically relevant endogenous inhibitor of glucocorticoid action. In the liver, glucocorticoid agonists increase hepatic glucose production by activating the glucocorticoid receptor, which subsequently leads to increased expression of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. Through gluconeogenesis, 10 glucose is formed through non-hexose precursors, such as lactate, pyruvate and alanine (Link, Curr Opin Investig Drugs, 2003, 4, 421-429). Steroidal glucocorticoid receptor antagonists such as RU 486 have been tested in rodent models of diabetes. Mice deficient in the leptin receptor gene, termed db/db mice, are genetically obese, diabetic and hyperinsulinemic. Treatment of hyperglycemic db/db mice with RU 486 decreased blood glucose levels by approximately 49%, without affecting plasma insulin levels. 15 Additionally, RU 486 treatment reduced the expression of glucocorticoid receptor responsive genes PEPCK, glucose-6-phosphatase, glucose transporter type 2 and tyrosine aminotransferase in db/db mice as compared to untreated animals (Friedman et al., J Biol Chem, 1997, 272, 31475-31481). RU 486 also ameliorates diabetes in the ob/ob mouse model of diabetes, obesity and hyperinsulinemia, through a reduction in serum insulin and blood glucose levels (Gettys et al., Int J Obes Relat Metab Disord, 1997, 20 21, 865-873). As increased gluconeogenesis is considered to be the major source of increased glucose production in diabetes, a number of therapeutic targets for the inhibition of hepatic glucose production have been investigated. Due to the ability of antagonists of the glucocorticoid receptor to ameliorate diabetes in animal models, such compounds are among the potential therapies being explored. However, 25 there are detrimental systemic effects of glucocorticoid receptor antagonists, including activation of the HPA axis (Link, Curr Opin Investig Drugs, 2003, 4, 421-429). Increased HPA axis activity is associated with suppression of immune-related inflammatory action, which can increase susceptibility to infectious agents and neoplasms. Conditions associated with suppression of immune-mediated inflammation through defects in the HPA axis, or its target tissues, include Cushing's syndrome, chronic stress, chronic 30 alcoholism and melancholic depression (Chrousos, N Engl J Med, 1995, 332, 1351-1362). Thus, it is of great value to develop liver-specific glucocorticoid receptor antagonists. Steroidal glucocorticoid receptor antagonists have been conjugated to bile acids for the purpose of targeting them to the liver (Apelqvist et al., 2000). Currently, there are no known therapeutic agents that target the glucocorticoid receptor without undesired peripheral effects (Link, Curr Opin Investig Drugs, 2003, 4, 421-429). 35 Consequently, there remains a long felt need for agents capable of effectively inhibiting hepatic glucocorticoid receptor.

WO 2007/146511 PCT/US2007/068401 -108 Definitions "Glucocorticoid receptor" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. Glucocorticoid receptor is generally referred to as GCCR. 5 "GCCR nucleic acid" means any nucleic acid encoding GCCR. For example, in certain embodiments, a GCCR nucleic acid includes, without limitation, a DNA sequence encoding GCCR, an RNA sequence transcribed from DNA encoding GCCR, and an mRNA sequence encoding GCCR. "GCCR mRNA" means an mRNA encoding GCCR. 10 Therapeutic indications Antisense technology is an effective means of reducing the expression of specific gene products and therefore is useful in a number of therapeutic, diagnostic and research applications for the modulation of glucocorticoid receptor expression. Furthermore, in certain embodiments, liver is one of the tissues in which the highest concentrations of antisense oligonucleotides are found following administration (Geary 15 et al., Curr. Opin. Investig. Drugs, 2001, 2, 562-573). Therefore, in such embodiments, antisense technology represents an attractive method for the liver-specific inhibition of glucocorticoid receptor. In certain embodiments, short antisense compounds targeted to a nucleic acid encoding glucocorticoid receptor are preferentially distributed to the liver. In certain embodiments, short antisense compounds have increased potency in the liver when compared to a longer parent compound. In certain 20 embodiments, target RNA is predominantly expressed in the liver. For therapeutics, a subject, suspected of having a disease or disorder which can be treated by modulating the expression of GCCR is treated by administering one or more short antisense compound. In a non-limiting example, the methods comprise the step of administering to an animal a therapeutically effective amount of a short antisense compound. Certain short antisense compounds inhibit the activity 25 of GCCR and/ or inhibit expression of GCCR. In certain embodiments, the activity or expression of GCCR in a subject is inhibited by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%. In certain embodiments, the activity or expression of GCCR in a subject is inhibited by at least 30%. In certain 30 embodiments, the activity or expression of GCCR in a subject is inhibited by at least 50% or more. The reduction of the expression of GCCR may be measured, for example, in blood, plasma, serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. In certain embodiments, cells contained within such fluids, tissues or organs being analyzed comprise nucleic acids encoding GCCR and/or they contain the GCCR protein itself. 35 Certain pharmaceutical and other compositions comprising short antisense compounds are also provided. In certain embodiments, short antisense compounds are be utilized in pharmaceutical compositions by adding to them an effective amount of a compound to a suitable pharmaceutically WO 2007/146511 PCT/US2007/068401 -109 acceptable diluent or carrier. In certain embodiments, short antisense compounds targeting a GCCR nucleic acid have any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a GCCR nucleic acid have a motif (wing 5 deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8 3, 2-8-2, 1-8-1, 3-6-3 or 1-6-1, . In certain embodiments, short antisense compounds targeting a GCCR nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-10-1, 2-10-2, 3-10-3, and 1-9-2. . In certain embodiments, short antisense compounds targeting a GCCR nucleic acid have a motif (wing deoxy gap -wing) selected from 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 2-8-2, 1-8-1, 3-6-3 or 1-6-1, 10 more preferably 2-10-2 and 2-8-2. In certain embodiments, provided herein are methods of treating an individual by administering one or more short antisense compound targeted to a GCCR nucleic acid or a pharmaceutical composition comprising such compound. Further provided are methods of treating a subject having a disease or conditions associated with GCCR activity by administering a short antisense compound targeted to a 15 GCCR nucleic acid. In addition to diabetes, particularly type 2 diabetes, diseases and conditions associated with GCCR include but are not limited to, obesity, Metabolic syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases such as asthma, rhinitis and arthritis, allergy, autoimmune disease, immunodeficiency, anorexia, cachexia, bone loss or bone frailty, and wound healing. Metabolic syndrome, metabolic syndrome X or simply Syndrome X refers to a cluster of risk 20 factors that include obesity, dyslipidemia, particularly high blood triglycerides, glucose intolerance, high blood sugar and high blood pressure. In certain embodiments, short antisense compounds targeted to GCCR are used for amelioration of hyperglycemia induced by systemic steroid therapy. Moreover, antisense technology provides a means of inhibiting the expression of the glucocorticoid receptor p isoform, demonstrated to be overexpressed in patients refractory to glucocorticoid treatment. 25 In certain embodiments, the invention provides short antisense compounds targeted to a nucleic acid encoding GCGR, and which modulate the expression of glucocorticoid receptor. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of screening for modulators of glucocorticoid receptor and methods of modulating the expression of glucocorticoid receptor in cells, tissues or animals comprising contacting said cells, tissues 30 or animals with one or more of the compounds or compositions of the invention. Methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of glucocorticoid receptor are also set forth herein. Such methods comprise administering a therapeutically or prophylactically effective amount of one or more of the compounds or compositions of the invention to the person in need of treatment. 35 Certain Short Antisense Compounds Targeted to a GCCR nucleic acid In certain embodiments, short antisense compounds are targeted to a GCCR nucleic acid having WO 2007/146511 PCT/US2007/068401 -110 the sequence of nucleotides 1 to 106000 of GENBANK@ Accession No. ACO 12634, incorporated herein as SEQ ID NO: 8. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 8 is at least 90% complementary to SEQ ID NO: 8. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 8 is at least 95% complementary to SEQ ID NO: 8. In certain such embodiments, 5 a short antisense compound targeted to SEQ ID NO: 8 is 100% complementary to SEQ ID NO: 8. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 8 includes a nucleotide sequence selected from the nucleotide sequences set forth in Tables 10 and 11. The nucleotide sequence set forth in each SEQ ID NO in Tables 10 and 11 is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense 10 compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Short antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an intemucleoside linkage, or a nucleobase. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise a 15 gapmer motif. In certain embodiments, a short antisense compound targeted to a GCCR nucleic acid comprises a 2-10-2 gapmer motif. Tables 10 and 11 illustrate examples of short antisense compounds targeted to SEQ ID NO: 8. Table 10 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 8. Table 11 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 8. 20 The column labeled 'gapmer motif' indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif' column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing 25 segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. 30 Table 10: Short Antisense Compounds targeted to SEQ ID NO: 8 5' 3' SEQ ISIS Target Target ID NO. Site Site Sequence (5'-3') Gapmer Motif NO 371644 88142 88155 TTTGGGAGGTGGTC 2-10-2 MOE 413 371645 88156 88169 CACACCAGGCAGAG 2-10-2 MOE 414 371649 88212 88225 CTTTACAGCTTCCA 2-10-2 MOE 415 371651 88242 88255 CACTACCTTCCACT 2-10-2 MOE 416 371652 88248 88261 AACACACACTACCT 2-10-2 MOE 417 371653 88256 88269 CTCTTCAAAACACA 2-10-2 MOE 418 WO 2007/146511 PCT/US2007/068401 -111 371665 92037 92050 GTAATTGTGCTGTC 2-10-2 MOE 419 371669 92086 92099 TTTTTCTTCGAATT 2-10-2 MOE 420 371671 92114 92127 CATTTTCGATAGCG 2-10-2 MOE 421 371673 92142 92155 ACCTTCCAGGTTCA 2-10-2 MOE 422 Table 11: Short antisense compounds targeted to SEQ ID NO: 8 and having 1 or 2 mismatches 5' 3' SEQ Target Target ID ISIS NO Site Site Sequence (5'-3') Gapmer Motif NO 371638 2039 2052 ATAGGAAGCATAAA 2-10-2 MOE 423 371650 4949 4962 TCTTTTAAAGAAGA 2-10-2 MOE 424 371673 10187 10200 ACCTTCCAGGTTCA 2-10-2 MOE 422 371660 13465 13478 AAGGATATTTTAAA 2-10-2 MOE 425 371660 14428 14441 AAGGATATTTTAAA 2-10-2 MOE 425 371654 15486 15499 GAACAAAAATTAAA 2-10-2 MOE 427 371661 16638 16651 TTCCACAGATCTGT 2-10-2 MOE 428 371653 17892 17905 CTCTTCAAAACACA 2-10-2 MOE 418 371679 18444 18457 TTTATAAAGTAAAG 2-10-2 MOE 429 371645 19816 19829 CACACCAGGCAGAG 2-10-2 MOE 414 371638 21555 21568 ATAGGAAGCATAAA 2-10-2 MOE 423 371650 21775 21788 TCTTAAAGAAGA 2-10-2 MOE 424 371679 21902 21915 TTTATAAAGTAAAG 2-10-2 MOE 429 371655 22507 22520 TACTGTGAGAAATA 2-10-2 MOE 433 371655 22722 22735 TACTGTGAGAAATA 2-10-2 MOE 433 371672 25662 25675 TTCCAGCTTGAAGA 2-10-2 MOE 435 371678 25926 25939 GATCAGTTCTCATG 2-10-2 MOE 436 371655 26041 26054 TACTGTGAGAAATA 2-10-2 MOE 433 371638 29770 29783 ATAGGAAGCATAAA 2-10-2 MOE 423 371668 30551 30564 TTATCAATGATGCA 2-10-2 MOE 439 371670 40584 40597 GCATGCTGGACAGT 2-10-2 MOE 440 371654 43331 43344 GAACAAAAATTAAA 2-10-2 MOE 427 371650 46024 46037 TCTTTTAAAGAAGA 2-10-2 MOE 424 371659 50372 50385 TTGCACCTGAACTA 2-10-2 MOE 443 371634 50565 50578 CAGAATATATTTCT 2-10-2 MOE 444 371673 56942 56955 ACCTTCCAGGTTCA 2-10-2 MOE 422 371654 62372 62385 GAACAAAAATTAAA 2-10-2 MOE 427 371679 63537 63550 TTTATAAAGTAAAG 2-10-2 MOE 429 371654 64908 64921 GAACAAAAATTAAA 2-10-2 MOE 427 371661 65795 65808 TTCCACAGATCTGT 2-10-2 MOE 428 371645 70997 71010 CACACCAGGCAGAG 2-10-2 MOE 414 371661 77400 77413 TTCCACAGATCTGT 2-10-2 MOE 428 371663 82329 82342 ATAAGAGATTAAAA 2-10-2 MOE 450 371633 83426 83439 TCCCCCTTCTCATT 2-10-2 MOE 451 371662 85873 85886 GGGCATTGTTAAAA 2-10-2 MOE 452 371654 86476 86489 GAACAAAAATTAAA 2-10-2 MOE 427 371679 86516 86529 TTTATAAAGTAAAG 2-10-2 MOE 429 371641 88097 88110 AGAACTCACATCTG 2-10-2 MOE 455 371642 88111 88124 GAGCTGGACGGAGG 2-10-2 MOE 456 371646 88170 88183 AAGCTTCATCGGAG 2-10-2 MOE 457 371647 88184 88197 ATAATGGCATCCCG 2-10-2 MOE 458 371650 88226 88239 TCTTTTAAAGAAGA 2-10-2 MOE 424 371673 91493 91506 ACCTTCCAGGTTCA 2-10-2 MOE 422 371664 92030 92043 TGCTGTCCTATAAG 2-10-2 MOE 460 WO 2007/146511 PCT/US2007/068401 -112 371666 92044 92057 CACAAAGGTAATTG 2-10-2 MOE 461 371667 92058 92071 ATCATTTCTTCCAG 2-10-2 MOE 462 371668 92072 92085 TTATCAATGATGCA 2-10-2 MOE 463 371670 92100 92113 GCATGCTGGACAGT 2-10-2 MOE 440 371672 92128 92141 TTCCAGCTTGAAGA 2-10-2 MOE 435 371674 92147 92160 CCATTACCTTCCAG 2-10-2 MOE 466 371637 92983 92996 GCATAAACAGGGTT 2-10-2 MOE 467 371654 93928 93941 GAACAAAAATTAAA 2-10-2 MOE 427 371641 99772 99785 AGAACTCACATCTG 2-10-2 MOE 455 371679 99883 99896 TTTATAAAGTAAAG 2-10-2 MOE 429 371660 99933 99946 AAGGATATTTTAAA 2-10-2 MOE 425 371635 105004 105017 TATGAAAGGAATGT 2-10-2 MOE 472 371654 105028 105041 GAACAAAAATTAAA 2-10-2 MOE 427 371676 106482 106495 TTCCTTAAGCTTCC 2-10-2 MOE 474 371650 107838 107851 TCTTTTAAAGAAGA 2-10-2 MOE 424 371673 110922 110935 ACCTTCCAGGTTCA 2-10-2 MOE 422 371673 111580 111593 ACCTTCCAGGTTCA 2-10-2 MOE 422 371634 114608 114621 CAGAATATATTTCT 2-10-2 MOE 444 371638 115040 115053 ATAGGAAGCATAAA 2-10-2 MOE 423 371660 116244 116257 AAGGATATTTTAAA 2-10-2 MOE 425 371663 116657 116670 ATAAGAGATTAAAA 2-10-2 MOE 450 371673 118068 118081 ACCTTCCAGGTTCA 2-10-2 MOE 422 371666 118834 118847 CACAAAGGTAATTG 2-10-2 MOE 461 371660 119858 119871 AAGGATATTTTAAA 2-10-2 MOE 425 371660 120210 120223 AAGGATATTTTAAA 2-10-2 MOE 425 371662 120876 120889 GGGCATTGTTAAAA 2-10-2 MOE 452 371655 124004 124017 TACTGTGAGAAATA 2-10-2 MOE 433 371656 124170 124183 GAACAGTTAAACAT 2-10-2 MOE 485 In certain embodiments, a target region is nucleotides 88142-88269 of SEQ ID NO: 8. In certain embodiments, a short antisense compound is targeted to nucleotides 88142-88269 of SEQ ID NO: 8. In certain such embodiments, a short antisense compound targeted to nucleotides 88142-88269 comprises a 5 nucleotide sequence selected from SEQ ID NO 413, 414, 415, 416, 417, or 418. In certain such embodiments, an antisense compound targeted to nucleotides 88142-88269 of SEQ ID NO: 8 is selected from Isis NO. 371644, 371645, 371649, 371651, 371652, or 371653. In certain embodiments, a target region is nucleotides 88142-88169 of SEQ ID NO: 8. In certain embodiments, a short antisense compound is targeted to nucleotides 88142-88169 of SEQ ID NO: 8. In 10 certain such embodiments, a short antisense compound targeted to nucleotides 88142-88169 comprises a nucleotide sequence selected from SEQ ID NO 413 or 414. In certain such embodiments, an antisense compound targeted to nucleotides 88142-88169 of SEQ ID NO: 8 is selected from Isis NO. 371644 or 371645. In certain embodiments, a target region is nucleotides 88242-88269 of SEQ ID NO: 8. In certain 15 embodiments, a short antisense compound is targeted to nucleotides 88242-88269 of SEQ ID NO: 8. In certain such embodiments, a short antisense compound targeted to nucleotides 88242-88269 comprises a nucleotide sequence selected from SEQ ID NO 416, 417, or 418. In certain such embodiments, an antisense compound targeted to nucleotides 88242-88269 of SEQ ID NO: 8 is selected from Isis NO.

WO 2007/146511 PCT/US2007/068401 -113 371651, 371652, or 371653. In certain embodiments, a target region is nucleotides 92037-92155 of SEQ ID NO: 8. In certain embodiments, a short antisense compound is targeted to nucleotides 92037-92155 of SEQ ID NO: 8. In certain such embodiments, a short antisense compound targeted to nucleotides 92037-92155 comprises a 5 nucleotide sequence selected from SEQ ID NO 419, 420, 421, or 422. In certain such embodiments, an antisense compound targeted to nucleotides 92037-92155 of SEQ ID NO: 8 is selected from Isis NO. 371665, 371669, 371671, or 171673. In certain embodiments, a target region is nucleotides 92114-92155 of SEQ ID NO: 8. In certain embodiments, a short antisense compound is targeted to nucleotides 92114-92155 of SEQ ID NO: 8. In 10 certain such embodiments, a short antisense compound targeted to nucleotides 92114-92155 comprises a nucleotide sequence selected from SEQ ID NO 421 or 422. In certain such embodiments, an antisense compound targeted to nucleotides 92114-92155 of SEQ ID NO: 8 is selected from Isis NO. 371671 or 171673. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 8 to 16, 15 preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. 20 In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a GCCR nucleic acid comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' 25 modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, p-D Methyleneoxy (4'-CH 2 -0-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2 -0-N(R) 2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, O-allyl, O-Cr-Clo alkyl, 30 OCF 3 , 0-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -O-N(Rm)(R.), and O-CH 2 -C(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C 1

-C

10 alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, 35 eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an WO 2007/146511 PCT/US2007/068401 -114 antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid have uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate 5 linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 8 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR 10 nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 14 monomers in length. In certain 15 embodiments, short antisense compounds targeted to a GCCR nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a GCCR 20 nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of GCCR. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to a GCCR nucleic acid, wherein the short antisense compound targeted to a GCCR nucleic acid is from about 25 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of GCCR using one or more short antisense compounds targeted to a GCCR nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating GCCR comprise use of a short antisense 30 compound targeted to a GCCR nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a 35 GCCR nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense WO 2007/146511 PCT/US2007/068401 -115 compound targeted to a GCCR nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 15 monomers in length. In certain 5 embodiments, methods of modulating GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of GCCR comprise use of a short antisense compound 10 targeted to a GCCR nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of GCCR comprise use of a short antisense compound targeted to a GCCR nucleic acid comprising 12 or 14 nucleotides or nucleosides. 15 7. Glucagon Receptor (GCGR) The maintenance of normal glycemia is a carefully regulated metabolic event. Glucagon, the 29 amino acid peptide responsible for maintaining blood glucose levels in the postabsorbative state, increases glucose release from the liver by activating hepatic glycogenolysis, gluconeogenesis, 20 stimulating lipolysis in adipose tissue, and stimulating insulin secretion. During high blood glucose levels, insulin reverses the glucagon-mediated enhancement of glycogenolysis and gluconeogenesis. In patients with diabetes, insulin is either not available or not fully effective. While treatment for diabetes has traditionally focused on increasing insulin levels, antagonism of glucagon function has been considered as an alternative therapy. As glucagon exerts its physiological effects by signaling through the 25 glucagon receptor, the glucagon receptor has been proposed as a potential therapeutic target for diabetes (Madsen et al., Curr. Pharm. Des., 1999, 5, 683-691). Glucagon receptor is belongs to the superfamily of G-protein-coupled receptors having seven transmembrane domains. It is also a member of the smaller sub-family of homologous receptors which bind peptides that are structurally similar to glucagon. The gene encoding human glucagon receptor was 30 cloned in 1994 and analysis of the genomic sequence revealed multiple introns and an 82% identity to the rat glucagon receptor gene (Lok et al., Gene, 1994, 140, 203-209.; MacNeil et al., Biochem. Biophys. Res. Commun., 1994, 198, 328-334). Cloning of the rat glucagon receptor gene also led to the description of multiple alternative splice variants (Maget et al., FEBS Lett., 1994, 351, 271-275). The human glucagon receptor gene is localized to chromosome 17q25 (Menzel et al., Genomics, 1994, 20, 35 327-328). A missense mutation of Gly to Ser at codon 40 in the glucagon receptor gene leads to a 3-fold lower affinity for glucagon (Fujisawa et al., Diabetologia, 1995, 38, 983-985) and this mutation has been linked to several disease states, including non-insulin-dependent diabetes mellitus (Fujisawa et al., WO 2007/146511 PCT/US2007/068401 -116 Diabetologia, 1995, 38, 983-985), hypertension (Chambers and Morris, Nat. Genet., 1996, 12, 122), and central adiposity (Siani et al., Obes. Res., 2001, 9, 722-726). Definitions 5 "Glucagon receptor" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. Glucagon receptor is generally referred to as GCGR but may also be referred to as GR, GGR, MGC138246, MGC93090. "GCGR nucleic acid" means any nucleic acid encoding GCGR. For example, in certain embodiments, a GCGR nucleic acid includes, without limitation, a GCGR sequence encoding GCGR, an 10 RNA sequence transcribed from DNA encoding GCGR, and an mRNA sequence encoding GCGR. "GCGR mRNA" means an mRNA encoding a GCGR protein. Therapeutic Indications Antisense technology is an effective means for reducing glucagon receptor (GCGR) expression 15 and has proven to be uniquely useful in a number of therapeutic, diagnostic, and research applications. As such, in certain embodiments, the present invention provides short antisense compounds targeted to a nucleic acid encoding glucagon receptor, and which modulate the expression of glucagon receptor. Further provided herein are short antisense compounds capable of inhibiting GCGR expression. Also provided herein are methods of treating an individual comprising administering one or more 20 pharmaceutical compositions comprising a short antisense compound targeted to a GCGR nucleic acid. In certain embodiments, because short antisense compounds targeted to a GCGR nucleic acid inhibit GCGR expression, provided herein are methods of treating a subject having a disease or condition associated with GCGR activity by administering one or more pharmaceutical compositions comprising a short antisense compound targeted to a GCGR nucleic acid. For example, provided herein are methods of 25 treating a subject having high blood glucose, hyperglycemia, prediabetes, diabetes, Type 2 diabetes, metabolic syndrome, obesity and/or insulin resistance. Also contemplated herein are pharmaceutical composition comprising one or more short antisense compounds targeted to GCGR and optionally a pharmaceutically acceptable carrier, diluent, enhancer or excipient. Certain compounds of the invention can also be used in the manufacture of a 30 medicament for the treatment of diseases and disorders related to glucagon effects mediated by GCGR. Certain embodiments of the present invention include methods of reducing the expression of GCGR in tissues or cells comprising contacting said cells or tissues with a short antisense compound targeted to a nucleic acid encoding GCGR or pharmaceutical composition comprising such a short antisense compound. In certain such embodiments, the invention provides methods of decreasing blood 35 glucose levels, blood triglyceride levels, or blood cholesterol levels in a subject comprising administering to the subject a short antisense compound or a pharmaceutical composition. Blood levels may be plasma levels or serum levels. Also contemplated are methods of improving insulin sensitivity, methods of WO 2007/146511 PCT/US2007/068401 -117 increasing GLP-1 levels and methods of inhibiting hepatic glucose output in an animal comprising administering to said animal an antisense oligonucleotide or a pharmaceutical composition of the invention. An improvement in insulin sensitivity may be indicated by a reduction in circulating insulin levels. 5 In certain embodiments, the invention provides methods of treating a subject having a disease or condition associated with glucagon activity via GCGR comprising administering to the subject a therapeutically or prophylactically effective amount of a short antisense compound or a pharmaceutical composition. In certain embodiments, such disease or condition may be a metabolic disease or condition. In certain embodiments, the metabolic disease or condition is diabetes, hyperglycemia, hyperlipidemia, 10 metabolic syndrome X, obesity, primary hyperglucagonemia, insulin deficiency, or insulin resistance. In some embodiments, the diabetes is Type 2 diabetes. In some embodiments the obesity is diet-induced. In some embodiments, hyperlipidemia is associated with elevated blood lipid levels. Lipids include cholesterol and triglycerides. In one embodiment, the condition is liver steatosis. In some embodiments, the steatosis is steatohepatitis or non-alcoholic steatohepatitis. 15 In certain embodiments, the invention provides methods of preventing or delaying the onset of elevated blood glucose levels in an animal as well as methods of preserving beta-cell function in an animal using the oligomeric compounds delineated herein. Certain short antisense compounds targeted to GCGR can be used to modulate the expression of GCGR in a subject in need thereof, such as an animal, including, but not limited to, a human In certain 20 embodiments, such methods comprise the step of administering to said animal an effective amount of a short antisense compound that reduces expression of GCGR RNA. In certain embodiments, short antisense compounds effectively reduce the levels or function of GCGR RNA. Because reduction in GCGR mRNA levels can lead to alteration in GCGR protein products of expression as well, such resultant alterations can also be measured. Certain antisense compounds that effectively reduce the levels 25 or function of GCGR RNA or protein products of expression is considered an active antisense compound. In certain embodiments, short antisense compounds reduce the expression of GCGR causing a reduction of RNA by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%. 30 Further provided are methods of screening for modulators of glucagon receptor and methods of modulating the expression of glucagon receptor in cells, tissues or animals comprising contacting said cells, tissues or animals with one or more short antisense compounds targeted to GCGR or with compositions comprising such compounds. Methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of glucagon 35 receptor are also set forth herein. Certain such methods comprise administering a therapeutically or prophylactically effective amount of one or more of the compounds or compositions of the invention to the person in need of treatment.

WO 2007/146511 PCT/US2007/068401 -118 The reduction of the expression of glucagon receptor may be measured, for example, in blood, plasma, serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding glucagon receptor protein and/or the glucagon receptor protein itself. 5 Pharmaceutical and other compositions comprising short antisense compounds are also provided. In certain embodiments short antisense compounds targeted to a nucleic acid encoding GCGR are utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. The short antisense compounds targeting a GCGR nucleic acid may have any one or more 10 properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a GCGR nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8-3, 2-8-2, 1 8-1, 3-6-3 or 1-6-1. In certain embodiments, short antisense compounds targeting a GCGR nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-12-1, 2-10-2, 3-10-3, 3-8-3, 1-1-10-2. 15 Certain Short Antisense Compounds Targeted to a GCGR nucleic acid In certain embodiments, short antisense compounds are targeted to a GCGR nucleic acid having the sequence GENBANK@ Accession No. NM_000160.1, incorporated herein as SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 9 is at least 90% 20 complementary to SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 9 is at least 95% complementary to SEQ ID NO: 9. In certain such embodiments, a short antisense compoundItargeted to SEQ ID NO: 9 is 100% complementary to SEQ ID NO: 9. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 9 includes a nucleotide sequence selected from the nucleotide sequences set forth in Tables 12 and 13. 25 The nucleotide sequences set forth in each SEQ ID NO in Tables 12 and 13 are independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Short antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar 30 moiety, an internucleoside linkage, or a nucleobase. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise a gapmer motif In certain embodiments, a short antisense compound targeted to a GCCR nucleic acid comprises a 3-10-3 gapmer motif. In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise a gapmer motif. In certain embodiments, a short antisense compound 35 targeted to a GCCR nucleic acid comprises a 3-8-3 gapmer motif In certain embodiments, short antisense compounds targeted to a GCCR nucleic acid comprise a gapmer motif. In certain embodiments, a short antisense compound targeted to a GCCR nucleic acid comprises a 2-10-2 gapmer motif.

WO 2007/146511 PCT/US2007/068401 -119 Tables 12 and 13 illustrate examples of short antisense compounds targeted to SEQ ID NO: 9. Table 12 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 9. Table 13 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 9. The column labeled 'gapmer motif' indicates the wing-gap-wing motif of each short antisense 5 compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif' column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense 10 compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. 15 Table 12: Short Antisense Compounds targeted to SEQ ID NO: 9 5' 3' SEQ ISIS Target Target Gapmer ID NO. Site Site Sequence (5'-3') Motif NO 338463 378 393 TAGAGCTTCCACTTCT 3-10-3 MOE 486 338534 378 391 GAGCTTCCACTTCT 3-8-3 MOE 487 327130 499 512 TGTTGGCCGTGGTA 3-8-3 MOE 488 327131 500 513 ATGTTGGCCGTGGT 3-8-3 MOE 489 327132 501 514 GATGTTGGCCGTGG 3-8-3 MOE 490 327133 502 515 AGATGTTGGCCGTG 3-8-3 MOE 491 327134 503 516 GAGATGTTGGCCGT 3-8-3 MOE 492 327135 504 517 GGAGATGTTGGCCG 3-8-3 MOE 493 327136 505 518 AGGAGATGTTGGCC 3-8-3 MOE 494 327137 506 519 CAGGAGATGTTGGC 3-8-3 MOE 495 327138 507 520 GCAGGAGATGTTGG 3-8-3 MOE 496 327139 508 521 GGCAGGAGATGTTG 3-8-3 MOE 497 327140 531 544 GTGGTGCCAAGGCA 3-8-3 MOE 498 327141 532 545 TGTGGTGCCAAGGC 3-8-3 MOE 499 327142 533 546 TTGTGGTGCCAAGG 3-8-3 MOE 500 327143 534 547 TTTGTGGTGCCAAG 3-8-3 MOE 501 327144 535 548 CTTTGTGGTGCCAA 3-8-3 MOE 502 327145 536 549 ACTTTGTGGTGCCA 3-8-3 MOE 503 327146 537 550 CACTTTGTGGTGCC 3-8-3 MOE 504 327147 538 551 GCACTTTGTGGTGC 3-8-3 MOE 505 327148 539 552 TGCACTTTGTGGTG 3-8-3 MOE 506 327149 540 553 TTGCACTTTGTGGT 3-8-3 MOE 507 327150 545 558 CGGTGTTGCACTTT 3-8-3 MOE 508 327151 546 559 GCGGTGTTGCACTT 3-8-3 MOE 509 327152 547 560 AGCGGTGTTGCACT 3-8-3 MOE 510 327153 548 561 AAGCGGTGTTGCAC 3-8-3 MOE 511 327154 549 562 GAAGCGGTGTTGCA 3-8-3 MOE 512 327155 550 563 CGAAGCGGTGTTGC 3-8-3 MOE 513 327156 551 564 ACGAAGCGGTGTTG 3-8-3 MOE 514 WO 2007/146511 PCT/US2007/068401 -120 327157 552 565 CACGAAGCGGTGTT 3-8-3 MOE 515 327158 553 566 ACACGAAGCGGTGT 3-8-3 MOE 516 327159 554 567 AACACGAAGCGGTG 3-8-3 MOE 517 345897 684 697 GCTGCTGTACATCT 2-10-2 MOE 518 327160 684 697 GCTGCTGTACATCT 3-8-3 MOE 518 327161 685 698 AGCTGCTGTACATC 3-8-3 MOE 520 327162 686 699 AAGCTGCTGTACAT 3-8-3 MOE 521 327163 687 700 GAAGCTGCTGTACA 3-8-3 MOE 522 327164 688 701 GGAAGCTGCTGTAC 3-8-3 MOE 523 327165 689 702 TGGAAGCTGCTGTA 3-8-3 MOE 524 327166 690 703 CTGGAAGCTGCTGT 3-8-3 MOE 525 327167 691 704 CCTGGAAGCTGCTG 3-8-3 MOE 526 327168 692 705 ACCTGGAAGCTGCT 3-8-3 MOE 527 327169 693 706 CACCTGGAAGCTGC 3-8-3 MOE 528 327170 694 707 TCACCTGGAAGCTG 3-8-3 MOE 529 327171 695 708 ATCACCTGGAAGCT 3-8-3 MOE 530 327172 696 709 CATCACCTGGAAGC 3-8-3 MOE 531 327173 697 710 ACATCACCTGGAAG 3-8-3 MOE 532 327174 698 711 TACATCACCTGGAA 3-8-3 MOE 533 327175 699 712 GTACATCACCTGGA 3-8-3 MOE 534 327176 700 713 TGTACATCACCTGG 3-8-3 MOE 535 327177 701 714 GTGTACATCACCTG 3-8-3 MOE 536 327178 869 882 TAGCGGGTCCTGAG 3-8-3 MOE 537 327179 870 883 GTAGCGGGTCCTGA 3-8-3 MOE 538 327180 871 884 TGTAGCGGGTCCTG 3-8-3 MOE 539 327181 872 885 CTGTAGCGGGTCCT 3-8-3 MOE 540 327182 873 886 GCTGTAGCGGGTCC 3-8-3 MOE 541 327183 874 887 GGCTGTAGCGGGTC 3-8-3 MOE 542 327184 875 888 TGGCTGTAGCGGGT 3-8-3 MOE 543 327185 876 889 CTGGCTGTAGCGGG 3-8-3 MOE 544 327186 877 890 TCTGGCTGTAGCGG 3-8-3 MOE 545 327187 878 891 TTCTGGCTGTAGCG 3-8-3 MOE 546 327188 955 968 TGAACACCGCGGCC 3-8-3 MOE 547 327189 956 969 ATGAACACCGCGGC 3-8-3 MOE 548 327190 957 970 CATGAACACCGCGG 3-8-3 MOE 549 327191 958 971 GCATGAACACCGCG 3-8-3 MOE 550 327192 959 972 TGCATGAACACCGC 3-8-3 MOE 551 327193 960 973 TTGCATGAACACCG 3-8-3 MOE 552 327194 961 974 ATTGCATGAACACC 3-8-3 MOE 553 327195 962 975 TATTGCATGAACAC 3-8-3 MOE 554 327196 963 976 ATATTGCATGAACA 3-8-3 MOE 555 327197 964 977 CATATTGCATGAAC 3-8-3 MOE 556 327198 1019 1032 AGGTTGTGCAGGTA 3-8-3 MOE 557 327199 1020 1033 CAGGTTGTGCAGGT 3-8-3 MOE 558 327200 1021 1034 GCAGGTTGTGCAGG 3-8-3 MOE 559 327201 1022 1035 AGCAGGTTGTGCAG 3-8-3 MOE 560 327202 1023 1036 CAGCAGGTTGTGCA 3-8-3 MOE 561 327203 1024 1037 CCAGCAGGTTGTGC 3-8-3 MOE 562 327204 1025 1038 CCCAGCAGGTTGTG 3-8-3 MOE 563 327205 1026 1039 GCCCAGCAGGTTGT 3-8-3 MOE 564 327206 1027 1040 GGCCCAGCAGGTTG 3-8-3 MOE 565 327207 1028 1041 AGGCCCAGCAGGTT 3-8-3 MOE 566 338491 1160 1175 TGTCATTGCTGGTCCA 3-10-3 MOE 567 WO 2007/146511 PCT/US2007/068401 -121 338562 1160 1173 TCATTGCTGGTCCA 3-8-3 MOE 568 338498 1307 1322 TGGCCAGCCGGAACTT 3-10-3 MOE 569 338569 1307 1320 GCCAGCCGGAACTT 3-8-3 MOE 570 338499 1329 1344 GGGATGAGGGTCAGCG 3-10-3 MOE 571 338570 1329 1342 GATGAGGGTCAGCG 3-8-3 MOE 572 385067 1364 1377 AAGGCAAAGACCAC 3-8-3 MOE 573 338573 1401 1414 GGAGCGCAGGGTGC 3-8-3 MOE 574 338580 1487 1500 TGCACCTCCTTGTT 3-8-3 MOE 575 Table 13: Short antisense compounds targeted to SEQ ID NO: 1 and having 1 or 2 mismatches 5' 3' ISIS Target Target SEQ NO. Site Site Sequence (5'-3') Gapmer Motif ID NO 338577 158 171 CAGCAGACCCTGGA 3-8-3 MOE 576 338458 237 252 ACATCTGGCAGAGGTT 3-10-3 MOE 577 338529 237 250 ATCTGGCAGAGGTT 3-8-3 MOE 578 338466 318 333 CAGGCCAGCAGGAGTA 3-10-3 MOE 579 338537 318 331 GGCCAGCAGGAGTA 3-8-3 MOE 580 338533 364 377 CAAACAAAAAGTCC 3-8-3 MOE 582 338462 364 379 CTCAAACAAAAAGTCC 3-10-3 MOE 581 338535 397 410 GGTGACATTGGTCA 3-8-3 MOE 584 338464 397 412 GTGGTGACATTGGTCA 3-10-3 MOE 583 338466 470 485 CAGGCCAGCAGGAGTA 3-10-3 MOE 579 338537 470 483 GGCCAGCAGGAGTA 3-8-3 MOE 580 385048 497 510 TTGGCAGTGGTGTT 3-8-3 MOE 587 385049 500 513 ATGTTGGCAGTGGT 3-8-3 MOE 588 338467 503 518 AGGAAATGTTGGCAGT 3-10-3 MOE 589 338538 503 516 GAAATGTTGGCAGT 3-8-3 MOE 590 385050 506 519 CAGGAAATGTTGGC 3-8-3 MOE 591 385051 509 522 GGGCAGGAAATGTT 3-8-3 MOE 592 385052 523 536 AAGGTAGGTACCAG 3-8-3 MOE 593 385053 526 539 ACCAAGGTAGGTAC 3-8-3 MOE 594 385056 535 548 CTTTGTGGCACCAA 3-8-3 MOE 595 385057 538 551 GCACTTTGTGGCAC 3-8-3 MOE 596 338539 539 552 TGCACTTTGTGGCA 3-8-3 MOE 597 385058 541 554 GCTGCACTTTGTGG 3-8-3 MOE 598 385059 544 557 GGTGCTGCACTTTG 3-8-3 MOE 599 385060 547 560 GGCGGTGCTGCACT 3-8-3 MOE 600 385063 556 569 TGAACACTAGGCGG 3-8-3 MOE 601 385064 559 572 TCTTGAACACTAGG 3-8-3 MOE 602 338469 561 576 CACCTCTTGAACACTA 3-10-3 MOE 603 338540 561 574 CCTCTTGAACACTA 3-8-3 MOE 604 385065 562 575 ACCTCTTGAACACT 3-8-3 MOE 605 385066 565 578 CACACCTCTTGAAC 3-8-3 MOE 606 338541 590 603 CCTCGAACCCACTG 3-8-3 MOE 607 338473 658 673 CTTCTGGACCTCGATC 3-10-3 MOE 608 338544 658 671 TCTGGACCTCGATC 3-8-3 MOE 609 338474 681 696 CTGCTATACATCTTGG 3-10-3 MOE 610 338545 681 694 GCTATACATCTTGG 3-8-3 MOE 611 338475 703 718 CACGGTGTACATCACC 3-10-3 MOE 612 338546 703 716 CGGTGTACATCACC 3-8-3 MOE 613 338547 718 731 ACAGACTGTAGCCC 3-8-3 MOE 615 338476 718 733 GGACAGACTGTAGCCC 3-10-3 MOE 614 WO 2007/146511 PCT/US2007/068401 -122 338550 889 902 CATCGCCAATCTTC 3-8-3 MOE 617 338479 889 904 GTCATCGCCAATCTTC 3-10-3 MOE 616 338551 899 912 ACACTGAGGTCATC 3-8-3 MOE 619 338480 899 914 TCACACTGAGGTCATC 3-10-3 MOE 618 338552 924 937 CGCCCCGTCACTGA 3-8-3 MOE 620 338555 992 1005 AGCAACCAGCAATA 3-8-3 MOE 622 338484 992 1007 CCAGCAACCAGCAATA 3-10-3 MOE 621 338485 1018 1033 CAGGCTGTACAGGTAC 3-10-3 MOE 623 338556 1018 1031 GGCTGTACAGGTAC 3-8-3 MOE 624 338558 1051 1064 AGCTCCTCTCAGAG 3-8-3 MOE 626 338487 1051 1066 GAAGCTCCTCTCAGAG 3-10-3 MOE 625 338559 1079 1092 CAGCCAATGCCCAG 3-8-3 MOE 628 338488 1079 1094 CCCAGCCAATGCCCAG 3-10-3 MOE 627 338560 1131 1144 AAACAGACACTTGA 3-8-3 MOE 630 338489 1131 1146 TCAAACAGACACTTGA 3-10-3 MOE 629 338490 1145 1160 AGCACTGAACATTCTC 3-10-3 MOE 631 338561 1145 1158 CACTGAACATTCTC 3-8-3 MOE 632 338563 1181 1194 ATCCACCAGAATCC 3-8-3 MOE 634 338492 1181 1196 GGATCCACCAGAATCC 3-10-3 MOE 633 338564 1216 1229 TGATCAGTAAGGCC 3-8-3 MOE 635 338565 1232 1245 ACAAAGATGAAAAA 3-8-3 MOE 637 338494 1232 1247 GGACAAAGATGAAAAA 3-10-3 MOE 636 338566 1267 1280 CACGCAGCTTGGCC 3-8-3 MOE 639 338495 1267 1282 GGCACGCAGCTTGGCC 3-10-3 MOE 638 338571 1344 1357 GACCCCCAGCAGAG 3-8-3 MOE 641 338500 1344 1359 TGGACCCCCAGCAGAG 3-10-3 MOE 640 385068 1366 1379 CAAAGGCAAAGACC 3-8-3 MOE 642 385069 1369 1382 TCACAAAGGCAAAG 3-8-3 MOE 643 385070 1372 1385 CAGTCACAAAGGCA 3-8-3 MOE 644 385071 1375 1388 CGTCAGTCACAAAG 3-8-3 MOE 645 385072 1378 1391 GCTCGTCAGTCACA 3-8-3 MOE 646 385073 1381 1394 CATGCTCGTCAGTC 3-8-3 MOE 647 386608 1384 1397 GGGCATGCTCGTCA 1-12-1 MOE 648 386593 1384 1397 GGGCATGCTCGTCA 2-10-2 MOE 648 396146 1384 1397 GGGCATGCTCGTCA 2-10-2 MOE 648 338572 1384 1397 GGGCATGCTCGTCA 3-8-3 MOE 648 1-1-10-2 2' (butylacetamido) palmitamide/OMe/ 396149 1384 1397 GGGCATGCTCGTCA OMe 648 2-10-2 Methyleneoxy 386627 1384 1397 GGGCATGCTCGTCA BNA 648 386610 1387 1400 CTTGGGCATGCTCG 1-12-1 MOE 654 386595 1387 1400 CTTGGGCATGCTCG 2-10-2 MOE 654 385074 1387 1400 CTTGGGCATGCTCG 3-8-3 MOE 654 385075 1390 1403 TGCCTTGGGCATGC 3-8-3 MOE 657 385076 1393 1406 GGGTGCCTTGGGCA 3-8-3 MOE 648 385077 1396 1409 GCAGGGTGCCTTGG 3-8-3 MOE 659 385078 1399 1412 AGCGCAGGGTGCCT 3-8-3 MOE 660 338502 1401 1416 GTGGAGCGCAGGGTGC 3-10-3 MOE 661 385079 1402 1415 TGGAGCGCAGGGTG 3-8-3 MOE 662 385080 1405 1418 TGGTGGAGCGCAGG 3-8-3 MOE 663 385081 1408 1421 GCTTGGTGGAGCGC 3-8-3 MOE 664 WO 2007/146511 PCT/US2007/068401 -123 385082 1411 1424 AGAGCTTGGTGGAG 3-8-3 MOE 665 338503 1412 1427 AAAAGAGCTTGGTGGA 3-10-3 MOE 666 338574 1412 1425 AAGAGCTTGGTGGA 3-8-3 MOE 667 385083 1414 1427 AAAAGAGCTTGGTG 3-8-3 MOE 668 385084 1417 1430 CAAAAAAGAGCTTG 3-8-3 MOE 669 338504 1434 1449 AAGGAGCTGAGGAACA 3-10-3 MOE 670 338575 1434 1447 GGAGCTGAGGAACA 3-8-3 MOE 671 327167 1441 1454 CCTGGAAGCTGCTG 3-8-3 MOE 526 338576 1445 1458 AGACCCTGGAAGGA 3-8-3 MOE 673 338505 1445 1460 GCAGACCCTGGAAGGA 3-10-3 MOE 672 338506 1449 1464 ACCAGCAGACCCTGGA 3-10-3 MOE 674 338577 1449 1462 CAGCAGACCCTGGA 3-8-3 MOE 576 338507 1464 1479 CAGTAGAGAACAGCCA 3-10-3 MOE 676 338578 1464 1477 GTAGAGAACAGCCA 3-8-3 MOE 677 338508 1475 1490 TGTTGAGGAAACAGTA 3-10-3 MOE 678 338579 1475 1488 TTGAGGAAACAGTA 3-8-3 MOE 679 338509 1487 1502 CCTGCACCTCCTTGTT 3-10-3 MOE 680 338580 1610 1623 TGCACCTCCTTGTT 3-8-3 MOE 575 In certain embodiments, a target region is nucleotides 378-391 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 378-391 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 378-391 comprises a nucleotide 5 sequence selected from SEQ ID NO 486 or 487. In certain such embodiments, a short antisense compound targeted to nucleotides 378-391 of SEQ ID NO: 9 is selected from Isis No 338463 or 338534. In certain embodiments, a target region is nucleotides 499-521 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 499-521 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 499-521 comprises a nucleotide 10 sequence selected from SEQ ID NO 488, 489, 490, 491, 492, 493, 494, 495, 496, or 497. In certain such embodiments, a short antisense compound targeted to nucleotides 499-521 of SEQ ID NO: 9 is selected from Isis No 327130, 327131, 327132, 327133, 327134, 327135, 327136, 327137, 327138, or 327139. In certain embodiments, a target region is nucleotides 531-553 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 531-553 of SEQ ID NO: 9. In certain 15 such embodiments, a short antisense compound targeted to nucleotides 531-553 comprises a nucleotide sequence selected from SEQ ID NO 498, 499, 500, 501, 502, 503, 504, 505, 506, or 507. In certain such embodiments, a short antisense compound targeted to nucleotides 531-553 of SEQ ID NO: 9 is selected from Isis No 327140, 327141, 327142, 327143, 327144, 327145, 327146, 327147, 327148, or 327149. In certain embodiments, a target region is nucleotides 545-567 of SEQ ID NO: 9. In certain 20 embodiments, a short antisense compound is targeted to nucleotides 545-567 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 545-567 comprises a nucleotide sequence selected from SEQ ID NO 508, 509, 510, 511, 512, 513, 514, 515, 516, or 517. In certain such embodiments, a short antisense compound targeted to nucleotides 545-567 of SEQ ID NO: 9 is selected from Isis No 327150, 327151, 327152, 327153, 327154, 327155, 327156, 327157, 327158, or 327159. 25 In certain embodiments, a target region is nucleotides 531-567 of SEQ ID NO: 9. In certain WO 2007/146511 PCT/US2007/068401 -124 embodiments, a short antisense compound is targeted to nucleotides 531-567 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 531-567 comprises a nucleotide sequence selected from SEQ ID NO 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, or 517. In certain such embodiments, a short antisense compound targeted to 5 nucleotides 531-567 of SEQ ID NO: 9 is selected from Isis No 327140, 327141, 327142, 327143, 327144, 327145, 327146, 327147, 327148, 327149, 327150, 327151, 327152, 327153, 327154, 327155, 327156, 327157, 327158, or 327159. In certain embodiments, a target region is nucleotides 684-714 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 684-714 of SEQ ID NO: 9. In certain 10 such embodiments, a short antisense compound targeted to nucleotides 684-714 comprises a nucleotide sequence selected from SEQ ID NO 518, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, or 536. In certain such embodiments, a short antisense compound targeted to nucleotides 684-714 of SEQ ID NO: 9 is selected from Isis No 345897, 327160, 327161, 327162, 327163, 327164, 327165, 327166, 327167, 327168, 327169, 327170, 327171, 327172, 327173, 327174, 327175, 327176, 15 or 327177. In certain embodiments, a target region is nucleotides 869-891 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 869-891 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 869-891 comprises a nucleotide sequence selected from SEQ ID NO 537, 538, 539, 540, 541, 542, 543, 544, 545, or 546. In certain such 20 embodiments, a short antisense compound targeted to nucleotides 869-891 of SEQ ID NO: 9 is selected from Isis No 327178, 327179, 327180, 327181, 327182, 327183, 327184, 327185, 327186, or 327187. In certain embodiments, a target region is nucleotides 955-977 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 955-977 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 955-977 comprises a nucleotide 25 sequence selected from SEQ ID NO 547, 548, 549, 550, 551, 552, 553, 554, 555, or 556. In certain such embodiments, a short antisense compound targeted to nucleotides 955-977 of SEQ ID NO: 9 is selected from Isis No 327188, 327189, 327190, 327191, 327192, 327193, 327194, 327195, 327196, or 327197. In certain embodiments, a target region is nucleotides 1019-1041 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 1019-1041 of SEQ ID NO: 9. In 30 certain such embodiments, a short antisense compound targeted to nucleotides 1019-1041 comprises a nucleotide sequence selected from SEQ ID NO 557, 558, 559, 560, 561, 562, 563, 564, 565, or 566. In certain such embodiments, a short antisense compound targeted to nucleotides 1019-1041 of SEQ ID NO: 9 is selected from Isis No 327198, 327199, 327200, 327201, 327202, 327203, 327204, 327205, 327206, or 327207. 35 In certain embodiments, a target region is nucleotides 1160-1175 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 1160-1175 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 1160-1175 comprises a WO 2007/146511 PCT/US2007/068401 -125 nucleotide sequence selected from SEQ ID NO 567 or 568. In certain such embodiments, a short antisense compound targeted to nucleotides 1160-1175 of SEQ ID NO: 9 is selected from Isis No 338491 or 338562. In certain embodiments, a target region is nucleotides 1307-1377 of SEQ ID NO: 9. In certain 5 embodiments, a short antisense compound is targeted to nucleotides 1307-1377 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 1307-1377 comprises a nucleotide sequence selected from SEQ ID NO 569, 570, 571, 572, or 573. In certain such embodiments, a short antisense compound targeted to nucleotides 1307-1377 of SEQ ID NO: 9 is selected from Isis No 338498,338569,338499,338570,or385067. 10 In certain embodiments, a target region is nucleotides 1307-1414 of SEQ ID NO: 9. In certain embodiments, a short antisense compound is targeted to nucleotides 1307-1414 of SEQ ID NO: 9. In certain such embodiments, a short antisense compound targeted to nucleotides 1307-1414 comprises a nucleotide sequence selected from SEQ ID NO 569, 570, 571, 572, 573, or 574. In certain such embodiments, a short antisense compound targeted to nucleotides 1307-1414 of SEQ ID NO: 9 is selected 15 from Isis No 338498, 338569, 338499, 338570, 385067, or 338573. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 10 to 14 20 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a GCGR nucleic acid comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short 25 antisense compounds targeted to a GCGR nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, P-D Methyleneoxy (4'-CH 2 -0-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -O-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

30 2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, O-C-Cio alkyl, OCF 3 , 0-(CH 2

)

2 -0-CH 3 , 2'-O(CH 2

)

2

SCH

3 , O-(CH 2

)

2 -0-N(Rm)(R,), and O-CH2-C(=0)-N(Rm)(R), where each Rm and R is, independently, H or substituted or unsubstituted C-Cio alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. 35 In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers WO 2007/146511 PCT/US2007/068401 -126 of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. 5 In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid have uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 8 10 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are monomers in length. In certain embodiments, short antisense 15 compounds targeted to a GCGR nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid comprise 9 20 to 15 monomers. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a GCGR nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of GCGR. In 25 certain embodiments, such methods comprise use of one or more short antisense compound targeted to a GCGR nucleic acid, wherein the short antisense compound targeted to a GCGR nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of GCGR using one or more short antisense compounds 30 targeted to a GCGR nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating GCGR comprise use 35 of a short antisense compound targeted to a GCGR nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating WO 2007/146511 PCT/US2007/068401 -127 GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic 5 acid that is 14 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of GCGR comprise use of a short 10 antisense compound targeted to a GCGR nucleic acid comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of 15 GCGR comprise use of a short antisense compound targeted to a GCGR nucleic acid comprising 12 or 14 nucleotides or nucleosides. 8. DGAT2 Diacylglycerol transferase 2 (also known as DGAT2, diacylglycerol 0-transferase 2, acyl 20 CoA:diacylglycerol acyltransferase 2), Diacylglycerol transferase 2 has been shown to be implicated in the absorption process of triglycerides (also called triacylglycerols) from food. The absorption of triglycerides from food is a very efficient process which occurs by a series of steps wherein the dietary triacylglycerols are hydrolyzed in the intestinal lumen and then resynthesized within enterocytes. The resynthesis of triacylglycerols can occur via the monoacylglycerol pathwaywhich 25 commences with monoacylglycerol acyltransferase (MGAT) catalyzing the synthesis of diacylglycerol from monoacylglycerol and fatty acyl-CoA. An alternative synthesis of diacylglycerols is provided by the glycerol-phosphate pathway which describes the coupling of two molecules of fatty acyl-CoA to glycerol-3-phosphate. In either case, diacylglycerol is then acylated with another molecule of fatty acyl CoA in a reaction catalyzed by one of two diacylglycerol acyltransferase enzymes to form the triglyceride 30 (Farese et al., Curr. Opin. Lipidol., 2000, 11, 229-234). The reaction catalyzed by diacylglycerol acyltransferase is the final and only committed step in triglyceride synthesis. As such, diacylglycerol acyltransferase is involved in intestinal fat absorption, lipoprotein assembly, regulating plasma triglyceride concentrations, and fat storage in adipocytes. The first diacylglycerol acyltransferase, diacylglycerol transferase 1, was identified in 1960 and the human 35 and mouse genes encoding this protein were isolated in 1998 (Cases et al., Proc. Nati. Acad. Sci. U. S. A., 1998, 95, 13018-13023; Oelkers et al., J. Biol. Chem., 1998, 273, 26765-26771). Mice lacking diacylglycerol acyltransferase 1 are viable and can still synthesize triglycerides through other biological WO 2007/146511 PCT/US2007/068401 -128 routes, suggesting the existence of multiple mechanisms- for triglyceride synthesis (Smith et al., Nat. Genet., 2000, 25, 87-90). A second diacylglycerol transferase, diacylglycerol transferase 2 (also known as DGAT2, diacylglycerol 0-transferase 2, acyl-CoA:diacylglycerol acyltransferase 2), was subsequently identified in 5 the fungus Mortierella, humans and mice (Cases et al., J Bio. Chem., 2001, 276, 38870-38876; Lardizabal et al., J. Biol. Chem., 2001, 276, 38862-38869). Enzymatic assays indicate that this recently identified protein does possess diacylglycerol transferase activity that utilizes a broad range of long chain fatty acyl-CoA substrates (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876). Diacylglycerol transferase 2 is a member of a family of genes whose sequences are unrelated to 10 diacylglycerol transferase 1. In addition to differing in sequence compared to diacylglycerol transferase 1, in vitro assays illustrate that diacylglycerol transferase 2 has higher activity at lower concentrations of magnesium chloride and oleoyl-CoA (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876). The predicted protein sequence of diacylglycerol transferase 2 contains at least one putative transmembrane domain, three potential N-linked glycosylation sites, six potential protein kinase C phosphorylation 15 consensus sites, as well as sequences in common with a putative glycerol phosphorylation site found in acyltransferase enzymes (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876). The International Radiation Hybrid Mapping Consortium has mapped human diacylglycerol transferase 2 to chromosome SIq13.3. In human tissues, the highest levels of diacylglycerol transferase 2 are detected in liver and white 20 adipose tissues, with lower levels found in mammary gland, testis and peripheral blood leukocytes (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876). Two mRNA species of 2.4 and 1.8 kilobases are detected in human tissues, whereas the major diacylglycerol transferase 2 mRNA species in mouse tissues is 2.4 kilobases. In addition to liver and white adipose tissues, diacylglycerol transferase 2 is expressed in all segments of the small intestine in mice, with higher expression in the proximal intestine and lower 25 expression in the distal intestine (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876). Diacylglycerol transferase activity exhibits distinct patterns during postnatal development of the rat liver. As there is no correlation between the mRNA expression and activity patterns, post-translational modifications may participate in the regulation of diacylglycerol transferase 2 activity during rat development (Waterman et al., J. Lipid. Res., 2002, 43, 1555-1562). 30 Diacylglycerol transferase 2 mRNA is preferentially upregulated by insulin treatment, as shown by in vitro assays measuring the diacylglycerol activity from the membrane fraction of cultured mouse adipocytes (Meegalla et al., Biochem. Biophys. Res. Commun., 2002, 298, 317-323). In fasting mice, diacylglycerol transferase 2 expression is greatly reduced, and dramatically increases upon refeeding. The expression patterns of two enzymes that participate in fatty acid synthesis, acetyl-CoA carboxylase 35 and fatty acid synthase, respond to fasting and refeeding in a similar fashion. These results, combined with the observation that diacylglycerol transferase 2 is abundantly expressed in liver, suggest that diacylglycerol transferase 2 is tightly linked to the endogenous fatty acid synthesis pathway (Meegalla et WO 2007/146511 PCT/US2007/068401 -129 al., Biochem. Biophys. Res. Commun., 2002, 298, 317-323). Studies of mice harboring a disruption in the diacylglycerol acyltransferase 1 gene provide evidence that diacylglycerol acyltransferase 2 contributes to triglyceride synthesis. Levels of diacylglycerol transferase 2 mRNA expression are similar in intestinal segments from both wild type and 5 diacylglycerol transferase 1-deficient mice (Buhman et al., J. Biol. Chem., 2002, 277, 25474-25479). Using magnesium chloride to distinguish between diacylglycerol transferase 1 and 2 activity, Buhman, et al. observed that, in diacylglycerol transferase 1-deficient mice, diacylglycerol transferase activity is reduced to 50% in the proximal intestine and to 10-15% in the distal intestine (Buhman et al., J. Biol. Chem., 2002, 277, 25474-25479). 10 Additionally, diacylglycerol transferase 2 mRNA levels are not up-regulated the liver or adipose tissues of diacylglycerol transferase 1-deficient mice, even after weeks of high-fat diet (Cases et al., J. Biol. Chem., 2001, 276, 38870-38876; Chen et al., J. Clin. Invest., 2002, 109, 1049-1055). However, in ob/ob mice, which have a mutation in the leptin gene that results in obesity, diacylglycerol transferase 2 is more highly expressed than in wild type mice, suggesting that diacylglycerol transferase 2 may be partly 15 responsible for the highly accumulated fat mass seen in these mice. Furthermore, the combined mutations of leptin and diacylglycerol transferase 1 leads to a three-fold elevation in diacylglycerol transferase 2 expression in white adipose tissue, compared to the levels in the same tissue from diacylglycerol transferase 1-deficient mice (Chen et al., J. Clin. Invest., 2002, 109, 1049-1055). Diacylglycerol transferase 2 mRNA is also upregulated in the skin of these mice (Chen et al., J. Clin. Invest., 2002, 109, 20 175-181). These data suggest leptin normally downregulates diacylglycerol transferase 2 expression, and that the upregulation of diacylglycerol transferase 2 in white adipose tissue in these mice may provide an alternate pathway for the triglyceride synthesis that still occurs in leptin deficient/ diacylglycerol transferase 1-deficient mice (Chen et al., J. Clin. Invest., 2002, 109, 1049-1055). Diacylglycerol acyltransferase 1 knockout mice exhibit interesting phenotypes in that they are 25 lean, resistant to diet-induce obesity, have decreased levels of tissue triglycerides and increased sensitivity to insulin and leptin (Chen et al., J. Clin. Invest., 2002, 109, 1049-1055; Smith et al., Nat. Genet., 2000, 25, 87-90). As diacylglycerol transferase 2 also participates in triglyceride synthesis, interfering with diacylglycerol transferase 2 may similarly lead to reduced body fat content. 30 Definitions "DGAT2" means the gene product or protein of which expression is to be modulated by administration of a short antisense compound. "DGAT2 nucleic acid" means any nucleic acid encoding DGAT2. For example, in certain embodiments, a DGAT2 nucleic acid includes, without limitation, a DNA sequence encoding DGAT2, an 35 RNA sequence transcribed from DNA encoding DGAT2, and an mRNA sequence encoding DGAT2. "DGAT2 mRNA" means an mRNA encoding DGAT2.

WO 2007/146511 PCT/US2007/068401 -130 Therapeutic indications Antisense technology is an effective means for reducing DGAT2 expression and has proven to be uniquely useful in a number of therapeutic, diagnostic, and research applications. As such, in certain embodiments, the present invention provides compounds targeted to nucleic acid encoding DGAT2, 5 which modulate the expression of DGAT2. Further provided herein are short antisense compounds capable of effectively inhibiting DGAT2 expression. In certain embodiments, a subject, suspected of having a disease or associated with DGAT2 is treated by administering one or more short antisense compounds targeted to a nucleic acid encoding DGAT2. For example, in a non-limiting embodiment, such methods comprise the step of administering 10 to an animal a therapeutically effective amount of a short antisense compound. In certain such embodiments, short antisense compounds effectively inhibit the activity of DGAT2 or inhibit the expression of DGAT2. In one embodiment, the activity or expression of DGAT2 in a subject is inhibited by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 15 95%, by at least 98%, by at least 99%, or by 100%. In certain embodiments, the activity or expression of DGAT2 in a subject is inhibited by about 30%. More preferably, the activity or expression of DGAT2 in a subject is inhibited by 50% or more. The reduction of the expression of DGAT2 may be measured, for example, in blood, plasma, serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells 20 contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding DGAT2 and/or the DGAT2 protein itself. In certain embodiments, pharmaceutical and other compositions comprising the compounds of the invention are also provided. For example, short antisense compounds targeted to a DGAT2 nucleic acid can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a 25 suitable pharmaceutically acceptable diluent or carrier. Certain short antisense compounds targeting DGAT2 may have any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a DGAT2 nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8-3, 2-8-2, 1-8-1, 3-6 30 3 or 1-6-1. In certain embodiments, short antisense compounds targeting a DGAT2 nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-10-1, 2-10-2 and 3-10-3. Provided herein are methods of treating an individual by administering one or more short antisense compound targeted to a DGAT2 nucleic acid or a pharmaceutical composition comprising such compound. Further provided are methods of treating a subject having a disease or conditions associated 35 with DGAT2 activity by administering a short antisense compound targeted to a DGAT2 nucleic acid. Diseases and conditions associated with DGAT2 include, but are not limited to, cardiovascular disorders, obesity, diabetes, cholesterolemia, and liver steatosis.

WO 2007/146511 PCT/US2007/068401 -131 Certain Short Antisense Compounds Targeted to a DGAT2 Nucleic Acid In certain embodiments, short antisense compounds are targeted to a DGAT2 nucleic acid having the sequence of GENBANK@ Accession No. NM_032564.2, incorporated herein as SEQ ID NO: 5 10. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 10 is at least 90% complementary to SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 10 is at least 95% complementary to SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 10 is 100% complementary to SEQ ID NO: 10. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 10 includes a nucleotide sequence 10 selected from the nucleotide sequences set forth in Tables 14 and 15. Each nucleotide sequence set forth in each Tables 14 and 15 is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds comprising a nucleotide sequence as set forth in Tables 14 and 15 may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds 15 described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Tables 14 and 15 illustrate examples of short antisense compounds targeted to SEQ ID NO: 10. Table 14 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 10. Table 15 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 20 10. The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing 25 segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. 30 Table 14: Short Antisense Compounds targeted to SEQ ID NO: 10 5' 3' Target Target Gapmer SEQ ISIS NO. Site Site Sequence (5'-3') Motif ID NO 372556 231 244 ATGAGGGTCTTCAT 2-10-2 MOE 681 372557 249 262 ACCCCGGAGTAGGC 2-10-2 MOE 682 382601 249 260 CCCGGAGTAGGC 1-10-1 MOE 683 372480 251 266 CAGGACCCCGGAGTAG 3-10-3 MOE 684 372481 252 267 GCAGGACCCCGGAGTA 3-10-3 MOE 685 372558 252 265 AGGACCCCGGAGTA 2-10-2 MOE 686 WO 2007/146511 PCT/US2007/068401 -132 372559 253 266 CAGGACCCCGGAGT 2-10-2 MOE 687 382603 331 342 CAGACCCCTCGC 1-10-1 MOE 688 382604 361 372 AGAGGATGCTGG 1-10-1 MOE 689 372485 392 407 GAGCCAGGTGACAGAG 3-10-3 MOE 690 372563 393 406 AGCCAGGTGACAGA 2-10-2 MOE 691 382605 397 408 TGAGCCAGGTGA 1-10-1 MOE 692 372565 414 427 TTTTCCACCTTGGA 2-10-2 MOE 693 382606 482 493 CTGCAGGCCACT 1-10-1 MOE 694 372497 651 666 TCACCAGCTGGATGGG 3-10-3 MOE 695 372498 652 667 TTCACCAGCTGGATGG 3-10-3 MOE 696 372575 652 665 CACCAGCTGGATGG 2-10-2 MOE 697 372576 653 666 TCACCAGCTGGATG 2-10-2 MOE 698 382607 655 666 TCACCAGCTGGA 1-10-1 MOE 699 372499 656 671 TGTCTTCACCAGCTGG 3-10-3 MOE 700 372577 657 670 GTCTTCACCAGCTG 2-10-2 MOE 701 372500 659 674 GTGTGTCTTCACCAGC 3-10-3 MOE 702 372578 660 673 TGTGTCTTCACCAG 2-10-2 MOE 703 372501 661 676 TTGTGTGTCTTCACCA 3-10-3 MOE 704 372579 662 675 TGTGTGTCTTCACC 2-10-2 MOE 705 372502 664 679 AGGTTGTGTGTCTTCA 3-10-3 MOE 706 372580 665 678 GGTTGTGTGTCTTC 2-10-2 MOE 707 372503 666 681 GCAGGTTGTGTGTCTT 3-10-3 MOE 708 372581 667 680 CAGGTTGTGTGTCT 2-10-2 MOE 709 372504 669 684 TCAGCAGGTTGTGTGT 3-10-3 MOE 710 372582 670 683 CAGCAGGTTGTGTG 2-10-2 MOE 711 372505 671 686 GGTCAGCAGGTTGTGT 3-10-3 MOE 712 372506 672 687 TGGTCAGCAGGTTGTG 3-10-3 MOE 713 372583 672 685 GTCAGCAGGTTGTG 2-10-2 MOE 714 372584 673 686 GGTCAGCAGGTTGT 2-10-2 MOE 715 372507 676 691 CTGGTGGTCAGCAGGT 3-10-3 MOE 716 372585 677 690 TGGTGGTCAGCAGG 2-10-2 MOE 717 382608 680 691 CTGGTGGTCAGC 1-10-1 MOE 718 372508 681 696 AGTTCCTGGTGGTCAG 3-10-3 MOE 719 372586 682 695 GTTCCTGGTGGTCA 2-10-2 MOE 720 372509 684 699 TATAGTTCCTGGTGGT 3-10-3 MOE 721 372587 685 698 ATAGTTCCTGGTGG 2-10-2 MOE 722 372510 686 701 GATATAGTTCCTGGTG 3-10-3 MOE 723 372588 687 700 ATATAGTTCCTGGT 2-10-2 MOE 724 372511 691 706 CCAAAGATATAGTTCC 3-10-3 MOE 725 372512 692 707 TCCAAAGATATAGTTC 3-10-3 MOE 726 372589 692 705 CAAAGATATAGTTC 2-10-2 MOE 727 372590 693 706 CCAAAGATATAGTT 2-10-2 MOE 728 382609 724 735 CCAGGCCCATGA 1-10-1 MOE 729 372514 725 740 GGCACCCAGGCCCATG 3-10-3 MOE 730 372592 726 739 GCACCCAGGCCCAT 2-10-2 MOE 731 372515 730 745 CAGAAGGCACCCAGGC 3-10-3 MOE 732 372593 731 744 AGAAGGCACCCAGG 2-10-2 MOE 733 382610 851 862 CCAGACATCAGG 1-10-1 MOE 734 382611 867 878 GACAGGGCAGAT 1-10-1 MOE 735 382602 868 879 TGACAGGGCAGA 1-10-1 MOE 736 382612 911 922 CCACTCCCATTC 1-10-1 MOE 737 372524 965 980 GCCAGGCATGGAGCTC 3-10-3 MOE 738 372602 966 979 CCAGGCATGGAGCT 2-10-2 MOE 739 WO 2007/146511 PCT/US2007/068401 -133 382613 968 979 CCAGGCATGGAG 1-10-1 MOE 740 382614 987 998 CAGGGTGACTGC 1-10-1 MOE 741 372525 989 1004 GTTCCGCAGGGTGACT 3-10-3 MOE 742 372603 990 1003 TTCCGCAGGGTGAC 2-10-2 MOE 743 372526 992 1007 GCGGTTCCGCAGGGTG 3-10-3 MOE 744 372604 993 1006 CGGTTCCGCAGGGT 2-10-2 MOE 745 372530 1106 1121 TCGGCCCCAGGAGCCC 3-10-3 MOE 746 372608 1107 1120 CGGCCCCAGGAGCC 2-10-2 MOE 747 372531 1109 1124 CCATCGGCCCCAGGAG 3-10-3 MOE 748 372609 1110 1123 CATCGGCCCCAGGA 2-10-2 MOE 749 372532 1112 1127 GACCCATCGGCCCCAG 3-10-3 MOE 750 372610 1113 1126 ACCCATCGGCCCCA 2-10-2 MOE 751 372533 1117 1132 TTCTGGACCCATCGGC 3-10-3 MOE 752 382615 1117 1128 GGACCCATCGGC 1-10-1 MOE 753 372611 1118 1131 TCTGGACCCATCGG 2-10-2 MOE 754 372536 1199 1214 CACCAGCCCCCAGGTG 3-10-3 MOE 755 372614 1200 1213 ACCAGCCCCCAGGT 2-10-2 MOE 756 372537 1204 1219 TAGGGCACCAGCCCCC 3-10-3 MOE 757 372615 1205 1218 AGGGCACCAGCCCC 2-10-2 MOE 758 372538 1209 1224 TGGAGTAGGGCACCAG 3-10-3 MOE 759 372616 1210 1223 GGAGTAGGGCACCA 2-10-2 MOE 760 382616 1215 1226 CTTGGAGTAGGG 1-10-1 MOE 761 372539 1218 1233 TGATGGGCTTGGAGTA 3-10-3 MOE 762 372617 1219 1232 GATGGGCTTGGAGT 2-10-2 MOE 763 372540 1293 1308 TGTGGTACAGGTCGAT 3-10-3 MOE 764 372618 1294 1307 GTGGTACAGGTCGA 2-10-2 MOE 765 382617 1294 1305 GGTACAGGTCGA 1-10-1 MOE 766 372541 1295 1310 GGTGTGGTACAGGTCG 3-10-3 MOE 767 372619 1296 1309 GTGTGGTACAGGTC 2-10-2 MOE 768 372542 1298 1313 CATGGTGTGGTACAGG 3-10-3 MOE 769 372620 1299 1312 ATGGTGTGGTACAG 2-10-2 MOE 770 372543 1300 1315 TACATGGTGTGGTACA 3-10-3 MOE 771 372621 1301 1314 ACATGGTGTGGTAC 2-10-2 MOE 772 372544 1303 1318 ATGTACATGGTGTGGT 3-10-3 MOE 773 372622 1304 1317 TGTACATGGTGTGG 2-10-2 MOE 774 382618 1313 1324 GCCTCCATGTAC 1-10-1 MOE 775 382619 1325 1336 AGCTTCACCAGG 1-10-1 MOE 776 382620 1383 1394 GTTCACCTCCAG 1-10-1 MOE 777 Table 15: Short antisense compounds targeted to SEQ ID NO: 10 and having 1 or 2 mismatches 5' 3' Target Target Gapmer SEQ ISIS NO Site Site Sequence (5'-3') Motif ID NO 372608 151 164 CGGCCCCAGGAGCC 2-10-2 MOE 747 372474 156 171 CATGCCCCAGCCGCCG 3-10-3 MOE 778 372552 157 170 ATGCCCCAGCCGCC 2-10-2 MOE 779 382609 167 178 CCAGGCCCATGA 1-10-1 MOE 729 372478 230 245 GATGAGGGTCTTCATG 3-10-3 MOE 780 372479 248 263 GACCCCGGAGTAGGCA 3-10-3 MOE 781 382611 317 328 GACAGGGCAGAT 1-10-1 MOE 735 372483 352 367 ATGCTGGAGCCAGTGC 3-10-3 MOE 782 372561 353 366 TGCTGGAGCCAGTG 2-10-2 MOE 783 372562 373 386 GTCTTGGAGGGCCG 2-10-2 MOE 784 WO 2007/146511 PCT/US2007/068401 -134 382602 388 399 TGACAGGGCAGA 1-10-1 MOE 736 372613 392 405 CCCAGGTGTCAGAG 2-10-2 MOE 785 372486 412 427 TTTTCCACCTTGGATC 3-10-3 MOE 786 372564 413 426 TTTCCACCTTGGAT 2-10-2 MOE 787 372487 413 428 TTTTTCCACCTTGGAT 3-10-3 MOE 788 372488 418 433 AGGTGTTTTTCCACCT 3-10-3 MOE 789 372566 419 432 GGTGTTTTTCCACC 2-10-2 MOE 790 372489 459 474 CCAGGAAGGATAGGAC 3-10-3 MOE 791 372567 460 473 CAGGAAGGATAGGA 2-10-2 MOE 792 382612 475 486 CCACTCCCATTC 1-10-1 MOE 737 372490 483 498 TGACACTGCAGGCCAC 3-10-3 MOE 793 372568 484 497 GACACTGCAGGCCA 2-10-2 MOE 794 372491 492 507 ACATGAGGATGACACT 3-10-3 MOE 795 372569 493 506 CATGAGGATGACAC 2-10-2 MOE 796 372492 503 518 GCAGAAGGTGTACATG 3-10-3 MOE 797 372570 504 517 CAGAAGGTGTACAT 2-10-2 MOE 798 372493 512 527 GCAGTCAGTGCAGAAG 3-10-3 MOE 799 372571 513 526 CAGTCAGTGCAGAA 2-10-2 MOE 800 372496 612 627 ACACGGCCCAGTTTCG 3-10-3 MOE 801 372574 613 626 CACGGCCCAGTTTC 2-10-2 MOE 802 372513 717 732 GGCCCATGATGCCATG 3-10-3 MOE 803 372591 718 731 GCCCATGATGCCAT 2-10-2 MOE 804 372516 732 747 TACAGAAGGCACCCAG 3-10-3 MOE 805 372594 733 746 ACAGAAGGCACCCA 2-10-2 MOE 806 372518 812 827 GAAGTTGCCAGCCAAT 3-10-3 MOE 807 372596 813 826 AAGTTGCCAGCCAA 2-10-2 MOE 808 372560 863 876 CAGGGCAGATCCTT 2-10-2 MOE 809 372519 887 902 CAAGTAGTCTATGGTG 3-10-3 MOE 810 372597 888 901 AAGTAGTCTATGGT 2-10-2 MOE 811 372520 894 909 TGGAAAGCAAGTAGTC 3-10-3 MOE 812 372598 895 908 GGAAAGCAAGTAGT 2-10-2 MOE 813 372527 1013 1028 GGCCAGCTTTACAAAG 3-10-3 MOE 814 372605 1014 1027 GCCAGCTTTACAAA 2-10-2 MOE 815 372606 1020 1033 CGCAGGGCCAGCTT 2-10-2 MOE 816 372529 1052 1067 AAAGGAATAGGTGGGA 3-10-3 MOE 817 372607 1053 1066 AAGGAATAGGTGGG 2-10-2 MOE 818 372534 1144 1159 GCGAAACCAATATACT 3-10-3 MOE 819 372612 1145 1158 CGAAACCAATATAC 2-10-2 MOE 820 372535 1192 1207 CCCCAGGTGTCAGAGG 3-10-3 MOE 821 372613 1193 1206 CCCAGGTGTCAGAG 2-10-2 MOE 822 372545 1332 1347 GATTGTCAAAGAGCTT 3-10-3 MOE 823 372623 1333 1346 ATTGTCAAAGAGCT 2-10-2 MOE 824 372546 1342 1357 TTGGTCTTGTGATTGT 3-10-3 MOE 825 372624 1343 1356 TGGTCTTGTGATTG 2-10-2 MOE 826 372547 1352 1367 AAGGCCGAATTTGGTC 3-10-3 MOE 827 372625 1353 1366 AGGCCGAATTTGGT 2-10-2 MOE 828 382601 1617 1628 CCCGGAGTAGGC 1-10-1 MOE 683 382606 1971 1982 CTGCAGGCCACT 1-10-1 MOE 694 382612 1988 1999 CCACTCCCATTC 1-10-1 MOE 737 In certain embodiments, a target region is nucleotides 231-267 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 231-267 of SEQ ID NO: 10. In WO 2007/146511 PCT/US2007/068401 -135 certain such embodiments, a short antisense compound targeted to nucleotides 231-267 comprises a nucleotide sequence selected from SEQ ID NO 681, 682, 683, 684, 685, 686, or 687. In certain such embodiments, a short antisense compound targeted to nucleotides 231-267 of SEQ ID NO: 10 is selected from Isis No 372556, 372557, 382601, 372480, 372481, 372558, or 372559. 5 In certain embodiments, a target region is nucleotides 249-267 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 249-267 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 249-267 comprises a nucleotide sequence selected from SEQ ID NO 683, 684, 685, 686, or 687. In certain such embodiments, a short antisense compound targeted to nucleotides 249-267 of SEQ ID NO: 10 is selected from Isis No 10 382601,372480,372481,372558,or372559. In certain embodiments, a target region is nucleotides 331-493 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 331-493 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 331-493 comprises a nucleotide sequence selected from SEQ ID NO 688, 689, 690, 691, 692, 693, or 694. In certain such 15 embodiments, a short antisense compound targeted to nucleotides 331-493 of SEQ ID NO: 10 is selected from Isis No 382603, 382604, 372485, 372563, 382605, 372565, or 382606. In certain embodiments, a target region is nucleotides 331-427 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 331-427 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 331-427 comprises a 20 nucleotide sequence selected from SEQ ID NO 688, 689, 690, 691, 692, or 693. In certain such embodiments, a short antisense compound targeted to nucleotides 331-427 of SEQ ID NO: 10 is selected from Isis No 382603, 382604, 372485, 372563, 382605, or 372565. In certain embodiments, a target region is nucleotides 392-408 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 392-408 of SEQ ID NO: 10. In 25 certain such embodiments, a short antisense compound targeted to nucleotides 392-408 comprises a nucleotide sequence selected from SEQ ID NO 690, 691, or 692. In certain such embodiments, a short antisense compound targeted to nucleotides 392-408 of SEQ ID NO: 10 is selected from Isis No 372485, 372563, or 382605. In certain embodiments, a target region is nucleotides 651-707 of SEQ ID NO: 10. In certain 30 embodiments, a short antisense compound is targeted to nucleotides 651-707 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 651-707 comprises a nucleotide sequence selected from SEQ ID NO 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, or 728. In certain such embodiments, a short antisense compound targeted to nucleotides 651-707 of 35 SEQ ID NO: 10 is selected from Isis No 372497, 372498, 372575, 372576, 382607, 372499, 372577, 372500, 372578, 372501, 372579, 372502, 372580, 372503, 372581, 372504, 372582, 372505, 372506, 372583, 372584, 372507, 372585, 382608, 372508, 372586, 372509, 372587, 372510, 372588, 372511, WO 2007/146511 PCT/US2007/068401 -136 372512, 372589, or 372590. In certain embodiments, a target region is nucleotides 724-745 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 724-745 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 724-745 comprises a 5 nucleotide sequence selected from SEQ ID NO 729, 730, 731, 732, or 733. In certain such embodiments, a short antisense compound targeted to nucleotides 724-745 of SEQ ID NO: 10 is selected from Isis No 382609, 372514, 372592, 372515, or 372593. In certain embodiments, a target region is nucleotides 651-745 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 651-745 of SEQ ID NO: 10. In 10 certain such embodiments, a short antisense compound targeted to nucleotides 651-745 comprises a nucleotide sequence selected from SEQ ID NO 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, or 733. In certain such embodiments, a short antisense compound targeted to nucleotides 651-745 of SEQ ID NO: 10 is selected from Isis No 372497, 372498, 372575, 372576, 15 382607, 372499, 372577, 372500, 372578, 372501, 372579, 372502, 372580, 372503, 372581, 372504, 372582, 372505, 372506, 372583, 372584, 372507, 372585, 382608, 372508, 372586, 372509, 372587, 372510, 372588, 372511, 372512, 372589, 372590, 382609, 372514, 372592, 372515, or 372593. In certain embodiments, a target region is nucleotides 851-922 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 851-922 of SEQ ID NO: 10. In 20 certain such embodiments, a short antisense compound targeted to nucleotides 851-922 comprises a nucleotide sequence selected from SEQ ID NO 734, 735, 736, or 737. In certain such embodiments, a short antisense compound targeted to nucleotides 851-922 of SEQ ID NO: 10 is selected from Isis No 382610, 382611, 382602, or 382612. In certain embodiments, a target region is nucleotides 851-879 of SEQ ID NO: 10. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 851-879 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 851-879 comprises a nucleotide sequence selected from SEQ ID NO 734, 735, or 736. In certain such embodiments, a short antisense compound targeted to nucleotides 851-879 of SEQ ID NO: 10 is selected from Isis No 382610, 382611, or 382602. 30 In certain embodiments, a target region is nucleotides 965-1007 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 965-1007 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 965-1007 comprises a nucleotide sequence selected from SEQ ID NO 738, 739, 740, 741, 742, 743, 744, or 745. In certain such embodiments, a short antisense compound targeted to nucleotides 965-1007 of SEQ ID NO: 10 is selected 35 from Isis No 372524, 372602, 382613, 382614, 372525, 372603, 372526, or 372604. In certain embodiments, a target region is nucleotides 965-979 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 965-979 of SEQ ID NO: 10. In WO 2007/146511 PCT/US2007/068401 -137 certain such embodiments, a short antisense compound targeted to nucleotides 965-979 comprises a nucleotide sequence selected from SEQ ID NO 738, 739, or 740. In certain such embodiments, a short antisense compound targeted to nucleotides 965-979 of SEQ ID NO: 10 is selected from Isis No 372524, 372602, or 382613. 5 In certain embodiments, a target region is nucleotides 987-1007 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 987-1007 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 987-1007 comprises a nucleotide sequence selected from SEQ ID NO 741, 742, 743, 744, or 745. In certain such embodiments, a short antisense compound targeted to nucleotides 987-1007 of SEQ ID NO: 10 is selected from Isis No 10 382614, 372525, 372603, 372526, or 372604. In certain embodiments, a target region is nucleotides 1106-1132 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 1106-1132 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 1106-1132 comprises a nucleotide sequence selected from SEQ ID NO 746, 747, 748, 749, 750, 751, 752, 753, or 754. In certain 15 such embodiments, a short antisense compound targeted to nucleotides 1106-1132 of SEQ ID NO: 10 is selected from Isis No 372530, 372608, 372531, 372609, 372532, 372610, 372533, 382615, or 372611. In certain embodiments, a target region is nucleotides 1199-1233 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 1199-1233 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 1199-1233 comprises a 20 nucleotide sequence selected from SEQ ID NO 755, 756, 757, 758, 759, 760, 761, 762, or 763. In certain such embodiments, a short antisense compound targeted to nucleotides 1199-1233 of SEQ ID NO: 10 is selected from Isis No 372536, 372614, 372537, 372615, 372538, 372616, 382616, 372539, or 372617. In certain embodiments, a target region is nucleotides 1293-1394 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 1293-1394 of SEQ ID NO: 10. In 25 certain such embodiments, a short antisense compound targeted to nucleotides 1293-1394 comprises a nucleotide sequence selected from SEQ ID NO 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, or 777. In certain such embodiments, a short antisense compound targeted to nucleotides 1293 1394 of SEQ ID NO: 10 is selected from Isis No 372540, 372618, 382617, 372541, 372619, 372542, 372620,372543,372621,372544,372622,382618,382619,or382620. 30 In certain embodiments, a target region is nucleotides 1293-1336 of SEQ ID NO: 10. In certain embodiments, a short antisense compound is targeted to nucleotides 1293-1336 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 1293-1336 comprises a nucleotide sequence selected from SEQ ID NO 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, or 776. In certain such embodiments, a short antisense compound targeted to nucleotides 1293-1336 35 of SEQ ID NO: 10 is selected from Isis No 372540, 372618, 382617, 372541, 372619, 372542, 372620, 372543, 372621, 372544, 372622, 382618, or 382619. In certain embodiments, a target region is nucleotides 1293-1324 of SEQ ID NO: 10. In certain WO 2007/146511 PCT/US2007/068401 -138 embodiments, a short antisense compound is targeted to nucleotides 1293-1324 of SEQ ID NO: 10. In certain such embodiments, a short antisense compound targeted to nucleotides 1293-1324 comprises a nucleotide sequence selected from SEQ ID NO 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, or 775. In certain such embodiments, a short antisense compound targeted to nucleotides 1293-1324 of SEQ 5 ID NO: 10 is selected from Isis No 372540, 372618, 382617, 372541, 372619, 372542, 372620, 372543, 372621, 372544, 372622, or 382618. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 9 to 14 nucleotides in 10 length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 10 to 14 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a DGAT2 nucleic acid comprise at 15 least one high affinity modification in one or more wings of the compound. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from a-L-Methyleneoxy (4'-CH 2 -0-2') BNA, p-D 20 Methyleneoxy (4'-CH 2 -0-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -0-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, O-allyl, O-Cj-C 0 alkyl, OCF 3 , O-(CH 2

)

2

-O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , 0-(CH 2

)

2 -0-N(Rn)(R.), and O-CH 2 -C(=O)-N(Rm)(R), where each Rm and Rn is, independently, H or substituted or unsubstituted C-Cio alkyl. In certain embodiments, 25 the monomers of a wing are 2'MOE nucleotides. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are 30 unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in a short antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid have uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate 35 linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 8 WO 2007/146511 PCT/US2007/068401 -139 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds 5 targeted to a DGAT2 nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 13 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid are 16 monomers 10 in length. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a DGAT2 nucleic acid comprise 12 to 14 nucleotides or nucleosides. 15 In certain embodiments, the invention provides methods of modulating expression of DGAT2. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to a DGAT2 nucleic acid, wherein the short antisense compound targeted to a DGAT2 nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this 20 comprehends methods of modulating expression of DGAT2 using one or more short antisense compounds targeted to a DGAT2 nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 25 nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 10 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 30 nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 13 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 35 nucleic acid that is 15 monomers in length. In certain embodiments, methods of modulating DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid that is 16 monomers in length.

WO 2007/146511 PCT/US2007/068401 -140 In certain embodiments, methods of modulating expression of DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid comprising 9 to 15 monomers. In certain embodiments, methods of modulating expression of DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of 5 modulating expression of DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of DGAT2 comprise use of a short antisense compound targeted to a DGAT2 nucleic acid comprising 12 or 14 nucleotides or nucleosides. 10 9. PTP1B PTPlB (also known as protein phosphatase 1B and PTPN1) is an endoplasmic reticulum (ER) associated enzyme originally isolated as the major protein tyrosine phosphatase of the human placenta (Tonks et al., J. Biol. Chem., 1988, 263, 6731-6737; Tonks et al., J. Biol. Chem., 1988, 263, 6722-6730). An essential regulatory role in signaling mediated by the insulin receptor has been established for 15 PTPlB. In certain instances, PTPlB interacts with and dephosphorylates the activated insulin receptor both in vitro and in intact cells resulting in the downregulation of the signaling pathway (Goldstein et al., Mol. Cell. Biochem., 1998, 182, 91-99; Seely et al., Diabetes, 1996, 45, 1379-1385). In addition, PTP1B modulates the mitogenic actions of insulin (Goldstein et al., Mol. Cell. Biochem., 1998, 182, 91-99). In rat adipose cells overexpressing PTP1B, the translocation of the GLUT4 glucose transporter was inhibited, 20 implicating PTP1 B as a negative regulator of glucose transport as well (Chen et al., J. Biol. Chem., 1997, 272, 8026-8031). Mouse knockout models lacking the PTPlB gene also point toward the negative regulation of insulin signaling by PTP1B. Mice harboring a disrupted PTP1B gene showed increased insulin sensitivity and increased phosphorylation of the insulin receptor. When placed on a high-fat diet, PTP1B 25 -/- mice were resistant to weight gain and remained insulin sensitive (Elchebly et al., Science, 1999, 283, 1544-1548). These studies clearly establish PTP1B as a therapeutic target in the treatment of diabetes and obesity. Diabetes and obesity (sometimes now collectively referred to as "diabesity") are interrelated. Most human obesity is associated with insulin resistance and leptin resistance. In fact obesity may have 30 an even greater impact on insulin action than does diabetes itself (Sindelka et al., Physiol Res., 2002, 51, 85-91). Syndrome X or metabolic syndrome is a new term for a cluster of conditions, that, when occurring together, may indicate a predisposition to diabetes and cardiovascular disease. These symptoms, including high blood pressure, high triglycerides, decreased HDL and obesity, tend to appear together in some individuals. Because of its role in both diabetes and obesity, PTP1B is believed to be a 35 therapeutic target for a range of metabolic conditions, including diabetes, obesity and metabolic syndrome. By improving blood glucose control, inhibitors of PTPlB may also be useful in slowing, preventing, delaying or ameliorating the sequelae of diabetes, which include retinopathy, neuropathy, WO 2007/146511 PCT/US2007/068401 -141 cardiovascular complications and nephropathy. PTP1B, which is differentially regulated during the cell cycle (Schievella et aL, Cell. Growth Differ., 1993, 4, 239-246), is expressed in insulin sensitive tissues as two different isoforms that arise from alternate splicing of the pre-mRNA (Shifrin and Neel, J. Bio. Chem., 1993, 268, 25376-25384). 5 The ratio of the alternatively spliced products is affected by growth factors, such as insulin, and differs in various tissues examined (Sell and Reese, Mol. Genet. Metab., 1999, 66, 189-192). In these studies the levels of the variants correlated with the plasma insulin concentration and percentage body fat. These variants may therefore be used as a biomarker for patients with chronic hyperinsulinemia or type 2 diabetes. 10 Definitions "Protein tyrosine phosphatase 1B" is the gene product or protein of which expression is to be modulated by administration of a short antisense compound. Protein tyrosine phosphatase lB is generally referred to as PTP lB but may also be referred to as protein tyrosine phosphatase; PTPN1; RKPTP; 15 protein tyrosine phosphatase, non-receptor type 1. "PTP1B nucleic acid" means any nucleic acid encoding PTPlB. For example, in certain embodiments, a PTPlB nucleic acid includes, without limitation, a DNA sequence encoding PTP1B, an RNA sequence transcribed from DNA encoding PTPlB, and an mRNA sequence encoding PTPlB. "PTP 1 B mRNA" means an mRNA encoding a PTP lB protein. 20 Therapeutic indications Antisense technology is an effective means for reducing PTPlB expression and has proven to be uniquely useful in a number of therapeutic, diagnostic, and research applications. As such, in certain embodiments, the present invention provides compounds targeted to a nucleic acid encoding PTPIB, 25 which modulate the expression of PTP1B. Further provided herein are short antisense compounds capable of effectively inhibiting PTPlB expression. In certain therapeutics, a subject, suspected of having a disease or disorder which can be treated by modulating the expression of PTPlB is treated by administering one or more short antisense compounds targeted to a nucleic acid encoding PTPlB. For example, in one non-limiting embodiment, 30 the methods comprise the step of administering to an animal a therapeutically effective amount of a short antisense compound. The short antisense compounds of the present invention effectively inhibit the activity of PTPlB or inhibit the expression of PTPlB. In one embodiment, the activity or expression of PTP1B in a subject is inhibited by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 35 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%. In certain embodiments, activity or expression of PTPIB in a subject is inhibited by about 30%. In certain embodiments, the activity or expression of PTP1B in a subject is inhibited by 50% or more.

WO 2007/146511 PCT/US2007/068401 -142 The reduction of the expression of PTPlB may be measured, for example, in blood, plasma, serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding PTP 1 B and/or the PTP I B protein itself. 5 Certain pharmaceutical and other compositions comprising the compounds of the invention are also provided. In certain embodiments short antisense compounds targeted to a PTPlB nucleic acid are utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. The short antisense compounds targeting PTP1B may have any one or more properties or 10 characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a PTP1B nucleic acid have a motif (wing - deoxy gap -wing) selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8-3, 2-8-2, 1-8-1, 3-6 3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. In certain embodiments provided herein are methods of treating an individual by administering 15 one or more short antisense compound targeted to a PTP 1 B nucleic acid or a pharmaceutical composition comprising such compound. Further provided are methods of treating a subject having a disease or conditions associated with PTP1B activity by administering a short antisense compound targeted to a PTPlB nucleic acid. Diseases and conditions associated with PTP1B include but are not limited to high blood glucose or hyperglycemia, prediabetes, diabetes, Type 2 diabetes, metabolic syndrome, obesity and 20 insulin resistance. Therefore, provided herein are methods of treating to high blood glucose or hyperglycemia, prediabetes, diabetes, Type 2 diabetes, metabolic syndrome, obesity and insulin resistance by administering a short antisense compound targeted to a PTP 1 B nucleic acid. In certain embodiments the present invention provides compositions and methods for decreasing blood glucose levels in a subject or for preventing or delaying the onset of a rise in blood glucose levels 25 in a subject, by administering to the subject a short antisense inhibitor of PTP1B expression. In certain embodiments, the present invention provides compositions and methods for improving insulin sensitivity in a subject or for preventing or delaying the onset of insulin resistance in a subject, by administering to the subject a short antisense inhibitor of PTP 1 B expression. In certain embodiments, the present invention provides compositions and methods for treating a 30 metabolic condition in a subject or for preventing or delaying the onset of a metabolic condition in a subject, by administering to the subject a short antisense compound targeted to a PTPlB nucleic acid. Such metabolic condition may be any metabolic condition associated with PTPlB expression, including but not limited to diabetes and obesity. Also provided are methods of reducing adiposity. Also provided is a method of treating obesity wherein metabolic rate is increased. 35 In certain embodiments, the subject has Type 2 diabetes. In certain embodiments the subject exhibits elevated HbAl c levels In certain embodiments, HbAlc levels are at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10% or at least about 11%. In preferred WO 2007/146511 PCT/US2007/068401 -143 embodiments, HbAIc levels are reduced to about 7% or below about 7%. In certain embodiments, the subject exhibits an elevated body mass index In certain embodiments, the elevated body mass index is greater than 25 kg/m2. In certain embodiments, the subject exhibits hyperglycemia or elevated blood glucose levels. In a particular embodiment, the blood glucose levels are fasting blood glucose levels. In 5 certain embodiments, the elevated fasting blood glucose levels are at least 130 mg/dL. In certain embodiments, the subject exhibits hyperglycemia prior to the start of treatment or exhibits fasting blood glucose levels above about 130 mg/dL, baseline HbAc levels of at least about 7%, or body mass index of greater than 25 kg/m 2 or any combination thereof. In certain embodiments a method of reducing one or more such levels by administering a short 10 antisense compound targeted to a PTPlB nucleic acid is provided. For example, provided is a method of reducing fasting glucose levels, IIbAc levels or, body mass index levels or any combination thereof in a subject by administering to a subject a short antisense compound targeting PTP1B. Fasting glucose may be fasting blood glucose, fasting serum glucose, or fasting plasma glucose. In some embodiments, fasting plasma glucose levels are reduced by at least about 25 mg/dL or by at least about 10 mg/dL. In a certain 15 embodiments, said subject does not achieve normal glucose levels on a therapeutic regimen of a glucose lowering agent such as insulin, sulfonylurea, or metformin. In certain embodiments the invention provides methods of altering lipid levels. Certain such methods reduce cholesterol, LDL and/or VLDL levels or any combination thereof in a subject by administering to the subject a short antisense compound targeted to a PTP1B nucleic acid. In certain 20 embodiments HDL levels in a subject are increased by administering to the subject a short antisense compound targeted to a PTPlB nucleic acid. In certain embodiments, LDL:HDL ratio and/or total cholesterol:HDL ratio in a subject is reduced by administering to the subject a short antisense compound targeted to a PTPlB nucleic acid. In certain embodiments HDL:LDL ratio and/or HDL:total cholesterol ratio in a subject's increased by administering to the subject a short antisense compound targeted to a 25 PTPlB nucleic acid. In certain embodiments lipid profile in a subject is improved by increasing HDL, lowering LDL, lowering VLDL, lowering triglycerides, lowering apolipoprotein B levels, or lowering total cholesterol levels, or a combination thereof, by administering to the subject a short antisense compound targeted to a PTPl B nucleic acid. In such embodiments, the subject is an animal, including a human. 30 Combination Therapy In certain embodiments, one or more pharmaceutical compositions comprising a short antisense compound targeted to a PTP1B nucleic acid are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the 35 same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the present invention. In certain WO 2007/146511 PCT/US2007/068401 -144 embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more 5 pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or 10 more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately. In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition comprising a short antisense compound targeted to a PTPIB nucleic acid include glucose-lowering agents and therapies. In some embodiments, the glucose-lowering agent is a 15 PPAR agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a GLP-l analog, insulin or an insulin analog, an insulin secretagogue, a SGLT2 inhibitor, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, or a sulfonylurea. In some embodiments, the glucose-lowering therapeutic is a GLP-1 analog. In some embodiments, the GLP-1 analog is exendin-4 or liraglutide. 20 In other embodiments, the glucose-lowering therapeutic is a sulfonylurea. In some embodiments, the sulfonylurea is acetohexamide, chlorpropamide, tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or a gliclazide. In some embodiments, the glucose lowering drug is a biguanide. In some embodiments, the biguanide is metformin, and in some embodiments, blood glucose levels are decreased without increased 25 lactic acidosis as compared to the lactic acidosis observed after treatment with metformin alone. In some embodiments, the glucose lowering drug is a meglitinide. In some embodiments, the meglitinide is nateglinide or repaglinide. In some embodiments, the glucose-lowering drug is a thiazolidinedione. In some embodiments, the thiazolidinedione is pioglitazone, rosiglitazone, or troglitazone. In some embodiments, blood glucose 30 levels are decreased without greater weight gain than observed with rosiglitazone treatment alone. In some embodiments, the glucose-lowering drug is an alpha-glucosidase inhibitor. In some embodiments, the alpha-glucosidase inhibitor is acarbose or miglitol. In a certain embodiment, a co-administered glucose-lowering agent is ISIS 113715. In a certain embodiment, glucose-lowering therapy is therapeutic lifestyle change. 35 In certain such embodiments, the glucose-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the glucose lowering agent is administered following administration of a pharmaceutical composition of the present WO 2007/146511 PCT/US2007/068401 -145 invention. In certain such embodiments the glucose -lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co administered glucose -lowering agent is the same as the dose that would be administered if the glucose lowering agent was administered alone. In certain such embodiments the dose of a co-administered 5 glucose -lowering agent is lower than the dose that would be administered if the glucose -lowering agent was administered alone. In certain such embodiments the dose of a co-administered glucose -lowering agent is greater than the dose that would be administered if the glucose -lowering agent was administered alone. In certain embodiments, pharmaceutical agents that may be co-administered with a 10 pharmaceutical composition comprising a short antisense compound targeted to a PTPlB nucleic acid include lipid-lowering agents. Such lipid lowering agents are discussed elsewhere in the application and are included here with respect to PTPlB. Such lipid lowering agents may be administered as described above for glucose lowering agents. In certain embodiments, pharmaceutical agents that may be co-administered with a 15 pharmaceutical composition comprising a short antisense compound targeted to a PTPlB nucleic acid include anti-obesity agents therapeutics. Such anti-obesity agents therapeutics may be administered as described above for glucose lowering agents. Further provided is a method of administering a short antisense compound targeted to a PTPlB nucleic acid via injection and further including administering a topical steroid at the injection site. 20 Medicaments Also provided herein are uses of a short antisense compound which is targeted to a PTPlB nucleic acid for the preparation of a medicament for reducing blood glucose levels including fasting glucose levels, and HbAlc levels, body mass index levels or any combination thereof. The medicament 25 can be administered during a loading period and a maintenance period. In some embodiments, the medicament is administered subcutaneously or intravenously. In other embodiments, the administration of said medicament occurs at least once daily, at least once weekly, or at least once monthly. In a particular embodiment the short antisense compound present in the medicament is administered in a dose lower than a short antisense compound with a longer sequence and particularly a sequence 20 or more 30 nucleobases. The medicament may be administered to a subject that exhibits high blood glucose or hyperglycemia, prediabetes, diabetes, Type 2 diabetes, metabolic syndrome, obesity and insulin resistance. Other aspects and advantages of short antisense compounds are provided herein. All aspect and advantages disclosed herein and specifically with regard to other targets is applicable with regard to 35 compositions including short antisense compounds targeted to a PTP1B nucleic acid and methods of their use.

WO 2007/146511 PCT/US2007/068401 -146 Certain Short Antisense Compounds Targeted to a PTPJB Nucleic Acid In certain embodiments, short antisense compounds are targeted to a PTP I B nucleic acid having the sequence of GENBANK@ Accession No. NM_002827.2, incorporated herein as SEQ ID NO: 11 or the nucleotides 14178000 to 1425600 of the sequence of GENBANK@ Accession No. NT_011362.9, 5 incorporated herein as SEQ ID NO: 12. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 11 is at least 90% complementary to SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 11 is at least 95% complementary to SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 12 is 100% complementary to SEQ ID NO: 12. In certain such embodiments, a short antisense compound 10 targeted to SEQ ID NO: 12 is at least 90% complementary to SEQ ID NO: 12. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 12 is at least 95% complementary to SEQ ID NO: 12. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 12 is 100% complementary to SEQ ID NO: 12. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 11 comprises a 15 nucleotide sequence selected from the nucleotide sequences set forth in Tables 16 and 17. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 12 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Tables 18 and 19. Each nucleotide sequence set forth in each Tables 16, 17, 18, and 19 is independent of any modification to a sugar moiety, an intemucleoside linkage, or a nucleobase. As such, short antisense 20 compounds comprising a nucleotide sequence as set forth in Tables 16, 17, 18, and 19 may comprise, independently, one or more modifications to a sugar moiety, an intemucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Tables 16 and 17 illustrate examples of short antisense compounds targeted to SEQ ID NO: 11. 25 Table 16 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 11. Table 17 illustrates short antisense compounds that have one or two mismatches with respect to SEQ ID NO: 11. Table 18 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 12. Table 19 illustrates short antisense compounds that have 1 or 2 mismatches with respect to SEQ ID NO: 12. The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense 30 compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif column. For example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2' deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Intemucleoside linkages are phosphorothioate. The short antisense 35 compounds comprise 5-methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap only" indicates that the gap segment has 5-methylcytosines, while the wing WO 2007/146511 PCT/US2007/068401 -147 segments have unmodified cytosines. Table 16: Short Antisense Compounds targeted to SEQ ID NO: 11 5' 3' ISIS Target Target Gapmer SEQ NO. Site Site Sequence (5'-3') Motif ID NO 147022 177 188 TTGTCGATCTCC 1-10-1 MOE 886 147023 178 189 CTTGTCGATCTC 1-10-1 MOE 859 147024 179 190 CCTTGTCGATCT 1-10-1 MOE 853 147019 195 206 TCGATCTCCTCG 1-10-1 MOE 877 147020 196 207 GTCGATCTCCTC 1-10-1 MOE 868 147021 197 208 TGTCGATCTCCT 1-10-1 MOE 882 147022 198 209 TTGTCGATCTCC 1-10-1 MOE 886 147023 199 210 CTTGTCGATCTC 1-10-1 MOE 859 147024 200 211 CCTTGTCGATCT 1-10-1 MOE 853 147025 201 212 GCCTTGTCGATC 1-10-1 MOE 865 147026 202 213 AGCCTTGTCGAT 1-10-1 MOE 835 147027 203 214 CAGCCTTGTCGA 1-10-1 MOE 843 147028 204 215 CCAGCCTTGTCG 1-10-1 MOE 846 147073 204 215 CACTGATCCTGC 1-10-1 MOE 842 147029 205 216 CCCAGCCTTGTC 1-10-1 MOE 848 147030 206 217 TCCCAGCCTTGT 1-10-1 MOE 874 147036 212 223 CCCAGTTCCCAG 1-10-1 MOE 849 147037 213 224 GCCCAGTTCCCA 1-10-1 MOE 863 147038 214 225 CGCCCAGTTCCC 1-10-1 MOE 855 147039 215 226 CCGCCCAGTTCC 1-10-1 MOE 850 147040 216 227 GCCGCCCAGTTC 1-10-1 MOE 864 147041 217 228 AGCCGCCCAGTT 1-10-1 MOE 834 147073 311 322 CACTGATCCTGC 1-10-1 MOE 842 147042 323 334 GGTCAAAAGGGC 1-10-1 MOE 866 147043 324 335 TGGTCAAAAGGG 1-10-1 MOE 881 147044 325 336 GTGGTCAAAAGG 1-10-1 MOE 869 147045 326 337 TGTGGTCAAAAG 1-10-1 MOE 883 147046 327 338 CTGTGGTCAAAA 1-10-1 MOE 858 147047 328 339 ACTGTGGTCAAA 1-10-1 MOE 833 147051 332 343 TCCGACTGTGGT 1-10-1 MOE 875 147052 333 344 ATCCGACTGTGG 1-10-1 MOE 837 147053 334 345 AATCCGACTGTG 1-10-1 MOE 829 147054 335 346 TAATCCGACTGT 1-10-1 MOE 871 147055 336 347 TTAATCCGACTG 1-10-1 MOE 884 147056 337 348 TTTAATCCGACT 1-10-1 MOE 887 147057 338 349 ATTTAATCCGAC 1-10-1 MOE 839 147058 339 350 AATTTAATCCGA 1-10-1 MOE 830 147059 340 351 CAATTTAATCCG 1-10-1 MOE 840 147060 341 352 GCAATTTAATCC 1-10-1 MOE 861 147061 342 353 TGCAATTTAATC 1-10-1 MOE 879 147045 679 690 TGTGGTCAAAAG 1-10-1 MOE 883 147046 680 691 CTGTGGTCAAAA 1-10-1 MOE 858 147045 787 798 TGTGGTCAAAAG 1-10-1 MOE 883 147046 788 799 CTGTGGTCAAAA 1-10-1 MOE 858 147066 816 827 CCTGCACTGACG 1-10-1 MOE 851 404131 992 1005 ACCTTCGATCACAG 2-10-2 MOE 831 WO 2007/146511 PCT/US2007/068401 -148 147062 1024 1035 CACTGACGAGTC 1-10-1 MOE 841 147063 1025 1036 GCACTGACGAGT 1-10-1 MOE 862 147064 1026 1037 TGCACTGACGAG 1-10-1 MOE 880 147065 1027 1038 CTGCACTGACGA 1-10-1 MOE 857 147066 1028 1039 CCTGCACTGACG 1-10-1 MOE 851 147067 1029 1040 TCCTGCACTGAC 1-10-1 MOE 876 147068 1030 1041 ATCCTGCACTGA 1-10-1 MOE 838 147069 1031 1042 GATCCTGCACTG 1-10-1 MOE 860 147070 1032 1043 TGATCCTGCACT 1-10-1 MOE 878 147071 1033 1044 CTGATCCTGCAC 1-10-1 MOE 856 147072 1034 1045 ACTGATCCTGCA 1-10-1 MOE 832 147073 1035 1046 CACTGATCCTGC 1-10-1 MOE 842 147067 1199 1210 TCCTGCACTGAC 1-10-1 MOE 876 147040 1288 1299 GCCGCCCAGTTC 1-10-1 MOE 864 147040 1396 1407 GCCGCCCAGTTC 1-10-1 MOE 864 147022 1868 1879 TTGTCGATCTCC 1-10-1 MOE 886 147023 1869 1880 CTTGTCGATCTC 1-10-1 MOE 859 147024 1870 1881 CCTTGTCGATCT 1-10-1 MOE 853 147019 1886 1897 TCGATCTCCTCG 1-10-1 MOE 877 147020 1887 1898 GTCGATCTCCTC 1-10-1 MOE 868 147021 1888 1899 TGTCGATCTCCT 1-10-1 MOE 882 147022 1889 1900 TTGTCGATCTCC 1-10-1 MOE 886 147023 1890 1901 CTTGTCGATCTC 1-10-1 MOE 859 147025 1892 1903 GCCTTGTCGATC 1-10-1 MOE 865 147027 1894 1905 CAGCCTTGTCGA 1-10-1 MOE 843 147028 1895 1906 CCAGCCTTGTCG 1-10-1 MOE 846 147030 1897 1908 TCCCAGCCTTGT 1-10-1 MOE 874 147037 1904 1915 GCCCAGTTCCCA 1-10-1 MOE 863 147038 1905 1916 CGCCCAGTTCCC 1-10-1 MOE 855 147040 1907 1918 GCCGCCCAGTTC 1-10-1 MOE 864 147041 1908 1919 AGCCGCCCAGTT 1-10-1 MOE 834 147022 1976 1987 TTGTCGATCTCC 1-10-1 MOE 886 147023 1977 1988 CTTGTCGATCTC 1-10-1 MOE 859 147024 1978 1989 CCTTGTCGATCT 1-10-1 MOE 853 147020 1995 2006 GTCGATCTCCTC 1-10-1 MOE 868 147021 1996 2007 TGTCGATCTCCT 1-10-1 MOE 882 147022 1997 2008 TTGTCGATCTCC 1-10-1 MOE 886 147023 1998 2009 CTTGTCGATCTC 1-10-1 MOE 859 147024 1999 2010 CCTTGTCGATCT 1-10-1 MOE 853 147025 2000 2011 GCCTTGTCGATC 1-10-1 MOE 865 147026 2001 2012 AGCCTTGTCGAT 1-10-1 MOE 835 147027 2002 2013 CAGCCTTGTCGA 1-10-1 MOE 843 147028 2003 2014 CCAGCCTTGTCG 1-10-1 MOE 846 147029 2004 2015 CCCAGCCTTGTC 1-10-1 MOE 848 147030 2005 2016 TCCCAGCCTTGT 1-10-1 MOE 874 147036 2011 2022 CCCAGTTCCCAG 1-10-1 MOE 849 147037 2012 2023 GCCCAGTTCCCA 1-10-1 MOE 863 147038 2013 2024 CGCCCAGTTCCC 1-10-1 MOE 855 147039 2014 2025 CCGCCCAGTTCC 1-10-1 MOE 850 147040 2015 2026 GCCGCCCAGTTC 1-10-1 MOE 864 147041 2016 2027 AGCCGCCCAGTT 1-10-1 MOE 834 404199 2366 2379 GGTCATGCACAGGC 2-10-2 MOE 867 404134 2369 2382 TCAGGTCATGCACA 2-10-2 MOE 873 WO 2007/146511 PCT/US2007/068401 -149 404132 2548 2561 CCTTGGAATGTCTG 2-10-2 MOE 852 147020 2613 2624 GTCGATCTCCTC 1-10-1 MOE 868 147020 2721 2732 GTCGATCTCCTC 1-10-1 MOE 868 404133 3289 3302 TATTCCATGGCCAT 2-10-2 MOE 872 147032 6220 6231 GTTCCCAGCCTT 1-10-1 MOE 870 147033 6221 6232 AGTTCCCAGCCT 1-10-1 MOE 836 147034 6222 6233 CAGTTCCCAGCC 1-10-1 MOE 844 147044 6288 6299 GTGGTCAAAAGG 1-10-1 MOE 869 147045 6289 6300 TGTGGTCAAAAG 1-10-1 MOE 883 147032 6329 6340 GTTCCCAGCCTT 1-10-1 MOE 870 147033 6330 6341 AGTTCCCAGCCT 1-10-1 MOE 836 147034 6331 6342 CAGTTCCCAGCC 1-10-1 MOE 844 147044 6397 6408 GTGGTCAAAAGG 1-10-1 MOE 869 147045 6398 6409 TGTGGTCAAAAG 1-10-1 MOE 883 147058 7057 7068 AATTTAATCCGA 1-10-1 MOE 830 147059 7058 7069 CAATTTAATCCG 1-10-1 MOE 840 147060 7059 '7070 GCAATTTAATCC 1-10-1 MOE 861 147058 7166 7177 AATTTAATCCGA 1-10-1 MOE 830 147059 7167 7178 CAATTTAATCCG 1-10-1 MOE 840 147041 8084 8095 AGCCGCCCAGTT 1-10-1 MOE 834 147041 8192 8203 AGCCGCCCAGTT 1-10-1 MOE 834 147027 8630 8641 CAGCCTTGTCGA 1-10-1 MOE 843 147028 8631 8642 CCAGCCTTGTCG 1-10-1 MOE 846 147027 8738 8749 CAGCCTTGTCGA 1-10-1 MOE 843 147028 8739 8750 CCAGCCTTGTCG 1-10-1 MOE 846 147043 10957 10968 TGGTCAAAAGGG 1-10-1 MOE 881 147044 10958 10969 GTGGTCAAAAGG 1-10-1 MOE 869 147043 11065 11076 TGGTCAAAAGGG 1-10-1 MOE 881 147044 11066 11077 GTGGTCAAAAGG 1-10-1 MOE 869 147071 11605 11616 CTGATCCTGCAC 1-10-1 MOE 856 147070 11611 11622 TGATCCTGCACT 1-10-1 MOE 878 147071 11612 11623 CTGATCCTGCAC 1-10-1 MOE 856 147072 12294 12305 ACTGATCCTGCA 1-10-1 MOE 832 147072 12299 12310 ACTGATCCTGCA 1-10-1 MOE 832 147030 12805 12816 TCCCAGCCTTGT 1-10-1 MOE 874 147031 12806 12817 TTCCCAGCCTTG 1-10-1 MOE 885 147053 12939 12950 AATCCGACTGTG 1-10-1 MOE 829 147030 12986 12997 TCCCAGCCTTGT 1-10-1 MOE 874 147031 12987 12998 TTCCCAGCCTTG 1-10-1 MOE 885 147053 13120 13131 AATCCGACTGTG 1-10-1 MOE 829 147051 13162 13173 TCCGACTGTGGT 1-10-1 MOE 875 147061 13316 13327 TGCAATTTAATC 1-10-1 MOE 879 147047 13339 13350 ACTGTGGTCAAA 1-10-1 MOE 833 147029 14058 14069 CCCAGCCTTGTC 1-10-1 MOE 848 147029 14239 14250 CCCAGCCTTGTC 1-10-1 MOE 848 147067 15560 15571 TCCTGCACTGAC 1-10-1 MOE 876 147068 15561 15572 ATCCTGCACTGA 1-10-1 MOE 838 147067 15742 15753 TCCTGCACTGAC 1-10-1 MOE 876 147069 15744 15755 GATCCTGCACTG 1-10-1 MOE 860 147042 16561 16572 GGTCAAAAGGGC 1-10-1 MOE 866 147042 16727 16738 GGTCAAAAGGGC 1-10-1 MOE 866 147030 17619 17630 TCCCAGCCTTGT 1-10-1 MOE 874 147064 17762 17773 TGCACTGACGAG 1-10-1 MOE 880 WO 2007/146511 PCT/US2007/068401 -150 147030 17787 17798 TCCCAGCCTTGT 1-10-1 MOE 874 147064 17930 17941 TGCACTGACGAG 1-10-1 MOE 880 147042 19201 19212 GGTCAAAAGGGC 1-10-1 MOE 866 147042 19369 19380 GGTCAAAAGGGC 1-10-1 MOE 866 147027 21190 21201 CAGCCTTGTCGA 1-10-1 MOE 843 147028 21191 21202 CCAGCCTTGTCG 1-10-1 MOE 846 147027 21358 21369 CAGCCTTGTCGA 1-10-1 MOE 843 147028 21359 21370 CCAGCCTTGTCG 1-10-1 MOE 846 147070 22021 22032 TGATCCTGCACT 1-10-1 MOE 878 147070 22189 22200 TGATCCTGCACT 1-10-1 MOE 878 147047 22606 22617 ACTGTGGTCAAA 1-10-1 MOE 833 147043 24318 24329 TGGTCAAAAGGG 1-10-1 MOE 881 147044 24319 24330 GTGGTCAAAAGG 1-10-1 MOE 869 147045 24320 24331 TGTGGTCAAAAG 1-10-1 MOE 883 147046 24321 24332 CTGTGGTCAAAA 1-10-1 MOE 858 147043 24486 24497 TGGTCAAAAGGG 1-10-1 MOE 881 147044 24487 24498 GTGGTCAAAAGG 1-10-1 MOE 869 147046 24489 24500 CTGTGGTCAAAA 1-10-1 MOE 858 147047 24490 24501 ACTGTGGTCAAA 1-10-1 MOE 833 147040 25065 25076 GCCGCCCAGTTC 1-10-1 MOE 864 147041 25066 25077 AGCCGCCCAGTT 1-10-1 MOE 834 147046 25160 25171 CTGTGGTCAAAA 1-10-1 MOE 858 147039 25232 25243 CCGCCCAGTTCC 1-10-1 MOE 850 147040 25233 25244 GCCGCCCAGTTC 1-10-1 MOE 864 147041 25234 25245 AGCCGCCCAGTT 1-10-1 MOE 834 147046 25328 25339 CTGTGGTCAAAA 1-10-1 MOE 858 147057 25508 25519 ATTTAATCCGAC 1-10-1 MOE 839 147061 25512 25523 TGCAATTTAATC 1-10-1 MOE 879 147057 25676 25687 ATTTAATCCGAC 1-10-1 MOE 839 147069 28878 28889 GATCCTGCACTG 1-10-1 MOE 860 147070 28879 28890 TGATCCTGCACT 1-10-1 MOE 878 147053 30133 30144 AATCCGACTGTG 1-10-1 MOE 829 147053 30278 30289 AATCCGACTGTG 1-10-1 MOE 829 147054 30864 30875 TAATCCGACTGT 1-10-1 MOE 871 147043 30985 30996 TGGTCAAAAGGG 1-10-1 MOE 881 147054 31011 31022 TAATCCGACTGT 1-10-1 MOE 871 147043 31133 31144 TGGTCAAAAGGG 1-10-1 MOE 881 147036 32233 32244 CCCAGTTCCCAG 1-10-1 MOE 849 147072 32372 32383 ACTGATCCTGCA 1-10-1 MOE 832 147072 32520 32531 ACTGATCCTGCA 1-10-1 MOE 832 147069 33056 33067 GATCCTGCACTG 1-10-1 MOE 860 147070 33057 33068 TGATCCTGCACT 1-10-1 MOE 878 147071 33058 33069 CTGATCCTGCAC 1-10-1 MOE 856 147051 33126 33137 TCCGACTGTGGT 1-10-1 MOE 875 147070 33205 33216 TGATCCTGCACT 1-10-1 MOE 878 147071 33206 33217 CTGATCCTGCAC 1-10-1 MOE 856 147051 33274 33285 TCCGACTGTGGT 1-10-1 MOE 875 147046 33318 33329 CTGTGGTCAAAA 1-10-1 MOE 858 147049 33321 33332 CGACTGTGGTCA 1-10-1 MOE 854 147051 33323 33334 TCCGACTGTGGT 1-10-1 MOE 875 147046 33466 33477 CTGTGGTCAAAA 1-10-1 MOE 858 147047 33467 33478 ACTGTGGTCAAA 1-10-1 MOE 833 147051 33471 33482 TCCGACTGTGGT 1-10-1 MOE 875 WO 2007/146511 PCT/US2007/068401 -151 147046 33640 33651 CTGTGGTCAAAA 1-10-1 MOE 858 147051 33645 33656 TCCGACTGTGGT 1-10-1 MOE 875 147046 33788 33799 CTGTGGTCAAAA 1-10-1 MOE 858 147051 33793 33804 TCCGACTGTGGT 1-10-1 MOE 875 147059 35437 35448 CAATTTAATCCG 1-10-1 MOE 840 147060 35438 35449 GCAATTTAATCC 1-10-1 MOE 861 147060 35586 35597 GCAATTTAATCC 1-10-1 MOE 861 147021 36093 36104 TGTCGATCTCCT 1-10-1 MOE 882 147061 36250 36261 TGCAATTTAATC 1-10-1 MOE 879 147061 36398 36409 TGCAATTTAATC 1-10-1 MOE 879 147073 37485 37496 CACTGATCCTGC 1-10-1 MOE 842 147073 37633 37644 CACTGATCCTGC 1-10-1 MOE 842 147043 40214 40225 TGGTCAAAAGGG 1-10-1 MOE 881 147061 40353 40364 TGCAATTTAATC 1-10-1 MOE 879 147043 40362 40373 TGGTCAAAAGGG 1-10-1 MOE 881 147061 40501 40512 TGCAATTTAATC 1-10-1 MOE 879 147031 42527 42538 TTCCCAGCCTTG 1-10-1 MOE 885 147032 42528 42539 GTTCCCAGCCTT 1-10-1 MOE 870 147034 42530 42541 CAGTTCCCAGCC 1-10-1 MOE 844 147031 42675 42686 TTCCCAGCCTTG 1-10-1 MOE 885 147032 42676 42687 GTTCCCAGCCTT 1-10-1 MOE 870 147033 42677 42688 AGTTCCCAGCCT 1-10-1 MOE 836 147034 42678 42689 CAGTTCCCAGCC 1-10-1 MOE 844 147074 43848 43859 CCACTGATCCTG 1-10-1 MOE 845 147074 43996 44007 CCACTGATCCTG 1-10-1 MOE 845 147051 45402 45413 TCCGACTGTGGT 1-10-1 MOE 875 147051 45550 45561 TCCGACTGTGGT 1-10-1 MOE 875 147074 46125 46136 CCACTGATCCTG 1-10-1 MOE 845 147057 46313 46324 ATTTAATCCGAC 1-10-1 MOE 839 147058 46314 46325 AATTTAATCCGA 1-10-1 MOE 830 147059 46315 46326 CAATTTAATCCG 1-10-1 MOE 840 147061 46317 46328 TGCAATTTAATC 1-10-1 MOE 879 147057 46461 46472 ATTTAATCCGAC 1-10-1 MOE 839 147059 46463 46474 CAATTTAATCCG 1-10-1 MOE 840 147061 46465 46476 TGCAATTTAATC 1-10-1 MOE 879 147058 47413 47424 AATTTAATCCGA 1-10-1 MOE 830 147073 48221 48232 CACTGATCCTGC 1-10-1 MOE 842 147073 48369 48380 CACTGATCCTGC 1-10-1 MOE 842 147074 48370 48381 CCACTGATCCTG 1-10-1 MOE 845 147027 48566 48577 CAGCCTTGTCGA 1-10-1 MOE 843 147027 48714 48725 CAGCCTTGTCGA 1-10-1 MOE 843 147028 48715 48726 CCAGCCTTGTCG 1-10-1 MOE 846 147067 49050 49061 TCCTGCACTGAC 1-10-1 MOE 876 147068 49051 49062 ATCCTGCACTGA 1-10-1 MOE 838 147067 49198 49209 TCCTGCACTGAC 1-10-1 MOE 876 147073 49524 49535 CACTGATCCTGC 1-10-1 MOE 842 147073 49672 49683 CACTGATCCTGC 1-10-1 MOE 842 147074 49673 49684 CCACTGATCCTG 1-10-1 MOE 845 147036 50421 50432 CCCAGTTCCCAG 1-10-1 MOE 849 147036 52292 52303 CCCAGTTCCCAG 1-10-1 MOE 849 147037 52293 52304 GCCCAGTTCCCA 1-10-1 MOE 863 147036 52438 52449 CCCAGTTCCCAG 1-10-1 MOE 849 147037 52439 52450 GCCCAGTTCCCA 1-10-1 MOE 863 WO 2007/146511 PCT/US2007/068401 -152 147034 53148 53159 CAGTTCCCAGCC 1-10-1 MOE 844 147034 53294 53305 CAGTTCCCAGCC 1-10-1 MOE 844 147042 53445 53456 GGTCAAAAGGGC 1-10-1 MOE 866 147043 53446 53457 TGGTCAAAAGGG 1-10-1 MOE 881 147044 53447 53458 GTGGTCAAAAGG 1-10-1 MOE 869 147042 53591 53602 GGTCAAAAGGGC 1-10-1 MOE 866 147030 53592 53603 TCCCAGCCTTGT 1-10-1 MOE 874 147043 53592 53603 TGGTCAAAAGGG 1-10-1 MOE 881 147031 53593 53604 TTCCCAGCCTTG 1-10-1 MOE 885 147044 53593 53604 GTGGTCAAAAGG 1-10-1 MOE 869 147030 53738 53749 TCCCAGCCTTGT 1-10-1 MOE 874 147031 53739 53750 TTCCCAGCCTTG 1-10-1 MOE 885 147040 53783 53794 GCCGCCCAGTTC 1-10-1 MOE 864 147041 53784 53795 AGCCGCCCAGTT 1-10-1 MOE 834 147041 53930 53941 AGCCGCCCAGTT 1-10-1 MOE 834 147042 55008 55019 GGTCAAAAGGGC 1-10-1 MOE 866 147043 55009 55020 TGGTCAAAAGGG 1-10-1 MOE 881 147042 55154 55165 GGTCAAAAGGGC 1-10-1 MOE 866 147043 55155 55166 TGGTCAAAAGGG 1-10-1 MOE 881 147058 55281 55292 AATTTAATCCGA 1-10-1 MOE 830 147058 55427 55438 AATTTAATCCGA 1-10-1 MOE 830 147019 55682 55693 TCGATCTCCTCG 1-10-1 MOE 877 147021 55684 55695 TGTCGATCTCCT 1-10-1 MOE 882 147021 55830 55841 TGTCGATCTCCT 1-10-1 MOE 882 147054 56275 56286 TAATCCGACTGT 1-10-1 MOE 871 147055 56276 56287 TTAATCCGACTG 1-10-1 MOE 884 147056 56277 56288 TTTAATCCGACT 1-10-1 MOE 887 147058 56279 56290 AATTTAATCCGA 1-10-1 MOE 830 147059 56280 56291 CAATTTAATCCG 1-10-1 MOE 840 147060 56281 56292 GCAATTTAATCC 1-10-1 MOE 861 147061 56282 56293 TGCAATTTAATC 1-10-1 MOE 879 147051 56418 56429 TCCGACTGTGGT 1-10-1 MOE 875 147053 56420 56431 AATCCGACTGTG 1-10-1 MOE 829 147054 56421 56432 TAATCCGACTGT 1-10-1 MOE 871 147055 56422 56433 TTAATCCGACTG 1-10-1 MOE 884 147056 56423 56434 TTTAATCCGACT 1-10-1 MOE 887 147057 56424 56435 ATTTAATCCGAC 1-10-1 MOE 839 147058 56425 56436 AATTTAATCCGA 1-10-1 MOE 830 147061 56428 56439 TGCAATTTAATC 1-10-1 MOE 879 147045 57118 57129 TGTGGTCAAAAG 1-10-1 MOE 883 147045 57264 57275 TGTGGTCAAAAG 1-10-1 MOE 883 147046 57265 57276 CTGTGGTCAAAA 1-10-1 MOE 858 147071 58028 58039 CTGATCCTGCAC 1-10-1 MOE 856 147071 58174 58185 CTGATCCTGCAC 1-10-1 MOE 856 147043 61111 61122 TGGTCAAAAGGG 1-10-1 MOE 881 147071 61130 61141 CTGATCCTGCAC 1-10-1 MOE 856 147020 61226 61237 GTCGATCTCCTC 1-10-1 MOE 868 147043 61257 61268 TGGTCAAAAGGG 1-10-1 MOE 881 147071 61276 61287 CTGATCCTGCAC 1-10-1 MOE 856 147035 61277 61288 CCAGTTCCCAGC 1-10-1 MOE 847 147036 61278 61289 CCCAGTTCCCAG 1-10-1 MOE 849 147037 61279 61290 GCCCAGTTCCCA 1-10-1 MOE 863 147038 61280 61291 CGCCCAGTTCCC 1-10-1 MOE 855 WO 2007/146511 PCT/US2007/068401 -153 147039 61281 61292 CCGCCCAGTTCC 1-10-1 MOE 850 147040 61282 61293 GCCGCCCAGTTC 1-10-1 MOE 864 147071 61309 61320 CTGATCCTGCAC 1-10-1 MOE 856 147020 61372 61383 GTCGATCTCCTC 1-10-1 MOE 868 147034 61422 61433 CAGTTCCCAGCC 1-10-1 MOE 844 147035 61423 61434 CCAGTTCCCAGC 1-10-1 MOE 847 147036 61424 61435 CCCAGTTCCCAG 1-10-1 MOE 849 147037 61425 61436 GCCCAGTTCCCA 1-10-1 MOE 863 147038 61426 61437 CGCCCAGTTCCC 1-10-1 MOE 855 147040 61428 61439 GCCGCCCAGTTC 1-10-1 MOE 864 147071 61455 61466 CTGATCCTGCAC 1-10-1 MOE 856 147073 62003 62014 CACTGATCCTGC 1-10-1 MOE 842 147073 62149 62160 CACTGATCCTGC 1-10-1 MOE 842 147066 63065 63076 CCTGCACTGACG 1-10-1 MOE 851 147068 63067 63078 ATCCTGCACTGA 1-10-1 MOE 838 147069 63146 63157 GATCCTGCACTG 1-10-1 MOE 860 147062 63207 63218 CACTGACGAGTC 1-10-1 MOE 841 147066 63211 63222 CCTGCACTGACG 1-10-1 MOE 851 147057 64054 64065 ATTTAATCCGAC 1-10-1 MOE 839 147036 64538 64549 CCCAGTTCCCAG 1-10-1 MOE 849 147037 64539 64550 GCCCAGTTCCCA 1-10-1 MOE 863 147037 64685 64696 GCCCAGTTCCCA 1-10-1 MOE 863 147066 64864 64875 CCTGCACTGACG 1-10-1 MOE 851 147067 64865 64876 TCCTGCACTGAC 1-10-1 MOE 876 147066 65010 65021 CCTGCACTGACG 1-10-1 MOE 851 147067 65011 65022 TCCTGCACTGAC 1-10-1 MOE 876 147045 65017 65028 TGTGGTCAAAAG 1-10-1 MOE 883 147045 65163 65174 TGTGGTCAAAAG 1-10-1 MOE 883 147046 65164 65175 CTGTGGTCAAAA 1-10-1 MOE 858 147068 65408 65419 ATCCTGCACTGA 1-10-1 MOE 838 147071 65411 65422 CTGATCCTGCAC 1-10-1 MOE 856 147069 65549 65560 GATCCTGCACTG 1-10-1 MOE 860 147068 65554 65565 ATCCTGCACTGA 1-10-1 MOE 838 147071 65557 65568 CTGATCCTGCAC 1-10-1 MOE 856 147029 67741 67752 CCCAGCCTTGTC 1-10-1 MOE 848 147030 67742 67753 TCCCAGCCTTGT 1-10-1 MOE 874 147031 67743 67754 TTCCCAGCCTTG 1-10-1 MOE 885 147028 67886 67897 CCAGCCTTGTCG 1-10-1 MOE 846 147029 67887 67898 CCCAGCCTTGTC 1-10-1 MOE 848 147030 67888 67899 TCCCAGCCTTGT 1-10-1 MOE 874 147031 67889 67900 TTCCCAGCCTTG 1-10-1 MOE 885 147043 68867 68878 TGGTCAAAAGGG 1-10-1 MOE 881 147044 68868 68879 GTGGTCAAAAGG 1-10-1 MOE 869 147045 68869 68880 TGTGGTCAAAAG 1-10-1 MOE 883 147043 69013 69024 TGGTCAAAAGGG 1-10-1 MOE 881 147044 69014 69025 GTGGTCAAAAGG 1-10-1 MOE 869 147045 69015 69026 TGTGGTCAAAAG 1-10-1 MOE 883 147046 69016 69027 CTGTGGTCAAAA 1-10-1 MOE 858 147071 69519 69530 CTGATCCTGCAC 1-10-1 MOE 856 147072 69520 69531 ACTGATCCTGCA 1-10-1 MOE 832 147073 69521 69532 CACTGATCCTGC 1-10-1 MOE 842 147071 69665 69676 CTGATCCTGCAC 1-10-1 MOE 856 147072 69666 69677 ACTGATCCTGCA 1-10-1 MOE 832 WO 2007/146511 PCT/US2007/068401 -154 147073 69667 69678 CACTGATCCTGC 1-10-1 MOE 842 147074 69668 69679 CCACTGATCCTG 1-10-1 MOE 845 147066 69869 69880 CCTGCACTGACG 1-10-1 MOE 851 147066 70015 70026 CCTGCACTGACG 1-10-1 MOE 851 147023 70465 70476 CTTGTCGATCTC 1-10-1 MOE 859 147023 70611 70622 CTTGTCGATCTC 1-10-1 MOE 859 147062 70615 70626 CACTGACGAGTC 1-10-1 MOE 841 147063 70616 70627 GCACTGACGAGT 1-10-1 MOE 862 147064 70617 70628 TGCACTGACGAG 1-10-1 MOE 880 147065 70618 70629 CTGCACTGACGA 1-10-1 MOE 857 147066 70619 70630 CCTGCACTGACG 1-10-1 MOE 851 147063 70762 70773 GCACTGACGAGT 1-10-1 MOE 862 147064 70763 70774 TGCACTGACGAG 1-10-1 MOE 880 147065 70764 70775 CTGCACTGACGA 1-10-1 MOE 857 147066 70765 70776 CCTGCACTGACG 1-10-1 MOE 851 147072 70998 71009 ACTGATCCTGCA 1-10-1 MOE 832 147073 70999 71010 CACTGATCCTGC 1-10-1 MOE 842 147072 71144 71155 ACTGATCCTGCA 1-10-1 MOE 832 147073 71145 71156 CACTGATCCTGC 1-10-1 MOE 842 147074 71146 71157 CCACTGATCCTG 1-10-1 MOE 845 147037 71351 71362 GCCCAGTTCCCA 1-10-1 MOE 863 147038 71352 71363 CGCCCAGTTCCC 1-10-1 MOE 855 147039 71353 71364 CCGCCCAGTTCC 1-10-1 MOE 850 147037 71497 71508 GCCCAGTTCCCA 1-10-1 MOE 863 147038 71498 71509 CGCCCAGTTCCC 1-10-1 MOE 855 147039 71499 71510 CCGCCCAGTTCC 1-10-1 MOE 850 147061 71641 71652 TGCAATTTAATC 1-10-1 MOE 879 147061 71787 71798 TGCAATTTAATC 1-10-1 MOE 879 Table 17: Short antisense compounds targeted to SEQ ID NO: 11 and having 1 or 2 mismatches 5' 3' ISIS Target Target Gapmer SEQ ID NO. Site Site Sequence (5'-3') Motif NO 147022 177 188 TTGTCGATCTCC 1-10-1 MOE 886 147023 178 189 CTTGTCGATCTC 1-10-1 MOE 859 147020 196 207 GTCGATCTCCTC 1-10-1 MOE 868 147022 198 209 TTGTCGATCTCC 1-10-1 MOE 886 147024 200 211 CCTTGTCGATCT 1-10-1 MOE 853 147026 202 213 AGCCTTGTCGAT 1-10-1 MOE 835 147028 204 215 CCAGCCTTGTCG 1-10-1 MOE 846 147029 205 216 CCCAGCCTTGTC 1-10-1 MOE 848 147030 206 217 TCCCAGCCTTGT 1-10-1 MOE 874 147036 212 223 CCCAGTTCCCAG 1-10-1 MOE 849 147073 311 322 CACTGATCCTGC 1-10-1 MOE 842 147046 327 338 CTGTGGTCAAAA 1-10-1 MOE 858 147047 328 339 ACTGTGGTCAAA 1-10-1 MOE 833 147048 329 340 GACTGTGGTCAA 1-10-1 MOE 888 147049 330 341 CGACTGTGGTCA 1-10-1 MOE 854 147050 331 342 CCGACTGTGGTC 1-10-1 MOE 889 147051 332 343 TCCGACTGTGGT 1-10-1 MOE 875 147052 333 344 ATCCGACTGTGG 1-10-1 MOE 837 147053 334 345 AATCCGACTGTG 1-10-1 MOE 829 147054 335 346 TAATCCGACTGT 1-10-1 MOE 871 WO 2007/146511 PCT/US2007/068401 -155 147055 336 347 TTAATCCGACTG 1-10-1 MOE 884 147056 337 348 TTTAATCCGACT 1-10-1 MOE 887 147057 338 349 ATTTAATCCGAC 1-10-1 MOE 839 147058 339 350 AATTTAATCCGA 1-10-1 MOE 830 147060 341 352 GCAATTTAATCC 1-10-1 MOE 861 147061 342 353 TGCAATTTAATC 1-10-1 MOE 879 147062 1024 1035 CACTGACGAGTC 1-10-1 MOE 841 147063 1025 1036 GCACTGACGAGT 1-10-1 MOE 862 147068 1030 1041 ATCCTGCACTGA 1-10-1 MOE 838 147071 1033 1044 CTGATCCTGCAC 1-10-1 MOE 856 147073 1035 1046 CACTGATCCTGC 1-10-1 MOE 842 147074 1036 1047 CCACTGATCCTG 1-10-1 MOE 845 147067 1091 1102 TCCTGCACTGAC 1-10-1 MOE 876 147024 1891 1902 CCTTGTCGATCT 1-10-1 MOE 853 147026 1893 1904 AGCCTTGTCGAT 1-10-1 MOE 835 147029 1896 1907 CCCAGCCTTGTC 1-10-1 MOE 848 147036 1903 1914 CCCAGTTCCCAG 1-10-1 MOE 849 147039 1906 1917 CCGCCCAGTTCC 1-10-1 MOE 850 147019 1994 2005 TCGATCTCCTCG 1-10-1 MOE 877 401385 2815 2828 CCCAGTGGGTTTGA 2-10-2 MOE 890 147033 5265 5276 AGTTCCCAGCCT 1-10-1 MOE 836 147033 5373 5384 AGTTCCCAGCCT 1-10-1 MOE 836 147060 7168 7179 GCAATTTAATCC 1-10-1 MOE 861 147053 10527 10538 AATCCGACTGTG 1-10-1 MOE 829 147053 10635 10646 AATCCGACTGTG 1-10-1 MOE 829 147070 11604 11615 TGATCCTGCACT 1-10-1 MOE 878 147071 11612 11623 CTGATCCTGCAC 1-10-1 MOE 856 147072 12294 12305 ACTGATCCTGCA 1-10-1 MOE 832 147072 12299 12310 ACTGATCCTGCA 1-10-1 MOE 832 147052 12938 12949 ATCCGACTGTGG 1-10-1 MOE 837 147052 13119 13130 ATCCGACTGTGG 1-10-1 MOE 837 147047 13158 13169 ACTGTGGTCAAA 1-10-1 MOE 833 147048 13159 13170 GACTGTGGTCAA 1-10-1 MOE 888 147049 13160 13171 CGACTGTGGTCA 1-10-1 MOE 854 147048 13340 13351 GACTGTGGTCAA 1-10-1 MOE 888 147049 13341 13352 CGACTGTGGTCA 1-10-1 MOE 854 147051 13343 13354 TCCGACTGTGGT 1-10-1 MOE 875 147061 13497 13508 TGCAATTTAATC 1-10-1 MOE 879 147069 15562 15573 GATCCTGCACTG 1-10-1 MOE 860 147068 15743 15754 ATCCTGCACTGA 1-10-1 MOE 838 147049 17181 17192 CGACTGTGGTCA 1-10-1 MOE 854 147049 17349 17360 CGACTGTGGTCA 1-10-1 MOE 854 147047 22438 22449 ACTGTGGTCAAA 1-10-1 MOE 833 147047 24322 24333 ACTGTGGTCAAA 1-10-1 MOE 833 147045 24488 24499 TGTGGTCAAAAG 1-10-1 MOE 883 147039 25064 25075 CCGCCCAGTTCC 1-10-1 MOE 850 147057 25508 25519 ATTTAATCCGAC 1-10-1 MOE 839 147057 25676 25687 ATTTAATCCGAC 1-10-1 MOE 839 147061 25680 25691 TGCAATTTAATC 1-10-1 MOE 879 147069 28731 28742 GATCCTGCACTG 1-10-1 MOE 860 147052 30132 30143 ATCCGACTGTGG 1-10-1 MOE 837 147052 30277 30288 ATCCGACTGTGG 1-10-1 MOE 837 147036 32085 32096 CCCAGTTCCCAG 1-10-1 MOE 849 WO 2007/146511 PCT/US2007/068401 -156 147072 32520 32531 ACTGATCCTGCA 1-10-1 MOE 832 147071 33058 33069 CTGATCCTGCAC 1-10-1 MOE 856 147050 33125 33136 CCGACTGTGGTC 1-10-1 MOE 889 147069 33204 33215 GATCCTGCACTG 1-10-1 MOE 860 147050 33273 33284 CCGACTGTGGTC 1-10-1 MOE 889 147047 33319 33330 ACTGTGGTCAAA 1-10-1 MOE 833 147050 33322 33333 CCGACTGTGGTC 1-10-1 MOE 889 147052 33324 33335 ATCCGACTGTGG 1-10-1 MOE 837 147049 33469 33480 CGACTGTGGTCA 1-10-1 MOE 854 147050 33470 33481 CCGACTGTGGTC 1-10-1 MOE 889 147052 33472 33483 ATCCGACTGTGG 1-10-1 MOE 837 147047 33641 33652 ACTGTGGTCAAA 1-10-1 MOE 833 147047 33789 33800 ACTGTGGTCAAA 1-10-1 MOE 833 147059 35585 35596 CAATTTAATCCG 1-10-1 MOE 840 147021 36241 36252 TGTCGATCTCCT 1-10-1 MOE 882 147073 37633 37644 CACTGATCCTGC 1-10-1 MOE 842 147033 42529 42540 AGTTCCCAGCCT 1-10-1 MOE 836 147050 45401 45412 CCGACTGTGGTC 1-10-1 MOE 889 147050 45549 45560 CCGACTGTGGTC 1-10-1 MOE 889 147074 46125 46136 CCACTGATCCTG 1-10-1 MOE 845 147057 46313 46324 ATTTAATCCGAC 1-10-1 MOE 839 147058 46462 46473 AATTTAATCCGA 1-10-1 MOE 830 147058 47413 47424 AATTTAATCCGA 1-10-1 MOE 830 147058 47561 47572 AATTTAATCCGA 1-10-1 MOE 830 147073 48221 48232 CACTGATCCTGC 1-10-1 MOE 842 147073 48369 48380 CACTGATCCTGC 1-10-1 MOE 842 147028 48567 48578 CCAGCCTTGTCG 1-10-1 MOE 846 147068 49199 49210 ATCCTGCACTGA 1-10-1 MOE 838 147036 50273 50284 CCCAGTTCCCAG 1-10-1 MOE 849 147040 53929 53940 GCCGCCCAGTTC 1-10-1 MOE 864 147047 54769 54780 ACTGTGGTCAAA 1-10-1 MOE 833 147048 54770 54781 GACTGTGGTCAA 1-10-1 MOE 888 147047 54915 54926 ACTGTGGTCAAA 1-10-1 MOE 833 147048 54916 54927 GACTGTGGTCAA 1-10-1 MOE 888 147019 55828 55839 TCGATCTCCTCG 1-10-1 MOE 877 147047 56268 56279 ACTGTGGTCAAA 1-10-1 MOE 833 147048 56269 56280 GACTGTGGTCAA 1-10-1 MOE 888 147049 56270 56281 CGACTGTGGTCA 1-10-1 MOE 854 147050 56271 56282 CCGACTGTGGTC 1-10-1 MOE 889 147051 56272 56283 TCCGACTGTGGT 1-10-1 MOE 875 147052 56273 56284 ATCCGACTGTGG 1-10-1 MOE 837 147053 56274 56285 AATCCGACTGTG 1-10-1 MOE 829 147056 56277 56288 TTTAATCCGACT 1-10-1 MOE 887 147057 56278 56289 ATTTAATCCGAC 1-10-1 MOE 839 147047 56414 56425 ACTGTGGTCAAA 1-10-1 MOE 833 147048 56415 56426 GACTGTGGTCAA 1-10-1 MOE 888 147049 56416 56427 CGACTGTGGTCA 1-10-1 MOE 854 147050 56417 56428 CCGACTGTGGTC 1-10-1 MOE 889 147052 56419 56430 ATCCGACTGTGG 1-10-1 MOE 837 147057 56424 56435 ATTTAATCCGAC 1-10-1 MOE 839 147058 56425 56436 AATTTAATCCGA 1-10-1 MOE 830 147059 56426 56437 CAATTTAATCCG 1-10-1 MOE 840 147060 56427 56438 GCAATTTAATCC 1-10-1 MOE 861 WO 2007/146511 PCT/US2007/068401 -157 147046 57119 57130 CTGTGGTCAAAA 1-10-1 MOE 858 147071 58174 58185 CTGATCCTGCAC 1-10-1 MOE 856 147071 61130 61141 CTGATCCTGCAC 1-10-1 MOE 856 147034 61276 61287 CAGTTCCCAGCC 1-10-1 MOE 844 147071 61309 61320 CTGATCCTGCAC 1-10-1 MOE 856 147039 61427 61438 CCGCCCAGTTCC 1-10-1 MOE 850 147071 61455 61466 CTGATCCTGCAC 1-10-1 MOE 856 147073 62003 62014 CACTGATCCTGC 1-10-1 MOE 842 147062 63061 63072 CACTGACGAGTC 1-10-1 MOE 841 147068 63213 63224 ATCCTGCACTGA 1-10-1 MOE 838 147069 63292 63303 GATCCTGCACTG 1-10-1 MOE 860 147057 64054 64065 ATTTAATCCGAC 1-10-1 MOE 839 147057 64200 64211 ATTTAATCCGAC 1-10-1 MOE 839 147070 64427 64438 TGATCCTGCACT 1-10-1 MOE 878 147070 64573 64584 TGATCCTGCACT 1-10-1 MOE 878 147036 64684 64695 CCCAGTTCCCAG 1-10-1 MOE 849 147046 65018 65029 CTGTGGTCAAAA 1-10-1 MOE 858 147071 65557 65568 CTGATCCTGCAC 1-10-1 MOE 856 147069 65695 65706 GATCCTGCACTG 1-10-1 MOE 860 147047 66163 66174 ACTGTGGTCAAA 1-10-1 MOE 833 147047 66309 66320 ACTGTGGTCAAA 1-10-1 MOE 833 147028 67740 67751 CCAGCCTTGTCG 1-10-1 MOE 846 147046 68870 68881 CTGTGGTCAAAA 1-10-1 MOE 858 147047 68871 68882 ACTGTGGTCAAA 1-10-1 MOE 833 147048 68872 68883 GACTGTGGTCAA 1-10-1 MOE 888 147049 68873 68884 CGACTGTGGTCA 1-10-1 MOE 854 147047 69017 69028 ACTGTGGTCAAA 1-10-1 MOE 833 147048 69018 69029 GACTGTGGTCAA 1-10-1 MOE 888 147049 69019 69030 CGACTGTGGTCA 1-10-1 MOE 854 147071 69519 69530 CTGATCCTGCAC 1-10-1 MOE 856 147073 69521 69532 CACTGATCCTGC 1-10-1 MOE 842 147071 69665 69676 CTGATCCTGCAC 1-10-1 MOE 856 147072 69666 69677 ACTGATCCTGCA 1-10-1 MOE 832 147024 70466 70477 CCTTGTCGATCT 1-10-1 MOE 853 147024 70612 70623 CCTTGTCGATCT 1-10-1 MOE 853 147062 70761 70772 CACTGACGAGTC 1-10-1 MOE 841 147072 70998 71009 ACTGATCCTGCA 1-10-1 MOE 832 147073 70999 71010 CACTGATCCTGC 1-10-1 MOE 842 147072 71144 71155 ACTGATCCTGCA 1-10-1 MOE 832 147073 71145 71156 CACTGATCCTGC 1-10-1 MOE 842 147048 71366 71377 GACTGTGGTCAA 1-10-1 MOE 888 147048 71512 71523 GACTGTGGTCAA 1-10-1 MOE 888 Table 18: Short Antisense Compounds targeted to SEQ ID NO: 12 5' 3' Seq ISIS Target Target ID NO. Site Site Sequence (5'-3') Gapmer Motif NO 398163 20 31 ATGTCAACCGGC 1-10-1 MOE 908 384545 23 34 CAAGTAGGATGT 1-10-1 MOE 951 147705 159 170 CGGTTTTTGTTC 1-10-1 MOE 1002 147703 245 256 TGGCTTCATGTC 1-10-1 MOE 971 398090 283 296 TTGTTCTTAGGAAG 2-10-2 MOE 972 WO 2007/146511 PCT/US2007/068401 -158 147704 285 296 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 291 302 CGGTTTTTGTTC 1-10-1 MOE 1002 147709 311 322 CCATTTTTATCA 1-10-1 MOE 978 147733 349 360 TTCTTGATGTCC 1-10-1 MOE 891 147707 360 371 TAGTCATTATCT 1-10-1 MOE 977 147708 366 377 TTGATATAGTCA 1-10-1 MOE 997 390030 381 392 TTTATAAAACTG 1-10-1 MOE 1074 147709 386 397 CCATTTTTATCA 1-10-1 MOE 978 147081 393 404 GCTCCTTCCACT 1-10-1 MOE 1006 398091 393 406 GGGCTTCTTCCATT 2-10-2 MOE 979 398166 395 406 GGGCTTCTTCCA 1-10-1 MOE 1070 147709 418 429 CCATTTTTATCA 1-10-1 MOE 978 147711 425 436 AAGGGCCCTGGG 1-10-1 MOE 1040 147712 461 472 ACACCATCTCCC 1-10-1 MOE 1005 147713 466 477 CTCCCACACCAT 1-10-1 MOE 985 147714 471 482 TTCTGCTCCCAC 1-10-1 MOE 986 147715 496 507 GTTGAGCATGAC 1-10-1 MOE 1077 147716 521 532 TTAACGAGCCTT 1-10-1 MOE 949 147717 574 585 ATCTTCAGAGAT 1-10-1 MOE 996 147717 607 618 ATCTTCAGAGAT 1-10-1 MOE 996 147708 612 623 TTGATATAGTCA 1-10-1 MOE 997 147718 621 632 TAATATGACTTG 1-10-1 MOE 998 147746 625 636 TAAAAACAACAA 1-10-1 MOE 1073 398167 704 715 CAGGCCATGTGG 1-10-1 MOE 1059 398092 705 718 AGTCAGGCCATGTG 2-10-2 MOE 1060 147723 715 726 GACTCCAAAGTC 1-10-1 MOE 892 398093 758 771 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 760 771 TCGGACTTTGAA 1-10-1 MOE 1008 147738 780 791 TGGGTGGCCGGG 1-10-1 MOE 1069 398094 848 861 ATCAGCCAGACAGA 2-10-2 MOE 1010 398169 849 860 TCAGCCAGACAG 1-10-1 MOE 909 398164 873 884 TTGTCGATCTGC 1-10-1 MOE 1014 147735 973 984 GGAGAAGCGCAG 1-10-1 MOE 1016 147737 984 995 ACAGCCAGGTAG 1-10-1 MOE 1067 368369 1025 1040 TCCTGCACTGACGAGT 3-10-3 MOE 893 368372 1031 1046 CACTGATCCTGCACTG 3-10-3 MOE 894 368353 1033 1046 CACTGATCCTGCAC 2-10-2 MOE 1007 368354 1035 1048 TCCACTGATCCTGC 2-10-2 MOE 1024 368388 1035 1050 CTTCCACTGATCCTTA 3-10-3 MOE 895 368355 1036 1049 TTCCACTGATCCTG 2-10-2 MOE 1025 368356 1037 1050 CTTCCACTGATCCT 2-10-2 MOE 1027 368376 1037 1052 TCCTTCCACTGATCCT 3-10-3 MOE 1028 147076 1038 1049 TTCCACTGATCC 1-10-1 MOE 1029 368357 1038 1051 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 1039 1050 CTTCCACTGATC 1-10-1 MOE 1047 368358 1039 1052 TCCTTCCACTGATC 2-10-2 MOE 1031 368378 1039 1054 GCTCCTTCCACTGATC 3-10-3 MOE 1032 368359 1041 1054 GCTCCTTCCACTGA 2-10-2 MOE 1033 147080 1042 1053 CTCCTTCCACTG 1-10-1 MOE 1021 147081 1043 1054 GCTCCTTCCACT 1-10-1 MOE 1006 368360 1043 1056 AAGCTCCTTCCACT 2-10-2 MOE 1035 368380 1043 1058 GAAAGCTCCTTCCACT 3-10-3 MOE 896 147082 1044 1055 AGCTCCTTCCAC 1-10-1 MOE 1036 368381 1045 1060 GGGAAAGCTCCTTCCA 3-10-3 MOE 1037 WO 2007/146511 PCT/US2007/068401 -159 147739 1107 1118 CGTTTGGGTGGC 1-10-1 MOE 1023 147741 1165 1176 CACCCACTGGTG 1-10-1 MOE 1055 398097 1194 1207 GGCAGTCTTTATCC 2-10-2 MOE 897 147742 1273 1284 AACTTCAGTGTC 1-10-1 MOE 1041 147743 1388 1399 AGGGCTTCCAGT 1-10-1 MOE 1042 147744 1392 1403 AGGAAGGGCTTC 1-10-1 MOE 1043 147745 1398 1409 TTGACCAGGAAG 1-10-1 MOE 1058 398157 1455 1468 GGAAACATACCCTG 2-10-2 MOE 1045 398167 1475 1486 CAGGCCATGTGG 1-10-1 MOE 1059 398092 1476 1489 AGTCAGGCCATGTG 2-10-2 MOE 1060 368357 1596 1609 CCTTCCACTGATCC 2-10-2 MOE 1046 398160 1691 1704 GAATAGGTTAAGGC 2-10-2 MOE 1048 398163 1711 1722 ATGTCAACCGGC 1-10-1 MOE 908 147746 1750 1761 TAAAAACAACAA 1-10-1 MOE 1073 389949 1777 1788 GCGCGAGCCCGA 1-10-1 MOE 1061 398161 1790 1803 AACAATGTGTTGTA 2-10-2 MOE 1049 147746 1799 1810 TAAAAACAACAA 1-10-1 MOE 1073 398163 1819 1830 ATGTCAACCGGC 1-10-1 MOE 908 389950 1848 1859 CCCTGAAGGTTC 1-10-1 MOE 1063 398164 1889 1900 TTGTCGATCTGC 1-10-1 MOE 1014 147702 1917 1928 CTGGTAAATAGC 1-10-1 MOE 898 147088 1971 1982 CCCTCTACACCA 1-10-1 MOE 1050 398102 2003 2016 CTACCTGAGGATTT 2-10-2 MOE 899 398103 2010 2023 CCCAGTACTACCTG 2-10-2 MOE 900 147737 2386 2397 ACAGCCAGGTAG 1-10-1 MOE 1067 398095 2407 2420 CATCAGCAAGAGGC 2-10-2 MOE 1011 398106 2441 2454 TGGAAAACTGCACC 2-10-2 MOE 1068 147745 2497 2508 TTGACCAGGAAG 1-10-1 MOE 1058 147712 2499 2510 ACACCATCTCCC 1-10-1 MOE 1005 147712 2607 2618 ACACCATCTCCC 1-10-1 MOE 1005 147745 2689 2700 TTGACCAGGAAG 1-10-1 MOE 1058 398167 2706 2717 CAGGCCATGTGG 1-10-1 MOE 1059 398092 2707 2720 AGTCAGGCCATGTG 2-10-2 MOE 1060 398166 2966 2977 GGGCTTCTTCCA 1-10-1 MOE 1070 147091 2992 3003 GTTCCCTCTACA 1-10-1 MOE 1004 147092 2993 3004 TGTTCCCTCTAC 1-10-1 MOE 901 389949 3008 3019 GCGCGAGCCCGA 1-10-1 MOE 1061 147087 3149 3160 CCTCTACACCAG 1-10-1 MOE 982 147088 3150 3161 CCCTCTACACCA 1-10-1 MOE 1050 398113 3160 3173 AGGAGGTTAAACCA 2-10-2 MOE 905 147087 3257 3268 CCTCTACACCAG 1-10-1 MOE 982 147088 3258 3269 CCCTCTACACCA 1-10-1 MOE 1050 147737 3591 3602 ACAGCCAGGTAG 1-10-1 MOE 1067 147737 3617 3628 ACAGCCAGGTAG 1-10-1 MOE 1067 147079 3637 3648 TCCTTCCACTGA 1-10-1 MOE 1001 147080 3638 3649 CTCCTTCCACTG 1-10-1 MOE 1021 398095 3638 3651 CATCAGCAAGAGGC 2-10-2 MOE 1011 398106 3672 3685 TGGAAAACTGCACC 2-10-2 MOE 1068 398107 3678 3691 TATTCCTGGAAAAC 2-10-2 MOE 902 147691 3806 3817 GAGGTGGGAAAA 1-10-1 MOE 966 147683 3848 3859 GCTTACGATTGT 1-10-1 MOE 922 147738 3853 3864 TGGGTGGCCGGG 1-10-1 MOE 1069 398167 3926 3937 CAGGCCATGTGG 1-10-1 MOE 1059 398109 3945 3958 CAAGAAGTGTGGTT 2-10-2 MOE 903 WO 2007/146511 PCT/US2007/068401 -160 398167 4034 4045 CAGGCCATGTGG 1-10-1 MOE 1059 398110 4083 4096 GTTCCCTTTGCAGG 2-10-2 MOE 952 398111 4168 4181 GTGAAAATGCTGGC 2-10-2 MOE 904 147706 4238 4249 GCTGACATCTCG 1-10-1 MOE 1071 398112 4282 4295 CAGCCTGGCACCTA 2-10-2 MOE 1072 147746 4315 4326 TAAAAACAACAA 1-10-1 MOE 1073 398113 4391 4404 AGGAGGTTAAACCA 2-10-2 MOE 905 398115 4484 4497 AGTAAATATTGGCT 2-10-2 MOE 1076 390030 4491 4502 TTTATAAAACTG 1-10-1 MOE 1074 390030 4537 4548 TTTATAAAACTG 1-10-1 MOE 1074 147703 5034 5045 TGGCTTCATGTC 1-10-1 MOE 971 147684 5035 5046 ACCCAGTCAGGG 1-10-1 MOE 964 398125 5075 5088 CAGTAAGGAATTTT 2-10-2 MOE 913 147696 5083 5094 TGGATGATTGGC 1-10-1 MOE 906 147684 5143 5154 ACCCAGTCAGGG 1-10-1 MOE 964 147712 5366 5377 ACACCATCTCCC 1-10-1 MOE 1005 147714 5416 5427 TTCTGCTCCCAC 1-10-1 MOE 986 398128 5443 5456 CTAAATTTAGTTCA 2-10-2 MOE 911 147712 5474 5485 ACACCATCTCCC 1-10-1 MOE 1005 147746 5498 5509 TAAAAACAACAA 1-10-1 MOE 1073 147714 5524 5535 TTCTGCTCCCAC 1-10-1 MOE 986 147736 5600 5611 AGGTAGGAGAAG 1-10-1 MOE 963 147085 5762 5773 TCTACACCAGGT 1-10-1 MOE 961 147679 5825 5836 CAAAAGGATCCC 1-10-1 MOE 907 390030 6803 6814 TTTATAAAACTG 1-10-1 MOE 1074 398142 6885 6898 CCAGCACACTGGAA 2-10-2 MOE 923 398142 6994 7007 CCAGCACACTGGAA 2-10-2 MOE 923 398166 7306 7317 GGGCTTCTTCCA 1-10-1 MOE 1070 147684 7551 7562 ACCCAGTCAGGG 1-10-1 MOE 964 147085 8308 8319 TCTACACCAGGT 1-10-1 MOE 961 147085 8416 8427 TCTACACCAGGT 1-10-1 MOE 961 398163 8473 8484 ATGTCAACCGGC 1-10-1 MOE 908 147718 8523 8534 TAATATGACTTG 1-10-1 MOE 998 147718 8631 8642 TAATATGACTTG 1-10-1 MOE 998 147691 8806 8817 GAGGTGGGAAAA 1-10-1 MOE 966 147728 8835 8846 GCCAGACAGAAG 1-10-1 MOE 1013 147728 8943 8954 GCCAGACAGAAG 1-10-1 MOE 1013 398169 8946 8957 TCAGCCAGACAG 1-10-1 MOE 909 147742 9060 9071 AACTTCAGTGTC 1-10-1 MOE 1041 404136 9162 9175 TAAGTGTCCCTTTG 2-10-2 MOE 910 147746 9963 9974 TAAAAACAACAA 1-10-1 MOE 1073 147746 9966 9977 TAAAAACAACAA 1-10-1 MOE 1073 147746 9969 9980 TAAAAACAACAA 1-10-1 MOE 1073 147746 9991 10002 TAAAAACAACAA 1-10-1 MOE 1073 147746 10071 10082 TAAAAACAACAA 1-10-1 MOE 1073 147746 10074 10085 TAAAAACAACAA 1-10-1 MOE 1073 147746 10077 10088 TAAAAACAACAA 1-10-1 MOE 1073 390030 10170 10181 TTTATAAAACTG 1-10-1 MOE 1074 147084 10220 10231 CTACACCAGGTC 1-10-1 MOE 993 390030 10278 10289 TTTATAAAACTG 1-10-1 MOE 1074 147085 10329 10340 TCTACACCAGGT 1-10-1 MOE 961 147711 10684 10695 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 10792 10803 AAGGGCCCTGGG 1-10-1 MOE 1040 398128 11333 11346 CTAAATTTAGTTCA 2-10-2 MOE 911 WO 2007/146511 PCT/US2007/068401 -161 147707 11960 11971 TAGTCATTATCT 1-10-1 MOE 977 147707 11965 11976 TAGTCATTATCT 1-10-1 MOE 977 147090 12013 12024 TTCCCTCTACAC 1-10-1 MOE' 955 398096 12146 12159 GGAGAAGCGCAGCT 2-10-2 MOE 1015 398166 12214 12225 GGGCTTCTTCCA 1-10-1 MOE 1070 398135 12308 12321 GACTACATTTTACA 2-10-2 MOE 912 147741 12389 12400 CACCCACTGGTG 1-10-1 MOE 1055 398125 12431 12444 CAGTAAGGAATTTT 2-10-2 MOE 913 147714 12585 12596 TTCTGCTCCCAC 1-10-1 MOE 986 147718 12594 12605 TAATATGACTTG 1-10-1 MOE 998 398125 12612 12625 CAGTAAGGAATTTT 2-10-2 MOE 913 147737 12803 12814 ACAGCCAGGTAG 1-10-1 MOE 1067 147746 12876 12887 TAAAAACAACAA 1-10-1 MOE 1073 147691 12900 12911 GAGGTGGGAAAA 1-10-1 MOE 966 398137 13111 13124 TGTGTCCCTCAGTC 2-10-2 MOE 914 398138 13254 13267 AACATCAAGCTTGA 2-10-2 MOE 931 398137 13292 13305 TGTGTCCCTCAGTC 2-10-2 MOE 914 398138 13435 13448 AACATCAAGCTTGA 2-10-2 MOE 931 389764 14020 14031 CTGCAACATGAT 1-9-2 MOE 1018 389948 14067 14078 CCGTTGGACCCC 1-10-1 MOE 915 389948 14248 14259 CCGTTGGACCCC 1-10-1 MOE 915 147738 14279 14290 TGGGTGGCCGGG 1-10-1 MOE 1069 147698 14572 14583 CCCGCCACCACC 1-10-1 MOE 928 147717 14750 14761 ATCTTCAGAGAT 1-10-1 MOE 996 147717 14932 14943 ATCTTCAGAGAT 1-10-1 MOE 996 398167 15374 15385 CAGGCCATGTGG 1-10-1 MOE 1059 147736 16444 16455 AGGTAGGAGAAG 1-10-1 MOE 963 147746 16510 16521 TAAAAACAACAA 1-10-1 MOE 1073 .147738 16590 16601 TGGGTGGCCGGG 1-10-1 MOE 1069 147746 16676 16687 TAAAAACAACAA 1-10-1 MOE 1073 398167 16797 16808 CAGGCCATGTGG 1-10-1 MOE 1059 398144 16911 16924 GACAGCTTCTATAA 2-10-2 MOE 916 389764 17096 17107 CTGCAACATGAT 1-9-2 MOE 1018 147709 17238 17249 CCATTTTTATCA 1-10-1 MOE 978 147709 17406 17417 CCATTTTTATCA 1-10-1 MOE 978 147695 17466 17477 TCATTCCCCACT 1-10-1 MOE 984 147746 17497 17508 TAAAAACAACAA 1-10-1 MOE 1073 147088 17539 17550 CCCTCTACACCA 1-10-1 MOE 1050 147711 17808 17819 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 17976 17987 AAGGGCCCTGGG 1-10-1 MOE 1040 398139 18049 18062 AGTGACTGACCACA 2-10-2 MOE 917 398139 18217 18230 AGTGACTGACCACA 2-10-2 MOE 917 398140 18596 18609 GTAGCATAGAGCCT 2-10-2 MOE 918 398140 18764 18777 GTAGCATAGAGCCT 2-10-2 MOE 918 398167 18927 18938 CAGGCCATGTGG 1-10-1 MOE 1059 398141 18947 18960 CAGATCTTGTCAAG 2-10-2 MOE 919 398167 19095 19106 CAGGCCATGTGG 1-10-1 MOE 1059 398141 19115 19128 CAGATCTTGTCAAG 2-10-2 MOE 919 147746 19207 19218 TAAAAACAACAA 1-10-1 MOE 1073 147711 19508 19519 AAGGGCCCTGGG 1-10-1 MOE 1040 147729 19554 19565 GTAAGAGGCAGG 1-10-1 MOE 920 147718 19617 19628 TAATATGACTTG 1-10-1 MOE 998 390030 19618 19629 TTTATAAAACTG 1-10-1 MOE 1074 147701 19671 19682 CCATGGCGGGAC 1-10-1 MOE 921 WO 2007/146511 PCT/US2007/068401 -162 147711 19676 19687 AAGGGCCCTGGG 1-10-1 MOE 1040 147718 19785 19796 TAATATGACTTG 1-10-1 MOE 998 147079 20515 20526 TCCTTCCACTGA 1-10-1 MOE 1001 389764 20620 20631 CTGCAACATGAT 1-9-2 MOE 1018 398142 20653 20666 CCAGCACACTGGAA 2-10-2 MOE 923 147078 20682 20693 CCTTCCACTGAT 1-10-1 MOE 1044 147079 20683 20694 TCCTTCCACTGA 1-10-1 MOE 1001 147080 20704 20715 CTCCTTCCACTG 1-10-1 MOE 1021 147081 20705 20716 GCTCCTTCCACT 1-10-1 MOE 1006 389965 20788 20799 CTGCAACATGAT 1-10-1 MOE 1018 147746 20870 20881 TAAAAACAACAA 1-10-1 MOE 1073 147746 21038 21049 TAAAAACAACAA 1-10-1 MOE 1073 147717 21080 21091 ATCTTCAGAGAT 1-10-1 MOE 996 147076 21222 21233 TTCCACTGATCC 1-10-1 MOE 1029 398094 21441 21454 ATCAGCCAGACAGA 2-10-2 MOE 1010 147746 21633 21644 TAAAAACAACAA 1-10-1 MOE 1073 147738 21884 21895 TGGGTGGCCGGG 1-10-1 MOE 1069 147683 21939 21950 GCTTACGATTGT 1-10-1 MOE 922 147743 22213 22224 AGGGCTTCCAGT 1-10-1 MOE 1042 147736 22759 22770 AGGTAGGAGAAG 1-10-1 MOE 963 147736 22927 22938 AGGTAGGAGAAG 1-10-1 MOE 963 398142 23008 23021 CCAGCACACTGGAA 2-10-2 MOE 923 398147 23784 23797 CTACAGGACAATAC 2-10-2 MOE 957 398147 23952 23965 CTACAGGACAATAC 2-10-2 MOE 957 147713 24434 24445 CTCCCACACCAT 1-10-1 MOE 985 389965 24543 24554 CTGCAACATGAT 1-10-1 MOE 1018 147713 24602 24613 CTCCCACACCAT 1-10-1 MOE 985 389965 24711 24722 CTGCAACATGAT 1-10-1 MOE 1018 147746 25384 25395 TAAAAACAACAA 1-10-1 MOE 1073 398143 25505 25518 GTCAGTCCCAGCTA 2-10-2 MOE 924 147691 25610 25621 GAGGTGGGAAAA 1-10-1 MOE 966 398130 25672 25685 TTAGTATGACAGCT 2-10-2 MOE 925 147746 25810 25821 TAAAAACAACAA 1-10-1 MOE 1073 147746 25978 25989 TAAAAACAACAA 1-10-1 MOE 1073 147746 26172 26183 TAAAAACAACAA 1-10-1 MOE 1073 398151 26718 26731 TCAGTGTAGGAAGA 2-10-2 MOE 926 147728 26917 26928 GCCAGACAGAAG 1-10-1 MOE 1013 398152 27708 27721 TGAATATACAGATG 2-10-2 MOE 927 147698 28629 28640 CCCGCCACCACC 1-10-1 MOE 928 389965 28714 28725 CTGCAACATGAT 1-10-1 MOE 1018 389764 28714 28725 CTGCAACATGAT 1-9-2 MOE 1018 389764 28861 28872 CTGCAACATGAT 1-9-2 MOE 1018 390030 29945 29956 TTTATAAAACTG 1-10-1 MOE 1074 147744 30654 30665 AGGAAGGGCTTC 1-10-1 MOE 1043 147093 30836 30847 TTGTTCCCTCTA 1-10-1 MOE 929 147746 30957 30968 TAAAAACAACAA 1-10-1 MOE 1073 147746 31105 31116 TAAAAACAACAA 1-10-1 MOE 1073 390030 31477 31488 TTTATAAAACTG 1-10-1 MOE 1074 384545 31829 31840 CAAGTAGGATGT 1-10-1 MOE 951 384545 31977 31988 CAAGTAGGATGT 1-10-1 MOE 951 401382 32094 32107 TCTACCTGAGTCCA 2-10-2 MOE 930 147089 32387 32398 TCCCTCTACACC 1-10-1 MOE 956 389950 32949 32960 CCCTGAAGGTTC 1-10-1 MOE 1063 398165 33002 33013 GTTCTTAGGAAG 1-10-1 MOE 968 WO 2007/146511 PCT/US2007/068401 -163 147081 33073 33084 GCTCCTTCCACT 1-10-1 MOE 1006 147082 33074 33085 AGCTCCTTCCAC 1-10-1 MOE 1036 389950 33097 33108 CCCTGAAGGTTC 1-10-1 MOE 1063 147736 33160 33171 AGGTAGGAGAAG 1-10-1 MOE 963 147081 33221 33232 GCTCCTTCCACT 1-10-1 MOE 1006 368360 33221 33234 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 33222 33233 AGCTCCTTCCAC 1-10-1 MOE 1036 398138 33244 33257 AACATCAAGCTTGA 2-10-2 MOE 931 147746 33250 33261 TAAAAACAACAA 1-10-1 MOE 1073 398138 33392 33405 AACATCAAGCTTGA 2-10-2 MOE 931 401383 33588 33601 GATCACCTTCAGAG 2-10-2 MOE 932 147746 33886 33897 TAAAAACAACAA 1-10-1 MOE 1073 147746 34606 34617 TAAAAACAACAA 1-10-1 MOE 1073 398165 34704 34715 GTTCTTAGGAAG 1-10-1 MOE 968 147717 34745 34756 ATCTTCAGAGAT 1-10-1 MOE 996 147746 34754 34765 TAAAAACAACAA 1-10-1 MOE 1073 398165 34852 34863 GTTCTTAGGAAG 1-10-1 MOE 968 147717 34893 34904 ATCTTCAGAGAT 1-10-1 MOE 996 401384 34905 34918 TGAACACATCACTA 2-10-2 MOE 933 147738 35391 35402 TGGGTGGCCGGG 1-10-1 MOE 1069 147736 35396 35407 AGGTAGGAGAAG 1-10-1 MOE 963 147738 35539 35550 TGGGTGGCCGGG 1-10-1 MOE 1069 147691 35554 35565 GAGGTGGGAAAA 1-10-1 MOE 966 147691 35702 35713 GAGGTGGGAAAA 1-10-1 MOE 966 147746 35814 35825 TAAAAACAACAA 1-10-1 MOE 1073 401385 36109 36122 CCCAGTGGGTTTGA 2-10-2 MOE 890 147691 36360 36371 GAGGTGGGAAAA 1-10-1 MOE 966 147746 36416 36427 TAAAAACAACAA 1-10-1 MOE 1073 147731 36620 36631 TTTCCTCTTGTC 1-10-1 MOE 934 147714 37881 37892 TTCTGCTCCCAC 1-10-1 MOE 986 147714 38029 38040 TTCTGCTCCCAC 1-10-1 MOE 986 147681 38512 38523 ATGTCATTAAAC 1-10-1 MOE 965 401386 38516 38529 TAATTGATGTCAAT 2-10-2 MOE 935 401387 38518 38531 AGTAATTGATGTCA 2-10-2 MOE 936 401388 38520 38533 ACAGTAATTGATGT 2-10-2 MOE 937 401389 38522 38535 TTACAGTAATTGAT 2-10-2 MOE 938 401390 38524 38537 ACTTACAGTAATTG 2-10-2 MOE 939 401391 38526 38539 AGACTTACAGTAAT 2-10-2 MOE 940 401392 38528 38541 TCAGACTTACAGTA 2-10-2 MOE 941 401393 38530 38543 AATCAGACTTACAG 2-10-2 MOE 942 401394 38532 38545 TGAATCAGACTTAC 2-10-2 MOE 943 401395 38534 38547 AATGAATCAGACTT 2-10-2 MOE 944 147738 38909 38920 TGGGTGGCCGGG 1-10-1 MOE 1069 147738 39057 39068 TGGGTGGCCGGG 1-10-1 MOE 1069 390030 39249 39260 TTTATAAAACTG 1-10-1 MOE 1074 390030 39397 39408 TTTATAAAACTG 1-10-1 MOE 1074 401396 39488 39501 TGCAGGATGTTGAG 2-10-2 MOE 945 147717 39545 39556 ATCTTCAGAGAT 1-10-1 MOE 996 147746 39641 39652 TAAAAACAACAA 1-10-1 MOE 1073 147717 39693 39704 ATCTTCAGAGAT 1-10-1 MOE 996 147746 39729 39740 TAAAAACAACAA 1-10-1 MOE 1073 147746 39877 39888 TAAAAACAACAA 1-10-1 MOE 1073 147746 40185 40196 TAAAAACAACAA 1-10-1 MOE 1073 147746 40478 40489 TAAAAACAACAA 1-10-1 MOE 1073 WO 2007/146511 PCT/US2007/068401 -164 398166 40589 40600 GGGCTTCTTCCA 1-10-1 MOE 1070 147735 40662 40673 GGAGAAGCGCAG 1-10-1 MOE 1016 147746 40706 40717 TAAAAACAACAA 1-10-1 MOE 1073 398166 40737 40748 GGGCTTCTTCCA 1-10-1 MOE 1070 147746 40854 40865 TAAAAACAACAA 1-10-1 MOE 1073 401397 41012 41025 CTGGTCAGCATTGA 2-10-2 MOE 946 147718 41070 41081 TAATATGACTTG 1-10-1 MOE 998 147718 41218 41229 TAATATGACTTG 1-10-1 MOE 998 147717 41221 41232 ATCTTCAGAGAT 1-10-1 MOE 996 147717 41369 41380 ATCTTCAGAGAT 1-10-1 MOE 996 147717 41599 41610 ATCTTCAGAGAT 1-10-1 MOE 996 147717 41747 41758 ATCTTCAGAGAT 1-10-1 MOE 996 401398 41768 41781 CAAAGTCCCTTAGC 2-10-2 MOE 947 390030 42056 42067 TTTATAAAACTG 1-10-1 MOE 1074 398153 42157 42170 ATTTCTCTTACAGG 2-10-2 MOE 948 398153 42305 42318 ATTTCTCTTACAGG 2-10-2 MOE 948 147710 42691 42702 TATAGCTCCTCT 1-10-1 MOE 994 147079 43322 43333 TCCTTCCACTGA 1-10-1 MOE 1001 147080 43323 43334 CTCCTTCCACTG 1-10-1 MOE 1021 147716 43477 43488 TTAACGAGCCTT 1-10-1 MOE 949 147746 43992 44003 TAAAAACAACAA 1-10-1 MOE 1073 147736 44137 44148 AGGTAGGAGAAG 1-10-1 MOE 963 384545 44242 44253 CAAGTAGGATGT 1-10-1 MOE 951 147687 44354 44365 CGACACGGGAAC 1-10-1 MOE 950 384545 44390 44401 CAAGTAGGATGT 1-10-1 MOE 951 398110 44713 44726 GTTCCCTTTGCAGG 2-10-2 MOE 952 147705 45092 45103 CGGTTTTTGTTC 1-10-1 MOE 1002 147705 45240 45251 CGGTTTTTGTTC 1-10-1 MOE 1002 147074 45977 45988 CCACTGATCCTG 1-10-1 MOE 845 147075 45978 45989 TCCACTGATCCT 1-10-1 MOE 1026 147076 45979 45990 TTCCACTGATCC 1-10-1 MOE 1029 147076 46127 46138 TTCCACTGATCC 1-10-1 MOE 1029 401399 46247 46260 ATTAGCCATATCTC 2-10-2 MOE 953 147705 46555 46566 CGGTTTTTGTTC 1-10-1 MOE 1002 147714 46685 46696 TTCTGCTCCCAC 1-10-1 MOE 986 147705 46703 46714 CGGTTTTTGTTC 1-10-1 MOE 1002 390030 46859 46870 TTTATAAAACTG 1-10-1 MOE 1074 390030 46933 46944 TTTATAAAACTG 1-10-1 MOE 1074 147681 46984 46995 ATGTCATTAAAC 1-10-1 MOE 965 390030 47007 47018 TTTATAAAACTG 1-10-1 MOE 1074 147746 47023 47034 TAAAAACAACAA 1-10-1 MOE 1073 390030 47081 47092 TTTATAAAACTG 1-10-1 MOE 1074 147681 47132 47143 ATGTCATTAAAC 1-10-1 MOE 965 147746 47171 47182 TAAAAACAACAA 1-10-1 MOE 1073 401400 47411 47424 AGCATTCAGCAGTG 2-10-2 MOE 954 147746 47461 47472 TAAAAACAACAA 1-10-1 MOE 1073 147086 47608 47619 CTCTACACCAGG 1-10-1 MOE 969 147087 47609 47620 CCTCTACACCAG 1-10-1 MOE 982 147088 47610 47621 CCCTCTACACCA 1-10-1 MOE 1050 147090 47612 47623 TTCCCTCTACAC 1-10-1 MOE 955 147691 47729 47740 GAGGTGGGAAAA 1-10-1 MOE 966 147086 47756 47767 CTCTACACCAGG 1-10-1 MOE 969 147088 47758 47769 CCCTCTACACCA 1-10-1 MOE 1050 147089 47759 47770 TCCCTCTACACC 1-10-1 MOE 956 WO 2007/146511 PCT/US2007/068401 -165 390030 47847 47858 TTTATAAAACTG 1-10-1 MOE 1074 390030 47995 48006 TTTATAAAACTG 1-10-1 MOE 1074 147691 48393 48404 GAGGTGGGAAAA 1-10-1 MOE 966 398147 48887 48900 CTACAGGACAATAC 2-10-2 MOE 957 147706 49133 49144 GCTGACATCTCG 1-10-1 MOE 1071 147706 49281 49292 GCTGACATCTCG 1-10-1 MOE 1071 398168 49742 49753 TCGGACTTTGAA 1-10-1 MOE 1008 401401 49791 49804 AACTGGGTTAAGTA 2-10-2 MOE 958 147689 49936 49947 CAGAGAAGGTCT 1-10-1 MOE 987 401402 50192 50205 TGAACACGCTATCC 2-10-2 MOE 959 398117 50241 50254 TTTCCACTTGGGTG 2-10-2 MOE 960 147736 50582 50593 AGGTAGGAGAAG 1-10-1 MOE 963 398168 50703 50714 TCGGACTTTGAA 1-10-1 MOE 1008 398168 50849 50860 TCGGACTTTGAA 1-10-1 MOE 1008 147746 51019 51030 TAAAAACAACAA 1-10-1 MOE 1073 147708 51101 51112 TTGATATAGTCA 1-10-1 MOE 997 147746 51178 51189 TAAAAACAACAA 1-10-1 MOE 1073 147708 51247 51258 TTGATATAGTCA 1-10-1 MOE 997 147083 51281 51292 TACACCAGGTCA 1-10-1 MOE 973 147081 51287 51298 GCTCCTTCCACT 1-10-1 MOE 1006 147082 51288 51299 AGCTCCTTCCAC 1-10-1 MOE 1036 147746 51331 51342 TAAAAACAACAA 1-10-1 MOE 1073 147085 51416 51427 TCTACACCAGGT 1-10-1 MOE 961 147083 51427 51438 TACACCAGGTCA 1-10-1 MOE 973 147081 51433 51444 GCTCCTTCCACT 1-10-1 MOE 1006 147082 51434 51445 AGCTCCTTCCAC 1-10-1 MOE 1036 147728 51522 51533 GCCAGACAGAAG 1-10-1 MOE 1013 147085 51562 51573 TCTACACCAGGT 1-10-1 MOE 961 147081 51633 51644 GCTCCTTCCACT 1-10-1 MOE 1006 368360 51633 51646 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 51634 51645 AGCTCCTTCCAC 1-10-1 MOE 1036 368361 51635 51648 GAAAGCTCCTTCCA 2-10-2 MOE 962 368360 51779 51792 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 51780 51791 AGCTCCTTCCAC 1-10-1 MOE 1036 147736 51859 51870 AGGTAGGAGAAG 1-10-1 MOE 963 147684 51867 51878 ACCCAGTCAGGG 1-10-1 MOE 964 147746 51918 51929 TAAAAACAACAA 1-10-1 MOE 1073 147077 51988 51999 CTTCCACTGATC 1-10-1 MOE 1047 147746 52064 52075 TAAAAACAACAA 1-10-1 MOE 1073 147084 52125 52136 CTACACCAGGTC 1-10-1 MOE 993 147079 52136 52147 TCCTTCCACTGA 1-10-1 MOE 1001 147681 52231 52242 ATGTCATTAAAC 1-10-1 MOE 965 147084 52271 52282 CTACACCAGGTC 1-10-1 MOE 993 147691 52312 52323 GAGGTGGGAAAA 1-10-1 MOE 966 401403 52318 52331 TTTCCTAGGAGGTG 2-10-2 MOE 967 398167 52527 52538 CAGGCCATGTGG 1-10-1 MOE 1059 147703 52670 52681 TGGCTTCATGTC 1-10-1 MOE 971 398167 52673 52684 CAGGCCATGTGG 1-10-1 MOE 1059 398165 52708 52719 GTTCTTAGGAAG 1-10-1 MOE 968 398090 52708 52721 TTGTTCTTAGGAAG 2-10-2 MOE 972 147705 52716 52727 CGGTTTTTGTTC 1-10-1 MOE 1002 147682 52717 52728 CGGGTACTATGG 1-10-1 MOE 992 398167 52762 52773 CAGGCCATGTGG 1-10-1 MOE 1059 147703 52816 52827 TGGCTTCATGTC 1-10-1 MOE 971 WO 2007/146511 PCT/US2007/068401 -166 398090 52854 52867 TTGTTCTTAGGAAG 2-10-2 MOE 972 147704 52856 52867 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 52862 52873 CGGTTTTTGTTC 1-10-1 MOE 1002 398167 52908 52919 CAGGCCATGTGG 1-10-1 MOE 1059 147084 53704 53715 CTACACCAGGTC 1-10-1 MOE 993 147088 53708 53719 CCCTCTACACCA 1-10-1 MOE 1050 147083 53849 53860 TACACCAGGTCA 1-10-1 MOE 973 147084 53850 53861 CTACACCAGGTC 1-10-1 MOE 993 147086 53852 53863 CTCTACACCAGG 1-10-1 MOE 969 147088 53854 53865 CCCTCTACACCA 1-10-1 MOE 1050 398167 53870 53881 CAGGCCATGTGG 1-10-1 MOE 1059 147703 54137 54148 TGGCTTCATGTC 1-10-1 MOE 971 398155 54172 54185 TGTTTTTACACAGA 2-10-2 MOE 970 390030 54263 54274 TTTATAAAACTG 1-10-1 MOE 1074 147705 54275 54286 CGGTTTTTGTTC 1-10-1 MOE 1002 147703 54283 54294 TGGCTTCATGTC 1-10-1 MOE 971 390030 54409 54420 TTTATAAAACTG 1-10-1 MOE 1074 147704 54965 54976 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 54971 54982 CGGTTTTTGTTC 1-10-1 MOE 1002 398090 55109 55122 TTGTTCTTAGGAAG 2-10-2 MOE 972 147705 55117 55128 CGGTTTTTGTTC 1-10-1 MOE 1002 147083 55206 55217 TACACCAGGTCA 1-10-1 MOE 973 147084 55207 55218 CTACACCAGGTC 1-10-1 MOE 993 147084 55353 55364 CTACACCAGGTC 1-10-1 MOE 993 147705 55524 55535 CGGTTTTTGTTC 1-10-1 MOE 1002 147685 55602 55613 GGCTGACATTCA 1-10-1 MOE 975 401404 55638 55651 TGAGCTACAGTAGG 2-10-2 MOE 974 147685 55748 55759 GGCTGACATTCA 1-10-1 MOE 975 147712 55819 55830 ACACCATCTCCC 1-10-1 MOE 1005 147712 55965 55976 ACACCATCTCCC 1-10-1 MOE 1005 147707 56300 56311 TAGTCATTATCT 1-10-1 MOE 977 147708 56306 56317 TTGATATAGTCA 1-10-1 MOE 997 390030 56321 56332 TTTATAAAACTG 1-10-1 MOE 1074 147709 56326 56337 CCATTTTTATCA 1-10-1 MOE 978 398091 56333 56346 GGGCTTCTTCCATT 2-10-2 MOE 979 401405 56408 56421 TGGTCAACTGAAAG 2-10-2 MOE 976 147707 56446 56457 TAGTCATTATCT 1-10-1 MOE 977 147708 56452 56463 TTGATATAGTCA 1-10-1 MOE 997 147709 56472 56483 CCATTTTTATCA 1-10-1 MOE 978 398091 56479 56492 GGGCTTCTTCCATT 2-10-2 MOE 979 401406 56570 56583 GGTGTGGATAACAG 2-10-2 MOE 980 368366 56664 56677 CTGATCCTTAGAAG 2-10-2 MOE 1019 398148 57157 57170 TCATAACTATTAAG 2-10-2 MOE 981 147082 57220 57231 AGCTCCTTCCAC 1-10-1 MOE 1036 398148 57303 57316 TCATAACTATTAAG 2-10-2 MOE 981 147082 57366 57377 AGCTCCTTCCAC 1-10-1 MOE 1036 147743 57758 57769 AGGGCTTCCAGT 1-10-1 MOE 1042 398093 57963 57976 TCGGACTTTGAAAA 2-10-2 MOE 1009 398093 58109 58122 TCGGACTTTGAAAA 2-10-2 MOE 1009 147735 58279 58290 GGAGAAGCGCAG 1-10-1 MOE 1016 147087 58821 58832 CCTCTACACCAG 1-10-1 MOE 982 147087 58967 58978 CCTCTACACCAG 1-10-1 MOE 982 390030 59180 59191 TTTATAAAACTG 1-10-1 MOE 1074 390030 59326 59337 TTTATAAAACTG 1-10-1 MOE 1074 WO 2007/146511 PCT/US2007/068401 -167 147711 59357 59368 AAGGGCCCTGGG 1-10-1 MOE 1040 147743 59382 59393 AGGGCTTCCAGT 1-10-1 MOE 1042 147711 59503 59514 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 59675 59686 AAGGGCCCTGGG 1-10-1 MOE 1040 401407 59710 59723 CAGCTTAGGCAGAG 2-10-2 MOE 983 147712 59711 59722 ACACCATCTCCC 1-10-1 MOE 1005 147713 59716 59727 CTCCCACACCAT 1-10-1 MOE 985 147714 59721 59732 TTCTGCTCCCAC 1-10-1 MOE 986 147695 59722 59733 TCATTCCCCACT 1-10-1 MOE 984 147715 59746 59757 GTTGAGCATGAC 1-10-1 MOE 1077 147711 59821 59832 AAGGGCCCTGGG 1-10-1 MOE 1040 390030 59847 59858 TTTATAAAACTG 1-10-1 MOE 1074 147712 59857 59868 ACACCATCTCCC 1-10-1 MOE 1005 147713 59862 59873 CTCCCACACCAT 1-10-1 MOE 985 147714 59867 59878 TTCTGCTCCCAC 1-10-1 MOE 986 390030 59993 60004 TTTATAAAACTG 1-10-1 MOE 1074 389949 60471 60482 GCGCGAGCCCGA 1-10-1 MOE 1061 147746 60619 60630 TAAAAACAACAA 1-10-1 MOE 1073 147689 61113 61124 CAGAGAAGGTCT 1-10-1 MOE 987 398105 61267 61280 TGCACAGGCAGGTT 2-10-2 MOE 1066 147680 61473 61484 GTATGCACTGCT 1-10-1 MOE 988 147080 61757 61768 CTCCTTCCACTG 1-10-1 MOE 1021 147078 61901 61912 CCTTCCACTGAT 1-10-1 MOE 1044 147079 61902 61913 TCCTTCCACTGA 1-10-1 MOE 1001 147088 62215 62226 CCCTCTACACCA 1-10-1 MOE 1050 401408 62600 62613 CAATGAAGCACAGG 2-10-2 MOE 989 147688 62843 62854 TCCCAAACAAAT 1-10-1 MOE 990 147746 63102 63113 TAAAAACAACAA 1-10-1 MOE 1073 147746 63248 63259 TAAAAACAACAA 1-10-1 MOE 1073 401409 63430 63443 ATTCTTAACACAGA 2-10-2 MOE 991 147682 63483 63494 CGGGTACTATGG 1-10-1 MOE 992 147084 63677 63688 CTACACCAGGTC 1-10-1 MOE 993 147710 64847 64858 TATAGCTCCTCT 1-10-1 MOE 994 147710 64993 65004 TATAGCTCCTCT 1-10-1 MOE 994 147746 65151 65162 TAAAAACAACAA 1-10-1 MOE 1073 401410 65263 65276 CATTTAGGGTCTAA 2-10-2 MOE 995 147717 65862 65873 ATCTTCAGAGAT 1-10-1 MOE 996 147717 65895 65906 ATCTTCAGAGAT 1-10-1 MOE 996 147708 65900 65911 TTGATATAGTCA 1-10-1 MOE 997 147718 65909 65920 TAATATGACTTG 1-10-1 MOE 998 147717 66008 66019 ATCTTCAGAGAT 1-10-1 MOE 996 147717 66041 66052 ATCTTCAGAGAT 1-10-1 MOE 996 147708 66046 66057 TTGATATAGTCA 1-10-1 MOE 997 147718 66055 66066 TAATATGACTTG 1-10-1 MOE 998 401411 66123 66136 AGCCGCCTGAAGTG 2-10-2 MOE 999 147697 66497 66508 CCCCAGCAGCGG 1-10-1 MOE 1000 368377 66562 66577 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 66563 66574 CTTCCACTGATC 1-10-1 MOE 1047 368358 66563 66576 TCCTTCCACTGATC 2-10-2 MOE 1031 147078 66564 66575 CCTTCCACTGAT 1-10-1 MOE 1044 147079 66565 66576 TCCTTCCACTGA 1-10-1 MOE 1001 147080 66566 66577 CTCCTTCCACTG 1-10-1 MOE 1021 147697 66643 66654 CCCCAGCAGCGG 1-10-1 MOE 1000 368358 66709 66722 TCCTTCCACTGATC 2-10-2 MOE 1031 WO 2007/146511 PCT/US2007/068401 -168 147078 66710 66721 CCTTCCACTGAT 1-10-1 MOE 1044 147079 66711 66722 TCCTTCCACTGA 1-10-1 MOE 1001 147075 66999 67010 TCCACTGATCCT 1-10-1 MOE 1026 147705 67067 67078 CGGTTTTTGTTC 1-10-1 MOE 1002 147088 67409 67420 CCCTCTACACCA 1-10-1 MOE 1050 147080 67430 67441 CTCCTTCCACTG 1-10-1 MOE 1021 147082 67432 67443 AGCTCCTTCCAC 1-10-1 MOE 1036 147737 67455 67466 ACAGCCAGGTAG 1-10-1 MOE 1067 147088 67555 67566 CCCTCTACACCA 1-10-1 MOE 1050 147082 67578 67589 AGCTCCTTCCAC 1-10-1 MOE 1036 401412 67637 67650 TAAATCCTCTAGCA 2-10-2 MOE 1003 147091 67729 67740 GTTCCCTCTACA 1-10-1 MOE 1004 147742 67737 67748 AACTTCAGTGTC 1-10-1 MOE 1041 147712 68527 68538 ACACCATCTCCC 1-10-1 MOE 1005 147712 68673 68684 ACACCATCTCCC 1-10-1 MOE 1005 147711 68760 68771 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 68906 68917 AAGGGCCCTGGG 1-10-1 MOE 1040 389965 69271 69282 CTGCAACATGAT 1-10-1 MOE 1018 389965 69417 69428 CTGCAACATGAT 1-10-1 MOE 1018 368353 69519 69532 CACTGATCCTGCAC 2-10-2 MOE 1007 147080 69630 69641 CTCCTTCCACTG 1-10-1 MOE 1021 147081 69631 69642 GCTCCTTCCACT 1-10-1 MOE 1006 368353 69665 69678 CACTGATCCTGCAC 2-10-2 MOE 1007 398167 69757 69768 CAGGCCATGTGG 1-10-1 MOE 1059 398092 69758 69771 AGTCAGGCCATGTG 2-10-2 MOE 1060 398093 69811 69824 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 69813 69824 TCGGACTTTGAA 1-10-1 MOE 1008 398167 69903 69914 CAGGCCATGTGG 1-10-1 MOE 1059 398093 69957 69970 TCGGACTTTGAAAA 2-10-2 MOE 1009 398094 70047 70060 ATCAGCCAGACAGA 2-10-2 MOE 1010 398095 70065 70078 CATCAGCAAGAGGC 2-10-2 MOE 1011 147704 70137 70148 TTGTTCTTAGGA 1-10-1 MOE 1012 147728 70450 70461 GCCAGACAGAAG 1-10-1 MOE 1013 398164 70464 70475 TTGTCGATCTGC 1-10-1 MOE 1014 398096 70562 70575 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 70564 70575 GGAGAAGCGCAG 1-10-1 MOE 1016 147737 70575 70586 ACAGCCAGGTAG 1-10-1 MOE 1067 147735 70710 70721 GGAGAAGCGCAG 1-10-1 MOE 1016 147737 70721 70732 ACAGCCAGGTAG 1-10-1 MOE 1067 404131 70729 70742 ACCTTCGATCACAG 2-10-2 MOE 831 368349 70762 70775 CTGCACTGACGAGT 2-10-2 MOE 1017 389965 70930 70941 CTGCAACATGAT 1-10-1 MOE 1018 368366 70995 71008 CTGATCCTTAGAAG 2-10-2 MOE 1019 368354 70999 71012 TCCACTGATCCTGC 2-10-2 MOE 1024 368375 71000 71015 CCTTCCACTGATCCTG 3-10-3 MOE 1020 368356 71001 71014 CTTCCACTGATCCT 2-10-2 MOE 1027 368376 71001 71016 TCCTTCCACTGATCCT 3-10-3 MOE 1028 368357 71002 71015 CCTTCCACTGATCC 2-10-2 MOE 1046 368377 71002 71017 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 71003 71014 CTTCCACTGATC 1-10-1 MOE 1047 368358 71003 71016 TCCTTCCACTGATC 2-10-2 MOE 1031 368378 71003 71018 GCTCCTTCCACTGATC 3-10-3 MOE 1032 147078 71004 71015 CCTTCCACTGAT 1-10-1 MOE 1044 368359 71005 71018 GCTCCTTCCACTGA 2-10-2 MOE 1033 WO 2007/146511 PCT/US2007/068401 -169 368379 71005 71020 AAGCTCCTTCCACTGA 3-10-3 MOE 1034 147080 71006 71017 CTCCTTCCACTG 1-10-1 MOE 1021 147082 71008 71019 AGCTCCTTCCAC 1-10-1 MOE 1036 401413 71019 71032 TGCAGCCATGTACT 2-10-2 MOE 1022 147738 71067 71078 TGGGTGGCCGGG 1-10-1 MOE 1069 147739 71071 71082 CGTTTGGGTGGC 1-10-1 MOE 1023 147741 71129 71140 CACCCACTGGTG 1-10-1 MOE 1055 368354 71145 71158 TCCACTGATCCTGC 2-10-2 MOE 1024 368355 71146 71159 TTCCACTGATCCTG 2-10-2 MOE 1025 147075 71147 71158 TCCACTGATCCT 1-10-1 MOE 1026 368356 71147 71160 CTTCCACTGATCCT 2-10-2 MOE 1027 368376 71147 71162 TCCTTCCACTGATCCT 3-10-3 MOE 1028 147076 71148 71159 TTCCACTGATCC 1-10-1 MOE 1029 368357 71148 71161 CCTTCCACTGATCC 2-10-2 MOE 1046 368377 71148 71163 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 71149 71160 CTTCCACTGATC 1-10-1 MOE 1047 368358 71149 71162 TCCTTCCACTGATC 2-10-2 MOE 1031 368378 71149 71164 GCTCCTTCCACTGATC 3-10-3 MOE 1032 147078 71150 71161 CCTTCCACTGAT 1-10-1 MOE 1044 368359 71151 71164 GCTCCTTCCACTGA 2-10-2 MOE 1033 368379 71151 71166 AAGCTCCTTCCACTGA 3-10-3 MOE 1034 368360 71153 71166 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 71154 71165 AGCTCCTTCCAC 1-10-1 MOE 1036 368381 71155 71170 GGGAAAGCTCCTTCCA 3-10-3 MOE 1037 390030 71986 71997 TTTATAAAACTG 1-10-1 MOE 1074 390030 72132 72143 TTTATAAAACTG 1-10-1 MOE 1074 147711 72300 72311 AAGGGCCCTGGG 1-10-1 MOE 1040 401414 72347 72360 TTGCAATGTCTGGC 2-10-2 MOE 1038 147741 72400 72411 CACCCACTGGTG 1-10-1 MOE 1055 401415 72415 72428 GATTTATCTGGCTG 2-10-2 MOE 1039 147711 72446 72457 AAGGGCCCTGGG 1-10-1 MOE 1040 147742 72575 72586 AACTTCAGTGTC 1-10-1 MOE 1041 147743 72690 72701 AGGGCTTCCAGT 1-10-1 MOE 1042 147744 72694 72705 AGGAAGGGCTTC 1-10-1 MOE 1043 147745 72700 72711 TTGACCAGGAAG 1-10-1 MOE 1058 147742 72721 72732 AACTTCAGTGTC 1-10-1 MOE 1041 147743 72836 72847 AGGGCTTCCAGT 1-10-1 MOE 1042 147744 72840 72851 AGGAAGGGCTTC 1-10-1 MOE 1043 368357 72898 72911 CCTTCCACTGATCC 2-10-2 MOE 1046 147078 72900 72911 CCTTCCACTGAT 1-10-1 MOE 1044 398157 72903 72916 GGAAACATACCCTG 2-10-2 MOE 1045 368357 73044 73057 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 73045 73056 CTTCCACTGATC 1-10-1 MOE 1047 147746 73052 73063 TAAAAACAACAA 1-10-1 MOE 1073 147746 73101 73112 TAAAAACAACAA 1-10-1 MOE 1073 398160 73139 73152 GAATAGGTTAAGGC 2-10-2 MOE 1048 147746 73198 73209 TAAAAACAACAA 1-10-1 MOE 1073 398161 73238 73251 AACAATGTGTTGTA 2-10-2 MOE 1049 147088 73419 73430 CCCTCTACACCA 1-10-1 MOE 1050 404140 73457 73470 GCACACAGCTGAGG 2-10-2 MOE 1051 404139 73459 73472 GTGCACACAGCTGA 2-10-2 MOE 1052 399301 73461 73474 GTGTGCACACAGCT 2-10-2 MOE 1542 404137 73463 73476 CAGTGTGCACACAG 2-10-2 MOE 1053 404138 73465 73478 CTCAGTGTGCACAC 2-10-2 MOE 1054 WO 2007/146511 PCT/US2007/068401 -170 147741 73705 73716 CACCCACTGGTG 1-10-1 MOE 1055 404135 73858 73871 CATTTCCATGGCCA 2-10-2 MOE 1056 398167 74008 74019 CAGGCCATGTGG 1-10-1 MOE 1059 398092 74009 74022 AGTCAGGCCATGTG 2-10-2 MOE 1060 398162 74114 74127 ACCAAACAGTTCAG 2-10-2 MOE 1057 147745 74137 74148 TTGACCAGGAAG 1-10-1 MOE 1058 398167 74154 74165 CAGGCCATGTGG 1-10-1 MOE 1059 398092 74155 74168 AGTCAGGCCATGTG 2-10-2 MOE 1060 389949 74310 74321 GCGCGAGCCCGA 1-10-1 MOE 1061 147740 74485 74496 TGTGAGGCTCCA 1-10-1 MOE 1062 389950 74527 74538 CCCTGAAGGTTC 1-10-1 MOE 1063 398101 74656 74669 TTTGATAAAGCCCT 2-10-2 MOE 1064 398104 74805 74818 CAAGAAGACCTTAC 2-10-2 MOE 1065 147737 74893 74904 ACAGCCAGGTAG 1-10-1 MOE 1067 398105 74894 74907 TGCACAGGCAGGTT 2-10-2 MOE 1066 147737 74919 74930 ACAGCCAGGTAG 1-10-1 MOE 1067 398106 74974 74987 TGGAAAACTGCACC 2-10-2 MOE 1068 404199 75045 75058 GGTCATGCACAGGC 2-10-2 MOE 867 404134 75048 75061 TCAGGTCATGCACA 2-10-2 MOE 873 398106 75120 75133 TGGAAAACTGCACC 2-10-2 MOE 1068 147738 75155 75166 TGGGTGGCCGGG 1-10-1 MOE 1069 404132 75227 75240 CCTTGGAATGTCTG 2-10-2 MOE 852 147738 75301 75312 TGGGTGGCCGGG 1-10-1 MOE 1069 398166 75499 75510 GGGCTTCTTCCA 1-10-1 MOE 1070 147746 75617 75628 TAAAAACAACAA 1-10-1 MOE 1073 147706 75686 75697 GCTGACATCTCG 1-10-1 MOE 1071 398112 75730 75743 CAGCCTGGCACCTA 2-10-2 MOE 1072 147746 75763 75774 TAAAAACAACAA 1-10-1 MOE 1073 398115 75786 75799 AGTAAATATTGGCT 2-10-2 MOE 1076 390030 75839 75850 TTTATAAAACTG 1-10-1 MOE 1074 398114 75916 75929 AGGCATATAGCAGA 2-10-2 MOE 1075 398115 75932 75945 AGTAAATATTGGCT 2-10-2 MOE 1076 404133 75968 75981 TATTCCATGGCCAT 2-10-2 MOE 872 147715 77045 77056 GTTGAGCATGAC 1-10-1 MOE 1077 147715 77190 77201 GTTGAGCATGAC 1-10-1 MOE 1077 147693 77385 77396 GTGCGCTCCCAT 1-10-1 MOE 1078 398173 40201 40212 CAGCCTGGGCAC 1-10-1 MOE 1543 398173 72764 72775 CAGCCTGGGCAC 1-10-1 MOE 1543 399096 1986 1999 TGCTCGAACTCCTT 2-10-2 MOE 1544 399102 52822 52835 GAAGTCACTGGCTT 2-10-2 MOE 1545 399103 52824 52837 GGGAAGTCACTGGC 2-10-2 MOE 1546 399113 59827 59840 GTTAGGCAAAGGGC 2-10-2 MOE 1547 399132 69977 69990 GGGCTGAGTGACCC 2-10-2 MOE 1548 399173 74592 74605 ATGCTAGTGCACTA 2-10-2 MOE 1549 399208 75900 75913 AGCTCGCTACCTCT 2-10-2 MOE 1550 399276 27559 27572 GAGGTATCCCATCT 2-10-2 MOE 1551 399315 74039 74052 GGCAACTTCAACCT 2-10-2 MOE 1552 Table 19: Short antisense compounds targeted to SEQ ID NO: 12 and having 1 or 2 mismatches ISIS NO. 5' Target 3' Target Sequence (5'-3') Gapmer Seq ID Site Site Motif NO 398163 20 31 ATGTCAACCGGC 1-10-1 MOE 908 384545 23 34 CAAGTAGGATGT 1-10-1 MOE 951 WO 2007/146511 PCT/US2007/068401 -171 147733 26 37 TTCTTGATGTCC 1-10-1 MOE 891 147721 59 70 AATGCAGGATCT 1-10-1 MOE 1118 147700 110 121 GCGCTAGGCCGC 1-10-1 MOE 1110 384545 130 141 CAAGTAGGATGT 1-10-1 MOE 951 147705 159 170 CGGTTTTTGTTC 1-10-1 MOE 1002 147701 167 178 CCATGGCGGGAC 1-10-1 MOE 921 398164 198 209 TTGTCGATCTGC 1-10-1 MOE 1014 147730 199 210 CTTGTCCATCAG 1-10-1 MOE 1121 147702 226 237 CTGGTAAATAGC 1-10-1 MOE 898 147703 245 256 TGGCTTCATGTC 1-10-1 MOE 971 147705 266 277 CGGTTTTTGTTC 1-10-1 MOE 1002 398165 283 294 GTTCTTAGGAAG 1-10-1 MOE 968 147704 285 296 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 291 302 CGGTTTTTGTTC 1-10-1 MOE 1002 147709 311 322 CCATTTTTATCA 1-10-1 MOE 978 147733 349 360 TTCTTGATGTCC 1-10-1 MOE 891 147707 360 371 TAGTCATTATCT 1-10-1 MOE 977 147708 366 377 TTGATATAGTCA 1-10-1 MOE 997 390030 381 392 TTTATAAAACTG 1-10-1 MOE 1074 147709 386 397 CCATTTTTATCA 1-10-1 MOE 978 147081 393 404 GCTCCTTCCACT 1-10-1 MOE 1006 398091 393 406 GGGCTTCTTCCATT 2-10-2 MOE 979 398166 395 406 GGGCTTCTTCCA 1-10-1 MOE 1070 147712 461 472 ACACCATCTCCC 1-10-1 MOE 1005 147713 466 477 CTCCCACACCAT 1-10-1 MOE 985 147714 471 482 TTCTGCTCCCAC 1-10-1 MOE 986 147710 502 513 TATAGCTCCTCT 1-10-1 MOE 994 147736 551 562 AGGTAGGAGAAG 1-10-1 MOE 963 147717 574 585 ATCTTCAGAGAT 1-10-1 MOE 996 147717 607 618 ATCTTCAGAGAT 1-10-1 MOE 996 147710 609 620 TATAGCTCCTCT 1-10-1 MOE 994 147708 612 623 TTGATATAGTCA 1-10-1 MOE 997 147718 621 632 TAATATGACTTG 1-10-1 MOE 998 147746 625 636 TAAAAACAACAA 1-10-1 MOE 1073 147736 658 669 AGGTAGGAGAAG 1-10-1 MOE 963 147720 676 687 GATCTCTCGAGT 1-10-1 MOE 1117 147721 683 694 AATGCAGGATCT 1-10-1 MOE 1118 398167 704 715 CAGGCCATGTGG 1-10-1 MOE 1059 398092 705 718 AGTCAGGCCATGTG 2-10-2 MOE 1060 147722 709 720 AAAGTCAGGCCA 1-10-1 MOE 1130 147723 715 726 GACTCCAAAGTC 1-10-1 MOE 892 147746 733 744 TAAAAACAACAA 1-10-1 MOE 1073 398093 758 771 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 760 771 TCGGACTTTGAA 1-10-1 MOE 1008 147725 761 772 CTCGGACTTTGA 1-10-1 MOE 1119 147726 766 777 TGACTCTCGGAC 1-10-1 MOE 1120 147738 780 791 TGGGTGGCCGGG 1-10-1 MOE 1069 147727 807 818 CAGTGGACCACA 1-10-1 MOE 1128 147728 846 857 GCCAGACAGAAG 1-10-1 MOE 1013 398094 848 861 ATCAGCCAGACAGA 2-10-2 MOE 1010 398169 849 860 TCAGCCAGACAG 1-10-1 MOE 909 147729 863 874 GTAAGAGGCAGG 1-10-1 MOE 920 398095 866 879 CATCAGCAAGAGGC 2-10-2 MOE 1011 398164 873 884 TTGTCGATCTGC 1-10-1 MOE 1014 WO 2007/146511 PCT/US2007/068401 -172 147730 874 885 CTTGTCCATCAG 1-10-1 MOE 1121 147731 880 891 TTTCCTCTTGTC 1-10-1 MOE 934 147732 885 896 GGGTCTTTCCTC 1-10-1 MOE 1122 147738 888 899 TGGGTGGCCGGG 1-10-1 MOE 1069 147733 906 917 TTCTTGATGTCC 1-10-1 MOE 891 398096 971 984 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 973 984 GGAGAAGCGCAG 1-10-1 MOE 1016 147736 978 989 AGGTAGGAGAAG 1-10-1 MOE 963 147729 979 990 GTAAGAGGCAGG 1-10-1 MOE 920 147737 984 995 ACAGCCAGGTAG 1-10-1 MOE 1067 368349 1025 1038 CTGCACTGACGAGT 2-10-2 MOE 1017 368369 1025 1040 TCCTGCACTGACGAGT 3-10-3 MOE 893 368350 1027 1040 TCCTGCACTGACGA 2-10-2 MOE 1079 368370 1027 1042 GATCCTGCACTGACGA 3-10-3 MOE 1080 368351 1029 1042 GATCCTGCACTGAC 2-10-2 MOE 1081 368371 1029 1044 CTGATCCTGCACTGAC 3-10-3 MOE 1082 368352 1031 1044 CTGATCCTGCACTG 2-10-2 MOE 1105 368372 1031 1046 CACTGATCCTGCACTG 3-10-3 MOE 894 368353 1033 1046 CACTGATCCTGCAC 2-10-2 MOE 1007 368373 1033 1048 TCCACTGATCCTGCAC 3-10-3 MOE 1083 368354 1035 1048 TCCACTGATCCTGC 2-10-2 MOE 1024 368368 1035 1048 TCCACTGATCCTTA 2-10-2 MOE 1127 368374 1035 1050 CTTCCACTGATCCTGC 3-10-3 MOE 1126 368388 1035 1050 CTTCCACTGATCCTTA 3-10-3 MOE 895 147074 1036 1047 CCACTGATCCTG 1-10-1 MOE 845 368355 1036 1049 TTCCACTGATCCTG 2-10-2 MOE 1025 368375 1036 1051 CCTTCCACTGATCCTG 3-10-3 MOE 1020 147075 1037 1048 TCCACTGATCCT 1-10-1 MOE 1026 368356 1037 1050 CTTCCACTGATCCT 2-10-2 MOE 1027 368376 1037 1052 TCCTTCCACTGATCCT 3-10-3 MOE 1028 147076 1038 1049 TTCCACTGATCC 1-10-1 MOE 1029 368357 1038 1051 CCTTCCACTGATCC 2-10-2 MOE 1046 368377 1038 1053 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 1039 1050 CTTCCACTGATC 1-10-1 MOE 1047 368358 1039 1052 TCCTTCCACTGATC 2-10-2 MOE 1031 368378 1039 1054 GCTCCTTCCACTGATC 3-10-3 MOE 1032 147078 1040 1051 CCTTCCACTGAT 1-10-1 MOE 1044 147079 1041 1052 TCCTTCCACTGA 1-10-1 MOE 1001 368359 1041 1054 GCTCCTTCCACTGA 2-10-2 MOE 1033 368379 1041 1056 AAGCTCCTTCCACTGA 3-10-3 MOE 1034 147080 1042 1053 CTCCTTCCACTG 1-10-1 MOE 1021 147081 1043 1054 GCTCCTTCCACT 1-10-1 MOE 1006 368360 1043 1056 AAGCTCCTTCCACT 2-10-2 MOE 1035 368380 1043 1058 GAAAGCTCCTTCCACT 3-10-3 MOE 896 147082 1044 1055 AGCTCCTTCCAC 1-10-1 MOE 1036 368361 1045 1058 GAAAGCTCCTTCCA 2-10-2 MOE 962 368381 1045 1060 GGGAAAGCTCCTTCCA 3-10-3 MOE 1037 147729 1087 1098 GTAAGAGGCAGG 1-10-1 MOE 920 147738 1103 1114 TGGGTGGCCGGG 1-10-1 MOE 1069 147739 1107 1118 CGTTTGGGTGGC 1-10-1 MOE 1023 147740 1124 1135 TGTGAGGCTCCA 1-10-1 MOE 1062 398117 1164 1177 TTTCCACTTGGGTG 2-10-2 MOE 960 147741 1165 1176 CACCCACTGGTG 1-10-1 MOE 1055 398097 1194 1207 GGCAGTCTTTATCC 2-10-2 MOE 897 WO 2007/146511 PCT/US2007/068401 -173 398098 1272 1285 TAACTTCAGTGTCT 2-10-2 MOE 1131 398117 1272 1285 TTTCCACTTGGGTG 2-10-2 MOE 960 147742 1273 1284 AACTTCAGTGTC 1-10-1 MOE 1041 147698 1293 1304 CCCGCCACCACC 1-10-1 MOE 928 147743 1388 1399 AGGGCTTCCAGT 1-10-1 MOE 1042 398099 1388 1401 GAAGGGCTTCCAGT 2-10-2 MOE 1132 147744 1392 1403 AGGAAGGGCTTC 1-10-1 MOE 1043 398100 1395 1408 TGACCAGGAAGGGC 2-10-2 MOE 1133 147745 1398 1409 TTGACCAGGAAG 1-10-1 MOE 1058 398157 1455 1468 GGAAACATACCCTG 2-10-2 MOE 1045 147745 1458 1469 TTGACCAGGAAG 1-10-1 MOE 1058 398167 1475 1486 CAGGCCATGTGG 1-10-1 MOE 1059 398118 1564 1577 CGCGAGATATCTAA 2-10-2 MOE 1084 147697 1575 1586 CCCCAGCAGCGG 1-10-1 MOE 1000 147076 1596 1607 TTCCACTGATCC 1-10-1 MOE 1029 368357 1596 1609 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 1597 1608 CTTCCACTGATC 1-10-1 MOE 1047 147078 1598 1609 CCTTCCACTGAT 1-10-1 MOE 1044 398118 1672 1685 CGCGAGATATCTAA 2-10-2 MOE 1084 398158 1681 1694 AGGCCCTGAGATTA 2-10-2 MOE 1134 147697 1683 1694 CCCCAGCAGCGG 1-10-1 MOE 1000 398159 1686 1699 GGTTAAGGCCCTGA 2-10-2 MOE 1135 398160 1691 1704 GAATAGGTTAAGGC 2-10-2 MOE 1048 398163 1711 1722 ATGTCAACCGGC 1-10-1 MOE 908 147733 1717 1728 TTCTTGATGTCC 1-10-1 MOE 891 147089 1747 1758 TCCCTCTACACC 1-10-1 MOE 956 147090 1748 1759 TTCCCTCTACAC 1-10-1 MOE 955 147746 1750 1761 TAAAAACAACAA 1-10-1 MOE 1073 389949 1777 1788 GCGCGAGCCCGA 1-10-1 MOE 1061 398161 1790 1803 AACAATGTGTTGTA 2-10-2 MOE 1049 147746 1799 1810 TAAAAACAACAA 1-10-1 MOE 1073 147700 1801 1812 GCGCTAGGCCGC 1-10-1 MOE 1110 147740 1806 1817 TGTGAGGCTCCA 1-10-1 MOE 1062 398163 1819 1830 ATGTCAACCGGC 1-10-1 MOE 908 147733 1825 1836 TTCTTGATGTCC 1-10-1 MOE 891 389950 1848 1859 CCCTGAAGGTTC 1-10-1 MOE 1063 147701 1858 1869 CCATGGCGGGAC 1-10-1 MOE 921 398164 1889 1900 TTGTCGATCTGC 1-10-1 MOE 1014 147730 1890 1901 CTTGTCCATCAG 1-10-1 MOE 1121 147700 1909 1920 GCGCTAGGCCGC 1-10-1 MOE 1110 398119 1920 1933 CGCACCTGGTAAAT 2-10-2 MOE 1085 147685 1957 1968 GGCTGACATTCA 1-10-1 MOE 975 147701 1966 1977 CCATGGCGGGAC 1-10-1 MOE 921 398120 1966 1979 GTTCAAGCGGCCTA 2-10-2 MOE 1086 398101 1977 1990 TTTGATAAAGCCCT 2-10-2 MOE 1064 398164 1997 2008 TTGTCGATCTGC 1-10-1 MOE 1014 147730 1998 2009 CTTGTCCATCAG 1-10-1 MOE 1121 147702 2025 2036 CTGGTAAATAGC 1-10-1 MOE 898 398119 2028 2041 CGCACCTGGTAAAT 2-10-2 MOE 1085 398120 2074 2087 GTTCAAGCGGCCTA 2-10-2 MOE 1086 398105 2099 2112 TGCACAGGCAGGTT 2-10-2 MOE 1066 147736 2204 2215 AGGTAGGAGAAG 1-10-1 MOE 963 147741 2257 2268 CACCCACTGGTG 1-10-1 MOE 1055 398104 2272 2285 CAAGAAGACCTTAC 2-10-2 MOE 1065 WO 2007/146511 PCT/US2007/068401 -174 147737 2360 2371 ACAGCCAGGTAG 1-10-1 MOE 1067 398105 2361 2374 TGCACAGGCAGGTT 2-10-2 MOE 1066 147737 2386 2397 ACAGCCAGGTAG 1-10-1 MOE 1067 398095 2407 2420 CATCAGCAAGAGGC 2-10-2 MOE 1011 398106 2441 2454 TGGAAAACTGCACC 2-10-2 MOE 1068 398107 2447 2460 TATTCCTGGAAAAC 2-10-2 MOE 902 398121 2474 2487 GTGCCTAGCACAGA 2-10-2 MOE 1097 147745 2497 2508 TTGACCAGGAAG 1-10-1 MOE 1058 147712 2499 2510 ACACCATCTCCC 1-10-1 MOE 1005 398108 2544 2557 GGAATGTCTGAGTT 2-10-2 MOE 1136 147691 2575 2586 GAGGTGGGAAAA 1-10-1 MOE 966 398121 2582 2595 GTGCCTAGCACAGA 2-10-2 MOE 1097 147738 2622 2633 TGGGTGGCCGGG 1-10-1 MOE 1069 398162 2666 2679 ACCAAACAGTTCAG 2-10-2 MOE 1057 147745 2689 2700 TTGACCAGGAAG 1-10-1 MOE 1058 398167 2706 2717 CAGGCCATGTGG 1-10-1 MOE 1059 398092 2707 2720 AGTCAGGCCATGTG 2-10-2 MOE 1060 398109 2714 2727 CAAGAAGTGTGGTT 2-10-2 MOE 903 398110 2852 2865 GTTCCCTTTGCAGG 2-10-2 MOE 952 147091 2854 2865 GTTCCCTCTACA 1-10-1 MOE 1004 147723 2924 2935 GACTCCAAAGTC 1-10-1 MOE 892 398111 2937 2950 GTGAAAATGCTGGC 2-10-2 MOE 904 398166 2966 2977 GGGCTTCTTCCA 1-10-1 MOE 1070 147089 2978 2989 TCCCTCTACACC 1-10-1 MOE 956 147090 2979 2990 TTCCCTCTACAC 1-10-1 MOE 955 147706 3007 3018 GCTGACATCTCG 1-10-1 MOE 1071 389949 3008 3019 GCGCGAGCCCGA 1-10-1 MOE 1061 147723 3032 3043 GACTCCAAAGTC 1-10-1 MOE 892 147740 3037 3048 TGTGAGGCTCCA 1-10-1 MOE 1062 398112 3051 3064 CAGCCTGGCACCTA 2-10-2 MOE 1072 389950 3079 3090 CCCTGAAGGTTC 1-10-1 MOE 1063 147746 3084 3095 TAAAAACAACAA 1-10-1 MOE 1073 398122 3148 3161 CCCTTTACACAAGT 2-10-2 MOE 1087 147089 3151 3162 TCCCTCTACACC 1-10-1 MOE 956 147090 3152 3163 TTCCCTCTACAC 1-10-1 MOE 955 398113 3160 3173 AGGAGGTTAAACCA 2-10-2 MOE 905 147685 3188 3199 GGCTGACATTCA 1-10-1 MOE 975 398101 3208 3221 TTTGATAAAGCCCT 2-10-2 MOE 1064 398102 3234 3247 CTACCTGAGGATTT 2-10-2 MOE 899 398123 3235 3248 CTCAAAATAGATTT 2-10-2 MOE 1088 398114 3237 3250 AGGCATATAGCAGA 2-10-2 MOE 1075 398103 3241 3254 CCCAGTACTACCTG 2-10-2 MOE 900 398115 3253 3266 AGTAAATATTGGCT 2-10-2 MOE 1076 398122 3256 3269 CCCTTTACACAAGT 2-10-2 MOE 1087 147089 3259 3270 TCCCTCTACACC 1-10-1 MOE 956 147090 3260 3271 TTCCCTCTACAC 1-10-1 MOE 955 398116 3266 3279 TAATGACCTGATGA 2-10-2 MOE 1137 390030 3306 3317 TTTATAAAACTG 1-10-1 MOE 1074 398123 3343 3356 CTCAAAATAGATTT 2-10-2 MOE 1088 147736 3435 3446 AGGTAGGAGAAG 1-10-1 MOE 963 398104 3503 3516 CAAGAAGACCTTAC 2-10-2 MOE 1065 147737 3591 3602 ACAGCCAGGTAG 1-10-1 MOE 1067 398105 3592 3605 TGCACAGGCAGGTT 2-10-2 MOE 1066 147719 3608 3619 CCAACTCCAACT 1-10-1 MOE 1116 WO 2007/146511 PCT/US2007/068401 -175 147737 3617 3628 ACAGCCAGGTAG 1-10-1 MOE 1067 401398 3621 3634 CAAAGTCCCTTAGC 2-10-2 MOE 947 147079 3637 3648 TCCTTCCACTGA 1-10-1 MOE 1001 147080 3638 3649 CTCCTTCCACTG 1-10-1 MOE 1021 398095 3638 3651 CATCAGCAAGAGGC 2-10-2 MOE 1011 398106 3672 3685 TGGAAAACTGCACC 2-10-2 MOE 1068 147733 3687 3698 TTCTTGATGTCC 1-10-1 MOE 891 147731 3688 3699 TTTCCTCTTGTC 1-10-1 MOE 934 147719 3716 3727 CCAACTCCAACT 1-10-1 MOE 1116 147745 3728 3739 TTGACCAGGAAG 1-10-1 MOE 1058 147683 3740 3751 GCTTACGATTGT 1-10-1 MOE 922 147079 3745 3756 TCCTTCCACTGA 1-10-1 MOE 1001 147080 3746 3757 CTCCTTCCACTG 1-10-1 MOE 1021 398108 3775 3788 GGAATGTCTGAGTT 2-10-2 MOE 1136 147733 3795 3806 TTCTTGATGTCC 1-10-1 MOE 891 147731 3796 3807 TTTCCTCTTGTC 1-10-1 MOE 934 147691 3806 3817 GAGGTGGGAAAA 1-10-1 MOE 966 147738 3853 3864 TGGGTGGCCGGG 1-10-1 MOE 1069 398167 3926 3937 CAGGCCATGTGG 1-10-1 MOE 1059 147691 3978 3989 GAGGTGGGAAAA 1-10-1 MOE 966 398167 4034 4045 CAGGCCATGTGG 1-10-1 MOE 1059 147091 4085 4096 GTTCCCTCTACA 1-10-1 MOE 1004 147691 4086 4097 GAGGTGGGAAAA 1-10-1 MOE 966 398111 4168 4181 GTGAAAATGCTGGC 2-10-2 MOE 904 398166 4197 4208 GGGCTTCTTCCA 1-10-1 MOE 1070 147091 4223 4234 GTTCCCTCTACA 1-10-1 MOE 1004 147092 4224 4235 TGTTCCCTCTAC 1-10-1 MOE 901 398112 4282 4295 CAGCCTGGCACCTA 2-10-2 MOE 1072 147746 4315 4326 TAAAAACAACAA 1-10-1 MOE 1073 398113 4391 4404 AGGAGGTTAAACCA 2-10-2 MOE 905 147723 4422 4433 GACTCCAAAGTC 1-10-1 MOE 892 398114 4468 4481 AGGCATATAGCAGA 2-10-2 MOE 1075 398115 4484 4497 AGTAAATATTGGCT 2-10-2 MOE 1076 390030 4491 4502 TTTATAAAACTG 1-10-1 MOE 1074 398116 4497 4510 TAATGACCTGATGA 2-10-2 MOE 1137 147723 4530 4541 GACTCCAAAGTC 1-10-1 MOE 892 390030 4599 4610 TTTATAAAACTG 1-10-1 MOE 1074 398124 4761 4774 CACATGAGCTATTC 2-10-2 MOE 1089 398124 4869 4882 CACATGAGCTATTC 2-10-2 MOE 1089 147703 4926 4937 TGGCTTCATGTC 1-10-1 MOE 971 147692 4928 4939 CTCACCTTCATG 1-10-1 MOE 1113 147696 4975 4986 TGGATGATTGGC 1-10-1 MOE 906 147703 5034 5045 TGGCTTCATGTC 1-10-1 MOE 971 147692 5036 5047 CTCACCTTCATG 1-10-1 MOE 1113 147098 5173 5184 AGTTGTTGTTCC 1-10-1 MOE 1112 398125 5183 5196 CAGTAAGGAATTTT 2-10-2 MOE 913 398126 5216 5229 GTGAAGTGAGTCAT 2-10-2 MOE 1090 147098 5281 5292 AGTTGTTGTTCC 1-10-1 MOE 1112 398127 5283 5296 GGTCACTCAAGATG 2-10-2 MOE 1091 398126 5324 5337 GTGAAGTGAGTCAT 2-10-2 MOE 1090 398128 5335 5348 CTAAATTTAGTTCA 2-10-2 MOE 911 398127 5391 5404 GGTCACTCAAGATG 2-10-2 MOE 1091 398128 5443 5456 CTAAATTTAGTTCA 2-10-2 MOE 911 147712 5474 5485 ACACCATCTCCC 1-10-1 MOE 1005 WO 2007/146511 PCT/US2007/068401 -176 147736 5600 5611 AGGTAGGAGAAG 1-10-1 MOE 963 147746 5606 5617 TAAAAACAACAA 1-10-1 MOE 1073 398129 5628 5641 TTTGAGGAGCTATT 2-10-2 MOE 1106 147085 5654 5665 TCTACACCAGGT 1-10-1 MOE 961 147736 5708 5719 AGGTAGGAGAAG 1-10-1 MOE 963 398129 5736 5749 TTTGAGGAGCTATT 2-10-2 MOE 1106 147679 5934 5945 CAAAAGGATCCC 1-10-1 MOE 907 147723 6229 6240 GACTCCAAAGTC 1-10-1 MOE 892 147723 6338 6349 GACTCCAAAGTC 1-10-1 MOE 892 390030 6803 6814 TTTATAAAACTG 1-10-1 MOE 1074 398142 6885 6898 CCAGCACACTGGAA 2-10-2 MOE 923 390030 6912 6923 TTTATAAAACTG 1-10-1 MOE 1074 398142 6994 7007 CCAGCACACTGGAA 2-10-2 MOE 923 147695 7054 7065 TCATTCCCCACT 1-10-1 MOE 984 147695 7163 7174 TCATTCCCCACT 1-10-1 MOE 984 398166 7197 7208 GGGCTTCTTCCA 1-10-1 MOE 1070 398166 7306 7317 GGGCTTCTTCCA 1-10-1 MOE 1070 147684 7442 7453 ACCCAGTCAGGG 1-10-1 MOE 964 398130 7694 7707 TTAGTATGACAGCT 2-10-2 MOE 925 398131 7711 7724 GGACTCACTCAGCA 2-10-2 MOE 1092 398130 7802 7815 TTAGTATGACAGCT 2-10-2 MOE 925 398125 7804 7817 CAGTAAGGAATTTT 2-10-2 MOE 913 398131 7819 7832 GGACTCACTCAGCA 2-10-2 MOE 1092 390030 7877 7888 TTTATAAAACTG 1-10-1 MOE 1074 398125 7912 7925 CAGTAAGGAATTTT 2-10-2 MOE 913 390030 7985 7996 TTTATAAAACTG 1-10-1 MOE 1074 398132 8031 8044 TCAGGGCTACTCAT 2-10-2 MOE 1093 398132 8139 8152 TCAGGGCTACTCAT 2-10-2 MOE 1093 147684 8148 8159 ACCCAGTCAGGG 1-10-1 MOE 964 147684 8256 8267 ACCCAGTCAGGG 1-10-1 MOE 964 398163 8365 8376 ATGTCAACCGGC 1-10-1 MOE 908 398166 8447 8458 GGGCTTCTTCCA 1-10-1 MOE 1070 398163 8473 8484 ATGTCAACCGGC 1-10-1 MOE 908 398166 8555 8566 GGGCTTCTTCCA 1-10-1 MOE 1070 147718 8631 8642 TAATATGACTTG 1-10-1 MOE 998 147691 8698 8709 GAGGTGGGAAAA 1-10-1 MOE 966 147691 8806 8817 GAGGTGGGAAAA 1-10-1 MOE 966 147728 8835 8846 GCCAGACAGAAG 1-10-1 MOE 1013 147727 8876 8887 CAGTGGACCACA 1-10-1 MOE 1128 147728 8943 8954 GCCAGACAGAAG 1-10-1 MOE 1013 398169 8946 8957 TCAGCCAGACAG 1-10-1 MOE 909 147727 8984 8995 CAGTGGACCACA 1-10-1 MOE 1128 147742 9060 9071 AACTTCAGTGTC 1-10-1 MOE 1041 398133 9112 9125 CAGCACTAGATTCA 2-10-2 MOE 1094 384545 9135 9146 CAAGTAGGATGT 1-10-1 MOE 951 147742 9168 9179 AACTTCAGTGTC 1-10-1 MOE 1041 398133 9220 9233 CAGCACTAGATTCA 2-10-2 MOE 1094 384545 9243 9254 CAAGTAGGATGT 1-10-1 MOE 951 398125 9368 9381 CAGTAAGGAATTTT 2-10-2 MOE 913 398125 9476 9489 CAGTAAGGAATTTT 2-10-2 MOE 913 401409 9516 9529 ATTCTTAACACAGA 2-10-2 MOE 991 147096 9594 9605 TTGTTGTTCCCT 1-10-1 MOE 1107 147733 9597 9608 TTCTTGATGTCC 1-10-1 MOE 891 147720 9689 9700 GATCTCTCGAGT 1-10-1 MOE 1117 WO 2007/146511 PCT/US2007/068401 -177 147096 9702 9713 TTGTTGTTCCCT 1-10-1 MOE 1107 147733 9705 9716 TTCTTGATGTCC 1-10-1 MOE 891 147720 9797 9808 GATCTCTCGAGT 1-10-1 MOE 1117 147746 9963 9974 TAAAAACAACAA 1-10-1 MOE 1073 147746 9966 9977 TAAAAACAACAA 1-10-1 MOE 1073 147746 9969 9980 TAAAAACAACAA 1-10-1 MOE 1073 147746 9991 10002 TAAAAACAACAA 1-10-1 MOE 1073 147746 10071 10082 TAAAAACAACAA 1-10-1 MOE 1073 147746 10074 10085 TAAAAACAACAA 1-10-1 MOE 1073 147746 10077 10088 TAAAAACAACAA 1-10-1 MOE 1073 147746 10099 10110 TAAAAACAACAA 1-10-1 MOE 1073 398134 10153 10166 TAGCTTAATGTAAC 2-10-2 MOE 1095 147085 10221 10232 TCTACACCAGGT 1-10-1 MOE 961 398134 10261 10274 TAGCTTAATGTAAC 2-10-2 MOE 1095 390030 10278 10289 TTTATAAAACTG 1-10-1 MOE 1074 147084 10328 10339 CTACACCAGGTC 1-10-1 MOE 993 147711 10684 10695 AAGGGCCCTGGG 1-10-1 MOE 1040 398128 11333 11346 CTAAATTTAGTTCA 2-10-2 MOE 911 398128 11340 11353 CTAAATTTAGTTCA 2-10-2 MOE 911 147730 11783 11794 CTTGTCCATCAG 1-10-1 MOE 1121 147731 11789 11800 TTTCCTCTTGTC 1-10-1 MOE 934 147730 11790 11801 CTTGTCCATCAG 1-10-1 MOE 1121 147731 11796 11807 TTTCCTCTTGTC 1-10-1 MOE 934 147707 11960 11971 TAGTCATTATCT 1-10-1 MOE 977 147090 12008 12019 TTCCCTCTACAC 1-10-1 MOE 955 147091 12009 12020 GTTCCCTCTACA 1-10-1 MOE 1004 147091 12014 12025 GTTCCCTCTACA 1-10-1 MOE 1004 398096 12141 12154 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 12143 12154 GGAGAAGCGCAG 1-10-1 MOE 1016 398096 12146 12159 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 12148 12159 GGAGAAGCGCAG 1-10-1 MOE 1016 398166 12209 12220 GGGCTTCTTCCA 1-10-1 MOE 1070 398166 12214 12225 GGGCTTCTTCCA 1-10-1 MOE 1070 398135 12303 12316 GACTACATTTTACA 2-10-2 MOE 912 147741 12389 12400 CACCCACTGGTG 1-10-1 MOE 1055 147741 12394 12405 CACCCACTGGTG 1-10-1 MOE 1055 398125 12431 12444 CAGTAAGGAATTTT 2-10-2 MOE 913 147714 12585 12596 TTCTGCTCCCAC 1-10-1 MOE 986 147718 12594 12605 TAATATGACTTG 1-10-1 MOE 998 398125 12612 12625 CAGTAAGGAATTTT 2-10-2 MOE 913 147737 12803 12814 ACAGCCAGGTAG 1-10-1 MOE 1067 147746 12876 12887 TAAAAACAACAA 1-10-1 MOE 1073 147691 12900 12911 GAGGTGGGAAAA 1-10-1 MOE 966 398136 12915 12928 TTGTGACATCTAGG 2-10-2 MOE 1096 147737 12984 12995 ACAGCCAGGTAG 1-10-1 MOE 1067 147746 13057 13068 TAAAAACAACAA 1-10-1 MOE 1073 147691 13081 13092 GAGGTGGGAAAA 1-10-1 MOE 966 398136 13096 13109 TTGTGACATCTAGG 2-10-2 MOE 1096 398138 13254 13267 AACATCAAGCTTGA 2-10-2 MOE 931 398138 13435 13448 AACATCAAGCTTGA 2-10-2 MOE 931 147691 13488 13499 GAGGTGGGAAAA 1-10-1 MOE 966 147681 13659 13670 ATGTCATTAAAC 1-10-1 MOE 965 147691 13669 13680 GAGGTGGGAAAA 1-10-1 MOE 966 389965 13839 13850 CTGCAACATGAT 1-10-1 MOE 1018 WO 2007/146511 PCT/US2007/068401 -178 389764 13839 13850 CTGCAACATGAT 1-9-2 MOE 1018 147681 13840 13851 ATGTCATTAAAC 1-10-1 MOE 965 389965 14020 14031 CTGCAACATGAT 1-10-1 MOE 1018 389764 14020 14031 CTGCAACATGAT 1-9-2 MOE 1018 389948 14067 14078 CCGTTGGACCCC 1-10-1 MOE 915 147736 14123 14134 AGGTAGGAGAAG 1-10-1 MOE 963 389948 14248 14259 CCGTTGGACCCC 1-10-1 MOE 915 147738 14279 14290 TGGGTGGCCGGG 1-10-1 MOE 1069 147736 14304 14315 AGGTAGGAGAAG 1-10-1 MOE 963 147731 14411 14422 TTTCCTCTTGTC 1-10-1 MOE 934 147738 14461 14472 TGGGTGGCCGGG 1-10-1 MOE 1069 147692 14475 14486 CTCACCTFCATG 1-10-1 MOE 1113 147731 14593 14604 TTTCCTCTTGTC 1-10-1 MOE 934 389950 14614 14625 CCCTGAAGGTTC 1-10-1 MOE 1063 147692 14657 14668 CTCACCTTCATG 1-10-1 MOE 1113 147717 14750 14761 ATCTTCAGAGAT 1-10-1 MOE 996 147698 14754 14765 CCCGCCACCACC 1-10-1 MOE 928 389950 14796 14807 CCCTGAAGGTTC 1-10-1 MOE 1063 398112 14863 14876 CAGCCTGGCACCTA 2-10-2 MOE 1072 398121 14875 14888 GTGCCTAGCACAGA 2-10-2 MOE 1097 147717 14932 14943 ATCTTCAGAGAT 1-10-1 MOE 996 398112 15045 15058 CAGCCTGGCACCTA 2-10-2 MOE 1072 398121 15057 15070 GTGCCTAGCACAGA 2-10-2 MOE 1097 147730 15117 15128 CTTGTCCATCAG 1-10-1 MOE 1121 147730 15299 15310 CTTGTCCATCAG 1-10-1 MOE 1121 401407 15339 15352 CAGCTTAGGCAGAG 2-10-2 MOE 983 398167 15556 15567 CAGGCCATGTGG 1-10-1 MOE 1059 147736 16444 16455 AGGTAGGAGAAG 1-10-1 MOE 963 147746 16510 16521 TAAAAACAACAA 1-10-1 MOE 1073 147738 16590 16601 TGGGTGGCCGGG 1-10-1 MOE 1069 147736 16610 16621 AGGTAGGAGAAG 1-10-1 MOE 963 398167 16631 16642 CAGGCCATGTGG 1-10-1 MOE 1059 401411 16657 16670 AGCCGCCTGAAGTG 2-10-2 MOE 999 147746 16676 16687 TAAAAACAACAA 1-10-1 MOE 1073 398144 16745 16758 GACAGCTTCTATAA 2-10-2 MOE 916 147738 16756 16767 TGGGTGGCCGGG 1-10-1 MOE 1069 398167 16797 16808 CAGGCCATGTGG 1-10-1 MOE 1059 398144 16911 16924 GACAGCTTCTATAA 2-10-2 MOE 916 389965 17096 17107 CTGCAACATGAT 1-10-1 MOE 1018 389764 17096 17107 CTGCAACATGAT 1-9-2 MOE 1018 389965 17264 17275 CTGCAACATGAT 1-10-1 MOE 1018 389764 17264 17275 CTGCAACATGAT 1-9-2 MOE 1018 147709 17406 17417 CCATTTTTATCA 1-10-1 MOE 978 147745 17443 17454 TTGACCAGGAAG 1-10-1 MOE 1058 147746 17497 17508 TAAAAACAACAA 1-10-1 MOE 1073 147720 17589 17600 GATCTCTCGAGT 1-10-1 MOE 1117 147745 17611 17622 TTGACCAGGAAG 1-10-1 MOE 1058 147695 17634 17645 TCATTCCCCACT 1-10-1 MOE 984 147746 17665 17676 TAAAAACAACAA 1-10-1 MOE 1073 147088 17707 17718 CCCTCTACACCA 1-10-1 MOE 1050 147720 17757 17768 GATCTCTCGAGT 1-10-1 MOE 1117 147711 17808 17819 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 17976 17987 AAGGGCCCTGGG 1-10-1 MOE 1040 398139 18049 18062 AGTGACTGACCACA 2-10-2 MOE 917 WO 2007/146511 PCT/US2007/068401 -179 398139 18217 18230 AGTGACTGACCACA 2-10-2 MOE 917 398140 18596 18609 GTAGCATAGAGCCT 2-10-2 MOE 918 398140 18764 18777 GTAGCATAGAGCCT 2-10-2 MOE 918 398167 18927 18938 CAGGCCATGTGG 1-10-1 MOE 1059 398167 19095 19106 CAGGCCATGTGG 1-10-1 MOE 1059 147724 19147 19158 GAAATTGAGGAA 1-10-1 MOE 1139 147746 19207 19218 TAAAAACAACAA 1-10-1 MOE 1073 147724 19315 19326 GAAATTGAGGAA 1-10-1 MOE 1139 147740 19348 19359 TGTGAGGCTCCA 1-10-1 MOE 1062 147746 19375 19386 TAAAAACAACAA 1-10-1 MOE 1073 147729 19386 19397 GTAAGAGGCAGG 1-10-1 MOE 920 147701 19503 19514 CCATGGCGGGAC 1-10-1 MOE 921 147711 19508 19519 AAGGGCCCTGGG 1-10-1 MOE 1040 147740 19516 19527 TGTGAGGCTCCA 1-10-1 MOE 1062 147718 19617 19628 TAATATGACTTG 1-10-1 MOE 998 390030 19618 19629 TTTATAAAACTG 1-10-1 MOE 1074 147679 19635 19646 CAAAAGGATCCC 1-10-1 MOE 907 147711 19676 19687 AAGGGCCCTGGG 1-10-1 MOE 1040 147694 19747 19758 CAGCCTACCAGT 1-10-1 MOE 1098 147718 19785 19796 TAATATGACTTG 1-10-1 MOE 998 390030 19786 19797 TTTATAAAACTG 1-10-1 MOE 1074 147679 19803 19814 CAAAAGGATCCC 1-10-1 MOE 907 147698 19852 19863 CCCGCCACCACC 1-10-1 MOE 928 147694 19915 19926 CAGCCTACCAGT 1-10-1 MOE 1098 147704 20011 20022 TTGTTCTTAGGA 1-10-1 MOE 1012 147698 20020 20031 CCCGCCACCACC 1-10-1 MOE 928 398142 20485 20498 CCAGCACACTGGAA 2-10-2 MOE 923 147078 20514 20525 CCTTCCACTGAT 1-10-1 MOE 1044 147079 20515 20526 TCCTTCCACTGA 1-10-1 MOE 1001 147080 20516 20527 CTCCTTCCACTG 1-10-1 MOE 1021 398143 20561 20574 GTCAGTCCCAGCTA 2-10-2 MOE 924 389965 20620 20631 CTGCAACATGAT 1-10-1 MOE 1018 389764 20620 20631 CTGCAACATGAT 1-9-2 MOE 1018 398142 20653 20666 CCAGCACACTGGAA 2-10-2 MOE 923 147078 20682 20693 CCTTCCACTGAT 1-10-1 MOE 1044 147079 20683 20694 TCCTTCCACTGA 1-10-1 MOE 1001 147080 20684 20695 CTCCTTCCACTG 1-10-1 MOE 1021 147080 20704 20715 CTCCTTCCACTG 1-10-1 MOE 1021 147081 20705 20716 GCTCCTTCCACT 1-10-1 MOE 1006 398143 20729 20742 GTCAGTCCCAGCTA 2-10-2 MOE 924 389965 20788 20799 CTGCAACATGAT 1-10-1 MOE 1018 389764 20788 20799 CTGCAACATGAT 1-9-2 MOE 1018 147746 20870 20881 TAAAAACAACAA 1-10-1 MOE 1073 147080 20872 20883 CTCCTTCCACTG 1-10-1 MOE 1021 147081 20873 20884 GCTCCTTCCACT 1-10-1 MOE 1006 147746 21038 21049 TAAAAACAACAA 1-10-1 MOE 1073 147717 21080 21091 ATCTTCAGAGAT 1-10-1 MOE 996 147076 21222 21233 TTCCACTGATCC 1-10-1 MOE 1029 147076 21390 21401 TTCCACTGATCC 1-10-1 MOE 1029 398094 21441 21454 ATCAGCCAGACAGA 2-10-2 MOE 1010 147746 21465 21476 TAAAAACAACAA 1-10-1 MOE 1073 398094 21609 21622 ATCAGCCAGACAGA 2-10-2 MOE 1010 398169 21610 21621 TCAGCCAGACAG 1-10-1 MOE 909 147746 21633 21644 TAAAAACAACAA 1-10-1 MOE 1073 WO 2007/146511 PCT/US2007/068401 -180 147738 21884 21895 TGGGTGGCCGGG 1-10-1 MOE 1069 147743 22045 22056 AGGGCTTCCAGT 1-10-1 MOE 1042 147738 22052 22063 TGGGTGGCCGGG 1-10-1 MOE 1069 147683 22107 22118 GCTTACGATTGT 1-10-1 MOE 922 147743 22213 22224 AGGGCTTCCAGT 1-10-1 MOE 1042 147681 22566 22577 ATGTCATTAAAC 1-10-1 MOE 965 389950 22619 22630 CCCTGAAGGTTC 1-10-1 MOE 1063 147681 22734 22745 ATGTCATTAAAC 1-10-1 MOE 965 147736 22759 22770 AGGTAGGAGAAG 1-10-1 MOE 963 389950 22787 22798 CCCTGAAGGTTC 1-10-1 MOE 1063 389949 22794 22805 GCGCGAGCCCGA 1-10-1 MOE 1061 147736 22927 22938 AGGTAGGAGAAG 1-10-1 MOE 963 389949 22962 22973 GCGCGAGCCCGA 1-10-1 MOE 1061 398144 22962 22975 GACAGCTTCTATAA 2-10-2 MOE 916 398142 23008 23021 CCAGCACACTGGAA 2-10-2 MOE 923 147727 23019 23030 CAGTGGACCACA 1-10-1 MOE 1128 398169 23064 23075 TCAGCCAGACAG 1-10-1 MOE 909 398144 23130 23143 GACAGCTTCTATAA 2-10-2 MOE 916 398145 23154 23167 ACATGTCAGTAATT 2-10-2 MOE 1099 398142 23176 23189 CCAGCACACTGGAA 2-10-2 MOE 923 147727 23187 23198 CAGTGGACCACA 1-10-1 MOE 1128 147735 23243 23254 GGAGAAGCGCAG 1-10-1 MOE 1016 398145 23322 23335 ACATGTCAGTAATT 2-10-2 MOE 1099 147735 23411 23422 GGAGAAGCGCAG 1-10-1 MOE 1016 398146 23478 23491 CTCATGGACACAAA 2-10-2 MOE 1100 398146 23646 23659 CTCATGGACACAAA 2-10-2 MOE 1100 398147 23784 23797 CTACAGGACAATAC 2-10-2 MOE 957 398114 23853 23866 AGGCATATAGCAGA 2-10-2 MOE 1075 398147 23952 23965 CTACAGGACAATAC 2-10-2 MOE 957 398114 24021 24034 AGGCATATAGCAGA 2-10-2 MOE 1075 147702 24319 24330 CTGGTAAATAGC 1-10-1 MOE 898 147702 24487 24498 CTGGTAAATAGC 1-10-1 MOE 898 389965 24543 24554 CTGCAACATGAT 1-10-1 MOE 1018 389764 24543 24554 CTGCAACATGAT 1-9-2 MOE 1018 147713 24602 24613 CTCCCACACCAT 1-10-1 MOE 985 389965 24711 24722 CTGCAACATGAT 1-10-1 MOE 1018 389764 24711 24722 CTGCAACATGAT 1-9-2 MOE 1018 147684 24918 24929 ACCCAGTCAGGG 1-10-1 MOE 964 147684 25086 25097 ACCCAGTCAGGG 1-10-1 MOE 964 398148 25152 25165 TCATAACTATTAAG 2-10-2 MOE 981 398144 25192 25205 GACAGCTTCTATAA 2-10-2 MOE 916 147746 25216 25227 TAAAAACAACAA 1-10-1 MOE 1073 147736 25313 25324 AGGTAGGAGAAG 1-10-1 MOE 963 398148 25320 25333 TCATAACTATTAAG 2-10-2 MOE 981 398143 25337 25350 GTCAGTCCCAGCTA 2-10-2 MOE 924 398144 25360 25373 GACAGCTTCTATAA 2-10-2 MOE 916 147746 25384 25395 TAAAAACAACAA 1-10-1 MOE 1073 147691 25442 25453 GAGGTGGGAAAA 1-10-1 MOE 966 147736 25481 25492 AGGTAGGAGAAG 1-10-1 MOE 963 398130 25504 25517 TTAGTATGACAGCT 2-10-2 MOE 925 147691 25610 25621 GAGGTGGGAAAA 1-10-1 MOE 966 147721 25662 25673 AATGCAGGATCT 1-10-1 MOE 1118 398130 25672 25685 TTAGTATGACAGCT 2-10-2 MOE 925 147688 25750 25761 TCCCAAACAAAT 1-10-1 MOE 990 WO 2007/146511 PCT/US2007/068401 -181 147746 25810 25821 TAAAAACAACAA 1-10-1 MOE 1073 147721 25830 25841 AATGCAGGATCT 1-10-1 MOE 1118 147688 25918 25929 TCCCAAACAAAT 1-10-1 MOE 990 147746 25978 25989 TAAAAACAACAA 1-10-1 MOE 1073 147746 26172 26183 TAAAAACAACAA 1-10-1 MOE 1073 147746 26340 26351 TAAAAACAACAA 1-10-1 MOE 1073 398149 26492 26505 GGAAGTTTTCAAGT 2-10-2 MOE 1101 398150 26526 26539 GAATCTGGAGGTAA 2-10-2 MOE 1102 398149 26641 26654 GGAAGTTTTCAAGT 2-10-2 MOE 1101 398150 26675 26688 GAATCTGGAGGTAA 2-10-2 MOE 1102 147729 26712 26723 GTAAGAGGCAGG 1-10-1 MOE 920 398151 26718 26731 TCAGTGTAGGAAGA 2-10-2 MOE 926 147729 26861 26872 GTAAGAGGCAGG 1-10-1 MOE 920 398151 26867 26880 TCAGTGTAGGAAGA 2-10-2 MOE 926 147728 26917 26928 GCCAGACAGAAG 1-10-1 MOE 1013 147728 27066 27077 GCCAGACAGAAG 1-10-1 MOE 1013 147076 27258 27269 TTCCACTGATCC 1-10-1 MOE 1029 147731 27267 27278 TTTCCTCTTGTC 1-10-1 MOE 934 147076 27407 27418 TTCCACTGATCC 1-10-1 MOE 1029 147731 27416 27427 TTTCCTCTTGTC 1-10-1 MOE 934 398152 27559 27572 TGAATATACAGATG 2-10-2 MOE 927 398152 27708 27721 TGAATATACAGATG 2-10-2 MOE 927 147696 28265 28276 TGGATGATTGGC 1-10-1 MOE 906 147696 28414 28425 TGGATGATTGGC 1-10-1 MOE 906 147698 28481 28492 CCCGCCACCACC 1-10-1 MOE 928 147720 28662 28673 GATCTCTCGAGT 1-10-1 MOE 1117 389965 28714 28725 CTGCAACATGAT 1-10-1 MOE 1018 389764 28714 28725 CTGCAACATGAT 1-9-2 MOE 1018 389965 28861 28872 CTGCAACATGAT 1-10-1 MOE 1018 389764 28861 28872 CTGCAACATGAT 1-9-2 MOE 1018 398153 28980 28993 ATTTCTCTTACAGG 2-10-2 MOE 948 398153 29126 29139 ATTTCTCTTACAGG 2-10-2 MOE 948 147719 29570 29581 CCAACTCCAACT 1-10-1 MOE 1116 398154 29692 29705 AGCCCCTTGGCCGT 2-10-2 MOE 1103 147719 29715 29726 CCAACTCCAACT 1-10-1 MOE 1116 398155 29785 29798 TGTTTTTACACAGA 2-10-2 MOE 970 398154 29837 29850 AGCCCCTTGGCCGT 2-10-2 MOE 1103 401384 29905 29918 TGAACACATCACTA 2-10-2 MOE 933 398155 29930 29943 TGTTTTTACACAGA 2-10-2 MOE 970 390030 29945 29956 TTTATAAAACTG 1-10-1 MOE 1074 390030 30090 30101 TTTATAAAACTG 1-10-1 MOE 1074 398156 30141 30154 GAATACTTCAAATC 2-10-2 MOE 1104 398156 30286 30299 GAATACTTCAAATC 2-10-2 MOE 1104 389948 30384 30395 CCGTTGGACCCC 1-10-1 MOE 915 389948 30530 30541 CCGTTGGACCCC 1-10-1 MOE 915 398142 30591 30604 CCAGCACACTGGAA 2-10-2 MOE 923 147744 30654 30665 AGGAAGGGCTTC 1-10-1 MOE 1043 147093 30689 30700 TTGTTCCCTCTA 1-10-1 MOE 929 398142 30738 30751 CCAGCACACTGGAA 2-10-2 MOE 923 147744 30801 30812 AGGAAGGGCTTC 1-10-1 MOE 1043 398168 31082 31093 TCGGACTTTGAA 1-10-1 MOE 1008 147746 31105 31116 TAAAAACAACAA 1-10-1 MOE 1073 398168 31230 31241 TCGGACTTTGAA 1-10-1 MOE 1008 390030 31329 31340 TTTATAAAACTG 1-10-1 MOE 1074 WO 2007/146511 PCT/US2007/068401 -182 147736 31458 31469 AGGTAGGAGAAG 1-10-1 MOE 963 390030 31477 31488 TTTATAAAACTG 1-10-1 MOE 1074 147736 31606 31617 AGGTAGGAGAAG 1-10-1 MOE 963 147698 31713 31724 CCCGCCACCACC 1-10-1 MOE 928 384545 31829 31840 CAAGTAGGATGT 1-10-1 MOE 951 147698 31861 31872 CCCGCCACCACC 1-10-1 MOE 928 147723 31941 31952 GACTCCAAAGTC 1-10-1 MOE 892 384545 31977 31988 CAAGTAGGATGT 1-10-1 MOE 951 147692 32061 32072 CTCACCTTCATG 1-10-1 MOE 1113 147723 32089 32100 GACTCCAAAGTC 1-10-1 MOE 892 147692 32209 32220 CTCACCTTCATG 1-10-1 MOE 1113 147089 32535 32546 TCCCTCTACACC 1-10-1 MOE 956 401396 32569 32582 TGCAGGATGTTGAG 2-10-2 MOE 945 147730 32714 32725 CTTGTCCATCAG 1-10-1 MOE 1121 398165 32854 32865 GTTCTTAGGAAG 1-10-1 MOE 968 147730 32862 32873 CTTGTCCATCAG 1-10-1 MOE 1121 389950 32949 32960 CCCTGAAGGTTC 1-10-1 MOE 1063 398165 33002 33013 GTTCTTAGGAAG 1-10-1 MOE 968 147736 33012 33023 AGGTAGGAGAAG 1-10-1 MOE 963 368352 33056 33069 CTGATCCTGCACTG 2-10-2 MOE 1105 147081 33073 33084 GCTCCTTCCACT 1-10-1 MOE 1006 368360 33073 33086 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 33074 33085 AGCTCCTTCCAC 1-10-1 MOE 1036 389950 33097 33108 CCCTGAAGGTTC 1-10-1 MOE 1063 147736 33160 33171 AGGTAGGAGAAG 1-10-1 MOE 963 368352 33204 33217 CTGATCCTGCACTG 2-10-2 MOE 1105 147081 33221 33232 GCTCCTTCCACT 1-10-1 MOE 1006 147082 33222 33233 AGCTCCTTCCAC 1-10-1 MOE 1036 398138 33244 33257 AACATCAAGCTTGA 2-10-2 MOE 931 147746 33250 33261 TAAAAACAACAA 1-10-1 MOE 1073 398138 33392 33405 AACATCAAGCTTGA 2-10-2 MOE 931 147746 33398 33409 TAAAAACAACAA 1-10-1 MOE 1073 147732 33652 33663 GGGTCTTTCCTC 1-10-1 MOE 1122 147724 33733 33744 GAAATTGAGGAA 1-10-1 MOE 1139 147732 33800 33811 GGGTCTTTCCTC 1-10-1 MOE 1122 147724 33881 33892 GAAATTGAGGAA 1-10-1 MOE 1139 147719 33976 33987 CCAACTCCAACT 1-10-1 MOE 1116 147746 34034 34045 TAAAAACAACAA 1-10-1 MOE 1073 398129 34045 34058 TTTGAGGAGCTATT 2-10-2 MOE 1106 147719 34124 34135 CCAACTCCAACT 1-10-1 MOE 1116 147721 34156 34167 AATGCAGGATCT 1-10-1 MOE 1118 398129 34193 34206 TTTGAGGAGCTATT 2-10-2 MOE 1106 147721 34304 34315 AATGCAGGATCT 1-10-1 MOE 1118 147746 34606 34617 TAAAAACAACAA 1-10-1 MOE 1073 398165 34704 34715 GTTCTTAGGAAG 1-10-1 MOE 968 147746 34754 34765 TAAAAACAACAA 1-10-1 MOE 1073 398165 34852 34863 GTTCTTAGGAAG 1-10-1 MOE 968 147717 34893 34904 ATCTTCAGAGAT 1-10-1 MOE 996 147719 34976 34987 CCAACTCCAACT 1-10-1 MOE 1116 147092 34987 34998 TGTTCCCTCTAC 1-10-1 MOE 901 147719 35124 35135 CCAACTCCAACT 1-10-1 MOE 1116 147092 35135 35146 TGTTCCCTCTAC 1-10-1 MOE 901 147736 35248 35259 AGGTAGGAGAAG 1-10-1 MOE 963 147738 35391 35402 TGGGTGGCCGGG 1-10-1 MOE 1069 WO 2007/146511 PCT/US2007/068401 -183 147736 35396 35407 AGGTAGGAGAAG 1-10-1 MOE 963 147738 35539 35550 TGGGTGGCCGGG 1-10-1 MOE 1069 147691 35554 35565 GAGGTGGGAAAA 1-10-1 MOE 966 147691 35702 35713 GAGGTGGGAAAA 1-10-1 MOE 966 147746 35814 35825 TAAAAACAACAA 1-10-1 MOE 1073 147733 35889 35900 TTCTTGATGTCC 1-10-1 MOE 891 147733 35923 35934 TTCTTGATGTCC 1-10-1 MOE 891 147746 35962 35973 TAAAAACAACAA 1-10-1 MOE 1073 147726 35978 35989 TGACTCTCGGAC 1-10-1 MOE 1120 147733 36037 36048 TTCTTGATGTCC 1-10-1 MOE 891 147733 36071 36082 TTCTTGATGTCC 1-10-1 MOE 891 147726 36126 36137 TGACTCTCGGAC 1-10-1 MOE 1120 147736 36359 36370 AGGTAGGAGAAG 1-10-1 MOE 963 147691 36360 36371 GAGGTGGGAAAA 1-10-1 MOE 966 147736 36507 36518 AGGTAGGAGAAG 1-10-1 MOE 963 147691 36508 36519 GAGGTGGGAAAA 1-10-1 MOE 966 147746 36564 36575 TAAAAACAACAA 1-10-1 MOE 1073 147723 36575 36586 GACTCCAAAGTC 1-10-1 MOE 892 147731 36620 36631 TTTCCTCTTGTC 1-10-1 MOE 934 147723 36723 36734 GACTCCAAAGTC 1-10-1 MOE 892 147731 36768 36779 TTTCCTCTTGTC 1-10-1 MOE 934 398169 37174 37185 TCAGCCAGACAG 1-10-1 MOE 909 147688 37380 37391 TCCCAAACAAAT 1-10-1 MOE 990 147688 37528 37539 TCCCAAACAAAT 1-10-1 MOE 990 147714 37881 37892 TTCTGCTCCCAC 1-10-1 MOE 986 147714 38029 38040 TTCTGCTCCCAC 1-10-1 MOE 986 147681 38364 38375 ATGTCATTAAAC 1-10-1 MOE 965 147736 38766 38777 AGGTAGGAGAAG 1-10-1 MOE 963 147738 38909 38920 TGGGTGGCCGGG 1-10-1 MOE 1069 147736 38914 38925 AGGTAGGAGAAG 1-10-1 MOE 963 147738 39057 39068 TGGGTGGCCGGG 1-10-1 MOE 1069 390030 39249 39260 TTTATAAAACTG 1-10-1 MOE 1074 390030 39397 39408 TTTATAAAACTG 1-10-1 MOE 1074 147717 39545 39556 ATCTTCAGAGAT 1-10-1 MOE 996 147717 39693 39704 ATCTTCAGAGAT 1-10-1 MOE 996 147746 39729 39740 TAAAAACAACAA 1-10-1 MOE 1073 147746 39789 39800 TAAAAACAACAA 1-10-1 MOE 1073 147691 39829 39840 GAGGTGGGAAAA 1-10-1 MOE 966 147746 39877 39888 TAAAAACAACAA 1-10-1 MOE 1073 147691 39977 39988 GAGGTGGGAAAA 1-10-1 MOE 966 147727 39983 39994 CAGTGGACCACA 1-10-1 MOE 1128 147727 40131 40142 CAGTGGACCACA 1-10-1 MOE 1128 147746 40333 40344 TAAAAACAACAA 1-10-1 MOE 1073 147719 40457 40468 CCAACTCCAACT 1-10-1 MOE 1116 147679 40467 40478 CAAAAGGATCCC 1-10-1 MOE 907 147746 40478 40489 TAAAAACAACAA 1-10-1 MOE 1073 147741 40565 40576 CACCCACTGGTG 1-10-1 MOE 1055 398166 40589 40600 GGGCTTCTTCCA 1-10-1 MOE 1070 147719 40605 40616 CCAACTCCAACT 1-10-1 MOE 1116 147679 40615 40626 CAAAAGGATCCC 1-10-1 MOE 907 147746 40626 40637 TAAAAACAACAA 1-10-1 MOE 1073 147735 40662 40673 GGAGAAGCGCAG 1-10-1 MOE 1016 147746 40706 40717 TAAAAACAACAA 1-10-1 MOE 1073 147741 40713 40724 CACCCACTGGTG 1-10-1 MOE 1055 WO 2007/146511 PCT/US2007/068401 -184 398166 40737 40748 GGGCTTCTTCCA 1-10-1 MOE 1070 147735 40810 40821 GGAGAAGCGCAG 1-10-1 MOE 1016 147746 40854 40865 TAAAAACAACAA 1-10-1 MOE 1073 147718 41218 41229 TAATATGACTTG 1-10-1 MOE 998 147717 41221 41232 ATCTTCAGAGAT 1-10-1 MOE 996 147717 41369 41380 ATCTTCAGAGAT 1-10-1 MOE 996 147723 41627 41638 GACTCCAAAGTC 1-10-1 MOE 892 147717 41747 41758 ATCTTCAGAGAT 1-10-1 MOE 996 147723 41775 41786 GACTCCAAAGTC 1-10-1 MOE 892 390030 41908 41919 TTTATAAAACTG 1-10-1 MOE 1074 390030 42056 42067 TTTATAAAACTG 1-10-1 MOE 1074 398153 42157 42170 ATTTCTCTTACAGG 2-10-2 MOE 948 398153 42305 42318 ATTTCTCTTACAGG 2-10-2 MOE 948 147690 42423 42434 TGAAGTTAATTC 1-10-1 MOE 1138 147695 42521 42532 TCATTCCCCACT 1-10-1 MOE 984 147710 42543 42554 TATAGCTCCTCT 1-10-1 MOE 994 147690 42571 42582 TGAAGTTAATTC 1-10-1 MOE 1138 147695 42669 42680 TCATTCCCCACT 1-10-1 MOE 984 147078 43321 43332 CCTTCCACTGAT 1-10-1 MOE 1044 147079 43322 43333 TCCTTCCACTGA 1-10-1 MOE 1001 147716 43329 43340 TTAACGAGCCTT 1-10-1 MOE 949 147078 43469 43480 CCTTCCACTGAT 1-10-1 MOE 1044 147079 43470 43481 TCCTTCCACTGA 1-10-1 MOE 1001 147080 43471 43482 CTCCTTCCACTG 1-10-1 MOE 1021 398102 43837 43850 CTACCTGAGGATTT 2-10-2 MOE 899 147074 43848 43859 CCACTGATCCTG 1-10-1 MOE 845 401408 43871 43884 CAATGAAGCACAGG 2-10-2 MOE 989 398102 43985 43998 CTACCTGAGGATTT 2-10-2 MOE 899 147736 44137 44148 AGGTAGGAGAAG 1-10-1 MOE 963 147746 44140 44151 TAAAAACAACAA 1-10-1 MOE 1073 147687 44206 44217 CGACACGGGAAC 1-10-1 MOE 950 147743 44223 44234 AGGGCTTCCAGT 1-10-1 MOE 1042 384545 44242 44253 CAAGTAGGATGT 1-10-1 MOE 951 147736 44285 44296 AGGTAGGAGAAG 1-10-1 MOE 963 147743 44371 44382 AGGGCTTCCAGT 1-10-1 MOE 1042 384545 44390 44401 CAAGTAGGATGT 1-10-1 MOE 951 147728 44589 44600 GCCAGACAGAAG 1-10-1 MOE 1013 389948 44628 44639 CCGTTGGACCCC 1-10-1 MOE 915 147720 44703 44714 GATCTCTCGAGT 1-10-1 MOE 1117 147728 44729 44740 GCCAGACAGAAG 1-10-1 MOE 1013 147728 44737 44748 GCCAGACAGAAG 1-10-1 MOE 1013 389948 44776 44787 CCGTTGGACCCC 1-10-1 MOE 915 147720 44851 44862 GATCTCTCGAGT 1-10-1 MOE 1117 398110 44861 44874 GTTCCCTTTGCAGG 2-10-2 MOE 952 147728 44877 44888 GCCAGACAGAAG 1-10-1 MOE 1013 147705 45092 45103 CGGTTTTTGTTC 1-10-1 MOE 1002 147705 45240 45251 CGGTTTTTGTTC 1-10-1 MOE 1002 147681 45337 45348 ATGTCATTAAAC 1-10-1 MOE 965 147681 45485 45496 ATGTCATTAAAC 1-10-1 MOE 965 147096 45660 45671 TTGTTGTTCCCT 1-10-1 MOE 1107 147096 45808 45819 TTGTTGTTCCCT 1-10-1 MOE 1107 368368 45976 45989 TCCACTGATCCTTA 2-10-2 MOE 1127 147074 45977 45988 CCACTGATCCTG 1-10-1 MOE 845 147075 45978 45989 TCCACTGATCCT 1-10-1 MOE 1026 WO 2007/146511 PCT/US2007/068401 -185 147076 45979 45990 TTCCACTGATCC 1-10-1 MOE 1029 368368 46124 46137 TCCACTGATCCTTA 2-10-2 MOE 1127 147075 46126 46137 TCCACTGATCCT 1-10-1 MOE 1026 147076 46127 46138 TTCCACTGATCC 1-10-1 MOE 1029 147705 46555 46566 CGGTTTTTGTTC 1-10-1 MOE 1002 147714 46685 46696 TTCTGCTCCCAC 1-10-1 MOE 986 147705 46703 46714 CGGTTTTTGTTC 1-10-1 MOE 1002 147714 46833 46844 TTCTGCTCCCAC 1-10-1 MOE 986 390030 47007 47018 TTTATAAAACTG 1-10-1 MOE 1074 147746 47023 47034 TAAAAACAACAA 1-10-1 MOE 1073 147746 47171 47182 TAAAAACAACAA 1-10-1 MOE 1073 147085 47607 47618 TCTACACCAGGT 1-10-1 MOE 961 147746 47609 47620 TAAAAACAACAA 1-10-1 MOE 1073 147089 47611 47622 TCCCTCTACACC 1-10-1 MOE 956 147091 47613 47624 GTTCCCTCTACA 1-10-1 MOE 1004 401384 47689 47702 TGAACACATCACTA 2-10-2 MOE 933 147691 47729 47740 GAGGTGGGAAAA 1-10-1 MOE 966 147085 47755 47766 TCTACACCAGGT 1-10-1 MOE 961 147087 47757 47768 CCTCTACACCAG 1-10-1 MOE 982 147090 47760 47771 TTCCCTCTACAC 1-10-1 MOE 955 147091 47761 47772 GTTCCCTCTACA 1-10-1 MOE 1004 147099 47770 47781 GAGTTGTTGTTC 1-10-1 MOE 1108 147100 47771 47782 CGAGTTGTTGTT 1-10-1 MOE 1109 390030 47847 47858 TTTATAAAACTG 1-10-1 MOE 1074 147691 47877 47888 GAGGTGGGAAAA 1-10-1 MOE 966 147099 47918 47929 GAGTTGTTGTTC 1-10-1 MOE 1108 147100 47919 47930 CGAGTTGTTGTT 1-10-1 MOE 1109 390030 47995 48006 TTTATAAAACTG 1-10-1 MOE 1074 147074 48222 48233 CCACTGATCCTG 1-10-1 MOE 845 147731 48340 48351 TTTCCTCTTGTC 1-10-1 MOE 934 147691 48393 48404 GAGGTGGGAAAA 1-10-1 MOE 966 147731 48488 48499 TTTCCTCTTGTC 1-10-1 MOE 934 147691 48541 48552 GAGGTGGGAAAA 1-10-1 MOE 966 398147 48887 48900 CTACAGGACAATAC 2-10-2 MOE 957 398147 49035 49048 CTACAGGACAATAC 2-10-2 MOE 957 147074 49525 49536 CCACTGATCCTG 1-10-1 MOE 845 398168 49742 49753 TCGGACTTTGAA 1-10-1 MOE 1008 384545 49858 49869 CAAGTAGGATGT 1-10-1 MOE 951 398168 49890 49901 TCGGACTTTGAA 1-10-1 MOE 1008 147724 49974 49985 GAAATTGAGGAA 1-10-1 MOE 1139 384545 50006 50017 CAAGTAGGATGT 1-10-1 MOE 951 147689 50084 50095 CAGAGAAGGTCT 1-10-1 MOE 987 147687 50102 50113 CGACACGGGAAC 1-10-1 MOE 950 147724 50122 50133 GAAATTGAGGAA 1-10-1 MOE 1139 147687 50250 50261 CGACACGGGAAC 1-10-1 MOE 950 398117 50389 50402 TTTCCACTTGGGTG 2-10-2 MOE 960 147736 50436 50447 AGGTAGGAGAAG 1-10-1 MOE 963 147736 50582 50593 AGGTAGGAGAAG 1-10-1 MOE 963 398168 50703 50714 TCGGACTTTGAA 1-10-1 MOE 1008 401397 50822 50835 CTGGTCAGCATTGA 2-10-2 MOE 946 147746 51019 51030 TAAAAACAACAA 1-10-1 MOE 1073 147708 51101 51112 TTGATATAGTCA 1-10-1 MOE 997 147746 51165 51176 TAAAAACAACAA 1-10-1 MOE 1073 147746 51185 51196 TAAAAACAACAA 1-10-1 MOE 1073 WO 2007/146511 PCT/US2007/068401 -186 147708 51247 51258 TTGATATAGTCA 1-10-1 MOE 997 147081 51287 51298 GCTCCTTCCACT 1-10-1 MOE 1006 147082 51288 51299 AGCTCCTTCCAC 1-10-1 MOE 1036 147746 51324 51335 TAAAAACAACAA 1-10-1 MOE 1073 147746 51331 51342 TAAAAACAACAA 1-10-1 MOE 1073 147728 51376 51387 GCCAGACAGAAG 1-10-1 MOE 1013 147729 51406 51417 GTAAGAGGCAGG 1-10-1 MOE 920 147081 51433 51444 GCTCCTTCCACT 1-10-1 MOE 1006 147082 51434 51445 AGCTCCTTCCAC 1-10-1 MOE 1036 147728 51492 51503 GCCAGACAGAAG 1-10-1 MOE 1013 147728 51522 51533 GCCAGACAGAAG 1-10-1 MOE 1013 147729 51552 51563 GTAAGAGGCAGG 1-10-1 MOE 920 368360 51633 51646 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 51634 51645 AGCTCCTTCCAC 1-10-1 MOE 1036 368361 51635 51648 GAAAGCTCCTTCCA 2-10-2 MOE 962 147728 51638 51649 GCCAGACAGAAG 1-10-1 MOE 1013 147695 51644 51655 TCATTCCCCACT 1-10-1 MOE 984 147736 51713 51724 AGGTAGGAGAAG 1-10-1 MOE 963 147684 51721 51732 ACCCAGTCAGGG 1-10-1 MOE 964 147081 51779 51790 GCTCCTTCCACT 1-10-1 MOE 1006 368360 51779 51792 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 51780 51791 AGCTCCTTCCAC 1-10-1 MOE 1036 368361 51781 51794 GAAAGCTCCTTCCA 2-10-2 MOE 962 147695 51790 51801 TCATTCCCCACT 1-10-1 MOE 984 147736 51859 51870 AGGTAGGAGAAG 1-10-1 MOE 963 147077 51988 51999 CTTCCACTGATC 1-10-1 MOE 1047 147079 51990 52001 TCCTTCCACTGA 1-10-1 MOE 1001 147746 52064 52075 TAAAAACAACAA 1-10-1 MOE 1073 147681 52085 52096 ATGTCATTAAAC 1-10-1 MOE 965 147077 52134 52145 CTTCCACTGATC 1-10-1 MOE 1047 147079 52136 52147 TCCTTCCACTGA 1-10-1 MOE 1001 147691 52166 52177 GAGGTGGGAAAA 1-10-1 MOE 966 147719 52252 52263 CCAACTCCAACT 1-10-1 MOE 1116 147691 52312 52323 GAGGTGGGAAAA 1-10-1 MOE 966 147719 52398 52409 CCAACTCCAACT 1-10-1 MOE 1116 147728 52428 52439 GCCAGACAGAAG 1-10-1 MOE 1013 147729 52483 52494 GTAAGAGGCAGG 1-10-1 MOE 920 398167 52527 52538 CAGGCCATGTGG 1-10-1 MOE 1059 147682 52571 52582 CGGGTACTATGG 1-10-1 MOE 992 147728 52574 52585 GCCAGACAGAAG 1-10-1 MOE 1013 147724 52615 52626 GAAATTGAGGAA 1-10-1 MOE 1139 147729 52629 52640 GTAAGAGGCAGG 1-10-1 MOE 920 147703 52670 52681 TGGCTTCATGTC 1-10-1 MOE 971 398167 52673 52684 CAGGCCATGTGG 1-10-1 MOE 1059 398165 52708 52719 GTTCTTAGGAAG 1-10-1 MOE 968 147704 52710 52721 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 52716 52727 CGGTTTTTGTTC 1-10-1 MOE 1002 147724 52761 52772 GAAATTGAGGAA 1-10-1 MOE 1139 398167 52762 52773 CAGGCCATGTGG 1-10-1 MOE 1059 147703 52816 52827 TGGCTTCATGTC 1-10-1 MOE 971 398165 52854 52865 GTTCTTAGGAAG 1-10-1 MOE 968 147704 52856 52867 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 52862 52873 CGGTTTTTGTTC 1-10-1 MOE 1002 398167 52908 52919 CAGGCCATGTGG 1-10-1 MOE 1059 WO 2007/146511 PCT/US2007/068401 -187 147689 53063 53074 CAGAGAAGGTCT 1-10-1 MOE 987 147727 53111 53122 CAGTGGACCACA 1-10-1 MOE 1128 147727 53158 53169 CAGTGGACCACA 1-10-1 MOE 1128 147689 53209 53220 CAGAGAAGGTCT 1-10-1 MOE 987 147727 53257 53268 CAGTGGACCACA 1-10-1 MOE 1128 147727 53304 53315 CAGTGGACCACA 1-10-1 MOE 1128 147680 53638 53649 GTATGCACTGCT 1-10-1 MOE 988 147722 53650 53661 AAAGTCAGGCCA 1-10-1 MOE 1130 147083 53703 53714 TACACCAGGTCA 1-10-1 MOE 973 147085 53705 53716 TCTACACCAGGT 1-10-1 MOE 961 147086 53706 53717 CTCTACACCAGG 1-10-1 MOE 969 398167 53724 53735 CAGGCCATGTGG 1-10-1 MOE 1059 147684 53747 53758 ACCCAGTCAGGG 1-10-1 MOE 964 147680 53784 53795 GTATGCACTGCT 1-10-1 MOE 988 147722 53796 53807 AAAGTCAGGCCA 1-10-1 MOE 1130 147085 53851 53862 TCTACACCAGGT 1-10-1 MOE 961 398167 53870 53881 CAGGCCATGTGG 1-10-1 MOE 1059 147684 53893 53904 ACCCAGTCAGGG 1-10-1 MOE 964 398155 54026 54039 TGTTTTTACACAGA 2-10-2 MOE 970 147703 54137 54148 TGGCTTCATGTC 1-10-1 MOE 971 398155 54172 54185 TGTTTTTACACAGA 2-10-2 MOE 970 147705 54275 54286 CGGTTTTTGTTC 1-10-1 MOE 1002 147703 54283 54294 TGGCTTCATGTC 1-10-1 MOE 971 147705 54421 54432 CGGTTTTTGTTC 1-10-1 MOE 1002 147727 54853 54864 CAGTGGACCACA 1-10-1 MOE 1128 398165 54963 54974 GTTCTTAGGAAG 1-10-1 MOE 968 398090 54963 54976 TTGTTCTTAGGAAG 2-10-2 MOE 972 147704 54965 54976 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 54971 54982 CGGTTTTTGTTC 1-10-1 MOE 1002 147727 54999 55010 CAGTGGACCACA 1-10-1 MOE 1128 398165 55109 55120 GTTCTTAGGAAG 1-10-1 MOE 968 147704 55111 55122 TTGTTCTTAGGA 1-10-1 MOE 1012 147705 55117 55128 CGGTTTTTGTTC 1-10-1 MOE 1002 147083 55352 55363 TACACCAGGTCA 1-10-1 MOE 973 147705 55378 55389 CGGTTTTTGTTC 1-10-1 MOE 1002 147705 55524 55535 CGGTTTTTGTTC 1-10-1 MOE 1002 147712 55819 55830 ACACCATCTCCC 1-10-1 MOE 1005 147712 55965 55976 ACACCATCTCCC 1-10-1 MOE 1005 147733 56289 56300 TTCTTGATGTCC 1-10-1 MOE 891 147707 56300 56311 TAGTCATTATCT 1-10-1 MOE 977 147708 56306 56317 TTGATATAGTCA 1-10-1 MOE 997 390030 56321 56332 TTTATAAAACTG 1-10-1 MOE 1074 147081 56333 56344 GCTCCTTCCACT 1-10-1 MOE 1006 398166 56335 56346 GGGCTTCTTCCA 1-10-1 MOE 1070 147733 56435 56446 TTCTTGATGTCC 1-10-1 MOE 891 147707 56446 56457 TAGTCATTATCT 1-10-1 MOE 977 147708 56452 56463 TTGATATAGTCA 1-10-1 MOE 997 390030 56467 56478 TTTATAAAACTG 1-10-1 MOE 1074 147081 56479 56490 GCTCCTTCCACT 1-10-1 MOE 1006 398091 56479 56492 GGGCTTCTTCCATT 2-10-2 MOE 979 398166 56481 56492 GGGCTTCTTCCA 1-10-1 MOE 1070 368366 56518 56531 CTGATCCTTAGAAG 2-10-2 MOE 1019 147743 57612 57623 AGGGCTTCCAGT 1-10-1 MOE 1042 147700 57709 57720 GCGCTAGGCCGC 1-10-1 MOE 1 1110 WO 2007/146511 PCT/US2007/068401 -188 147743 57758 57769 AGGGCTTCCAGT 1-10-1 MOE 1042 147700 57855 57866 GCGCTAGGCCGC 1-10-1 MOE 1110 398093 57963 57976 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 57965 57976 TCGGACTTTGAA 1-10-1 MOE 1008 147698 58105 58116 CCCGCCACCACC 1-10-1 MOE 928 398093 58109 58122 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 58111 58122 TCGGACTTTGAA 1-10-1 MOE 1008 147698 58251 58262 CCCGCCACCACC 1-10-1 MOE 928 147735 58279 58290 GGAGAAGCGCAG 1-10-1 MOE 1016 147735 58425 58436 GGAGAAGCGCAG 1-10-1 MOE 1016 404135 58946 58959 CATTTCCATGGCCA 2-10-2 MOE 1056 390030 59326 59337 TTTATAAAACTG 1-10-1 MOE 1074 147711 59357 59368 AAGGGCCCTGGG 1-10-1 MOE 1040 147743 59382 59393 AGGGCTTCCAGT 1-10-1 MOE 1042 147711 59503 59514 AAGGGCCCTGGG 1-10-1 MOE 1040 147743 59528 59539 AGGGCTTCCAGT 1-10-1 MOE 1042 147695 59576 59587 TCATTCCCCACT 1-10-1 MOE 984 147713 59716 59727 CTCCCACACCAT 1-10-1 MOE 985 147714 59721 59732 TTCTGCTCCCAC 1-10-1 MOE 986 147715 59746 59757 GTTGAGCATGAC 1-10-1 MOE 1077 147716 59771 59782 TTAACGAGCCTT 1-10-1 MOE 949 147712 59857 59868 ACACCATCTCCC 1-10-1 MOE 1005 147714 59867 59878 TTCTGCTCCCAC 1-10-1 MOE 986 147715 59892 59903 GTTGAGCATGAC 1-10-1 MOE 1077 147716 59917 59928 TTAACGAGCCTT 1-10-1 MOE 949 390030 59993 60004 TTTATAAAACTG 1-10-1 MOE 1074 147690 60270 60281 TGAAGTTAATTC 1-10-1 MOE 1138 389949 60325 60336 GCGCGAGCCCGA 1-10-1 MOE 1061 147690 60416 60427 TGAAGTTAATTC 1-10-1 MOE 1138 389949 60471 60482 GCGCGAGCCCGA 1-10-1 MOE 1061 147746 60619 60630 TAAAAACAACAA 1-10-1 MOE 1073 384545 60676 60687 CAAGTAGGATGT 1-10-1 MOE 951 147746 60765 60776 TAAAAACAACAA 1-10-1 MOE 1073 384545 60822 60833 CAAGTAGGATGT 1-10-1 MOE 951 147689 60967 60978 CAGAGAAGGTCT 1-10-1 MOE 987 147689 61008 61019 CAGAGAAGGTCT 1-10-1 MOE 987 147689 61049 61060 CAGAGAAGGTCT 1-10-1 MOE 987 398105 61121 61134 TGCACAGGCAGGTT 2-10-2 MOE 1066 147689 61154 61165 CAGAGAAGGTCT 1-10-1 MOE 987 147689 61195 61206 CAGAGAAGGTCT 1-10-1 MOE 987 398105 61267 61280 TGCACAGGCAGGTT 2-10-2 MOE 1066 147692 61365 61376 CTCACCTTCATG 1-10-1 MOE 1113 147692 61511 61522 CTCACCTTCATG 1-10-1 MOE 1113 147680 61619 61630 GTATGCACTGCT 1-10-1 MOE 988 147078 61755 61766 CCTTCCACTGAT 1-10-1 MOE 1044 147079 61756 61767 TCCTTCCACTGA 1-10-1 MOE 1001 147080 61757 61768 CTCCTTCCACTG 1-10-1 MOE 1021 147078 61901 61912 CCTTCCACTGAT 1-10-1 MOE 1044 147079 61902 61913 TCCTTCCACTGA 1-10-1 MOE 1001 147080 61903 61914 CTCCTTCCACTG 1-10-1 MOE 1021 147088 62361 62372 CCCTCTACACCA 1-10-1 MOE 1050 401384 62573 62586 TGAACACATCACTA 2-10-2 MOE 933 147688 62697 62708 TCCCAAACAAAT 1-10-1 MOE 990 147746 63102 63113 TAAAAACAACAA 1-10-1 MOE 1073 WO 2007/146511 PCT/US2007/068401 -189 147721 63225 63236 AATGCAGGATCT 1-10-1 MOE 1118 147742 63226 63237 AACTTCAGTGTC 1-10-1 MOE 1041 147746 63248 63259 TAAAAACAACAA 1-10-1 MOE 1073 147682 63337 63348 CGGGTACTATGG 1-10-1 MOE 992 147721 63371 63382 AATGCAGGATCT 1-10-1 MOE 1118 147742 63372 63383 AACTTCAGTGTC 1-10-1 MOE 1041 147688 63401 63412 TCCCAAACAAAT 1-10-1 MOE 990 147097 63449 63460 GTTGTTGTTCCC 1-10-1 MOE 1111 147098 63450 63461 AGTTGTTGTTCC 1-10-1 MOE 1112 401409 63458 63471 ATTCTTAACACAGA 2-10-2 MOE 991 147084 63531 63542 CTACACCAGGTC 1-10-1 MOE 993 147688 63547 63558 TCCCAAACAAAT 1-10-1 MOE 990 147097 63595 63606 GTTGTTGTTCCC 1-10-1 MOE 1111 147098 63596 63607 AGTTGTTGTTCC 1-10-1 MOE 1112 147721 64086 64097 AATGCAGGATCT 1-10-1 MOE 1118 147721 64232 64243 AATGCAGGATCT 1-10-1 MOE 1118 147692 64233 64244 CTCACCTTCATG 1-10-1 MOE 1113 147692 64379 64390 CTCACCTTCATG 1-10-1 MOE 1113 147729 64633 64644 GTAAGAGGCAGG 1-10-1 MOE 920 401403 64746 64759 TTTCCTAGGAGGTG 2-10-2 MOE 967 147729 64779 64790 GTAAGAGGCAGG 1-10-1 MOE 920 147746 65151 65162 TAAAAACAACAA 1-10-1 MOE 1073 147746 65297 65308 TAAAAACAACAA 1-10-1 MOE 1073 147689 65302 65313 CAGAGAAGGTCT 1-10-1 MOE 987 147689 65448 65459 CAGAGAAGGTCT 1-10-1 MOE 987 147717 65862 65873 ATCTTCAGAGAT 1-10-1 MOE 996 147717 65895 65906 ATCTTCAGAGAT 1-10-1 MOE 996 147729 66000 66011 GTAAGAGGCAGG 1-10-1 MOE 920 147717 66008 66019 ATCTTCAGAGAT 1-10-1 MOE 996 147717 66041 66052 ATCTTCAGAGAT 1-10-1 MOE 996 147708 66046 66057 TTGATATAGTCA 1-10-1 MOE 997 147718 66055 66066 TAATATGACTTG 1-10-1 MOE 998 147729 66146 66157 GTAAGAGGCAGG 1-10-1 MOE 920 147089 66236 66247 TCCCTCTACACC 1-10-1 MOE 956 368363 66281 66294 CTTAGAAGGCAGCA 2-10-2 MOE 1114 147727 66293 66304 CAGTGGACCACA 1-10-1 MOE 1128 147093 66319 66330 TTGTTCCCTCTA 1-10-1 MOE 929 147094 66320 66331 GTTGTTCCCTCT 1-10-1 MOE 1115 147089 66382 66393 TCCCTCTACACC 1-10-1 MOE 956 368363 66427 66440 CTTAGAAGGCAGCA 2-10-2 MOE 1114 147727 66439 66450 CAGTGGACCACA 1-10-1 MOE 1128 147719 66441 66452 CCAACTCCAACT 1-10-1 MOE 1116 147093 66465 66476 TTGTTCCCTCTA 1-10-1 MOE 929 147094 66466 66477 GTTGTTCCCTCT 1-10-1 MOE 1115 147075 66561 66572 TCCACTGATCCT 1-10-1 MOE 1026 368357 66562 66575 CCTTCCACTGATCC 2-10-2 MOE 1046 147076 66562 66573 TTCCACTGATCC 1-10-1 MOE 1029 368377 66562 66577 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 66563 66574 CTTCCACTGATC 1-10-1 MOE 1047 368358 66563 66576 TCCTTCCACTGATC 2-10-2 MOE 1031 147078 66564 66575 CCTTCCACTGAT 1-10-1 MOE 1044 147079 66565 66576 TCCTTCCACTGA 1-10-1 MOE 1001 147080 66566 66577 CTCCTTCCACTG 1-10-1 MOE 1021 147081 66567 66578 GCTCCTTCCACT 1-10-1 MOE 1006 WO 2007/146511 PCT/US2007/068401 -190 147719 66587 66598 CCAACTCCAACT 1-10-1 MOE 1116 147075 66707 66718 TCCACTGATCCT 1-10-1 MOE 1026 368377 66708 66723 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147076 66708 66719 TTCCACTGATCC 1-10-1 MOE 1029 368357 66708 66721 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 66709 66720 CTTCCACTGATC 1-10-1 MOE 1047 147078 66710 66721 CCTTCCACTGAT 1-10-1 MOE 1044 147079 66711 66722 TCCTTCCACTGA 1-10-1 MOE 1001 147080 66712 66723 CTCCTTCCACTG 1-10-1 MOE 1021 147081 66713 66724 GCTCCTTCCACT 1-10-1 MOE 1006 147089 66842 66853 TCCCTCTACACC 1-10-1 MOE 956 147089 66988 66999 TCCCTCTACACC 1-10-1 MOE 956 147075 66999 67010 TCCACTGATCCT 1-10-1 MOE 1026 147075 67145 67156 TCCACTGATCCT 1-10-1 MOE 1026 147705 67213 67224 CGGTTTTTGTTC 1-10-1 MOE 1002 401413 67301 67314 TGCAGCCATGTACT 2-10-2 MOE 1022 147737 67309 67320 ACAGCCAGGTAG 1-10-1 MOE 1067 147080 67430 67441 CTCCTTCCACTG 1-10-1 MOE 1021 147737 67455 67466 ACAGCCAGGTAG 1-10-1 MOE 1067 147080 67576 67587 CTCCTTCCACTG 1-10-1 MOE 1021 147082 67578 67589 AGCTCCTTCCAC 1-10-1 MOE 1036 147090 67582 67593 TTCCCTCTACAC 1-10-1 MOE 955 147091 67583 67594 GTTCCCTCTACA 1-10-1 MOE 1004 147742 67591 67602 AACTTCAGTGTC 1-10-1 MOE 1041 147090 67728 67739 TTCCCTCTACAC 1-10-1 MOE 955 147698 68036 68047 CCCGCCACCACC 1-10-1 MOE 928 147698 68182 68193 CCCGCCACCACC 1-10-1 MOE 928 147681 68267 68278 ATGTCATTAAAC 1-10-1 MOE 965 147721 68386 68397 AATGCAGGATCT 1-10-1 MOE 1118 147681 68413 68424 ATGTCATTAAAC 1-10-1 MOE 965 147712 68527 68538 ACACCATCTCCC 1-10-1 MOE 1005 147721 68532 68543 AATGCAGGATCT 1-10-1 MOE 1118 147711 68760 68771 AAGGGCCCTGGG 1-10-1 MOE 1040 147711 68906 68917 AAGGGCCCTGGG 1-10-1 MOE 1040 147696 69045 69056 TGGATGATTGGC 1-10-1 MOE 906 147696 69191 69202 TGGATGATTGGC 1-10-1 MOE 906 147723 69194 69205 GACTCCAAAGTC 1-10-1 MOE 892 147723 69210 69221 GACTCCAAAGTC 1-10-1 MOE 892 389965 69271 69282 CTGCAACATGAT 1-10-1 MOE 1018 389764 69271 69282 CTGCAACATGAT 1-9-2 MOE 1018 147723 69340 69351 GACTCCAAAGTC 1-10-1 MOE 892 147723 69356 69367 GACTCCAAAGTC 1-10-1 MOE 892 398101 69357 69370 TTTGATAAAGCCCT 2-10-2 MOE 1064 389965 69417 69428 CTGCAACATGAT 1-10-1 MOE 1018 389764 69417 69428 CTGCAACATGAT 1-9-2 MOE 1018 398101 69503 69516 TTTGATAAAGCCCT 2-10-2 MOE 1064 368353 69519 69532 CACTGATCCTGCAC 2-10-2 MOE 1007 147074 69522 69533 CCACTGATCCTG 1-10-1 MOE 845 147081 69631 69642 GCTCCTTCCACT 1-10-1 MOE 1006 368353 69665 69678 CACTGATCCTGCAC 2-10-2 MOE 1007 147720 69729 69740 GATCTCTCGAGT 1-10-1 MOE 1117 147721 69736 69747 AATGCAGGATCT 1-10-1 MOE 1118 398167 69757 69768 CAGGCCATGTGG 1-10-1 MOE 1059 147722 69762 69773 AAAGTCAGGCCA 1-10-1 MOE 1130 WO 2007/146511 PCT/US2007/068401 -191 147723 69768 69779 GACTCCAAAGTC 1-10-1 MOE 892 147080 69776 69787 CTCCTTCCACTG 1-10-1 MOE 1021 147081 69777 69788 GCTCCTTCCACT 1-10-1 MOE 1006 398093 69811 69824 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 69813 69824 TCGGACTTTGAA 1-10-1 MOE 1008 147725 69814 69825 CTCGGACTTTGA 1-10-1 MOE 1119 147726 69819 69830 TGACTCTCGGAC 1-10-1 MOE 1120 147727 69860 69871 CAGTGGACCACA 1-10-1 MOE 1128 147720 69875 69886 GATCTCTCGAGT 1-10-1 MOE 1117 147721 69882 69893 AATGCAGGATCT 1-10-1 MOE 1118 147728 69899 69910 GCCAGACAGAAG 1-10-1 MOE 1013 398094 69901 69914 ATCAGCCAGACAGA 2-10-2 MOE 1010 398167 69903 69914 CAGGCCATGTGG 1-10-1 MOE 1059 398092 69904 69917 AGTCAGGCCATGTG 2-10-2 MOE 1060 147722 69908 69919 AAAGTCAGGCCA 1-10-1 MOE 1130 147723 69914 69925 GACTCCAAAGTC 1-10-1 MOE 892 147729 69916 69927 GTAAGAGGCAGG 1-10-1 MOE 920 398095 69919 69932 CATCAGCAAGAGGC 2-10-2 MOE 1011 398093 69957 69970 TCGGACTTTGAAAA 2-10-2 MOE 1009 398168 69959 69970 TCGGACTTTGAA 1-10-1 MOE 1008 147725 69960 69971 CTCGGACTTTGA 1-10-1 MOE 1119 147726 69965 69976 TGACTCTCGGAC 1-10-1 MOE 1120 147704 69991 70002 TTGTTCTTAGGA 1-10-1 MOE 1012 147727 70006 70017 CAGTGGACCACA 1-10-1 MOE 1128 147728 70045 70056 GCCAGACAGAAG 1-10-1 MOE 1013 398094 70047 70060 ATCAGCCAGACAGA 2-10-2 MOE 1010 398169 70048 70059 TCAGCCAGACAG 1-10-1 MOE 909 147729 70062 70073 GTAAGAGGCAGG 1-10-1 MOE 920 398095 70065 70078 CATCAGCAAGAGGC 2-10-2 MOE 1011 147704 70137 70148 TTGTTCTTAGGA 1-10-1 MOE 1012 147697 70161 70172 CCCCAGCAGCGG 1-10-1 MOE 1000 147697 70307 70318 CCCCAGCAGCGG 1-10-1 MOE 1000 147728 70450 70461 GCCAGACAGAAG 1-10-1 MOE 1013 398164 70464 70475 TTGTCGATCTGC 1-10-1 MOE 1014 147730 70465 70476 CTTGTCCATCAG 1-10-1 MOE 1121 147731 70471 70482 TTTCCTCTTGTC 1-10-1 MOE 934 147732 70476 70487 GGGTCTTTCCTC 1-10-1 MOE 1122 147733 70497 70508 TTCTTGATGTCC 1-10-1 MOE 891 398096 70562 70575 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 70564 70575 GGAGAAGCGCAG 1-10-1 MOE 1016 147736 70569 70580 AGGTAGGAGAAG 1-10-1 MOE 963 147737 70575 70586 ACAGCCAGGTAG 1-10-1 MOE 1067 147728 70596 70607 GCCAGACAGAAG 1-10-1 MOE 1013 398164 70610 70621 TTGTCGATCTGC 1-10-1 MOE 1014 147730 70611 70622 CTTGTCCATCAG 1-10-1 MOE 1121 368349 70616 70629 CTGCACTGACGAGT 2-10-2 MOE 1017 147731 70617 70628 TTTCCTCTTGTC 1-10-1 MOE 934 147732 70622 70633 GGGTCTTTCCTC 1-10-1 MOE 1122 147733 70643 70654 TTCTTGATGTCC 1-10-1 MOE 891 398096 70708 70721 GGAGAAGCGCAGCT 2-10-2 MOE 1015 147735 70710 70721 GGAGAAGCGCAG 1-10-1 MOE 1016 147736 70715 70726 AGGTAGGAGAAG 1-10-1 MOE 963 147737 70721 70732 ACAGCCAGGTAG 1-10-1 MOE 1067 389764 70784 70795 CTGCAACATGAT 1-9-2 MOE 1018 WO 2007/146511 PCT/US2007/068401 -192 389965 70784 70795 CTGCAACATGAT 1-10-1 MOE 1018 389965 70930 70941 CTGCAACATGAT 1-10-1 MOE 1018 389764 70930 70941 CTGCAACATGAT 1-9-2 MOE 1018 368386 70995 71010 CACTGATCCTTAGAAG 3-10-3 MOE 1123 368367 70997 71010 CACTGATCCTTAGA 2-10-2 MOE 1124 368387 70997 71012 TCCACTGATCCTTAGA 3-10-3 MOE 1125 368354 70999 71012 TCCACTGATCCTGC 2-10-2 MOE 1024 368374 70999 71014 CTTCCACTGATCCTGC 3-10-3 MOE 1126 368368 70999 71012 TCCACTGATCCTTA 2-10-2 MOE 1127 368388 70999 71014 CTTCCACTGATCCTTA 3-10-3 MOE 895 368355 71000 71013 TTCCACTGATCCTG 2-10-2 MOE 1025 147074 71000 71011 CCACTGATCCTG 1-10-1 MOE 845 368375 71000 71015 CCTTCCACTGATCCTG 3-10-3 MOE 1020 147075 71001 71012 TCCACTGATCCT 1-10-1 MOE 1026 368376 71001 71016 TCCTTCCACTGATCCT 3-10-3 MOE 1028 147076 71002 71013 TTCCACTGATCC 1-10-1 MOE 1029 368357 71002 71015 CCTTCCACTGATCC 2-10-2 MOE 1046 368377 71002 71017 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 71003 71014 CTTCCACTGATC 1-10-1 MOE 1047 368378 71003 71018 GCTCCTTCCACTGATC 3-10-3 MOE 1032 147078 71004 71015 CCTTCCACTGAT 1-10-1 MOE 1044 368359 71005 71018 GCTCCTTCCACTGA 2-10-2 MOE 1033 368379 71005 71020 AAGCTCCTTCCACTGA 3-10-3 MOE 1034 147079 71005 71016 TCCTTCCACTGA 1-10-1 MOE 1001 147080 71006 71017 CTCCTTCCACTG 1-10-1 MOE 1021 368360 71007 71020 AAGCTCCTTCCACT 2-10-2 MOE 1035 368380 71007 71022 GAAAGCTCCTTCCACT 3-10-3 MOE 896 147081 71007 71018 GCTCCTTCCACT 1-10-1 MOE 1006 147082 71008 71019 AGCTCCTTCCAC 1-10-1 MOE 1036 368361 71009 71022 GAAAGCTCCTTCCA 2-10-2 MOE 962 368381 71009 71024 GGGAAAGCTCCTTCCA 3-10-3 MOE 1037 147738 71067 71078 TGGGTGGCCGGG 1-10-1 MOE 1069 147739 71071 71082 CGTTTGGGTGGC 1-10-1 MOE 1023 147740 71088 71099 TGTGAGGCTCCA 1-10-1 MOE 1062 147741 71129 71140 CACCCACTGGTG 1-10-1 MOE 1055 368366 71141 71154 CTGATCCTTAGAAG 2-10-2 MOE 1019 368386 71141 71156 CACTGATCCTTAGAAG 3-10-3 MOE 1123 368367 71143 71156 CACTGATCCTTAGA 2-10-2 MOE 1124 368387 71143 71158 TCCACTGATCCTTAGA 3-10-3 MOE 1125 368374 71145 71160 CTTCCACTGATCCTGC 3-10-3 MOE 1126 368354 71145 71158 TCCACTGATCCTGC 2-10-2 MOE 1024 368368 71145 71158 TCCACTGATCCTTA 2-10-2 MOE 1127 368388 71145 71160 CTTCCACTGATCCTTA 3-10-3 MOE 895 368355 71146 71159 TTCCACTGATCCTG 2-10-2 MOE 1025 368375 71146 71161 CCTTCCACTGATCCTG 3-10-3 MOE 1020 147075 71147 71158 TCCACTGATCCT 1-10-1 MOE 1026 368356 71147 71160 CTTCCACTGATCCT 2-10-2 MOE 1027 368376 71147 71162 TCCTTCCACTGATCCT 3-10-3 MOE 1028 147076 71148 71159 TTCCACTGATCC 1-10-1 MOE 1029 368357 71148 71161 CCTTCCACTGATCC 2-10-2 MOE 1046 368377 71148 71163 CTCCTTCCACTGATCC 3-10-3 MOE 1030 147077 71149 71160 CTTCCACTGATC 1-10-1 MOE 1047 368358 71149 71162 TCCTTCCACTGATC 2-10-2 MOE 1031 368378 71149 71164 GCTCCTTCCACTGATC 3-10-3 MOE 1032 WO 2007/146511 PCT/US2007/068401 -193 147078 71150 71161 CCTTCCACTGAT 1-10-1 MOE 1044 368359 71151 71164 GCTCCTTCCACTGA 2-10-2 MOE 1033 147079 71151 71162 TCCTTCCACTGA 1-10-1 MOE 1001 368379 71151 71166 AAGCTCCTTCCACTGA 3-10-3 MOE 1034 147080 71152 71163 CTCCTTCCACTG 1-10-1 MOE 1021 368380 71153 71168 GAAAGCTCCTTCCACT 3-10-3 MOE 896 147081 71153 71164 GCTCCTTCCACT 1-10-1 MOE 1006 368360 71153 71166 AAGCTCCTTCCACT 2-10-2 MOE 1035 147082 71154 71165 AGCTCCTTCCAC 1-10-1 MOE 1036 368381 71155 71170 GGGAAAGCTCCTTCCA 3-10-3 MOE 1037 368361 71155 71168 GAAAGCTCCTTCCA 2-10-2 MOE 962 398097 71158 71171 GGCAGTCTTTATCC 2-10-2 MOE 897 147738 71213 71224 TGGGTGGCCGGG 1-10-1 MOE 1069 147739 71217 71228 CGTTTGGGTGGC 1-10-1 MOE 1023 147740 71234 71245 TGTGAGGCTCCA 1-10-1 MOE 1062 147741 71275 71286 CACCCACTGGTG 1-10-1 MOE 1055 398097 71304 71317 GGCAGTCTTTATCC 2-10-2 MOE 897 147727 71702 71713 CAGTGGACCACA 1-10-1 MOE 1128 147727 71848 71859 CAGTGGACCACA 1-10-1 MOE 1128 390030 71986 71997 TTTATAAAACTG 1-10-1 MOE 1074 147102 72015 72026 TGCGAGTTGTTG 1-10-1 MOE 1129 390030 72132 72143 TTTATAAAACTG 1-10-1 MOE 1074 147102 72161 72172 TGCGAGTTGTTG 1-10-1 MOE 1129 147722 72199 72210 AAAGTCAGGCCA 1-10-1 MOE 1130 147696 72232 72243 TGGATGATTGGC 1-10-1 MOE 906 147741 72254 72265 CACCCACTGGTG 1-10-1 MOE 1055 147722 72345 72356 AAAGTCAGGCCA 1-10-1 MOE 1130 147696 72378 72389 TGGATGATTGGC 1-10-1 MOE 906 147741 72400 72411 CACCCACTGGTG 1-10-1 MOE 1055 147711 72446 72457 AAGGGCCCTGGG 1-10-1 MOE 1040 398098 72574 72587 TAACTTCAGTGTCT 2-10-2 MOE 1131 147742 72575 72586 AACTTCAGTGTC 1-10-1 MOE 1041 147698 72595 72606 CCCGCCACCACC 1-10-1 MOE 928 147743 72690 72701 AGGGCTTCCAGT 1-10-1 MOE 1042 398099 72690 72703 GAAGGGCTTCCAGT 2-10-2 MOE 1132 147744 72694 72705 AGGAAGGGCTTC 1-10-1 MOE 1043 398100 72697 72710 TGACCAGGAAGGGC 2-10-2 MOE 1133 147745 72700 72711 TTGACCAGGAAG 1-10-1 MOE 1058 398098 72720 72733 TAACTTCAGTGTCT 2-10-2 MOE 1131 147742 72721 72732 AACTTCAGTGTC 1-10-1 MOE 1041 147698 72741 72752 CCCGCCACCACC 1-10-1 MOE 928 398157 72757 72770 GGAAACATACCCTG 2-10-2 MOE 1045 147743 72836 72847 AGGGCTTCCAGT 1-10-1 MOE 1042 398099 72836 72849 GAAGGGCTTCCAGT 2-10-2 MOE 1132 147744 72840 72851 AGGAAGGGCTTC 1-10-1 MOE 1043 398100 72843 72856 TGACCAGGAAGGGC 2-10-2 MOE 1133 147745 72846 72857 TTGACCAGGAAG 1-10-1 MOE 1058 147076 72898 72909 TTCCACTGATCC 1-10-1 MOE 1029 368357 72898 72911 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 72899 72910 CTTCCACTGATC 1-10-1 MOE 1047 147078 72900 72911 CCTTCCACTGAT 1-10-1 MOE 1044 398157 72903 72916 GGAAACATACCCTG 2-10-2 MOE 1045 398158 72983 72996 AGGCCCTGAGATTA 2-10-2 MOE 1134 398159 72988 73001 GGTTAAGGCCCTGA 2-10-2 MOE 1135 WO 2007/146511 PCT/US2007/068401 -194 398160 72993 73006 GAATAGGTTAAGGC 2-10-2 MOE 1048 147076 73044 73055 TTCCACTGATCC 1-10-1 MOE 1029 368357 73044 73057 CCTTCCACTGATCC 2-10-2 MOE 1046 147077 73045 73056 CTTCCACTGATC 1-10-1 MOE 1047 147078 73046 73057 CCTTCCACTGAT 1-10-1 MOE 1044 147746 73052 73063 TAAAAACAACAA 1-10-1 MOE 1073 398161 73092 73105 AACAATGTGTTGTA 2-10-2 MOE 1049 147746 73101 73112 TAAAAACAACAA 1-10-1 MOE 1073 398158 73129 73142 AGGCCCTGAGATTA 2-10-2 MOE 1134 398159 73134 73147 GGTTAAGGCCCTGA 2-10-2 MOE 1135 398160 73139 73152 GAATAGGTTAAGGC 2-10-2 MOE 1048 147746 73198 73209 TAAAAACAACAA 1-10-1 MOE 1073 398161 73238 73251 AACAATGTGTTGTA 2-10-2 MOE 1049 147746 73247 73258 TAAAAACAACAA 1-10-1 MOE 1073 147088 73273 73284 CCCTCTACACCA 1-10-1 MOE 1050 398105 73401 73414 TGCACAGGCAGGTT 2-10-2 MOE 1066 398105 73547 73560 TGCACAGGCAGGTT 2-10-2 MOE 1066 147741 73559 73570 CACCCACTGGTG 1-10-1 MOE 1055 147741 73705 73716 CACCCACTGGTG 1-10-1 MOE 1055 398162 73968 73981 ACCAAACAGTTCAG 2-10-2 MOE 1057 147745 73991 74002 TTGACCAGGAAG 1-10-1 MOE 1058 398167 74008 74019 CAGGCCATGTGG 1-10-1 MOE 1059 398092 74009 74022 AGTCAGGCCATGTG 2-10-2 MOE 1060 398162 74114 74127 ACCAAACAGTTCAG 2-10-2 MOE 1057 147745 74137 74148 TTGACCAGGAAG 1-10-1 MOE 1058 398167 74154 74165 CAGGCCATGTGG 1-10-1 MOE 1059 147089 74280 74291 TCCCTCTACACC 1-10-1 MOE 956 147090 74281 74292 TTCCCTCTACAC 1-10-1 MOE 955 389949 74310 74321 GCGCGAGCCCGA 1-10-1 MOE 1061 147740 74339 74350 TGTGAGGCTCCA 1-10-1 MOE 1062 389950 74381 74392 CCCTGAAGGTTC 1-10-1 MOE 1063 147089 74426 74437 TCCCTCTACACC 1-10-1 MOE 956 147090 74427 74438 TTCCCTCTACAC 1-10-1 MOE 955 389949 74456 74467 GCGCGAGCCCGA 1-10-1 MOE 1061 147685 74490 74501 GGCTGACATTCA 1-10-1 MOE 975 398101 74510 74523 TTTGATAAAGCCCT 2-10-2 MOE 1064 398102 74536 74549 CTACCTGAGGATTT 2-10-2 MOE 899 398103 74543 74556 CCCAGTACTACCTG 2-10-2 MOE 900 147685 74636 74647 GGCTGACATTCA 1-10-1 MOE 975 398102 74682 74695 CTACCTGAGGATTT 2-10-2 MOE 899 398103 74689 74702 CCCAGTACTACCTG 2-10-2 MOE 900 147736 74737 74748 AGGTAGGAGAAG 1-10-1 MOE 963 398104 74805 74818 CAAGAAGACCTTAC 2-10-2 MOE 1065 147736 74883 74894 AGGTAGGAGAAG 1-10-1 MOE 963 147737 74893 74904 ACAGCCAGGTAG 1-10-1 MOE 1067 398105 74894 74907 TGCACAGGCAGGTT 2-10-2 MOE 1066 147737 74919 74930 ACAGCCAGGTAG 1-10-1 MOE 1067 398095 74940 74953 CATCAGCAAGAGGC 2-10-2 MOE 1011 398104 74951 74964 CAAGAAGACCTTAC 2-10-2 MOE 1065 398106 74974 74987 TGGAAAACTGCACC 2-10-2 MOE 1068 398107 74980 74993 TATTCCTGGAAAAC 2-10-2 MOE 902 147745 75030 75041 TTGACCAGGAAG 1-10-1 MOE 1058 147737 75039 75050 ACAGCCAGGTAG 1-10-1 MOE 1067 398105 75040 75053 TGCACAGGCAGGTT 2-10-2 MOE 1066 WO 2007/146511 PCT/US2007/068401 -195 147737 75065 75076 ACAGCCAGGTAG 1-10-1 MOE 1067 398108 75077 75090 GGAATGTCTGAGTT 2-10-2 MOE 1136 398095 75086 75099 CATCAGCAAGAGGC 2-10-2 MOE 1011 147691 75108 75119 GAGGTGGGAAAA 1-10-1 MOE 966 398106 75120 75133 TGGAAAACTGCACC 2-10-2 MOE 1068 398107 75126 75139 TATTCCTGGAAAAC 2-10-2 MOE 902 147738 75155 75166 TGGGTGGCCGGG 1-10-1 MOE 1069 147745 75176 75187 TTGACCAGGAAG 1-10-1 MOE 1058 398108 75223 75236 GGAATGTCTGAGTT 2-10-2 MOE 1136 398109 75247 75260 CAAGAAGTGTGGTT 2-10-2 MOE 903 147691 75254 75265 GAGGTGGGAAAA 1-10-1 MOE 966 147738 75301 75312 TGGGTGGCCGGG 1-10-1 MOE 1069 398110 75385 75398 GTTCCCTTTGCAGG 2-10-2 MOE 952 147091 75387 75398 GTTCCCTCTACA 1-10-1 MOE 1004 398109 75393 75406 CAAGAAGTGTGGTT 2-10-2 MOE 903 398111 75470 75483 GTGAAAATGCTGGC 2-10-2 MOE 904 401385 75494 75507 CCCAGTGGGTTTGA 2-10-2 MOE 890 398166 75499 75510 GGGCTTCTTCCA 1-10-1 MOE 1070 147091 75525 75536 GTTCCCTCTACA 1-10-1 MOE 1004 147092 75526 75537 TGTTCCCTCTAC 1-10-1 MOE 901 398110 75531 75544 GTTCCCTTTGCAGG 2-10-2 MOE 952 147091 75533 75544 GTTCCCTCTACA 1-10-1 MOE 1004 147706 75540 75551 GCTGACATCTCG 1-10-1 MOE 1071 398112 75584 75597 CAGCCTGGCACCTA 2-10-2 MOE 1072 398111 75616 75629 GTGAAAATGCTGGC 2-10-2 MOE 904 147746 75617 75628 TAAAAACAACAA 1-10-1 MOE 1073 398166 75645 75656 GGGCTTCTTCCA 1-10-1 MOE 1070 147091 75671 75682 GTTCCCTCTACA 1-10-1 MOE 1004 147092 75672 75683 TGTTCCCTCTAC 1-10-1 MOE 901 398113 75693 75706 AGGAGGTTAAACCA 2-10-2 MOE 905 398112 75730 75743 CAGCCTGGCACCTA 2-10-2 MOE 1072 147746 75763 75774 TAAAAACAACAA 1-10-1 MOE 1073 398114 75770 75783 AGGCATATAGCAGA 2-10-2 MOE 1075 398115 75786 75799 AGTAAATATTGGCT 2-10-2 MOE 1076 398116 75799 75812 TAATGACCTGATGA 2-10-2 MOE 1137 398113 75839 75852 AGGAGGTTAAACCA 2-10-2 MOE 905 390030 75839 75850 TTTATAAAACTG 1-10-1 MOE 1074 398115 75932 75945 AGTAAATATTGGCT 2-10-2 MOE 1076 398116 75945 75958 TAATGACCTGATGA 2-10-2 MOE 1137 398106 75982 75995 TGGAAAACTGCACC 2-10-2 MOE 1068 390030 75985 75996 TTTATAAAACTG 1-10-1 MOE 1074 398106 76127 76140 TGGAAAACTGCACC 2-10-2 MOE 1068 147690 76196 76207 TGAAGTTAATTC 1-10-1 MOE 1138 147690 76341 76352 TGAAGTTAATTC 1-10-1 MOE 1138 147724 76740 76751 GAAATTGAGGAA 1-10-1 MOE 1139 147089 76873 76884 TCCCTCTACACC 1-10-1 MOE 956 147679 76881 76892 CAAAAGGATCCC 1-10-1 MOE 907 147724 76885 76896 GAAATTGAGGAA 1-10-1 MOE 1139 147089 77018 77029 TCCCTCTACACC 1-10-1 MOE 956 147679 77026 77037 CAAAAGGATCCC 1-10-1 MOE 907 147693 77240 77251 GTGCGCTCCCAT 1-10-1 MOE 1078 147697 77759 77770 CCCCAGCAGCGG 1-10-1 MOE 1000 In certain embodiments, a target region is nucleotides 177-190 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -196 embodiments, a short antisense compound is targeted to nucleotides 177-190 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 177-190 comprises a nucleotide sequence selected from SEQ ID NO 886, 859, or 853. In certain such embodiments, a short antisense compound targeted to nucleotides 177-190 of SEQ ID NO: 11 is selected from Isis No 147022, 5 147023, or 147024. In certain embodiments, a target region is nucleotides 195-228 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 195-228 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 195-228 comprises a nucleotide sequence selected from SEQ ID NO 877, 868, 882, 886, 859, 853, 865, 835, 843, 846, 842, 10 848, 874, 849, 863, 855, 850, 864, or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 195-228 of SEQ ID NO: 11 is selected from Isis No 147019, 147020, 147021, 147022, 147023, 147024, 147025, 147026, 147027, 147028, 147073, 147029, 147030, 147036, 147037, 147038, 147039, 147040, or 147041. In certain embodiments, a target region is nucleotides 323-353 of SEQ ID NO: 11. In certain 15 embodiments, a short antisense compound is targeted to nucleotides 323-353 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 323-353 comprises a nucleotide sequence selected from SEQ ID NO 866, 881, 869, 883, 858, 833, 875, 837, 829, 871, 884, 887, 839, 830, 840, 861, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 323-353 of SEQ ID NO: 11 is selected from Isis No 147042, 147043, 147044, 147045, 20 147046, 147047, 147051, 147052, 147053, 147054, 147055, 147056, 147057, 147058, 147059, 147060, or 147061. In certain embodiments, a target region is nucleotides 322-353 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 322-353 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 322-353 comprises a 25 nucleotide sequence selected from SEQ ID NO 842, 866, 881, 869, 883, 858, 833, 875, 837, 829, 871, 884, 887, 839, 830, 840, 861, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 322-353 of SEQ ID NO: 11 is selected from Isis No 147073, 147042, 147043, 147044, 147045, 147046, 147047, 147051, 147052, 147053, 147054, 147055, 147056, 147057, 147058, 147059, 147060, or 147061. 30 In certain embodiments, a target region is nucleotides 679-799 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 679-799 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 679-799 comprises a nucleotide sequence selected from SEQ ID NO 883, 858, 883, or 858. In certain such embodiments, a short antisense compound targeted to nucleotides 679-799 of SEQ ID NO: 11 is selected from Isis No 35 147045, 147046, 147045, or 147046. In certain embodiments, a target region is nucleotides 679-827 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 679-827 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 679-827 comprises a nucleotide sequence selected from SEQ ID NO 883, 858, 883, 858, or 851. In certain such embodiments, WO 2007/146511 PCT/US2007/068401 -197 a short antisense compound targeted to nucleotides 679-827 of SEQ ID NO: 11 is selected from Isis No 147045, 147046, 147045, 147046, or 147066. In certain embodiments, a target region is nucleotides 1024-1046 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 1024-1046 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted to nucleotides 1024-1046 comprises a nucleotide sequence selected from SEQ ID NO 841, 862, 880, 857, 851, 876, 838, 860, 878, 856, 832, or 842. In certain such embodiments, a short antisense compound targeted to nucleotides 1024-1046 of SEQ ID NO: 11 is selected from Isis No 147062, 147063, 147064, 147065, 147066, 147067, 147068, 147069, 147070, 147071, 147072, or 147073. 10 In certain embodiments, a target region is nucleotides 992-1046 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 992-1046 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 992-1046 comprises a nucleotide sequence selected from SEQ ID NO 831, 841, 862, 880, 857, 851, 876, 838, 860, 878, 856, 832, or 842. In certain such embodiments, a short antisense compound targeted to nucleotides 992-1046 15 of SEQ ID NO: 11 is selected from Isis No 404131, 147062, 147063, 147064, 147065, 147066, 147067, 147068, 147069, 147070, 147071, 147072, or 147073. In certain embodiments, a target region is nucleotides 1868-1881 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 1868-1881 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 1868-1881 comprises a 20 nucleotide sequence selected from SEQ ID NO 886, 859, or 853. In certain such embodiments, a short antisense compound targeted to nucleotides 1868-1881 of SEQ ID NO: 11 is selected from Isis No 147022, 147023, or 147024. In certain embodiments, a target region is nucleotides 1886-1919 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 1886-1919 of SEQ ID NO: 11. In 25 certain such embodiments, a short antisense compound targeted to nucleotides 1886-1919 comprises a nucleotide sequence selected from SEQ ID NO 877, 868, 882, 886, 859, 865, 843, 846, 874, 863, 855, 864, or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 1886-1919 of SEQ ID NO: 11 is selected from Isis No 147019, 147020, 147021, 147022, 147023, 147025, 147027, 147028, 147030, 147037, 147038, 147040, or 147041. 30 In certain embodiments, a target region is nucleotides 1869-1919 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 1869-1919 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 1869-1919 comprises a nucleotide sequence selected from SEQ ID NO 859, 853, 877, 868, 882, 886, 859, 865, 843, 846, 874, 863, 855, 864, or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 35 1869-1919 of SEQ ID NO: 11 is selected from Isis No 147023, 147024, 147019, 147020, 147021, 147022,147023,147025,147027,147028,147030,147037, 147038,147040,or 147041. In certain embodiments, a target region is nucleotides 1976-1989 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 1976-1989 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 1976-1989 comprises a WO 2007/146511 PCT/US2007/068401 -198 nucleotide sequence selected from SEQ ID NO 886, 859, or 853. In certain such embodiments, a short antisense compound targeted to nucleotides 1976-1989 of SEQ ID NO: 11 is selected from Isis No 147022, 147023, or 147024. In certain embodiments, a target region is nucleotides 1995-2027 of SEQ ID NO: 11. In certain 5 embodiments, a short antisense compound is targeted to nucleotides 1995-2027 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 1995-2027 comprises a nucleotide sequence selected from SEQ ID NO 868, 882, 886, 859, 853, 865, 835, 843, 846, 848, 874, 849, 863, 855, 850, 864, or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 1995-2027 of SEQ ID NO: 11 is selected from Isis No 147020, 147021, 147022, 147023, 10 147024, 147025, 147026, 147027, 147028, 147029, 147030, 147036, 147037, 147038, 147039, 147040, or 147041. In certain embodiments, a target region is nucleotides 2366-2382 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 2366-2382 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 2366-2382 comprises a 15 nucleotide sequence selected from SEQ ID NO 867 or 873. In certain such embodiments, a short antisense compound targeted to nucleotides 2366-2382 of SEQ ID NO: 11 is selected from Isis No 404199 or 404134. In certain embodiments, a target region is nucleotides 6220-6233 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 6220-6233 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted to nucleotides 6220-6233 comprises a nucleotide sequence selected from SEQ ID NO 870, 836, or 844. In certain such embodiments, a short antisense compound targeted to nucleotides 6220-6233 of SEQ ID NO: 11 is selected from Isis No 147032, 147033, or 147034. In certain embodiments, a target region is nucleotides 6288-6300 of SEQ ID NO: 11. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 6288-6300 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 6288-6300 comprises a nucleotide sequence selected from SEQ ID NO 869 or 883. In certain such embodiments, a short antisense compound targeted to nucleotides 6288-6300 of SEQ ID NO: 11 is selected from Isis No 147044 or 147045. 30 In certain embodiments, a target region is nucleotides 6329-6342 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 6329-6342 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 6329-6342 comprises a nucleotide sequence selected from SEQ ID NO 870, 836, or 844. In certain such embodiments, a short antisense compound targeted to nucleotides 6329-6342 of SEQ ID NO: 11 is selected from Isis No 35 147032, 147033, or 147034. In certain embodiments, a target region is nucleotides 6397-6409 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 6397-6409 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to nucleotides 6397-6409 comprises a nucleotide sequence selected from SEQ ID NO 869 or 883. In certain such embodiments, a short WO 2007/146511 PCT/US2007/068401 -199 antisense compound targeted to nucleotides 6397-6409 of SEQ ID NO: 11 is selected from Isis No 147044 or 147045. In certain embodiments, a target region is nucleotides 7057-7178 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 7057-7178 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted to 7057-7178 comprises a nucleotide sequence selected from SEQ ID NO 830, 840, 861, 830, or 840. In certain such embodiments, a short antisense compound targeted to nucleotides 7057-7178 of SEQ ID NO: 11 is selected from Isis No 147058, 147059, 147060, 147058, or 147059. In certain embodiments, a target region is nucleotides 8630-8750 of SEQ ID NO: 11. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 8630-8750 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 8630-8750 comprises a nucleotide sequence selected from SEQ ID NO 843, 846, 843, or 846. In certain such embodiments, a short antisense compound targeted to nucleotides 8630-8750 of SEQ ID NO: 11 is selected from Isis No 147027, 147028, 147027, or 147028. 15 In certain embodiments, a target region is nucleotides 10957-11077 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 10957-11077 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 10957-11077 comprises a nucleotide sequence selected from SEQ ID NO 881, 869, 881, or 869. In certain such embodiments, a short antisense compound targeted to nucleotides 10957-11077 of SEQ ID NO: 11 is selected from Isis No 20 147043, 147044, 147043, or 147044. In certain embodiments, a target region is nucleotides 11605-11623 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 11605-11623 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 11605-11623 comprises a nucleotide sequence selected from SEQ ID NO 856, 878, or 856. In certain such embodiments, a short antisense 25 compound targeted to nucleotides 11605-11623 of SEQ ID NO: 11 is selected from Isis No 147071, 147070, or 147071. In certain embodiments, a target region is nucleotides 12805-12817 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 12805-12817 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 12805-12817 comprises a nucleotide 30 sequence selected from SEQ ID NO 874 or 885. In certain such embodiments, a short antisense compound targeted to nucleotides 12805-12817 of SEQ ID NO: 11 is selected from Isis No 147030 or 147031. In certain embodiments, a target region is nucleotides 12986-12998 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 12986-12998 of SEQ ID NO: 11. In 35 certain such embodiments, a short antisense compound targeted to 12986-12998 comprises a nucleotide sequence selected from SEQ ID NO 874 or 885. In certain such embodiments, a short antisense compound targeted to nucleotides 12986-12998 of SEQ ID NO: 11 is selected from Isis No 147030 or 147031. In certain embodiments, a target region is nucleotides 15560-15572 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -200 embodiments, a short antisense compound is targeted to nucleotides 15560-15572 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 15560-15572 comprises a nucleotide sequence selected from SEQ ID NO 876 or 838. In certain such embodiments, a short antisense compound targeted to nucleotides 15560-15572 of SEQ ID NO: 11 is selected from Isis No 147067 or 5 147068. In certain embodiments, a target region is nucleotides 17787-17941 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 17787-17941 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 17787-17941 comprises a nucleotide sequence selected from SEQ ID NO 874 or 880. In certain such embodiments, a short antisense 10 compound targeted to nucleotides 17787-17941 of SEQ ID NO: 11 is selected from Isis No 147030 or 147064. In certain embodiments, a target region is nucleotides 21190-21202 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 21190-21202 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 21190-21202 comprises a nucleotide 15 sequence selected from SEQ ID NO 843 or 846. In certain such embodiments, a short antisense compound targeted to nucleotides 21190-21202 of SEQ ID NO: 11 is selected from Isis No 147027 or 147028. In certain embodiments, a target region is nucleotides 21358-21370 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 21358-21370 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted to 21358-21370 comprises a nucleotide sequence selected from SEQ ID NO 843 or 846. In certain such embodiments, a short antisense compound targeted to nucleotides 21358-21370 of SEQ ID NO: 11 is selected from Isis No 017027 or 147028. In certain embodiments, a target region is nucleotides 24318-24332 of SEQ ID NO: 11. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 24318-24332 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 24318-24332 comprises a nucleotide sequence selected from SEQ ID NO 881, 869, 883, or 858. In certain such embodiments, a short antisense compound targeted to nucleotides 24318-24332 of SEQ ID NO: 11 is selected from Isis No 147043, 147044, 147045, or 147046. 30 In certain embodiments, a target region is nucleotides 24486-24501 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 24486-24501 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 24486-24501 comprises a nucleotide sequence selected from SEQ ID NO 881, 869, 858, or 833. In certain such embodiments, a short antisense compound targeted to nucleotides 24486-24501 of SEQ ID NO: 11 is selected from Isis No 35 147043, 147044, 147046, or 147047. In certain embodiments, a target region is nucleotides 25065-25077 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 25065-25077 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 25065-25077 comprises a nucleotide sequence selected from SEQ ID NO 864 or 834. In certain such embodiments, a short antisense WO 2007/146511 PCT/US2007/068401 -201 compound targeted to nucleotides 25065-25077 of SEQ ID NO: 11 is selected from Isis No 147040 or 147041. In certain embodiments, a target region is nucleotides 25232-25245 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 25232-25245 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted to 25232-25245 comprises a nucleotide sequence selected from SEQ ID NO 850, 864, or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 25232-25245 of SEQ ID NO: 11 is selected from Isis No 147039, 147040, or 147041. In certain embodiments, a target region is nucleotides 25508-25523 of SEQ ID NO: 11. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 25508-25523 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 25508-25523 comprises a nucleotide sequence selected from SEQ ID NO 839 or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 25508-25523 of SEQ ID NO: 11 is selected from Isis No 147057 or 147061. 15 In certain embodiments, a target region is nucleotides 25676-28890 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 25676-28890 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 25676-28890 comprises a nucleotide sequence selected from SEQ ID NO 839, 860, or 878. In certain such embodiments, a short antisense compound targeted to nucleotides 25676-28890 of SEQ ID NO: 11 is selected from Isis No 147057, 20 147069, or 147070. In certain embodiments, a target region is nucleotides 33056-33069 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 33056-33069 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 33056-33069 comprises a nucleotide sequence selected from SEQ ID NO 860, 878, or 856. In certain such embodiments, a short antisense 25 compound targeted to nucleotides 33056-33069 of SEQ ID NO: 11 is selected from Isis No 147069, 147070, or 147071. In certain embodiments, a target region is nucleotides 33205-33217 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 33205-33217 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted to 33205-33217 comprises a nucleotide 30 sequence selected from SEQ ID NO 878 or 856. In certain such embodiments, a short antisense compound targeted to nucleotides 33205-33217 of SEQ ID NO: 11 is selected from Isis No 14707 or 147071. In certain embodiments, a target region is nucleotides 33318-33334 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 33318-33334 of SEQ ID NO: 11. In 35 certain such embodiments, a short antisense compound targeted to 33318-33334 comprises a nucleotide sequence selected from SEQ ID NO 858, 854, or 875. In certain such embodiments, a short antisense compound targeted to nucleotides 33318-33334 of SEQ ID NO: 11 is selected from Isis No 147046, 147049, or 147051. In certain embodiments, a target region is nucleotides 33466-33482 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -202 embodiments, a short antisense compound is targeted to nucleotides 33466-33482 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 33466-33482 comprises a nucleotide sequence selected from SEQ ID NO 858, 833, or 875. In certain such embodiments, a short antisense compound targeted to nucleotides 33466-33482 of SEQ ID NO: 11 is selected from Isis No 147046, 5 147047, or 147051. In certain embodiments, a target region is nucleotides 33640-33656 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 33640-33656 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 33640-33656 comprises a nucleotide sequence selected from SEQ ID NO 858 or 875. In certain such embodiments, a short antisense 10 compound targeted to nucleotides 33640-33656 of SEQ ID NO: 11 is selected from Isis No 147046 or 147051. In certain embodiments, a target region is nucleotides 33788-33804 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 33788-33804 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 33788-33804 comprises a nucleotide 15 sequence selected from SEQ ID NO 858 or 875. In certain such embodiments, a short antisense compound targeted to nucleotides 33788-33804 of SEQ ID NO: 11 is selected from Isis No 147046 or 147051. In certain embodiments, a target region is nucleotides 35437-35449 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 35437-35449 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted 35437-35449 comprises a nucleotide sequence selected from SEQ ID NO 840 or 861. In certain such embodiments, a short antisense compound targeted to nucleotides 35437-35449 of SEQ ID NO: 11 is selected from Isis No 147059 or 147060. In certain embodiments, a target region is nucleotides 40353-40373 of SEQ ID NO: 11. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 40353-40373 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 40353-40373 comprises a nucleotide sequence selected from SEQ ID NO 879 or 881. In certain such embodiments, a short antisense compound targeted to nucleotides 40353-40373 of SEQ ID NO: 11 is selected from Isis No 147061 or 147043. 30 In certain embodiments, a target region is nucleotides 42527-42541 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 42527-42541 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 42527-42541 comprises a nucleotide sequence selected from SEQ ID NO 885, 870, or 844. In certain such embodiments, a short antisense compound targeted to nucleotides 42527-42541 of SEQ ID NO: 11 is selected from Isis No 147031, 35 147032, or 147034. In certain embodiments, a target region is nucleotides 42675-42689 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 42675-42689 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 42675-42689 comprises a nucleotide sequence selected from SEQ ID NO 885, 870, 836, or 844. In certain such embodiments, a WO 2007/146511 PCT/US2007/068401 -203 short antisense compound targeted to nucleotides 42675-42689 of SEQ ID NO: 11 is selected from Isis No 147031, 147032, 147033, or 147034. In certain embodiments, a target region is nucleotides 46313-46328 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 46313-46328 of SEQ ID NO: 5 11. In certain such embodiments, a short antisense compound targeted 46313-46328 comprises a nucleotide sequence selected from SEQ ID NO 839, 830, 840, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 46313-46328 of SEQ ID NO: 11 is selected from Isis No 147057, 147058, 147059, or 147061. In certain embodiments, a target region is nucleotides 46461-46476 of SEQ ID NO: 11. In 10 certain embodiments, a short antisense compound is targeted to nucleotides 46461-46476 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 46461-46476 comprises a nucleotide sequence selected from SEQ ID NO 839, 840, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 46461-46476 of SEQ ID NO: 11 is selected from Isis No 147057, 147059, or 147061. 15 In certain embodiments, a target region is nucleotides 48369-48381 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 48369-48381 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 48369-48381 comprises a nucleotide sequence selected from SEQ ID NO 842 or 845. In certain such embodiments, a short antisense compound targeted to nucleotides 48369-48381 of SEQ ID NO: 11 is selected from Isis No 147073 or 20 147074. In certain embodiments, a target region is nucleotides 48714-48726 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 48714-48726 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 48714-48726 comprises a nucleotide sequence selected from SEQ ID NO 843 or 846. In certain such embodiments, a short antisense 25 compound targeted to nucleotides 48714-48726 of SEQ ID NO: 11 is selected from Isis No 147027 or 147028. In certain embodiments, a target region is nucleotides 49050-49062 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 49050-49062 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 49050-49062 of comprises a nucleotide 30 sequence selected from SEQ ID NO 876 or 838. In certain such embodiments, a short antisense compound targeted to nucleotides 49050-49062 of SEQ ID NO: 11 is selected from Isis No 147067 or 147068. In certain embodiments, a target region is nucleotides 49672-49684 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 49672-49684 of SEQ ID NO: 11. In 35 certain such embodiments, a short antisense compound targeted 49672-49684 of comprises a nucleotide sequence selected from SEQ ID NO 842 or 845. In certain such embodiments, a short antisense compound targeted to nucleotides 49672-49684 of SEQ ID NO: 11 is selected from Isis No 147073 or 147074. In certain embodiments, a target region is nucleotides 52292-52304 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -204 embodiments, a short antisense compound is targeted to nucleotides 52292-52304 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 52292-52304 of comprises a nucleotide sequence selected from SEQ ID NO 849 or 863. In certain such embodiments, a short antisense compound targeted to nucleotides 52292-52304 of SEQ ID NO: 11 is selected from Isis No 147036 or 5 147037. In certain embodiments, a target region is nucleotides 52438-52450 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 52438-52450 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 52438-52450 of comprises a nucleotide sequence selected from SEQ ID NO 849 or 863. In certain such embodiments, a short antisense 10 compound targeted to nucleotides 52438-52450 of SEQ ID NO: 11 is selected from Isis No 147036 or 147037. In certain embodiments, a target region is nucleotides 53445-53458 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 53445-53458 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 53445-53458 of comprises a nucleotide 15 sequence selected from SEQ ID NO 866, 881, or 869. In certain such embodiments, a short antisense compound targeted to nucleotides 53445-53458 of SEQ ID NO: 11 is selected from Isis No 147042, 147043, or 147044. In certain embodiments, a target region is nucleotides 53591-53604 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 53591-53604 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted 53591-53604 of comprises a nucleotide sequence selected from SEQ ID NO 866, 874, 881, 885, or 869. In certain such embodiments, a short antisense compound targeted to nucleotides 53591-53604 of SEQ ID NO: 11 is selected from Isis No 147042, 147030, 147043, 147031, or 147044. In certain embodiments, a target region is nucleotides 53738-53750 of SEQ ID NO: 11. In 25 certain embodiments, a short antisense compound is targeted to nucleotides 53738-53750 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 53738-53750 of comprises a nucleotide sequence selected from SEQ ID NO 874 or 885. In certain such embodiments, a short antisense compound targeted to nucleotides 53738-53750 of SEQ ID NO: 11 is selected from Isis No 147030 or 147031. 30 In certain embodiments, a target region is nucleotides 53783-53795 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 53783-53795 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 53783-53795 of comprises a nucleotide sequence selected from SEQ ID NO 864 or 834. In certain such embodiments, a short antisense compound targeted to nucleotides 53783-53795 of SEQ ID NO: 11 is selected from Isis No 35 147040 or 147041. In certain embodiments, a target region is nucleotides 55008-55020 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 55008-55020 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 55008-55020 of comprises a nucleotide sequence selected from SEQ ID NO 866 or 881. In certain such embodiments, a short antisense WO 2007/146511 PCT/US2007/068401 -205 compound targeted to nucleotides 55008-55020 of SEQ ID NO: 11 is selected from Isis No 147042 or 147043. In certain embodiments, a target region is nucleotides 55154-55166 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 55154-55166 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted 55154-55166 of comprises a nucleotide sequence selected from SEQ ID NO 866 or 881. In certain such embodiments, a short antisense compound targeted to nucleotides 55154-55166 of SEQ ID NO: 11 is selected from Isis No 147042 or 147043. In certain embodiments, a target region is nucleotides 55682-55695 of SEQ ID NO: 11. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 55682-55695 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 55682-55695 of comprises a nucleotide sequence selected from SEQ ID NO 877 or 882. In certain such embodiments, a short antisense compound targeted to nucleotides 55682-55695 of SEQ ID NO: 11 is selected from Isis No 147019 or 147021. 15 In certain embodiments, a target region is nucleotides 56275-56293 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 56275-56293 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 56275-56293 of comprises a nucleotide sequence selected from SEQ ID NO 871, 884, 887, 830, 840, 861, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 56275-56293 of SEQ ID NO: 11 is selected from Isis 20 No 147054, 147055, 147056, 147058, 147059, 147060, or 147061. In certain embodiments, a target region is nucleotides 56418-56439 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 56418-56439 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 56418-56439 of comprises a nucleotide sequence selected from SEQ ID NO 875, 829, 871, 884, 887, 839, 830, or 879. In certain such 25 embodiments, a short antisense compound targeted to nucleotides 56418-56439 of SEQ ID NO: 11 is selected from Isis No 147051, 147053, 147054, 147055, 147056, 147057, 147058, or 147061. In certain embodiments, a target region is nucleotides 57264-57276 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 57264-57276 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 57264-57276 of comprises a nucleotide 30 sequence selected from SEQ ID NO 883 or 858. In certain such embodiments, a short antisense compound targeted to nucleotides 57264-57276 of SEQ ID NO: 11 is selected from Isis No 147045 or 147046. In certain embodiments, a target region is nucleotides 61276-61293 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 61276-61293 of SEQ ID NO: 11. In 35 certain such embodiments, a short antisense compound targeted 61276-61293 of comprises a nucleotide sequence selected from SEQ ID NO 856, 847, 849, 863, 855, 850, or 864. In certain such embodiments, a short antisense compound targeted to nucleotides 61276-61293 of SEQ ID NO: 11 is selected from Isis No 147071, 147035, 147036, 147037, 147038, 147039, or 147040. In certain embodiments, a target region is nucleotides 61257-61320 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -206 embodiments, a short antisense compound is targeted to nucleotides 61257-61320 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 61257-61320 of comprises a nucleotide sequence selected from SEQ ID NO 881, 856, 847, 849, 863, 855, 850, 864, or 886. In certain such embodiments, a short antisense compound targeted to nucleotides 61257-61320 of SEQ ID NO: 11 is 5 selected from Isis No 147043, 147071, 147035, 147036, 147037, 147038, 147039, 147040, or 147071. In certain embodiments, a target region is nucleotides 61422-61439 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 61422-61439 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 61422-61439 of comprises a nucleotide sequence selected from SEQ ID NO 844, 847, 849, 863, 855, or 864. In certain such embodiments, a 10 short antisense compound targeted to nucleotides 61422-61439 of SEQ ID NO: 11 is selected from Isis No 147034, 147035, 147036, 147037, 147038, or 147040. In certain embodiments, a target region is nucleotides 61422-61466 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 61422-61466 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 61422-61466 of comprises a nucleotide 15 sequence selected from SEQ ID NO 844, 847, 849, 863, 855, 864, or 856. In certain such embodiments, a short antisense compound targeted to nucleotides 61422-61466 of SEQ ID NO: 11 is selected from Isis No 147034, 147035, 147036, 147037, 147038, 147040, or 147071. In certain embodiments, a target region is nucleotides 63065-63078 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 63065-63078 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted 63065-63078 of comprises a nucleotide sequence selected from SEQ ID NO 851 or 838. In certain such embodiments, a short antisense compound targeted to nucleotides 63065-63078 of SEQ ID NO: 11 is selected from Isis No 147066 or 147068. In certain embodiments, a target region is nucleotides 63207-63222 of SEQ ID NO: 11. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 63207-63222 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 63207-63222 of comprises a nucleotide sequence selected from SEQ ID NO 841 or 851. In certain such embodiments, a short antisense compound targeted to nucleotides 63207-63222 of SEQ ID NO: 11 is selected from Isis No 147062 or 147066. 30 In certain embodiments, a target region is nucleotides 64538-64550 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 64538-64550 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 64538-64550 of comprises a nucleotide sequence selected from SEQ ID NO 849 or 863. In certain such embodiments, a short antisense compound targeted to nucleotides 64538-64550 of SEQ ID NO: 11 is selected from Isis No 147036 or 35 147037. In certain embodiments, a target region is nucleotides 64864-64876 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 64864-64876 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 64864-64876 of comprises a nucleotide sequence selected from SEQ ID NO 851 or 876. In certain such embodiments, a short antisense WO 2007/146511 PCT/US2007/068401 -207 compound targeted to nucleotides 64864-64876 of SEQ ID NO: 11 is selected from Isis No 147066 or 147067. In certain embodiments, a target region is nucleotides 65010-65028 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 65010-65028 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted 65010-65028 of comprises a nucleotide sequence selected from SEQ ID NO 851, 876, or 883. In certain such embodiments, a short antisense compound targeted to nucleotides 65010-65028 of SEQ ID NO: 11 is selected from Isis No 147066, 147067, or 147045. In certain embodiments, a target region is nucleotides 65163-65175 of SEQ ID NO: 11. In certain 10 embodiments, a short antisense compound is targeted to nucleotides 65163-65175 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 65163-65175 of comprises a nucleotide sequence selected from SEQ ID NO 883 or 858. In certain such embodiments, a short antisense compound targeted to nucleotides 65163-65175 of SEQ ID NO: 11 is selected from Isis No 147045 or 147046. 15 In certain embodiments, a target region is nucleotides 65408-65422 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 65408-65422 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 65408-65422 of comprises a nucleotide sequence selected from SEQ ID NO 883 or 856. In certain such embodiments, a short antisense compound targeted to nucleotides 65408-65422 of SEQ ID NO: 11 is selected from Isis No 147068 or 20 147071. In certain embodiments, a target region is nucleotides 65549-65568 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 65549-65568 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 65549-65568 of comprises a nucleotide sequence selected from SEQ ID NO 860, 838, or 856. In certain such embodiments, a short antisense 25 compound targeted to nucleotides 65549-65568 of SEQ ID NO: 11 is selected from Isis No 147069, 147068, or 147071. In certain embodiments, a target region is nucleotides 67741-67754 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 67741-67754 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 67741-67754 of comprises a nucleotide 30 sequence selected from SEQ ID NO 848, 874, or 885. In certain such embodiments, a short antisense compound targeted to nucleotides 67741-67754 of SEQ ID NO: 11 is selected from Isis No 147029, 147030, or 147031. In certain embodiments, a target region is nucleotides 67886-67900 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 67886-67900 of SEQ ID NO: 11. In 35 certain such embodiments, a short antisense compound targeted 67886-67900 of comprises a nucleotide sequence selected from SEQ ID NO 846, 848, 874, or 885. In certain such embodiments, a short antisense compound targeted to nucleotides 67886-67900 of SEQ ID NO: 11 is selected from Isis No 147028,147029,147030,or147031. In certain embodiments, a target region is nucleotides 68867-68880 of SEQ ID NO: 11. In certain WO 2007/146511 PCT/US2007/068401 -208 embodiments, a short antisense compound is targeted to nucleotides 68867-68880 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 68867-68880 of comprises a nucleotide sequence selected from SEQ ID NO 881, 869, or 883. In certain such embodiments, a short antisense compound targeted to nucleotides 68867-68880 of SEQ ID NO: 11 is selected from Isis No 147043, 5 147044, or 147045. In certain embodiments, a target region is nucleotides 69013-69532 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 69013-69532 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 69013-69532 of comprises a nucleotide sequence selected from SEQ ID NO 881, 869, 883, 858, 856, 832, or 842. In certain such embodiments, a 10 short antisense compound targeted to nucleotides 69013-69532 of SEQ ID NO: 11 is selected from Isis No 147043, 147044, 147045, 147046, 147071, 147072, or 147073. In certain embodiments, a target region is nucleotides 69665-69880 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 69665-69880 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 69665-69880 of comprises a nucleotide 15 sequence selected from SEQ ID NO 856, 832, 842, 845, or 851. In certain such embodiments, a short antisense compound targeted to nucleotides 69665-69880 of SEQ ID NO: 11 is selected from Isis No 147071, 147072, 147073, 147074, or 147066. In certain embodiments, a target region is nucleotides 70611-70630 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 70611-70630 of SEQ ID NO: 11. In 20 certain such embodiments, a short antisense compound targeted 70611-70630 of comprises a nucleotide sequence selected from SEQ ID NO 859, 841, 862, 880, 857, or 851. In certain such embodiments, a short antisense compound targeted to nucleotides 70611-70630 of SEQ ID NO: 11 is selected from Isis No 147023, 147062, 147063, 147064, 147065, or 147066. In certain embodiments, a target region is nucleotides 70762-70776 of SEQ ID NO: 11. In certain 25 embodiments, a short antisense compound is targeted to nucleotides 70762-70776 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 70762-70776 of comprises a nucleotide sequence selected from SEQ ID NO 862, 880, 857, or 851. In certain such embodiments, a short antisense compound targeted to nucleotides 70762-70776 of SEQ ID NO: 11 is selected from Isis No 147063, 147064, 147065, or 147066. 30 In certain embodiments, a target region is nucleotides 70998-71010 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 70998-71010 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 70998-71010 of comprises a nucleotide sequence selected from SEQ ID NO 832 or 842. In certain such embodiments, a short antisense compound targeted to nucleotides 70998-71010 of SEQ ID NO: 11 is selected from Isis No 35 147072 or 147073. In certain embodiments, a target region is nucleotides 71144-714364 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 71144-714364 of SEQ ID NO: 11. In certain such embodiments, a short antisense compound targeted 71144-714364 of comprises a nucleotide sequence selected from SEQ ID NO 832, 842, 845, 863, 855, or 850. In certain such WO 2007/146511 PCT/US2007/068401 -209 embodiments, a short antisense compound targeted to nucleotides 71144-714364 of SEQ ID NO: 11 is selected from Isis No 147072, 147073, 147074, 147037, 147038, or 147039. In certain embodiments, a target region is nucleotides 71497-71652 of SEQ ID NO: 11. In certain embodiments, a short antisense compound is targeted to nucleotides 71497-71652 of SEQ ID NO: 11. In 5 certain such embodiments, a short antisense compound targeted 71497-71652 of comprises a nucleotide sequence selected from SEQ ID NO 863, 855, 850, or 879. In certain such embodiments, a short antisense compound targeted to nucleotides 71497-71652 of SEQ ID NO: 11 is selected from Isis No 147037, 147038, 147039, or 147061. 10 In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are 8 to 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are 9 to 14 nucleotides in length. In certain embodiments, short antisense compounds targeted to a PTP lB nucleic acid are 10 to 14 15 nucleotides in length. In certain embodiments, such short antisense compounds are short antisense oligonucleotides. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are short gapmers. In certain such embodiments, short gapmers targeted to a PTP lB nucleic acid comprise at least one high affinity modification in one or more wings of the compound. In certain embodiments, short 20 antisense compounds targeted to a PTP1B nucleic acid comprise 1 to 3 high-affinity modifications in each wing. In certain such embodiments, the nucleosides or nucleotides of the wing comprise a 2' modification. In certain such embodiments, the monomers of the wing are BNA's. In certain such embodiments, the monomers of the wing are selected from ax-L-Methyleneoxy (4'-CH 2 -O-2') BNA , P-D Methyleneoxy (4'-CH 2 -O-2') BNA , Ethyleneoxy (4'-(CH 2

)

2 -O-2') BNA , Aminooxy (4'-CH 2

-O-N(R)

25 2') BNA and Oxyamino (4'-CH 2 -N(R)-O-2') BNA. In certain embodiments, the monomers of a wing comprise a substituent at the 2' position selected from allyl, amino, azido, thio, 0-allyl, O-Cl-Clo alkyl, OCF 3 , O-(CH 2

)

2

O-CH

3 , 2'-O(CH 2

)

2

SCH

3 , O-(CH 2

)

2 O-N(Rm)(Rn), and O-CH 2 C(=0)-N(Rm)(R), where each Rm and R. is, independently, H or substituted or unsubstituted C 1

-C

10 alkyl. In certain embodiments, the monomers of a wing are 2'MOE nucleotides. 30 In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid comprise a gap between the 5' wing and the 3' wing. In certain embodiments the gap comprises five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen monomers. In certain embodiments, the monomers of the gap are unmodified deoxyribonucleotides. In certain embodiments, the monomers of the gap are unmodified ribonucleotides. In certain embodiments, gap modifications (if any) gap result in an 35 antisense compound that, when bound to its target nucleic acid, supports cleavage by an RNase, including, but not limited to, RNase H. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid have uniform monomeric linkages. In certain such embodiments, those linkages are all phosphorothioate WO 2007/146511 PCT/US2007/068401 -210 linkages. In certain embodiments, the linkages are all phosphodiester linkages. In certain embodiments, short antisense compounds targeted to a PTP 1 B nucleic acid have mixed backbones. In certain embodiments, short antisense compounds targeted to a PTPlB nucleic acid are 8 monomers in length. In certain embodiments, short antisense compounds targeted to a PTPlB nucleic 5 acid are 9 monomers in length. In certain embodiments, short antisense compounds targeted to a PTP I B nucleic acid are 10 monomers in length. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are 11 monomers in length. In certain embodiments, short antisense compounds targeted to a PTPlB nucleic acid are monomers in length. In certain embodiments, short antisense compounds targeted to a PTPlB nucleic acid are 13 monomers in length. In certain embodiments, short 10 antisense compounds targeted to a PTPIB nucleic acid are 14 monomers in length. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are 15 monomers in length. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid are 16 monomers in length. In certain embodiments, short antisense compounds targeted to a PTPIB nucleic acid comprise 9 to 15 monomers. In certain embodiments, short antisense compounds targeted to a PTPlB nucleic acid 15 comprise 10 to 15 monomers. In certain embodiments, short antisense compounds targeted to a PTP1B nucleic acid comprise 12 to 14 monomers. In certain embodiments, short antisense compounds targeted to a PTPIB nucleic acid comprise 12 to 14 nucleotides or nucleosides. In certain embodiments, the invention provides methods of modulating expression of PTP1B. In certain embodiments, such methods comprise use of one or more short antisense compound targeted to a 20 PTP1B nucleic acid, wherein the short antisense compound targeted to a PTPIB nucleic acid is from about 8 to about 16, preferably 9 to 15, more preferably 9 to 14, more preferably 10 to 14 monomers (i.e. from about 8 to about 16 linked monomers). One of ordinary skill in the art will appreciate that this comprehends methods of modulating expression of PTP1B using one or more short antisense compounds targeted to a PTP1B nucleic acid of 8, 9, 10, 11, 12, 13, 14, 15 or 16 monomers. 25 In certain embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTPlB nucleic acid that is 8 monomers in length. In certain embodiments, methods of modulating PTPlB comprise use of a short antisense compound targeted to a PTPlB nucleic acid that is 9 monomers in length. In certain embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTP lB nucleic acid that is 10 monomers in length. In certain 30 embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTP 1 B nucleic acid that is 11 monomers in length. In certain embodiments, methods of modulating PTPlB comprise use of a short antisense compound targeted to a PTPlB nucleic acid that is 12 monomers in length. In certain embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTP1B nucleic acid that is 13 monomers in length. In certain 35 embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTP1B nucleic acid that is 14 monomers in length. In certain embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTPlB nucleic acid that is 15 WO 2007/146511 PCT/US2007/068401 -211 monomers in length. In certain embodiments, methods of modulating PTP1B comprise use of a short antisense compound targeted to a PTP 1 B nucleic acid that is 16 monomers in length. In certain embodiments, methods of modulating expression of PTP1B comprise use of a short antisense compound targeted to a PTPIB nucleic acid comprising 9 to 15 monomers. In certain 5 embodiments, methods of modulating expression of PTP1B comprise use of a short antisense compound targeted to a PTP1B nucleic acid comprising 10 to 15 monomers. In certain embodiments, methods of modulating expression of PTP1B comprise use of a short antisense compound targeted to a PTPlB nucleic acid comprising 12 to 14 monomers. In certain embodiments, methods of modulating expression of PTP1B comprise use of a short antisense compound targeted to a PTPIB nucleic acid comprising 12 or 10 14 nucleotides or nucleosides. 10. PTEN In certain embodiments, the invention provides short antisense compounds targeted to a nucleic acid encoding PTEN. In certain embodiments, such compounds are used to modulate PTEN expression if 15 cells. In certain such embodiments, short antisense compounds targeted to a PTEN nucleic acid are administered to an animal. In certain embodiments, short antisense compounds targeted to a PTEN nucleic acid are useful for studying PTEN, for studying certain nucleases and/or for assessing antisense activity. In certain such embodiments, short antisense compounds targeted to PTEN nucleic acids are useful for assessing certain motifs and/or chemical modifications. In certain embodiments, administration 20 of a short antisense compound targeted to PTEN nucleic acid to an animal results in a measurable phenotypic change. The short antisense compounds targeting PTEN may have any one or more properties or characteristics of the short antisense compounds generally described herein. In certain embodiments, short antisense compounds targeting a PTP1B nucleic acid have a motif (wing - deoxy gap -wing) 25 selected from 1-12-1, 1-1-10-2, 2-10-1-1, 3-10-3, 2-10-3, 2-10-2, 1-10-1,1-10-2, 3-8-3, 2-8-2, 1-8-1, 3-6 3 or 1-6-1, more preferably 1-10-1, 2-10-2, 3-10-3, and 1-9-2. Certain Short Antisense Compounds Targeted to a PTEN Nucleic Acid In certain embodiments, short antisense compounds are targeted to a PTEN nucleic acid having 30 the sequence of GENBANK® Accession No. NM_000314.4, incorporated herein as SEQ ID NO: 14. In certain embodiments, short antisense compounds are targeted to a PTEN nucleic acid having the sequence of nucleotides 8063255 to 8167140 of the sequence of GENBANK@ Accession No. NT_033890.3, incorporated herein as SEQ ID NO: 15. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 14 is at least 90% complementary to SEQ ID NO: 14. In certain such 35 embodiments, a short antisense compound targeted to SEQ ID NO: 14 is at least 95% complementary to SEQ ID NO: 14. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 15 is 100% complementary to SEQ ID NO: 15. In certain such embodiments, a short antisense compound WO 2007/146511 PCT/US2007/068401 -212 targeted to SEQ ID NO: 15 is at least 90% complementary to SEQ ID NO: 15. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 15 is at least 95% complementary to SEQ ID NO: 15. In certain such embodiments, a short antisense compound targeted to SEQ ID NO: 15 is 100% complementary to SEQ ID NO: 15. 5 In certain embodiments, a short antisense compound targeted to SEQ ID NO: 14 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Tables 20 and 21. In certain embodiments, a short antisense compound targeted to SEQ ID NO: 15 comprises a nucleotide sequence selected from the nucleotide sequences set forth in Tables 22 and 23. Each nucleotide sequence set forth in Tables 20, 21, 22, and 23 is independent of any 10 modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, short antisense compounds comprising a nucleotide sequence as set forth in Tables 20, 21, 22, and 23 may comprise, independently, one or more modifications to a sugar moiety, an intemucleoside linkage, or a nucleobase. Antisense compounds described by Isis Number (Isis NO.) indicate a combination of nucleobase sequence and one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. 15 Table 20 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 14. Table 22 illustrates short antisense compounds that are 100% complementary to SEQ ID NO: 15. The column labeled 'gapmer motif indicates the wing-gap-wing motif of each short antisense compounds. The gap segment comprises 2'-deoxynucleotides and each nucleotide of each wing segment comprises a 2'-modified sugar. The particular 2'-modified sugar is also indicated in the 'gapmer motif' column. For 20 example, '2-10-2 MOE' means a 2-10-2 gapmer motif, where a gap segment of ten 2'-deoxynucleotides is flanked by wing segments of two nucleotides, where the nucleotides of the wing segments are 2'-MOE nucleotides. Internucleoside linkages are phosphorothioate. The short antisense compounds comprise 5 methylcytidine in place of unmodified cytosine, unless "unmodified cytosine" is listed in the gapmer motif column, in which case the indicated cytosines are unmodified cytosines. For example, "5-mC in gap 25 only" indicates that the gap segment has 5-methylcytosines, while the wing segments have unmodified cytosines. The 2'-modified nucleotides and abbreviations include: 2'-O-methoxyethyl (MOE); 2'-O-methyl (OMe); 2'-O-(2,2,3,3,3-pentafluoropropyl) (PentaF); 2'-O-[(2-methoxy)ethyl]-4'-thio (2'-MOE-4'-thio);. (R)-CMOE-BNA. As illustrated in Tables 20 and 22, a wing may comprise monomers comprising more 30 than type of 2' substituent. For example, 1-2-10-2 MOE/PentaF/MOE indicates one MOE-modified nucleotide, followed by two PentaF-modified nucleotides, followed by a gap of ten deoxynucleotides, followed by two PentaF-modified nucleotides. For example, 1-1-10-2 2'-(butylacetomido)-palmitamide Methyleneoxy BNA/Methyleneoxy BNA indicates that the 5'-most nucleotide is 2'-(butylacetomide) palmitamide, the second nucleotide is a methyleneoxy BNA nucleotide, and the 3' wing is methyleneoxy 35 BNA. Unless otherwise indicated, cytosines are 5-methylcytosines and internucleoside linkages are phosphorothioate.

WO 2007/146511 PCT/US2007/068401 -213 Table 20: Short Antisense Compounds Targeted to SEQ ID NO: 14 5' 3' Isis 51 3 SEQ No Target Target Sequence (5'-3') Gapmer Motif E Site Site NO 390092 5530 5541 AGAATGAGACTT 1-10-1 MOE 1514 390091 5435 5446 TGAGGCATTATC 1-10-1 MOE 1522 390090 5346 5357 AGAGTATCTGAA 1-10-1 MOE 1227 390088 5162 5173 CACATTAACAGT 1-10-1 MOE 1511 390087 5126 5137 GTGGCAACCACA 1-10-1 MOE 1501 390085 5031 5042 ATTTGATGCTGC 1-10-1 MOE 1505 390084 4982 4993 CAAAGAATGGTG 1-10-1 MOE 1215 390082 4910 4921 AGGACTTGGGAT 1-10-1 MOE 1503 390080 4833 4844 TGCTGCACATCC 1-10-1 MOE 1150 2-10-2 Methyleneoxy BNA 392067 4832 4845 CTGCTGCACATCCA Unmodified cytosines in gap 1510 390078 4714 4725 CTTTCAGTCATA 1-10-1 MOE 1520 390077 4693 4704 GTCAAATTCTAT 1-10-1 MOE 1252 390076 4599 4610 TTCCAATGACTA 1-10-1 MOE 1506 390075 4576 4587 GTAAGCAAGGCT 1-10-1 MOE #N/A 390074 4533 4544 ACCCTCATTCAG 1-10-1 MOE 1513 390068 4191 4202 GTAAATCCTAAG 1-10-1 MOE 1515 390064 4001 4012 ACCACAGCTAGT 1-10-1 MOE 1498 390063 3977 3988 CACCAATAAGTT 1-10-1 MOE 1219 390058 3828 3839 AGTAGTTGTACT 1-10-1 MOE 1192 390056 3793 3804 GGGCATATCAAA 1-10-1 MOE 1521 390054 3705 3716 AACACTGCACAT 1-10-1 MOE 1493 390052 3623 3634 GACAATTTCTAC 1-10-1 MOE 1492 390050 3503 3514 GTATTCAAGTAA 1-10-1 MOE 1140 390049 3479 3490 GTTAATGACATT 1-10-1 MOE 1491 390047 3428 3439 TGTGTAAGGTCA 1-10-1 MOE 1490 390041 3175 3186 TTAGCACTGGCC 1-10-1 MOE 1489 398076 3171 3182 CACTGGCCTTGA 1-10-1 MOE 1488 398009 3170 3183 GCACTGGCCTTGAT 2-10-2 MOE 1487 398075 3111 3122 AAATCATTGTCA 1-10-1 MOE 1233 398008 3110 3123 TAAATCATTGTCAA 2-10-2 MOE 1486 398074 2913 2924 GCACCAATATGC 1-10-1 MOE 1248 398007 2912 2925 AGCACCAATATGCT 2-10-2 MOE 1247 398073 2681 2692 TTAGCCAACTGC 1-10-1 MOE 1485 398006 2680 2693 CTTAGCCAACTGCA 2-10-2 MOE 1484 390033 2679 2690 AGCCAACTGCAA 1-10-1 MOE 1483 398072 2671 2682 GCAAACTTATCT 1-10-1 MOE 1482 398005 2670 2683 TGCAAACTTATCTG 2-10-2 MOE 1481 390030 2534 2545 TTTATAAAACTG 1-10-1 MOE 1074 398071 2533 2544 TTATAAAACTGG 1-10-1 MOE 1480 398004 2532 2545 TTTATAAAACTGGA 2-10-2 MOE 1479 390029 2510 2521 AAAGTGCCATCT 1-10-1 MOE 1478 390028 2491 2502 TCCTAATTGAAT 1-10-1 MOE 1477 398070 2481 2492 ATTTTAAATGTC 1-10-1 MOE 1476 398003 2480 2493 AATTTTAAATGTCC 2-10-2 MOE 1475 390027 2455 2466 AGGTATATACAT 1-10-1 MOE 1206 398069 2451 2462 ATATACATGACA 1-10-1 MOE 1474 398002 2450 2463 TATATACATGACAC 2-10-2 MOE 1473 WO 2007/146511 PCT/US2007/068401 -214 398068 2440 2451 ACAGCTACACAA 1-10-1 MOE 1472 398001 2439 2452 CACAGCTACACAAC 2-10-2 MOE 1471 390026 2438 2449 AGCTACACAACC 1-10-1 MOE 1470 390025 2406 2417 GTGTCAAAACCC 1-10-1 MOE 1211 398067 2405 2416 TGTCAAAACCCT 1-10-1 MOE 1210 398000 2404 2417 GTGTCAAAACCCTG 2-10-2 MOE 1469 398066 2372 2383 AGATTGGTCAGG 1-10-1 MOE 1468 397999 2371 2384 AAGATTGGTCAGGA 2-10-2 MOE 1467 398065 2349 2360 GTTCCTATAACT 1-10-1 MOE 1466 397998 2348 2361 TGTTCCTATAACTG 2-10-2 MOE 1465 398064 2331 2342 CTGACACAATGT 1-10-1 MOE 1464 397997 2330 2343 TCTGACACAATGTC 2-10-2 MOE 1463 398063 2321 2332 GTCCTATTGCCA 1-10-1 MOE 1205 397996 2320 2333 TGTCCTATTGCCAT 2-10-2 MOE 1462 390022 2286 2297 CAGTTTATTCAA 1-10-1 MOE 1142 336221 2230 2243 TCAGACTTTTGTAA 3-8-3 MOE 1461 336220 2224 2237 TTTTGTAATTTGTG 3-8-3 MOE 1460 336219 2209 2222 ATGCTGATCTTCAT 3-8-3 MOE 1459 390021 2203 2214 CTTCATCAAAAG 1-10-1 MOE 1458 336218 2201 2214 CTTCATCAAAAGGT 3-8-3 MOE 1457 389779 2201 2212 TCATCAAAAGGT 1-9-2 MOE 1176 389979 2201 2212 TCATCAAAAGGT 1-10-1 MOE 1176 397995 2200 2213 TTCATCAAAAGGTT 2-10-2 MOE 1456 336217 2192 2205 AAGGTTCATTCTCT 3-8-3 MOE 1455 390020 2183 2194 TCTGGATCAGAG 1-10-1 MOE 1149 336216 2182 2195 CTCTGGATCAGAGT 3-8-3 MOE 1454 336215 2169 2182 TCAGTGGTGTCAGA 3-8-3 MOE 1453 398062 2166 2177 GGTGTCAGAATA 1-10-1 MOE 1255 397994 2165 2178 TGGTGTCAGAATAT 2-10-2 MOE 1452 390019 2163 2174 GTCAGAATATCT 1-10-1 MOE 1173 336214 2157 2170 GAATATCTATAATG 3-8-3 MOE 1573 398061 2151 2162 ATAATGATCAGG 1-10-1 MOE 1451 397993 2150 2163 TATAATGATCAGGT 2-10-2 MOE 1450 336213 2146 2159 ATGATCAGGTTCAT 3-8-3 MOE 1449 389778 2144 2155 TCAGGTTCATTG 1-9-2 MOE 1448 389978 2144 2155 TCAGGTTCATTG 1-10-1 MOE 1448 398060 2137 2148 CATTGTCACTAA 1-10-1 MOE 1447 336212 2136 2149 TCATTGTCACTAAC 3-8-3 MOE 1446 397992 2136 2149 TCATTGTCACTAAC 2-10-2 MOE 1446 336211 2112 2125 ACAGAAGTTGAACT 3-8-3 MOE 1445 390017 2111 2122 GAAGTTGAACTG 1-10-1 MOE 1444 398059 2108 2119 GTTGAACTGCTA 1-10-1 MOE 1443 397991 2107 2120 AGTTGAACTGCTAG 2-10-2 MOE 1442 336210 2104 2117 TGAACTGCTAGCCT 3-8-3 MOE 1441 335340 2104 2118 TTGAACTGCTAGCCT 1-10-4 MOE 1440 335339 2103 2117 TGAACTGCTAGCCTC 1-10-4 MOE 1439 335338 2102 2116 GAACTGCTAGCCTCT 1-10-4 MOE 1438 335337 2101 2115 AACTGCTAGCCTCTG 1-10-4 MOE 1437 335336 2100 2114 ACTGCTAGCCTCTGG 1-10-4 MOE 1436 1-10-2 MOE 390430 2099 2111 GCTAGCCTCTGGA Unmodified cytosines 1163 1-10-2 MOE Unmodified cytosines 390431 2099 2111 GCTAGCCTCTGGA C in wing 9- 1163 WO 2007/146511 PCT/US2007/068401 -215 (aminoethoxy)phenoxazine 390432 2099 2111 GCTAGCCTCTGGA 1-10-2 MOE 1163 1-10-2 MOE Unmodified cytosines 390433 2099 2111 GCTAGCCTCTGGA Nt 6 is 9-(aminoethoxy)phenoxazine 1163 1-10-2 MOE Unmodified cytosines 390434 2099 2111 GCTAGCCTCTGGA Nt 7 is 9-(aminoethoxy)phenoxazine 1163 1-10-2 MOE Unmodified cytosines 390435 2099 2111 GCTAGCCTCTGGA Nt 9 is 9-(aminoethoxy)phenoxazine 1163 335335 2099 2113 CTGCTAGCCTCTGGA 1-10-4 MOE 1435 389777 2098 2109 TAGCCTCTGGAT 1-9-2 MOE 1434 389954 2098 2109 TAGCCTCTGGAT 1-10-1 MOE 1434 335334 2098 2112 TGCTAGCCTCTGGAT 1-10-4 MOE 1433 331429 2097 2110 CTAGCCTCTGGATT 2-10-2 MOE 1431 335349 2097 2110 CTAGCCTCTGGATT 2-10-2 MOE 1431 335367 2097 2110 CTAGCCTCTGGATT 2-10-2 Methyleneoxy BNA 1431 335378 2097 2110 CTAGCCTCTGGATT 2-10-2 Methyleneoxy BNA 1431 2-10-2 Methyleneoxy BNA 392061 2097 2110 CTAGCCTCTGGATT Unmodified cytosines in gap 1431 1-10-2 2'-(acetylamino-butyl-acetamido) 383991 2097 2109 TAGCCTCTGGATT cholesterol/MOE 1432 1-10-2 2'-(acetylamino-butyl-acetamido) 383992 2097 2109 TAGCCTCTGGATT cholic acid/MOE 1432 386970 2097 2109 TAGCCTCTGGATT 1-10-2 MOE 1432 1-10-2 MOE Unmodified cytosines 390578 2097 2109 TAGCCTCTGGATT Ts in wings are 2-thiothymines 1432 390614 2097 2109 TAGCCTCTGGATT 1-10-2 PentaF 1432 335333 2097 2111 GCTAGCCTCTGGATT 1-10-4 MOE 1430 1-10-2 2'-(butylacetamido) 386683 2097 2109 TAGCCTCTGGATT palmitamide/MOE 1432 371975 2096 2110 CTAGCCTCTGGATTT 3-10-2 MOE 1429 335341 2096 2111 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 335350 2096 2111 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 3-10-3 Methyleneoxy BNA 335368 2096 2111 GCTAGCCTCTGGATTT Phosphodiester linkages in wings 1428 335379 2096 2111 GCTAGCCTCTGGATTT 3-10-3 Methyleneoxy BNA 1428 3-10-3 MOE 383739 2096 2111 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 3-10-3 OMe 384071 2096 2111 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 3-10-3 Methyleneoxy BNA 384073 2096 2111 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 3-10-3 MOE 5-methylcytosine in gap 390576 2096 2111 GCTAGCCTCTGGATTT T's in wings are 2-thiothymines 1428 3-10-3 MOE Pyrimidines in wings are 5-thiazole 390580 2096 2111 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 3-10-3 MOE 390581 2096 2111 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 WO 2007/146511 PCT/US2007/068401 -216 3-10-3 MOE 391863 2096 2111 GCTAGCCTCTGGATTT Unmodified cytosines 1428 3-10-3 Methyleneoxy BNA 391864 2096 2111 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 3-10-3 Methyleneoxy BNA 391865 2096 2111 GCTAGCCTCTGGATTT Unmodified cytosines 1428 375560 2096 2110 CTAGCCTCTGGATTT 2-10-3 MOE 1429 2-10-2 Methyleneoxy BNA 391172 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines 1429 391175 2096 2110 CTAGCCTCTGGATTT 2-10-3 Methyleneoxy BNA 1429 2-10-3 MOE 391449 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines 1429 2-10-3 Methyleneoxy BNA 392054 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines in gap 1429 2-10-3 MOE 392055 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines in gap 1429 362977 2096 2111 GCTAGCCTCTGGATTT 2-12-2 MOE 1428 386770 2096 2109 TAGCCTCTGGATTT 1-11-2 MOE 1427 1-10-3 MOE Unmodified cytosines 390577 2096 2109 TAGCCTCTGGATTT T's in wings are 2-thiothymines 1427 335332 2096 2110 CTAGCCTCTGGATTT 1-10-4 MOE 1429 1-1-1-10-3 MOE/4'-thio/2'-O-[(2 methoxy)ethyl]-4'-thio/2'-O-[(2 methoxy)ethyl]-4'-thio Unmodified cytosines in wings 390579 2096 2111 GCTAGCCTCTGGATTT Phosphorodiester linkage in wings 1428 2-10-3 (5'R)-5'-methyl Methyleneoxy BNA 391173 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines 1429 2-10-3 (5'S)-5'-methyl Methyleneoxy BNA 391174 2096 2110 CTAGCCTCTGGATTT Unmodified cytosines 1429 390607 2096 2111 GCTAGCCTCTGGATTT 3-10-3 MOE/pentaF 1428 Unmodified cytosines in wing 390609 2096 2111 GCTAGCCTCTGGATTT 3-10-2-1 MOE/MOE/pentaF 1428 Unmodified cytosines in wing 384072 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 MOE/pentaF/pentaF 1428 Unmodified cytosines in wings 390606 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 MOE/pentaF/pentaF 1428 Unmodified cytosines in wing 390608 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 MOE/pentaF/pentaF 1428 Unmodified cytosines in wing 391869 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 Methyleneoxy BNA /{5'S)- 1428 5'-methyl- Methyleneoxy BNA /(5'S)-5'-methyl- Methyleneoxy BNA Unmodified cytosines 385036 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 OMe/2'-O-methyl-4'- 1428 thio/2'-O-methyl-4'-thio Unmodified cytosines in wing 385871 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 OMe/ 2'-0-[(2- 1428 methoxy)ethyl]-4'-thio/ 2'-0-[(2 methoxy)ethyl]-4'-thio Unmodified cytosines in wing WO 2007/146511 PCT/US2007/068401 -217 386682 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 2'-(butylacetamido)- 1428 palmitamide /MOE /MOE 390582 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 MOE/2'-O-[(2- 1428 methoxy)ethyl]-4'-thio / 2'-0-[(2 methoxy)ethyl]-4'-thio Unmodified cytosines in wings Phosphodiester linkage in wings 391868 2096 2111 GCTAGCCTCTGGATTT 1-2-10-3 (5'R)-5'-methyl- 1428 Methyleneoxy BNA / Methyleneoxy BNA /(5'R)-5'-methyl Methyleneoxy BNA Unmodified cytosines 336209 2095 2108 AGCCTCTGGATTTG 3-8-3 MOE 1425 335331 2095 2109 TAGCCTCTGGATTTG 1-10-4 MOE 1426 335376 2095 2109 TAGCCTCTGGATTTG 1-10-4 Methyleneoxy BNA 1426 1-10-4 Methyleneoxy BNA 335377 2095 2109 TAGCCTCTGGATTTG Phosphodiester in 3' wing 1426 335330 2094 2108 AGCCTCTGGATTTGA 1-10-4 MOE 1424 336208 2079 2092 GGCTCCTCTACTGT 3-8-3 MOE 1423 336207 2073 2086 TCTACTGTTTTTGT 3-8-3 MOE 1422 336206 2047 2060 CACCTTAAAATTTG 3-8-3 MOE 1518 389776 2046 2057 CTTAAAATTTGG 1-9-2 MOE 1421 389977 2046 2057 CTTAAAATTTGG 1-10-1 MOE 1421 397990 2045 2058 CCTTAAAATTTGGA 2-10-2 MOE 1420 336205 2043 2056 TTAAAATTTGGAGA 3-8-3 MOE 1419 398058 2029 2040 AGTATCGGTTGG 1-10-1 MOE 1418 336204 2028 2041 AAGTATCGGTTGGC 3-8-3 MOE 1417 397989 2028 2041 AAGTATCGGTTGGC 2-10-2 MOE 1417 336203 2002 2015 TGCTTTGTCAAGAT 3-8-3 MOE 1416 389775 2002 2013 CTTTGTCAAGAT 1-9-2 MOE 1177 389976 2002 2013 CTTTGTCAAGAT 1-10-1 MOE 1177 397988 2001 2014 GCTTTGTCAAGATC 2-10-2 MOE 1415 336202 1959 1972 TCCTTGTCATTATC 3-8-3 MOE 1414 389774 1945 1956 CACGCTCTATAC 1-9-2 MOE 1413 389975 1945 1956 CACGCTCTATAC 1-10-1 MOE 1413 336201 1944 1957 GCACGCTCTATACT 3-8-3 MOE 1412 336200 1929 1942 CAAATGCTATCGAT 3-8-3 MOE 1411 389773 1904 1915 AGACTTCCATTT 1-9-2 MOE 1410 389974 1904 1915 AGACTTCCATTT 1-10-1 MOE 1410 336199 1902 1915 AGACTTCCATTTTC 3-8-3 MOE 1409 336198 1884 1897 TTTTCTGAGGTTTC 3-8-3 MOE 1408 398057 1878 1889 GGTTTCCTCTGG 1-10-1 MOE 1407 397987 1877 1890 AGGTTTCCTCTGGT 2-10-2 MOE 1406 336197 1873 1886 TTCCTCTGGTCCTG 3-8-3 MOE 1405 390015 1868 1879 GGTCCTGGTATG 1-10-1 MOE 1404 398056 1865 1876 CCTGGTATGAAG 1-10-1 MOE 1403 336196 1864 1877 TCCTGGTATGAAGA 3-8-3 MOE 1402 397986 1864 1877 TCCTGGTATGAAGA 2-10-2 MOE 1402 398055 1849 1860 TATTTACCCAAA 1-10-1 MOE 1401 397985 1848 1861 GTATTTACCCAAAA 2-10-2 MOE 1400 336195 1847 1860 TATTTACCCAAAAG 3-8-3 MOE 1399 389772 1846 1857 TTACCCAAAAGT 1-9-2 MOE 1398 389973 1846 1857 TTACCCAAAAGT 1-10-1 MOE 1398 336194 1838 1851 AAAAGTGAAACATT 3-8-3 MOE 1145 WO 2007/146511 PCT/US2007/068401 -218 398054 1836 1847 GTGAAACATTTT 1-10-1 MOE 1144 397984 1835 1848 AGTGAAACATTTTG 2-10-2 MOE 1397 336193 1828 1841 CATTTTGTCCTTTT 3-8-3 MOE 1182 336192 1810 1823 CATCTTGTTCTGTT 3-8-3 MOE 1396 336191 1800 1813 TGTTTGTGGAAGAA 3-8-3 MOE 1395 398053 1796 1807 TGGAAGAACTCT 1-10-1 MOE 1394 397983 1795 1808 GTGGAAGAACTCTA 2-10-2 MOE 1393 389771 1794 1805 GAAGAACTCTAC 1-9-2 MOE 1392 389972 1794 1805 GAAGAACTCTAC 1-10-1 MOE 1392 336190 1789 1802 GAACTCTACTTTGA 3-8-3 MOE 1391 336189 1773 1786 TCACCACACACAGG 3-8-3 MOE 1390 336188 1754 1767 GCTGAGGGAACTCA 3-8-3 MOE 1389 398052 1751 1762 GGGAACTCAAAG 1-10-1 MOE 1388 389770 1750 1761 GGAACTCAAAGT 1-9-2 MOE 1386 389971 1750 1761 GGAACTCAAAGT 1-10-1 MOE 1386 397982 1750 1763 AGGGAACTCAAAGT 2-10-2 MOE 1387 336187 1747 1760 GAACTCAAAGTACA 3-8-3 MOE 1385 390012 1745 1756 TCAAAGTACATG 1-10-1 MOE 1384 336186 1688 1701 TCTTCACCTTTAGC 3-8-3 MOE 1383 398051 1684 1695 CCTTTAGCTGGC 1-10-1 MOE 1220 397981 1683 1696 ACCTTTAGCTGGCA 2-10-2 MOE 1382 336185 1677 1690 AGCTGGCAGACCAC 3-8-3 MOE 1381 389769 1676 1687 TGGCAGACCACA 1-9-2 MOE 1249 389970 1676 1687 TGGCAGACCACA 1-10-1 MOE 1249 2-10-2 Methyleneoxy BNA 392060 1675 1688 CTGGCAGACCACAA Unmodified cytosines in gap 1380 398050 1672 1683 AGACCACAAACT 1-10-1 MOE 1379 397980 1671 1684 CAGACCACAAACTG 2-10-2 MOE 1378 390011 1658 1669 GGATTGCAAGTT 1-10-1 MOE 1238 336184 1655 1668 GATTGCAAGTTCCG 3-8-3 MOE 1508 336183 1644 1657 CCGCCACTGAACAT 3-8-3 MOE 1377 390010 1643 1654 CCACTGAACATT 1-10-1 MOE 1240 398049 1641 1652 ACTGAACATTGG 1-10-1 MOE 1376 397979 1640 1653 CACTGAACATTGGA 2-10-2 MOE 1375 336182 1633 1646 CATTGGAATAGTTT 3-8-3 MOE 1374 389768 1630 1641 GAATAGTTTCAA 1-9-2 MOE 1373 389969 1630 1641 GAATAGTTTCAA 1-10-1 MOE 1373 398048 1626 1637 AGTTTCAAACAT 1-10-1 MOE 1372 397978 1625 1638 TAGTTTCAAACATC 2-10-2 MOE 1371 336181 1623 1636 GTTTCAAACATCAT 3-8-3 MOE 1370 398047 1614 1625 CATCTTGTGAAA 1-10-1 MOE 1369 336180 1613 1626 TCATCTTGTGAAAC 3-8-3 MOE 1368 390009 1613 1624 ATCTTGTGAAAC 1-10-1 MOE 1175 397977 1613 1626 TCATCTTGTGAAAC 2-10-2 MOE 1368 390007 1563 1574 CAGGTAGCTATA 1-10-1 MOE 1367 336179 1561 1574 CAGGTAGCTATAAT 3-8-3 MOE 1366 336178 1541 1554 CATAGCGCCTCTGA 3-8-3 MOE 1365 336177 1534 1547 CCTCTGACTGGGAA 3-8-3 MOE 1364 389767 1534 1545 TCTGACTGGGAA 1-9-2 MOE 1151 389968 1534 1545 TCTGACTGGGAA 1-10-1 MOE 1151 335344 1503 1516 TCTCTGGTCCTTAC 2-10-2 MOE 1363 2-10-2 MOE 335355 1503 1516 TCTCTGGTCCTTAC Phosphodiester linkage in wings 1363 335370 1503 1516 TCTCTGGTCCTTAC 2-10-2 Methyleneoxy BNA 1363 WO 2007/146511 PCT/US2007/068401 -219 Phosphodiester linkage in wings 335381 1503 1516 TCTCTGGTCCTTAC 2-10-2 Methyleneoxy BNA 1363 2-10-2 MOE 335411 1503 1516 TCTCTGGTCCTTAC 3' C is 9-(aminoethoxy)phenoxazine 1363 2-10-2 MOE C in 5' wing is 9 335412 1503 1516 TCTCTGGTCCTTAC (aminoethoxy)phenoxazine 1363 2-10-2 MOE C in wings are 335413 1503 1516 TCTCTGGTCCTTAC 9-(aminoethoxy)phenoxazine 1363 336176 1502 1515 CTCTGGTCCTTACT 3-8-3 MOE 1361 335345 1502 1517 GTCTCTGGTCCTTACT 3-10-3 MOE 1362 3-10-3 MOE 335356 1502 1517 GTCTCTGGTCCTTACT Phosphodiester linkage in wings 1362 3-10-3 Methyleneoxy BNA 335371 1502 1517 GTCTCTGGTCCTTACT Phosphodiester linkage in wings 1362 335382 1502 1517 GTCTCTGGTCCTTACT 3-10-3 Methyleneoxy BNA 1362 3-10-3 MOE C in 3' wing is 9 335414 1502 1517 GTCTCTGGTCCTTACT (aminoethoxy)phenoxazine 1362 3-10-3 MOE C in 5' wing is 9 335415 1502 1517 GTCTCTGGTCCTTACT (aminoethoxy)phenoxazine 1362 3-10-3 MOE C's in wings are 335416 1502 1517 GTCTCTGGTCCTTACT 9-(aminoethoxy)phenoxazine 1362 336175 1495 1508 CCTTACTTCCCCAT 3-8-3 MOE 1360 336174 1472 1485 GGGCCTCTTGTGCC 3-8-3 MOE 1359 336173 1465 1478 TTGTGCCTTTAAAA 3-8-3 MOE 1358 398046 1465 1476 GTGCCTTTAAAA 1-10-1 MOE 1199 389766 1464 1475 TGCCTTTAAAAA 1-9-2 MOE 1217 389967 1464 1475 TGCCTTTAAAAA 1-10-1 MOE 1217 397976 1464 1477 TGTGCCTTTAAAAA 2-10-2 MOE 1357 336172 1437 1450 AATAAATATGCACA 3-8-3 MOE 1356 398045 1423 1434 TCATTACACCAG 1-10-1 MOE 1355 336171 1422 1435 ATCATTACACCAGT 3-8-3 MOE 1354 389765 1422 1433 CATTACACCAGT 1-9-2 MOE 1353 389966 1422 1433 CATTACACCAGT 1-10-1 MOE 1353 397975 1422 1435 ATCATTACACCAGT 2-10-2 MOE 1354 390005 1400 1411 CCAGCTTTACAG 1-10-1 MOE 1352 336170 1392 1405 TTACAGTGAATTGC 3-8-3 MOE 1351 398044 1382 1393 GCTGCAACATGA 1-10-1 MOE 1350 336169 1381 1394 TGCTGCAACATGAT 3-8-3 MOE 1349 389764 1381 1392 CTGCAACATGAT 1-9-2 MOE 1018 389965 1381 1392 CTGCAACATGAT 1-10-1 MOE 1018 397974 1381 1394 TGCTGCAACATGAT 2-10-2 MOE 1349 336168 1362 1375 TCTTCACTTAGCCA 3-8-3 MOE 1348 390004 1362 1373 TTCACTTAGCCA 1-10-1 MOE 1208 336167 1353 1366 AGCCATTGGTCAAG 3-8-3 MOE 1347 398043 1345 1356 CAAGATCTTCAC 1-10-1 MOE 1244 336166 1344 1357 TCAAGATCTTCACA 3-8-3 MOE 1346 390003 1344 1355 AAGATCTTCACA 1-10-1 MOE 1243 397973 1344 1357 TCAAGATCTTCACA 2-10-2 MOE 1346 336165 1329 1342 AAGGGTTTGATAAG 3-8-3 MOE 1345 WO 2007/146511 PCT/US2007/068401 -220 390002 1322 1333 ATAAGTTCTAGC 1-10-1 MOE 1344 336164 1318 1331 AAGTTCTAGCTGTG 3-8-3 MOE 1343 398042 1305 1316 TGGGTTATGGTC 1-10-1 MOE 1214 336163 1304 1317 GTGGGTTATGGTCT 3-8-3 MOE 1342 397972 1304 1317 GTGGGTTATGGTCT 2-10-2 MOE 1342 398089 1298 1309 TGGTCTTCAAAA 1-10-1 MOE 1341 389763 1296 1307 GTCTTCAAAAGG 1-9-2 MOE 1197 389964 1296 1307 GTCTTCAAAAGG 1-10-1 MOE 1197 398041 1294 1305 CTTCAAAAGGAT 1-10-1 MOE 1196 336162 1293 1306 TCTTCAAAAGGATA 3-8-3 MOE 1340 397971 1293 1306 TCTTCAAAAGGATA 2-10-2 MOE 1340 398040 1279 1290 GTGCAACTCTGC 1-10-1 MOE 1236 336161 1278 1291 TGTGCAACTCTGCA 3-8-3 MOE 1235 397970 1278 1291 TGTGCAACTCTGCA 2-10-2 MOE 1235 398039 1264 1275 TAAATTTGGCGG 1-10-1 MOE 1339 397969 1263 1276 TTAAATTTGGCGGT 2-10-2 MOE 1338 336160 1261 1274 AAATTTGGCGGTGT 3-8-3 MOE 1337 336159 1253 1266 CGGTGTCATAATGT 3-8-3 MOE 1336 398038 1252 1263 TGTCATAATGTC 1-10-1 MOE 1200 390000 1251 1262 GTCATAATGTCT 1-10-1 MOE 1194 397968 1251 1264 GTGTCATAATGTCT 2-10-2 MOE 1195 336158 1227 1240 AGATTGTATATCTT 3-8-3 MOE 1335 389762 1220 1231 ATCTTGTAATGG 1-9-2 MOE 1334 389963 1220 1231 ATCTTGTAATGG 1-10-1 MOE 1334 336157 1215 1228 TTGTAATGGTTTTT 3-8-3 MOE 1333 336156 1202 1215 TATGCTTTGAATCC 3-8-3 MOE 1332 389998 1199 1210 TTTGAATCCAAA 1-10-1 MOE 1331 397967 1198 1211 CTTTGAATCCAAAA 2-10-2 MOE 1330 336155 1190 1203 CCAAAAACCTTACT 3-8-3 MOE 1500 336154 1176 1189 ACATCATCAATATT 3-8-3 MOE 1329 389761 1171 1182 CAATATTGTTCC 1-9-2 MOE 1328 389962 1171 1182 CAATATTGTTCC 1-10-1 MOE 1328 398037 1170 1181 AATATTGTTCCT 1-10-1 MOE 1202 397966 1169 1182 CAATATTGTTCCTG 2-10-2 MOE 1327 336153 1164 1177 TTGTTCCTGTATAC 3-8-3 MOE 1326 336152 1149 1162 CCTTCAAGTCTTTC 3-8-3 MOE 1325 389996 1141 1152 TTTCTGCAGGAA 1-10-1 MOE 1165 336151 1138 1151 TTCTGCAGGAAATC 3-8-3 MOE 1324 398036 1138 1149 CTGCAGGAAATC 1-10-1 MOE 1323 397965 1137 1150 TCTGCAGGAAATCC 2-10-2 MOE 1322 389760 1129 1140 ATCCCATAGCAA 1-9-2 MOE 1321 389961 1129 1140 ATCCCATAGCAA 1-10-1 MOE 1321 398035 1126 1137 CCATAGCAATAA 1-10-1 MOE 1320 336150 1125 1138 CCCATAGCAATAAT 3-8-3 MOE 1319 397964 1125 1138 CCCATAGCAATAAT 2-10-2 MOE 1319 336149 1110 1123 TTTGGATAAATATA 3-8-3 MOE 1496 389995 1106 1117 TAAATATAGGTC 1-10-1 MOE 1516 336148 1100 1113 TATAGGTCAAGTCT 3-8-3 MOE 1495 398034 1099 1110 AGGTCAAGTCTA 1-10-1 MOE 1300 397963 1098 1111 TAGGTCAAGTCTAA 2-10-2 MOE 1494 389994 1095 1106 CAAGTCTAAGTC 1-10-1 MOE 1299 336147 1090 1103 GTCTAAGTCGAATC 3-8-3 MOE 1298 389993 1083 1094 GAATCCATCCTC 1-10-1 MOE 1297 336146 1080 1093 AATCCATCCTCTTG 3-8-3 MOE 1296 WO 2007/146511 PCT/US2007/068401 -221 398033 1077 1088 ATCCTCTTGATA 1-10-1 MOE 1198 397962 1076 1089 CATCCTCTTGATAT 2-10-2 MOE 1295 336145 1070 1083 CTTGATATCTCCTT 3-8-3 MOE 1294 336144 1057 1070 TTTGTTTCTGCTAA 3-8-3 MOE 1293 389759 1056 1067 GTTTCTGCTAAC 1-9-2 MOE 1292 389960 1056 1067 GTTTCTGCTAAC 1-10-1 MOE 1292 2-10-2 Methyleneoxy BNA 392059 1055 1068 TGTTTCTGCTAACG Unmodified cytosines in gap 1291 336143 1044 1057 ACGATCTCTTTGAT 3-8-3 MOE 1290 398032 1038 1049 TTTGATGATGGC 1-10-1 MOE 1222 397961 1037 1050 CTTTGATGATGGCT 2-10-2 MOE 1289 389992 1036 1047 TGATGATGGCTG 1-10-1 MOE 1288 336142 1032 1045 ATGATGGCTGTCAT 3-8-3 MOE 1287 389991 1021 1032 TGTCTGGGAGCC 1-10-1 MOE 1286 2-10-2 Methyleneoxy BNA 392058 1020 1033 ATGTCTGGGAGCCT Unmodified cytosines in gap 1285 397960 1020 1033 ATGTCTGGGAGCCT 2-10-2 MOE 1285 389990 1007 1018 TGGCTGAAGAAA 1-10-1 MOE 1284 397959 1006 1019 GTGGCTGAAGAAAA 2-10-2 MOE 1283 398031 987 998 GAGAGATGGCAG 1-10-1 MOE 1282 397958 986 999 AGAGAGATGGCAGA 2-10-2 MOE 1281 389758 983 994 GATGGCAGAAGC 1-9-2 MOE 1280 389959 983 994 GATGGCAGAAGC 1-10-1 MOE 1280 398030 976 987 GAAGCTGCTGGT 1-10-1 MOE 1143 397957 975 988 AGAAGCTGCTGGTG 2-10-2 MOE 1279 389989 953 964 TTCTGCAGGATG 1-10-1 MOE 1170 389757 941 952 GAAATGGCTCTG 1-9-2 MOE 1278 389958 941 952 GAAATGGCTCTG 1-10-1 MOE 1278 397956 940 953 GGAAATGGCTCTGG 2-10-2 MOE 1277 398029 931 942 TGGACTTGGCGG 1-10-1 MOE 1186 397955 930 943 CTGGACTTGGCGGT 2-10-2 MOE 1276 398028 914 925 GATGCCCCTCGC 1-10-1 MOE 1275 397954 913 926 TGATGCCCCTCGCT 2-10-2 MOE 1274 398027 883 894 GGACCGCAGCCG 1-10-1 MOE 1155 397953 882 895 TGGACCGCAGCCGG 2-10-2 MOE 1273 389756 874 885 CCGGGTAATGGC 1-9-2 MOE 1272 389957 874 885 CCGGGTAATGGC 1-10-1 MOE 1272 398026 867 878 ATGGCTGCTGCG 1-10-1 MOE 1160 397952 866 879 AATGGCTGCTGCGG 2-10-2 MOE 1271 389987 848 859 CTGGATGGTTGC 1-10-1 MOE 1270 389755 806 817 AGAGGCCTGGCA 1-9-2 MOE 1269 389956 806 817 AGAGGCCTGGCA 1-10-1 MOE 1269 389985 584 595 ATGGTGACAGGC 1-10-1 MOE 1268 398025 581 592 GTGACAGGCGAC 1-10-1 MOE 1267 397951 580 593 GGTGACAGGCGACT 2-10-2 MOE 1266 389754 312 323 TGCTCACAGGCG 1-9-2 MOE 1158 389955 312 323 TGCTCACAGGCG 1-10-1 MOE 1158 398024 231 242 CAGCGGCTCAAC 1-10-1 MOE 1265 397950 230 243 ACAGCGGCTCAACT 2-10-2 MOE 1264 389982 205 216 CATGGCTGCAGC 1-10-1 MOE 1161 392056 204 217 TCATGGCTGCAGCT 2-10-2 Methyleneoxy BNA 1263 394424 204 217 TCATGGCTGCAGCT 2-10-2 MOE 1263 2-10-2 (R)-CMOE BNA 396007 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 WO 2007/146511 PCT/US2007/068401 -222 2-10-2 (S)-CMOE BNA 396008 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 a-L-methyleneoxy BNA 396009 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 Oxyamino BNA 396566 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 N-Methyl-Oxyamino BNA 396567 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (6R)-6-Methyl Methyleneoxy BNA 396568 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 OMe 397913 204 217 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 2-10-2 OMe 401974 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 Methyleneoxy BNA 403737 204 217 TCATGGCTGCAGCT 5-thiazole nucleobases in wings 1263 2-10-2 Methyleneoxy BNA 5-methylcytosine in gaps 404121 204 217 TCATGGCTGCAGCT 3' Terminal THF phosphorothioate 1263 2-10-2 Methyleneoxy BNA 5-methylcytosinse in gaps 404228 204 217 TCATGGCTGCAGCT 5'-terminal reverse abasic 1263 2-10-2 (6'S)-6'-methyl Methyleneoxy BNA 396024 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (5'S)-5'-methyl Methyleneoxy BNA 396569 204 217 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-1-1 Methyleneoxy BNA / Methyleneoxy BNA /2' (butylacetamido)-palmitamide/ 396577 204 217 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 396576 204 217 TCATGGCTGCAGCT 1-1-10-2 2'-(butylacetamido)- 1263 palmitamide/ Methyleneoxy BNA / Methyleneoxy BNA Unmodified cytosines in gap 398023 191 202 CCGAGAGGAGAG 1-10-1 MOE 1262 397949 190 203 TCCGAGAGGAGAGA 2-10-2 MOE 1261 398022 126 137 AAGAGTCCCGCC 1-10-1 MOE 1260 397948 125 138 AAAGAGTCCCGCCA 2-10-2 MOE 1259 Table 22: Short Antisense Compounds targeted to SEQ ID NO: 15 ISIS 5' 3' Sequence (5'-3') Gapmer Motif SEQ No. Target Target ID Site Site NO 397948 525 538 AAAGAGTCCCGCCA 2-10-2 MOE 1259 398022 526 537 AAGAGTCCCGCC 1-10-1 MOE 1260 397949 590 603 TCCGAGAGGAGAGA 2-10-2 MOE 1261 398023 591 602 CCGAGAGGAGAG 1-10-1 MOE 1262 WO 2007/146511 PCT/US2007/068401 -223 394424 604 617 TCATGGCTGCAGCT 2-10-2 MOE 1263 2-10-2 OMe 397913 604 617 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 2-10-2 Ome 401974 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 Methyleneoxy BNA 5-thiazole nucleobases in 403737 604 617 TCATGGCTGCAGCT wings 1263 2-10-2 Methyleneoxy BNA 392056 604 617 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 1-1-10-2 2' (butylacetamido) palmitamide / Methyleneoxy BNA / Methyleneoxy BNA 396576 604 617 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 2-10-1-2 Methyleneoxy BNA / Methyleneoxy BNA /2'-(butylacetamido) palmitamide/ 396577 604 617 TCATGGCTGCAGCT Unmodified cytosines in gap 1263 2-10-2 Methyleneoxy BNA 5-methylcytosine in gaps 3' Terminal THF 404121 604 617 TCATGGCTGCAGCT phosphorothioate 1263 2-10-2 Methyleneoxy BNA 5-methylcytosinse in gaps 404228 604 617 TCATGGCTGCAGCT 5'-terminal reverse abasic 1263 2-10-2 (R)-CMOE BNA 396007 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (S)-CMOE BNA 396008 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 a-L-methyleneoxy BNA 396009 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (6'S)-6'-methyl Methyleneoxy BNA 396024 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 Oxyamino BNA 396566 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 N-Methyl-Oxyamino BNA 396567 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (6R)-6-Methyl Methyleneoxy BNA 396568 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 2-10-2 (5'S)-5'-methyl Methyleneoxy BNA 396569 604 617 TCATGGCTGCAGCT Unmodified cytosines 1263 389982 605 616 CATGGCTGCAGC 1-10-1 MOE 1161 397950 630 643 ACAGCGGCTCAACT 2-10-2 MOE 1264 398024 631 642 CAGCGGCTCAAC 1-10-1 MOE 1265 389955 712 723 TGCTCACAGGCG 1-10-1 MOE 1158 WO 2007/146511 PCT/US2007/068401 -224 389754 712 723 TGCTCACAGGCG 1-9-2 MOE 1158 397951 980 993 GGTGACAGGCGACT 2-10-2 MOE 1266 398025 981 992 GTGACAGGCGAC 1-10-1 MOE 1267 389985 984 995 ATGGTGACAGGC 1-10-1 MOE 1268 389956 1206 1217 AGAGGCCTGGCA 1-10-1 MOE 1269 389755 1206 1217 AGAGGCCTGGCA 1-9-2 MOE 1269 389987 1248 1259 CTGGATGGTTGC 1-10-1 MOE 1270 397952 1266 1279 AATGGCTGCTGCGG 2-10-2 MOE 1271 398026 1267 1278 ATGGCTGCTGCG 1-10-1 MOE 1160 389957 1274 1285 CCGGGTAATGGC 1-10-1 MOE 1272 389756 1274 1285 CCGGGTAATGGC 1-9-2 MOE 1272 397953 1282 1295 TGGACCGCAGCCGG 2-10-2 MOE 1273 398027 1283 1294 GGACCGCAGCCG 1-10-1 MOE 1155 397954 1313 1326 TGATGCCCCTCGCT 2-10-2 MOE 1274 398028 1314 1325 GATGCCCCTCGC 1-10-1 MOE 1275 397955 1330 1343 CTGGACTTGGCGGT 2-10-2 MOE 1276 398029 1331 1342 TGGACTTGGCGG 1-10-1 MOE 1186 397956 1340 1353 GGAAATGGCTCTGG 2-10-2 MOE 1277 389958 1341 1352 GAAATGGCTCTG 1-10-1 MOE 1278 389757 1341 1352 GAAATGGCTCTG 1-9-2 MOE 1278 389989 1353 1364 TTCTGCAGGATG 1-10-1 MOE 1170 397957 1375 1388 AGAAGCTGCTGGTG 2-10-2 MOE 1279 398030 1376 1387 GAAGCTGCTGGT 1-10-1 MOE 1143 389959 1383 1394 GATGGCAGAAGC 1-10-1 MOE 1280 389758 1383 1394 GATGGCAGAAGC 1-9-2 MOE 1280 397958 1386 1399 AGAGAGATGGCAGA 2-10-2 MOE 1281 398031 1387 1398 GAGAGATGGCAG 1-10-1 MOE 1282 397959 1406 1419 GTGGCTGAAGAAAA 2-10-2 MOE 1283 389990 1407 1418 TGGCTGAAGAAA 1-10-1 MOE 1284 397960 1420 1433 ATGTCTGGGAGCCT 2-10-2 MOE 1285 2-10-2 Methyleneoxy BNA 392058 1420 1433 ATGTCTGGGAGCCT 5-methylcytosine in wing 1285 389991 1421 1432 TGTCTGGGAGCC 1-10-1 MOE 1286 336142 1432 1445 ATGATGGCTGTCAT 3-8-3 MOE 1287 389992 1436 1447 TGATGATGGCTG 1-10-1 MOE 1288 397961 1437 1450 CTTTGATGATGGCT 2-10-2 MOE 1289 398032 1438 1449 TTTGATGATGGC 1-10-1 MOE 1222 336143 1444 1457 ACGATCTCTTTGAT 3-8-3 MOE 1290 2-10-2 Methyleneoxy BNA 392059 1455 1468 TGTTTCTGCTAACG 5-methylcytosine in wing 1291 389960 1456 1467 GTTTCTGCTAAC 1-10-1 MOE 1292 389759 1456 1467 GTTTCTGCTAAC 1-9-2 MOE 1292 336144 1457 1470 TTTGTTTCTGCTAA 3-8-3 MOE 1293 336145 1470 1483 CTTGATATCTCCTT 3-8-3 MOE 1294 397962 1476 1489 CATCCTCTTGATAT 2-10-2 MOE 1295 398033 1477 1488 ATCCTCTTGATA 1-10-1 MOE 1198 336146 1480 1493 AATCCATCCTCTTG 3-8-3 MOE 1296 389993 1483 1494 GAATCCATCCTC 1-10-1 MOE 1297 336147 1490 1503 GTCTAAGTCGAATC 3-8-3 MOE 1298 389994 1495 1506 CAAGTCTAAGTC 1-10-1 MOE 1299 398034 1499 1510 AGGTCAAGTCTA 1-10-1 MOE 1300 398010 1500 1513 TACAGGTCAAGTCT 2-10-2 MOE 1166 398077 1501 1512 ACAGGTCAAGTC 1-10-1 MOE 1167 398011 1512 1525 CGCAGAAATGGATA 2-10-2 MOE 1301 WO 2007/146511 PCT/US2007/068401 -225 398078 1513 1524 GCAGAAATGGAT 1-10-1 MOE 1302 398012 1570 1583 TTCGCATCCGTCTA 2-10-2 MOE 1303 398079 1571 1582 TCGCATCCGTCT 1-10-1 MOE 1304 398013 1663 1676 CCCTAGGTTGAATA 2-10-2 MOE 1305 398080 1664 1675 CCTAGGTTGAAT 1-10-1 MOE 1306 398014 2025 2038 GTTATGCAAATCAG 2-10-2 MOE 1307 398081 2026 2037 TTATGCAAATCA 1-10-1 MOE 1308 398015 2620 2633 TGACTCAGTAAATT 2-10-2 MOE 1309 398082 2621 2632 GACTCAGTAAAT 1-10-1 MOE 1310 398016 2655 2668 TTAAAATTCTTGGG 2-10-2 MOE 1311 398083 2656 2667 TAAAATTCTTGG 1-10-1 MOE 1312 398017 2687 2700 CCTAACTTTTAGAC 2-10-2 MOE 1313 398084 2688 2699 CTAACTTTTAGA 1-10-1 MOE 1314 398018 2745 2758 ACCTGAAACTGCAA 2-10-2 MOE 1315 398085 2746 2757 CCTGAAACTGCA 1-10-1 MOE 1157 398019 13166 13179 GTGTCAAAACCACT 2-10-2 MOE 1316 398086 13167 13178 TGTCAAAACCAC 1-10-1 MOE 1204 398020 14675 14688 CCTATTCCCACTGA 2-10-2 MOE 1317 398087 14676 14687 CTATTCCCACTG 1-10-1 MOE 1318 390033 15351 15362 AGCCAACTGCAA 1-10-1 MOE 1483 398021 30985 30998 TTGGATAAATATCT 2-10-2 MOE 1168 398088 30986 30997 TGGATAAATATC 1-10-1 MOE 1169 397964 31001 31014 CCCATAGCAATAAT 2-10-2 MOE 1319 336150 31001 31014 CCCATAGCAATAAT 3-8-3 MOE 1319 398035 31002 31013 CCATAGCAATAA 1-10-1 MOE 1320 389961 31005 31016 ATCCCATAGCAA 1-10-1 MOE 1321 389760 31005 31016 ATCCCATAGCAA 1-9-2 MOE 1321 397965 31013 31026 TCTGCAGGAAATCC 2-10-2 MOE 1322 398036 31014 31025 CTGCAGGAAATC 1-10-1 MOE 1323 336151 31014 31027 TTCTGCAGGAAATC 3-8-3 MOE 1324 389996 31017 31028 TTTCTGCAGGAA 1-10-1 MOE 1165 336152 31025 31038 CCTTCAAGTCTTTC 3-8-3 MOE 1325 336153 31040 31053 TTGTTCCTGTATAC 3-8-3 MOE 1326 397966 31045 31058 CAATATTGTTCCTG 2-10-2 MOE 1327 398037 31046 31057 AATATTGTTCCT 1-10-1 MOE 1202 389962 31047 31058 CAATATTGTTCC 1-10-1 MOE 1328 389761 31047 31058 CAATATTGTTCC 1-9-2 MOE 1328 336154 31052 31065 ACATCATCAATATT 3-8-3 MOE 1329 389977 31480 31491 CTTAAAATTTGG 1-10-1 MOE 1421 389776 31480 31491 CTTAAAATTTGG 1-9-2 MOE 1421 397967 62446 62459 CTTTGAATCCAAAA 2-10-2 MOE 1330 389998 62447 62458 TTTGAATCCAAA 1-10-1 MOE 1331 336156 62450 62463 TATGCTTTGAATCC 3-8-3 MOE 1332 336157 62463 62476 TTGTAATGGTTTTT 3-8-3 MOE 1333 389963 62468 62479 ATCTTGTAATGG 1-10-1 MOE 1334 389762 62468 62479 ATCTTGTAATGG 1-9-2 MOE 1334 336158 62475 62488 AGATTGTATATCTT 3-8-3 MOE 1335 390000 67987 67998 GTCATAATGTCT 1-10-1 MOE 1194 397968 67987 68000 GTGTCATAATGTCT 2-10-2 MOE 1195 398038 67988 67999 TGTCATAATGTC 1-10-1 MOE 1200 336159 67989 68002 CGGTGTCATAATGT 3-8-3 MOE 1336 336160 67997 68010 AAATTTGGCGGTGT 3-8-3 MOE 1337 397969 67999 68012 TTAAATTTGGCGGT 2-10-2 MOE 1338 398039 68000 68011 TAAATTTGGCGG 1-10-1 MOE 1339 WO 2007/146511 PCT/US2007/068401 -226 397971 69952 69965 TCTTCAAAAGGATA 2-10-2 MOE 1340 336162 69952 69965 TCTTCAAAAGGATA 3-8-3 MOE 1340 398041 69953 69964 CTTCAAAAGGAT 1-10-1 MOE 1196 389964 69955 69966 GTCTTCAAAAGG 1-10-1 MOE 1197 389763 69955 69966 GTCTTCAAAAGG 1-9-2 MOE 1197 398089 69957 69968 TGGTCTTCAAAA 1-10-1 MOE 1341 397972 69963 69976 GTGGGTTATGGTCT 2-10-2 MOE 1342 336163 69963 69976 GTGGGTTATGGTCT 3-8-3 MOE 1342 398042 69964 69975 TGGGTTATGGTC 1-10-1 MOE 1214 336164 69977 69990 AAGTTCTAGCTGTG 3-8-3 MOE 1343 390002 69981 69992 ATAAGTTCTAGC 1-10-1 MOE 1344 336165 69988 70001 AAGGGTTTGATAAG 3-8-3 MOE 1345 390003 70003 70014 AAGATCTTCACA 1-10-1 MOE 1243 397973 70003 70016 TCAAGATCTTCACA 2-10-2 MOE 1346 336166 70003 70016 TCAAGATCTTCACA 3-8-3 MOE 1346 398043 70004 70015 CAAGATCTTCAC 1-10-1 MOE 1244 336167 70012 70025 AGCCATTGGTCAAG 3-8-3 MOE 1347 390004 70021 70032 TTCACTTAGCCA 1-10-1 MOE 1208 336168 70021 70034 TCTTCACTTAGCCA 3-8-3 MOE 1348 389965 70040 70051 CTGCAACATGAT 1-10-1 MOE 1018 389764 70040 70051 CTGCAACATGAT 1-9-2 MOE 1018 397974 70040 70053 TGCTGCAACATGAT 2-10-2 MOE 1349 336169 70040 70053 TGCTGCAACATGAT 3-8-3 MOE 1349 398044 70041 70052 GCTGCAACATGA 1-10-1 MOE 1350 336170 70051 70064 TTACAGTGAATTGC 3-8-3 MOE 1351 390005 70059 70070 CCAGCTTTACAG 1-10-1 MOE 1352 389966 70081 70092 CATTACACCAGT 1-10-1 MOE 1353 389765 70081 70092 CATTACACCAGT 1-9-2 MOE 1353 397975 70081 70094 ATCATTACACCAGT 2-10-2 MOE 1354 336171 70081 70094 ATCATTACACCAGT 3-8-3 MOE 1354 398045 70082 70093 TCATTACACCAG 1-10-1 MOE 1355 336172 70096 70109 AATAAATATGCACA 3-8-3 MOE 1356 389967 70123 70134 TGCCTTTAAAAA 1-10-1 MOE 1217 389766 70123 70134 TGCCTTTAAAAA 1-9-2 MOE 1217 397976 70123 70136 TGTGCCTTTAAAAA 2-10-2 MOE 1357 398046 70124 70135 GTGCCTTTAAAA 1-10-1 MOE 1199 336173 70124 70137 TTGTGCCTTTAAAA 3-8-3 MOE 1358 336174 70131 70144 GGGCCTCTTGTGCC 3-8-3 MOE 1359 336175 70154 70167 CCTTACTTCCCCAT 3-8-3 MOE 1360 335345 70161 70176 GTCTCTGGTCCTTACT 3-10-3 MOE 1362 3-10-3 MOE Phosphodiester linkage in 335356 70161 70176 GTCTCTGGTCCTTACT wings 1362 3-10-3 MOE C in 3' wing is 9 335414 70161 70176 GTCTCTGGTCCTTACT (aninoethoxy)phenoxazine 1362 3-10-3 MOE C in 5' wing is 9 335415 70161 70176 GTCTCTGGTCCTTACT (aminoethoxy)phenoxazine 1362 3-10-3 MOE C's in wings are 9 335416 70161 70176 GTCTCTGGTCCTTACT (aminoethoxy)phenoxazine 1362 336176 70161 70174 CTCTGGTCCTTACT 3-8-3 MOE 1361 WO 2007/146511 PCT/US2007/068401 -227 3-10-3 Methyleneoxy BNA Phosphodiester linkage in 335371 70161 70176 GTCTCTGGTCCTTACT wings 1362 335382 70161 70176 GTCTCTGGTCCTTACT 3-10-3 Methyleneoxy BNA 1362 335344 70162 70175 TCTCTGGTCCTTAC 2-10-2 MOE 1363 2-10-2 MOE Phosphodiester linkage in 335355 70162 70175 TCTCTGGTCCTTAC wings 1363 2-10-2 MOE 3' C is 9 335411 70162 70175 TCTCTGGTCCTTAC (aminoethoxy)phenoxazine 1363 2-10-2 MOE 2 nd C is 9 335412 70162 70175 TCTCTGGTCCTTAC (aminoethoxy)phenoxazine 1363 2-10-2 MOE 2 "d and 3' terminal C's are 9 335413 70162 70175 TCTCTGGTCCTTAC (aminoethoxy)phenoxazine 1363 2-10-2 Methyleneoxy BNA Phosphodiester linkage in 335370 70162 70175 TCTCTGGTCCTTAC wings 1363 335381 70162 70175 TCTCTGGTCCTTAC 2-10-2 Methyleneoxy BNA 1363 398068 79799 79810 ACAGCTACACAA 1-10-1 MOE 1472 389968 89056 89067 TCTGACTGGGAA 1-10-1 MOE 1151 389767 89056 89067 TCTGACTGGGAA 1-9-2 MOE 1151 336177 89056 89069 CCTCTGACTGGGAA 3-8-3 MOE 1364 336178 89063 89076 CATAGCGCCTCTGA 3-8-3 MOE 1365 336179 89083 89096 CAGGTAGCTATAAT 3-8-3 MOE 1366 390007 89085 89096 CAGGTAGCTATA 1-10-1 MOE 1367 390009 89135 89146 ATCTTGTGAAAC 1-10-1 MOE 1175 397977 89135 89148 TCATCTTGTGAAAC 2-10-2 MOE 1368 336180 89135 89148 TCATCTTGTGAAAC 3-8-3 MOE 1368 398047 89136 89147 CATCTTGTGAAA 1-10-1 MOE 1369 336181 89145 89158 GTTTCAAACATCAT 3-8-3 MOE 1370 397978 89147 89160 TAGTTTCAAACATC 2-10-2 MOE 1371 398048 89148 89159 AGTTTCAAACAT 1-10-1 MOE 1372 389969 89152 89163 GAATAGTTTCAA 1-10-1 MOE 1373 389768 89152 89163 GAATAGTTTCAA 1-9-2 MOE 1373 336182 89155 89168 CATTGGAATAGTTT 3-8-3 MOE 1374 397979 89162 89175 CACTGAACATTGGA 2-10-2 MOE 1375 398049 89163 89174 ACTGAACATTGG 1-10-1 MOE 1376 390010 89165 89176 CCACTGAACATT 1-10-1 MOE 1240 336183 89166 89179 CCGCCACTGAACAT 3-8-3 MOE 1377 397980 94786 94799 CAGACCACAAACTG 2-10-2 MOE 1378 398050 94787 94798 AGACCACAAACT 1-10-1 MOE 1379 2-10-2 Methyleneoxy BNA 392060 94790 94803 CTGGCAGACCACAA Unmodified cytosines in gap 1380 389970 94791 94802 TGGCAGACCACA 1-10-1 MOE 1249 389769 94791 94802 TGGCAGACCACA 1-9-2 MOE 1249 336185 94792 94805 AGCTGGCAGACCAC 3-8-3 MOE 1381 397981 94798 94811 ACCTTTAGCTGGCA 2-10-2 MOE 1382 398051 94799 94810 CCTTTAGCTGGC 1-10-1 MOE 1220 336186 94803 94816 TCTTCACCTTTAGC 3-8-3 MOE 1383 390012 94860 94871 TCAAAGTACATG 1-10-1 MOE 1384 WO 2007/146511 PCT/US2007/068401 -228 336187 94862 94875 GAACTCAAAGTACA 3-8-3 MOE 1385 389971 94865 94876 GGAACTCAAAGT 1-10-1 MOE 1386 389770 94865 94876 GGAACTCAAAGT 1-9-2 MOE 1386 397982 94865 94878 AGGGAACTCAAAGT 2-10-2 MOE 1387 398052 94866 94877 GGGAACTCAAAG 1-10-1 MOE 1388 336188 94869 94882 GCTGAGGGAACTCA 3-8-3 MOE 1389 336189 94888 94901 TCACCACACACAGG 3-8-3 MOE 1390 336190 94904 94917 GAACTCTACTTTGA 3-8-3 MOE 1391 389972 94909 94920 GAAGAACTCTAC 1-10-1 MOE 1392 389771 94909 94920 GAAGAACTCTAC 1-9-2 MOE 1392 397983 94910 94923 GTGGAAGAACTCTA 2-10-2 MOE 1393 398053 94911 94922 TGGAAGAACTCT 1-10-1 MOE 1394 336191 94915 94928 TGTTTGTGGAAGAA 3-8-3 MOE 1395 336192 94925 94938 CATCTTGTTCTGTT 3-8-3 MOE 1396 397984 97824 97837 AGTGAAACATTTTG 2-10-2 MOE 1397 398054 97825 97836 GTGAAACATTTT 1-10-1 MOE 1144 336194 97827 97840 AAAAGTGAAACATT 3-8-3 MOE 1145 389973 97835 97846 TTACCCAAAAGT 1-10-1 MOE 1398 389772 97835 97846 TTACCCAAAAGT 1-9-2 MOE 1398 336195 97836 97849 TATTTACCCAAAAG 3-8-3 MOE 1399 397985 97837 97850 GTATTTACCCAAAA 2-10-2 MOE 1400 398055 97838 97849 TATTTACCCAAA 1-10-1 MOE 1401 397986 97853 97866 TCCTGGTATGAAGA 2-10-2 MOE 1402 336196 97853 97866 TCCTGGTATGAAGA 3-8-3 MOE 1402 398056 97854 97865 CCTGGTATGAAG 1-10-1 MOE 1403 390015 97857 97868 GGTCCTGGTATG 1-10-1 MOE 1404 336197 97862 97875 TTCCTCTGGTCCTG 3-8-3 MOE 1405 397987 97866 97879 AGGTTTCCTCTGGT 2-10-2 MOE 1406 398057 97867 97878 GGTTTCCTCTGG 1-10-1 MOE 1407 336198 97873 97886 TTTTCTGAGGTTTC 3-8-3 MOE 1408 336199 97891 97904 AGACTTCCATTTTC 3-8-3 MOE 1409 389974 97893 97904 AGACTTCCATTT 1-10-1 MOE 1410 389773 97893 97904 AGACTTCCATTT 1-9-2 MOE 1410 336200 97918 97931 CAAATGCTATCGAT 3-8-3 MOE 1411 336201 97933 97946 GCACGCTCTATACT 3-8-3 MOE 1412 389975 97934 97945 CACGCTCTATAC 1-10-1 MOE 1413 389774 97934 97945 CACGCTCTATAC 1-9-2 MOE 1413 336202 97948 97961 TCCTTGTCATTATC 3-8-3 MOE 1414 397988 97990 98003 GCTTTGTCAAGATC 2-10-2 MOE 1415 389976 97991 98002 CTTTGTCAAGAT 1-10-1 MOE 1177 389775 97991 98002 CTTTGTCAAGAT 1-9-2 MOE 1177 336203 97991 98004 TGCTTTGTCAAGAT 3-8-3 MOE 1416 397989 98017 98030 AAGTATCGGTTGGC 2-10-2 MOE 1417 336204 98017 98030 AAGTATCGGTTGGC 3-8-3 MOE 1417 398058 98018 98029 AGTATCGGTTGG 1-10-1 MOE 1418 336205 98032 98045 TTAAAATTTGGAGA 3-8-3 MOE 1419 397990 98034 98047 CCTTAAAATTTGGA 2-10-2 MOE 1420 389977 98035 98046 CTTAAAATTTGG 1-10-1 MOE 1421 389776 98035 98046 CTTAAAATTTGG 1-9-2 MOE 1421 336207 102230 102243 TCTACTGTTTTTGT 3-8-3 MOE 1422 336208 102236 102249 GGCTCCTCTACTGT 3-8-3 MOE 1423 335330 102251 102265 AGCCTCTGGATTTGA 1-10-4 MOE 1424 335331 102252 102266 TAGCCTCTGGATTTG 1-10-4 MOE 1426 336209 102252 102265 AGCCTCTGGATTTG 3-8-3 MOE 1425 WO 2007/146511 PCT/US2007/068401 -229 1-10-4 Methyleneoxy BNA 335377 102252 102266 TAGCCTCTGGATTTG Phosphodiester in 3' wing 1426 335376 102252 102266 TAGCCTCTGGATTTG 1-10-4 Methyleneoxy BNA 1426 1-10-3 MOE Unmodified cytosines T's in wings are 2 390577 102253 102266 TAGCCTCTGGATTT thiothymines 1427 335332 102253 102267 CTAGCCTCTGGATTT 1-10-4 MOE 1429 386770 102253 102266 TAGCCTCTGGATTT 1-11-2 MOE 1427 375560 102253 102267 CTAGCCTCTGGATTT 2-10-3 MOE 1429 2-10-3 MOE 391449 102253 102267 CTAGCCTCTGGATTT Unmodified cytosines 1429 2-10-3 MOE 392055 102253 102267 CTAGCCTCTGGATTT Unmodified cytosines in gap 1429 362977 102253 102268 GCTAGCCTCTGGATTT 2-12-2 MOE 1428 371975 102253 102267 CTAGCCTCTGGATTT 3-10-2 MOE 1429 386556 102253 102268 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 335341 102253 102268 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 335350 102253 102268 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 3-10-3 MOE 383739 102253 102268 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 3-10-3 MOE 5-methylcytosine in gap T's in wings are 2 390576 102253 102268 GCTAGCCTCTGGATTT thiothymines 1428 3-10-3 MOE Pyrimidines in wings are 5 thiazole 390580 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 3-10-3 MOE 390581 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 391096 102253 102268 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 391098 102253 102268 GCTAGCCTCTGGATTT 3-10-3 MOE 1428 3-10-3 MOE 391863 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines 1428 3-10-3 OMe 384071 102253 102268 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 1-2-10-3 OMe/2'-O-methyl 4'-thio/2'-O-methyl-4'-thio Unmodified cytosines in 385036 102253 102268 GCTAGCCTCTGGATTT wing 1428 3-10-3 Methyleneoxy BNA Phosphodiester linkages in 335368 102253 102268 GCTAGCCTCTGGATTT wings 1428 3-10-3 Methyleneoxy BNA 391864 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines in gap 1428 2-10-3 Methyleneoxy BNA 392054 102253 102267 CTAGCCTCTGGATTT Unmodified cytosines in gap 1429 2-10-3 Methyleneoxy BNA 391172 102253 102267 CTAGCCTCTGGATTT Unmodified cytosines 1429 3-10-3 Methyleneoxy BNA 391865 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines 1428 1-2-10-3 (5'R)-5'-methyl Methyleneoxy BNA / 391868 102253 102268 GCTAGCCTCTGGATTT Methyleneoxy BNA /(5'R)- 1428 WO 2007/146511 PCT/US2007/068401 -230 5'-methyl- Methyleneoxy BNA Unmodified cytosines 1-2-10-3 Methyleneoxy BNA /(5'S)-5'-methyl Methyleneoxy BNA /(5'S) 5'-methyl- Methyleneoxy BNA 391869 102253 102268 GCTAGCCTCTGGATTT Unmodified cytosines 1428 3-10-3 Methyleneoxy BNA 384073 102253 102268 GCTAGCCTCTGGATTT 5-methylcytosine in gap 1428 335379 102253 102268 GCTAGCCTCTGGATTT 3-10-3 Methyleneoxy BNA 1428 1-1-1-10-3 MOE/4'thio/2' O-[(2-methoxy)ethyl]-4' thio/2'-O-[(2 methoxy)ethyl]-4'-thio Unmodified cytosines in wings Phosphorodiester linkage in 390579 102253 102268 GCTAGCCTCTGGATTT wings 1428 1-2-10-3 MOE/4'thio/2'-O [(2-methoxy)ethyl]-4'-thio Unmodified cytosines in wings Phosphorodiester linkage in 390582 102253 102268 GCTAGCCTCTGGATTT wings 1428 1-2-10-3 MOE/pentaF/pentaF Unmodified cytosines in wings Phosphodiester linkage in 390606 102253 102268 GCTAGCCTCTGGATTT wings 1428 1-2-10-3 MOE/pentaF/pentaF Unmodified cytosines in 384072 102253 102268 GCTAGCCTCTGGATTT wings 1428 1-2-10-3 OMe/ 2'-0-[(2 methoxy)ethyl]-4'-thio/ 2'-0 [(2-methoxy)ethyl]-4'-thio Unmodified cytosines in 385871 102253 102268 GCTAGCCTCTGGATTT wing 1428 3-10-3 MOE/pentaF Unmodified cytosines in 390607 102253 102268 GCTAGCCTCTGGATTT wing 1428 1-2-10-3 MOE/pentaF/pentaF Unmodified cytosines in 390608 102253 102268 GCTAGCCTCTGGATTT wing 1428 3-10-2-1 MOE/MOE/pentaF Unmodified cytosines in 390609 102253 102268 GCTAGCCTCTGGATTT wing 1428 1-2-10-3 2' (butylacetamido) 386682 102253 102268 GCTAGCCTCTGGATTT palmitamide /MOE /MOE 1428 391173 102253 102267 CTAGCCTCTGGATTT 2-10-3 (5'R)-5'-methvl- 1429 WO 2007/146511 PCT/US2007/068401 -231 Methyleneoxy BNA Unmodified cytosines 2-10-3 (5'S)-5'-methyl Methyleneoxy BNA 391174 102253 102267 CTAGCCTCTGGATTT Unmodified cytosines 1429 386970 102254 102266 TAGCCTCTGGATT 1-10-2 MOE 1432 1-10-2 MOE Unmodified cytosines Ts in wings are 2 390578 102254 102266 TAGCCTCTGGATT thiothymines 1432 335333 102254 102268 GCTAGCCTCTGGATT 1-10-4 MOE 1430 331429 102254 102267 CTAGCCTCTGGATT 2-10-2 MOE 1431 335349 102254 102267 CTAGCCTCTGGATT 2-10-2 MOE 1431 2-10-2 Methyleneoxy BNA Phosphodiester linkages in 335367 102254 102267 CTAGCCTCTGGATT wings 1431 2-10-2 Methyleneoxy BNA 392061 102254 102267 CTAGCCTCTGGATT Unmodified cytosines in gap 1431 335378 102254 102267 CTAGCCTCTGGATT 2-10-2 Methyleneoxy BNA 1431 1-10-2 2'-(acetylamino-butyl acetamido)-cholesterol 383991 102254 102266 TAGCCTCTGGATT /MOE 1432 1-10-2 2'-(acetylamino-butyl 383992 102254 102266 TAGCCTCTGGATT acetamido)-cholic acid/MOE 1432 1-10-2 5' terminal 2' (butylacetamido) 386683 102254 102266 TAGCCTCTGGATT palmitamide/MOE 1432 390614 102254 102266 TAGCCTCTGGATT 1-10-2 PentaF 1432 389954 102255 102266 TAGCCTCTGGAT 1-10-1 MOE 1434 335334 102255 102269 TGCTAGCCTCTGGAT 1-10-4 MOE 1433 389777 102255 102266 TAGCCTCTGGAT 1-9-2 MOE 1434 1-10-2 MOE 390430 102256 102268 GCTAGCCTCTGGA Unmodified cytosines 1163 1-10-2 MOE Unmodified cytosines C in wing 9 390431 102256 102268 GCTAGCCTCTGGA (aminoethoxy)phenoxazine 1163 390432 102256 102268 GCTAGCCTCTGGA 1-10-2 MOE 1163 1-10-2 MOE Unmodified cytosines Nt 6 is 9 390433 102256 102268 GCTAGCCTCTGGA (aminoethoxy)phenoxazine 1163 1-10-2 MOE Unmodified cytosines Nt 7 is 9 390434 102256 102268 GCTAGCCTCTGGA (aminoethoxy)phenoxazine 1163 1-10-2 MOE Unmodified cytosines Nt 9 is 9 390435 102256 102268 GCTAGCCTCTGGA (aminoethoxy)phenoxazine 1163 335335 102256 102270 CTGCTAGCCTCTGGA 1-10-4 MOE 1435 335336 102257 102271 ACTGCTAGCCTCTGG 1-10-4 MOE 1436 WO 2007/146511 PCT/US2007/068401 -232 335337 102258 102272 AACTGCTAGCCTCTG 1-10-4 MOE 1437 335338 102259 102273 GAACTGCTAGCCTCT 1-10-4 MOE 1438 335339 102260 102274 TGAACTGCTAGCCTC 1-10-4 MOE 1439 335340 102261 102275 TTGAACTGCTAGCCT 1-10-4 MOE 1440 336210 102261 102274 TGAACTGCTAGCCT 3-8-3 MOE 1441 397991 102264 102277 AGTTGAACTGCTAG 2-10-2 MOE 1442 398059 102265 102276 GTTGAACTGCTA 1-10-1 MOE 1443 390017 102268 102279 GAAGTTGAACTG 1-10-1 MOE 1444 336211 102269 102282 ACAGAAGTTGAACT 3-8-3 MOE 1445 397992 102293 102306 TCATTGTCACTAAC 2-10-2 MOE 1446 336212 102293 102306 TCATTGTCACTAAC 3-8-3 MOE 1446 398060 102294 102305 CATTGTCACTAA 1-10-1 MOE 1447 389978 102301 102312 TCAGGTTCATTG 1-10-1 MOE 1448 389778 102301 102312 TCAGGTTCATTG 1-9-2 MOE 1448 336213 102303 102316 ATGATCAGGTTCAT 3-8-3 MOE 1449 397993 102307 102320 TATAATGATCAGGT 2-10-2 MOE 1450 398061 102308 102319 ATAATGATCAGG 1-10-1 MOE 1451 336214 102314 102327 GAATATCTATAATG 3-8-3 MOE 1139 390019 102320 102331 GTCAGAATATCT 1-10-1 MOE 1173 397994 102322 102335 TGGTGTCAGAATAT 2-10-2 MOE 1452 398062 102323 102334 GGTGTCAGAATA 1-10-1 MOE 1255 336215 102326 102339 TCAGTGGTGTCAGA 3-8-3 MOE 1453 336216 102339 102352 CTCTGGATCAGAGT 3-8-3 MOE 1454 390020 102340 102351 TCTGGATCAGAG 1-10-1 MOE 1149 336217 102349 102362 AAGGTTCATTCTCT 3-8-3 MOE 1455 397995 102357 102370 TTCATCAAAAGGTT 2-10-2 MOE 1456 389979 102358 102369 TCATCAAAAGGT 1-10-1 MOE 1176 389779 102358 102369 TCATCAAAAGGT 1-9-2 MOE 1176 336218 102358 102371 CTTCATCAAAAGGT 3-8-3 MOE 1457 390021 102360 102371 CTTCATCAAAAG 1-10-1 MOE 1458 336219 102366 102379 ATGCTGATCTTCAT 3-8-3 MOE 1459 336220 102381 102394 TTTTGTAATTTGTG 3-8-3 MOE 1460 336221 102387 102400 TCAGACTTTTGTAA 3-8-3 MOE 1461 390022 102443 102454 CAGTTTATTCAA 1-10-1 MOE 1142 397996 102477 102490 TGTCCTATTGCCAT 2-10-2 MOE 1462 398063 102478 102489 GTCCTATTGCCA 1-10-1 MOE 1205 397997 102487 102500 TCTGACACAATGTC 2-10-2 MOE 1463 398064 102488 102499 CTGACACAATGT 1-10-1 MOE 1464 397998 102505 102518 TGTTCCTATAACTG 2-10-2 MOE 1465 398065 102506 102517 GTTCCTATAACT 1-10-1 MOE 1466 397999 102528 102541 AAGATTGGTCAGGA 2-10-2 MOE 1467 398066 102529 102540 AGATTGGTCAGG 1-10-1 MOE 1468 398000 102561 102574 GTGTCAAAACCCTG 2-10-2 MOE 1469 398067 102562 102573 TGTCAAAACCCT 1-10-1 MOE 1210 390025 102563 102574 GTGTCAAAACCC 1-10-1 MOE 1211 390026 102595 102606 AGCTACACAACC 1-10-1 MOE 1470 398001 102596 102609 CACAGCTACACAAC 2-10-2 MOE 1471 398068 102597 102608 ACAGCTACACAA 1-10-1 MOE 1472 398002 102607 102620 TATATACATGACAC 2-10-2 MOE 1473 398069 102608 102619 ATATACATGACA 1-10-1 MOE 1474 390027 102612 102623 AGGTATATACAT 1-10-1 MOE 1206 398003 102637 102650 AATTTTAAATGTCC 2-10-2 MOE 1475 398070 102638 102649 ATTTTAAATGTC 1-10-1 MOE 1476 390028 102648 102659 TCCTAATTGAAT 1-10-1 MOE 1477 WO 2007/146511 PCT/US2007/068401 -233 390029 102667 102678 AAAGTGCCATCT 1-10-1 MOE 1478 398004 102689 102702 TTTATAAAACTGGA 2-10-2 MOE 1479 398071 102690 102701 TTATAAAACTGG 1-10-1 MOE 1480 390030 102691 102702 TTTATAAAACTG 1-10-1 MOE 1074 398005 102827 102840 TGCAAACTTATCTG 2-10-2 MOE 1481 398072 102828 102839 GCAAACTTATCT 1-10-1 MOE 1482 390033 102836 102847 AGCCAACTGCAA 1-10-1 MOE 1483 398006 102837 102850 CTTAGCCAACTGCA 2-10-2 MOE 1484 398073 102838 102849 TTAGCCAACTGC 1-10-1 MOE 1485 398007 103069 103082 AGCACCAATATGCT 2-10-2 MOE 1247 398074 103070 103081 GCACCAATATGC 1-10-1 MOE 1248 398008 103267 103280 TAAATCATTGTCAA 2-10-2 MOE 1486 398075 103268 103279 AAATCATTGTCA 1-10-1 MOE 1233 398009 103327 103340 GCACTGGCCTTGAT 2-10-2 MOE 1487 398076 103328 103339 CACTGGCCTTGA 1-10-1 MOE 1488 390041 103332 103343 TTAGCACTGGCC 1-10-1 MOE 1489 390047 103585 103596 TGTGTAAGGTCA 1-10-1 MOE 1490 390049 103636 103647 GTTAATGACATT 1-10-1 MOE 1491 390050 103660 103671 GTATTCAAGTAA 1-10-1 MOE 1140 390052 103780 103791 GACAATTTCTAC 1-10-1 MOE 1492 390054 103862 103873 AACACTGCACAT 1-10-1 MOE 1493 Salts, prodrugs and bioequivalents The antisense compounds provided herein comprise any pharmaceutically acceptable salts, 5 esters, or salts of such esters, or any other functional chemical equivalent which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the antisense compounds, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. 10 The term "prodrug" indicates a therapeutic agent that is prepared in an inactive or less active form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes, chemicals, and/or conditions. In particular, prodrug versions of the oligonucleotides are prepared as SATE ((S-acetyl-2-thioethyl) phosphate) derivatives according to the methods disclosed in WO 93/24510 or WO 94/26764. Prodrugs can also include antisense compounds 15 wherein one or both ends comprise nucleobases that are cleaved (e.g., by incorporating phosphodiester backbone linkages at the ends) to produce the active compound. In certain embodiments, one or more non-drug moieties is cleaved from a prodrug to yield the active form. In certain such embodiments, such non-drug moieties is not a nucleotide or oligonucleotide. The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically 20 acceptable salts of the compounds described herein: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. Sodium salts of antisense oligonucleotides are useful and are well accepted for therapeutic administration to humans. In certain- embodiments, salts, including, but not limited to sodium salts, of double stranded WO 2007/146511 PCT/US2007/068401 -234 nucleic acids (including but not limited to dsRNA compounds) are also provided. G. Certain Pharmaceutical Compositions In certain embodiments, pharmaceutical compositions of the present invention comprise one or 5 more short antisense compound and one or more excipients. In certain such embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone. In certain embodiments, a pharmaceutical composition of the present invention is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-making, 10 levigating, emulsifying, encapsulating, entrapping or tabletting processes. In certain embodiments, a pharmaceutical composition of the present invention is a liquid (e.g., a suspension, elixir and/or solution). In certain of such embodiments, a liquid pharmaceutical composition is prepared using ingredients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. 15 In certain embodiments, a pharmaceutical composition of the present invention is a solid (e.g., a powder, tablet, and/or capsule). In certain of such embodiments, a solid pharmaceutical composition comprising one or more oligonucleotides is prepared using ingredients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents. In certain embodiments, a pharmaceutical composition of the present invention is formulated as a 20 depot preparation. Certain such depot preparations are typically longer acting than non-depot preparations. In certain embodiments, such preparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot preparations are prepared using suitable polymeric or hydrophobic materials (for example an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly 25 soluble salt. In certain embodiments, a pharmaceutical composition of the present invention comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as 30 dimethylsulfoxide are used. In certain embodiments, a pharmaceutical composition of the present invention comprises one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody. 35 In certain embodiments, a pharmaceutical composition of the present invention comprises a co solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co- WO 2007/146511 PCT/US2007/068401 -235 solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80.TM., and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering 5 their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80.TM.; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. In certain embodiments, a pharmaceutical composition of the present invention comprises a 10 sustained-release system. A non-limiting example of such a sustained-release system is a semi-permeable matrix of solid hydrophobic polymers. In certain embodiments, sustained-release systems may, depending on their chemical nature, release pharmaceutical agents over a period of hours, days, weeks or months. In certain embodiments, a pharmaceutical composition of the present invention is prepared for oral administration. In certain of such embodiments, a pharmaceutical composition is formulated by 15 combining one or more oligonucleotides with one or more pharmaceutically acceptable carriers. Certain of such carriers enable pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject. In certain embodiments, pharmaceutical compositions for oral use are obtained by mixing oligonucleotide and one or more solid excipient. Suitable excipients include, but are not limited to, fillers, such as sugars, 20 including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical compositions are formed to obtain tablets or dragee cores. In certain embodiments, 25 disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate) are added. In certain embodiments, dragee cores are provided with coatings. In certain such embodiments, concentrated sugar solutions may be used, which may optionally comprise gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable 30 organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings. In certain embodiments, pharmaceutical compositions for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more pharmaceutical agents of the present invention in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In certain embodiments, 35 pharmaceutical compositions for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more pharmaceutical agents of the present invention are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or WO 2007/146511 PCT/US2007/068401 -236 liquid polyethylene glycols. In addition, stabilizers may be added. In certain embodiments, pharmaceutical compositions are prepared for buccal administration. Certain of such pharmaceutical compositions are tablets or lozenges formulated in conventional manner. In certain embodiments, a pharmaceutical composition is prepared for administration by injection 5 (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid 10 carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are-suspensions, solutions or emulsions in oily or aqueous vehicles, and may comprise formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and 15 fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may comprise substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also comprise suitable stabilizers or agents that increase the solubility of the pharmaceutical agents to allow for the preparation of highly concentrated solutions. 20 In certain embodiments, a pharmaceutical composition is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. In certain embodiments, a pharmaceutical composition is prepared for administration by inhalation. Certain of such pharmaceutical compositions for inhalation are prepared in the form of an 25 aerosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical compositions comprise a propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aerosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufflator may be formulated. Certain of such formulations comprise a powder 30 mixture of a pharmaceutical agent of the invention and a suitable powder base such as lactose or starch. In certain embodiments, a pharmaceutical composition is prepared for rectal administration, such as a suppositories or retention enema. Certain of such pharmaceutical compositions comprise known ingredients, such as cocoa butter and/or other glycerides. In certain embodiments, a pharmaceutical composition is prepared for topical administration. 35 Certain of such pharmaceutical compositions comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as Eucerin.TM., available from Beiersdorf WO 2007/146511 PCT/US2007/068401 -237 (Cincinnati, Ohio). Exemplary suitable cream bases include, but are not limited to, Nivea.TM. Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose Cream.TM., available from Johnson & Johnson (New Brunswick, N.J.), hydrophilic ointment (USP) and Lubriderm.TM., available from Pfizer (Morris Plains, N.J.). 5 In certain embodiments, a pharmaceutical composition of the present invention comprises an oligonucleotide in a therapeutically effective amount. In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art. 10 In certain embodiments, one or more short antisense compound of the present invention is formulated as a prodrug. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form of the short antisense compound. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., 15 through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, a prodrug is an ester. In certain such embodiments, the ester is metabolically hydrolyzed to 20 carboxylic acid upon administration. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is cleaved upon administration to form the corresponding active form. In certain embodiments, a prodrug is produced by modifying a pharmaceutically active 25 compound such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g., 30 Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392). In certain embodiments, a pharmaceutical composition comprising one or more pharmaceutical agents of the present invention is useful for treating a conditions or disorders in a mammalian, and particularly in a human, subject. Suitable administration routes include, but are not limited to, oral, rectal, 35 transmucosal, intestinal, enteral, topical, suppository, through inhalation, intrathecal, intraventricular, intraperitoneal, intranasal, intraocular and parenteral (e.g., intravenous, intramuscular, intramedullary, and subcutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local WO 2007/146511 PCT/US2007/068401 -238 rather than systemic exposures. For example, pharmaceutical compositions may be injected directly in the area of desired effect (e.g., in the renal or cardiac area). In certain embodiments, short antisense compounds, compared to their parent oligonucleotides, make them particularly suited to oral administration. In certain embodiments, short antisense compounds 5 are better suited for oral administration than their parent oligonucleotides because they have increased potency compared to those parent oligonucleotides. In certain embodiments, short antisense compounds are better suited for oral administration than their parent oligonucleotides because they have better stability, availability or solubility properties compared to those parent oligonucleotides. In a further aspect, a pharmaceutical agent is sterile lyophilized oligonucleotide that is 10 reconstituted with a suitable diluent, e.g., sterile water for injection. The reconstituted product is administered as a subcutaneous injection or as an intravenous infusion after dilution into saline. The lyophilized drug product consists of the oligonucleotide which has been prepared in water for injection, adjusted to pH 7.0-9.0 with acid or base during preparation, and then lyophilized. The lyophilized oligonucleotide may be 25-800 mg of the oligonucleotide. It is understood that this encompasses 25, 50, 15 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 425, 450,475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, and 800 mg of lyophilized oligonucleotide. The lyophilized drug product may be packaged in a 2 mL Type I, clear glass vial (ammonium sulfate-treated), stoppered with a bromobutyl rubber closure and sealed with an aluminum FLIP-OFF® overseal. The compositions of the present invention may additionally comprise other adjunct components 20 conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may comprise additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may comprise additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents 25 and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the oligonucleotide(s) of the formulation. 30 The antisense compounds provided herein may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds. Also described herein are pharmaceutical compositions and formulations which include the antisense compounds provided herein. The pharmaceutical compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be 35 treated. In a preferred embodiment, administration is topical to the surface of the respiratory tract, particularly pulmonary, e.g., by nebulization, inhalation, or insufflation of powders or aerosols, by mouth and/or nose.

WO 2007/146511 PCT/US2007/068401 -239 The pharmaceutical formulations described herein, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and 5 intimately bringing into association the active ingredients with liquid carriers, finely divided solid carriers, or both, and then, if necessary, shaping the product (e.g., into a specific particle size for delivery). In a preferred embodiment, the pharmaceutical formulations are prepared for pulmonary administration in an appropriate solvent, e.g., water or normal saline, possibly in a sterile formulation, with carriers or other agents to allow for the formation of droplets of the desired diameter for delivery 10 using inhalers, nasal delivery devices, nebulizers, and other devices for pulmonary delivery. Alternatively, the pharmaceutical formulations may be formulated as dry powders for use in dry powder inhalers. A "pharmaceutical carrier" or "excipient" can be a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to 15 an individual and are known in the art. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. H. Certain Therapeutic Uses In certain embodiments, antisense compounds are used to modulate the expression of a target 20 gene in an animal, such as a human. In certain embodiments, such compounds can be used to treat metabolic disorders or modulate one or more disease indications. For example, the methods comprise the step of administering to said animal in need of therapy for a disease or condition associated with a target gene an effective amount of an antisense compound that modulates expression of the target gene. Antisense compounds provided herein which effectively modulate expression of a target RNA or protein 25 products of expression are considered active antisense compounds. Active antisense compounds also include compounds which effectively modulate one or more of a number of disease indications, including metabolic and cardiovascular disease indications, examples of which are described below. Modulation of expression of a target gene can be measured in a bodily fluid, which may or may not contain cells; tissue; or organ of the animal. Methods of obtaining samples for analysis, such as body 30 fluids (e.g., sputum, serum, urine), tissues (e.g., biopsy), or organs, and methods of preparation of the samples to allow for analysis are well known to those skilled in the art. Methods for analysis of RNA and protein levels are discussed above and are well known to those skilled in the art. The effects of treatment can be assessed by measuring biomarkers, or disease indications, associated with the target gene expression in the aforementioned fluids, tissues or organs, collected from an animal contacted with one or 35 more compounds described herein, by routine clinical methods known in the art. These biomarkers include but are not limited to: liver transaminases, bilirubin, albumin, blood urea nitrogen, creatine and other markers of kidney and liver function; interleukins, tumor necrosis factors, intracellular adhesion WO 2007/146511 PCT/US2007/068401 -240 molecules, C-reactive protein, chemokines, cytokines, and other markers of inflammation. The antisense compounds provided herein can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Acceptable carriers and diluents are well known to those skilled in the art. Selection of a diluent or carrier is based 5 on a number of factors, including, but not limited to, the solubility of the compound and the route of administration. Such considerations are well understood by those skilled in the art. In one aspect, the antisense compounds described herein inhibit expression of a target gene. The compounds can also be used in the manufacture of a medicament for the treatment of diseases and disorders related to a target gene. 10 Methods whereby bodily fluids, organs or tissues are contacted with an effective amount of one or more of the antisense compounds or compositions provided herein are also contemplated. Bodily fluids, organs or tissues can be contacted with one or more of the compounds resulting in modulation of target gene expression in the cells of bodily fluids, organs or tissues. An effective amount can be determined by monitoring the modulatory effect of the antisense compound or compounds or 15 compositions on target nucleic acids or their products by methods routine to the skilled artisan. Co-administration In certain embodiments, two or more antisense compounds are co-administered. In certain embodiments, pharmaceutical compositions include one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more antisense compounds targeted to a 20 second nucleic acid target. One or more of those antisense compounds may be a short antisense compound. In certain embodiments, pharmaceutical compositions include two or more antisense compounds targeted to different regions of the same nucleic acid target. One or more of such antisense compounds may be a short antisense compound. Two or more combined compounds may be used together or sequentially. 25 In certain embodiments, one or more pharmaceutical compositions are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease or condition as the one or more pharmaceutical compositions of the present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease or condition as the one or more pharmaceutical compositions of the 30 present invention. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired effect of one or more pharmaceutical compositions of the present invention. In certain embodiments, one or more pharmaceutical compositions of the present invention are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more 35 other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions of the WO 2007/146511 PCT/US2007/068401 -241 present invention and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions of the present invention and one or more other pharmaceutical agents are prepared separately. In certain embodiments, pharmaceutical agents that may be co-administered with a 5 pharmaceutical composition of the present invention include lipid-lowering agents. In certain such embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include, but are not limited to atorvastatin, simvastatin, rosuvastatin, and ezetimibe. In certain such embodiments, the lipid-lowering agent is administered prior to administration of a pharmaceutical composition of the present invention. In certain such embodiments, the lipid-lowering 10 agent is administered following administration of a pharmaceutical composition of the present invention. In certain such embodiments the lipid-lowering agent is administered at the same time as a pharmaceutical composition of the present invention. In certain such embodiments the dose of a co administered lipid-lowering agent is the same as the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering 15 agent is lower than the dose that would be administered if the lipid-lowering agent was administered alone. In certain such embodiments the dose of a co-administered lipid-lowering agent is greater than the dose that would be administered if the lipid-lowering agent was administered alone. In certain embodiments, a co-administered lipid-lowering agent is a HMG-CoA reductase inhibitor. In certain such embodiments the HMG-CoA reductase inhibitor is a statin. In certain such 20 embodiments the statin is selected from atorvastatin, simvastatin, pravastatin, fluvastatin, and rosuvastatin. In certain embodiments, a co-administered lipid-lowering agent is a cholesterol absorption inhibitor. In certain such embodiments, cholesterol absorption inhibitor is ezetimibe. In certain embodiments, a co-administered lipid-lowering agent is a co-formulated HMG-CoA reductase inhibitor and cholesterol absorption inhibitor. In certain such embodiments the co-formulated lipid-lowering agent 25 is ezetimibe/simvastatin. In certain embodiments, a co-administered lipid-lowering agent is a microsomal triglyceride transfer protein inhibitor. In certain embodiments, a co-administered pharmaceutical agent is a bile acid sequestrant. In certain such embodiments, the bile acid sequestrant is selected from cholestyramine, colestipol, and colesevelam. 30 In certain embodiments, a co-administered pharmaceutical agent is a nicotinic acid. In certain such embodiments, the nicotinic acid is selected from immediate release nicotinic acid, extended release nicotinic acid, and sustained release nicotinic acid. In certain embodiments, a co-administered pharmaceutical agent is a fibric acid. In certain such embodiments, a fibric acid is selected from gemfibrozil, fenofibrate, clofibrate, bezafibrate, and 35 ciprofibrate. Further examples of pharmaceutical agents that may be co-administered with a pharmaceutical composition of the present invention include, but are not limited to, corticosteroids, including but not WO 2007/146511 PCT/US2007/068401 -242 limited to prednisone; immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgesics (e.g., acetaminophen); anti-inflammatory agents, including, but not limited to non steroidal anti-inflammatory drugs (e.g., ibuprofen, COX- 1 inhibitors, and COX-2, inhibitors); salicylates; antibiotics; antivirals; antifungal agents; antidiabetic agents (e.g., biguanides, glucosidase inhibitors, 5 insulins, sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestin, somatostan, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sedatives; poison oak or poison sumac products; antibodies; and vaccines. 10 In certain embodiments, the pharmaceutical compositions of the present invention may be administered in conjuction with a lipid-lowering therapy. In certain such embodiments, a lipid-lowering therapy is therapeutic lifestyle change. In certain such embodiments, a lipid-lowering therapy is LDL apheresis. 15 . Kits, Research Reagents and Diagnostics The antisense compounds provided herein can be utilized for diagnostics, and as research reagents and kits. Furthermore, antisense compounds, which are able to inhibit gene expression or modulate gene expression with specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological 20 pathway. For use in kits and diagnostics, the antisense compounds described herein, either alone or in combination with other compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues. Methods of gene expression analysis are well known to those skilled 25 in the art. J. Certain Advantages of Short Antisense Compounds In certain embodiments, short antisense compounds have advantages when compared to their parent oligonucleotides. For example, in certain embodiments, short antisense compounds have greater affinity for a target nucleic acid than their parent oligonucleotide. In certain embodiments, short antisense 30 compounds have greater potency in vitro than their parent oligonucleotide. In certain such embodiments, that increased in vitro potency is not entirely explained by increased affinity. In certain embodiments, such increased in vitro potency may be attributable to increased ability of short antisense compounds to penetrate cells and/or increased ability to access target nucleic acids in a cell. In certain embodiments, short antisense compounds have greater potency in vivo than their parent oligonucleotides. In certain 35 embodiments, such greater in vivo potency is not attributable to increased in vitro potency or increased affinity. In certain embodiments, short antisense compounds have even greater in vivo potency compared to their parent oligonucleotides than would be predicted based on in vitro potencies or on affinities. In WO 2007/146511 PCT/US2007/068401 -243 certain embodiments, such increased in vivo potency may be attributable to increased bioavailability, better penetration into the cell, better access to target nucleic acid once in the cell, or other factors. In certain embodiments, one would expect short antisense compounds to be less specific for their target nucleic acid compared to their parent oligonucleotides. In certain such embodiments, one 5 would expect increased side-effects, including potential for toxic effects, from short antisense compounds. In certain embodiments, such additional side-effects are not observed. In certain embodiments, non-target nucleic acids to which a particular short antisense compound may bind are not available to the short antisense compound. In such embodiments, side-effects, including toxicity, are less problematic than would be predicted. 10 In certain embodiments, because they are smaller, short antisense compounds are less likely to bind proteins. In certain such embodiments, such less binding of proteins results in lower toxicity, since protein binding may have undesired consequences. In certain embodiments, such less binding of proteins results in greater potency, since it leaves more antisense compound available for therapeutic effect. In certain embodiments, less binding of proteins results in decreased drug-drug interaction toxicity. 15 Nonlimiting disclosure and incorporation by reference While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank 20 accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety. 25 WO 2007/146511 PCT/US2007/068401 -244 Example 1 Cell culture and treatment with short antisense compounds The effect of short antisense compounds on target nucleic acid expression can be tested in any one of a number of cultured or primary cell lines. Cells lines can be obtained from publicly available 5 sources, such as the American Type Culture Collection (Manassas, VA). Cells are cultured according to methods well known to those of ordinary skill in the art. When cells reached appropriate confluency, they were treated with oligonucleotide using LIPOFECTIN@ as described. When cells reached 65-75% confluency, they were treated with oligonucleotide. Oligonucleotide was mixed with LIPOFECTIN@ Invitrogen Life Technologies, 10 Carlsbad, CA) in Opti-MEM@-1 reduced serum medium (Invitrogen Life Technologies, Carlsbad, CA) to achieve the desired concentration of oligonucleotide and a LIPOFECTIN@ concentration of 2.5 or 3 ptg/mL per 100 nM oligonucleotide. This transfection mixture was incubated at room temperature for approximately 0.5 hours. For cells grown in 96-well plates, wells were washed once with 100 gL OPTI MEM@-1 and then treated with 130 iL of the transfection mixture. Cells grown in 24-well plates or 15 other standard tissue culture plates were treated similarly, using appropriate volumes of medium and oligonucleotide. Cells were treated and data were obtained in duplicate or triplicate. After approximately 4-7 hours of treatment at 37*C, the medium containing the transfection mixture was replaced with fresh culture medium. Cells were harvested 16-24 hours after oligonucleotide treatment. Control oligonucleotides are used to determine the optimal oligomeric compound concentration 20 for a particular cell line. Furthermore, when oligomeric compounds are tested in oligomeric compound screening experiments or phenotypic assays, control oligonucleotides are tested in parallel. The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. The concentration of positive control oligonucleotide that 25 results in 80% inhibition of the target mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of the target mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide 30 transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM when the antisense oligonucleotide is transfected using a liposome reagent and 1 nM to 40 nM when the antisense oligonucleotide is transfected by electroporation. Example 2: Real-time Quantitative PCR Analysis of Target mRNA Levels 35 Quantitation of target mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM® 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions.

WO 2007/146511 PCT/US2007/068401 -245 Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured were evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. After isolation the RNA is subjected to sequential reverse transcriptase (RT) reaction and real-time PCR, both of which are performed in the same well. RT and PCR reagents were obtained from Invitrogen Life Technologies 5 (Carlsbad, CA). RT, real-time PCR was carried out in the same by adding 20 pL PCR cocktail (2.5x PCR buffer minus MgCl 2 , 6.6 mM MgCl 2 , 375 gM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM@ Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 gL total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48'C. 10 Following a 10 minute incubation at 95'C to activate the PLATINUM@ Taq, 40 cycles of a two-step PCR protocol were carried out: 95'C for 15 seconds (denaturation) followed by 60*C for 1.5 minutes (annealing/extension). Gene target quantities obtained by RT, real-time PCR were normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using 15 RiboGreen@ (Molecular Probes, Inc. Eugene, OR). GAPDH expression was quantified by RT, real-time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA was quantified using RiboGreen@ RNA quantification reagent (Molecular Probes, Inc. Eugene, OR). 170 gL of RiboGreen@ working reagent (RiboGreen@ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) was pipetted into a 96-well plate containing 30 gL purified cellular RNA. The 20 plate was read in a CytoFluor@ 4000 (PE Applied Biosystems) with excitation at 485nm and emission at 530nm. The GAPDH PCR probes have JOE covalently linked to the 5' end and TAMRA or MGB covalently linked to the 3' end, where JOE is the fluorescent reporter dye and TAMRA or MGB is the quencher dye. In some cell types, primers and probe designed to a GAPDH sequence from a different 25 species are used to measure GAPDH expression. For example, a human GAPDH primer and probe set is used to measure GAPDH expression in monkey-derived cells and cell lines. Probes and primers for use in real-time PCR were designed to hybridize to target nucleic acids using routine methods. For example, PrimerExpress@ (Applied Biosystems, Foster City, CA) software is routinely used to design probes and primers for use in real-time PCR. Examples of primer and probe 30 sequences and the target nucleic acids to which they hybridize are presented in Table 24. The target specific PCR probes have FAM covalently linked to the 5' end and TAMRA or MGB covalently linked to the 3' end, where FAM is the fluorescent dye and TAMRA or MGB is the quencher dye. Table 24 Target-specific primers and probes for use in real-time PCR Target Species Sequence Sequence (5' to )ID Name Description

NO

WO 2007/146511 PCT/US2007/068401 -246 Target Species Sequence Sequence (5' to 3') SEQ ID Name Description NO Forward ApoB Mouse Primer CGTGGGCTCCAGCATTCTA 1524 Reverse ApoB Mouse Primer AGTCATTTCTGCCTTTGCGTC 1525 ApoB Mouse Probe CCAATGGTCGGGCACTGCTCAA 1526 Forward ApoB Mouse Primer GAAAATAGACTTCCTGAATAACTATGCATT 1527 Reverse ApoB Mouse Primer ACTCGCTTGCCAGCTTGC 1528 ApoB Mouse Probe TTTCTGAGTCCCCGTGCCCAACA 1529 Forward GCGR Mouse Primer TGAGCCTTGCCACCTTCTCT 1530 Reverse GCGR Mouse Primer GCGCACCCCAGCCAA 1531 GCGR Mouse Probe AGAGGAGCTTCTTTTCCCTCTACCTGGGC 1532 Forward GCGR Mouse Primer ATTTCCTGCCCCTGGTACCT 1533 Reverse GCGR Mouse Primer CGGGCCCACACCTCTTG 1534 GCGR Mouse Probe CCACAAAGTGCAGCACCGCCTAGTGT 1535 Forward PTEN Mouse Primer GCCACAGGCTCCCAGACAT 1536 Reverse PTEN Mouse Primer TCCATCCTCTTGATATCTCCTTTTG 1537 PTEN Mouse Probe ACAGCCATCATCAAAGAGATCGTTAGCAGAA 1538 Forward PTEN Mouse Primer ATGACAATCATGTTGCAGCAATTC 1539 Reverse PTEN Mouse Primer CGATGCAATAAATATGCACAAATCA 1540 PTEN Mouse Probe CTGTAAAGCTGGAAAGGGACGGACTGGT 1541 Example 3: Short Antisense Compounds Targeted to an ApoB nucleic acid and having 2'-MOE or methyleneoxy (4'-CH 2 -O-2') BNA modifications 5 Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were injected intraperitoneally (i.p.) with antisense compounds targeted to ApoB, at a frequency of twice per week for three weeks. Antisense compound doses included 2.4, 1.2, 0.6, 0.3 and 0.15 pmol/kg. For antisense compounds 14 nucleotides in length, these doses equate to approximately 12, 6, 3, 1.5 or 0.75 mg/kg, respectively. Shown in Table 25 are the sequences and motifs of the antisense compounds used in this 10 study. The antisense compounds are either 20 or 14 nucleotides in length and have a central "gap" region consisting of ten 2'-deoxynucleotides flanked by wings having 2'-O-methoxyethyl (2'-MOE) or BNA modified "wings." For example, the 2-10-2 MOE gapmer motif indicates an antisense compound with a gap of ten nucleotides flanked by 2 nucleotide wings with 2'-MOE modifications. Bolded residues WO 2007/146511 PCT/US2007/068401 -247 indicate 2'-O-methoxyethyl moieties and italicized residues indicate methyleneoxy (4'-CH 2 -0-2') BNAs. The internucleoside linkages of each compound are phosphorothioate throughout. All cytosine residues of ISIS 147764 and ISIS 372938 are replaced by 5-methyl cytosines. For ISIS 387462, only the cytosine residue in the wing of the compound is replaced by 5-methyl cytosine. ApoB antisense compounds are 5 targeted to publicly available ApoB-100 sequences, including Genbank Accession No. XM_137955.5 (SEQ ID NO: 2). Table 25: Antisense Compounds Targeted to an ApoB nucleic acid ISIS Target 5' SEQ NO SEQ Target Sequence (5'-3') Gapmer Motif ID NO ID NO Site 147764 2 8865 GTCCCTGAAGATGTCAATGC 5-10-5 MOE 1561 372938 2 8235 GGTACATGGAAGTC 2-10-2 MOE 190 2-10-2 387462 2 8235 GGTACATGGAAGTC methyleneoxy (4'- 190

CH

2 -0-2') BNA Forty-eight hours following the final injection, mice were sacrificed to evaluate transaminases 10 (Table 26); liver and kidney weight (Table 27); triglyceride, LDL, HDL and free fatty acid levels (Table 28); target mRNA level in liver (Table 29); target protein level in plasma; and oligonucleotide tissue concentration (Table 30). These endpoints were determined using methods described herein and well known to those of ordinary skill in the art. 15 Table 26: ALT and AST Levels (IU/L) Dose ISIS NO ALT AST smol/kg Saline N/A 27.8 46.3 147764 2.4 29.5 64.0 372938 2.4 26.0 49.0 372938 1.2 24.8 49.5 372938 0.6 28.0 79.3 372938 0.3 28.3 60.0 372938 0.15 28.3 50.3 387462 2.4 41.3 84.0 387462 1.2 35.3 63.5 387462 0.6 32.0 77.3 387462 0.3 27.8 55.0 387462 0.15 29.3 68.3 Table 27: Liver and Kidney Weight (% of saline control) WO 2007/146511 PCT/US2007/068401 -248 Dose ISIS NO Liver Kidney stmol/kg Saline N/A 100 100 147764 2.4 102 105 372938 2.4 100 100 372938 1.2 90 101 372938 0.6 96 112 372938 0.3 91 107 372938 0.15 96 98 387462 2.4 116 90 387462 1.2 113 90 387462 0.6 106 97 387462 0.3 101 126 387462 0.15 95 100 Total body weight and food consumption did not differ significantly between saline-treated or oligonucleotide-treated animals. Glucose levels also were similar among all treatment groups. 5 Table 28: Triglyceride (TRIG), Total Cholesterol (CHOL), HDL, LDL and Free Fatty Acid (FFA) Levels Dose TRIG CHOL HDL LDL FFA ISIS NO tmol/kg (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) Saline N/A 167 107 81.8 11.0 1.76 147764 2.4 167 107 81.3 10.3 1.29 372938 2.4 153 104 79.0 10.3 1.28 372938 1.2 136 101 77.8 9.5 1.70 372938 0.6 184 110 83.3 10.8 1.66 372938 0.3 138 109 84.3 11.0 1.53 372938 0.15 151 106 82.8 10.8 1.57 387462 2.4 49 14 9.0 1.5 0.74 387462 1.2 71 23 16.5 2.0 0.76 387462 0.6 150 55 39.3 3.7 1.43 387462 0.3 136 92 72.8 7.5 1.14 387462 0.15 163 104 81.5 9.3 1.47 Table 29: % ApoB mRNA Level (relative to saline control) WO 2007/146511 PCT/US2007/068401 -249 ISIS NO 2.4 1.2 0.6 0.3 0.15 smol/kg tmol/kg imol/kg tmol/kg smol/kg 147764 57.7 ND ND ND ND 372938 77.0 90.0 87.3 92.6 93.1 387462 1.5 8.5 27.4 58.9 75.8 Treatment with ISIS 387462 resulted in a significant and dose-dependent decrease in triglycerides, total cholesterol, HDL, LDL and free fatty acids. In accordance with these phenotypic 5 findings, treatment with ISIS 387462 also led to a dose-dependent reduction in ApoB mRNA (Table 29) and protein (not shown) levels in mouse plasma. To determine whether the observed increase in efficiency with the methyleneoxy (4'-CH 2 -O-2') BNA gapmer is due to an increase in oligonucleotide accumulation, full-length and total oligonucleotide concentration in the liver and kidney were determined. 10 Table 30: Full-length and Total Antisense Compound Tissue Concentration (ItM) Relative to ApoB mRNA level (% of saline control) Dose Kidney Liver Kidney Liver ApoB ISIS NO Full- Total Total mRNA stmol/kg Length Full-Length 147764 2.4 28.6 22.9 33.5 31.3 58 372938 2.4 32.0 5.49 34.0 7.76 77 387462 2.4 37.2 5.69 38.9 7.31 1.5 387462 1.2 29.8 3.71 31.3 4.91 8.5 387462 0.6 18.9 1.97 20.0 2.57 27 387462 0.3 9.11 0.73 9.49 0.78 59 387462 0.15 6.97 0.19 7.43 0.24 76 Levels of the 2-10-2 methyleneoxy (4'-CH2-0-2') BNA gapmer were similar to the 5-10-5 and 2-10-2 MOE gapmers in the kidney, but significantly reduced in the liver. The EC 50 for ISIS 387462 in 15 the liver was determined by comparing oligonucleotide concentration in the liver to inhibition of ApoB mRNA. The approximate ECs for ISIS 387462 is 1 ptM. In contrast, an effective 5-10-5 MOE gapmer compound typically has an ECs 0 of approximately 15 pM in the liver. Taken together, these results demonstrate that the ApoB short gapmer having methyleneoxy (4'

CH

2 -0-2') in the wings is a potent inhibitor of target mRNA expression and can effectively lower 20 triglycerides, cholesterol and free fatty acids. The potency of the short antisense compound does not appear to be a result of increased tissue accumulation since similar levels of the compound were observed in kidney and reduced levels were found in the liver, relative to the 5-10-5 MOE gapmer. In addition, the WO 2007/146511 PCT/US2007/068401 -250 methyleneoxy (4'-CH 2 -O-2') BNA gapmer exhibited little to no adverse side effects. Example 4: Short Antisense Compounds Targeted to a GCGR nucleic acid and having 2'-MOE Modifications 5 Eight-week old male C57/BL6 mice (Jackson Laboratory, Bar Harbor, ME) were administered a single dose of GCGR oligonucleotide by intraperitoneal injection at a concentration of 6.25, 12.5, 25 or 50 mg. Each dose group consisted of four animals. Shown in Table 31 are the sequences, motifs and conjugates of the GCGR antisense compounds used in this study. Bolded residues indicate 2'-O methoxyethyl (2'-MOE) moieties. All compounds comprise phosphorothioate internucleoside linkages 10 throughout and each cytosine is replaced with 5-methylcytosine. ISIS 386626, ISIS 386627 and ISIS 386628 further comprise a C 16 conjugate group attached to the 2'-O position of the sugar via a diamide linkage (2'-OCH 2

C(=O)N(H)(CH

2

)

4

N(H)C(=O)-(CH

2

)

15

CH

3 ). GCGR antisense compounds target published GCGR sequences, including Genbank@ Accession No. BC031885.1 (SEQ ID NO: 7). 15 Table 31: Short antisense compounds targeted to a GCGR nucleic acid Target 5'SE ISIS Target S e Gapmer SEQ SEQ Target Sequence (5'-3') Conjugate ID NO Motif ID NO Site NO 148364 7 393 TGCACTTTGTGGTACCAAGG 5-10-5 MOE None 1562 386626 7 1768 GC 6 CTTCTCCATCATA 2-10-2 MOE C16 1563 386627 7 1244 GCi 6 GGCATGCTCGTCA 2-10-2 MOE C16 653 386593 7 1244 GGGCATGCTCGTCA 2-10-2 MOE None 649 386628 7 1680 Tci 6 GTCTTGCTGCTTT 2-10-2 MOE C16 1564 386594 7 1680 TGTCTTGCTGCTTT 2-10-2 MOE None 1565 Mice were sacrificed 48 hours following injection to determine serum transaminase levels (Table 32); liver, white adipose tissue (WAT), spleen and kidney weight (Table 33); cholesterol, triglyceride and glucose levels (Table 34); GCGR mRNA levels (Tables 35-41); and full-length and total oligonucleotide 20 concentration in liver and kidney (Table 42). Endpoints were assessed using methods described herein and well known to those of ordinary skill in the art. Data is included from a pre-treatment bleed (Pre Bleed) and post-treatment bleed (Post-Bleed). Table 32: ALT & AST Levels (IU/L) ALT ALT AST AST ISIS NO Dose (mg/kg) Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed Saline N/A 36 51 55 85 148364 50 24 40 40 115 148364 25 26 35 42 87 WO 2007/146511 PCT/US2007/068401 -251 ALT ALT AST AST ISIS NO Dose (mg/kg) Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed 148364 12.5 23 32 44 69 148364 6.25 28 34 47 76 386626 50 28 40 48 120 386626 25 30 36 44 92 386626 12.5 28 34 44 90 386626 6.25 26 42 46 69 386627 50 27 457 42 451 386627 25 29 97 45 142 386627 12.5 29 62 46 81 386627 6.25 23 87 38 96 386593 50 23 33 46 58 386593 25 25 32 41 95 386593 12.5 26 33 43 74 386593 6.25 28 31 43 53 386628 50 28 68 44 76 386628 25 24 32 40 57 386628 12.5 28 35 42 75 386628 6.25 22 29 40 59 386594 50 29 34 46 92 386594 25 27 31 47 82 386594 12.5 28 33 45 74 386594 6.25 23 48 42 67 Table 33: Organ Weights (% saline control) ISIS NO Dose (mg/kg) Liver WAT Kidney Spleen Saline N/A 100 100 100 100 148364 50 103 80 108 123 148364 25 103 75 112 115 148364 12.5 100 84 108 96 148364 6.25 101 89 104 113 386626 50 112 77 104 130 386626 25 109 97 103 120 386626 12.5 96 73 97 114 386626 6.25 100 90 100 95 WO 2007/146511 PCT/US2007/068401 -252 ISIS NO Dose (mg/kg) Liver WAT Kidney Spleen 386627 50 90 113 102 165 386627 25 99 87 99 143 386627 12.5 109 93 102 136 386627 6.25 103 96 102 131 386593 50 96 98 102 118 386593 25 83 94 100 104 386593 12.5 99 82 101 129 386593 6.25 96 77 98 144 386628 50 104 100 99 126 386628 25 102 97 109 113 386628 12.5 101 111 99 114 386628 6.25 98 106 102 151 386594 50 90 80 99 131 386594 25 93 76 99 128 386594 12.5 94 98 100 113 386594 6.25 102 85 101 119 Overall, the GCGR antisense compounds exhibited little to no adverse side effects. Table 34: Triglyceride (TRIG), Cholesterol (CHOL) and Glucose Levels (IU/L) TRIG TRIG CHOL CHOL Glucose Glucose ISIS NO Dose (mg/kg) Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed Saline N/A 132 181 91 96 208 285 148364 50 110 177 81 94 207 228 148364 25 115 200 83 96 219 239 148364 12.5 106 179 85 89 198 256 148364 6.25 86 162 86 89 226 215 386626 50 87 163 79 57 239 179 386626 25 100 187 87 72 235 186 386626 12.5 100 148 82 76 232 185 386626 6.25 86 162 85 90 222 221 386627 50 106 120 83 126 227 150 386627 25 101 148 90 115 218 203 386627 12.5 99 203 86 98 237 219 386627 6.25 111 165 88 104 238 228 WO 2007/146511 PCT/US2007/068401 -253 TRIG TRIG CHOL CHOL Glucose Glucose ISIS NO Dose (mg/kg) Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed Pre-Bleed Post-Bleed 386593 50 130 128 100 95 244 213 386593 25 119 135 83 77 206 208 386593 12.5 122 128 83 79 222 233 386593 6.25 120 138 84 78 214 219 386628 50 102 98 88 95 209 232 386628 25 102 129 84 85 210 223 386628 12.5 90 123 90 94 231 240 386628 6.25 117 121 83 85 228 229 386594 50 93 99 84 85 203 274 386594 25 106 94 90 86 219 272 386594 12.5 118 133 85 95 200 292 386594 6.25 112 146 78 94 222 275 GCGR 2-10-2 MOE gapmers exhibited a trend toward lower post-bleed triglyceride levels, relative to the 5-10-5 MOE gapmer, with ISIS 386628 and ISIS 386594 having the greatest dose dependent effect. Glucose levels also were decreased in a dose-dependent manner following treatment 5 with ISIS 386626 and ISIS 386627. Treatment with ISIS 386628, ISIS 386593 and ISIS 386594 also generally led to a decrease in post-bleed glucose levels. Cholesterol levels did not appear to significantly differ among treatment groups. To determine whether the phenotypic changes shown above correlated with a decrease in GCGR mRNA, treated animals were evaluated for levels of target mRNA in liver by real time PCR according to 10 methods described herein. Tables 35 to 41 show results from direct comparisons of the antisense compounds targeting GCGR nucleic acid for their effect on target expression. Results are expressed as percent of saline control. Table 35: GCGR mRNA levels following treatment with ISIS 148364 & ISIS 386626 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 148364 36 79 87 62 386626 0 8 3 7 15 Table 36: GCGR mRNA levels following treatment with ISIS 148364 & ISIS 386627 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 148364 63 87 105 86 386627 3 30 57 74 WO 2007/146511 PCT/US2007/068401 -254 Table 37: GCGR mRNA levels following treatment with ISIS 148364 & ISIS 386593 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 148364 56 74 105 86 386593 9 38 74 90 Table 38: GCGR mRNA levels following treatment with ISIS 148364 & ISIS 386628 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 148364 42 77 98 101 386628 2 18 53 77 5 Table 39: GCGR mRNA levels following treatment with ISIS 148364 & ISIS 386594 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 148364 59 98 102 96 386594 25 47 50 96 Table 40: GCGR mRNA levels following treatment with ISIS 386627 & ISIS 386593 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 386627 5 40 58 42 386593 10 29 34 71 Table 41: GCGR mRNA levels following treatment with ISIS 386628 & ISIS 386594 ISIS NO 50 mg/kg 25 mg/kg 12.5 mg/kg 6.25 mg/kg 386628 4 13 38 97 386594 19 50 56 99 10 Treatment with the 2-10-2 MOE gapmers led to a significant dose-dependent decrease in GCGR mRNA expression. ISIS 386626 exhibited the greatest decrease in target mRNA. To determine whether the observed increase in efficiency with the short antisense compounds is due to an increase in antisense compound accumulation, full-length and total antisense compound concentration in the liver and kidney 15 were determined. Table 42: Total and Full-length Antisense Compound Concentrations in Liver and Kidney (pg/g) Full Total Total Full-length length ISIS NO Kidney Liver Kidney Liver 148364 90 54 58 46 386626 757 274 355 125 WO 2007/146511 PCT/US2007/068401 -255 Full Total Total Full-length length ISIS NO Kidney Liver Kidney Liver 386593 91 12 77 12 386628 496 286 305 202 The results shown in Table 42 demonstrate that short antisense compounds comprising a C 16 conjugate exhibit a significant increase in antisense compound accumulation in both liver and kidney. However, ISIS 386593, which was effective at reducing target mRNA, triglycerides and glucose levels, 5 accumulates to a level similar to the 5-10-5 MOE gapmer in liver and to a lower level in kidney. These results suggest that while conjugation with C 16 can increase liver and kidney antisense compound concentration, it does not entirely account for the effectiveness of the short antisense compounds. Taken together, these results demonstrate that GCGR short antisense compounds are capable of significantly inhibiting target mRNA expression while also lowering triglyceride and glucose levels. In 10 addition, with the exception of ISIS 386627, the short MOE gapmers exhibited little to no toxic effects. Example 5: Short antisense compounds targeting to a GCGR nucleic acid and having 2'-MOE and Methyleneoxy (4'-CH 2 -O-2') BNA modifications Eight-week old male C57/BL6 mice (Jackson Laboratory, Bar Harbor, ME) were administered a 15 single dose of GCGR antisense compound by intraperitonel (i.p.) injection at a concentration of 10, 3.2, 1, and 0.32 ptmol.kg. Each dose group consisted of four animals. Shown in Table 43 are the sequences, motifs and conjugates of the GCGR antisense compounds used in this study. Bolded residues indicate 2' O-methoxyethyl (2'-MOE) modifications and the italicized residues indicate methyleneoxy (4'-CH 2

-O

2') BNA modifications. All antisense compounds comprise phosphorothioate internucleoside linkages 20 throughout and each cytosine is replaced with 5-methylcytosine. GCGR antisense compounds target published GCGR nucleic acids, including Genbank Accession No. BC031885.1 (SEQ ID NO: 7). Table 43: Antisense Compounds targeted to a GCGR nucleic acid ISIS Target 5' NO SEQ ID Target Sequence (5'-3') Gapmer Motif SEQ ID NO NO Site 148364 7 393 TGCACTTTGTGGTACCAAGG 5-10-5 MOE 1562 396144 7 1768 GCTTCTCCATCATA 2-10-2 MOE 1566 2-10-2 396148 7 1768 GCTTCTCCATCATA Methyleneoxy 1567 (4'-CH 2 -O-2') BNA 396145 7 1765 ATGGCTTCTCCATCATATCC 5-10-5 MOE 1568 396146 7 1244 GGGCATGCTCGTCA 2-10-2 MOE 650 396149 7 1244 GGGCATGCTCGTCA 2-10-2 652 1_ Methyleneoxy WO 2007/146511 PCT/US2007/068401 -256 Isis Target 5' NO SEQ ID Target Sequence (5'-3') Gapmer Motif SEQ ID NO NO Site (4'-CH 2 -O-2') BNA 396147 7 1241 CTTGGGCATGCTCGTCAGTC 5-10-5 MOE 1569 To determine whether the phenotypic changes shown above correlated with a decrease in GCGR mRNA, treated animals were evaluated for levels of target mRNA in liver by RT, real time PCR according to methods described herein. Table 44 show results from direct comparisons of the antisense 5 compounds targeting GCGR nucleic acid for their effect on target expression. Results are expressed as percent of saline control. TABLE 44: GCGR mRNA levels ISIS NO. 0.32 smol/kg 1 pmol/kg 3.2 stmol/kg 10 tmol/kg 148364 105 106 73 38 396144 122 117 40 35 396148 20 6 2 1 396145 nd Nd 33 8 396146 98 135 95 35 396149 91 41 30 7 396147 nd Nd 68 28 As shown in Table 44, each short antisense compound having methyleneoxy (4'-CH 2 -O-2') BNA 10 modifications demonstrated a dose-dependent reduction in GCGR mRNA levels. Furthermore, the short antisense compounds were more effective at target reduction than the 5-10-5 MOE gapmer. Each short antisense compound comprising methyleneoxy (4'-CH 2 -O-2') BNA in the wings resulted in a significant reduction in GCGR protein relative to both saline control and ISIS 148364 treatment. Next, estimated

ED

50 concentrations for each antisense were calculated using Graphpad Prism; ED 50 is the dose at which 15 50% mRNA reduction is observed. The results are shown below in Table 45. Table 45: Estimated ED 50 Concentration ISIS Gapmer Motif NO ED 50 (pmole/kg) ED 50 (mg/kg) 5-10-5 MOE 148364 7 50.6 2-10-2 MOE 396144 4 18.1 2-10-2 methyleneoxy BNA 396148 0.1 0.4 5-10-5 MOE 396145 2.1 9.3 2-10-2 MOE 396146 8.3 40 2-10-2 methylenexy BNA 396149 1.1 5 WO 2007/146511 PCT/US2007/068401 -257 ISiS Gapmer Motif NO ED 50 (stmole/kg) ED 50 (mg/kg) 5-10-5 MOE 396147 5.2 37.5 Example 6: Short Antisense Compounds Targeting a PTEN nucleic acid and having methyleneoxy (4'-CH 2 -O-2') BNA Modifications Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a 5 single i.p. injection of PTEN antisense compound at a dose of 8 pmol/kg. Each dose group consisted of four animals. Shown in Table 46 are the sequences and motifs of the PTEN antisense compounds used in this study. Bolded residues indicate 2'-O-methoxyethyl moieties (2'-MOE) and italicized residues indicate Methyleneoxy BNA nucleotides. Each antisense compound comprises phosphorothioate linkages throughout. In addition, the cytosine residues in the gap of ISIS 384073 and in the wings of ISIS 10 392056, ISIS 392057, ISIS 392061 and ISIS 392063 are replaced with 5-methylcytosines. Antisense compounds target published PTEN nucleic acids, including Genbank Accession No. U92437.1 (SEQ ID NO: 13). Table 46: Antisense Compounds targeted to a PTEN nucleic acid Isis Target 5' SEQ NO SEQ ID Target Sequence (5'-3') Gapmer Motif ID NO NO Site 141923 Control N/A CCTTCCCTGAAGGTTCCTCC 5-10-5 MOE 1570 116847 29 2011 TCAAATCCAGAGGCTAGCAG 5-10-5 MOE 1571 384073 29 2013 AAATCCAGAGGCTAGC 3-10-3 methyleneoxy 1428 (4'-CH 2 -O-2') BNA 391172 29 2013 AAATCCAGAGGCTAG 2-10-3 methyleneoxy 1429 (4'-CH 2 -5-2') BNA 392056 29 140 AGCTGCAGCCATGA 2-10-2 methyleneoxy 1263 (4'-CH 2 -O-2') BNA 392057 29 807 GGTCCAGGGCCAAG 2-10-2 methyleneoxy 1162 ____ ______ _______________________(4'-CH 2 -O-2') BNA ___ 392061 29 2014 AATCCAGAGGCTAG 2-10-2 methyleneoxy 1431 (4'-CH 2 -O-2') BNA 392063 29 3099 AGGCCAGTGCTAAG 2-10-2 methyleneoxy 1226 (4'-CH 2 -O-2') BNA 15 Mice were sacrificed 72 hours following injection to determine serum transaminase levels (Table 47); liver and spleen weights (Table 47); and PTEN mRNA levels in liver, kidney and fat (Table 48), according to procedures described herein and well know to one of ordinary skill in the art. Table 47: Transaminase Levels and Organ Weights ISIS AST ALT Wigt Spleen Weight NO (IU/L) (IU/L) % Saline % Saline 98.5 37.5 100 100 WO 2007/146511 PCT/US2007/068401 -258 ISIS AST ALT Wigt Spleen Weight NO (IU/L) (IU/L) % Saline % Saline 141923 89.5 34.8 101 108 116847 59.8 29.5 109 108 384073 57.8 29.3 115 111 391172 48.5 32.8 120 112 392056 516 892 125 167 392057 63.8 34.5 125 101 392061 189 42.0 123 111 392063 67.3 21.8 127 134 Overall, the short antisense compounds with methyleneoxy (4'-CH 2 -O-2') BNA modifications exhibited little to no adverse effects. In addition, total body weight did not significantly differ between treatment groups. 5 Table 48: %PTEN mRNA levels in Liver, Kidney and Fat ISIS NO Liver Kidney Fat Saline 100 100 100 141923 102 133 118 116847 37 96 85 384073 24 74 77 391172 18 63 101 392056 27 88 74 392057 33 79 96 392061 24 61 85 392063 6.5 52 72 As shown in Table 48, each antisense compound targeted to a PTEN nucleic acid led to a significant reduction in target mRNA levels in liver as compared with saline treated and control treated animals. The antisense compounds had various effects on target mRNA levels in kidney and fat. 10 Example 7: Short Antisense Compounds Targeting a PTEN nucleic acid and having BNA Modifications Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal (i.p.) injection of antisense compound targeted a PTEN nucleic acid at a dose of 8, 15 4, 2 or I pmol/kg. Each dose group consisted of four animals. Shown in Table 49 are the sequence, wing chemistry and motif of each antisense compound used in this study. Bold residues indicate 2'-MOE WO 2007/146511 PCT/US2007/068401 -259 modified nucleotides, italicized letters indicate methyleneoxy (4'-CH 2 -O-2') BNA modifications. All antisense compounds comprise phosphorothioate linkages at each position. Each cytosine of ISIS 116847 and the cytosine residues in the methyleneoxy (4'-CH 2 -O-2') BNA wings of ISIS 392063 are replaced with 5-methylcytosines, while the thymidine residues in the methyleneoxy (4'-CH 2 -O-2') BNA wings of 5 ISIS 392745 are replaced with 5-methyl thymidines. Antisense compounds target published PTEN nucleic acids, including Genbank Accession No. U92437.1 (SEQ ID NO: 13). Table 49: Antisense Compounds Targeted to a PTEN Nucleic Acid ISIS t T aget SEQ NO SEQ Site Sequence (5'-3') Gapmer Motif ID ID NO NO 116847 13 2011 TCAAATCCAGAGGCTAGCAG 5-10-5 1571 MOE 392063 13 3099 CT'AGCACTGGCCT 2-10-2 1226 Methyleneoxy BNA 392745 13 3099 CITAGCACTGGCCT 2-10-2 methyleneoxy 1226 1_ 1_ 1_ BNA 10 Mice were sacrificed 72 hours following injection to determine serum transaminase levels (Table 50); liver, kidney and spleen weights (Table 50); PTEN mRNA levels in liver (Table 51); and estimated

ED

50 oligonucleotide concentration (Table 52). These endpoints were measured using methods described herein and well known to those of ordinary skill in the art. Table 50: AST, ALT and Bilirubin Levels and Organ Weights Liver ISIS Dose AST ALT Bilirubin Weight Kidney Spleen NO smol/kg (IU/L) (IU/L) (mg/dL) % Weight Weight % Saline % Saline Saline Saline N/A 64.0 31.8 0.15 100 100 100 116847 8 73.0 32.0 0.1 114 92 106 392063 8 50.3 17.3 0.1 115 98 115 392063 4 100.8 31.3 0.15 122 94 116 392063 2 60.5 32.8 0.1 112 99 106 392063 1 57.5 29.3 0.1 104 95 107 392745 8 75.5 23.5 0.13 125 99 100 392745 4 77.0 29.3 0.13 121 100 96 392745 2 69.0 32.0 0.13 110 98 103 392745 1 52.0 27.3 0.1 109 97 104 15 Overall, the PTEN antisense compounds did not show significant signs of toxicity. Kidney, liver and spleen weights were all within normal ranges. Total body weight did not significantly differ between WO 2007/146511 PCT/US2007/068401 -260 treatment groups. Table 51: % PTEN mRNA levels in Liver (relative to saline control) ISIS 4 2 1 smol/kg 8 ptmol/kg NO smol/kg smol/kg 116847 36 ND ND ND 392063 7.4 16 32 60 392745 5.2 11 31 60 As shown in Table 51, each short antisense compound having methyleneoxy (4'-CH 2 -0-2') BNA 5 modifications demonstrated a dose-dependent reduction in PTEN mRNA levels. Furthermore, the short antisense compounds were more effective at target reduction than the 5-10-5 MOE gapmer. Levels of PTEN protein in liver were also determined following administration of each antisense compound at a dose of 8 pmol/kg. Each short antisense compound comprising methyleneoxy (4'-CH 2 -0-2') BNA in the wings resulted in a significant reduction in PTEN protein relative to both saline control and ISIS 116847 10 treatment. Next, estimated ED 50 concentrations for each oligonucleotide were calculated using Graphpad Prism. The results are shown below in Table 52. Table 52: Estimated ED 50 Concentration ISIS Wing Chemistry NO ED 50 (pmole/kg) ED 50 (mg/kg) MOE (with 5-MeC) 116847 6.3 45.2 methyleneoxy BNA (with 5-MeC) 392063 1.3 5.8 methyleneoxy BNA 392745 1.2 5.6 15 To further investigate different types of bicyclic nucleic acid compounds, an additional set of short antisense compounds targeting a PTEN nucleic acid was designed and tested. Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal (i.p.) injection of antisense compound at a dose of 8, 4, 2 or 1 gmol/kg. Each dose group consisted of four animals. Shown in Table 53 are the sequence, wing chemistry and motif of each antisense compound 20 used in this study. All antisense compounds comprise phosphorothioate linkages at each position. The cytosine residues in the methyleneoxy (4'-CH 2 -0-2') BNA wings of ISIS 392063 are replaced with 5 methylcytosines. The antisense compound target published PTEN nucleic acids, including Genbank Accession No. U92437.1 (SEQ ID NO: 13). 25 Table 53: Antisense Compounds Targeting a PTEN Nucleic Acid WO 2007/146511 PCT/US2007/068401 -261 Ii Target 5' IS SEQ Target Sequence (5'-3') Gapmer Motif SENO ID NO Site 392063 29 3099 CTTAGCACTGGCCT 2-10-2 1226 Methyleneoxy BNA 2-10-2 396564 29 3099 CTTAGCACTGGCCT Oxyamino 1226 (4'-CH 2 -N(R)-O-2') 12 BNA 2-10-2 a-L 396006 29 3099 CTTAGCACTGGCCT Methyleneoxy 1226 BNA Mice were sacrificed 72 hours following injection to determine serum transaminase levels (Table 54); liver and spleen weights (Table 54); and PTEN mRNA levels in liver (Table 55), according to methods described herein and well known to those of ordinary skill in the art. 5 Table 54: AST and ALT Levels and Organ Weights ISIS Dose AST ALT Liver Spleen NO pmol/kg (IU/L) (IU/L) Weight Weight Saline N/A 71 33 100 100 392063 8 97 38 118 103 392063 4 179 36 115 107 392063 2 67 32 109 116 392063 1 68 27 102 105 396564 8 67 25 100 104 396564 4 96 30 102 106 396564 2 68 27 100 119 396564 1 79 39 97 109 396006 8 56 28 110 104 396006 2 139 36 97 105 Table 55: % PTEN mRNA levels in Liver (relative to saline control) ISIS NO 8 tmol/kg 4 tmol/kg 2 smol/kg 1 tmol/kg 392063 6.9 18 39 71 396564 86 97 100 96 396006 6.5 ND ND 70 10 As shown above, short antisense compounds having a-L-methyleneoxy (4'-CH 2 -O-2') BNA modifications led to a dose-dependent reduction in target mRNA levels. Treatment with the short WO 2007/146511 PCT/US2007/068401 -262 antisense compound having oxyamino BNA modifications led to a modest reduction in target expression. Example 8. Single Dose Administration Dose Response Study with Short Antisense Compounds Targeting ApoB and PTEN nucleic acids 5 Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal (i.p.) injection of antisense compound at a dose of 8, 4, 2 or 1 pmol/kg. Each dose group consisted of four animals. Shown in Table 56 are the sequence, wing chemistry and motif of each antisense compound used in this study. Italicized residues indicate methyleneoxy (4'-CH 2 -O-2') BNA modifications, underlined residues indicate N-methyl-oxyamino (4'-CH 2

-N(CH

3 )-O-2') BNA 10 modifications, and boxed residues indicate a-L-methyleneoxy (4'-CH 2 -O-2') BNA modifications. All antisense compounds comprise phosphorothioate linkages at each position. Each cytosine of ISIS 116847 and the cytosine residues in the methyleneoxy (4'-CH 2 -O-2') BNA wings of ISIS 392063 are replaced with 5-methylcytosines, while the thymidine residues in the methyleneoxy (4'-CH 2 -O-2') BNA wings of ISIS 392745 are replaced with 5-methyl thymidines. PTEN antisense compounds target published PTEN 15 nucleic acid, including Genbank Accession No. U92437.1 (SEQ ID NO: 13). ApoB antisense compounds target published ApoB nucleic acid, including Genbank Accession No. XM1 37955.5 (SEQ ID NO: 2). Table 56: Short Antisense Compounds Targeted to ApoB and PTEN Nucleic Acids ISIS Target Target 5' Target NO Sq ID SiteSEQUENCE Gapmer SEQ ID NO NO Seq ID Site 2-10-2 387462 ApoB 19 8235 GGTACATGGAAGTC 193 Methyleneoxy BNA 2-10-2 392063 PTEN 29 3099 CTJAGCACTGGCCT 1226 Methyleneoxy BNA 2-10-2 396565 PTEN 29 3099 CUTAGCACTGGCCU 1226 N-Me-oxyamino BNA ~1TACACTGC~2-10-2 396006 PTEN 29 3099 AGCACTGGC 1226 a-L-methyleneoxy BNA 20 Table 57: %ApoB and PTEN mRNA Reduction (relative to saline control) ISIS Dose %ApoB mRNA Reduction %PTEN mRNA Reduction NO (tmol/kg) (relative to saline) (relative to saline) 387462 8 0.62 92.8 4 6.55 103 2 18.6 105 1 42.0 98.0 392063 8 126 6.79 WO 2007/146511 PCT/US2007/068401 -263 4 111 18.1 2 112 42.4 1 114 62.3 396565 8 116 23.8 4 1.04 46.6 2 94.4 76.1 1 115 89.5 396006 8 94.3 62.9 4 101 18.2 2 79.7 52.4 1 111 82.4 As shown in Table 57, each short antisense compound having Methyleneoxy BNA modifications demonstrated a dose-dependent reduction in target mRNA levels. Notably, the short antisense compound with N-methyl-oxyamino BNA wings (ISIS 396565) also demonstrated dose-dependent reduction in 5 PTEN expression similar to both the p-D-methyleneoxy BNA and a-L-methyleneoxy BNA short antisense compounds. Next, estimated ED 50 concentrations for each antisense were calculated using Graphpad Prism. The results are shown below in Table 58. Table 58: Estimated ED 50 Concentrations ISIS Wing Chemistry NO ED 50 (pmole/kg) ED 50 (mg/kg) Methyleneoxy BNA 387462 0.8 3.9 Methyleneoxy BNA 392063 1.5 7 N-Me-oxyamino BNA 396565 3.8 17.4 a-L-methyleneoxy BNA 396006 2.1 9.3 10 EXAMPLE 9: Administration of a Parent and Parent Mixed Backbone Antisense Compound Targeting SGLT-2 mRNA. ISIS 257016 was administered to db/db mice (Charles River Laboratories, Wilmington, MA) 15 intraperitoneally at a dose of 1, 7.5, 14 or 17 mg/kg twice a week. Control groups included a group receiving saline on the same dosing schedule and a group receiving ISIS 145733. ISIS 257016 and ISIS 145733 both comprise the sequence GAAGTAGCCACCAACTGTGC (SEQ ID NO: 1572) further comprising a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) 20 nucleotides. All cytidine residues are 5-methylcytidines. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide for ISIS 145733; however ISIS 257016 has a WO 2007/146511 PCT/US2007/068401 -264 mixed backbone. The internucleoside linkages for ISIS 257016 are phosphodiester (P=O) in the wings and phosphorothioate in the gap. Forty-eight hours following administration of the last dose the mice were sacrificed and kidney tissue was analyzed for SGLT-2 mRNA levels. The results are shown below in Table 59. 5 Table 59: Antisense inhibition of SGLT2 mRNA expression in vivo by 5-10-5 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide nmol/kg ISIS 145733 ISIS 257016 17 -37.5 -76 14 -31.25 -74 7.5 -12.5 -62.5 1 +3 -44 Both ISIS 257016 and ISIS 145733 markedly reduced SGLT-2 levels compared to saline control. (mRNA levels determined using RT, real-time PCR as described above) However, ISIS 257016 has been 10 shown to be about 20-50 times more potent for reducing SGLT-2 mRNA compared to ISIS 145733. An associated reduction in plasma glucose levels was seen for the treatment groups (661 ±14 for the saline group compared to 470 ±23 for the group receiving ISIS 257016). Accumulation of ISIS 257016 and ISIS 145733 in the kidney was similar over the dose range, however little of the full length 257016 antisense was detected in the kidney which supports the theory that a degradation product is responsible 15 for the increased activity. Also the onset of action following a single dose of 25 mg/kg correlated to a time pint were little intact 257016 antisense compound was left. Similar studies were performed in lean mice, ob/ob mice and in ZDF rats (Charles Rivers Laboratories) using ISIS 257016, ISIS 145733 or saline in a similar same dosing schedule as described above. The sequence of the binding site for ISIS 145733 and ISIS 257016 is conserved between mouse 20 and rat (see Table 60). Reduction of SGLT-2 mRNA in the kidney was similar to that seen above. In a study utilizing rats, at a dose of 10 mg/kg given two times a week for two weeks, ISIS 145733 was shown to reduce SGLT-2 mRNA levels by about 40% whereas the reduction achieved with ISIS 257016 was greater than 80%. ISIS 257016 reduces SGLT2 expression maximally at a low dose of 12.5 mg/kg. Additional studies at lower dosing ranges show significant reduction of SGLT2 mRNA levels with the 25 mixed backbone antisense compound at doses less than 1 mg/kg/wk. EXAMPLE 10: Administration of a Parent and Short Antisense Compound Targeting SGLT-2 mRNA Pharmacokinetic studies indicated that ISIS 257016 was acting as a prodrug that was metabolized WO 2007/146511 PCT/US2007/068401 -265 to a 12 nucleobase pharmacophore. In a next study, ZDF rats were dosed intraperitoneally twice per week with 1.5 mg/kg of either ISIS 257016 or ISIS 370717, or with saline at a similar dosing schedule. ISIS 370717 is a 12 nucleobase antisense compound targeted to SGLT-2 nucleic acid comprising the sequence TAGCCACCAACT (SEQ ID NO: 154) and further comprising central "gap" region consisting 5 of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by one-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. All cytidine residues are 5 methylcytidines. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Following five weeks of dosing the animals were sacrificed and kidney tissue was analyzed for 10 SGLT-2 mRNA levels. The pharmacological activity of ISIS 257016 and ISIS 370717 were similar, however, the 12 nucleotide antisense compound displayed a faster onset of action. ISIS 370717 displayed nearly 80% inhibition of SGLT2 expression in kidney on day two after a single dose of 2.8 umoles/kg whereas ISIS 257016 displayed only about 25% inhibition on day 2 after the same single dose administration. The date support that ISIS 257016 is a prodrug having a 12 nucleotide pharmacophore. 15 EXAMPLE 11: Potency and Bioavailability of a Short Antisense Compound The improved potency displayed by ISIS 370717 and the improved oral bioavailability for these short antisense compounds makes these compounds useful for oral administration. Normal rats received ISIS 370717, ISIS 145733 or saline at 100 mg/kg twice per week via intrajejunal administration. About 20 48 hours following the last dose, the animals were sacrificed and kidney tissue was analyzed for antisense compound concentration and SGLT-2 mRNA levels. There was a significantly higher accumulation of ISIS 370717 in the kidney tissue (approximately 500 micro grams per gram of tissue) compared to the controls. Moreover, SGLT-2 mRNA was reduced by more than 80% over the controls. 25 EXAMPLE 12: Wing, Gap and Total Length Variations Around a 12 nucleotide short antisense compound ISIS 370717 1-10-1 MOE gapmer was used as a template to make sequence related oligos with varying motifs. These variations are provided in Table 60. The antisense compounds were designed to target different regions of the mouse or rat SGLT2 nucleic acid, using published sequences (GenBank 30 accession number U2988 1.1, incorporated herein as SEQ ID NO: 1575, and GenBank accession number AJ292928. 1, incorporated herein as SEQ ID NO: 1576, respectively). Table 60: Short Antisense compounds targeting SGLT2 nucleic acids 5' Target Site 5' Target Site SEQ ISIS on mouse on rat Gapmer SEQ NO SEQ ID NO: SEQ ID NO: Motif Sequence (5'-3') ID 1575 1576 NO 257016 2680 148 5-10-5 GAAGTAGCCACCAACTGTGC 1553 41 MOE 370717 1 2684 152 1-10-1 T:AGCCACCAACT 1554 WO 2007/146511 PCT/US2007/068401 -266 MOE 386169 2684 152 MOE TAGCCACCAACT 1555 386176 2685 153 MOE AGCCACCAAC 1556 386196 2684 152 MOE TAGCCACCAACT 1557 The antisense compounds were analyzed for their effect on mouse SGLT2 mRNA levels. Data are ranges taken from three experiments in which mice were dosed twice per week for three weeks with 2.5, 0.5 or 0.1 umol/kg of the above MOE gapmers given by intraperitoneal injection. Mice were 5 sacrificed 48 hours following last administration and evaluated for SGLT2 levels in kidney. SGLT2 mRNA levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 61. Table 61: Antisense inhibition of SGLT2 in vivo by 1-10-1 and 1-10-2 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide ISIS ISIS ISIS ISIS ISIS umol/kg 370717 386169 386176 386196 386197 2.5 -82 -85 -80 -50 -20 0.5 -70 -80 -68 -30 -15 0.1 -55 -70 -65 -35 -20 10 These results illustrate that all the various motifs tested inhibit the expression of SGLT2 in vivo in a dose-dependent manner. The 1-10-1, 2-8-2 and 1-8-1 gapmers were found to be particularly potent. EXAMPLE 13: Antisense Inhibition of Rat SGLT-2 by 1-10-1 and 1-10-2 MOE Gapmers 15 1-10-1 and 1-10-2 MOE gapmer antisense compounds, provided in Table 62, were designed to target different regions of the mouse or rat SGLT2 RNA. All short antisense compounds in Table 62 are chimeric oligonucleotides ("gapmers") either 12 or 13 nucleotides in length, composed of a central "gap" segment consisting of ten 2'-deoxynucleotides, which are flanked on the 5' side by a one-nucleoside "wing" and on the 3' side by a two or one-nucleotide "wing". The wings are composed of 2' 20 methoxyethyl (2'-MOE) nucleotides. The intemucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. Table 62: Antisense compounds targeting SGLT2 nucleic acid 5' Target Site 5' Target Site ISIS NO on SEQ ID on SEQ ID Sequence (5'-3') Motif IDc5NO NO: XXX NO: XXX WO 2007/146511 PCT/US2007/068401 -267 (mouse) (rat) 370717 2684 152 1-10-1 MOE TAGCCACCAACT 1554 382675 2683 151 1-10-1 MOE TAGCCACCAACTG 1559 379692 508 1-10-1 MOE TGTTCCAGCCCA 246 382676 507 1-10-2 MOE TGTTCCAGCCCAG 246 379699 1112 1-10-2 MOE GGCATGAGCTTC 281 382677 1111 1-10-2 MOE GGCATGAGCTTCA 281 382677 958 1-10-2 MOE GGCATGAGCTTCA 281 The short antisense compounds were analyzed for their effect on rat SGLT2 mRNA levels. Data are ranges taken from three experiments in which Male Sprague-Dawley rats (170-200g) were dosed twice per week for three weeks with 450, 150 or 50 nmol/kg of either a 1-10-1 or 1-10-2 MOE gapmer 5 given by intraperitoneal injection. Rats were sacrificed 48 hours following last administration and evaluated for SGLT2 mRNA levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 63. 10 Table 63: Antisense inhibition of SGLT2 mRNA in vivo by 1-10-1 and 1-10-2 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide ISIS ISIS ISIS ISIS ISIS ISIS nmol/kg 370717 382675 379692 382676 379699 382677 1-10-1 1-10-2 1-10-1 1-10-2 1-10-1 1-10-2 450 -70 -80 -90 -85 -83 -75 150 -70 -65 -85 -80 -75 -60 50 -55 -50 -80 -65 -60 -40 These results illustrate that both the 1-10-1 and 1-10-2 MOE gapmers reduce SGLT2 mRNA in vivo in a dose-dependent manner. Rats were further evaluated for total body weight, liver, spleen and kidney weight. Significant 15 changes in spleen, liver or body weight can indicate that a particular compound causes toxic effects. All changes were within the margin of error of the experiment. No significant changes in body weight were observed during the treatment or at study termination. No significant changes in liver or spleen weights were observed. Toxic effects of short antisense compounds administered in vivo can also be assessed by 20 measuring the levels of enzymes and proteins associated with disease or injury of the liver or kidney. Elevations in the levels of the serum transaminases aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are often indicators of liver disease or injury. Serum total bilirubin is an WO 2007/146511 PCT/US2007/068401 -268 indicator of liver and biliary function, and albumin and blood urea nitrogen (BUN) are indicators of renal function. Glucose and triglyceride levels are sometimes altered due to toxicity of a treatment. Serum glucose also depends in part upon the activity of SGLT2. The levels of ALT, AST, total bilirubin, albumin, BUN, glucose and triglyceride were measured in rats treated with the short antisense 5 compounds. The levels of routine clinical indicators of liver and kidney injury and disease were within normal ranges and are not significantly changed relative to saline-treated animals, demonstrating that the short antisense compounds do not significantly affect renal or hepatic function. Triglyceride and glucose levels were not significantly elevated relative to saline-treated animals. 10 EXAMPLE 14: Antisense Inhibition of Mouse and Rat SGLT2 by 1-10-1 MOE Gapmers 1-10-1 MOE gapmer antisense compounds designed to target different regions of mouse SGLT2 mRNA are shown in Table 64. Table 64: Composition of Antisense Compounds Targeting SGLT2 mRNA ISIS 5' Target Site 5' Target Site Motif Sequence (5'-3') SEQ NO on SEQ ID on SEQ ID ID NO NO: XXX NO: XXX (mouse) (rat) 370717 2684 152 1-10-1 MOE TAGCCACCAACT 1554 379692 508 1-10-1 MOE TGTTCCAGCCCA 246 379699 1112 1-10-1 MOE GGCATGAGCTTC 281 379702 1525 1-10-1 MOE GCACACAGCTGC 293 381408 3034** 1-10-1 MOE TACCGAACACCT 1560 ** indicates 3 mismatches to a target sequence 15 The short antisense compounds were analyzed for their effect on mouse SGLT2 mRNA levels. Data was taken from three experiments in which Male 6-week old Balb/c mice were dosed twice per week for two weeks with 450, 150, or 50 nmol/kg of one of the above 1-10-1 MOE gapmers given by intraperitoneal injection. Mice were sacrificed 48 hours following last administration and evaluated for 20 SGLT2 mRNA levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 65. Table 65: Antisense inhibition of SGLT2 mRNA in vivo by 1-10-1 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide ISIS ISIS ISIS ISIS ISIS nmol/kg 370717 379692 379699 379702 381408 WO 2007/146511 PCT/US2007/068401 -269 450 -65 -80 -80 -75 150 -55 -70 -62.5 -72.5 50 -47.5 -52.5 -42.5 -52.5 These results illustrate that all the 1-10-1 MOE gapmers except, ISIS 381408, inhibit the expression of SGLT2 in vivo in a dose-dependent manner in mouse. Activity of ISIS 381408 has been shown in Rat studies (See Table 65). 5 Evaluation of 1-10-1 Gapmers in Rat The effect of the above 1-10-1 gapmers (see Table 64 above) on rat SGLT2 mRNA levels. Data are taken from four experiments in which male Sprague-Dawley rats (170-200g) were dosed twice per week for three weeks with 250 nmol/kg given by intraperitoneal injection. Rats were sacrificed 48 hours 10 following last administration and evaluated for SGLT2 mRNA levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 66. Table 66: Antisense inhibition of SGLT2 mRNA in vivo by 1-10-1 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide ISIS ISIS ISIS ISIS ISIS g 370717 379692 379699 379702 381408 250 -70 -85 -75 -25 -5 15 These results illustrate that all the 1-10-1 MOE gapmers inhibit the expression of SGLT2 in in vivo rat studies. EXAMPLE 15: Antisense Inhibition of Mouse and Rat SGLT2 Expression by Additional 1-10-1 20 and 2-8-2 MOE Gapmers 1-10-1 and 2-8-2 MOE gapmer short antisense compounds were designed to target different regions of the mouse SGLT2 RNA but have complementarity across species. The short antisense compounds are shown in Table 67. All short antisense compounds in Table 67 are gapmers 12 nucleotides in length, composed of a central "gap" segment consisting of 2'-deoxynucleotides, which are 25 flanked on both sides (5' and 3' directions) by wing segments having 2'-modifications. The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

WO 2007/146511 PCT/US2007/068401 -270 Table 67: Short Antisense Compounds Targeting SGLT2 nucleic acid ISIS NO 5' Target Gapmer Sequence (5'-3') SEQ ID Target SEQ ID Motif NO Site (rat) (rat) 379692 508 1-10-1 MOE TGTTCCAGCCCA 246 388625 508 1-10-1 MOE TGTTCCAGCCCA 246 379699 1112 1-10-1 MOE GGCATGAGCTTC 281 388626 1112 2-8-2 MOE GGCATGAGCTTC 281 379702 1525 2-8-2 MOE GCACACAGCTGC 293 388627 1525 2-8-2 MOE GCACACAGCTGC 293 The short antisense compounds were analyzed for their effect on mouse SGLT2 mRNA levels in vivo. Data was taken from three experiments in which male 6-week old Balb/c mice were dosed twice 5 per week for three weeks with 0.5, 0.1, or 0.02 umol/kg of either a 1-10-1 or 2-8-2 MOE gapmer given by intraperitoneal injection. Mice were sacrificed 48 hours following last administration and evaluated for SGLT2 levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 68. 10 Table 68: Antisense inhibition of SGLT2 mRNA in vivo by 1-10-1 and 2-8-2 MOE gapmers % change in SGLT2 expression relative to saline Dose of oligonucleotide ISIS ISIS ISIS ISIS ISIS ISIS umol/kg 379692 388625 379699 388626 379702 388627 1-10-1 2-8-2 1-10-1 2-8-2 1-10-1 2-8-2 0.5 -85 -90 -75 -80 -70 -65 0.1 -75 -88 -60 -60 -65 -50 0.02 -55 -65 -30 -45 -40 -38 These results illustrate that both the 1-10-1 and 2-8-2 MOE gapmers inhibit the expression of SGLT2 in vivo in a dose-dependent manner. 15 Mice were further evaluated for total body weight, liver, spleen and kidney weight. All changes were within the margin of error of the experiment. No significant changes in body weight were observed during the treatment or at study termination. No significant changes in liver or spleen weights were observed. The levels of ALT, AST, BUN, transaminases, plasma creatinine, glucose and triglyceride were 20 measured in mice treated with the short antisense compounds. The levels of routine clinical indicators of WO 2007/146511 PCT/US2007/068401 -271 liver and kidney injury and disease were within normal ranges and are not significantly changed relative to saline-treated animals, demonstrating that the short antisense compounds do not significantly affect renal or hepatic function. Triglyceride and glucose levels were not significantly elevated relative to saline-treated animals. 5 Evaluation of ISIS 379692 1-10-1 MOE Gapmer, ISIS 392170 1-10-1 Methyleneoxy BNA Gapmer, ISIS 388625 2-8-2 MOE Gapmer and ISIS 392173 2-8-2 Methyleneoxy BNA Gapmer in Mice The effect of ISIS 379692 1-10-1 MOE gapmer and ISIS 388625 2-8-2 MOE gapmer are 10 compared with the effect of ISIS 392170 1-10-1 Methyleneoxy BNA Gapmer and ISIS 392173 2-8-2 Methyleneoxy BNA Gapmer (see Table 69) on mouse SGLT2 mRNA levels in vivo. Data are taken from three experiments in which male 6-week old Balb/c mice were dosed twice per week for three weeks with 5, 25 and 125 nmol/kg of either the ISIS 379692 1-10-1 MOE gapmer or the ISIS 388625 2-8-2 MOE gapmer given by intraperitoneal injection. Mice were sacrificed 48 hours following last administration 15 and evaluated for SGLT2 mRNA levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The data are expressed as percent change ("+" indicates an increase, "-" indicates a decrease) relative to saline treated animals and are illustrated in Table 69. 20 Table 69: Antisense inhibition of SGLT2 mRNA in vivo by a 1-10-1 and a 2-8-2 MOE gapmer ISIS ISIS ISIS 392170 ISIS 392173 Dose of oligonucleotide 379692 1-10-1 388625 2-8-2 nmollkg 1-10-1 MOE Methyleneo 2-8-2 MOE Methyleneo xy BNA xy BNA 125 -58 -69 -70 -75 25 -46 -54 -47 -57 5 -7 -23 -18 -44 These results illustrate that both the 1-10-1 and 2-8-2 MOE gapmer inhibit the expression of SGLT2 in vivo at the highest three dosing ranges in a dose-dependent manner. The results also illustrate that the Methyleneoxy BNA constructs are more potent then the MOE constructs. No significant changes 25 in body weight were observed during the treatment or at study termination. No significant changes in liver or spleen weights were observed. The toxicity parameters including levels of ALT, AST, BUN, and creatinine were within normal ranges and are not significantly changed relative to saline-treated animals, demonstrating that the compounds do not significantly affect renal or hepatic function. 30 Evaluation of ISIS 379692 1-10-1 MOE Gapmer and ISIS 388625 2-8-2 MOE Gapmer in Rat WO 2007/146511 PCT/US2007/068401 -272 The effect of ISIS 379692 1-10-1 MOE gapmer and ISIS 388625 MOE 2-8-2 gapmer (see Table 70) on rat SGLT2 mRNA levels in vivo. Data are taken from four experiments in which male Sprague Dawley rats (170-200g) were dosed twice per week for three weeks with 200, 50, 12.5, or 3.125 nmol/kg of either the ISIS 379692 1-10-1 MOE gapmer or the ISIS 388625 2-8-2 MOE gapmer given by 5 intraperitoneal injection. Rats were sacrificed 48 hours following last administration and evaluated for SGLT2 levels in kidney. Target levels were determined by RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal ISIS control. The results are shown below in Table 70. 10 Table 70: Antisense inhibition of SGLT2 mRNA in vivo by a 1-10-1 and a 2-8-2 MOE gapmer % change in SGLT2 expression relative to saline ISIS ISIS Dose of oligonucleotide 3 38862 uo/g379692 388625 1-10-1 2-8-2 200 -80 -80 50 -65 -65 12.5 -15 -15 3.125 +30 +25 These results illustrate that both the 1-10-1 and 2-8-2 MOE gapmer inhibit the expression of SGLT2 in vivo at the highest three dosing ranges in a dose-dependent manner. Rats were further evaluated for total body weight, liver, spleen and kidney weight. All changes 15 were within the margin of error of the experiment. No significant changes in body weight were observed during the treatment or at study termination. No significant changes in liver or spleen weights were observed. The levels of ALT, AST, BUN, cholesterol, plasma creatinine and triglycerides were measured in rats treated with the short antisense compounds. The levels of routine clinical indicators of liver and 20 kidney injury and disease were within normal ranges and are not significantly changed relative to saline treated animals, demonstrating that the short antisense compounds do not significantly affect renal or hepatic function. EXAMPLE 16: Antisense Inhibition of SGLT2 Expression in ZDF rat 25 ISIS 388625, 388626 and control oligo ISIS 388628 were analyzed for their effect on ZDF rat plasma glucose levels and HbAlc. The leptin receptor deficient Zucker diabetic fatty (ZDF) rat is a useful model for the investigation of type 2 diabetes. Diabetes develops spontaneously in these male rats at ages 8-10 weeks, and is associated with hyperphagia, polyuria, polydipsia, and impaired weight gain, symptoms which parallel the clinical symptoms of diabetes (Phillips MS, et al., 1996, Nat Genet 13, 18- WO 2007/146511 PCT/US2007/068401 -273 19). Six week old ZDF rats were injected intraperitoneally with short antisense compound at a dose of 40 OnM/kg once a week for twelve weeks. Data are illustrated in Tables 71 and 72. Table 71: Plasma glucose Seq Plasma glucose levels recorded on specific ISIS ID dates (mg/dl) NO. NO Sequence (5'-3') Motif Day 10 Day 40 Day 55 Day 66 PBS n/a n/a 450.7 478.5 392.8 526.2 388625 246 TGTTCCAGCCCA 2-8-2 MOE 435.5 278.7 213.8 325.5 388626 281 GGCATGAGCTTC 2-8-2 MOE 434.7 300.5 219.8 379.8 388628 226 TAGCCGCCCACA 2-8-2 MOE 436.0 502.0 411.2 668.8 5 Table 72: HbAlc Status Percentage HbAl c on specific dates (%) Seq p < 0.001 ID ISIS NO. NO Sequence (5'-3') Motif Day 40 Day 55 Day 68 PBS n/a n/a 8.0 8.9 10.0 388625 246 TGTTCCAGCCCA 2-8-2 MOE 6.5 5.8 4.3 388626 281 GGCATGAGCTTC 2-8-2 MOE 6.6 5.9 4.0 388628 226 TAGCCGCCCACA 2-8-2 MOE 8.0 9.1 7.8 ISIS 388625 and 388626 significantly reduced plasma glucose levels and HbA1C compared to 10 PBS and control treated animals. EXAMPLE 17: Antisense Inhibition of SGLT2 Expression in Dog Kidney (ISIS 388625) ISIS 388625 is a 2-8-2 MOE Gapmer with sequence TGTTCCAGCCCA (SEQ ID NO: 246) 15 (e.g. see Table 71). The effect of ISIS 388625 on dog SGLT2 mRNA levels. Data are taken from two dosing groups in which a total of nine male beagle dogs were dosed with either one or ten mg/kg/week of ISIS 388625 or saline given by subcutaneous injection twice weekly. On day 46 of the study all dogs were sacrificed and evaluated for SGLT2 levels in kidney. Target levels were determined by quantitative RT, real-time PCR as described by other examples herein. PCR results were normalized to an internal 20 ISIS control. The results are shown below in Table 73. Table 73: Antisense inhibition of SGLT2 mRNA in vivo by ISIS 388625 WO 2007/146511 PCT/US2007/068401 -274 % change in SGLT2 expression Relative to saline Dose of oligonucleotide mg/kg/wk ISIS 388625 -85 10 -95 These results illustrate that greater than 80% reduction of SGLT2 mRNA can be achieved at a 1 mg/kg/wk dose of ISIS 388625. Even greater reduction can be achieved at slightly higher doses. Administration of ISIS 388625 in dog was also shown to improve glucose tolerance. Peak plasma glucose 5 levels were decreased by over 50% on average and the subsequent drop in glucose was lessened compared to saline controls in a standard glucose tolerance test. Urinary glucose excretion was also increased. EXAMPLE 18: In vivo testing of short antisense compounds targeted to SGLT2 nucleic acid 10 Twenty 1-10-1 MOE gapmers that are complementary to human/monkey/mouse/rat SGLT2 were designed, synthesized and tested in vivo for suppression of SGLT2 mRNA levels in kidney. Target sites for mouse and rat are indicated in Table 74. Target sites for human are indicated in Tables 4 and 5. Data are averages from two experiments in which male 6-week old Balb/c mice were administered intraperitoneal injections of 350 nmol/kg of oligonucleotide, twice per week, over a period of two weeks 15 (a total of four injections). Mice were sacrificed 48 hours following the last administration and evaluated for SGLT2 mRNA levels in kidney. SGLT2 mRNA levels were determined by quantitative real-time PCR analysis according to standard procedures, using two different PCR primer probe sets, primer probe set (PPS) 534 and PPS 553. SGLT2 mRNA levels were normalized to cyclophilin mRNA levels, which were also measured by quantitative real-time PCR. The results are shown below in Table 74. 20 Table 74: Antisense inhibition of SGLT2 in vivo 5' Target 5' Target ISIS Site on Site on 534 553 SEQ NO SEQ ID SEQ ID Sequence (5'-3') Motif ID NO: XXX NO: XXX Sli Sli NO (mouse) (rat) PBS N/A - - 370717 2684 152 TAGCCACCAACT 1-10-1 -84.4 -84.3 1554 _____MOEI 379684 2070 64 TGTCAGCAGGAT 1-10-1 -45.0 -43.2 214 MOE 379685 2103 97 TGACCAGCAGGA 1-10-1 -10.3 -20.5 219 MOE 379686 2121* 115 ACCACAAGCCAA 1-10-1 -71.9 -75.1 225 1__ _MOE I 379687 2824 216 GATGTTGCTGGC 1-10-1 -47.1 -52.1 230 WO 2007/146511 PCT/US2007/068401 -275 MOE 379688 2876 268 CCAAGCCACTTG 1-10-1 -62.6 -70.4 240 MOE __ 379689 298 AGAGCGCATTCC 1-10-1 -17.5 -30.4 241 MOE__ _ 379690 415 ACAGGTAGAGGC 1-10-1 -18.9 -22.5 242 MOE__ _ 379691 454 AGATCTTGGTGA 1-10-1 -35.0 -48.6 243 _____ ______ MOE _____ 379692 508 TGTTCCAGCCCA 1-10-1 -88.1 -88.5 246 _______MOE 379693 546 CATGGTGATGCC 1-10-1 -51.6 -59.9 254 _____MOE 379694 609 GACGAAGGTCTG 1-10-1 -42.1 -54.4 264 _____MOE 379695 717 GGACACCGTCAG 1-10-1 -52.5 -64.1 266 ___MOE11 379696 954 CAGCTTCAGGTA 1-10-1 -24.6 -36.2 267 _______MOE I__ 379697 982 CTGGCATGACCA 1-10-1 -32.0 -46.3 272 MOE 379698 1071 GCAGCCCACCTC 1-10-1 -11.8 -27.0 275 MOE 379699 1112 GGCATGAGCTTC 1-10-1 -83.5 -85.8 281 ______ __________ MOE 379700 1138 CCAGCATGAGTC 1-10-1 -2.8 -16.4 285 _______MOE 379701 1210 CCATGGTGAAGA 1-10-1 -0.3 -11.9 288 MOE 379702 1525 GCACACAGCTGC 1-10-1 -87.8 -89.5 293 MOE ___ __ _ 379703 1681 GCCGGAGACTGA 1-10-1 -44.2 -45.9 295 _____1 1___ ___ _____ MOE ________ * indicates I or 2 mismatches to a target sequence Example 19: Antisense inhibition of human PCSK9 in Hep3B cells Short antisense compounds targeted to a PCSK9 nucleic acid were tested for their effects on 5 PCSK9 mRNA in vitro. The short antisense compounds are presented in Table 6. The Isis No, gapmer motif and SEQ ID NO of each short antisense compound are shown again in Table 75. Cultured Hep3B cells were treated with 100 nM of short antisense compound. 5-10-5 MOE gapmers targeted to a PCSK9 nucleic acid were used as positive controls. After the treatment period, RNA was isolated from the cells and PCSK9 mRNA levels were measured by quantitative real-time PCR, as described herein. PCSK9 10 mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented in Table 75 as percent inhibition of PCSK9 (%Inhib), relative to untreated control cells. In the "% Inhib" column, a "0" indicates that no reduction of PCSK9 mRNA was observed with that particular short antisense compound. 15 Table 75: Antisense inhibition of PCSK9 by short antisense compounds WO 2007/146511 PCT/US2007/068401 -276 5' 3' ISIS SEQ ID Target Target Gapmer % No. NO Site on Site on Motif Inhibition Inhib SEQ ID SEQ ID Range NO: 4 NO: 4 400297 329 695 708 2-10-2 MOE 0 400298 330 696 709 2-10-2 MOE 0 400299 331 697 710 2-10-2 MOE 0 400300 332 742 755 2-10-2 MOE 9 400301 333 757 770 2-10-2 MOE 20-30% 27 400302 334 828 841 2-10-2 MOE 0 400303 335 829 842 2-10-2 MOE 0 400304 336 830 843 2-10-2 MOE 10-20% 11 400305 337 937 950 2-10-2 MOE 30-40% 38 400306 338 952 965 2-10-2 MOE 40-50% 40 400307 339 988 1001 2-10-2 MOE 70-80% 76 400308 340 989 1002 2-10-2 MOE 50-60% 55 400309 341 990 1003 2-10-2 MOE 40-50% 44 400310 342 991 1004 2-10-2 MOE 8 400311 343 992 1005 2-10-2 MOE 10-20% 18 400312 344 993 1006 2-10-2 MOE 20-30% 28 400313 345 994 1007 2-10-2 MOE 10-20% 10 400314 346 1057 1070 2-10-2 MOE 20-30% 26 400315 347 1075 1088 2-10-2 MOE 0 400316 348 1076 1089 2-10-2 MOE 8 400317 349 1077 1090 2-10-2 MOE 7 400318 350 1078 1091 2-10-2 MOE 20-30% 26 400319 351 1093 1106 2-10-2 MOE 0 400320 352 1094 1107 2-10-2 MOE 0 400321 353 1095 1108 2-10-2 MOE 0 400322 354 1096 1109 2-10-2 MOE 0 400323 355 1147 1160 2-10-2 MOE 0 400324 356 1255 1268 2-10-2 MOE 7 400325 357 1334 1347 2-10-2 MOE 4 400326 358 1335 1348 2-10-2 MOE 0 400327 359 1336 1349 2-10-2 MOE 30-40% 36 400328 360 1453 1466 2-10-2 MOE 10-20% 13 400329 361 1454 1467 2-10-2 MOE 10-20% 14 400330 362 1455 1468 2-10-2 MOE 40-50% 43 400331 363 1456 1469 2-10-2 MOE 30-40% 35 400332 364 1569 1582 2-10-2 MOE 0 400333 365 1570 1583 2-10-2 MOE 0 400334 366 1571 1584 2-10-2 MOE 0 WO 2007/146511 PCT/US2007/068401 -277 400335 367 1572 1585 2-10-2 MOE 0 400336 368 1573 1586 2-10-2 MOE 4 400337 369 1574 1587 2-10-2 MOE 0 400338 370 1575 1588 2-10-2 MOE 9 400339 371 1576 1589 2-10-2 MOE 0 400340 372 1577 1590 2-10-2 MOE 0 400341 373 1578 1591 2-10-2 MOE 0 400342 374 1621 1634 2-10-2 MOE 0 400343 375 1622 1635 2-10-2 MOE 0 400344 376 1623 1636 2-10-2 MOE 0 400345 377 1624 1637 2-10-2 MOE 0 400346 378 1738 1751 2-10-2 MOE 5 400347 379 1739 1752 2-10-2 MOE 0 400348 380 1740 1753 2-10-2 MOE 0 400349 381 1741 1754 2-10-2 MOE 10-20% 13 400350 382 1834 1847 2-10-2 MOE 10-20% 15 400351 383 1835 1848 2-10-2 MOE 10-20% 14 400352 384 1836 1849 2-10-2 MOE 20-30% 29 400353 385 1837 1850 2-10-2 MOE 10-20% 19 400354 386 1838 1851 2-10-2 MOE 10-20% 19 400355 387 1839 1852 2-10-2 MOE 0 400356 388 1840 1853 2-10-2 MOE 0 400357 389 2083 2096 2-10-2 MOE 0 400358 390 2084 2097 2-10-2 MOE 10-20% 12 400359 391 2085 2098 2-10-2 MOE 0 400360 392 2086 2099 2-10-2 MOE 30-40% 38 400361 393 2316 2329 2-10-2 MOE 2 400362 394 2317 2330 2-10-2 MOE 10-20% 16 400363 395 2318 2331 2-10-2 MOE 8 400364 396 2319 2332 2-10-2 MOE 0 400365 397 2320 2333 2-10-2 MOE 20-30% 25 400366 398 2321 2334 2-10-2 MOE 10-20% 15 400367 399 2322 2335 2-10-2 MOE 10-20% 12 400368 400 2323 2336 2-10-2 MOE 10-20% 11 400369 401 2324 2337 2-10-2 MOE 0 400370 402 2325 2338 2-10-2 MOE 10-20% 13 400371 403 3543 3556 2-10-2 MOE 0 As illustrated in Table 75, short antisense compounds targeted to a PCSK9 nucleic acid, having a 2-10-2 MOE gapmer motif, reduced PCSK9 mRNA in cultured cells. Short antisense compounds targeted to a PCSK9 nucleic acid were tested in a dose response 5 experiment Hep3B cells. Cells were treated as described herein with nM concentrations of short antisense compound as indicated in Tables 76. After the treatment period, RNA was isolated from the cells and WO 2007/146511 PCT/US2007/068401 -278 PCSK9 mRNA levels were measured by quantitative real-time PCR, as described herein. PCSK9 mRNA levels were normalized to cyclophilin mRNA levels, as measured by real-time PCR using a cyclophilin specific primer probe set. Results are presented as percent inhibition of PCSK9, relative to untreated control cells. Also shown is the EC 50 (concentration at which 50% reduction of mRNA is observed) for 5 each short antisense compound tested in the dose response experiment, as calculated using Graphpad Prism. As illustrated in the following table, PCSK9 mRNA levels were reduced in a dose-dependent manner. Table 76: Dose-dependent antisense inhibition of PCSK9 by short antisense compounds % Inhibition 160 nM 80 nM 40 nM 20nM lOnM 5nM 5-10-5 95 96 85 78 58 38 400307 93 92 56 45 39 35 400308 86 77 40 26 10 31 400309 78 72 12 38 23 49 400327 55 43 49 23 37 5 400330 71 82 69 40 32 8 400331 82 75 63 47 40 29 400352 64 63 44 40 16 7 400353 48 54 43 23 27 15 10 Example 20: Antisense inhibition of PCSK9 by short antisense compounds comprising BNAs Short antisense compounds targeted to a PCSK9 nucleic acid were tested in dose response experiments, in both mouse and human cultured cells. The compounds tested included ISIS 403739 and 15 ISIS 403740. ISIS 403739 is a short antisense compound consisting of the nucleotide sequence of SEQ ID NO: 404 and having a 2-10-2 gapmer motif, where the nucleotides in the wings comprise (6'S)-6'methyl BNA. ISIS 403740 is a short antisense compound consisting of the nucleotide sequence of SEQ ID NO: 405 and having a 2-10-2 gapmer motif, where the nucleotides in the wings comprise (6'S)-6'methyl BNA. Also tested was a 5-10-5 MOE gapmer targeted to a PCSK9 nucleic acid. 20 Mouse hepatocytes were plated and treated as described herein with nM concentrations of short antisense compound as indicated in Table 77. After the treatment period, RNA was isolated from the cells and PCSK9 mRNA levels were measured by quantitative real-time PCR, as described herein. PCSK9 mRNA levels were normalized to cyclophilin mRNA levels, as measured by real-time PCR using a cyclophilin-specific primer probe set. Results are presented as percent inhibition of PCSK9, relative to 25 untreated control cells. Where present, "0" indicates no observed reduction in PCSK9 mRNA. ISIS 403739 exhibited dose-dependent reduction of mouse PCSK9 mRNA at the doses of 30 nM and higher. ISIS 403740 exhibited reduction of mouse PCSK9 mRNA at the two highest doses of short antisense WO 2007/146511 PCT/US2007/068401 -279 compound. Table 77: Antisense inhibition of mouse PCSK9 by short antisense compounds comprising BNAs % Inhibition 3.75 nM 7.5 nM 15 nM 30 nM 60 nM 120 nM 240 nM 5-10-5 10 15 21 18 44 43 77 403739 40 19 29 29 32 49 57 403740 3 0 29 13 0 40 33 5 Human Hep3B cells were treated with nM concentrations of short antisense compound as described herein. After the treatment period, RNA was isolated from the cells and PCSK9 mRNA levels were measured by quantitative real-time PCR, as described herein. PCSK9 mRNA levels were normalized to cyclophilin mRNA levels, as measured by real-time PCR using a cyclophilin-specific primer probe set. Results are presented as percent inhibition of PCSK9, relative to untreated control cells. 10 The data are shown in Table 78 and demonstrate a dose-dependent reduction in human PCSK9 mRNA following treatment with ISIS 403740. ISIS 403739 exhibited dose-dependent reduction at higher doses. Table 78: Antisense inhibition of mouse PCSK9 by short antisense compounds comprising BNAs % Inhibition 2.5 nM 5 nM 10 nM 20 nM 40 nM 80 nM 160 nM 5-10-5 7 2 21 33 30 59 71 403739 10 5 7 6 25 52 65 403740 6 12 16 29 45 48 59 15 Example 21: Antisense inhibition of GCGR in HepG2 cells Short antisense compounds targeted to a GCGR nucleic acid were tested for their effects on GCGR mRNA in vitro. HepG2 Cells Cultured HepG2 cells at a density of 10000 cells per well in a 96-well plate were treated as described herein with 25, 50, 100 or 200 nM of antisense oligonucleotide. After the treatment period, RNA was isolated from the cells and GCGR mRNA levels were measured by quantitative real-time PCR, as described herein. GCGR mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented as percent reduction in GCGR mRNA, relative to untreated control cells. Table 79 presents data following treatment with the indicated doses of ISIS 327161, a 3-10-3 MOE gapmer. ISIS 327161 reduced GCGR mRNA in a dose-dependent manner.

WO 2007/146511 PCT/US2007/068401 -280 Table 79: Antisense inhibition of GCGR in HepG2 cells by a short antisense compound ISIS Seq ED Sequence (5'-3') Gapmer 25 nM 50 nM 100 nM 200 nM NO. NO Motif 327161 520 AGCTGCTGTACATC MOE -36 -30 -33 -64 Monkey hepatocytes Additional short antisense compounds targeted to a GCGR nucleic acid were tested for their effects on monkey GCGR mRNA in vitro. Cultured primary monkey hepatocytes were treated as described herein with 25, 50, 100 or 200 nM of short antisense compound. After the treatment period, RNA was isolated from the cells and GCGR mRNA levels were measured by quantitative real-time PCR, as described herein. GCGR mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented in Table 80 as percent reduction in GCGR mRNA, relative to untreated control cells. Table 80: Antisense inhibition of GCGR in primary monkey hepatocytes by short antisense compounds ISIS Se Sequence (5'-3') Gapmer 25 nM 50 nM 100 nM 200 nM NO. NO Motif___ ______ 327131 489 ATGTTGGCCGTGGT 3-8-3 0 -8 -36 -36 _____ ___ ___________ MOE _________ 327161 520 AGCTGCTGTACATC -19 -33 -55 -54 Example 22: Antisense inhibition of DGAT2 by short antisense compounds Short antisense compounds targeted to a DGAT2 nucleic acid were tested for their effects on DGAT2 mRNA in vitro. Cultured A10 cells in a 96-well plate were treated with 75 nM of short antisense compound. After a treatment period of approximately 24 hours, RNA was isolated from the cells and DGAT2 mRNA levels were measured by quantitative real-time PCR, as described herein. DGAT2 mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented as percent inhibition of DGAT2, relative to untreated control cells in Table 81. Table 81: Antisense inhibition of DGAT2 in A10 cells Seq ID ISIS NO. NO Sequence (5'-3') Gapmer Motif % Control 372491 795 ACATGAGGATGACACT 3-10-3 MOE 80 372500 702 GTGTGTCTTCACCAGC 3-10-3 MOE 16 372501 704 TTGTGTGTCTTCACCA 3-10-3 MOE 28 372503 708 GCAGGTTGTGTGTCTT 3-10-3 MOE 35 372508 719 AGTTCCTGGTGGTCAG 3-10-3 MOE 35 372516 805 TACAGAAGGCACCCAG 3-10-3 MOE 27 WO 2007/146511 PCT/US2007/068401 -281 372524 738 GCCAGGCATGGAGCTC 3-10-3 MOE 21 372530 746 TCGGCCCCAGGAGCCC 3-10-3 MOE 35 372546 825 TTGGTCTTGTGATTGT 3-10-3 MOE 34 372563 691 AGCCAGGTGACAGA 2-10-2 MOE 48 372569 796 CATGAGGATGACAC 2-10-2 MOE 104 372578 703 TGTGTCTTCACCAG 2-10-2 MOE 59 372580 707 GGTTGTGTGTCTTC 2-10-2 MOE 48 372586 720 GTTCCTGGTGGTCA 2-10-2 MOE 40 372594 806 ACAGAAGGCACCCA 2-10-2 MOE 77 372602 739 CCAGGCATGGAGCT 2-10-2 MOE 39 372618 765 GTGGTACAGGTCGA 2-10-2 MOE 29 372624 826 TGGTCTTGTGATTG 2-10-2 MOE 56 Additional short antisense compounds targeted to DGAT2 mRNA were tested in vitro in a dose response experiment. A10 cells were prepared as described above and treated with 6.25, 12.5, 25.0, 50.0, 100.0, and 200.0 nM short antisense compounds to determine if DGAT2 inhibition occurs in a dose dependent manner. The data demonstrate that each of the short antisense compounds presented in Table 82 reduces rat DGAT2 mRNA in a dose-dependent manner. Results are presented as percent inhibition, relative to untreated control cells. A "0" indicates that DGAT2 mRNA was not reduced. Table 82: Dose-Depen ent Inhibition of DGAT2 in A10 cells Isis Seq Gapmer 6.25 12.5 25.0 50.0 100.0 200.0 NO. NO Sequence (5'3') Motif nM nM nM nM nM nM 372562 784 GTCTTGGAGGGCCG 2-10-2 0 0 0 36 48 75 ___ MOE 372568 794 GACACTGCAGGCCA 2-10-2 0 0 15 26 72 69 MOE __ 372586 720 GTTCCTGGTGGTCA 2-10-2 19 0 7 22 45 77 MOE 372602 739 CCAGGCATGGAGCT 2-10-2 0 0 0 18 47 76 MOE 372618 765 GTGGTACAGGTCGA 2-10-2 0 5 0 27 65 80 ___MOE I__I__I Additional short antisense compounds targeted to DGAT2 mRNA were tested in vitro. A10 cells were prepared as described above and treated with 0.62, 1.85, 5.56, 16.67, 50.0, and 150.0 nM short antisense compounds to determine if DGAT2 inhibition occurs in a dose-dependent manner. DGAT2 mRNA was measured using quantitative real-time PCR, as described herein. The data demonstrate that each of the short antisense compounds presented in Table 83 below inhibit rat DGAT2 mRNA in a dose dependent manner. Results are presented as percent inhibition of rat DGAT2, relative to untreated control cells. Where present, "0" indicates that no reduction in DGAT2 mRNA was observed. Table 83: Dose-Dependent Inhibition of DGAT2 in A10 cells Isis Seq Gapm 0.62 1.85 5.56 16.67 50 150 NO. ND Sequence (5'-3') M nM nM nM nM nM nM WO 2007/146511 PCT/US2007/068401 -282 372500 702 GTGTGTCTTCACCAGC 3-10-3 0 0 0 18 64 88 MOE 0 0 0 1 4 8 372501 704 TTGTGTGTCTTCACCA 3-10-3 1 5 10 11 25 68 MOE 1 5 10 1 25 6 372503 708 GCAGGTTGTGTGTCTT 3-10-3 7 10 4 25 54 80 MOE 7 10 4 2 54 8 372508 719 AGTTCCTGGTGGTCAG 3-10-3 0 0 6 14 39 71 MOE 0 0 6 1 9 7 372516 805 TACAGAAGGCACCCAG 3-10-3 1 10 0 4 35 81 MOE 1 1 5 8 372524 738 GCCAGGCATGGAGCTC 3-10-3 7 0 5 30 68 91 ____ ~~MOE 7 0 5 3 8 9 372530 746 TCGGCCCCAGGAGCCC 3-10-3 0 2 0 10 38 78 MOE 0 2 0 1 8 7 372546 825 TTGGTCTTGTGATTGT 3-10-3 0 2 11 4 48 78 MOE 0 2 1 8 7 372563 691 AGCCAGGTGACAGA 2-10-2 1 46 ______ ~MOE 0 0 0 1 4 4 372578 703 TGTGTCTTCACCAG 2-10-2 0 0 0 2 7 42 _______ ~MOE 0 0 0 2 7 4 372580 707 GGTTGTGTGTCTTC 2-10-2 0 5 5 3 16 42 ______ ~~MOE 0 5 5 3 16 4 372586 720 GTTCCTGGTGGTCA 2-10-2 0 0 0 0 7 55 _______ ~MOE 0 0 0 0 7 5 372594 806 ACAGAAGGCACCCA 2-10-2 0 0 0 0 2 15 ______ ~MOE 0 0 0 0 2 1 372602 739 CCAGGCATGGAGCT 2-10-2 0 0 10 0 19 51 ______ ~~MOE 0 0 1 9 5 372618 765 GTGGTACAGGTCGA 2-10-2 0 0 0 0 30 60 _______ ~MOE 0 0 0 0 30 6 372624 826 TGGTCTTGTGATTG 2-10-2 1 16 38 F___ ______________ MOE 0 0 0 1 16 3 Example 23: Antisense inhibition of human PTP1B in HuVEC cells Short antisense compounds targeted to a PTP1B nucleic acid were tested for their effects on PTP1B mRNA in vitro. Cultured HuVEC cells at a density of 5000 cells per well in a 96-well plate were treated as described herein with 3 nM of short antisense compound. After the treatment period, RNA was isolated from the cells and PTPlB mRNA levels were measured by quantitative real-time PCR, as described herein. PTP1B mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented as percent inhibition of PTP1B (% Inhib), relative to untreated control cells. The data demonstrated that short antisense compounds targeted to a PTP1B nucleic acid and having a 2-10-2 gapmer motif can inhibit PTP lB in HuVEC cells in Table 84. Table 84: Antisense inhibition of PTP1B in HuVEC cells by short antisense compounds ISIS NO. SEQ ID NO Gapmer Motif % Inhib WO 2007/146511 PCT/US2007/068401 -283 399301 1542 2-10-2 OMe 55 404137 1053 2-10-2 MOE 76 404138 1054 2-10-2 MOE 76 404139 1052 2-10-2 MOE 80 404140 1051 2-10-2 MOE 73 Example 24: Antisense inhibition of human PTP1B in HepG2 cells Short antisense compounds targeted to a PTP1B nucleic acid were tested for their effects on PTPIB mRNA in vitro. Cultured HepG2 cells at a density of 10000 cells per well in a 96-well plate were treated with 25 nM of antisense oligonucleotide. After the treatment period, RNA was isolated from the cells and PTP 1 B mRNA levels were measured by quantitative real-time PCR, as described herein. PTP 1 B mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Results are presented as percent inhibition (% Inhib) of PTPlB, relative to untreated control cells. The data demonstrated that short antisense compounds targeted to a PTPlB nucleic acid and having a 2-10-2 gapmer motif can inhibit PTP1B in HepG2 cells in Table 85. Table 85: Antisense inhibition of PTP1B in HepG2 cells by short antisense compounds ISIS NO. SEQ ID NO Gapmer Motif % Inhib 399301 1542 2-10-2 OMe 43 404137 1053 2-10-2 MOE 71 404138 1054 2-10-2 MOE 86 404139 1052 2-10-2 MOE 45 404140 1051 2-10-2 MOE 93 Example 25: Antisense inhibition of PTP1B in HuVEC cells: Dose response experiment Human vascular endothelial (HuVEC) cells were plated at a density of 5000 cells per well and treated as described herein with nM concentrations of short antisense compound as indicated in Table 86. After the treatment period, RNA was isolated from the cells and PTP1B mRNA levels were measured by quantitative real-time PCR, as described herein. PTPlB mRNA levels were adjusted according to total RNA content as measured by RIBOGREEN@. Two different human PTP 1 B primer probe sets were used to measure mRNA levels. Results with Primer Probe Set (PPS) 198 are shown in Table 86, and results with Primer Probe Set (PPS) 3000 are shown in Table 87. Results are presented as percent inhibition of PTP1B mRNA expression relative to untreated control cells. Where present, "0" indicates that no PTP1B mRNA reduction was observed. As illustrated in Tables 86 and 87, PTPlB mRNA levels were reduced in a dose-dependent manner. Table 86: Dose Response for Human PTP1B in HuVEC cells, using PPS 198 % Inhibition WO 2007/146511 PCT/US2007/068401 -284 ISIS NO. Seq ID Gapmer 1.11 nM 3.33 nM 10.0 nM 30.0 nM NO Motif____ 398105 1066 2-10-2 MOE 0 25 79 90 398112 1072 2-10-2 MOE 1 10 73 93 398120 1086 2-10-2 MOE 0 31 80 96 399096 1544 2-10-2 MOE 3 30 78 96 399102 1545 2-10-2 MOE 0 15 62 88 399113 1547 2-10-2 MOE 0 31 72 90 399132 1548 2-10-2 MOE 0 32 75 95 399173 1549 2-10-2 MOE 0 24 63 89 399208 1550 2-10-2 MOE 0 37 86 93 399276 1551 2-10-2 MOE 0 8 61 89 399301 1542 2-10-2 MOE 8 63 91 97 399315 1552 2-10-2 MOE 0 20 68 88 398173 1543 1-10-1 MOE 0 4 80 97 Table 87: Dose Response for Human PTP1B in HuVEC cells, using PPS 3000 % Inhibition ISIS NO. Seq ID Gapmer 1.11 nM 3.33 nM 10.0 nM 30.0 nM NO Motif 398105 1066 2-10-2 MOE 0 35 79 93 398112 1072 2-10-2 MOE 0 26 77 94 398120 1086 2-10-2 MOE 0 35 79 93 399096 1544 2-10-2 MOE 0 23 75 94 399102 1545 2-10-2 MOE 0 9 60 87 399113 1547 2-10-2 MOE 0 9 65 90 399132 1548 2-10-2 MOE 0 26 76 91 399173 1549 2-10-2 MOE 0 11 59 92 399208 1550 2-10-2 MOE 0 47 85 96 399276 1551 2-10-2 MOE 0 14 64 86 399301 1542 2-10-2 MOE 16 65 93 99 399315 1552 2-10-2 MOE 0 25 71 93 398173 1543 1-10-1 MOE 0 18 80 90 Example 26: Antisense inhibition of ApoB by short antisense compounds The short antisense compounds shown in Table 88 were tested for their effects in vivo. Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered intraperitoneal doses of 3.2, 1, 0.32, or .1 umol/kg, twice per week for three weeks. A 5-10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 48 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. ApoB mRNA levels were measured by real-time PCR as described herein. ApoB mRNA levels were normalized to RNA levels as determined by RIBOGREEN, and are presented in Table 89 as percent inhibition relative to ApoB mRNA levels in saline-treated control animals. Table 88: Short Antisense Compounds Targeting an ApoB nucleic acid WO 2007/146511 PCT/US2007/068401 -285 ISIS Sequence (5'-3') Gapmer Motif SEQ NO SequenceE(5'-3')_ GapmerMotif _ID NO 387462 GGTACATGGAAGTC 2-10-2 Methyleneoxy BNA 190 398296 2-10-2 GGTACATGGAAGTC 6'-(S)-methyl Methyleneoxy BNA 190 Table 89: Antisense inhibition of ApoB by Short Antisense Compounds Comprising BNA Dose Isis No (umol/kg) % Inhib 379818 1 56 387462 0.1 33 0.32 57 1 93 3.2 99 398296 0.1 17 0.32 35 1 80 3.2 98 Table 89 shows that ApoB mRNA levels were reduced in a dose-dependent manner following treatment with short antisense compounds having a 2-10-2 gapmer motif and BNA modifications in the wings. At the 1 umol/kg dose, ApoB inhibition by the short antisense compounds was greater than observed with a 5-10-5 MOE gapmer at an equivalent dose. Cholesterol was reduced at the I and 3.2 umol/kg doses of short antisense compound. The short antisense compounds exhibited little to no adverse side effects, as judged by organ and body weights, serum transaminases, bilirubin, blood urea nitrogen, and creatinine. Example 27: Antisense inhibition of PTEN by short antisense compounds The short antisense compounds shown in Table 90 were tested for their effects in vivo. Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered intraperitoneal doses of 3.2, 1, 0.32, or .1 umol/kg, twice per week for three weeks. A 5-10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 48 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. PTEN mRNA levels were measured by real-time PCR as described herein. PTEN mRNA levels were normalized to RNA levels as determined by RIBOGREEN, and are presented in Table 91 as percent inhibition relative to PTEN mRNA levels in saline-treated control animals.

WO 2007/146511 PCT/US2007/068401 -286 Table 90: Short Antisense Compounds targeted to a PTEN nucleic acid Isis Sequence (5'-3') Gapmer Motif SEQ NO ED NO 392063 AGGCCAGTGCTAAG 2-10-2 Methyleneoxy BNA 1226 2-10-2 392749 AGGCCAGTGCTAAG (6'S)-6'-methyl Methyleneoxy 1226 BNA 396006 AGGCCAGTGCTAAG 2-10-2 1226 alpha-L-methyleneoxy BNA Table 91: Antisense inhibition of PTEN by short antisense compounds comprising BNA modifications Dose Isis No (umol/kg) % Inhib 116847 1 47 392063 0.1 26 0.32 43 1 74 3.2 96 392749 0.1 17 0.32 34 1 64 3.2 96 396006 0.1 20 0.32 32 1 67 3.2 88 Table 91 shows that PTEN mRNA levels were reduced in a dose-dependent manner following treatment with short antisense compounds having a 2-10-2 gapmer motif and BNA modifications in the wings. At the 1 umol/kg dose, PTEN inhibition by the short antisense compounds was greater than observed with a 5-10-5 MOE gapmer at an equivalent dose. With the exception of the highest dose of ISIS 392063, no significant increases in serum transaminases were observed. Overall, the short antisense compounds exhibited little to no adverse side effects. Example 28: Single dose administration of short antisense compounds comprising BNA modifications Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a WO 2007/146511 PCT/US2007/068401 -287 single intraperitoneal injection of short antisense compound at a dose of 8, 4, 2 or 1 gmol/kg. The short antisense compounds tested were ISIS 387462 and ISIS 398296. Each dose group consisted of four animals. A 5-10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 48 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. ApoB mRNA levels were measured by real-time PCR as described herein. ApoB mRNA levels were normalized to RNA levels as determined by RIBOGREEN, and are presented in Table 92 as percent inhibition relative to ApoB mRNA levels in saline-treated control animals. Table 92: Antisense inhibition of ApoB by Short Antisense Compounds Comprising BNA Dose Isis No (umol/kg) % Inhib 379818 8 77 387462 8 99 4 93 2 81 1 58 398296 8 97 4 81 2 54 1 19 Table 92 shows that ApoB mRNA levels were reduced in a dose-dependent manner following a single administration of short antisense compounds having a 2-10-2 gapmer motif and BNA modifications in the wings. At the 8 umol/kg dose, ApoB inhibition by the short antisense compounds was greater than observed with a 5-10-5 MOE gapmer at an equivalent dose. The ED 50 of ISIS 387462 was 3.9 mg/kg, and the ED 50 of ISIS 398296 was 8.7 mg/kg. Cholesterol was also reduced in a dose dependent manner. Triglycerides were reduced at the highest dose. The short antisense compounds exhibited little to no adverse side effects, as judged by organ and body weights, serum transaminases, bilirubin, blood urea nitrogen, and creatinine. In a similar single dose administration study, ISIS 392748, having SEQ ID NO: 1226, a 2-10-2 gapmer motif, where the nucleotides of the wings comprise (6'R)-6'-methyl methyleneoxy BNA modifications, reduced PTEN mRNA in a dose-dependent manner. Additionally, ISIS 392749, having SEQ ID NO: 1226, a 2-10-2 gapmer motif, where the nucleotides of the wings comprise (6'S)-6'-methyl methyleneoxy BNA modifications, reduced PTEN mRNA in a dose-dependent manner. A short antisense compound having 2-10-2 gapmer motifs, the sequence of SEQ ID NO: 1226, and 6-(S)-CH2-O-CH3 BNA modifications also reduced PTEN mRNA in a similar in vivo study. A short antisense compound having 2-10-2 gapmer motifs, the sequence of SEQ ID NO: 1226, and 6-(R)-CH2-0-CH3-BNA WO 2007/146511 PCT/US2007/068401 -288 modifications also reduced PTEN mRNA in a similar in vivo study. Example 29: Single dose administration of short antisense compounds comprising BNA modifications Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal injection of antisense compound at a dose of 8, 4, 2 or 1 ptmol/kg. Each dose group consisted of four animals. The compounds tested were ISIS 392063, ISIS 392749, and ISIS 366006. A 5 10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 48 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. ApoB mRNA levels were measured by real-time PCR as described herein. ApoB mRNA levels were normalized to RNA levels as determined by RIBOGREEN, and are presented in Table 93 as percent inhibition relative to ApoB mRNA levels in saline-treated control animals. Table 93: Antisense inhibition of PTEN by short antisense compounds comprising BNA modifications Dose Isis No (umol/kg) % Inhib 116847 8 62 392063 8 92 4 82 2 58 1 38 396565 8 76 4 38 2 24 1 11 396006 8 94 4 82 2 48 1 18 Table 93 shows that PTEN mRNA levels were reduced in a dose-dependent manner following treatment with short antisense compounds having a 2-10-2 gapmer motif and BNA modifications in the wings. At the 8 umol/kg dose, PTEN inhibition by the short antisense compounds was greater than observed with a 5-10-5 MOE gapmer at an equivalent dose. The estimated ED 50 s were 7 mg/kg for ISIS 392063, 17.4 mg/kg for ISIS 396565, and 9.3 mg/kg for ISIS 396006. With the exception of the highest dose of ISIS 392063, no significant increases in serum transaminases were observed. Overall, the short antisense compounds exhibited little to no adverse side WO 2007/146511 PCT/US2007/068401 -289 effects. Example 30: Antisense inhibition of ApoB by short antisense compounds comprising palmitic acid conjugates Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal injection of antisense compound at a dose of 2.5, 1.0. 0.4, and 0.16 umol/kg. Each dose group consisted of four animals. The compounds tested are shown in Table 94. A 5-10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 48 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. ApoB mRNA levels were measured by real-time PCR as described herein. ApoB mRNA levels were normalized to RNA levels as determined by RIBOGREEN, and are presented in Table 95 as percent inhibition relative to ApoB mRNA levels in saline-treated control animals. Table 94: Short antisense compounds comprising palmitic conjugates ISIS Sequence (5'-3') Gapmer Motif SEQ NO ID NO 387462 GGTACATGGAAGTC 2-10-2 Methyleneoxy BNA 190 1-1 - 10-2 2'-(butylacetomido) palmitamide/MOE/MOE 391871 GGTACATGGAAGTC Unmodified cytosines in gap 190 (i.e., 2-10-2 MOE with 2' (butylacetomido)-palmitamide substituted at 5' nucleotide 1-1-10-2 2'-(butylacetomido) palmitamide Methyleneoxy BNA/Methyleneoxy BNA 391872 GGTACATGGAAGTC Unmodified cytosines in gap 190 (i.e., 2-10-2 methyleneoxy BNA with 2'-(butylacetomido) palmitamide substituted at 5' nucleotide) Table 95: Antisense inhibition by short antisense compounds comprising palmitic acid conjugates Dose Isis No % Inhib (umol/kg) 5-10-5 2.5 54 387462 2.5 99 1.0 91 0.4 65 0.16 16 391871 2.5 49 1.0 18 WO 2007/146511 PCT/US2007/068401 -290 0.4 5 0.16 0 391872 2.5 99 1.0 92 0.4 50 0.16 18 Table 95 shows that ApoB mRNA levels were reduced in a dose-dependent manner following treatment with short antisense compounds having a palmitic acid (C16) conjugate. At the 2.5 umol/kg dose, ApoB inhibition by the short antisense compounds was greater than observed with a 5-10-5 MOE gapmer at an equivalent dose. In this study, the estimated ED 50 s were 1.5 mg/kg for ISIS 387462, 13.1 mg/kg for ISIS 391871, and 1.9 mg/kg for ISIS 391872. The estimated ED 50 for the 5-10-5 MOE gapmer was 17.4 mg/kg. Triglycerides were reduced at the 2.5 and 1.0 mg/kg doses of ISIS 387462 and ISIS 391872. ISIS 387462 and ISIS 391872 markedly reduced total cholesterol, HDL-C and LDL-C in a dose dependent manner; reduction in LDL-C was so marked that it fell below the limit of detection. Overall, the short antisense compounds exhibited little to no adverse effects. Example 31: Antisense inhibition of PCSK9 in vivo by short antisense compounds comprising BNA modifications Six-week old male Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were administered a single intraperitoneal injection of antisense compound at a dose of 15, 4.7, 1.5 and .47 umol/kg of ISIS 403739 or 403740. Each dose group consisted of four animals. A 5-10-5 MOE gapmer was used for a control treatment. Mice were sacrificed approximately 72 hours following the final dose. Liver tissue was collected for RNA isolation, and blood was collected for serum chemistry analyses. PCSK9 mRNA levels were measured by real-time PCR as described herein. PCSK9 mRNA levels were normalized to cyclophilin mRNA levels as determined by real-time PCR. ISIS 403739 reduced PCSK9 mRNA by approximately 70%, relative to saline controls. ISIS 403740 reduced PCSK9 by approximately 13% relative to saline controls, however, the reduction was not statistically significant. The lower doses did not significantly reduce PCSK9 mRNA. Overall, the short antisense compounds exhibited little to no adverse side effects.

Claims (55)

1. A short antisense compound 8 to 16 monomers in length, comprising a 2'-deoxyribonucleotide gap region flanked on each side by a wing, wherein each wing independently comprises I to 3 high affinity modified monomers.

2. The short antisense compound of claim 1, wherein said high-affinity modified monomers are sugar modified nucleotides.

3. The short antisense compound of claim 2, wherein at least one of the sugar-modified nucleotides comprises a bridge between the 4' and the 2' position of the sugar.

4. The short antisense compound of claim 2, wherein each of said high-affinity modified nucleotides confers a Tm of 1 to 4 degrees per nucleotide.

5. The short antisense compound of claim 2, wherein each of said sugar-modified nucleotides comprises a 2'-substituent group that is other than H or OH.

6. The short antisense compound of claim 5, wherein at least one of said sugar-modified nucleotides is a 4' to 2' bridged bicyclic nucleotide.

7. The short antisense compound of claim 5, wherein each of the 2'-substituent groups is, independently, alkoxy, substituted alkoxy, or halogen.

8. The short antisense compound of claim 7, wherein each of the 2'-substituent groups is OCH 2 CH 2 OCH 3 .

9. The short antisense compound claim 3, wherein the conformation of each of said sugar-modified nucleotides is, independently, p-D or a-L.

10. The short antisense compound claim 5, wherein each of said bridges independently comprises 1 or from 2 to 4 linked groups independently selected from -[C(Ri)(R 2 )]n-, -C(R 1 )=C(R 2 )-, -C(Ri)=N-, -C(=NRI)-, -C(=O)-, -C(=S)-, -0-, -Si(RI) 2 -, -S(=O).- and -N(R 1 )-; wherein x is 0, 1, or 2; n is 1, 2, 3, or 4; each R 1 and R 2 is, independently, H, a protecting group, hydroxyl, Cl-C 12 alkyl, substituted CI-C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 1 2 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5 -C 7 alicyclic radical, substituted C 5 -C 7 alicyclic radical, halogen, OJI, NJIJ 2 , SJi, N 3 , COOJi, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=0) 2 -JI), or sulfoxyl (S(=O)-Ji); and each Ji and J 2 is, independently, H, C 1 -C 1 2 alkyl, substituted C 1 -C 1 2 alkyl, C 2 -C 1 2 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, CI-C 12 aminoalkyl, substituted C 1 -C 12 aminoalkyl or a protecting group. WO 2007/146511 PCT/US2007/068401 -292

11. The short antisense compound of claim 10, wherein each of said bridges is, independently, 4'-CH 2 2', 4'-(CH 2 ) 2 -2', 4'-CH 2 -O-2', 4'-(CH 2 ) 2 -O-2', 4'-CH 2 -O-N(R)-2' and 4'-CH 2 -N(Ri)-O-2'- wherein each R, is, independently, H, a protecting group or C 1 -C 12 alkyl.

12. The short antisense compound of claim 1, wherein each of the high-affinity modified monomer is independently selected from bicyclic nucleotides or other 2'-modified nucleotides.

13. The short antisense compound of claim 12, wherein the 2'-modified nucleotides are selected from halogen, allyl, amino, azido, thio, 0-allyl, O-C-C 1 0 alkyl, -OCF 3 , O-(CH 2 ) 2 -O-CH 3 , 2' O(CH 2 ) 2 SCH 3 , O-(CH 2 ) 2 -O-N(Rm)(Rn) or O-CH 2 C(=O)-N(Rm)(R.), where each Rm and Rn is, independently, H or substituted or unsubstituted CI-Cio alkyl.

14. The short antisense compound of claim 13, wherein the 2'-modified nucleotide is a 2' OCH 2 CH 2 OCH 3 nucleotide.

15. The short antisense compound of claim 1, wherein at least one monomeric linkage is a modified monomeric linkage.

16. The antisense compound of claim 15, wherein the modified monomeric linkage is a phosphorothioate linkage.

17. The short antisense compound of claim 1, wherein each monomeric linkage is a phosphorothioate internucleoside linkage.

18. The short antisense compound of any of claims 1-17, that is 8-15 monomers in length.

19. The short antisense compound of claim 18 that is 9-15 monomers in length.

20. The short antisense compound of claim 18 that is 10-15 monomers in length.

21. The short antisense compound of claim 18 that is 9-14 monomers in length.

22. The short antisense compound of claim 18 that is 10-14 monomers in length.

23. The short antisense compound of claim 18 that is 9-13 monomers in length.

24. The short antisense compound of claim 18 that is 10-13 monomers in length.

25. The short antisense compound of claim 18 that is 9-12 monomers in length.

26. The short antisense compound of claim 18 that is 10-12 monomers in length.

27. The short antisense compound of claim 18 that is 9-11 monomers in length.

28. The short antisense compound of claim 18 that is 10-11 monomers in length.

29. The short antisense compound of claim 18 that is 8 monomers in length.

30. The short antisense compound of claim 18 that is 9 monomers in length.

31. The short antisense compound of claim 18 that is 10 monomers in length.

32. The short antisense compound of claim 18 that is 11 monomers in length.

33. The short antisense compound of claim 18 that is 12 monomers in length.

34. The short antisense compound of claim 18 that is 13 monomers in length.

35. The short antisense compound of claim 18 that is 14 monomers in length.

36. The short antisense compound of claim 18 that is 15 monomers in length.

37. The short antisense compound of claim 18 that is 16 monomers in length. WO 2007/146511 PCT/US2007/068401 -293

38. The short antisense compound of any of claims 1-18, having a motif selected from 1-12-1; 3-10-3; 2-10-3; 2-10-2; 1-10-1; 1-10-2; 3-8-3; 2-8-2; 1-8-1; 3-6-3; and 1-6-11 wherein, the first number represents the number of monomers in the 5'-wing, the second number represents the number of monomers in the gap, and the third number represents the number of monomers in the 3' wing.

39. The short antisense compound of claim 38 wherein the motif is selected from 1-10-1; 2-10-2; 3-10 3; and 1-9-2.

40. The short antisense compound of any of claims 1-18 having a motif selected from 1-1-10-2, 1-1-8 2, 1-1-6-3, and 1-2-8-2, wherein the first number represents the number of monomers in a first 5' wing, the second number represents the number of monomers in a second 5' wing, the third number represents the number of monomers in the gap, and the fourth number represents the number of monomers in the 3' wing.

41. The short antisense compound of any of claims 1-18 having a motif selected from 2-10-1-1, 2-8-1 1, 3-6-1-1,and 2-8-2-1, wherein the first number represents the number of monomers in the 5' wing, the second number represents the number of monomers in the gap, the third number represents the number of monomers in a first 3' wing, and the fourth number represents the number of monomers in a second 3' wing.

42. The short antisense compound of any of claims 1-18 having a motif selected from 1-2-10-1-1; 1-1 8-1-1; 2-1-6-1-1; and 1- 2-8-2-1, wherein the first number represents the number of monomers in a first 5' wing, the second number represents the number of monomers in a second 5' wing, the third number represents the number of monomers in the gap, the fourth number represents the number of monomers in a first 3' wing and the fifth number represents the number of monomers in a second 3'wing.

43. The short antisense compound of any of claims 1-42, wherein the short antisense compound is targeted to a nucleic acid encoding a target protein selected from ApoB, SGLT2, PCSK9, SOD1, CRP, GCCR, GCGR, DGAT2, PTP1B and PTEN.

44. A method of modulating expression of a target by contacting a target nucleic acid with a short antisense compound.

45. The method of claim 44 wherein the target nucleic acid is in a cell.

46. The method of claim 44, wherein the target nucleic acid is in an animal.

47. The method of claim 45, wherein the animal is a human.

48. The method of any of claims 44-47, wherein the target is selected from ApoB, SGLT2, PCSK9, SOD1, CRP, GCCR, GCGR, DGAT2, PTP1B and PTEN.

49. The method of any of claims 44-48, wherein the short antisense compound is the short antisense compound of any of claims 1-38.

50. Use of the short antisense compound of any of claims 1-43 for the preparation of a medicament for reducing the expression of a target RNA in an animal.

51. The use of claim 50, wherein the medicament treats a metabolic disorder in an animal. WO 2007/146511 PCT/US2007/068401 -294

52. The use of claim 51, wherein the medicament increases insulin sensitivity, decreases blood glucose and/or decreases HbAjc in the animal.

53. The use of claim 51, wherein the medicament decreases total serum cholesterol, serum LDL, serum VLDL, serum HDL, serum triglycerides, serum apolipoprotein(a) and/or free fatty acids in an animal.

54. A method of inhibiting expression of a target RNA in an animal, comprising administering to said animal the short antisense compound of any of claims 1-43.

55. A method of treating a metabolic disorder in an animal, comprising administering to an animal in need of such therapy the short antisense compound of any of claims 1-43. 1 of 771 SEQUENCE LISTING <110> Isis Pharmaceuticals, Inc. Sanjay Bhanot Richard S. Geary Robert McKay Brett P. Monia Punit P. Seth Andrew M. Siwkowski Eric E. Swayze Edward Wancewitz <120> COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION <130> CORE0061US7 <150> PCT/US2007/061183 <151> 2007-01-27 <150> 60/746,631 <151> 2006-05-05 <150> 60/747,059 <151> 2006-05-11 <150> 60/805,660 <151> 2006-06-23 2013203064 09 Apr 2013 2 of 771 <150> 60/864,554 <151> 2006-11-06 <160> 1576 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 14121 <212> DNA <213> H. sapiens <400> 1 attcccaccg ggacctgcgg ggctgagtgc ccttctcggt tgctgccgct gaggagcccg 60 cccagccagc cagggccgcg aggccgaggc caggccgcag cccaggagcc gccccaccgc 120 agctggcgat ggacccgccg aggcccgcgc tgctggcgct gctggcgctg cctgcgctgc 180 tgctgctgct gctggcgggc gccagggccg aagaggaaat gctggaaaat gtcagcctgg 240 tctgtccaaa agatgcgacc cgattcaagc acctccggaa gtacacatac aactatgagg 300 ctgagagttc cagtggagtc cctgggactg ctgattcaag aagtgccacc aggatcaact 360 gcaaggttga gctggaggtt ccccagctct gcagcttcat cctgaagacc agccagtgca 420 ccctgaaaga ggtgtatggc ttcaaccctg agggcaaagc cttgctgaag aaaaccaaga 480 actctgagga gtttgctgca gccatgtcca ggtatgagct caagctggcc attccagaag 540 ggaagcaggt tttcctttac ccggagaaag atgaacctac ttacatcctg aacatcaaga 600 ggggcatcat ttctgccctc ctggttcccc cagagacaga agaagccaag caagtgttgt 660 ttctggatac cgtgtatgga aactgctcca ctcactttac cgtcaagacg aggaagggca 720 atgtggcaac agaaatatcc actgaaagag acctggggca gtgtgatcgc ttcaagccca 780 tccgcacagg catcagccca cttgctctca tcaaaggcat gacccgcccc ttgtcaactc 840 tgatcagcag cagccagtcc tgtcagtaca cactggacgc taagaggaag catgtggcag 900 aagccatctg caaggagcaa cacctcttcc tgcctttctc ctacaacaat aagtatggga 960 tggtagcaca agtgacacag actttgaaac ttgaagacac accaaagatc aacagccgct 1020 2013203064 09 Apr 2013 3 of 771 tctttggtga aggtactaag aagatgggcc tcgcatttga gagcaccaaa tccacatcac 1080 ctccaaagca ggccgaagct gttttgaaga ctctccagga actgaaaaaa ctaaccatct 1140 ctgagcaaaa tatccagaga gctaatctct tcaataagct ggttactgag ctgagaggcc 1200 tcagtgatga agcagtcaca tctctcttgc cacagctgat tgaggtgtcc agccccatca 1260 ctttacaagc cttggttcag tgtggacagc ctcagtgctc cactcacatc ctccagtggc 1320 tgaaacgtgt gcatgccaac ccccttctga tagatgtggt cacctacctg gtggccctga 1380 tccccgagcc ctcagcacag cagctgcgag agatcttcaa catggcgagg gatcagcgca 1440 gccgagccac cttgtatgcg ctgagccacg cggtcaacaa ctatcataag acaaacccta 1500 cagggaccca ggagctgctg gacattgcta attacctgat ggaacagatt caagatgact 1560 gcactgggga tgaagattac acctatttga ttctgcgggt cattggaaat atgggccaaa 1620 ccatggagca gttaactcca gaactcaagt cttcaatcct caaatgtgtc caaagtacaa 1680 agccatcact gatgatccag aaagctgcca tccaggctct gcggaaaatg gagcctaaag 1740 acaaggacca ggaggttctt cttcagactt tccttgatga tgcttctccg ggagataagc 1800 gactggctgc ctatcttatg ttgatgagga gtccttcaca ggcagatatt aacaaaattg 1860 tccaaattct accatgggaa cagaatgagc aagtgaagaa ctttgtggct tcccatattg 1920 ccaatatctt gaactcagaa gaattggata tccaagatct gaaaaagtta gtgaaagaag 1980 ctctgaaaga atctcaactt ccaactgtca tggacttcag aaaattctct cggaactatc 2040 aactctacaa atctgtttct cttccatcac ttgacccagc ctcagccaaa atagaaggga 2100 atcttatatt tgatccaaat aactaccttc ctaaagaaag catgctgaaa actaccctca 2160 ctgcctttgg atttgcttca gctgacctca tcgagattgg cttggaagga aaaggctttg 2220 agccaacatt ggaagctctt tttgggaagc aaggattttt cccagacagt gtcaacaaag 2280 ctttgtactg ggttaatggt caagttcctg atggtgtctc taaggtctta gtggaccact 2340 ttggctatac caaagatgat aaacatgagc aggatatggt aaatggaata atgctcagtg 2400 ttgagaagct gattaaagat ttgaaatcca aagaagtccc ggaagccaga gcctacctcc 2460 gcatcttggg agaggagctt ggttttgcca gtctccatga cctccagctc ctgggaaagc 2520 tgcttctgat gggtgcccgc actctgcagg ggatccccca gatgattgga gaggtcatca 2580 ggaagggctc aaagaatgac ttttttcttc actacatctt catggagaat gcctttgaac 2640 tccccactgg agctggatta cagttgcaaa tatcttcatc tggagtcatt gctcccggag 2700 ccaaggctgg agtaaaactg gaagtagcca acatgcaggc tgaactggtg gcaaaaccct 2760 ccgtgtctgt ggagtttgtg acaaatatgg gcatcatcat tccggacttc gctaggagtg 2820 2013203064 09 Apr 2013 4 of 771 gggtccagat gaacaccaac ttcttccacg agtcgggtct ggaggctcat gttgccctaa 2880 aagctgggaa gctgaagttt atcattcctt ccccaaagag accagtcaag ctgctcagtg 2940 gaggcaacac attacatttg gtctctacca ccaaaacgga ggtgatccca cctctcattg 3000 agaacaggca gtcctggtca gtttgcaagc aagtctttcc tggcctgaat tactgcacct 3060 caggcgctta ctccaacgcc agctccacag actccgcctc ctactatccg ctgaccgggg 3120 acaccagatt agagctggaa ctgaggccta caggagagat tgagcagtat tctgtcagcg 3180 caacctatga gctccagaga gaggacagag ccttggtgga taccctgaag tttgtaactc 3240 aagcagaagg tgcgaagcag actgaggcta ccatgacatt caaatataat cggcagagta 3300 tgaccttgtc cagtgaagtc caaattccgg attttgatgt tgacctcgga acaatcctca 3360 gagttaatga tgaatctact gagggcaaaa cgtcttacag actcaccctg gacattcaga 3420 acaagaaaat tactgaggtc gccctcatgg gccacctaag ttgtgacaca aaggaagaaa 3480 gaaaaatcaa gggtgttatt tccatacccc gtttgcaagc agaagccaga agtgagatcc 3540 tcgcccactg gtcgcctgcc aaactgcttc tccaaatgga ctcatctgct acagcttatg 3600 gctccacagt ttccaagagg gtggcatggc attatgatga agagaagatt gaatttgaat 3660 ggaacacagg caccaatgta gataccaaaa aaatgacttc caatttccct gtggatctct 3720 ccgattatcc taagagcttg catatgtatg ctaatagact cctggatcac agagtccctg 3780 aaacagacat gactttccgg cacgtgggtt ccaaattaat agttgcaatg agctcatggc 3840 ttcagaaggc atctgggagt cttccttata cccagacttt gcaagaccac ctcaatagcc 3900 tgaaggagtt caacctccag aacatgggat tgccagactt ccacatccca gaaaacctct 3960 tcttaaaaag cgatggccgg gtcaaatata ccttgaacaa gaacagtttg aaaattgaga 4020 ttcctttgcc ttttggtggc aaatcctcca gagatctaaa gatgttagag actgttagga 4080 caccagccct ccacttcaag tctgtgggat tccatctgcc atctcgagag ttccaagtcc 4140 ctacttttac cattcccaag ttgtatcaac tgcaagtgcc tctcctgggt gttctagacc 4200 tctccacgaa tgtctacagc aacttgtaca actggtccgc ctcctacagt ggtggcaaca 4260 ccagcacaga ccatttcagc cttcgggctc gttaccacat gaaggctgac tctgtggttg 4320 acctgctttc ctacaatgtg caaggatctg gagaaacaac atatgaccac aagaatacgt 4380 tcacactatc atgtgatggg tctctacgcc acaaatttct agattcgaat atcaaattca 4440 gtcatgtaga aaaacttgga aacaacccag tctcaaaagg tttactaata ttcgatgcat 4500 ctagttcctg gggaccacag atgtctgctt cagttcattt ggactccaaa aagaaacagc 4560 atttgtttgt caaagaagtc aagattgatg ggcagttcag agtctcttcg ttctatgcta 4620 2013203064 09 Apr 2013 5 of 771 aaggcacata tggcctgtct tgtcagaggg atcctaacac tggccggctc aatggagagt 4680 ccaacctgag gtttaactcc tcctacctcc aaggcaccaa ccagataaca ggaagatatg 4740 aagatggaac cctctccctc acctccacct ctgatctgca aagtggcatc attaaaaata 4800 ctgcttccct aaagtatgag aactacgagc tgactttaaa atctgacacc aatgggaagt 4860 ataagaactt tgccacttct aacaagatgg atatgacctt ctctaagcaa aatgcactgc 4920 tgcgttctga atatcaggct gattacgagt cattgaggtt cttcagcctg ctttctggat 4980 cactaaattc ccatggtctt gagttaaatg ctgacatctt aggcactgac aaaattaata 5040 gtggtgctca caaggcgaca ctaaggattg gccaagatgg aatatctacc agtgcaacga 5100 ccaacttgaa gtgtagtctc ctggtgctgg agaatgagct gaatgcagag cttggcctct 5160 ctggggcatc tatgaaatta acaacaaatg gccgcttcag ggaacacaat gcaaaattca 5220 gtctggatgg gaaagccgcc ctcacagagc tatcactggg aagtgcttat caggccatga 5280 ttctgggtgt cgacagcaaa aacattttca acttcaaggt cagtcaagaa ggacttaagc 5340 tctcaaatga catgatgggc tcatatgctg aaatgaaatt tgaccacaca aacagtctga 5400 acattgcagg cttatcactg gacttctctt caaaacttga caacatttac agctctgaca 5460 agttttataa gcaaactgtt aatttacagc tacagcccta ttctctggta actactttaa 5520 acagtgacct gaaatacaat gctctggatc tcaccaacaa tgggaaacta cggctagaac 5580 ccctgaagct gcatgtggct ggtaacctaa aaggagccta ccaaaataat gaaataaaac 5640 acatctatgc catctcttct gctgccttat cagcaagcta taaagcagac actgttgcta 5700 aggttcaggg tgtggagttt agccatcggc tcaacacaga catcgctggg ctggcttcag 5760 ccattgacat gagcacaaac tataattcag actcactgca tttcagcaat gtcttccgtt 5820 ctgtaatggc cccgtttacc atgaccatcg atgcacatac aaatggcaat gggaaactcg 5880 ctctctgggg agaacatact gggcagctgt atagcaaatt cctgttgaaa gcagaacctc 5940 tggcatttac tttctctcat gattacaaag gctccacaag tcatcatctc gtgtctagga 6000 aaagcatcag tgcagctctt gaacacaaag tcagtgccct gcttactcca gctgagcaga 6060 caggcacctg gaaactcaag acccaattta acaacaatga atacagccag gacttggatg 6120 cttacaacac taaagataaa attggcgtgg agcttactgg acgaactctg gctgacctaa 6180 ctctactaga ctccccaatt aaagtgccac ttttactcag tgagcccatc aatatcattg 6240 atgctttaga gatgagagat gccgttgaga agccccaaga atttacaatt gttgcttttg 6300 taaagtatga taaaaaccaa gatgttcact ccattaacct cccatttttt gagaccttgc 6360 aagaatattt tgagaggaat cgacaaacca ttatagttgt agtggaaaac gtacagagaa 6420 2013203064 09 Apr 2013 6 of 771 acctgaagca catcaatatt gatcaatttg taagaaaata cagagcagcc ctgggaaaac 6480 tcccacagca agctaatgat tatctgaatt cattcaattg ggagagacaa gtttcacatg 6540 ccaaggagaa actgactgct ctcacaaaaa agtatagaat tacagaaaat gatatacaaa 6600 ttgcattaga tgatgccaaa atcaacttta atgaaaaact atctcaactg cagacatata 6660 tgatacaatt tgatcagtat attaaagata gttatgattt acatgatttg aaaatagcta 6720 ttgctaatat tattgatgaa atcattgaaa aattaaaaag tcttgatgag cactatcata 6780 tccgtgtaaa tttagtaaaa acaatccatg atctacattt gtttattgaa aatattgatt 6840 ttaacaaaag tggaagtagt actgcatcct ggattcaaaa tgtggatact aagtaccaaa 6900 tcagaatcca gatacaagaa aaactgcagc agcttaagag acacatacag aatatagaca 6960 tccagcacct agctggaaag ttaaaacaac acattgaggc tattgatgtt agagtgcttt 7020 tagatcaatt gggaactaca atttcatttg aaagaataaa tgatgttctt gagcatgtca 7080 aacactttgt tataaatctt attggggatt ttgaagtagc tgagaaaatc aatgccttca 7140 gagccaaagt ccatgagtta atcgagaggt atgaagtaga ccaacaaatc caggttttaa 7200 tggataaatt agtagagttg acccaccaat acaagttgaa ggagactatt cagaagctaa 7260 gcaatgtcct acaacaagtt aagataaaag attactttga gaaattggtt ggatttattg 7320 atgatgctgt gaagaagctt aatgaattat cttttaaaac attcattgaa gatgttaaca 7380 aattccttga catgttgata aagaaattaa agtcatttga ttaccaccag tttgtagatg 7440 aaaccaatga caaaatccgt gaggtgactc agagactcaa tggtgaaatt caggctctgg 7500 aactaccaca aaaagctgaa gcattaaaac tgtttttaga ggaaaccaag gccacagttg 7560 cagtgtatct ggaaagccta caggacacca aaataacctt aatcatcaat tggttacagg 7620 aggctttaag ttcagcatct ttggctcaca tgaaggccaa attccgagag actctagaag 7680 atacacgaga ccgaatgtat caaatggaca ttcagcagga acttcaacga tacctgtctc 7740 tggtaggcca ggtttatagc acacttgtca cctacatttc tgattggtgg actcttgctg 7800 ctaagaacct tactgacttt gcagagcaat attctatcca agattgggct aaacgtatga 7860 aagcattggt agagcaaggg ttcactgttc ctgaaatcaa gaccatcctt gggaccatgc 7920 ctgcctttga agtcagtctt caggctcttc agaaagctac cttccagaca cctgatttta 7980 tagtccccct aacagatttg aggattccat cagttcagat aaacttcaaa gacttaaaaa 8040 atataaaaat cccatccagg ttttccacac cagaatttac catccttaac accttccaca 8100 ttccttcctt tacaattgac tttgtcgaaa tgaaagtaaa gatcatcaga accattgacc 8160 agatgcagaa cagtgagctg cagtggcccg ttccagatat atatctcagg gatctgaagg 8220 2013203064 09 Apr 2013 7 of 771 tggaggacat tcctctagcg agaatcaccc tgccagactt ccgtttacca gaaatcgcaa 8280 ttccagaatt cataatccca actctcaacc ttaatgattt tcaagttcct gaccttcaca 8340 taccagaatt ccagcttccc cacatctcac acacaattga agtacctact tttggcaagc 8400 tatacagtat tctgaaaatc caatctcctc ttttcacatt agatgcaaat gctgacatag 8460 ggaatggaac cacctcagca aacgaagcag gtatcgcagc ttccatcact gccaaaggag 8520 agtccaaatt agaagttctc aattttgatt ttcaagcaaa tgcacaactc tcaaacccta 8580 agattaatcc gctggctctg aaggagtcag tgaagttctc cagcaagtac ctgagaacgg 8640 agcatgggag tgaaatgctg ttttttggaa atgctattga gggaaaatca aacacagtgg 8700 caagtttaca cacagaaaaa aatacactgg agcttagtaa tggagtgatt gtcaagataa 8760 acaatcagct taccctggat agcaacacta aatacttcca caaattgaac atccccaaac 8820 tggacttctc tagtcaggct gacctgcgca acgagatcaa gacactgttg aaagctggcc 8880 acatagcatg gacttcttct ggaaaagggt catggaaatg ggcctgcccc agattctcag 8940 atgagggaac acatgaatca caaattagtt tcaccataga aggacccctc acttcctttg 9000 gactgtccaa taagatcaat agcaaacacc taagagtaaa ccaaaacttg gtttatgaat 9060 ctggctccct caacttttct aaacttgaaa ttcaatcaca agtcgattcc cagcatgtgg 9120 gccacagtgt tctaactgct aaaggcatgg cactgtttgg agaagggaag gcagagttta 9180 ctgggaggca tgatgctcat ttaaatggaa aggttattgg aactttgaaa aattctcttt 9240 tcttttcagc ccagccattt gagatcacgg catccacaaa caatgaaggg aatttgaaag 9300 ttcgttttcc attaaggtta acagggaaga tagacttcct gaataactat gcactgtttc 9360 tgagtcccag tgcccagcaa gcaagttggc aagtaagtgc taggttcaat cagtataagt 9420 acaaccaaaa tttctctgct ggaaacaacg agaacattat ggaggcccat gtaggaataa 9480 atggagaagc aaatctggat ttcttaaaca ttcctttaac aattcctgaa atgcgtctac 9540 cttacacaat aatcacaact cctccactga aagatttctc tctatgggaa aaaacaggct 9600 tgaaggaatt cttgaaaacg acaaagcaat catttgattt aagtgtaaaa gctcagtata 9660 agaaaaacaa acacaggcat tccatcacaa atcctttggc tgtgctttgt gagtttatca 9720 gtcagagcat caaatccttt gacaggcatt ttgaaaaaaa cagaaacaat gcattagatt 9780 ttgtcaccaa atcctataat gaaacaaaaa ttaagtttga taagtacaaa gctgaaaaat 9840 ctcacgacga gctccccagg acctttcaaa ttcctggata cactgttcca gttgtcaatg 9900 ttgaagtgtc tccattcacc atagagatgt cggcattcgg ctatgtgttc ccaaaagcag 9960 tcagcatgcc tagtttctcc atcctaggtt ctgacgtccg tgtgccttca tacacattaa 10020 2013203064 09 Apr 2013 8 of 771 tcctgccatc attagagctg ccagtccttc atgtccctag aaatctcaag ctttctcttc 10080 cacatttcaa ggaattgtgt accataagcc atatttttat tcctgccatg ggcaatatta 10140 cctatgattt ctcctttaaa tcaagtgtca tcacactgaa taccaatgct gaacttttta 10200 accagtcaga tattgttgct catctccttt cttcatcttc atctgtcatt gatgcactgc 10260 agtacaaatt agagggcacc acaagattga caagaaaaag gggattgaag ttagccacag 10320 ctctgtctct gagcaacaaa tttgtggagg gtagtcataa cagtactgtg agcttaacca 10380 cgaaaaatat ggaagtgtca gtggcaaaaa ccacaaaagc cgaaattcca attttgagaa 10440 tgaatttcaa gcaagaactt aatggaaata ccaagtcaaa acctactgtc tcttcctcca 10500 tggaatttaa gtatgatttc aattcttcaa tgctgtactc taccgctaaa ggagcagttg 10560 accacaagct tagcttggaa agcctcacct cttacttttc cattgagtca tctaccaaag 10620 gagatgtcaa gggttcggtt ctttctcggg aatattcagg aactattgct agtgaggcca 10680 acacttactt gaattccaag agcacacggt cttcagtgaa gctgcagggc acttccaaaa 10740 ttgatgatat ctggaacctt gaagtaaaag aaaattttgc tggagaagcc acactccaac 10800 gcatatattc cctctgggag cacagtacga aaaaccactt acagctagag ggcctctttt 10860 tcaccaacgg agaacataca agcaaagcca ccctggaact ctctccatgg caaatgtcag 10920 ctcttgttca ggtccatgca agtcagccca gttccttcca tgatttccct gaccttggcc 10980 aggaagtggc cctgaatgct aacactaaga accagaagat cagatggaaa aatgaagtcc 11040 ggattcattc tgggtctttc cagagccagg tcgagctttc caatgaccaa gaaaaggcac 11100 accttgacat tgcaggatcc ttagaaggac acctaaggtt cctcaaaaat atcatcctac 11160 cagtctatga caagagctta tgggatttcc taaagctgga tgtaaccacc agcattggta 11220 ggagacagca tcttcgtgtt tcaactgcct ttgtgtacac caaaaacccc aatggctatt 11280 cattctccat ccctgtaaaa gttttggctg ataaattcat tactcctggg ctgaaactaa 11340 atgatctaaa ttcagttctt gtcatgccta cgttccatgt cccatttaca gatcttcagg 11400 ttccatcgtg caaacttgac ttcagagaaa tacaaatcta taagaagctg agaacttcat 11460 catttgccct caacctacca acactccccg aggtaaaatt ccctgaagtt gatgtgttaa 11520 caaaatattc tcaaccagaa gactccttga ttcccttttt tgagataacc gtgcctgaat 11580 ctcagttaac tgtgtcccag ttcacgcttc caaaaagtgt ttcagatggc attgctgctt 11640 tggatctaaa tgcagtagcc aacaagatcg cagactttga gttgcccacc atcatcgtgc 11700 ctgagcagac cattgagatt ccctccatta agttctctgt acctgctgga attgtcattc 11760 cttcctttca agcactgact gcacgctttg aggtagactc tcccgtgtat aatgccactt 11820 2013203064 09 Apr 2013 9 of 771 ggagtgccag tttgaaaaac aaagcagatt atgttgaaac agtcctggat tccacatgca 11880 gctcaaccgt acagttccta gaatatgaac taaatgtttt gggaacacac aaaatcgaag 11940 atggtacgtt agcctctaag actaaaggaa cacttgcaca ccgtgacttc agtgcagaat 12000 atgaagaaga tggcaaattt gaaggacttc aggaatggga aggaaaagcg cacctcaata 12060 tcaaaagccc agcgttcacc gatctccatc tgcgctacca gaaagacaag aaaggcatct 12120 ccacctcagc agcctcccca gccgtaggca ccgtgggcat ggatatggat gaagatgacg 12180 acttttctaa atggaacttc tactacagcc ctcagtcctc tccagataaa aaactcacca 12240 tattcaaaac tgagttgagg gtccgggaat ctgatgagga aactcagatc aaagttaatt 12300 gggaagaaga ggcagcttct ggcttgctaa cctctctgaa agacaacgtg cccaaggcca 12360 caggggtcct ttatgattat gtcaacaagt accactggga acacacaggg ctcaccctga 12420 gagaagtgtc ttcaaagctg agaagaaatc tgcagaacaa tgctgagtgg gtttatcaag 12480 gggccattag gcaaattgat gatatcgacg tgaggttcca gaaagcagcc agtggcacca 12540 ctgggaccta ccaagagtgg aaggacaagg cccagaatct gtaccaggaa ctgttgactc 12600 aggaaggcca agccagtttc cagggactca aggataacgt gtttgatggc ttggtacgag 12660 ttactcaaaa attccatatg aaagtcaagc atctgattga ctcactcatt gattttctga 12720 acttccccag attccagttt ccggggaaac ctgggatata cactagggag gaactttgca 12780 ctatgttcat aagggaggta gggacggtac tgtcccaggt atattcgaaa gtccataatg 12840 gttcagaaat actgttttcc tatttccaag acctagtgat tacacttcct ttcgagttaa 12900 ggaaacataa actaatagat gtaatctcga tgtataggga actgttgaaa gatttatcaa 12960 aagaagccca agaggtattt aaagccattc agtctctcaa gaccacagag gtgctacgta 13020 atcttcagga ccttttacaa ttcattttcc aactaataga agataacatt aaacagctga 13080 aagagatgaa atttacttat cttattaatt atatccaaga tgagatcaac acaatcttca 13140 atgattatat cccatatgtt tttaaattgt tgaaagaaaa cctatgcctt aatcttcata 13200 agttcaatga atttattcaa aacgagcttc aggaagcttc tcaagagtta cagcagatcc 13260 atcaatacat tatggccctt cgtgaagaat attttgatcc aagtatagtt ggctggacag 13320 tgaaatatta tgaacttgaa gaaaagatag tcagtctgat caagaacctg ttagttgctc 13380 ttaaggactt ccattctgaa tatattgtca gtgcctctaa ctttacttcc caactctcaa 13440 gtcaagttga gcaatttctg cacagaaata ttcaggaata tcttagcatc cttaccgatc 13500 cagatggaaa agggaaagag aagattgcag agctttctgc cactgctcag gaaataatta 13560 aaagccaggc cattgcgacg aagaaaataa tttctgatta ccaccagcag tttagatata 13620 2013203064 09 Apr 2013 10 of 771 aactgcaaga tttttcagac caactctctg attactatga aaaatttatt gctgaatcca 13680 aaagattgat tgacctgtcc attcaaaact accacacatt tctgatatac atcacggagt 13740 tactgaaaaa gctgcaatca accacagtca tgaaccccta catgaagctt gctccaggag 13800 aacttactat catcctctaa ttttttaaaa gaaatcttca tttattcttc ttttccaatt 13860 gaactttcac atagcacaga aaaaattcaa actgcctata ttgataaaac catacagtga 13920 gccagccttg cagtaggcag tagactataa gcagaagcac atatgaactg gacctgcacc 13980 aaagctggca ccagggctcg gaaggtctct gaactcagaa ggatggcatt ttttgcaagt 14040 taaagaaaat caggatctga gttattttgc taaacttggg ggaggaggaa caaataaatg 14100 gagtctttat tgtgtatcat a 14121 <210> 2 <211> 13928 <212> DNA <213> Mus musculus <400> 2 atcagtgcct gcagtggatc aagtacctgc ctgagctccg cctccgaaga ccctgtagag 60 caagcagcag gggctaggcc cgtggccagg ccacagccag gaagccaccc caccatccat 120 ccgccatggg cccacgaaag cctgccctgc ggacgccgtt actgctgctg ttcctgctac 180 tgttcttgga caccagcgtc tgggctcaag atgaagtcct ggaaaactta agcttcagct 240 gtccaaaaga tgcaactcga ttcaagcacc tccgaaagta cgtgtacaac tatgaagctg 300 aaagttccag cggtgtccag ggcacagctg actccagaag cgccaccaag atcaactgta 360 aggtagagct ggaggtcccc caaatctgtg gtttcatcat gaggaccaac cagtgtaccc 420 ttaaagaggt gtatggcttc aaccctgagg gcaaggcctt gatgaagaaa accaagaact 480 ctgaagagtt tgcagctgcc atgtccaggt acgaactcaa gctggccatt cctgaaggga 540 aacaaattgt tctttaccct gacaaggatg aacctaaata tatcctgaac atcaagaggg 600 gcatcatctc tgctcttctg gttcccccag agacagaaga ggaccaacaa gagttgttcc 660 tggataccgt gtatggaaac tgctcaactc aggttaccgt gaattcaaga aagggaaccg 720 taccaacaga aatgtccaca gagagaaacc tgcagcaatg tgacggcttc cagcccatca 780 2013203064 09 Apr 2013 11 of 771 gtacaagtgt cagccctctc gctctcatca aaggcctggt ccaccccttg tcaactctta 840 tcagcagcag ccaaacttgc cagtacaccc tggatcctaa gaggaagcat gtgtctgaag 900 ctgtctgtga tgagcagcat cttttcctgc ctttctccta caagaataag tatgggatca 960 tgacacgtgt tacacagaaa ctgagtcttg aagacacacc taagatcaac agtcgcttct 1020 tcagtgaagg taccaaccgg atgggtctgg cctttgagag caccaagtcc acgtcatccc 1080 caaagcaggc tgatgctgtt ttgaagaccc ttcaagaact gaaaaaattg tccatctcag 1140 agcagaatgc tcagagagca aatctcttca ataaactggt tactgagctg agaggcctca 1200 ctggtgaagc aatcacatcc ctcttgccac agctgattga agtgtccagc cccatcactt 1260 tacaagcctt ggttcagtgt ggacagccac agtgctatac tcacatcctc cagtggctga 1320 aaactgagaa ggctcacccc ctcctggttg acattgtcac ctacctgatg gctctgatcc 1380 caaatccctc aacacagagg ctgcaggaaa tctttaatac tgccaaggag cagcagagcc 1440 gagccactct gtatgcactg agccacgcag ttaacagcta ttttgatgtg gaccattcaa 1500 ggagcccagt tctgcaggat atcgctggtt acctgttgaa acagatcgac aatgaatgca 1560 cgggcaatga agaccacacc ttcttgattc tgagggtcat tggaaatatg ggaagaacca 1620 tggaacaagt aatgccagcc ctcaagtcct cagtcctgag ctgtgtacga agtacaaaac 1680 catctctgct gattcagaaa gctgctctcc aggccctgag gaagatggaa ctggaagatg 1740 aggtccggac gatccttttt gatacatttg taaatggtgt cgctcccgtg gagaagagac 1800 tggctgccta tctcttgctg atgaagaacc cttcctcatc agatattaac aaaattgccc 1860 aacttctcca atgggaacag agtgagcagg tgaagaactt cgtggcatct cacattgcca 1920 acatcttgaa ctcggaagaa ctgtatgtcc aagatctgaa agttttgatc aaaaatgctc 1980 tggagaattc tcaatttcca acgatcatgg acttcagaaa attttcccga aactatcaga 2040 tttccaaatc tgcttctctc ccaatgttcg acccagtctc agtcaaaata gaagggaatc 2100 ttatatttga tccaagcagt tatcttccca gagaaagctt gctgaaaaca accctcacag 2160 tctttggact tgcttcactt gatctctttg agattggttt agaaggaaaa gggtttgagc 2220 caacactaga agctcttttt ggtaagcaag gattcttccc agacagtgtc aacaaggctt 2280 tgtattgggt caatggccga gttccagatg gtgtctccaa ggtcttggtg gaccactttg 2340 gctatactac agatggcaag catgaacagg acatggtgaa tggaatcatg cccattgtgg 2400 acaagttgat caaagatctg aaatctaaag aaattcctga agccagggcc tatctccgca 2460 tcctaggaaa agagctaagc tttgtcagac tccaagacct ccaagtcctg gggaagctgt 2520 tgctgagtgg tgcacaaact ttgcagggaa tcccccagat ggttgtacag gccatcagag 2580 2013203064 09 Apr 2013 12 of 771 aagggtcaaa gaatgacttg tttctccact acatcttcat ggacaatgcc tttgagctcc 2640 ccactggagc agggttacag ctgcaagtgt cctcgtctgg agtcttcacc cccgggatca 2700 aggctggtgt aagactggaa ttagccaaca tacaggcaga gctagtggca aagccctctg 2760 tgtccttgga gtttgtgaca aatatgggca tcatcatccc agacttcgct aagagcagtg 2820 tccagatgaa caccaacttc ttccacgagt caggcctgga ggcgcgagtg gccctgaagg 2880 ctgggcagct gaaggtcatc attccttctc caaagaggcc agtcaagctg ttcagtggca 2940 gcaacacact gcatctggtc tctaccacca aaacagaagt gatcccacct ctggttgaga 3000 acaggcagtc ctggtcaact tgcaagcctc tcttcactgg aatgaactac tgtaccacag 3060 gagcttactc caacgccagc tccacggagt ctgcctctta ctacccactg acaggggaca 3120 caaggtatga gctggagctg aggcccacgg gagaagtgga gcagtattct gccactgcaa 3180 cctatgaact cctaaaagag gacaagtctt tggttgacac attgaagttc ctagttcaag 3240 cagaaggagt gcagcagtct gaagctactg tactgttcaa atataatcgg agaagcagga 3300 ccttatctag tgaagtccta attccagggt ttgatgtcaa cttcgggaca atactaagag 3360 ttaatgatga atctgctaag gacaaaaaca cttacaaact catcctggac attcagaaca 3420 agaaaatcac tgaggtctct ctcgtgggcc acttgagtta tgataaaaag ggagatggca 3480 agatcaaagg tgttgtttcc ataccacgtt tgcaagcaga agccaggagt gaggtccaca 3540 cccactggtc ctccaccaaa ctgctcttcc aaatggactc atctgctaca gcttacggct 3600 caacaatttc caagagagtg acatggcgtt acgataatga gataatagaa tttgattgga 3660 acacgggaac caatgtggat accaaaaaag tggcctccaa tttccctgtg gatctttccc 3720 attatcctag aatgttgcat gagtatgcca atggtctcct ggatcacaga gtccctcaaa 3780 cagatgtgac ttttcgggac atgggttcca aattaattgt tgcaacaaac acatggcttc 3840 agatggcaac caggggtctt ccttaccccc aaactctaca ggatcacctc aatagcctct 3900 cagagttgaa cctcctgaaa atgggactgt ctgacttcca tattccagac aacctcttcc 3960 taaagactga tggcagagtc aaatacacaa tgaacaggaa caaaataaac attgacatcc 4020 ctttgccttt gggtggcaag tcttcaaaag acctcaagat gccagagagt gtgaggacac 4080 cagccctcaa cttcaagtct gtgggattcc atctgccatc tcgagaggtc caggtcccca 4140 cttttacaat ccccaagaca catcagcttc aagtgcctct cttgggtgtt ctagaccttt 4200 ccacaaatgt ctacagcaat ttgtacaact ggtcagcctc ctacactggt ggcaacacca 4260 gcagagacca cttcagcctt caggctcagt accgcatgaa gactgactct gtggttgacc 4320 tgttttccta cagtgtgcaa ggatctggag aaacaacata tgacagcaag aacacattta 4380 2013203064 09 Apr 2013 13 of 771 cattgtcctg tgatggatct ctacaccata aatttctaga ctcaaaattc aaagtcagcc 4440 acgtagaaaa atttggaaac agcccagtct caaaaggttt actaacattt gaaacatcta 4500 gtgccttggg accacagatg tctgctactg ttcacctaga ctcaaaaaag aaacaacatc 4560 tatacgtcaa agatatcaag gttgatggac agttcagagc ttcttcattt tatgctcaag 4620 gcaaatatgg cctgtcttgt gagagagatg ttacaactgg ccagctgagc ggcgaatcca 4680 acatgagatt taactccacc tacttccagg gcaccaacca gatcgtggga atgtaccagg 4740 atggagccct gtccatcacc tccacttctg acctgcaaga tggcatattc aagaacacag 4800 cttccttgaa atatgaaaac tatgagctga ctctgaaatc tgatagcagt gggcagtatg 4860 agaacttcgc tgcttccaac aagctggatg tgaccttctc tacgcaaagt gcactgctgc 4920 gttctgaaca ccaggccaat tacaagtccc tgaggcttgt cacccttctt tcaggatccc 4980 tcacttccca gggtgtagaa ttaaatgctg acatcttggg cacagacaaa attaatactg 5040 gtgctcacaa ggcaacacta aagattgcac gtgatggact atcaaccagt gcgaccacca 5100 acttgaagta cagccccctg ctgctggaga atgagttgaa tgcagagctt gggctctctg 5160 gggcatccat gaaattatca acaaacggcc gcttcaaaga acaccatgca aaattcagtc 5220 ttgatgggag agctgccctc acagaggtgt cactggggag catttaccag gccatgattc 5280 tgggtgcaga cagcaaaaac atcttcaact tcaaactcag ccgagaaggg ctgaggctgt 5340 ccaatgattt gatgggctcc tatgctgaga tgaaacttga ccacacacac agtctgaaca 5400 ttgcaggtct ctcactggac ttcttctcaa aaatggacaa tatttacagt ggagacaagt 5460 tctataagca gaattttaac ttacagctac agccctattc tttcataact actttaagca 5520 acgacctgag atatggtgct ctagatttga ccaacaatgg aaggtttcgg ctggagccac 5580 tgaagctgaa tgtgggtggc aactttaaag gaacctatca aaataatgag ctgaaacata 5640 tctataccat atcttatact gacctggtag tagcaagtta cagagcagac actgtggcta 5700 aggttcaggg tgtcgaattc agccataggc taaatgcaga cattgaagga ctgacttcct 5760 ctgttgatgt cactaccagc tacaattcag atccactgca ttttaacaat gttttccact 5820 tttctctggc accttttacc ttgggcatcg acacacatac aagtggtgat gggaaactgt 5880 ccttctgggg agaacacact gggcagctat atagtaagtt tctgttgaaa gcagaacctc 5940 tggcacttat tgtctctcat gactacaaag gatccacaag ccacagtctc ccgtacgaga 6000 gcagcatcag cacggctctt gaacacacag tcagtgcctt gctgacgcca gctgagcaga 6060 caagcacctg gaaattcaag accaaactga atgacaaagt atacagccag gactttgaag 6120 cctacaacac taaagacaaa atcggtgttg agcttagtgg acgggctgac ctctctgggc 6180 2013203064 09 Apr 2013 14 of 771 tgtattctcc aattaaacta ccgtttttct acagtgagcc tgtcaatgtc cttaatggct 6240 tagaggtaaa tgatgctgtt gacaagcccc aagaattcac aattattgct gtggtgaagt 6300 acgataagaa ccaggatgtt cacaccatca acctcccatt cttcaaaagc ctgccagact 6360 atttggagag aaatcgaaga ggaatgataa gtctactgga agccatgcga ggggaattgc 6420 aacgcctcag tgttgatcag tttgtgagga aatacagagc ggccctgagc agacttcctc 6480 agcagattca tcattatctg aatgcatctg actgggagag acaagtagct ggtgccaagg 6540 aaaaaataac ttctttcatg gaaaattata gaattacaga taatgatgta ctaattgcca 6600 tagatagtgc caaaatcaac ttcaatgaaa aactctctca acttgagaca tacgcgatac 6660 aatttgatca gtatattaaa gataattatg atccacatga cttaaaaaga actattgctg 6720 agattattga tcgaatcatt gaaaagttaa aaattcttga tgaacagtat catatccgtg 6780 taaatctagc aaaatcaatc cataatctct atttatttgt tgaaaacgtt gatcttaacc 6840 aagtcagtag tagtaacacc tcttggatcc aaaatgtgga ttccaattat caagtcagaa 6900 tccaaattca agaaaaacta cagcagctca ggacacaaat tcagaatata gacattcagc 6960 agcttgctgc agaggtaaaa cgacagatgg acgctattga tgtcacaatg catttagatc 7020 aattgagaac tgcaattcta ttccaaagaa taagtgacat tattgaccgt gtcaaatact 7080 ttgttatgaa tcttattgaa gattttaaag taactgagaa aatcaatact tttagagtta 7140 tagtccgtga gctaattgag aaatatgaag tagaccaaca catccaggtt ttaatggata 7200 aatcagtaga gttggcccac agatatagcc tgagcgagcc tcttcagaaa ctcagtaatg 7260 tgctacagcg aattgagata aaagattact atgagaaatt ggttgggttt attgatgata 7320 ctgttgagtg gcttaaagca ttgtctttca aaaataccat tgaagaacta aatagattga 7380 ctgacatgtt ggtgaagaag ttgaaagcat ttgattatca ccagtttgta gacaaaacca 7440 acagcaaaat ccgtgagatg actcagagaa tcaatgctga aatccaagct ctcaaacttc 7500 cacaaaaaat ggaagcatta aaactgttgg tagaagactt caaaaccaca gtctccaatt 7560 ccctggaaag actcaaggac accaaagtaa ctgtggtcat tgattggctg caggatattt 7620 tgactcaaat gaaagaccat ttccaagata ctctggaaga tgtaagagac cgaatttatc 7680 aaatggacat tcagagggaa ctggagcact tcttgtctct ggtaaaccaa gtttacagta 7740 cactggtcac ctatatgtct gactggtgga ctctgactgc taaaaacata acagactttg 7800 cagagcaata ttccatccaa aactgggctg agagtataaa agtactggtg gaacaaggat 7860 tcatagttcc tgaaatgcaa acatttctgt ggaccatgcc tgcttttgag gtcagtctcc 7920 gtgctctcca agaaggtaac tttcagaccc ctgtctttat agtccccttg acagatttga 7980 2013203064 09 Apr 2013 15 of 771 ggattccatc aattcggata aactttaaaa tgttaaagaa tataaaaatc ccattgagat 8040 tttccactcc agaattcact cttctcaaca ccttccatgt ccattccttt acaattgact 8100 tgctggaaat aaaagcaaag atcattagaa ctatcgacca aattttgagc agtgagctac 8160 agtggcctct tccagaaatg tatttgagag acctggatgt agtgaacatt cctcttgcaa 8220 gactgactct gccagacttc catgtaccag aaatcacaat tccagaattc acaatcccaa 8280 atgtcaatct caaagattta cacgttcctg atcttcacat accagaattc caacttcctc 8340 acctctcaca tacaattgaa atacctgctt ttggcaaact gcatagcatc cttaagatcc 8400 aatctcctct ctttatatta gatgctaatg ccaacataca gaatgtaaca acttcaggga 8460 acaaagcaga gattgtggct tctgtcactg ctaaaggaga gtcccaattt gaagctctca 8520 attttgattt tcaagcacaa gctcaattcc tggagttaaa tcctcatcct ccagtcctga 8580 aggaatccat gaacttctcc agtaagcatg tgagaatgga gcatgagggt gagatagtat 8640 ttgatggaaa ggccattgag gggaaatcag acacagtcgc aagtttacac acagagaaaa 8700 atgaagtaga gtttaataat ggtatgactg tcaaagtaaa caatcagctc acccttgaca 8760 gtcacacaaa gtacttccac aagttgagtg ttcctaggct ggacttctcc agtaaggctt 8820 ctcttaataa tgaaatcaag acactattag aagctggaca tgtggcattg acatcttcag 8880 ggacagggtc atggaactgg gcctgtccca acttctcgga tgaaggcata cattcgtccc 8940 aaattagctt tactgtggat ggtcccattg cttttgttgg actatccaat aacataaatg 9000 gcaaacactt acgggtcatc caaaaactga cttatgaatc tggcttcctc aactattcta 9060 agtttgaagt tgagtcaaaa gttgaatctc agcacgtggg ctccagcatt ctaacagcca 9120 atggtcgggc actgctcaag gacgcaaagg cagaaatgac tggtgagcac aatgccaact 9180 taaatggaaa agttattgga actttgaaaa attctctctt cttttcagca caaccatttg 9240 agattactgc atccacaaat aatgaaggaa atttgaaagt gggttttcca ctaaagctga 9300 ctgggaaaat agacttcctg aataactatg cattgtttct gagtccccgt gcccaacaag 9360 caagctggca agcgagtacc agattcaatc agtacaaata caatcaaaac ttttctgcta 9420 taaacaatga acacaacata gaagccagta taggaatgaa tggagatgcc aacctggatt 9480 tcttaaacat acctttaaca attcctgaaa ttaacttgcc ttacacggag ttcaaaactc 9540 ccttactgaa ggatttctcc atatgggaag aaacaggctt gaaagaattt ttgaagacaa 9600 caaagcaatc atttgatttg agtgtaaagg ctcaatataa aaagaacagt gacaagcatt 9660 ccattgttgt ccctctgggt atgttttatg aatttattct caacaatgtc aattcgtggg 9720 acagaaaatt tgagaaagtc agaaacaatg ctttacattt tcttaccacc tcctataatg 9780 2013203064 09 Apr 2013 16 of 771 aagcaaaaat taaggttgat aagtacaaaa ctgaaaattc ccttaatcag ccctctggga 9840 cctttcaaaa tcatggctac actatcccag ttgtcaacat tgaagtatct ccatttgctg 9900 tagagacact ggcttccagc catgtgatcc ccacagcaat aagcacccca agtgtcacaa 9960 tccctggtcc taacatcatg gtgccttcat acaagttagt gctgccaccc ctggagttgc 10020 cagttttcca tggtcctggg aatctattca agtttttcct cccagatttc aagggattca 10080 acactattga caatatttat attccagcca tgggcaactt tacctatgac ttttctttta 10140 aatcaagtgt catcacactg aataccaatg ctggacttta taaccaatca gatatcgttg 10200 cccatttcct ttcttcctct tcatttgtca ctgacgccct gcagtacaaa ttagagggaa 10260 catcacgtct gatgcgaaaa aggggattga aactagccac agctgtctct ctaactaaca 10320 aatttgtaaa gggcagtcat gacagcacca ttagtttaac caagaaaaac atggaagcat 10380 cagtgagaac aactgccaac ctccatgctc ccatattctc aatgaacttc aagcaggaac 10440 ttaatggaaa taccaagtca aaacccactg tttcatcatc cattgaacta aactatgact 10500 tcaattcctc aaagctgcac tctactgcaa caggaggcat tgatcacaag ttcagcttag 10560 aaagtctcac ttcctacttt tccattgagt cattcaccaa aggaaatatc aagagttcct 10620 tcctttctca ggaatattca ggaagtgttg ccaatgaagc caatgtatat ctgaattcca 10680 agggtactcg gtcttcagtg aggctacaag gagcttccaa agttgatggt atctggaacg 10740 ttgaagtagg agaaaatttt gctggagaag ccaccctcca acgcatctac accacatggg 10800 agcacaatat gaaaaaccat ttgcaggtat atagctactt cttcacaaaa ggaaagcaaa 10860 catgcagagc tactttggag ctctccccat ggaccatgtc aaccttgcta caggttcatg 10920 tgagtcaact cagttccctc cttgacctcc atcactttga ccaggaagtg atcctaaaag 10980 ctaacactaa gaaccagaag atcagctgga aaggtggggt ccaggttgaa tcacgggttc 11040 ttcagcacaa tgcacagttc tccaatgacc aagaagaaat acggcttgac cttgcaggat 11100 ccttagacgg acagctgtgg gaccttgaag ctatcttttt accagtatat ggcaagagct 11160 tgcaggaact cctacaaatg gatggaaagc gacagtatct tcaagcttca acttctcttc 11220 tatataccaa aaaccctaat ggctatctcc tctcactccc cgtgcaagaa ctggctgata 11280 gatttattat accagggata aaactaaatg acttcagtgg agtaaaaatc tataagaagt 11340 taagtacttc accatttgcc ctcaacctaa caatgctccc caaagtaaaa ttccctggga 11400 ttgatctgtt aacacagtac tctacaccag agggctcctc tgtccctatt tttgaggcaa 11460 ctatacctga aattcattta actgtatccc agtttacact tccaaagagc cttccagttg 11520 gcaacacagt ctttgatctg aataagttgg ccaacatgat tgccgatgtt gacctgccta 11580 2013203064 09 Apr 2013 17 of 771 gtgtcaccct gcctgagcag actattgtaa tcccaccctt ggagttctct gtacctgctg 11640 ggatttttat tcctttcttt ggagaactga ctgcacgtgc tgggatggct tctcccctgt 11700 ataatgtcac ttggagcgct ggttggaaaa ccaaagcaga tcatgttgaa acgttcctag 11760 attccatgtg cacttcaacc ttgcagtttc tggagtatgc tttaaaagtt gtagaaacac 11820 acaaaattga agaagatctg ttaacctata atatcaaagg aacacttcaa cactgtgact 11880 tcaatgtgga gtataatgaa gatggtctat ttaaaggact ttgggactgg cagggagagg 11940 ctcacctgga catcaccagc ccagcactga ctgactttca tctgtactac aaagaagaca 12000 agacaagtct gtctgcctca gcagcctcct cgaccatcgg cactgtgggt ctggattcga 12060 gcacagatga ccagagtgtg gagctgaatg tctacttcca cccacagtcc cctccagaga 12120 agaaactcag catattcaaa actgagtgga ggtacaagga gtctgatggt gaaaggtaca 12180 tcaaaattaa ttgggaagaa gaggcagctt ccagattgct aggctcccta aaaagcaatg 12240 tgcccaaggc ttctaaggct atttatgatt atgccaataa gtaccacctg gaatacgttt 12300 cttcagaact aagaaaaagt ctacaggtca atgctgaaca tgccagaagg atggttgatg 12360 aaatgaacat gagtttccag agagtagccc gtgataccta ccagaatctc tatgaggaga 12420 tgttggctca gaagagcctg agcatccctg agaatctcaa gaagagggtg ttagacagta 12480 tagtacatgt tactcagaag taccacatgg cagtcatgtg gctgatggac tcattcattc 12540 attttctgaa attcaataga gtccagttcc cagggtacgc tggaacatat actgtggacg 12600 aactctacac tatagtcatg aaggaaacca agaagtcact gtctcagctg tttaatgggt 12660 taggaaacct actttcctac gttcaaaacc aagtagagaa atcaagatta atcaatgaca 12720 taacatttaa atgtcctttt ttctcaaaac cttgtaaact aaaagatctc atattgattt 12780 tcagggagga gttaaacatt ttatcaaaca taggccaaca ggatatcaag tttacaacaa 12840 tactaagtag tcttcagggc tttttggaga gagttttaga catcatagaa gaacaaatta 12900 aatgcctaaa ggacaatgaa tctacttgtg ttgctgacca tatcaacatg gttttcaaaa 12960 tacaggtccc atatgctttt aaatccctaa gagaagacat atactttgtc ctcggtgagt 13020 tcaatgactt tcttcaatcc atacttcagg aggggtccta caagctacag caggtccatc 13080 agtatatgaa ggcccttcgt gaagagtatt ttgatccgag catggttggg tggacagtga 13140 aatattatga aatagaagaa aatatggttg agctgatcaa gaccctttta gtttccttta 13200 gggatgtcta ctctgaatat agtgtgacag ctgctgattt tgcttccaaa atgtcaactc 13260 aagttgaaca atttgtgtcc agggatatca gagagtatct tagcatgctt actgatataa 13320 atggaaagtg gatggaaaag attgcagagc tttctattgt ggcaaaggaa acaatgaaaa 13380 2013203064 09 Apr 2013 18 of 771 gctgggtcac tgccgtggcc aaaataatgt ctgattaccc ccagcagttc cactccaatc 13440 tgcaggattt ttcagaccaa ctctctagct actatgaaaa atttgttggt gagtccacaa 13500 gattgattga cctgtccatt caaaactacc acgtgtttct cagatacatc accgagttac 13560 tgagaaagct gcaggtggcc acagccaata atgtgagccc ctatataaag cttgctcaag 13620 gagagctgat gatcaccttc tgattcatct actaacaaat tcaaattaaa ccttcacata 13680 gtaggagact ttgtagacta ctataaagac catcctgagc cagacctgca gtcaacagca 13740 agagcaagaa gcacatagga actatacctg caaccaagct ggcataagaa ccaagacctt 13800 caaagcagcc tgaactcaag atgacatatt ttacaagtta gagtaaagtc aagagctgag 13860 ttgttttgtc caactcagga tggagggagg gagggaaggg gaaataaata aatacttcct 13920 tattgtgc 13928 <210> 3 <211> 2273 <212> DNA <213> H. sapiens <400> 3 gggggcagat cctggggaga atggaggagc acacagaggc aggctcggca ccagagatgg 60 gggcccagaa ggccctgatt gacaatcctg ctgacatcct agtcattgct gcatatttcc 120 tgctggtcat tggcgttggc ttgtggtcca tgtgcagaac caacagaggc actgtgggcg 180 gctacttcct ggcaggacgc agcatggtgt ggtggccggt tggggcctct ctcttcgcca 240 gcaacatcgg cagtggccac tttgtgggcc tggcagggac tggcgctgca agtggcttgg 300 ctgttgctgg attcgagtgg aatgcgctct tcgtggtgct gctactgggc tggctgtttg 360 cacccgtgta cctgacagcg ggggtcatca cgatgccaca gtacctgcgc aagcgcttcg 420 gcggccgccg catccgcctc tacctgtctg tgctctccct tttcctgtac atcttcacca 480 agatctcagt ggacatgttc tccggagctg tattcatcca gcaggctctg ggctggaaca 540 tctatgcctc cgtcatcgcg cttctgggca tcaccatgat ttacacggtg acaggagggc 600 tggccgcgct gatgtacacg gacacggtac agaccttcgt cattctgggg ggcgcctgca 660 tcctcatggg ttacgccttc cacgaggtgg gcgggtattc gggtctcttc gacaaatacc 720 2013203064 09 Apr 2013 19 of 771 tgggagcagc gacttcgctg acggtgtccg aggatccagc cgtgggaaac atctccagct 780 tctgctatcg accccggccc gactcctacc acctgctccg gcaccccgtg accggggatc 840 tgccgtggcc cgcgctgctc ctcggactca caatcgtctc gggctggtac tggtgcagcg 900 accaggtcat cgtgcagcgc tgcctggccg ggaagagcct gacccacatc aaggcgggct 960 gcatcctgtg tgggtacctg aagctgacgc ccatgtttct catggtcatg ccaggcatga 1020 tcagccgcat tctgtaccca gacgaggtgg cgtgcgtggt gcctgaggtg tgcaggcgcg 1080 tgtgcggcac ggaggtgggc tgctccaaca tcgcctaccc gcggctcgtc gtgaagctca 1140 tgcccaacgg tctgcgcgga ctcatgctgg cggtcatgct ggccgcgctc atgtcctcgc 1200 tggcctccat cttcaacagc agcagcacgc tcttcaccat ggacatctac acgcgcctgc 1260 ggccacgcgc cggcgaccgc gagctgctgc tggtgggacg gctctgggtg gtgttcatcg 1320 tggtagtgtc ggtggcctgg cttcccgtgg tgcaggcggc acagggcggg cagctcttcg 1380 attacatcca ggcagtctct agctacctgg caccgcccgt gtccgccgtc ttcgtgctgg 1440 cgctcttcgt gccgcgcgtt aatgagcagg gcgccttctg gggactcatc gggggcctgc 1500 tgatgggcct ggcacgcctg attcccgagt tctccttcgg ctcgggcagc tgtgtgcagc 1560 cctcggcgtg cccagctttc ctctgcggcg tgcactacct ctacttcgcc attgtgctgt 1620 tcttctgctc tggcctcctc accctcacgg tctccctgtg caccgcgccc atccccagaa 1680 agcacctcca ccgcctggtc ttcagtctcc ggcatagcaa ggaggaacgg gaggacctgg 1740 atgctgatga gcagcaaggc tcctcactcc ctgtacagaa tgggtgccca gagagtgcca 1800 tggagatgaa tgagccccag gccccggcac caagcctctt ccgccagtgc ctgctctggt 1860 tttgtggaat gagcagaggt ggggtgggca gtcctccgcc ccttacccag gaggaggcag 1920 cggcagcagc caggcggctg gaggacatca gcgaggaccc gagctgggcc cgtgtggtca 1980 acctcaatgc cctgctcatg atggcagtgg ccgtgttcct ctggggcttc tatgcctaag 2040 accaactgcg ttggacacca taagccacag cctcacagga agtgggggtg aggagcctgc 2100 ggtgctcccc agaaaagggg aaggggcagt ggggtgagaa ggtcctggct ccccttctcc 2160 cggccttcct ctgcctgggg cccactgcat ctgattggca gtcacttccc atgagggcct 2220 ggcccacccg ctgcagttgc cctaaggaaa aataaagctg cctttcccct gta 2273 <210> 4 <211> 3636 <212> DNA 2013203064 09 Apr 2013 20 of 771 <213> H. sapiens <400> 4 cagcgacgtc gaggcgctca tggttgcagg cgggcgccgc cgttcagttc agggtctgag 60 cctggaggag tgagccaggc agtgagactg gctcgggcgg gccgggacgc gtcgttgcag 120 cagcggctcc cagctcccag ccaggattcc gcgcgcccct tcacgcgccc tgctcctgaa 180 cttcagctcc tgcacagtcc tccccaccgc aaggctcaag gcgccgccgg cgtggaccgc 240 gcacggcctc taggtctcct cgccaggaca gcaacctctc ccctggccct catgggcacc 300 gtcagctcca ggcggtcctg gtggccgctg ccactgctgc tgctgctgct gctgctcctg 360 ggtcccgcgg gcgcccgtgc gcaggaggac gaggacggcg actacgagga gctggtgcta 420 gccttgcgtt ccgaggagga cggcctggcc gaagcacccg agcacggaac cacagccacc 480 ttccaccgct gcgccaagga tccgtggagg ttgcctggca cctacgtggt ggtgctgaag 540 gaggagaccc acctctcgca gtcagagcgc actgcccgcc gcctgcaggc ccaggctgcc 600 cgccggggat acctcaccaa gatcctgcat gtcttccatg gccttcttcc tggcttcctg 660 gtgaagatga gtggcgacct gctggagctg gccttgaagt tgccccatgt cgactacatc 720 gaggaggact cctctgtctt tgcccagagc atcccgtgga acctggagcg gattacccct 780 ccacggtacc gggcggatga ataccagccc cccgacggag gcagcctggt ggaggtgtat 840 ctcctagaca ccagcataca gagtgaccac cgggaaatcg agggcagggt catggtcacc 900 gacttcgaga atgtgcccga ggaggacggg acccgcttcc acagacaggc cagcaagtgt 960 gacagtcatg gcacccacct ggcaggggtg gtcagcggcc gggatgccgg cgtggccaag 1020 ggtgccagca tgcgcagcct gcgcgtgctc aactgccaag ggaagggcac ggttagcggc 1080 accctcatag gcctggagtt tattcggaaa agccagctgg tccagcctgt ggggccactg 1140 gtggtgctgc tgcccctggc gggtgggtac agccgcgtcc tcaacgccgc ctgccagcgc 1200 ctggcgaggg ctggggtcgt gctggtcacc gctgccggca acttccggga cgatgcctgc 1260 ctctactccc cagcctcagc tcccgaggtc atcacagttg gggccaccaa tgcccaagac 1320 cagccggtga ccctggggac tttggggacc aactttggcc gctgtgtgga cctctttgcc 1380 ccaggggagg acatcattgg tgcctccagc gactgcagca cctgctttgt gtcacagagt 1440 gggacatcac aggctgctgc ccacgtggct ggcattgcag ccatgatgct gtctgccgag 1500 ccggagctca ccctggccga gttgaggcag agactgatcc acttctctgc caaagatgtc 1560 atcaatgagg cctggttccc tgaggaccag cgggtactga cccccaacct ggtggccgcc 1620 2013203064 09 Apr 2013 21 of 771 ctgcccccca gcacccatgg ggcaggttgg cagctgtttt gcaggactgt atggtcagca 1680 cactcggggc ctacacggat ggccacagcc gtcgcccgct gcgccccaga tgaggagctg 1740 ctgagctgct ccagtttctc caggagtggg aagcggcggg gcgagcgcat ggaggcccaa 1800 gggggcaagc tggtctgccg ggcccacaac gcttttgggg gtgagggtgt ctacgccatt 1860 gccaggtgct gcctgctacc ccaggccaac tgcagcgtcc acacagctcc accagctgag 1920 gccagcatgg ggacccgtgt ccactgccac caacagggcc acgtcctcac aggctgcagc 1980 tcccactggg aggtggagga ccttggcacc cacaagccgc ctgtgctgag gccacgaggt 2040 cagcccaacc agtgcgtggg ccacagggag gccagcatcc acgcttcctg ctgccatgcc 2100 ccaggtctgg aatgcaaagt caaggagcat ggaatcccgg cccctcagga gcaggtgacc 2160 gtggcctgcg aggagggctg gaccctgact ggctgcagtg ccctccctgg gacctcccac 2220 gtcctggggg cctacgccgt agacaacacg tgtgtagtca ggagccggga cgtcagcact 2280 acaggcagca ccagcgaagg ggccgtgaca gccgttgcca tctgctgccg gagccggcac 2340 ctggcgcagg cctcccagga gctccagtga cagccccatc ccaggatggg tgtctgggga 2400 gggtcaaggg ctggggctga gctttaaaat ggttccgact tgtccctctc tcagccctcc 2460 atggcctggc acgaggggat ggggatgctt ccgcctttcc ggggctgctg gcctggccct 2520 tgagtggggc agcctccttg cctggaactc actcactctg ggtgcctcct ccccaggtgg 2580 aggtgccagg aagctccctc cctcactgtg gggcatttca ccattcaaac aggtcgagct 2640 gtgctcgggt gctgccagct gctcccaatg tgccgatgtc cgtgggcaga atgactttta 2700 ttgagctctt gttccgtgcc aggcattcaa tcctcaggtc tccaccaagg aggcaggatt 2760 cttcccatgg ataggggagg gggcggtagg ggctgcaggg acaaacatcg ttggggggtg 2820 agtgtgaaag gtgctgatgg ccctcatctc cagctaactg tggagaagcc cctgggggct 2880 ccctgattaa tggaggctta gctttctgga tggcatctag ccagaggctg gagacaggtg 2940 cgcccctggt ggtcacaggc tgtgccttgg tttcctgagc cacctttact ctgctctatg 3000 ccaggctgtg ctagcaacac ccaaaggtgg cctgcgggga gccatcacct aggactgact 3060 cggcagtgtg cagtggtgca tgcactgtct cagccaaccc gctccactac ccggcagggt 3120 acacattcgc acccctactt cacagaggaa gaaacctgga accagagggg gcgtgcctgc 3180 caagctcaca cagcaggaac tgagccagaa acgcagattg ggctggctct gaagccaagc 3240 ctcttcttac ttcacccggc tgggctcctc atttttacgg gtaacagtga ggctgggaag 3300 gggaacacag accaggaagc tcggtgagtg atggcagaac gatgcctgca ggcatggaac 3360 tttttccgtt atcacccagg cctgattcac tggcctggcg gagatgcttc taaggcatgg 3420 2013203064 09 Apr 2013 22 of 771 tcgggggaga gggccaacaa ctgtccctcc ttgagcacca gccccaccca agcaagcaga 3480 catttatctt ttgggtctgt cctctctgtt gcctttttac agccaacttt tctagacctg 3540 ttttgctttt gtaacttgaa gatatttatt ctgggttttg tagcattttt attaatatgg 3600 tgacttttta aaataaaaac aaacaaacgt tgtcct 3636 <210> 5 <211> 874 <212> DNA <213> H. sapiens <400> 5 ctgcagcgtc tggggtttcc gttgcagtcc tcggaaccag gacctcggcg tggcctagcg 60 agttatggcg acgaaggccg tgtgcgtgct gaagggcgac ggcccagtgc agggcatcat 120 caatttcgag cagaaggaaa gtaatggacc agtgaaggtg tggggaagca ttaaaggact 180 gactgaaggc ctgcatggat tccatgttca tgagtttgga gataatacag caggctgtac 240 cagtgcaggt cctcacttta atcctctatc cagaaaacac ggtgggccaa aggatgaaga 300 gaggcatgtt ggagacttgg gcaatgtgac tgctgacaaa gatggtgtgg ccgatgtgtc 360 tattgaagat tctgtgatct cactctcagg agaccattgc atcattggcc gcacactggt 420 ggtccatgaa aaagcagatg acttgggcaa aggtggaaat gaagaaagta caaagacagg 480 aaacgctgga agtcgtttgg cttgtggtgt aattgggatc gcccaataaa cattcccttg 540 gatgtagtct gaggcccctt aactcatctg ttatcctgct agctgtagaa atgtatcctg 600 ataaacatta aacactgtaa tcttaaaagt gtaattgtgt gactttttca gagttgcttt 660 aaagtacctg tagtgagaaa ctgatttatg atcacttgga agatttgtat agttttataa 720 aactcagtta aaatgtctgt ttcaatgacc tgtattttgc cagacttaaa tcacagatgg 780 gtattaaact tgtcagaatt tctttgtcat tcaagcctgt gaataaaaac cctgtatggc 840 acttattatg aggctattaa aagaatccaa attc 874 <210> 6 <211> 1631 <212> DNA 2013203064 09 Apr 2013 23 of 771 <213> H. sapiens <400> 6 ggacttctag cccctgaact ttcagccgaa tacatctttt ccaaaggagt gaattcaggc 60 ccttgtatca ctggcagcag gacgtgacca tggagaagct gttgtgtttc ttggtcttga 120 ccagcctctc tcatgctttt ggccagacag acatgtcgag gaaggctttt gtgtttccca 180 aagagtcgga tacttcctat gtatccctca aagcaccgtt aacgaagcct ctcaaagcct 240 tcactgtgtg cctccacttc tacacggaac tgtcctcgac ccggggtaca gtattttctc 300 gtatgccacc aagagacaag acaatgagat tcttcatatt ttggtctaag gatataggat 360 acagttttac agtgggtggg tctgaaatat tattcgaggt tcctgaagtc acagtagctc 420 cagtacacat ttgtacaagc tgggagtccg cctcagggat cgtggagttc tgggtagatg 480 ggaagcccag ggtgaggaag agtctgaaga agggatacac tgtgggggca gaagcaagca 540 tcatcttggg gcaggagcag gattccttcg gtgggaactt tgaaggaagc cagtccctgg 600 tgggagacat tggaaatgtg aacatgtggg actttgtgct gtcaccagat gagattaaca 660 ccatctatct tggcgggccc ttcagtccta atgtcctgaa ctggcgggca ctgaagtatg 720 aagtgcaagg cgaagtgttc accaaacccc agctgtggcc ctgaggccca gctgtgggtc 780 ctgaaggtac ctcccggttt tttacaccgc atgggcccca cgtctctgtc tctggtacct 840 cccgcttttt tacactgcat ggttcccacg tctctgtctc tgggcctttg ttcccctata 900 tgcattgcag gcctgctcca ccctcctcag cgcctgagaa tggaggtaaa gtgtctggtc 960 tgggagctcg ttaactatgc tgggaaacgg tccaaaagaa tcagaatttg aggtgttttg 1020 ttttcatttt tatttcaagt tggacagatc ttggagataa tttcttacct cacatagatg 1080 agaaaactaa cacccagaaa ggagaaatga tgttataaaa aactcataag gcaagagctg 1140 agaaggaagc gctgatcttc tatttaattc cccacccatg acccccagaa agcaggagca 1200 ttgcccacat tcacagggct cttcagtatc agaatcagga cactggccag gtgtctggtt 1260 tgggtccaga gtgctcatca tcatgtcata gaactgctgg gcccaggtct cctgaaatgg 1320 gaagcccagc aataccacgc agtccctcca ctttctcaaa gcacactgga aaggccatta 1380 gaattgcccc agcagagcag atctgctttt tttccagagc aaaatgaagc actaggtata 1440 aatatgttgt tactgccaag aacttaaatg actggttttt gtttgcttgc agtgctttct 1500 taattttatg gctcttctgg gaaactcctc cccttttcca cacgaacctt gtggggctgt 1560 gaattctttc ttcatccccg cattcccaat atacccaggc cacaagagtg gacgtgaaca 1620 2013203064 09 Apr 2013 24 of 771 caggtgccgt g 1631 <210> 7 <211> 1898 <212> DNA <213> Mus musculus <400> 7 cggacgcgtg ggcgaggacc gcgaggagcg cagccctagc cccggcgact gagcacacct 60 gaggagaggt gcacacactc tgaggaccta ggtgtgcaac ctctgccaga tgtggggcgt 120 ggctacccag aggcatgccc ctcacccagc tccactgtcc ccacctgctg ctgctgctgt 180 tggtgctgtc atgtctgcca gaggcaccct ctgcccaggt aatggacttt ttgtttgaga 240 agtggaagct ctatagtgac caatgccacc acaacctaag cctgctgccc ccacctactg 300 agctggtctg taacagaacc ttcgacaagt actcctgctg gcctgacacc cctcccaaca 360 ccactgccaa catttcctgc ccctggtacc taccttggta ccacaaagtg cagcaccgcc 420 tagtgttcaa gaggtgtggg cccgatgggc agtgggttcg agggccacgg gggcagccgt 480 ggcgcaacgc ctcccaatgt cagttggatg atgaagagat cgaggtccag aagggggtgg 540 ccaagatgta tagcagccag caggtgatgt acaccgtggg ctacagtctg tccctggggg 600 ccttgctcct tgcgctggtc atcctgctgg gcctcaggaa gctgcactgc acccgaaact 660 acatccatgg gaacctgttt gcgtcctttg tgctcaaggc tggctctgtg ttggtcatcg 720 attggctgct gaagacacgg tacagccaga agattggcga tgacctcagt gtgagcgtct 780 ggctcagtga cggggcgatg gccggctgca gagtggccac agtgatcatg cagtacggca 840 tcatagccaa ctattgctgg ttgctggtag agggcgtgta cctgtacagc ctgctgagcc 900 ttgccacctt ctctgagagg agcttctttt ccctctacct gggcattggc tggggtgcgc 960 ccctgctgtt tgtcatcccc tgggtggtgg tcaagtgtct gtttgagaat gttcagtgct 1020 ggaccagcaa tgacaacatg ggattctggt ggatcctgcg tattcctgtc ttcctggcct 1080 tactgatcaa ttttttcatc tttgtccaca tcattcacct tcttgtggcc aagctgcgtg 1140 cccatcagat gcactatgct gactataagt tccggctggc caggtccacg ctgaccctca 1200 tccctctgct gggggtccac gaggtggtct ttgcctttgt gactgacgag catgcccaag 1260 gcaccctgcg ctccaccaag ctcttttttg acctgttcct cagctccttc cagggtctgc 1320 2013203064 09 Apr 2013 25 of 771 tggtggctgt tctctactgt ttcctcaaca aggaggtgca ggcagagctg atgcggcgtt 1380 ggaggcaatg gcaagaaggc aaagctcttc aggaggaaag gttggccagc agccatggca 1440 gccacatggc cccagcaggg ccttgtcatg gtgatccctg tgagaaactt cagcttatga 1500 gtgcaggcag cagcagtggg actggctgtg tgccctctat ggagacctcg ctggccagta 1560 gtctcccaag gttggctgac agccccacct gaatctccac tggagcctag ccaggctgcg 1620 ttcagaaagg gcctcagagg acaacccaga gccagatgcc cggccaaggc tgaagagaca 1680 aagcagcaag acagcagctt gtactgtgca cactccccta acctgtccta gcctggcaca 1740 ggccacagtg acagagtagg ggttggatat gatggagaag ccatgttatc tatgaactct 1800 gagtgttccc atgtgtgttg acatggtccc tgtacccaga tatgtccttc agtaaaaagc 1860 tcgagtggga aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1898 <210> 8 <211> 106000 <212> DNA <213> H. sapiens <400> 8 aagcttatgg tttatgggtg ttacattcaa gacatttgta ggacacattc taaaatgcca 60 tccaatttca ggctctttcc agcagaaact gtggaatatt tttccgttca ttcagcattt 120 acttagtgcc tgctctgcca ggaattgaag agaaagccca aagacaggca gaccttacct 180 gagaggtagt gaactgacca ggatgactgt gggcagtaga cttgtttccc aaactagcct 240 caccatttct gtatttgcat atacgaggaa aggattagat atagggattc atgtcagcat 300 acaccccagg gacatttgtt tttagtgaaa ggtgccagtc ttcatccctg tacccagtac 360 acaaaccacg aagaagtatg ctcccgtcat tgtcaaagaa tcatagaatt ccaaatggag 420 ctagttttga tatccagatc tcacttcata tgaggaaact aggtccagta ttgtgagtaa 480 gaattaggac tcttcagatt ccctgggtat gaatctgact aacaactgtg tgaacttgac 540 caaattcata accctgtaaa ctctgtttcc tcacttttaa aatgggcaca acaaagtgat 600 gcatgtaaac tgcatagcac agtgtctggc acttaaaaag cactcctgaa gttattttta 660 gtgatgtgtt ttaagattag acaactcctt aatgccaaag gtttttactt gagaactctg 720 tctgtgtgcc atactacacg ctgttcataa gataagcctt tttcattaat tgatctcaaa 780 2013203064 09 Apr 2013 26 of 771 ctggcttcat tatgatctta actttatttc agttttattt ttaaaattta tttttaattt 840 ttatgggtat atagtaggca tatatattta tggggtacag gtcatgtttt aatgcaagca 900 tgcaattgtg ggggtgatat ataattgact ggggtgagat atctcattgt agttttgatt 960 tgcatttctc tgatgattaa ggatgttgaa catttcttca tacacctgtt ggccatttgt 1020 atgtcttttg agaaatgtct attcagatct tttgtccatt ttttaagttg gattgtttga 1080 ttttttcctg ttgtctgaac tctttatata ttctagttat taatcccttc tcagatgggt 1140 agcttgcaaa tattttcttc cattttgtgg gttgcttctt tgttgtttcc gttgctgtgc 1200 agaagttttt tagcttgatg tgatcccatt tgtccatttt tgcattggtt gcctgtgcat 1260 ttgaggtatt actaaagaaa tctttgccca taccagtgtc ctggagagct tcccaaatgt 1320 tttcttttag tatcctagtt tcaggtctta gatttagggc tttagtccat ttttatttga 1380 tttttatatg tggtgagaga taggggtcta gtttcattct gcctatggat atccagtttt 1440 cccagcacca tttattgaag agactgtcct ttccctagtg tatgttcttg gcacctttgc 1500 tgaaaatgag ttcactgtag gtgtatgaat ttgtttctgg gttctctagg tctgtgtatc 1560 tgtttttatg ctagaactat gttgtttggg ttattatagt tttgtagcat aatttgaagt 1620 cagataatgt aattcctcca gttttatttt ttttgttcag gatggctttg gctattccgg 1680 ggcttttgtg gttccatata aatcctatga tttttttttt ctatttctgt gaagaatgtc 1740 attgatattt attaataaag attgcattga atctgtagat tgctttgggt agtatggaca 1800 ttttaacaat attgattctt ccaatccatg agcatggact atctttcttt ttttgtgtgt 1860 cctcttcaat atttttcctc agtgttttat tgttttcatt gtagagctct ttcacttctt 1920 tcgttgagtt tattcctagg tgttttattt tatctgtagc tattgtaaat gagattactt 1980 tctgatttct tttttagatt gtcctctgtt ggcatctaga aatgccacag atttttgtat 2040 gttgattttg tatcctgtaa ctgtactgaa tttatctgtt ctaatatttt tttggtggag 2100 tctttaggct tttccaataa gatcatacag tctgcaaaca agaataattt gacttcttcc 2160 attccatttt ggattccctt tatatctttc tcttgtctga ttactctagg taggtcttcc 2220 agtacttcca gttgaataac agtgggcact cttgtcttgt tgtagatctt agaagaaagg 2280 ctttcagttt ttccccattc agtatgatac tagctgtcag tttgttgcag atggcataac 2340 tttcaaacta attgattata gttaggaagt ggatacttta acttgtggta ccattatcag 2400 atttatattt cggccataag cttgaagagg agctgaaaaa tgcatatgtg atgcatatgc 2460 ttcctatttg gctctcttct cccacccccc tgccctataa tccacacaag ttcctctctc 2520 agtcactcat caactacttg aacctctgag gaacttgggg ttaaggtaaa ttagaataaa 2580 2013203064 09 Apr 2013 27 of 771 actgtctgaa gaagagcaag cctttcatgt cttgagaaat tcttggggtt ttagaaataa 2640 cttcattgct ttttttctcc agttactttg gcttcttctt aaagagaata ctaacacttt 2700 gaacgtcata atactaaggt tctgcctctt caaataaaga ctttaaaaaa aaatggtttt 2760 tgtatgattc agtgtgaatt aaatcccaca gtgtaaagga ctttactttc ttaatgtaga 2820 ttttcaaata cacaattact gatgtttata agtagattta ttacaccaaa gcacctagca 2880 aattcttgaa tggatcaggt cttatttttc agtcttactt tgcaaattta agccaaataa 2940 ttaaggattt gttaaatatt tgtcttaata tcaagctttt gcatatcggg gccctctttt 3000 ataagcttta taagcaatct tttgttttct ctgcttgctc aaagtagcta tgtttgttgt 3060 atctgttagt atttgctcta taacaaacat actgggtgcc ttcccactta gatttggcaa 3120 ttatcactcc tgtaaatgag atattacata agataggaaa aagaacagta tctttccaag 3180 aagaatagta tccttccata ttaacagttt agagctgact gcttttaaaa tttagtggct 3240 ttaaaataac aaccatttat tattcttcat gagtctacaa atgaggtggg cagttctgct 3300 gatctggcca agctgaactt atctcagctg ggcacattca gcgtatctgc tgtcagttgg 3360 ctggttggct gtagcaatga atggtgaaag taggctgccc ttaacttttt cacacagtag 3420 cattagagtt acaaaagaac cagcagaacc atgcaaaact ctttaagacc taggcttgga 3480 acaactatat ttctaccaca ttctattggt caaagcaaat cacggggcta gtctagattc 3540 aagtgggtgg aggagctgca attacactgc aaaggagtgt gactgtaggg agaggtgttt 3600 ttttattttt atttttttgc gatttgtcac agtagttgta ggaatcaggt gtatttaaaa 3660 ttctgatcct tctgtgatat ccgaattgtt catgaacctt gcctctggtg gaaaggcaga 3720 atcattgtga cagaaggata aaatcttgga atttagagac taacaaaggt tcagattcca 3780 gctccatcac ttatttctgc aatcctgcag aagttaatct tcctgatagg cattcagtaa 3840 tgattgattc acctgaacct cagattcttt atgtatttta aagaaagggc taggtaaatg 3900 caaagcactt atgtaactgc ttttattatt gcaaacctgg ctcccacact ccattcaagg 3960 tgtaagactc agtgtcttcc ttgaattaaa aaggaagaga aagtgtgtta gggaaaggaa 4020 gagaaatatt tgactaattg tggccccaat aaagtgacca ctcactgggg gtattttcct 4080 gtaagaaaag aatggttgag gctcagagtt aagagataca aatccaaaag tctccttggg 4140 gtaggattcc ctgtgattca tgggttgaga ggtgtaacat tagacacagt cccagtctag 4200 attttttttt taaagaattg tggtccatcc tatacacact gggtgcctta atactatatg 4260 tggcaattat cactcctata aatcaggttt tacataagat aggaaaaaga acagtatcat 4320 tccacattaa caattgaaag atgactgctt ttaaaaaatt aaaagggcca tatagaaata 4380 2013203064 09 Apr 2013 28 of 771 aaatcacata aatttcttgt gttaaacata gttgtcatat tggatgagga ctaaacacct 4440 aaattcatcc aactagtagt aatagaaaag atgaaacaca cacacagtaa aactagatta 4500 atttaattta tacaaagggc cagatatctc agaattcaga cagtcagaga tgttgactag 4560 agttaatgcc tcttttagga gaggtaccag gtaagtgttc tcaaagaact ggaaactgag 4620 accaccacct ctggcattat ctgtttgtga acacaagcaa gtctgaattt ttccgcacca 4680 tagctacctt tcatgtaagc ttcttttctt agaagaaaag aaggtaacat ttgggtgtaa 4740 ttttttatta agggtgaaat ttagtgtaga gagtaaaggc atttggcata gaagccctta 4800 gttttttttg tttttaagtt gaactgccag cctttatgga ttgcagtctt cgctgttttg 4860 attgacattt cccaattcat tttgtattat ttattttttt aagagacagg gtctcactct 4920 gttacccagg ctggagtgca atggggcaaa cttggatcac tgcagccttg aactcctggg 4980 ctcaagcaat cctcccacct cagcctccca agtagcttgg actataggtg tgcaccacca 5040 tccttggcta attttttaaa tcttttgtag agacagggta gtgctctgtt gcccaggctg 5100 gtctcacatt cctggcctca gttgatgctc tggtctcagc cttccaaaat gctgggatta 5160 caagtgtgag ccactgcacc tggcccccaa tttcatcctt tacaaagact actttcaacc 5220 ataaatcaac ggaaacttca gctccctcag acatatttgg gatccaagga tattttccca 5280 aatgattaat gctaatttca tatcaataca tttttgcaaa acctacaaaa atggactagt 5340 aaagaaagac tcttaatttg ggaaagacag ttacttggag agaagagaaa cttaagaggc 5400 aggtcgagtt cagtgttcag aaatgagagg atcataaaga gatagccata aaaatgtttc 5460 tccctatatt gcctgctgat agggtgtatc agtgaaggtc ttactaagga ccttgtacct 5520 tttcagcgct gcactgcgtg ctcataggga ggaaagataa atcatgtgtt ttttctgacc 5580 tcaaaggagc ctgtatctgg ctagagagac atgatgcaga cacatgaaat aattaagaaa 5640 caattaactg tagcaggtgc tgaagaatat accaggaggt cagagaatgg tagagctagt 5700 gtgggcgaag gtatagccca gagcatcatc agatgattct tccttatgca aattcacatc 5760 tcctctgggt caagtatcat cctggcatgc agcagctcca taggtaatgc cctaaggcta 5820 gcctgaggca agttgcaaaa gccatcatat tgagtcatgg cctttttttg tgtgggggga 5880 ggggaatggc atccccttcc tgtctgccaa atcaaggaat acagtgccct cctaaacctg 5940 ctttgtttta gtggattgtt aaaaagaagt gaatgaattt atgcttcatt agggaaaggt 6000 tacagtggaa tactgaggag taaggggtat ttctatttaa caaatgacat aacttgaagg 6060 aatgaaatca taaggatgga atttcaggca ttaataaaaa gctgatgaga gatactttga 6120 gacaaaagag ccttcccagt gtaaccgaga tcacagcacc tacttcacat acacaggaaa 6180 2013203064 09 Apr 2013 29 of 771 ccagtcctat ctgtctctcc catagagcag tagctgcctt gtttttcctc cctcctccat 6240 cattcattct aaatctccag tcctccaccg caccttatcc aaaccctgat acccttaagt 6300 cacagatggt gaatcagtca aaagtagtat taaaaactag tggtacacag ctacacctgg 6360 aatgcagtaa gaaaaatacg gatttctgta catcatcttc cctccctgct cttaccccca 6420 tttaagagtt acagggtcag aacccaagag tgtgagtttt tgaaagtccc taaaaatttt 6480 ggatgatcac ctacatttag aaccactgca ctaagaagga caacaaatat gccaataaat 6540 tctgttgcca aggaggtgat tatgcaagct ggaaccctga taacatgagg agaatcccac 6600 aatagccaaa tagtccatgt actagttaca ttataataaa gccaaaagca gcaggcctac 6660 ctgactttct cctgaggtct atcatgagct tagagagaag gaacgtggac atacagaggt 6720 agctctagat ggagaagggc actaggtgtc atggaaagaa tcatgtgcaa gaagtaaaga 6780 ggtgctctga atgtcctagc cctgcttagg tgtctgtgtc ctcacatgag aatttatcca 6840 cagttctttc ccgctgtaac aatctttggt tccaactgca tttgtgagac agcaaaaagc 6900 tatggtccag tctccttcca ttgtatcatc tcatcaatgt atttctccca ctacccttgt 6960 gtgaaataca aacttttttg gcttattgtg attatgcaag gtgtatgcca actttttttt 7020 ttctccacat ctttcagctt tctgatgggt aaaaattttc cttattttgc tttagaaaaa 7080 ttctcattgg catagatcta atttcaggga gcctcccttg aaagctaaat aacattgaga 7140 attcatgaaa atataatgta gagcattatg cctgttagca tattagttta aatagaagtg 7200 gttcatgaaa atttttgaaa tgccagaccc tgtcctgtgt tttgtattct cccaaatact 7260 catccagata ctgttcagaa tgtaacatga ttattttgaa ataaagattt tcccctagtt 7320 tttaaaaaag ttactttata cattaaccct tatgttcctc tttgatcaat ttttccagta 7380 gtgtaaacag tcttcaggga agtagatttc ttacagaaat tgtcaagtgg ctctctgctg 7440 ttagcatggt tactaatctt ttggttactt ttcatatttt ttatactttc tggaagtgga 7500 caacttactt gtaaataaaa gtgcataatt tgtattaaaa atttttagta acaatctaat 7560 ttgtaaaata gatgtgagca gcatgaatgt gtgtgatatg cgtacatacg aattatgtct 7620 cttaaaaatg tatcacagac atctttccgt gtccaaacaa atctacctca ttctttctaa 7680 tagccatatg ggtataccat aatatattta actaggcccc tattaaaaga attttgactc 7740 ttttgtagct actatagtgt tgcagtgtgt atctgtgtat gtatctttgt gtgtgtatct 7800 ttgtacgagt gtacatatat tttccccttg gctatttcag attttttttt aggtttaaat 7860 cttaggaaag gttttgaaat tgtcttaagt attttcagaa gcattaaatc atggtttttt 7920 tacatttttc ttttagaagt tttatgtcat ctctatgagt agctttcagt aatttgttct 7980 2013203064 09 Apr 2013 30 of 771 gcataaaatt cccgaaaact tccatttaaa aataggtggc atgactagac tttctcagcc 8040 gaaagagtga ggtcccagga aggattttgg agaagctgtg ttcaaatata gctgctgacc 8100 tgatgtctgc ctagagtctg gcaaggtgat gtgttgaatc tagtgtctgc ctgcatgcca 8160 gcatcccttt actgatgaga tttgtggttt tcatcacttc atggtaatca tcccaagtta 8220 taagatggag tctctagaaa atcagtagag tatgaaggcc caagtaaaat acatgtgagt 8280 gcatgtatgt gtgcatacaa attacttctc ttaaaaacgt atcctgggca tttaaagaat 8340 gaggacctcc gaaggatttt gtggaagctg tgttcaagta cagctgctga gcgtatgtca 8400 gcctggagcc tggcaaggtg aagtgttgaa tctagtgtct ttttgactca ctgttttttt 8460 tgactcactg tgctttgaag cccttgtcat ttgggctcat aaaatagatt tctgtatact 8520 gtctctcctc cctgccctcg cccccattta aaagtatagt ggcagaaccc aagaatcaga 8580 gttactaaaa actctctaga aaatttggat gatcacccac ctgatcatgt cttttttact 8640 cactatgttt tttttttttt tgagacagag tctcgctctg tcgcccaggc tggagtgcag 8700 tggcatgatc ttggctcact gcaagctccg cctccctggt tcacgccatt ctcctgcctc 8760 agcctcccat gtagctggga ctacagggcc tgccaccgcg cccggctaat tttttgtatt 8820 tttagtagag tcggggtttc actgtgttag ccaggatggt cccgatctcc tgacctcgtg 8880 atccacccgc ctcggcctcc caaagtgctg ggattacagg cgtgagccac cacacccggc 8940 cctttactca ctatgttttt aagcccttgt tttcatttgc tccactgtaa aacattcccc 9000 aagccaatct ggagctgagg caaattttta acaatttaaa atctggggaa tataaatatt 9060 ggataatgat catcctgaaa aaacaatgaa ggtagtagca taatacttta tatatcaata 9120 aaatggcaaa ataagacagt tgttgaagga cagaaagagt aactgaagtt aggagcttat 9180 cttaacacat tttttgtgtc ataccatagg catcatattt tttaaatttt ttttatttca 9240 tacacatagg aaaatatatg tgtgtaagaa ataataaaca cctctttgta cctaccaccc 9300 aacttaagga acagctcatt gctattccct ttggtgctcg ctggatgccc tttcccagtc 9360 acatccccct cccttcccat ctgcaggact atactagtaa attttgtatt ttttgcatta 9420 ttttgctttg ttttatgatt ttactaccta tctacatatc cctaaataat acattattta 9480 gtttcatatg ttttaacttt atgttgtgga atcacattaa atgtagtctt ttttttttat 9540 attatacttt aagttctagg gtacatgtgc acaacgtgca ggtttgttac gtaggtatac 9600 atgcgccatg ttggtttgct gcacccatca actcgtcatt tacactgggt atttctccta 9660 atgctatccc tcccctagcc ccccaccccc cgataaatgt agtctttata acttgttttt 9720 ttaactcaac attgtttgta agattcatcc atgtaagctg aagctttttt atagagatct 9780 2013203064 09 Apr 2013 31 of 771 ttgttaagcc ttttaatgaa tacagtacat acatttctct gttcccctgt tagtggacac 9840 ttggattgtt tccagagttt tgctgttttg aacaacgctg ctgtgaaaat gtctcctgaa 9900 acacatttat aagagttttt ttttccccaa gggaattata cctagaaatt gaataactag 9960 atcacaaggc atacacatct acaacttctg ctaggtaatg ccaaattgtt tccaaggagc 10020 gttagaagtg ttctcatcaa cttttactag tgctagtctt ttacatttgt ggcagtatgg 10080 tgggtgtgaa atatttatgt ttagtttttc ttggtgccat ttaataattt ttataaaaaa 10140 tatttagaag tcaaggcagt tttttgtttt tgtttttatt ttttgcttgt tttgttttaa 10200 tgcagacatt gagattacga cttggaataa acattggttg caaagttcct aaaaggaaaa 10260 ctttttttgg tattctggag cttttctggt actgaataaa ataagtatgt taaattatgc 10320 atgtgtagtt tagaagtcag agcaataatt gtgattgttg aacagaatgg cagtaaaaag 10380 tttctaaacg attgtactgt acaagggaca cttgttgtgg gtcagtttta gcctccccaa 10440 cttttatgtt aaaagttgca acaaggttta agggcttatg tttgataggc cagatggtga 10500 ccagctgtga taaaacacag ggaacccttg caaaggattt caaaatttat gcagtagtcc 10560 gccttatctg cagttttgct ttccaaggtt tcagttaccc gcagtcaact gtgttctgaa 10620 aatattaagt gaaaaattac agaaataaag aatcgaagag ttttaaattt tatgcttccc 10680 acccatccca cctgggatgt gaatcattcc tttgttcagc atctccatgc tgtaggtgct 10740 gcctgcccct tagtcacttg gtagccatcc aggttatcag attgactctt ctagtattac 10800 aacacttggc ttcaagtaat ccttatttta cttcatagtg gccccaaagt gcaggagtgg 10860 tgatcctggc aattcagata tgtcaaagag aagctgtaaa ttgcttccct taagtgaaag 10920 atgaaaattc tagacttata tataaagaaa agaaatcata tgctgagact gctaagatct 10980 atgataagaa tgaatctttt atacatgaaa ttgtgaagaa tgaaaaagaa atgcgtgctg 11040 gttttgctgt catatctcag actgcaaaag tttgcagcca atgtgtatga taagtgctta 11100 gttaaaagga aaaaggcatt taaggtaagt atatatagtg tttggtacta cctgtgattt 11160 caggcatcca ttgggggtct cctgagtata aggggagact actcttttag tgttaaatga 11220 acactaagga acagagatgg ggaagaggtt ggagaagatt agttcagcag tttgagtata 11280 ggtaaacagt tgtttgagaa agaagaaaaa tgtgattagt attttacctt agcaatagtg 11340 gcatagataa tgataaatta tagtcacaca gaactcttag tatttacaga acgttcacat 11400 ttgtgatccc atttaacaat aactctgaaa gaaaggtatc atctaccact gctttattga 11460 taaagatata aaaggtaaga gagatgaaac atattggcca atgataccca tctggtaaga 11520 gacagggatg gggtgggacc ccaaggctct tctcgccaag cccacggttt ttttgcttta 11580 2013203064 09 Apr 2013 32 of 771 tacttttttg cctcctgatc accatggctg cagtttctac tgtggacaat gtctgtcagc 11640 aagcattgat cccctgcctt cagcactctt acgtcttagc aaggactgga aagaaaaagc 11700 caggagttta cagtctgctg gagcaacaga aaagaatgat atgaaatatg aagagaccaa 11760 aatgatttat aataaggtgc tagactatgt agtaaaaatc tgctttagct gtaagtcaaa 11820 agcaagagca gtcttttcag aatggaatag aaatgttgga attaaaggaa ttttcaaagt 11880 tgtgaatttt tttcaagata aacatgtttt attttggtaa ttatggtatt actaatttga 11940 taaccttcag ggagccacct aatattatag aagatgtaca tataatgaca aaagcaaaca 12000 ttttattttt aaggaccaca atctaatcta aaacaaaatt tccccctttt ctggtctttg 12060 gttaattaag gacttattta aatatcaaag aaagacacat agaaaacatt tagtatattt 12120 ctatactttt attaatgtcc tccatacctt acacagatac ttgacttggc tatggtctag 12180 ataatccatg aaaatttaaa ggacagattt taacaacttt atgctaaatt gatagatctc 12240 taggatcaga ttgccatcac tctcagatgc gaagcttcca accacttata ggttcctgat 12300 atcttgcttt tatacagacc taatttctct tcctttaaac tttcttttcc tcagttgcta 12360 tttgattgaa atattgagtc attaaaaatt tccaagtggg aatttttgtg tttcttcatc 12420 tatcatgaag ctgctcaaat aagtaggtgt ttgaatagga gtagaaacag taataggctg 12480 aagccagacc aatacagctt cagctaaatg ccgaccttgc taaagtctgg gaggaccggt 12540 gtggtattct acaatgtaca agtctgtagc cggtgccctt aatatgttgg cttcatgtct 12600 catgactctc ttctgtaaat atgcagttta aaaaatacaa gttattctgc tgtagaagat 12660 acatttgcaa aattgatgta tcccctctaa gtaaagttgg ctaaacaata aggacatatt 12720 tataattaat gaatttgaga agaatgctga cgatatgcat tattctttga agttaacatt 12780 tttcaggtcc taaataaaca aaaagtaggt tacttctgtc tggagtgtat gcaaggggta 12840 ccatcttgtc cttggttcct ggctgctatt ccaaggtgct ataaagtcag ctaaagagag 12900 caatcataat acattgatag catccctcaa tgtgtttctg agctacttga gaatcttatt 12960 tttgaatagg tagcaggaaa ccatctttgc agggcagcat gggcaaaggg attggaggga 13020 ctattattat aaagatccac tgaactgctt cagtatcata atatcttaaa ctaaaggact 13080 ggaaagagcc agattccaat ttaatctgct cttctatgaa ttcttagctg ggttcattta 13140 aaaagaaaaa acttgaagat tgcaagattt tgaagacatc ttaaaatagg tgaactccaa 13200 ggtgcacttt aaacttgaga ctgataactg aatactcctt caccttttga tctgatattg 13260 tcaaaatgaa tgaggactta gtgctctagt aagtttggaa cagaatgata ttaatttatt 13320 ttctcatgat tgattctttt ttgcttttta atagattaaa cttcaccgta gaacagtttc 13380 2013203064 09 Apr 2013 33 of 771 tcaacctctg gactattgac atttttgatt ggataattct ttgctgtcag ggctgttctg 13440 tgtgttgcag gatagttagc aacatccctg acaatcacaa atgttacttt ctgtctctat 13500 ggatttgcct attctggaca tttcgtataa atagaatcat atatatgtgg cttcttgtac 13560 ctggcttatt tcacttaaca tgttttcaag gttcatccat attgtagcat gtaacagcac 13620 ttcattttct ttttatggct gagtaatatt ctgttatgtg gatatactac catattttgt 13680 ctatccactc cttagctgat ggtcttttag gttgtgtcca ttctttggct attataaata 13740 atgctgttaa gaacattcat atacaagttt ctgtgtagac atatatcttt atttctcttg 13800 tgtggatacc taggagtaga attactggat catatgataa ctctatgtgt taccttttga 13860 ggaactgcca aacatttttc tacagtggct gtatcatttt acactcccat cagcaatgta 13920 taagaattcc aatttctctg tccttgccta tatttattaa ctgtcttttc ttattagcca 13980 actgctgtgg ttcgaatgtt tgtcccctcc aaaactcatg ttggaacata atccccaatg 14040 tggcagtatt gagatgtgag gcctttaaga agtgcttggg tcatcagagg tctgccctca 14100 tgaataggct aatccattca tgagttaatg tactaatggg ttatcactgg attgggacta 14160 gtggctttat aagaagagga agagaactaa tctagtaagc tcagccttct cactatgtga 14220 ttgctgccct gtgtcacctt gggactctgc agagagtcct ccagcagcaa gaagttcttc 14280 atcagctgtg gccccttgac cttggacttc ccagcctcca gaaatgtaag aaatccattt 14340 ctttttttta ataaattaca cagtctcacg tattcagtta taccaacaga acacagacta 14400 agacaccatc ctattgggta tgggtatctc attgtgtttt ttatttgtgt ctcccaaatg 14460 actaacgatg ttgaacatct tttcatctgc tttttggaca tttgtgtatt ttctttgaag 14520 aaatgtcttt aacattcttt gcccatttta aaattaggtt gtctttttat tgttgagttg 14580 tcggtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtatcta gaatatatgt gtatgtatat 14640 atgcagatat attctaaaca ctagaccctt atgaaatata taatttgagg acaatttctc 14700 ccatttaaaa ggccatcttt tcacttcttg atagtgtcat ttgactcaca agtttttaat 14760 ttttatgaag tccaatttat tttttaattc tttgtttttg gcactgtatc tttaaaaagt 14820 tgcctgatct aaggtcaaac tgattttcac ctatgttttc atctaagaat tatagtttta 14880 gctcttacat ttaggccttt gatccatttt gaattaattt gtgtatatgg tgtgaagtag 14940 ggctctaact tattcttttg tgtaatgata cctagttgtc ccagcaccat ttgttgaaaa 15000 gattattctt tccccattga atggtcttga taccttgttg aaatcaactg accataaata 15060 tataggctta ttcctggact cacaattcta tgagtctgta tgtctaatct tatgccagta 15120 ccacactgtt ttgattatta catctttgta caaagttttg aaattgggaa atgtgagtct 15180 2013203064 09 Apr 2013 34 of 771 tccaactttg ttctttttta agattacttt gcctatattc cgtgttcgtt gcaaactcat 15240 atgaatttta aatcaactct ccatttctgg aagaaaaaaa gaggcaattg aagttcagat 15300 agggattgca ttgaacctgt agatcagttt ggggaatatt gccatcataa caattagtag 15360 gtcttccaac ccatgaatac aagacttctt tccatttctg tagatattta gtttctttca 15420 ttaatatttt gtagttttca atataaaagt cttgtacttc gattaaattt attcttgaat 15480 attttgggtt ttgatgcttt tatgaatttg ttttcttaat ttcactttaa gattgttcat 15540 tgctactgat tagtaatgca actgattttt gtgtgttgat ttttgtatcc tgcaacctag 15600 ctgaaatcat tgattagcat aatagagtat ttaatagatt taggatttct atatataaga 15660 tcatgtcatc tgcaattaga gataatttta cttcttccct ttcaatctgg acatttttta 15720 cttctttttc ttgcctagtt gccctagcta gaacctccag tgcagtgttg aatagcagtg 15780 gtgagaatga gcatctttgt gttggtcttc atcttgtggg gaaacctttc agtttaagtg 15840 tgttgttgtg gggttttcat agttgtcctt tatcagattg agaatgttcc tttctgttcc 15900 tagtttgttg agtgttttct ttttgattgt tttaatcagg aaagggcatt agattttgtc 15960 aaatgctttt tctgcagcta ttgagatttt tgtgtgtttt tctggtcttt tatggtttat 16020 cacattaatt gattttcata tgtcaaacaa accctgtgtt cttgggtttc atctcacttg 16080 gttatggttt ataatccttt ttatatactt gtagattcag tttgccagta ttttgttgag 16140 gatgcttgca tttatattta taagggatat tggtctgttg tagctgacca gtaagtatag 16200 taagctgtat agtttactaa gtgttccctc tgttttgggg gagactttga gaagaaggat 16260 tgttggtaat tgttctttaa acatttggta aaattcacta gtgaagccat ctggggtctt 16320 ctttggaagt tttttgatta ctaacttaat gtctttactt gtttgttata agtccattca 16380 gatttttttc tccttgagtc atttttgaca gttggttgag gaatttgttc atttcatgta 16440 gttatctaat tggttagtgt ataattattc atagtattcc tttataatct tatttttttg 16500 ctgtaaggtc agtcataatg ttcactcttt catttcggat tctggtaatt taagagtctt 16560 ctctcctttt ttttcttggt cagtctagct aaagtaaagt tttgtccgtt ttcaggggaa 16620 cagctttttt tttttttttg aggcagaatt tccatcttgt cacccagtct agagtgcagt 16680 ggtgcaatct cggctcattg cagcctccgc ttcccgggtt caagagattc tcctgcctca 16740 gcttgccaag tagctgggat tacaagcgcc caccaccacg cctggctaat tttttatatt 16800 tttagtagag acggggtttc accatgttgg gcaggctggt ctcgaactcc tgacctcagg 16860 tgatctgcct gccttggcct cccaaagtgc tgggattaca ggtgtgagct accgtgccca 16920 acccagcttt ggttattttt gttgacctac tctattgttt ttctcttctc tatttcactt 16980 2013203064 09 Apr 2013 35 of 771 atttctacac tggtctttat tattttcttc cttatgcttg ctttggactt agttcttctt 17040 tttctagtct cttaaggtgg ataattaagt tcctgatttg aattcttact tctttgtaag 17100 gtggtcatgt actgctatga atttccttct cagaaatgta tatgctttca ctgcatccct 17160 taagatttgg tatgttgtat ttttgttttc atttgtctca aggtatagtc ttctgatttc 17220 cattgtgatt tcttccccct ctaacccgtt tattatttag gaacttgttg atttccacat 17280 acctgtgaac tttccagatt tccttctttg ttaattctca gtgtcattcc attctggtcc 17340 gagaacatac tttgtatgat ttctatcttt taaaatttat ttggcttgtc ttatgaccta 17400 atacattgtc tatcctggag gatgtttcat gtacacttga gaagaatgtg tattctgctt 17460 ttgttgggta gagtgtttga caggtgtgtt ggtacatagt tctgttcaaa tctgtttcct 17520 tgcagatttc tatctagttg ttctgtctat tggaagtagg atattgaaat ctccaactaa 17580 tattgctgaa ttgtttattg ttttcttcag ttctgtcact ttttgcttta tatattttga 17640 aattctattg ttaggtacaa gtaagtttat gattattata tcttcttgat agattgattc 17700 ttttatcatt atacagtgcc ctataagaac aatttttatc ttaagtctat tggtctatat 17760 tagtatagcc acttcagctt tcttttgttt actgtttgca tggaatattt tcttctttta 17820 ctttctattt gtgttcttga gtctaaggtg aatctctgta gatagcaatt ggatctgcca 17880 atctttgctt tttatttggg gagtttaaac cattgacatt taatgtaatt attgatgagg 17940 aagattactt ctgatatttt gccatttgtt tcctttattt tgtgtctctt gttcttaaat 18000 tcttccatta ctaccttctt tcttttgtat tacatatttt ctagtgtaac gattttaatt 18060 tctttgtcat ttcttttgtt gtatgttttt agttattttc ttagtggttg ccacggagat 18120 tttattgtca ttttaacagc ctaggttggg cacagtggct catgcctgta atcccagcac 18180 tttgggagac tgaggcagga ggatagcttg agtccaggag ttcaagacca gcctgggcaa 18240 cttactgaga tactgtctct acaaaaaaat acaaaaatta gccaggcatg gtggtgtgtg 18300 cctgtagtcc cagatgcttg agaggctgag ttgggaggat agcttgagcc caggaggttg 18360 aggctgcagt gaactttgat cacaccactg cactccagcc tgggtaccag ggcaaaacta 18420 gcccaaagaa atgaaggaaa aaaaaaatct aatttagatt aatatcaact caacttcaac 18480 agtgtataaa aactttgcct ctgtatacct cttctgcttc cactctgtgc tgttattgtc 18540 atagattttc atctttctac actgtgtgtt tatcaatgta gatttaaaaa tattgcttag 18600 tagttgtctt tagaatccga tacggagaaa aggagatata aacaaaagat gcatttttac 18660 tgtcttgtat gtttacttat gtaattccct ttcctgatgt tgtatttcta aaggcaaagt 18720 agggttattg tgagtgtcct tttgtttcaa cctgaaagac tccttttagc atgtgttgga 18780 2013203064 09 Apr 2013 36 of 771 gatatgctaa tgatggactc tcacagtttt tgttatctgg gaatgtgtta atttatcctt 18840 catttttgaa ggatagtgtt ggcaggatac agaattcttg gttgacatgt aattctttca 18900 gcattatgaa tatgtcatcg tactgtcttc tgacctccat ggtttctgat aaggaatcaa 18960 ctgttaatct tattgaggat cacttgtttg taatgacttg cttgtcgtgc tgctttcaag 19020 attcattctt tgcctttagc ttttggtagt ttgattgtga tgcatttagg tgtgtacttt 19080 attagtctgt tctacttgga gtttgttgag ctttgtagat gtatttcatc agatgtgtca 19140 agttcttttg ccactatttt ttttttaaat aatctttttg cccctttccg ctccttctgt 19200 cactctgatt atttgtgtgt tgctttgttt ggtggtgtcc cagaagtctc tgagactctg 19260 tccagttttt tcctccccat tcttttttct ttcacttcct cagactggat gatctcaatt 19320 tgacctatct tcgagttcat ggattttctc ttctccaagt gacatctgtg agatgaattt 19380 ttttctagag aatttttcat ttcagttatt ctacttcaaa atttctcttt ggttcagttt 19440 tatcattgct atctttatat tattctcagt ttaatgagat actgttttat actttccttt 19500 agttctttag acatagttta tgtcactgaa tatatttaaa atagctgatt ttaagtcttt 19560 tttttttatt tttttggaga tggagtctcg ctctgtcacc caggctggag tgcagtggca 19620 cgatctcagc tcactgcaag ctccacctcc tgggttcacg caatgatttt aagtctttgt 19680 ctatgaagtc tagtatctgg gcttcctcag gcatagtttc tgttttcttt ctttcttttc 19740 ctgtgtactt cgtttctttg tataccttgt aattgttgtt gttaactgga cattttgaat 19800 attatagtgt aacaactctg gcagtcagac tgtctcccct ccccagtatt tgttgttggt 19860 gagtattgta gatgtttgtt tagtgacttt tcatggctaa ttctgtaaat tttatattct 19920 ttgaagattg tgggcaccct gaagtctctg tttgttagtt tagtggtcac ctaataatta 19980 acagagattt cattaaatgc ctagaagcaa aatatcttcc agtctttgcc catggcctct 20040 gtgtatgcat tagggcaggc cttgaactct tacccaggga gtttacaacc ctgccttagc 20100 ctttactacc agcttctgca gagcattaag gtcaacaggt ggtgagagtt tggagcctac 20160 tccatctttc ctgagcgtat acacagccct actcatgcat gtggccctct agatttccag 20220 gaatatgttg gaccctttca aagcccttac agactcccca gcttttcctc tcaatcttta 20280 gactagtgtg ttgttttctt caacagttat ctgtcaggca gcagcaaatt aagagattag 20340 cataaatgtt ttcaactcct ccacccgtca tgtgccccag ggaagcacta agccagttct 20400 aagttaggca aaataaagac aatccttttg aggtggtctt ccatggagtc accagacagg 20460 taaaccaaat aattaattac aagtctttgg ctggatacag tggctcacac ctgtaatccc 20520 ggcactttgg gaggctgagg caggtggatc acaaggtcag gagattgaga ccatcctggc 20580 2013203064 09 Apr 2013 37 of 771 taacacggtg aaaccctgtc tctactaaaa aatacgaaaa aataggtggc tgtggtggcg 20640 ggcgcctgta gtcccagcta ctcgggaggc tgaggcagga gaatggaatg aacccaggag 20700 gtggagcttg ccgtgagccg agatcacact actgcactcc agcctgggtg acagagcaag 20760 actccgtctc aacaaaaaaa aaaaaaaaca agtcttcatg aaagaggtcc attctgctgt 20820 ctttcatacc aggaatgtgg aatgtggact gttattttca tggctactgc taagctagga 20880 atcaagggat agatggggac tgggtaaaac accacagagt ttgctgttct taccaagaat 20940 aagctgggga agagggttgt ttttgttttt cagtaaaaat tccctgggct gcttcaagcc 21000 gttgattaat tttcaggttc cgaaaaagtt cagtttgaca gtttttgccc tttttatttg 21060 cttttatgga tatgtagaac ttgagttctt ttttccacca gttttgctga cattgtttta 21120 aaagcacttt ttgtaaaacc caaatgttgt ctctctcaag gctagccaat aattaaaaat 21180 actgttactc ccctttgatt ttggaaatga attcgtattg accaaaattc aatactagag 21240 gtctttcaag ctgttttacc atttatctaa actttagaat ctaatgattc ctgtacattg 21300 tctagcatac tggtggtcct caattgtcat aagttcaact ttggaacaaa tgaacttttt 21360 gtgtgcaagt ttccaattgt ttggaaatta cattgatgcc ccctccatca aactgttatt 21420 cgtgggacat ctaggaattt cttacagcag ctgacaaata tttcaagtca gtgcctggta 21480 gtactgtcca ccaggcaaca gcttcagtag tagagcgatc tttatctata aggcagtgtt 21540 tgagcaattg tttattagtg ttttcctaac tactcagaag aactatcagg ggttatagag 21600 gtagctcaga gagttgggtg caagtagaga aatccacccg gcttgcatta cacatcttat 21660 ttctagagaa gctttccttt gaagaaagag ttctaaggtt taaaaaatta ccttgaatgc 21720 cacttatatt gcattttaat tttattttag agaaatcaat ggaaagtaga aaaattaagg 21780 cactgatact agtgttaaga atgttggtta aagcttctgg caattaattt tttatttcct 21840 tttttaattt tattaaaatt taacaatttt cagtttatgc tgtaatccag accaaggttt 21900 caatctaatg aagttaatgc cagtgttgct gctacctatt ttgtctttag tcattcagcc 21960 atgcttccta cttatactga ataagctagc ttaatctaac aatcaaaaaa gaaagctgtt 22020 gcctaagtta agaaaaacag tttgaactgt tttcaaacta aatacccagt agactctcta 22080 gttgttgaca ggagaatgct taattcagaa ttgtcctgca gtagatcatt ttatctcatt 22140 cctgttcttc tataggatag cttatttgtt tgaaattgta tttaatatgt tgtgattttt 22200 gtgtgcttgt ttctattttt cactggatag actcaagata aaacctggta ccctgcagtg 22260 tagctatcag tttatagcag aggaaattta cattagaact tggctgtgta tttacatgta 22320 tctaacttgg aggtcactct gcttactgtt gatatatcag tcatattaga tgagtcccta 22380 2013203064 09 Apr 2013 38 of 771 atgagatacc agaaaccccg gaaacatcat taggtggaac agtgtcctta atgctttatt 22440 aagtgttata ggtaagacaa agcctagtac tatttgtggc atcaaggtta ggtgtttaaa 22500 gacctgtatt cttctattgt catgttgaaa ttgttccctt gatgtagcaa tagaaaattt 22560 tagattaggc ttaagttaat cagcaaacaa agataaaagt ctgatactat cctaaatatt 22620 ttgtgtttct aaataattta acagtgatcc aattagctac tcctgtagaa atgtaattga 22680 taaacttttc actctctttt aaattgccat cttgaatttt acctgttttt taaagctgtc 22740 tcaagtcctc tctaaaaaaa ggcagtcatt tataaattta gaaaagcttg atagcacaga 22800 aagtcacaga aaaatgtaaa catagtttaa aactgaattg tatacaagcc actagaagta 22860 cttttattaa gtttacaaat attagtagag tggaactcat gcatttaata tgtttgaaac 22920 ttttgatcaa atactgtgct atgaaaaaca ttttagataa ttattcttta atcatgtgtg 22980 tgtaaaatgt ggcttttttt gacaaccaag tagcttttct gtgtgccaaa ctgtgacttt 23040 aaaattttaa agtactcaac agagtaaaca aaccacaaat accacttaaa ctgtacacat 23100 ttgcacatgc atttcctata aatagtacat gggtttcaag tcttcacttt tgaaattcag 23160 aaatgggttt tttctccttc cagtagaaat aaaaacttga tttattttat ttatttattt 23220 attttatttt tgagacggag tctcgttctg tggcccaggc tatggtgcag gagggtgatc 23280 tcagctcact gcaacctctg cctcctgggt tcaagtgatt ctcctgcctc agcctgccga 23340 gtagctggga ttacaggtgc ctgccaccat gcccagctaa tttttgtatt tttagtagag 23400 atggggtttc tccatgttgg gcaggctggt ctcgaactcc tggcctcagg tgatctgtct 23460 gtctcagcct tccaaagtgc tggggattac aggtgtgagc caccgcatcc agctaaaaac 23520 ttgattttta aaaatccaaa tcgaagacag aattgtgtat tttagtacat ttattagcag 23580 ccttgacgct ataccatatg gctgtttatc atttaaacag cttgtaaaag caaacacttc 23640 aggattcatg agtggcagaa ggactgagta ctttgggaaa taagagagaa cttttgttga 23700 ggatggttga ggaagagtcc aagacaataa taggcagaat aagcaaaaat ctagagactc 23760 attgtaggca ctcaagtatg tatttgttag aatgaatggc tgaacttggt atattgagga 23820 acactgagaa agccatactg actggaagat agttcctaca agaaactggt gagacatatg 23880 ttacagtcta gattttggtg agccttgtta aagtttgggc tttattttta tacggggaga 23940 aagtttcaca ggggtttgga aatgaggctt ggagctgtta atggggacac agtgaggttt 24000 tagggtagtg gctttcaaac tgtttaaatc caaactttga tgataaccct gacataacta 24060 ttgtttataa cttccatttc agttgtattg gttttatcaa aacatcttca ttgatcttac 24120 tgattgcttc ctatgcagat taatattata aatttgaatg tacaaaggaa gctttagcag 24180 2013203064 09 Apr 2013 39 of 771 taaaatagca acttttatct gtcttacgta ttggaggttc tgcataagat ttaatttttt 24240 ttttttttga aatggagttt tgctcttgtt cacggggctg gagtgcaatg gtgtgatctc 24300 ggctcaccac aacctctgcc tcccgggttt aagtgattct cctggctcag cctcccaagt 24360 agctgggatt acaggcatgt gccaccatgc ccggctaatt ttgaatttta gtagagacgg 24420 ggtttctcca tgttggtcag gctggtctcg aactcctgac ctcaggtgat ccgcctgcct 24480 cagcctccca aagtgctggg attacaggcg tgagccaccg cgcccggcca agatttaatt 24540 ttttaaaaga aaatattttg ctaagggttt ggaaactctt gttttagcaa gaatggatta 24600 agactgatta aaactaaagg caaagaggag gctcttatgt ttggaattct ttgctaatat 24660 ttacacaata taattctctc cacaaatatt taatggtacc agatattaga tggttataat 24720 ggcaaaagtg ttcaaaggat gctatcatat tcatgattca tgatcaaaat gaacattata 24780 aggctatccc tcttcagaat taaatacgtt actcctgtgg aaaacttgct tttaatgtag 24840 aagttgtccc agagcctttc ttcctttctc atgtcctctt atgtccactg ctgagctaac 24900 atgggtctca ctgaatgatt aagaaaaaac atcttaggtg gggagttctg tatatagtaa 24960 atgtttaatt tattggggtg gtgaacggga agtgctgctg gcaagagagg atgggaagag 25020 aaatctaccc aaatccttac ccgctttaca gaacataaac ttcctattca gtagtacaca 25080 ataacttaac gatcaaggca tcttaacttt tctgttttca gatgaaagaa ctatcgtttg 25140 gcttgatcaa gtatttagta tttattcgtt cactcaagtg cttacgtttt tttgttatct 25200 cagggtttta cgttagttat taaccaaaag aactagtttt agttctggaa gtctaaaata 25260 tataagagaa ggtgaggagt aataagagaa gatgaaggga gactttcgga atggcctatg 25320 aacttctagt aactatacca ccttaaaata gacaaattac aatgcagtta tgaagatatg 25380 tatttttcag tgaagacaac taaaatgttt gcacagaatt ttctttttta ttgagtgtta 25440 gaaattctat tttggagata ctaccttgca caacataaaa agaaaaagtg agtgtggaat 25500 ctaggaatct acgtggctct aggaaatttt ttaagtgtgg aaactgaagg agagcaagag 25560 aaagggagca tggcattccc ctgtttgtag ttcatgaggt gggtttaaat tgccttttgc 25620 caatgcagct gcacactgag gattacagaa ttctttttaa atgtttgtag aattattttt 25680 cacttattag gtaaaacgtg tattttttga ttttctccaa tttcagcttt ctcatgttgc 25740 tatgctcaat tttgtatacc atatatagtt ttgttaaatt gacaaagtgg tgttttttgt 25800 tcttcttttt cccattggtt aaaatttaaa gagaaagtgg aagctagaaa tttatctaaa 25860 aaatgtaact ttccctgtaa ttattaaagt atcaaatcta aatttgaatt ttctttgtgc 25920 ataatctttt ttcaagctat ttaccatgtt gacaaacttg ctttcctgtg gcaaatacac 25980 2013203064 09 Apr 2013 40 of 771 tagcaatacg ttataaatat gtaactttca acctatttac agttgatgct tttttagccc 26040 tttggattta aaatacaagc actgaagagg tgaggaagta ccactgctgc ctcagcatta 26100 tttcgaaatt ctgtttataa actatacaat ttccaaggtc atgaatccag cacctttcca 26160 ggtactaact attgggacaa agatagaatt tgattttatt tatttaccta ttgactgaag 26220 tctaacttaa atcttgcacc tagtaagatc ttagaaataa cgtgtgtact ctgacctgta 26280 aactaatcct agtattctgt gtgtatattc tttctcattt gggctcttaa aaggaaaagt 26340 aacgtacatc tgatgatcat tagcactgag ctttttcagc aaaaagtata tgtttataaa 26400 gaagtatagg ataatttagt aatttaataa tgtgacaaca tttgcgtgtg tttttttttt 26460 tgagaaatac aaattgtgag aaacagaaaa gtaaaagaag cagcagcaga aatatcacta 26520 taggatcaaa agattgcagg aaccaaaact ccaaaattat tgggcataat gtactaaaaa 26580 cagggcagtg gaggaaaggg acagtccaga ctagctctga gggtccaaag aaagtattaa 26640 atattgttac tggagtgatt tgctctgcta tttgggcttg ggaattaagt gaaattgttg 26700 atatactaga cagatacttc ccacccattt ttctcttgat aatcagggtt cattttttct 26760 attttctatt tctctggatg ctccatttct taatattaat attaatatta agctctcagt 26820 ctttatgcta aaaattggtt atttaaaaca atttaaatca acttcagtct aattggctta 26880 agttcaaatc cattttaaga tcgatattgt gtcctttaaa aattttattt aaaagatatt 26940 taaactgatg agaggatact acccattcca ctgataaact attactgtaa gtttgtctat 27000 tgagggctag ttatttggtt taaaaatgct gagattatgg aaagtggatt ggaatatttt 27060 ggagcaatat taaaaacagt atctgtaaca atttaataaa cttataaatt cctctttctc 27120 tgttgatcta tcttgaaaag acactctatg tctctaggca ttccttctct gtggtgtgat 27180 tggtagacag ggagtaaaca acttactgta aatgggcacc atgccagttg gcttcaggca 27240 gcatcaagct tgtgactcac agtcagggtt aggaaaatgc cttttaactt gtttgtctct 27300 gcctctttta aacattaaag gcacaactgt actaattatt aagtatttca taaggtcttt 27360 tagggcttat aagatctttt aggaatggcc tggaagttat tagtactgtt tcattgaatc 27420 tgaatacctt taacatgata atgagaagtt tttaaagggt ggttttatag ttaaacggaa 27480 tttctcaaat tggcttgctc cttatgttga tttatttagg atcacatttg ggagtttctc 27540 tgccctactt tcaatgtatt taatttactg accatcacta tttgggggga aaatgttata 27600 tgatatttag aaaccaagag ttttggagtt tttcccccat tagatgtatt tatttattta 27660 tttattattt tttaaagaca gggtcttgct ctgtcaccca ggctggagca cagtggcatg 27720 atcctagctc actgtattct tgaactcctg ggctcagact gtcctcccac ctcagcccaa 27780 2013203064 09 Apr 2013 41 of 771 gtggctaagt atcaagtaag aatcacctgg caaattccaa ggctgtatac cagatttcct 27840 aaattagaat tttggggttg ggtatctgaa ttttagtaaa gccctccaaa tgtttctggt 27900 attgcttcta agaacaattg ataacataat agctgtggcc attatagggg tattctgtca 27960 tatttagata taggcatacc ttgttttatt gtacttccca aatattgcgt gtttattttg 28020 ttttgtttca cttacaaatt gaaggtttgt ggcaacccta tattaagcga gtctgtcagt 28080 gccatttttc caacagcttg tgctcatttt gtgtctctgt gtcacatttt ggtaattctc 28140 tcaatatatc aaactttttc atcatttttg tatctgttac gaccagtgat cagtgatctt 28200 tgattttttc tttttttttt tttttttgag acggactttt gctctgtcac ccaggctgga 28260 gtgcagtggt tcaatcttgg ctcacagcaa cctctgcctc ccaggttcaa gcaatcctcc 28320 tgcctcagcc tccccagtag ccgggcctac aggcgtgtgc caccacgcct ggctaatttt 28380 tgtattttta gtagagatgg ggattcccca tgttggccag gctggtctcg aactcctgac 28440 ctcaggtgat ccgctcacct tggcctccca aagtgctggg attaccgtgc cagcctgatg 28500 ttactatttt aattgttttc aggcaccata aacctcacct gtataaggca ccgtacttaa 28560 ttggtaaata ttgcgcatga tctgactgct cttccaactg gccattccct gtctgtctcc 28620 ctcttcctgg gactctcaaa tccctgagag acaataatat taaaattaag ctaattaata 28680 accctacagt ggcctctaag tgttgaagtg aaagagttgc atgtctctca ctttaaataa 28740 aaagctagaa gtggctaaac ttagtgagga aggcacatca aaagccaaga caggccaaaa 28800 gcaaggactc ttgtactaaa cagctaaatt gtgaatgcaa aggaaaagct cttgaaggaa 28860 ataactagtg ctactccagc aaacatgtga atgatcagaa agtgaaacag ccttcttgct 28920 gatacgaaga aagttttagt ggtctggaca gaagatcaaa ccattcacaa cattccttta 28980 agccaaagct taactctctt caattctatg aaggctgtga gaggtgagaa agctgcagaa 29040 gaaaaattgg aagctagcag aggtcggttg atgaggttta gggaaagaag ccagcgctgt 29100 aacataaaag tgtaaggtga agcagcaagt gctgatacag aaactgcagc aagttatgta 29160 gaagatctag ctaagattac taaataatag attttccatg tagatgaaaa agccttttgt 29220 tggaagaaga tgccatctag gactttcata gctagaaagg agtcaatgtc tggcttcaga 29280 ggacaggctg acattcttgt taggggctaa tgtagttggt gactttaagt tgaagccagg 29340 tctcatttac cactccaaaa atccgaagac ccttaagact tatgcttaat ctactctgct 29400 tgtactctag aaatgaaaca acaaagcctg gatgacagca catctgttta tagtatgctt 29460 cactgaatat tttaaggcca ctgtaaagac ctgttcaact gctcagaaaa aaatgattac 29520 tttcaaaata ttgctgttca ttgacagtgc acctgggctc acccaagagc tctaatggaa 29580 2013203064 09 Apr 2013 42 of 771 ttgtacaaca agatggatgt tgttctcatg cctgccaaca catcatccat ttgtagccca 29640 tgaatcaggg agtgatttca agtttcaaat cagtacattt tgtaaggcta tagctgctat 29700 agacagtgat tgctctggtg gacctgggca aagtaaatca aaaaccttct gaaaaggatt 29760 ggccattcta gatgctatta agaatttgtg attcgcagga ggaggtcaaa ggatcaacat 29820 tagtagcagt ttgaaagaag ttgattccaa cagttataga tgaatttgag gggttcaaca 29880 cttcagttta ggaagtcact gcagatgtgg tagaaacagc aagagaacta gaattagaag 29940 tggagcccga aaatgtgacg gaattgctgc aatctcatga gaaaacgtga atggatgagg 30000 agttgcttct tatggacaaa tgagcaaata aatttttttc ttgagatgga atctactcct 30060 ggtgaagatt ctgtgaacct tgttgaaata acaacaaagg atttagaata ttacataaac 30120 ttaattggta aagcagcagc atggtttgag tggattcatt ccagttttga aagagtttct 30180 actgtgggta aaatgctatc aaacagcatc tcgtgctaca aagaaatctt ttatgaaaag 30240 aaaagtgaaa cttcattgtt gtctacttta agaaattgcc acagccaccc caccttcagc 30300 aaccacctct ctgatcagtc agcaggcatc aacactgaag caagaccctc cacaaggaaa 30360 aagattacaa ctcactgaaa gttcaaatga ttgttagcat ttttaagcaa tattttaaga 30420 ttaaggtaaa tacattttta aagacacaat gctattgcac acttaataga ctacagtata 30480 gtataaatat aacttttata tgtagtggga aaccaaaaaa ttcgtctgac ttgctttgtt 30540 gcaatattca ctttattgtg gtctagaacc gaacctgaaa tatctcagag gtatgcctgt 30600 attaatatta ttttgcaagt aaaaaaccca gcatataaaa aaaacgtaga atatgttgag 30660 agttcagtaa tatggatgaa aatgtttttc tctaactgaa gaacatgata aattataatt 30720 agggaaggat ataaaccaag aaaatatgtc tgagatagcc aattcttgca gttcataata 30780 tgaaaactca ttataccaat ctcagtaaga atacttttaa tagctgttat ttctttggga 30840 tatagaattt ataaagtaca cagtaatctt cttatgatca atcctaggat cactttacaa 30900 ccacttaccc catattacaa tgtagtacca agacaagcag accaaattat agaaggacaa 30960 agtttttgct aagcatattt tgtcatcagc ataccgcatt gtgtgtgcat gcatgtgtgt 31020 gtttgtgcat gtgtgtgatt gtataaaata ttagaaagcc accccagaaa agttaaatga 31080 ctaggaatgt tgtgaaggga ttaagctacc cctaaaatta tataacaaaa ctctcttcat 31140 ctattattag gtcatcttta gaacatcttc tcttaaattt gttataggtc tctctcatct 31200 gtttggatta aaattggtct gaaagcctaa aatggctttt tacctatata attatttccc 31260 aactagcttg tagtataggt gcaaagctat cacacttgct aggttagtga agtatgtaaa 31320 aactaccatc tttcaattag gaaccatcgg atagcttcta caggattgct ggggagaacc 31380 2013203064 09 Apr 2013 43 of 771 tttataaaga aagttatatc tttataaatt ttttgtcatt ttacttagct gagaatataa 31440 aataagttag ctaataatag agtagaaatg ttttctgtaa cagattaata ttgatcaaat 31500 gtgttattaa atgctaaaac accatttttt ttctctgtaa gccatgtgtt tcatgccaca 31560 acacaaaagg gacaattgtc tgtgttttat gacagttctg ttctgtcaga tgctgtttgt 31620 tcattttggt gaataaatga agagagccct ggacacatct ttttttcctc aacaaaagag 31680 gaaaattatt cttgtctgta tgtctataat cctgactctt tgaatggctt taattttttt 31740 aaagtcagca tttttttata aagataggtg tttggaatgt gggcgatatg gctggacagt 31800 tagattggga ccaaataatg gaaggctttg aacatcatgc taagaggttt gggttttact 31860 ctgaaggcag tagagaacca ttatgttttt aagccaggat tgacttgttc taagctgtac 31920 cttagaaata ttactctggc agttgtacat aggatgagct gtatgttgct ttgttttgtt 31980 tggggagaca gttctcgaag agagactaca tacgaaggca gttatatgag tcattactaa 32040 aggtctggca agaagtagta aaagcattaa ctggagtggt agcagtaggg aaggaaataa 32100 aaggatagat gtgggagtca tttggaaagt atgaggcaat tcattgacct tacagaatca 32160 ctggttttct gcttccactc cattcacatt gacctttcca aggttatcag tgacctgctt 32220 gtccttaaat tcagtgggca ctttccagta acctactgtt ggcaccagcc ctgtgctaga 32280 caccaggatc ctgtttgtaa aggcatctgc cagtggtttc tgtgacacaa ttctgtttct 32340 agttttcctc cttctacttc tctagcctct tggcaagttc ttctttcaga gtttctcaga 32400 gctttgtgct aggccctctt ctcattttct ccttctctaa gtgatcccat ccttttctgt 32460 tgcttcagtt accatttgtc cttatgcaaa ggacagccat atctactgta tctccagctc 32520 agatgtatct ctttgcctcc tgacccatat ttccaactat ctaactgggt atcttttctt 32580 ggatgagtta taggtctctc aaacacaaca tgtccagaat aattcattga cttattctaa 32640 ggcctgcttc ctctttctcc tgtagtccct atctcaggaa atatatggtg ctatcaaccc 32700 caaagcagaa atctggacat aatccctaac tacccttttc ccctctctgt gcacataatt 32760 tcagtcatta ggcctcatag attggactaa ataaatacct cgcaaaccct tctacttata 32820 ttcttaactg ctcctacctt aagccaggct accataattt tgtagctgga tgactgcatc 32880 atcatcttga ctggctccct tgtcatcttc aatctatatt ctatactgca gctagagctt 32940 tcaaacataa acatgtgatc agattagtcc cctctttaga acaccctagg gttctcactg 33000 tcctgagtac agtctaaggg tttaccatgg cttacagggt cttttatgat ttggtgagct 33060 ttttattgta taacctttct aaactgcctt tacttccctc tttcttggct ctgtgtcttt 33120 gcataatgct gttccctata cttcacctca cgtctaacct tcatctcctt ttcacttctc 33180 2013203064 09 Apr 2013 44 of 771 ctcttcctcc aaaatccagc tgaatatcac attgtcatgc aggcccattc ttgatctccc 33240 acgtttgggt tagatatccc tcttcagtac catcaccgca ccaggtgtgt cccctatcct 33300 agcatttgcc tcattgtatt acaactactg tgtactcgtc tctacagctc ctgctagtct 33360 aaaagttttg ggagagcaaa ggttcatgtt tgtgtttttc actgtggtat accccagtgc 33420 ctagtatatg ataagctctc aaaatatttg ttagatgtat gaagaaatga gaaagagaac 33480 aggaagaggg taagtttcaa gactaggaaa caaggctatg aaagctgcag gaaagcagca 33540 ggttaaaacc tagaagaaga gtttgtttta ggaaatactg tgttttaaac cactataact 33600 gaagcaaaaa cccaaggcct gggtgtggat agagtccact atctgataac agtggatact 33660 gatgcatggc agagttggag aggaagagag ccagattcca aaacagaagg ggtaaagtct 33720 tctaagaaga tagattatag taagaaggat taggggatag aaatatgagc ctgttccact 33780 catagatctc aaacatgaaa tgatgagtca tcatgaagag agtaggcaat tgtccagtga 33840 agaaggggat gctaaccctt cttaaccttg aatctctcag gtagaagcag ttagagaagg 33900 aacagccatc atcagatagt gttgtaagga aaatgatatc cttggggaaa cctgcatttt 33960 ggtaaagcaa agcaactaag aaagaatata ctaccactgt ttaacaatcg ccacaaaaag 34020 acagtaggat catctttgac ccccctcatc ctttctcagg aacttggagg actaagaaga 34080 gagaaatctg tagaagaggc ttctctctct gatcctccct ccacttcagt tttaccacat 34140 gtaatgcaac aataattaag aatttgtgta aaatttcacc aggttggcat gcatggagag 34200 aaaaattatt cagatgtttt cctttgtcaa taatacaagg agcatttgta gggaaaaata 34260 tttacaaata cagtaagacc tattctcttt ctatatttat gggaaaattt taagttgtgc 34320 ccttgtttca tgtgtgtttc tatttaaaga taccatactt aatatatatt gttgattcat 34380 taacattgaa ctcatggcta acagcactat aaatcatgtc tgatcaaaac ttatgataca 34440 tgtactttct tcgtaaggta catcatagtc ttctcgtaca tgggaactct aggtagtact 34500 tcaggactat gcatagaggc cattttaaac agcaaaattc ccaacaaaaa gcacaaaact 34560 caaaaaatgt gccactaaat ttaccatgaa aaggacactt gtttacagtt tgagagctaa 34620 aacaagaagg tggcgtgtca cttcgtttga cttcagctgg gaacatgcat atcagtcgac 34680 tcaaattttt tgctattctg tgcttatcca cgaatcgata ggaaagcaag tgtggatttg 34740 ggggttacaa ataaaatgta gcaaatgtgt aaacttgcag atgtggaatc tacaagtagt 34800 tagaatcaac tatgttagtc tgatcattaa atcagttttt taaagtacta ttgtaacacc 34860 ttataacctg ccccattcac tgagtgttgt agtttatagt ttcattgggc attttcagta 34920 gttttatctg aagtcacatt tcaaattttg taattgaagc tccaaagtat gctaccggaa 34980 2013203064 09 Apr 2013 45 of 771 acacgagctg atgctgtgag acaaaatcaa caggtaatcc accatcacaa ctgtgggcta 35040 gaatgctcaa gaaaccttgg aggcccagag agctgagatg aatactgaag aatcataggc 35100 aggtttactc tgtcaagctg cctgtatttt gagggtgtag tcctcaaacc aaaaagacac 35160 caaatgaaca aactcagatg gcctcactgg ggaacagaga ttgaaagctg acactggaat 35220 gtgtacttaa aaaaatgaga gcccgttttg gaaaggcaga ctgggcacag aatgtggaga 35280 gctatatttg ctaactgaag aaatttagac tttatcctct acaaaacaaa gctattggtt 35340 tttgaaggtt gcataaaagc tgcattttag cagcatatat tttggtagag ctgttacctg 35400 cctgaaaaca tcaatgtcat ttcacacaaa tgatacttat cccttggtgt ttgatctaaa 35460 tttctacaat gagaatgtga ttttatagtc tttactgggg aaggaagtag gtttttcagg 35520 ccgaaattct tgtgtagcaa aaattaacac ttaagttagc ccttggcaat ctccagttct 35580 ataatggtaa aatggatttc ccagaaagtc actctctatc cctttgaata gacattagaa 35640 ataacatgta ctttaagtgg gatttacaga ggaagggggc ctttaattct ttactagtgt 35700 gatgccctgt aaaaaaataa ctaacattag agttgaggcc tagaaatagc agcactgggt 35760 taaagtctgt tttcaagtgc aagtttttct ttttattcgt gtgtgtgtgt gtctgtgtgt 35820 gtttcacata gaaggaggaa atgccaattt cagttcttac aaatattaat gactgcaact 35880 tataaaaatg ttacagacta tattcttccc ttttgtaaca gatgagaaga ttttgaaatt 35940 tagtctctac tttttagttt ggtaagacaa tttgaataaa ctgcaataat tgcaaaagaa 36000 ttctgaatat ttgaacattt gacattttct atgtcaaata tacatttctt gtactatata 36060 aacattctag aaaagagaga caggcaggga ggaaagtgct cattaaaaag agcttcaccc 36120 tctctgaaaa gggatttcct ttacagtgct gtgtactaaa gcctgtgttg taaatcagaa 36180 agcactgagc acacatgttg ctgctttggt agcatcagaa gtcgattttc attagcctta 36240 taccattcac tatttctgcc aagcaatctt aaattataaa agaatcttat ttgattttgt 36300 gattctcttg ttttctgctc ataaagaaaa tatcctaaat tgaacaatgg catgctacgt 36360 ttttagtttt taagacagct aatgtgtaaa aagacattta aagtatagtt gtgttaagtt 36420 tttgaagttt acagttgttt caattttgct gctatacttt gttaacatat tttaggaata 36480 tttcatttta gtcacaacta ggatataaac attattttgg tggcgatctc cttgtaatca 36540 cgacatcaac caaatttggg aaattttgat ttgttagatt tataaatttt acagtaacac 36600 aaaagtctaa tttcctatat attttcaagg cccctatacc tttgtcaaaa taaagtatca 36660 atgaaaaatg aaaaaatcat aaactatgtt caggccaaac tgatactgac tttgttaaaa 36720 ggctagatag aaatctgttt tcctcttctg ttacatctcc tcttctggag accactctgt 36780 2013203064 09 Apr 2013 46 of 771 gtggactgaa ggtttgagat cctaggacct aggctagaac agattaggag attgtgctgt 36840 atgttaagtg gcagatacca tggaattcta agcctgttac gaaggaggag aagaagaggc 36900 acaatgaccc tgacacagcc cctgggttga ccacagcaga tatctcactt gagcaagtag 36960 atatcatctc aattgcttgc tgattatctc taacttgtca gtaacttact ttgataacct 37020 agatttagga gtctgacagc atgcagtgta tgcctcataa taatctgctg tttatgaaag 37080 tcataacatt gtatgtttag cataatggtg aagagcctgc catctggaat ggtctactta 37140 tttgggatcc acatacagta agctctcact taacatcatc agtaggttct tggaaactgt 37200 gaccttaagc aaaacaacct ctaatgaaac caattttacc acaggctaat tgatataaac 37260 aagagttaag ttcctgtggc atatttctgg tcacaaaaac atcactaaac ttctaaataa 37320 agacccaaaa cacttataat attaaccact gaaataaatg tgagctatat atatacattt 37380 aagaataata aaaacaaaaa ataattattt acccaatttt tggtgaacca gtgagtgata 37440 gtgatcatag tgatggtgga tgaaatcaag gaataaatat ttgcaaagtg aaaattgtaa 37500 gaagcacccc ctgtcaccac atagctcaga aataataatt agggcaggct tgctgagcat 37560 ttttaaactg cactgtttat tgtcatgcat ttgaatgatt atcgcagact ttatgaattt 37620 tcattttata ataatttgta ggccaggcac agtggctcac gtctgtaatc ccggcacttt 37680 gggaggccaa ggcaggcggg tcactggagg tcaggagttc aacaccagcc tgaccaacat 37740 ggggaatccc catctctact aaaaatacaa aaattagcca ggtgtggtgg tacacacctg 37800 taatcccagc tatttgggag gctgaggcag gagaattgct tgaacctggg aggtggaggt 37860 tgcagtaagc cgagattgtg cccctgcact ccggcctggt gacagagcta gactctgtct 37920 caaaaaacaa taataataat ttgtattcat tcattttcca atgtgttcat tccagttcag 37980 ggtccagggg gcctgcagct tatactcata gctcagagca actgacccta tagacaggac 38040 gccaccccat tgtagggtgc actcaaatgc acactcacac tcaaactggg acccttcaga 38100 catgccagtt accgtatcac acacagcttc gggatgtggg aggaaagcga agtatctgga 38160 gaaaaactac acagacatgg gaagaacgag ccaactctac acagacagtg gccctggaca 38220 gagctgggca ggcatcagtt ttttttcttt tttttgtggg gggtgagggt ggggcatgga 38280 gtcttactct gtcacccagg ctggattgca gtgcagtggt gtgatctcag ctcactacaa 38340 cctccacctc ccgggttcaa gagtttctcc tgcctcagcc tcccaagtag ctgggattac 38400 aggcgcccgc caccacacct ggctaatttt tgtattttta gtagagacaa ggtttcacca 38460 tgttggccaa gctggtctgg aactcctgac ctcaggtgat ccacccgcct tggcctccca 38520 aagtgatggg attacaggcg tgagctaccg cgcccagtca gcatcatttt ttttttctca 38580 2013203064 09 Apr 2013 47 of 771 tcaacgttaa aacaatgttg aacaaaacat tattcaaaga cctgccgtat ggctattttc 38640 tagttgtgtg actttctttg ggaaagttag caaccctttc tgagcttaaa tgtcctcatt 38700 cataaaatgg ggctagtaat aatgcataag gtttttgtaa gaattagaat taataaagta 38760 cttagaccat aataactaat tagtattagt tgttgtcttt gctattattt tgatgtggtg 38820 gttgtttggt ttcacctgtg tactatcagg acatgctgaa ataaaattta agaattggct 38880 ttataatatt agaaaagcaa acttttgtac gatatgggta tgaaaaattg ttgggagtct 38940 actttttctc tcttacctaa tttgtcttag tctttttaaa gcttagattt tccaaatgag 39000 ccatagcaaa atataatgtt taaaaatgtt taaattctaa gcactatgtc atagttaaat 39060 aacttaaagg tgctacatct tatacagtcc aaaaggaaca taattagtaa aattctacaa 39120 tttagaaaaa aaaatagctg acagtgactg atttataaaa gtaaaatatc ttttgttaat 39180 actaatattc tttttataaa ttaattgatg acaaaaaatt gagtgaatga gatttgcagt 39240 tcatttatct atgatgctgg tttatttaat ctctataatt tgctgtattt gaaagagcat 39300 agtgatagag gtcatgataa aatctaggcc cagtgccaca agtaaatccc tgtaggaact 39360 ctcaaggttt tgatttcatc tctgaatggg aataacacct tccaagaata ttatgaagat 39420 taaaaagtta cgtatcataa atacacacag agtaacaata ctgggaatat tgcaacttgt 39480 aagaaagagg aagcatatgg catattctga tggttaggga tatggactct gtagctggga 39540 tgcctgaaag agaactctga ctccactaat ggctagttat atgaaattgt gcagataatt 39600 taacttctct gagtttgcat ttttctttgt ctatataatg gggataataa tagtacctac 39660 ctcacacata gtgttaattt ctattagtgg ttctcattaa gatagtattg ttgttcatcc 39720 ctggttgtta gccatcatgt atctgagtta gagagtcatt gattttagaa agtcccgagg 39780 agactatcag gtcaagcaac ctgcctcctg ctagacaatt agctttatcc atgagttacc 39840 aaagagggag ccgaaaccca gggaagctga aagagctgtt gattgtcacc ctgtgagttg 39900 gtgatagaaa gatatctgga atcccagtag ttgcccattt cctagttctg ggctctgcat 39960 tgcactagaa tactgtgcca ttctaaatat gaaaaggcag tatgaccatt gtgcttgtca 40020 ctttccattc cctagatgct atcttatatt tgtccttatg aaatttaacc tgtgactttc 40080 agatcactta gaaccttggt tggacagtgt tttctagtgt tatttagtat atttttttgt 40140 catcttctgt tgtctttggg ttcccctaaa agagctatac tctgggtgcc aggaaacttc 40200 acacatgact gtcttctctt cctcgacttc cctctctact tacctttcca gctcgtagca 40260 aatcagaaga cttctctgac acctctctat gtctaaaggt cctttgatat tctcacatgg 40320 cggcatgaat cacagtgtat tttaactggc cttttccttg tgtgtctcct acaatgagct 40380 2013203064 09 Apr 2013 48 of 771 gttgaagctt catgaaaaca caatctgttt tactcagggc agttataatt ccaattacaa 40440 agcacatttc ctggctcctg gctaggaact cgatcatttt tcgatgcttc cttgctcagg 40500 actttctgat tccttcttaa aacattttgg ggcatctcct tctcctggtt tttggaaaca 40560 tattctcata ctgctatgaa ggtttttact gacatttcca acttctctta aattgattca 40620 gcaaatgttt ttccataata aatgtcattg atatgtcatc aatatggaga gcaacaacag 40680 aatgcattga gtaaactcct cccctggagg tctgagaatc tagattccag ttctcacaga 40740 gccaccacct tggtgacctt ggacagtaga ccttctaagc ctcagtttcc ttatccctta 40800 agtggggata ttaatagaac ccattctcag agatgttgcc aagattaaaa taaccaagat 40860 aattcctgta gatgatttgg catagtgcct gccacgtact aagcaagagt tagcctccgt 40920 cattatagta tgatcataaa aaatgaacag actaaacgaa gtaaccagaa ggaaagaaat 40980 tttaattctt aaaatgtaat agtttcttgg tttttttttt tctgtgaaac acctgcatgg 41040 cacctttttg ttattcatac tgttttgact gtggctgtcg tagattcttg ttgaaagtct 41100 gagagactga gacttgtcat tttgaacatg gcatcagtgg aacagcttat gattcaataa 41160 ttgcatcatc ctggacaagc accagtagaa gtgagtcagg acatgtgata aaaagacatt 41220 cattttgccc ctcctccctc tctgtatttt ctttgctata aaattattga tgttaagccc 41280 atagtactaa tatttcagtt caattcataa taaaatttga gggcatttga atatattatc 41340 tgttgtaaat tataatttta tatttgacca cagagtattt gaagtgggtc ttttctttcc 41400 ccaaaattct attttaataa ctaaaaaata ttcttaggag aagtattatt taagaacagg 41460 tttatattaa ataacatcat ttcactttca actttctggt ggtcaaaaaa tatgctaata 41520 ctaattagga tatgatacac atgttctgtt agaacagttt tggcagttag aagacttctc 41580 ttcttgtgtt tgaaagggat gttacttggg gtagttatga gccatgtatc cagatgtcct 41640 gaaaggacca gtggtagatg tatttctatt tttgtctttt cttttttctt tctggcattc 41700 tagttgctga gtgactgact tttgttttca gctcttctca caatcaccat tgttctaata 41760 actttgctta aatagaatgt ctccttttgc tataagccat ggggccattt accgttaatt 41820 ttttaaagta ctgaaatgag aacctcataa attaaagaac actcctgatt ctgagttagc 41880 agatcctact aagccttttg cagatggaaa tttcctttaa attggtttgt tttcctttaa 41940 cattccatta tcctattgtt cattctttgg agctgtgatt tgtttaatat atttcaggct 42000 tcttaataaa tcaagtcatg taagttatta tttggatcat ttcgaaacta caacagctta 42060 tcaaacctct gaaagaagaa ttttgtgttt gcccacagac tgaagaactg attcagtttt 42120 attggctgag ctaccttcat tattcatatt taattcctgg tactgagggt gggaggaggg 42180 2013203064 09 Apr 2013 49 of 771 agaggagcag aaaagataca actattgggt actgggccta atatctgggt gatgaaataa 42240 tatgtacaac aagcccccgt gacatgtgtt tacctattta acgaaccctc acatgtatcc 42300 ccaagcctaa aagtttaaaa atatatattt ggtaaatcaa ttgatgtgtt ttaaaaaata 42360 tcgccttttg gccgggtgtg gtggcccatg tctgtaaccc cagcactttg ggaggccaag 42420 ccgggcggat cacgaggtca ggagttcaag accagcctgg ccaacatggt gaaaccctgt 42480 ctctactaaa aatacaaaaa atagctgggc gtggtggcgc gcacctgtaa tcccagctac 42540 tcgggaggct gaggcagggg aatctcttca acccaggagg cggaggttgc agtgagccaa 42600 gattgtgcca ttggactcca gcctgggcga cagagcgaga ctctgtctca aaaaaaaaaa 42660 aaaaaaaaaa aatcatcttt aaagagataa ctaacccttc cccagaaggc agggccaaag 42720 tctaaggttc ttccaggtcc tttgtattcc ctataaattt tagagtcagc ctgtcaattt 42780 ctatacacac acaaaaaaaa gcctgctggg attatgattg gtattgcatt gaaattaaat 42840 caatttgggt ataagagact tcaatttggg gattgagtct atattgagtc ttccaatcca 42900 ggaacactgt atatctctcc atttagtcag atatttagtt tatttcaaca atattttcag 42960 atctttagtt cctttcagca atattttctc atttttcctg taaagctctt gcacatcttt 43020 tgtcccatat ctattgtgta tatgtgtttt gctagttatt aaattatatt aatataaatt 43080 ttattttcca attgtttgtc gcatatatag aatgttttaa aaatattgtg tcctgtgacc 43140 atgctaaatt aactaattct agtcattatg tcttcattat ctttctcttg aattttcatt 43200 gtcttcccct tctgggactc cattcatatg taaggccatt tgatactgtc tctcaggtcc 43260 atgaagttct gttaattttt cttcattctt ctttttctct gtgttcttca actgaatgaa 43320 tgccattaat aatttggtat gtaatggctc acttaaactt ccttttgttt ttaagatatt 43380 tctactctca gctgtgtctg gaatccttta gtccggagcc ccaccaaccc tcagcctaga 43440 aggaaggagg agaaggatag ggtgaaagga aggggagagc ttctagcttc aggacagaga 43500 tcagaacaaa caacagagca gtcatcttgg ataaggaaac ttccctcaaa cctattactt 43560 atatcctcag aaataagaaa aataatgcat ttatcaaatt aaaggatttt gaaaaaggga 43620 acattcagag aataaaacta aactcttgaa agttaaaagg atgataacat aaatgaaaag 43680 ctcagttgaa ggattgaaag ataaaagtaa gaaaatatcc cagaaataag agcaaaaaga 43740 cagcaatgta aaatagggga gaagataaga gaattagaga accagcttag gagttctaga 43800 aagagaaaat gtagacaaca aaaggtaaga aatcatcaaa gactggagta ggggaggtca 43860 tgctatctgt ttctttttct attttttatt ttgagttaca ttttttttac tgtgaaacaa 43920 gcatatgtac atgagaatga acaaaacaaa tatgcagtca tgtattgctt aacaacagag 43980 2013203064 09 Apr 2013 50 of 771 ataggttctg agaaatgcat cattaggcga tgtcatcatt gtgcagacat catagagtga 44040 acttacacaa atctgaatgg tatgtcctac agtacacctg gaccatatgg tatagctgtt 44100 gcttccaggc cacaaactta cagcatgtta ctgtactgaa cactgcaggc acctctaata 44160 catcggtaag tatttatgta tctaaacata gaaaaggtac aataaaaata caatataaaa 44220 gaggaaaaaa atagtacacc tgtataggtg cttactgtga atagggcttc caggattgga 44280 agttgctgtg agtcattgag tagtgagtga atgtgaaggc ctaggacatt tattatatga 44340 agtctactgt agtgtaaact ctgtagactt aggctacact aaatttatag aaaaattttc 44400 ttcaataata aattaacctt agcctactgt aactttttta ctttgtaaac ttttaatttt 44460 tttaacattt tgactccttt ttagtaacac ttagcttaaa acacacacat tgtacagctg 44520 taaagaaaat tttatgtcct tcttctgtaa gcttttttcc atttttaaga tgtttttatt 44580 tttaaaactg ttactaaaaa ctaatacaca aacacacaca ttaacctagg cctatacaaa 44640 gtcagtgtca tcagtgttca accttcacat gttatcccac tggaaggcct tcaggggcaa 44700 taacaaacac agagctgtcg ttttctgtga taacagtgcc tttttctgat atacctactg 44760 aaagacctgg ctgagagtgt ttgacagtta acaaaaaaaa aaaaaggaca agaagtacac 44820 tctaaaataa tgaaaaaagt ataatacagt aaatacataa accaccaaca tagtcattta 44880 ttatcattat cgagtattat gtactgtaca cagttgtatt tgctgtactt ttctataact 44940 ggtagcacgg taggtttgtt tataccagca tcaccacaaa cataagcatg gtgttgtatt 45000 acaatgcaca gctgcagcta agtgatagga ctttttcagc tccattataa ttttatggga 45060 ccatcactat aaatgctgtc catcattgac tgaaatttat gtcgtgcatg accatacata 45120 caatttaatg aaaaataata ataataaagc tagcagtgtg taattaccaa ccagggcaag 45180 aaatagaata ttgccaatac cttggaggcc tccagtatga ccatataagt ttacaaatcc 45240 tattttgttc ctcctcccca gaggtaacca ctgccctgac aaatgtgatc gttgttttct 45300 tgtttttctt actacctata taaacatcct taaacaatat aactcagttt gtatattttg 45360 aattccatgt taatagaata tcatatgtat atgaatttta tgtgaataga atattatata 45420 tgtcattttg catcttgctt ttttcattca acattgtagg attcattcat gttgtagtgt 45480 acagctgtcg tttattcatt gctgtataga attatatcct cagagataag atatatggat 45540 gtttataaat cattccacta ttatgaacat ttgactagtt tgtagttttt atttaaccaa 45600 aaaaatgctg ctgccaacat tcttacacat tttactgtat atgcacatta atttatttac 45660 aagtataaat ttctttttga atacatatct attgatggag ttgctacatc ataggacatt 45720 cttgtctttg actttactgg ataataccaa actgtcttcc aaaatgatta catccttaaa 45780 2013203064 09 Apr 2013 51 of 771 ctcaggacac atcttattgt caaatgttta atttttgtca gtctgatggg tatgtaagtt 45840 attttattgt cgttttaatt tgcatttccc tgattactaa ttaagctgag taacttttca 45900 tatgtttatt ggccatttgg agttcctgta ttgtaaagta taagtttttt tgtccatttt 45960 tctagttttc tgtcctttta gttgaaatcc aaatttgcct aaatctgtta ttctctgagc 46020 acaagtaact tgggatgctt tcctttagat ttagcctaat tctttatcat tttgtcagct 46080 tgatggtgct tttaaggaga tatatatgtg tgtgtgcgca cacatgtgcg tgtgtgtata 46140 tatatatatg tatatgtatg tatgtatttt ttgagacagg gtctcactct gtcacccagg 46200 ctggagtgca gcggcacagt cttggctcac tgcagcctcc acctcctggg ttcaagcttt 46260 tccctgtctc agcaacccga gtagctagga ttacaggtat gccaccatac ccgctaattt 46320 ttgtatttaa tagaaacagg gtttcgccat gttgacaggc tggacttgaa ctcctcactt 46380 gaactcctca cgtcaagtga tctgcctgct ttagcctccc aaagtgctgg gattacaggc 46440 atgagctacc gcgcctggcc tggatatttt ttaaaaatat tttttatcta gcactttggt 46500 ttttggcagg caggttggca ctcatagtct gacctaccat ttctataaaa agaaacctgt 46560 aaatgttctt aaacagactt tgaaccagtc ttcctgattt tgaaccccta cctttacccc 46620 cagtttttga gcctttcaga attttttttc ataataatta ggttgcttct tagctttccc 46680 cactggtgac ttaacagatc ttaggaagcc aacaatcctt gtccatctgc tttctgtctt 46740 gtgaactgtt gctggtattg tctcttctct ttattcttag aggtgtatgc ttttaaaaac 46800 atatactggg tttgagaggg agctgaaata aaagcatgtg ttaaatatac catctttaac 46860 cagaactaca tttgactggt cattttattt tcaagctcac atacacttca aacagagata 46920 tggctaaagg aattatcatg tgaacaacag ccagggctct gaacatcaca gattatatca 46980 tcatacttga aatatttgaa attttgattc aaaatgagag ctttatagct atgtcctcaa 47040 tggactaagt gtttaagtac ttaacatcca aaacattctt actaatcaag agaagacaaa 47100 caccccaaca gagaaatagg caaattttat caatagccag ttcaccagat ttgttttctg 47160 ttagaagcga atatggggaa atacatgtgt ccatgttttg cctacttttc ctggagcagg 47220 taaggagagg cagtttaagg atccatgtga taaaccctaa agttgtccat cggctttcca 47280 gtcccttcta ggaatttaac ttagggaaat aatcagacat ttgcaaaggt gtgtacagtg 47340 gtatttataa tagtgaaaaa ccaaagaatg accaataacg ggagaatgga agttacagcc 47400 aaatacttta caactactaa agaatcatgt aaaatatcta ttgacatagg agttttatca 47460 aaatgtgaag tatacagatg aatagtacca cacataaaaa gcaaggtgca aattagccat 47520 ttatattgtt atccccaaaa taaatagatg cagttttttt aaaagatgca ggctatatat 47580 2013203064 09 Apr 2013 52 of 771 ggaagtgttt gctggttttc tgtcaaaaga atggcgactt tattttctaa tttaaacttt 47640 ttgctgtttt ctaaattgtc taaatagtta tagtttttat aatgtaaaag tatcttccaa 47700 tttagcttca tttgacaaat taccttttca ttctatctag ctatgtaatt ctaaatgaat 47760 ttacagcagt aatcttagag cagatgaatt tacaacaata atcttagagt agactacgga 47820 ttagatgtaa aaacatgagt tgggctttat ggttacagag agttttcctc agtgtgggga 47880 tcatagctgt attgagttta ttcagttttc ctttcccaca tgaatgaaaa atggggccag 47940 cctacaactg gaagggcctc ggcatgtacc actgtactgt gtatgatgtg atttcttgat 48000 gctagtaggg agagaatcaa attgcctcct attcaaacca agacccacaa atagcgtcaa 48060 ccagtcattt cagctactcc ctgcagtgtc aagaaggtgt gaacccctca tgttctctat 48120 tgcataccct tgtctaattc agtgtttctt cttcttttca ggttttggct ttatgctaca 48180 tttcagaaat cataataacc ttttctggta ttattttatt ctttttcgca ctgtgagaaa 48240 aattaaactt tcaagtggat gcttcttata aactatttat acccttttgc tcccttttgg 48300 gaggcaggga cagggacaga gttcctcctc aggctaacta agaaaactta ctgcttccaa 48360 tgtaatttaa aagatctccc tctttctatt gctctctgta ctcttaattc tttttttttt 48420 ttttcacagc agagacaagt gaacatttat ttttatgcct ttcttcctat gtgtatttca 48480 agtctttatc aaaacaaggc cccaggactc tccagattca attatgtcct tgggcttggt 48540 cgactgctgt aggagtctca gggagccttc tacaaatgct agagtgactc atttaccaac 48600 attaaaccct aggatacatg caacaaagca ggactccttc ctccatggaa tgtgccgatt 48660 tcagatgaca cagcacccaa tgtagaaaac gctggaattt ttccttggaa ctagactgtg 48720 atgagaggtg cttgacatga acataagcta ctgtcttttc tttttttttg agacagagtt 48780 tcgcttgttg cccaggctgg agtgcaatgg cgtgatctca gctcactgca acttccacct 48840 cccaggttca agcgattctc ctgcctcagc ctcctgagta gctgggatta caggcacgtg 48900 ccaccatgcc cggctaattt ttgtattttt agtagagatg gcatttctcc atgttggtca 48960 ggctggtctc gaactcccaa cctcaggtga tctgcctgcc tcagcctccc aaagtgttgg 49020 gattacaggc atgagccacc acgaccggcc agctactgtc ttttctttga cccttccttt 49080 ccagtttttg aagataaagc aggaaataat cttctctgaa gatacttgat aaaaattccc 49140 aaaacaacaa aacgcatgct tccacttcac tgataaaaaa tttaccgcag tttgtcacct 49200 aagagtatga caacagcaat aaaaagtaat ttcaaaaagt taagatttct tcagcaaaat 49260 agatgattca catcttcaag tcctttttga aatcagttat taatattatt ctttccccat 49320 ttccatctga atgactgcag caatagtttt ttgtttgttt gtttgtttgt ttgtttgttt 49380 2013203064 09 Apr 2013 53 of 771 tttgagatgg agtctcgctc tgtcgcccag ctggagtgca ctggcgcaat cttggctcac 49440 tgcagtctct gcctcctggg ttcaagcgat tttcctgcct tagcctctcg agtagctggg 49500 actacaggca cgtgccacca cacccagctc atttttgtat ttttagtaga gacagggttt 49560 caccatgttg gccaggatgg tctcaatctc ctgacctcat ggtctgcccg ccttggcctc 49620 ccaaagtgct gggattacag gcgtgagcca ccgcgcccgg ccagcaatac agtttttagt 49680 tactcgacat ctttaagcct ataactctta ggctatgcat agccccatgt cctaatcagg 49740 cattcactga tcccagcagg tctccatcta tttgtaccag cctcctcttt cctcccaatc 49800 tcaaggttac tcttaaatac tagtaaatgc aaaaagaact tgtaaagtgg caaggcatgg 49860 cctatcaaaa gtcagcccaa gggcagtttt cagccctgcc tcacctgggt ctagttcagc 49920 tgacggatga gctgattgat gcgttcaccc cgatagccag gtgtgcccat ctccttgagg 49980 aagcccactc ttatttttgg tagcatgatg ggccactgag aggtggaaag ggcgcaagaa 50040 ccatgagatc tcctggaaat gcttccctgg gaaggcaatt tcatgaatga ggtcttccaa 50100 gcaaatgaag ccaaacttcc ccaggtgctc ctcaatcact gtgttgtctg tcagagggat 50160 ggtcttattc ttgaccttgg cttgtccacg tttcaaaatg agttctcgga cagacttcag 50220 atttggaaat ccccaggtca cataaggttc cactatatgc agcattttta gattctaggg 50280 ggtaactttt acaaagatac cactaaaaat tttctttagg cgaagtcttg cagtggttct 50340 ctgcacccgt aaactcacgc catcaatcct ttcgatgcgt acaacaaagg ccaaggaatg 50400 tttatctggc aattccaagg catgaggttt cacttctagt cgtctgagac gcaccttgtc 50460 acgtttctgc cgccaggaat catgtaggaa tgattccagt cgcttaaacc tgagcccttt 50520 tcctttcttc tgtcttgctc tgccatcttt ctagtggtgc agctactcaa ttcttttttt 50580 aattataatt tttattttaa gttccagggt acatgtgcag gatttgcagg ttacataggt 50640 aaacatgtgg ccatggtggt ttgctgtacc tatcaactca tcaggtatta agcccggcat 50700 gcgttagcta tttttcctaa tgctgtcccg cccccccacc caacgggccc cagttacact 50760 cttaatcctt atagctcaga tgttatgatc cacagtgtgg ttcttacaga aagttatgga 50820 ttaaaaaaaa aaaaaaacac tcaaagtgcc cgaactttct taaaataatc ctggtacagc 50880 taaactcatg cactgactgt ccacctaata tttaacagtc tgtgttgtga tatattgttt 50940 taatgttctg aatgcttgtc agctttcagt attgaagatg tgaatcattt atcagcaatg 51000 acacatttag tctaaggttg tcagctattt atgctacaaa ttaatgactt gtccttaaaa 51060 tatcaatttt gtgattcatg ttttggcagg tggttagatg ttttgtgttc taattttaaa 51120 ctatggataa aggttttgtc ataatcattg ttttattggt tccttttctc ccctgcccac 51180 2013203064 09 Apr 2013 54 of 771 tccccaaaaa accctgcaat tcttttttgt taaactttta ttttaggttc agaggtacat 51240 gtgcaggttt gttatatagg caaattttgt gccacagggg tttgctgtac agattatttc 51300 atcacccagg aaataaacac agtacttgat ggataggttt ttagtcttca ttctcttccc 51360 accctcaagt aggccccagt gtctgtcctt cccttctttg tgtccctgtg tactcaatgt 51420 ttagttccta gttataactg agaagaacat gtggtatttg gttttctatt cctgtgttag 51480 tttgcttagg ataatggctg ccagctccat ccatgttgcc gcaaaggaca tgatttcatt 51540 ctttttatcg ctgtgtagaa ttccatggtg tatatgtacc acattttctt tatgcagtct 51600 tctgttgatg ggcttttagg ttgattctat gtctttgcta ttgtgagtag tactgcagtg 51660 aacatacaca tgcatgcgtc tttatggtag aatcatttat attcctctgg gtatataccc 51720 agtgatggga ttgctgggtc gaatggtagt tctgttttaa gttctttgag aaatcatcaa 51780 actgctttcc acaatggctg gattaattta cacttccacc aggagtgtat aagcatttcc 51840 ctttctctgc aacctcacca ggatctatta ttttctgact ttttaataat agctgttctg 51900 actggtgtga gatggtatcc cagcaccatt tattgaatag ggagtccttt ccccattact 51960 tgtttttgtt gactttgttg aagattggat ggttttaagt gtgtggtctt atttctgggc 52020 tctattctgt tgcattggtc tatgtgtctg ttttgtacca ataccatgct gttttggtta 52080 ctttagcctt gtagtagttt gaagtcgggt aatacggtgc ctccagcttt gttcttttgg 52140 cttaggattg ctttggctat ttgtgccctt ttttgattct atatgaattt taaaatagtt 52200 tttttctaat tctgtgatga atgtcattgg tattttgaga gcaatagcac tgaacccgct 52260 aattgctttg ggcagtatgg cgattttaac aatatcgatt ctttctatcc cctgcaattc 52320 tttgttgttg tatttaacta tttttacttg tgaagttttt tcagggatga ttttgttgaa 52380 agtgacaact ctaaaaatta tgttggtaat taaaatttta agtaatgact tttattttca 52440 gagattccac ttctcttaga ctttggagct gttaacagca gtgtccaatc tgcagtggta 52500 ctcagcagtt tctgtttcct gcatgcagaa ctgcttatat gaaaacacag ttttaaaaat 52560 gctttcttat ggctgacatt cacattctta ttccttttga ttcttttcaa gagggatttg 52620 gtttgttaaa attaattttt gcaatacttt tatgaagata caaactctga caaagctttt 52680 aaaacaagtt tgagagaata cagtattgat ttcacttgta aatctgacga ttattttaga 52740 aaaaaggaaa atattattta ctattatttt gcttataaat gtttatcaat tttaaagctt 52800 ccacattgca catctcccac tacaacagta gctaccattt attctttctc aaaaaaagtg 52860 ctaagtgtgc ccttgaaatt tttacattgt gcagaatatc cctaaaattt taaaacaaaa 52920 attacatcat cacttgcttt aaatgtttct tctttattta acatacagtt tctaaaatgt 52980 2013203064 09 Apr 2013 55 of 771 tagcaaatag cattttagaa gagacacgtt acttttctaa tgaatgttct aaaatgaacc 53040 acagtaacct atacttactt agactgtgaa aaacaaaact tatattctat tgttaaattt 53100 tcaaaagtga aactacacga tagtttactt ggcacatcac tctgttattg tgaattgaca 53160 aatgtatatg tagacaaata tgtgaaaatc agagtacata tacattatat gcagcaccac 53220 aatacatttt ttagtatgtt ttgactgata tttaattata taatttacca agaggatctc 53280 accagaatgt agaaaagtat tgaattttag aacaattcac atatttaaaa aaaatgtagt 53340 cagccctttt atctgtatct ggagaatgca gggtaaagga ataatacatg agtattggta 53400 tttaaaaaaa ggtgttaatt tcttacctat gatacctgtt actttgggta tcatttaacc 53460 tttatttctg tgaaatagag gagttctaac atcctctaat tattataata ttgttctaat 53520 ttaatctatc ttaatctgtg atacagtttg aaaaccaagc ttttactatt ggcatgtgca 53580 aaaaaataaa gcagcagtag acttggaatc ttgaatgcaa atttagattt tgcctcttaa 53640 taaatgtata atatagtgtt ctgggaccaa ttctctaaca tttctgagtc ctagtttctg 53700 catctgtcaa atgggattag agatacctac tttcaggatg tgatatggtt tggctctgtg 53760 tccccaccca aatcttatct tgaattgtaa tccccatata ttgagggagg gacctggtgt 53820 gaggtgtttg gatcatggaa gtgatttcct ccatgctgtt cttgtgatag tgtgggagat 53880 cgcaaaacat ctgatggttt aaatatggca gtttcccctg tgctttctct ctctcctgcc 53940 accatgtaag actttccttg cttcctcttt gccttctgcc gtgattgtat gtttcttgag 54000 gcctccccag ctatgcagaa ctatgagtaa attaaacctc ccttataaat tacccagtct 54060 cagatattct ttatagtagt gtaaaaactg actaatacag agaattggta ctggcagggt 54120 tgggtactgc tataaagata atctgaaaat gcggaagtga ctttggaact gggtaacagg 54180 cagtggttag aacagtttgg agggctcaga agaaaactgg aagatatagg aaagtttgga 54240 acgtcgtaga gacttgtttt gaatactttt gaccaaaatg ctgatagtga cgtggacaat 54300 gaagtccagg ctgaaatggt cccagagatg aggaacttat tgggaactgg agcaaaggtt 54360 atttttgcta tgctttagca aaaagactgg cagcatttta cccctgccct agagaactga 54420 tgaactttga gatgatttag ggtatttggc agaagaaaat ttctaagcag caaagcatcc 54480 tagtggtgac ttggctgatt ctgaaagcgt tcagtcatgt gcattcacga agatatggtc 54540 tgaaattgga acttaggttt agaagtgaag cagaacataa aggtttggaa aatttgcagc 54600 ctgaccatgt agtagaaaag aaaaccccat tttctgggga ggaattcaag ccagctgcag 54660 aaatctgaat aagtaacaag gagtaataag taataataag taaaaagtaa taagtaataa 54720 gtaacaagga gccaaatgtt aataaccaag acaatggaga aaatgtctcc agggcatggc 54780 2013203064 09 Apr 2013 56 of 771 agagatcttc ggggcagccc ctcccatcac aggcctgaga actaggaggg aaaaatggtt 54840 tcctgctcag ggccttgctg ctctgtacag cctcacgaca tggtgccctg catccctgat 54900 gctccagctc cagctgtggc tgtaaggggc caagttacag ctcgcaccat tgcttcagag 54960 ggtgcaagcc ccaagctttg gcagctttca cgtggtgttg ggcctgcagg tgcgcagaag 55020 acaagagttg aggtttggga acctgtgcct atatttaaga ggatgtatag aaacgcctgg 55080 atgtccaggc agaagtctgc catggaggca gagccttcat ggagaacctc tgctagggca 55140 atgcggaagg gaaatatggg gttggatccc tcatacagag tccccactgg ggcactacct 55200 agtggagctg tgagaagagg gcctctgtcc tccaggcccc agaaaggtag attcaccgac 55260 agtttgcagt atacgtctgg aaaagccaca gaatgccagc ctgtgaaagc cacaggggta 55320 ccctgctgag ccacaggggc ggagctgccc aagggtatga aagcccaccc cttacttcag 55380 tgtgccctga atgtgagaca tggagtcaaa ggagattttg gagcttttag atttaagggc 55440 tgcccagctg ggtttcagat ttcatggggc ctgtggccct tggtttgacc agtttctccc 55500 atttggaaca ggaacattta cccaatgcct gttccctcat tgtatcttgg aagtaactaa 55560 cttgcttttg attttatagg ctcatacgtg gaagggactt gccatgtctc agatgagact 55620 ttggtcttgg acttttgagt taatgctgta ataagacttt gggggactgt tgtgaaggca 55680 taattggttt taaaatgtaa aaagacatgg gatttgagag ggagcaagtg caaaataata 55740 tggtttggct ctgtgtcccc acccaaatct aatcttgaat tgtaacccgc atgttttggg 55800 ggagggacct ggtgggaggc agttggatca tgggggggtt ttttccatgc tgttcttgtg 55860 atagggagtt ctcaggagag ttgatggttt aaatgtggca gtttcccttg tgctctttct 55920 ctctcctgct gccaggtgag acgtgtcttg cttcccctgc cccttccacc atgatcataa 55980 gtttcctgag gcctccccag ccatgcagaa ctgtgagtca attaaacctc ctttccgtat 56040 aaattaccca gtctcagata gtatctttat agcagtgtca gaatggacta atacaggata 56100 gtaatgaaga ttacagaata tgtagatgaa gaagtgctaa gtaaatagca gctattatta 56160 tgtagtcaaa ttgaatgtat acattgtggt acttcagtgt cctttaaatt gaataactag 56220 aaatttgttg gctttctcaa tctgctcaca tcagatgaca tgttaattta tgcctatact 56280 tttttctagt taatagatat aaatctattc actcaacttc tattgacaga actggtagtg 56340 tggcaagaca tctcatttct agttaaggct gtataatatt aagttcattt tacttaaatt 56400 aactatggtt tgggaaatgc ttttcatgtc atcatgtatg cccaatttga tactttagtg 56460 ggacagtata tttcagaaaa aaacaaatgc ttccccaaaa attccagggt tgaatacatt 56520 agtcagacat ataacaatgt acttcagagt tcctctaagg gcaaaaatcg tggtatgaat 56580 2013203064 09 Apr 2013 57 of 771 atacaaaaca ctcctattta tacttttgta tttttgaaat gtagtcttca tgttaattta 56640 gcatttcaat gaccagcatg acattatctt aataatttgg aatgccaata tgttcattta 56700 agacttaata tagtaagtat ctaaagaaaa aaatggaagt gactgaatgc ttttgtatct 56760 cttaattata atttgtgctc cattgtgata tgaaggatag aaggggcagg atagatagaa 56820 aacagaaatt aactttgatg tttaacctta ccttaagact gtctgttaag tgacccacat 56880 aatcttaaaa aactctgtca agcttaatgg atgctactct gcaggcccct gccaggcaac 56940 agtcacaagg ttatgaggtg catagatttt ggaattaggc agagctgaat tcagatccag 57000 gtgttgcctt ataatgcgac tttgggcaaa taaaaggccc aatttttgta ttcttatctg 57060 taaaatggac tcagtaaaaa ttatttgaga taatttattt gtgtactgta cctaggcatg 57120 cagcttgaca cacagaatta caagtcagta gtttccagta tgattattat tgtgaaagag 57180 atattttgtt tcacctactg aaaacttttt tcagtcttaa attttttatc taactggctg 57240 tattgcagat gtctgctata taacttttat ataattttaa aaactatttc ttttctcctt 57300 gatcttctag gggtaaggtt accaatgttt tcattattta ctaaatatag cagcccccac 57360 cccttattca tggaggatag gttccaaaac ccctagtgta tgcttgaaac cacagaccac 57420 agataatccc aaatcctata tgtatattgt ttttcctata catacatacc tatggttaat 57480 gtttaaccta ctaattagga agagtaaaag agtaatagta actaataata aaataaaaca 57540 attgtaacaa tattccagca tcactattct tgtgctttag ggccaccatt aagtaaaata 57600 agggttactt gaacacaagc actgtgatac tgtggcagtc caactggtaa cagagatagt 57660 gatgcggttt ggctgtgtcc tcaccagaat ctcaacgtga attgtatctc ccagaattcc 57720 tatgtgttgt gggagggacc cagggggagc taattgaatc acagggtctg gtctttccct 57780 tgctattctc gtgatagtta ataagtctca catgatctga tgggtttatc aggggtttcc 57840 ccttttgcct cttcctcatt tttcttttgc caccaccatg taagaagtac cttttgcctc 57900 ccgccatgat tctgaggcct ccccagccct gtggaactct aagtccaatt aaacctcttt 57960 ttgttcccag ttttgggtgt gtctttatca caagcatgaa aatggactaa tacagtaaat 58020 tggtaccagt agagtgggtg ttgctgaaaa gatacccaaa aatgtggaag cgactttgga 58080 actttggagg actcagaaga agacgggaaa atgtgggaaa gttaggaacc tcctagagac 58140 atgttgaatg gctttgacca acatgctgat agtgatatga acaataagat ccaggctgag 58200 gtggtctcag atggatatta ggaacttttt gggaactgga gcaaaggtta ctatgttatg 58260 ttttagcaaa aagactggca gcattttgcc tctgccctag agatttgtgg aactttgaac 58320 ttgagagaga tgatttaggg tatctggtgg aagaaatttc taagcagcaa agcactcaaa 58380 2013203064 09 Apr 2013 58 of 771 aggtgacttc ggtgctgtta aaagcattct gttttaaaag ggaaacagca taaaacttca 58440 gaaaatttgc agcctgacaa tgcagttgaa aagagaaacc cattttttga gaagaaatta 58500 aagctggctg cagatatttg cataagtagc aaggagccta atgttaatcc ccaagaccat 58560 ggggaaaatg tctccatggc catgtcagag accttcacag cagcccttcc catcacaggc 58620 ccagagaccc aggaggaaaa agtggtttcg tgggccaggc ccacggtcct catgctatgt 58680 gtaggctagg gactttgtgc cctgtgtccc agctgctcca gctgtggctg aaaggagcca 58740 atatagagct caggctgtga cttcagaggg tggaggcccc aagccttggc agcttccaca 58800 tggtgctgag cctgtgggta cacagaagtc aagaattgag gtttgggaac ctctgcctag 58860 attttagaag acgtatggaa acacctagat gcccaggcag aagtattact gcagggcagg 58920 gctgtcatgg agaacctttg ctagggcagt gcagaaggga aatgtgggat tggagccctc 58980 acacagaatc cctactgggg cactgcccag tggagctgtg ggaagagagc cgtcatcctc 59040 cagaccccag aatggtagat ccaccaacaa cttgcaccat gtacctggaa aagccacaga 59100 cactcaatgc cagcctgtga aagcagccgg gaggtaggct gcaaagtcac aggggcggag 59160 ctgcccaaga ccatgggaat ccatcttttg catcagcatg acctggatat gagacctgga 59220 gtcaaaggag atcattttgg ggctttaaaa tttgactaac tcactggatt tcagacttgc 59280 atgggccccg taaccccttt gttttggcca atttctccca tttggaacag ctgtatttaa 59340 cctgtgacac ccccctaccc cctgcccccc atccctccgg cccttgtatc tggaagtaac 59400 tagcttgctt ttgattttat aggctcatag gcagaagaga cttactagcc ttgtctcaga 59460 tgagactttg gactgtggac ttctgggtta atactgaaat aagctaagac tttgggggac 59520 tattgggaag gcatgattgg ttttgaaatg tgaggacatg agatttggag gggccagggg 59580 tggaatgata tggtttggct gtgtccccac cctaatctca acttgaattg tatgtcccag 59640 aattcccatg tgttgtggga gggacccggg ggtgggggtg cagtaattga atcatggggg 59700 ctggtctttc ctgtgctatt ctcatgatag tgaataagac tgacgagatc tcatgggttt 59760 atcaggggtt tccaaaactt ttgcctcttc ctcatttttc tcttgccacc accatgtaag 59820 aagtaccttt cacctcctgc catgattctg aggcttcccc agccatgtgg aactgtaagt 59880 ccaattaaac ctctttttct tcccagtttt aggtatatct ttatcagcag tgtgaaaaca 59940 actaatacag atggctagta agggactaac cggcagggag cgtctccagt gtggatatgc 60000 tggacaaagg gatgattcac gttccagggc ataagatttc attactcaga attgcacaga 60060 atttaaaact tattaattat ttctggaatt ttccacttaa tgttttcaaa ctgtggttga 60120 ctgcaggtac ctgaaactgt caaaagtgaa accacagata agtggggagt cctgtaccta 60180 2013203064 09 Apr 2013 59 of 771 agattattcc tttaaattgt ttcagtggat atgtagggac ctgagtgtga agtgagagca 60240 gcagcatcaa aacctgaggg aaatccagat agcaaaagaa acttgtctag tatactggca 60300 tgacagagaa accaaaaagt tctcaagtta atgtgagaat ctaagaatta aagaattaag 60360 cctttgcctt tgagggaagg aaaggggtaa tgtggcttta aatcaggttg agattggttc 60420 tgagggttcc ttttccttcc tttatattga tatgaatata gacacaactg ttctgcattt 60480 ccatttgttt ttataaatgt ctttttagga tttaggaact gctaattatg caatatgaga 60540 tatctgttag tttgaggaac atttgaaaat ttggtcaaat gacacagatc gtcacacagt 60600 tttaagacaa atgtttttac ctatttgacc tagtctggca atccctattt gggcaaaaat 60660 cttcatttgc aggtcatgat tggaggcagg cacagaaaaa aaattgccac cttttttgca 60720 ttatgtcatc aagacatcaa acttcagcct acaaagtaga aagtgttatt tctcaagttg 60780 aaggcctgga tatacctcag cttctcagtt ctgacacttt atcatagtgg aaaatgaaga 60840 agattgctta agaacactga tgttggtgtc agaaagacct gggtttgaac cctgacttta 60900 ctagttactt agatcacttt aggcaactca acttttctaa atcttgtttc ttcatctgta 60960 aatgctgaaa atagtaccca cctcttaggt ctgtggagag gattaaatga gataatctat 61020 acaaagaaag agcttgcata atagtgccaa gtaatggtga ggttatacct gtattctgat 61080 tataatctca taaatattta ccatgttagc tgtctcagag ttcttttgca aaacagataa 61140 agatagaaag tataaataag aaaaataagt gaacatatac tgaactttgt acaagatgct 61200 ggcgatatgg agagacccaa gacatgggcc ctacctaaaa gagattattg atagaaacag 61260 gatacatata catcaaaagg taacatagga tcatctgtgc aaagtgctat atggcagtgt 61320 tttaggaagt ctagaagctg tcatggatca ggaataccat ggtggacact tcaggcaggg 61380 aaaacagatc ttagcaaaag ctactcctat cataggtact tgataaatat ttgtagaatc 61440 caggatccct gtagtgataa agaaactaca tggattatgt aggggagtga taagacatat 61500 gactggaaaa ataaaaagac caaattatgg accatactga gcttgtacta taaacagtgg 61560 aggagccctt cagattttta atcatgttga gaaaagagtt ttagcagtgt gtgggggata 61620 gaatggaaag agaagccagt gccagaagga ctacttagta tcaaccattg cagtggttaa 61680 agcaagaggt gagagaaggc atgcattaga atggcagcgg tcagagtgga tgggaaggaa 61740 taggtcctga catagtgtta cagggagtaa taaataggat gtggaagatg ggttagaatt 61800 ggcaaaatct ctgcatgtaa gtctgggtta ctaaatatag tgagagaaat tcaaatctct 61860 ctttaagaat cgaataaaat atttagaaat aagttactgt tgtatttgag gtgaacacaa 61920 atggcatttc aaagatgctc gagatacctt gttggaaaaa gtcaataact gcactattgt 61980 2013203064 09 Apr 2013 60 of 771 ctccaacatg ttcttgcctt ctctgaagac atcatgttcc taattctgaa ttatgaacca 62040 tctattatcc ttgtatgctc ttatgtgtga ggaaccataa ggtgggaaca aaatccggtc 62100 ttcattctag aaataactat gcgatcaaaa agtttttagt ctttcttctt accatactgg 62160 ttcttggtat tctgtttacc attcaatgta ctattattgc ttctgcttaa aactcacatc 62220 ccctaatgca agcctgagca aacagaactg ataacacaca gcctgagaag ggagtgcttg 62280 gggtctcaag acttattctg tttttctcca tctttgacac ttggtttgaa gagcaaagaa 62340 ggatacagct gttaggaagt aagttaccca aacacagtga ccaaactgga ttaattcttc 62400 caatgagaaa gaaatacatt atttctgtga gacagattag actttaagta gcatagataa 62460 catgattata ttctctctac aaataaatac acaggaccta agaaaccctt tacagatcca 62520 agtgttttcc tctccacttt tccatcccca aacccatctt gcaagatatg gccagcttat 62580 ttggagttaa ttaaatcaag accttcgttt tacagacagg gaaaccaagc ccagagacac 62640 tgagtagtag gccactggtg tcttagaggt ctgaaaaatc ctttactgaa cattctcttg 62700 atctattaat gtataggttt tgttgctgta accctctccc caagaggagt gaatataaat 62760 gatgcagagt ttggatgaac tatcttaata agaacctaaa gttgaaacca atgcaaacct 62820 ctctcaataa atgcaaagca aagagaataa tcagtctttc tttggcttgt taaataagat 62880 aaaatgtgtt ctgctaaaac catttaacag aaatattgtg aaaggtttcc cctaaagcat 62940 ttttctattt gatttgaaaa ctattccata gcttattatc aaacaaatca gtaatccttt 63000 agctaatgca gagataaatg ggcagtcaga aaatataatc acctggtgtg tgcagctgag 63060 tatttacatt tttcctaatg aacaaagata agaaaagtgc aggtgacttt aatgtgtaaa 63120 aactaccttt tagtgctagc gctagaggga aaaagaaatt actggctcaa gccaatcctg 63180 tacttgataa ctaagccgta tagtccatgg cttggcttca gttctgtttt gaatctcttt 63240 ttggacttgt cttgaatgga ctgtttaggg ctgcttcagt agtgcagttg ttgcattttt 63300 aagcatagtt taggttttaa aatgtttctg gtcccttttt ttttttcttt tccactttat 63360 gttgcttaaa gctttatggc caggttttct catcctcagc attattgaca tttgaagctg 63420 gatacttctt tgtggtgggg gctgtcctgt gccttgtagg ctggttagca gcatccctcg 63480 cctcttctca cttagatgcc aatagcattt ccccaaccgt gataaccaaa agtgttttca 63540 gacactgcca aatgtctcct agagagcaaa attgctctct gttgagaact actgtgttac 63600 ggtgtttgga caaaaactga caagccaatg ggaatattct attggtagtt gtaaaaaatt 63660 aatccagtta tagcagctgt atttctggaa tttttttcca tattaacact tgctttctga 63720 ggtgataata tctttgtttt ttttctccca aatagatttc ttgcattaca ctgaaaaatt 63780 2013203064 09 Apr 2013 61 of 771 gctgattaat tcacttaaat tgaagactaa gccaatcatg tcatttgggt aatagtttac 63840 caactctgcc cctttctctg tcagggaagc ctctaattta gtaagcgata ctgtatcctt 63900 ttgtcaggta cattaccatt cctattagca atagggcaat tgagattgag aaagattaaa 63960 aggtcaccaa gctattacat tgtagaatta ggttatgaat tgtagcctat ctggtttaga 64020 atctttacct tactagtctc cataacaaca attcttccag tgtggtccat ggggccctgg 64080 gagtctcccc ttaaagggca gactattttc acagtaacac gtactttatt tgccatttca 64140 ttatgtcagc atttgcaata atggtacaaa agcaaagatg agtaaaactg ttggcatctt 64200 agtatacagt agttactgta ttcactgtca tgcacttaaa atctttgaag aagcaaaaaa 64260 attattaatt acattaaatt tcaaccctta aatacatgtg gtctttctca tgtcagtgtg 64320 acaaaatgag aaggtgcata atccacttat atcgcatata gcatttgata gttgtctcaa 64380 agaaaagtgt ataagattaa actgtgagtt aacctacttt ttttcatgga gtaccatgag 64440 agataaactc tggttttcag ccttgggtat ttggcgatgt tttcccaaaa atgactgaag 64500 taaacttagc actttaagga aaacaactta aagtatttgt tgccaattga taaaatatag 64560 gtttcaagca aaaatcagaa tttttgaaga cttgtatctg ccactgtgag cttgacaaat 64620 gtgactcttt tatattacat aatgaactat gtcaacattt gaaagatctg cataactcag 64680 tgaaccagta ttttccagat gactaatgca tgataataca aaatcatgca tgggtaaaag 64740 atacattcaa agtgcaagat agactgacat atttcaatgt aacaatcaaa agttcattga 64800 taacagtttt ggattccaca ttgcaatact aaaaccttta aaaaacgaaa ttgtccaatt 64860 ttggtgtagt aatcagaaaa ggcaatctat aattacctga acttaagttt ctggaggacc 64920 attaaccttc tacaggctca tggggaagac tgtagcactt ctctttccct aagatcctcc 64980 agaaaggaag aaggtaatcc ttgggggtag ggtagagacc tattgtgtga tgatcaccaa 65040 gtatgtaaca atgctttata taactctaat atatataatc cacacaaacc ccctaaaatg 65100 gcactaataa gggaatggac tcaaagaagt taagtcagct agccactgtc acagctatta 65160 gagcactgga actaggattt gaacccagat ttgtctgtat gtaaagctga ttctcttcgt 65220 aatagtactg agacacaaga ggcggctaca aaatattctg gtactccatc ctagaccaga 65280 gtttcaaggt tcgttatcat ttgtagcatg atactggatc ctcacagtgc ttgcctttca 65340 ttcaggtgcc aggaaacgtc tgcctgaatg aatgggtgta atttacctgc acattttaca 65400 tgcttctcta ggtgtgtgat taactcataa tccatccatg actttcaccc ataatcctcc 65460 ttgtagcaat tgctttgctt gcaacaaaac taagtagaca tatctagctt tatgcatggt 65520 tttctctctc tgaactctaa cataaactca gcctcaggaa ttattcggtt tctactacat 65580 2013203064 09 Apr 2013 62 of 771 ttgccattct gattgggaac caccagcatt caggtattca cctggaacaa ggcattttgt 65640 tccaagggtt cctcacttaa aagcaagcac cctagcaata gttcataatg gaacttctta 65700 acattctcag aatgtttggc acagctgtga gtgaacacac attgagcaat caataactat 65760 tacagataat gatgccctta agaccaggat attttagctt tcccattcaa agggggtgaa 65820 atatgcactc ttactatggt atacttttgg ttccttctgc catgtatcct taataaaaga 65880 tgtcaattcc atatggtttt ctcttgagtt ctaaccattt tgttgtaccc tagccctttt 65940 aacaatatca aacttgcaac tgaataccat ttagcattca tccatttttt ccaatggtgt 66000 tcattatagg ctatcttact cctcctattt gtatgacaaa aattggcttt tttcaccgat 66060 gtctatggta catctggcag ctttccatgt actcagttct tatctgatgt agcccagaac 66120 gactgcctga agggatgcca aaagcctgat tgaggttcca aattttcagc tactgtacta 66180 tcaatccatt tgttcatttt tactttccct tgtcatctgt agcttacagt tgagtggcct 66240 gaacatgttt tgcatacatt gtaatatcta agaatttggg aatacggtcc taggatttag 66300 acttaatact accttccatt tatataatac ttactcataa aatcttcagt gttcctgaaa 66360 aagaaaaagg aacatgtatt gagtgcctgc tagaagcagg aacttgtagt agattttcta 66420 tgtgttacct tattttcaca acacacacac aggtgatatc cttcccagtt tactgatgag 66480 gaaactcagg ggtcaaagta gtagatacct acccaaggta acagaagctg tgaagtggta 66540 cagctgggat ctaaaatatg tcagcttcac cgtagatagg ctccctgatg aaccacctgc 66600 cacggcccgt atgaccgcat ccaggggtga tgatgtcatt ttcacagggt tattgagagc 66660 taaaactacg aagtactata aactattatt taaaatataa atacatacta tatatgcata 66720 tgtgtgtata tataattaat ggggtaaaca ttacagaata ctgtcctaac ctttaaacaa 66780 tgcactcgtt ttctgtaaac taatatacaa acaactgttt ggtccctaaa aatagatgtc 66840 aggtgacaga gactggctga gcaagaatag gagtatcttc agaatagaag ccagaggagt 66900 ttttgcttcc ccaacacatt gtcgcaccat tcactgttcc aggaccttcc tacttctctg 66960 gaaaactctg gcccaaagca gctcctctac attagtcaca agtttccatt aatcaggggt 67020 ggcctgtgcc ggacctacag cagagtcatt tcaggttatt ctgttacagg ctttcgacgt 67080 gtagtcagtc cactcgccca aatctagcag ggaatgaatg ccttgtaata cggaagcatc 67140 tacaaattct tcttaacagt gttcagagaa caatgtgaaa ccctggggcc ttttcccaga 67200 attagggtgg tgggaatgct gtcctattga ctaagcctgt taggtaagca ggcagttggc 67260 aagattcagg aagcttcatt tgaagataga atttagggcg atcgtttgga tttactggct 67320 taattactta aggtaacatt tataaaagaa attgtcattc cattattatt accttttaac 67380 2013203064 09 Apr 2013 63 of 771 ttttattcct aaacggaaca ttagcaacaa actacattac ttgataaatg taatttctaa 67440 ccagattgat aactagaaaa aaattttaag ttactttgct ctgtgaatta gtttaaacat 67500 atttgtaatt gagacttact actgttattg gctgaaataa ataaaagcaa gagataataa 67560 agaataacag agacaacgaa cacccaattt aagtttattt ctaagttcca tcttttttag 67620 agaaaaggca aattaagaaa agtttagaga gaggtactag tatatttatg aacttgtata 67680 gatgataagc aaaacggact ttaatatgta gaattccaga atcaacaggt tgccagcatc 67740 catgtttttg aagatttgct taagaacaca accaaaaatg gaatgggcag tctctaatta 67800 caagcagaag gctacaaaat cattttagct gcataataca gttttggttc taaagtcagc 67860 acgtaagagg aaaattcctt aggaaaatac aacattgaaa accattgtgt catgtaatat 67920 gaaatgcaat aattaatttt tcctccagta atagaaagat cactgtttca ttggtttata 67980 aaaatatatc tttatcatta aatgtggcaa aatgttaaga cttggtgaat attggtgaaa 68040 agtatatatc cattgtacaa ttctttccaa ttttttttga gattgaaaat ttttaaaaca 68100 acaaattatc ttttaaacag ctaataatca ctagacctgc actctttgtg gtgagactat 68160 gaaaaatgtt agagacctag taagagaagc agattcacat ttctgtcttc ttcttcaagc 68220 caaacagtca tagagtggag tgggcagaat ggaactcact tttgaaagcc tagtgctttg 68280 tccaatctta ctgcaagcca gacaggaagg ttatagaaaa tgtttctgga tcagtcttct 68340 ctgagtcata tgaaattgtg gtttcagcca agatgacatt aggaattaga gacatgggac 68400 aaaaacttta agattgtaaa aaaattttga ctctagtagg aaacatgggt agaattgtaa 68460 tgacacttga ttgaatttta aaagatgcct gtataagatc ttaaaattag gaaaaaaatt 68520 atggcctaag caattaaagg cataggaggc atctttttgg gatgatggaa atatcctctc 68580 tcctgattgt gatagtagtt acatgaatat tcatttaaca aaaaccataa attatagact 68640 tagaaaacag taaatgttac tgtatgtgac accttaataa acgtgattat aaaaataaat 68700 cctaagcatc taaaaaaaaa aaaaaaaaga agaagaagtg aaccagaacc acaccattct 68760 attttggaga cacttcaaaa gaaatgacct cattcttaat tttgtttaaa gaagaatata 68820 acatgatttg aatatattta gctaggatat tttagtgcct gctagcactt gaagccagag 68880 ttcactgtga gcattctgac tatgaagtga gaagctaaga gaactgtatt ttgatattcc 68940 tttgacagtt aaatcataac actgttcttc cccttcttta gccccagcat gagaccagat 69000 gtaagctctc ctccatccag ctcctcaaca gcaacaacag gaccacctcc caaactctgc 69060 ctggtgtgct ctgatgaagc ttcaggatgt cattatggag tcttaacttg tggaagctgt 69120 aaagttttct tcaaaagagc agtggaaggt agtgtgtgtt ttgaagagtt tatttttcct 69180 2013203064 09 Apr 2013 64 of 771 ctacttggtt ttcatttctc agggtggatt ttgaaatttc cattatatgc aaagcccatg 69240 aaaggctaaa tatcagttaa gaggggagag gagggtggct cctaggtcct ctaatgggca 69300 ggaaagtatt taaaacgaca atacaaaaag atctagaata aaatagaaaa gtacaagttg 69360 atgtctggga gtttggtcag ggagcataag gtaacactat aagaaagtgc tatcatatga 69420 aatgatggtg ttaagtttgg gcataacata atgttcattg tattagaaac atgggcttta 69480 acttccataa gctaataggt ttcaaagtca ccaactttac tggcctggca aaaatgagtc 69540 acagtgagaa ctgtgacagg aaaaaaaaaa gatattcatt tcatttctta ttcatttttt 69600 ttttctatta agccagggca ctgtgctaag tggtataaat accaataaga cctgatcctt 69660 accctctggg aagtcacact ccactgaagt gaaagatgag ttaacaatga caaggtacag 69720 agattataat atagatgagg gagagagaaa ctcggcctga ggaggtcagg aaaggtattt 69780 tagagaaact gatttcacta tataaatgtt gtattaacac aaatcttact ttgttatgga 69840 ttcagactgc tgacagggca acagcattat ctccctaaag aatgagaaat tcattccata 69900 gcaaatttat tagaagagag tctaaaatgt cctaatacta ccagtgactc ctctaggaaa 69960 aaaattgtca tataatttag ttatttctaa agcagtttga aagtagcttg gcctaaagct 70020 ctgattatat taatttttta aagaaacaat tattcattca ctgtatgagg attattatta 70080 tttgtctcat gttgtgtttg catatccatg agagttagat gagtcatttt cttttgtttt 70140 actttttaat acattagcaa attataaaat tactcatatt acaccacaaa gattacaagg 70200 atggcagctt tggccagtgt agtagtccca cctattgatt agagtcaaaa gtaaagccca 70260 gccctgcttt gtgcattgct cctaataaag tggatgttac ttaacacata cgcagaagac 70320 agaagcgtct tcgtgtcctc actttactcc tcactttctt aactgcttaa gtatttccac 70380 gatataaatg cagtgataat aataatacgg acagtccctg acttaacgat ttttcaactt 70440 ttatgatggt gggaaagtga tacgcattca gtatggctcc tcgacttaca atggggttgc 70500 ctccagataa acccattgtg aattgaaaat atcttacact tagcactcca ttcttaatac 70560 ctgctagaat tatagattat ccctcaaaat tggcatagta taatatgggt atcagcaagt 70620 tgttgcactt tattcagagc tttacactag gcaggggtgg gctttacttt tgactctaat 70680 caataggtgg gactactaca ctagccaaag ctggcatcct tgtggtctct gtggagtaac 70740 gtgagtagca ttataattta catcccccat aacaaatgat ccaagagagt atgtgatcaa 70800 tgcagcagaa ctattgtctt ttattatctg atttcacatg taacatgcca tcacttctgc 70860 catattttat tggccacaca gaccaatctt ggtaaaggac ggaaagggac tgcacaagac 70920 catgcattca aggaggcaga gatcactggg ggccatcttg ggaggctggc taccacaccc 70980 2013203064 09 Apr 2013 65 of 771 accataaata gaaaaccaga attatttgcc aaaaatagac tttaaccaca aaaatgaata 71040 ccatataaac aaaacaaagt cacaaaattt cagctgactt gaagactcat ctttctatta 71100 gttagaaagg gaatttacca agtagtagaa gacacaggaa ctccaaaata agatatctca 71160 ttgtcttatc agaagggttg acaggaaaat gggctgggca ctgtggctca aggaaaatgg 71220 gctgtgcact gtggctcaca cctattatcc cagcaatttg ggaggccaag atgggaggat 71280 tgcttgaggc ctggagtttg agaccagcct gagcaacata acgagacccc gtctctacag 71340 gaaaaaaaaa aaaaaaaaaa cgttatccag gcatcgcacc tgtagtctca gctactcagg 71400 aagctaaagc aggagattca ggctgcaaag agctatgaca caccactgta ctccagccta 71460 ggcaacgtag caagaacttg tctaaaaata aataaataaa tgagtcaagg aatgaatgaa 71520 tggattgaca ggaaatgact attagttgta cgtggccatg tgttatgaaa tagtgaatac 71580 tagttaaaac tcctcatttt atagataagg aacagataga tagacttgtc caacttcatg 71640 ctaataacca caaagggcta tttttaactt atgaaggtac attgcctctg atcctatagc 71700 tcagagtctt agctgtgcac aagacatacc tgggataaag aaatcaagat tggcgtaatg 71760 tgcacatcct gacatttcag ttggatataa acaaaacttt ggaatttttc atttttagca 71820 gtgggtgatt ttttttcttt ttttcttcca gtaactgtag gacagtgatt tagagattcc 71880 ttatagggta taactttttt gtattataac cacttcatca atagatgtat ctgttgatcg 71940 tacttttgat ttatagggga tagaattggg ttagtgcttc cattttctgt ccaagtaaag 72000 aagctaggat atttatagag tacaaaaaga aattgaaaca gctggtacag atatttggca 72060 ttggagagca gctctgaaca aaggtgaatt atagtctagt ggtcaatttt gtggcctgtt 72120 ctttacaaag aattgaacct gatacagtta accatctacc ccaaactatt atttgtttaa 72180 aacacaatct attggctggg cgtggtggct catgcctgta atcccagcac atcgggaggc 72240 cgaggcgggt ggatcacgag gtcctgagat cgagacaatc ctagccaaca tggtgaaacc 72300 ctgtctctac taaaaatata aaaattagcc aggcgtggtg gcgtgcacct gtaatcccag 72360 ctactcggga gtctgagcca ggagaattgc ttgaacctgg gaggcagagg ttgcagtgag 72420 gtcatgccac tacactacta cactcccagc ctgggcgaca gagcgagact ccatctcaaa 72480 aaaataaaaa taaaaaaaca taatctatca aactgtgtaa aacacagttt atcaaaaaag 72540 tagttaccct tggtgggtac tggctggaat tgggcagaaa gggggcctgt tggggtactg 72600 ttctgtttct tgatctgaga gctgattaca taaaggttct tggtttgtaa aaatttatta 72660 aatggttcac tgatttgtgt acttttttta tatgtgaata ctgcaataag gttttttatt 72720 gcactgtttt cagtttgttg aacagaaaaa gggagactct ttttgttgtt tttgacctct 72780 2013203064 09 Apr 2013 66 of 771 cgacctcata atggcaatgt aggcaagaac attccctcaa ggcaatacct gtgggtgtct 72840 tggttatatt ccaccggaaa caaagacaga ggctgtcctt ataaaatatg tttgaagacc 72900 tgtgaaactt taatagtgcc ttttattcca tataggacag cacaattacc tatgtgctgg 72960 aaggaatgat tgcatcatcg ataaaattcg aagaaaaaac tgcccagcat gccgctatcg 73020 aaaatgtctt caggctggaa tgaacctgga aggtaatata aatatctgaa agcaattgtt 73080 tgtctctgta gcttataaaa atttatcatt ttacttttga agatacacgt aagcagatgt 73140 aattaatgta gtcagttcag tatatatatg cttgactagc ataatgttac tgcccaataa 73200 aaatgggaaa tttttttcat gaatatgtca tattgtttgt ttatccacca gttcttctta 73260 cacacactga attcagtaca gccagactat atacaaagaa aggaaattat gtaataatga 73320 aacttacaca acatgcagca actttattat tcttactcct tttttcagcc tcaaaactat 73380 tccctagggt tggaaatgtt tctgtatcag acatatttac atgtccattt ttctgtttgc 73440 cttttaaaag catacctttt acttggagat ctgtgtttta ttacagatct tcaagcgggg 73500 ggtggtggga aaaaaaaaac ctcaaggaag aactggatgg gttttgtttt ggttttcaag 73560 taaagaagaa acctgggccg ggtgcagtgg ctcacgcctg taatccccga agtttgtgag 73620 aatccttctg tctagttttt atgtgaagat attacctttt ccaccgtagg cctcaaagcg 73680 ctccaaatat ccacttgcag attctataaa atgagtgttt gaaaaactgc tcaatcaaaa 73740 gaaacgttca actccatgac ctgaatgcac acaacagtga gaagtttctg agaaagtttc 73800 ttggtctccc cgcactttgg gagaccaagg caggcggatc acgaggtcaa gagatcaaga 73860 tcatcctggc taacatggtg aaaccctgtc tctgctaaaa acacaaaaat tagcggagcg 73920 tggtggtgtc acctgtagtc ccagctactc aggaggctga ggcaggagaa tcacttgaac 73980 ccgggaggca gaggttgcag tgagccgaga tcacaccact gtactccagc ttggcgacag 74040 agcaagactc cgtcttggaa aaaaaaaaaa aaaaagaaac ctgaaactag ttataagtta 74100 gagtttcata tccctgttta tataacaagt tgtataatta acactgatct cagcattaaa 74160 aaattttcct ctgaaaaaag tttggaattc tgctgtggtt gaaattgcaa gttctgtgaa 74220 ggtagtggtg atctcataac acatatgctt agtatttatt gtgaaattag cacttttatt 74280 caacaaatat gcaccaacaa ggcagtcact aggtataaaa tgaataaaat agtgcctgta 74340 ttcaagtagt ttatctgcta gttaggttgc agagtcagtc acaaaatagc gtggcacacc 74400 atagagggca tagggccaca ggaacaagag gaaggtcacc taattctgtc ttggaagtca 74460 aggaagaagt aacattgaat tttaaatcta taagctgagt aggaattaga tagatgaaaa 74520 ataagggcag agacatgatc agatttgtat tttacaaaga ctaatcttac atggagagac 74580 2013203064 09 Apr 2013 67 of 771 caattaagtg aatatggcag tcctccagat aagagatggc agtactgaga gagaatggaa 74640 accatgtggt tccttttatg attatgatga ttattattat tttagagaca gagtctaact 74700 cttgtcaccc aggctggagt gcagtgacat gaacatggct cactgcagcc ttgaactcct 74760 agactcaagc catcttccca cccagtaggg ctacggatgt acactaccat gcccagctga 74820 ttttttttta atttttgttt taattttttg tagagacaaa ggggtcttgc tatgttccca 74880 ggctggtgtc taactcctgg ccttaagtga tcctcccaac gtggcctccc aaagtgctgg 74940 tattacaggt gtgagccact gcaactgacc tatgtggttc ttttgatagg agagactaat 75000 tgttggtgct atctagcaca cactgtgtgt agacatcttg ttaaatagaa aatagattta 75060 tgggtatgac tatgaagagt ctaattcccc aaaccacaca cacaactcta tctacgtttg 75120 accaggctat ttaaacttaa ctgcagagtg tcagcatgtt aaacattgat ttacataaaa 75180 tgatagctgc ccactttctt gtaaatgtta taaaaactgc agagattaac taaaaaatgc 75240 acacagaagt ttgctttcag ttccacaagg gtagtttatt tttgttataa aaacagtatt 75300 ccccactttc ttagatacca gatctctgcc cagattttac ccagtttcat cttgctgctc 75360 tctaatctcc tatgtatgta atatactttg accatttaaa tatgtattaa gacacttgag 75420 tttttagtgc cctttggttt attttctccg gtcccaatta tctctaatct tcattttttc 75480 attttaccta ttttatattt cgaaataggt tttgaatgaa gctcaaagga caaacccaaa 75540 taaaattctg tcgtatctct aatatattgt ggttgcttac ccagtaacat ttttaggtgc 75600 ttttctgaat acatataaag tttaagatct ttggagtttt aagtatataa tgtttttctg 75660 ggcaatttct ccctatccaa actatgaggg ccttctttca tcaaaagaaa aaagatatat 75720 caactacaaa gtaatgattt tgatggacta ggctacgaaa tctgtccatt ttttcctcct 75780 tcttacagtt taatagcaat tgcagtgccc tttgccctta ctgtactaga agacgacccc 75840 aggcagtgac tgacatctga tttttctatt aattatacca tcactgccat ttccagttga 75900 atcttttgtt ggacatcaga aatttttctt acatgaataa aatttaagca tacggttggg 75960 cgcggtggct catgcctgta atcccagcac tttgggaggc ctaggcaggt ggatcacgag 76020 gtcaggagat cgagactatc ctggctaaca cggtgaaacc ccgtctctac taaaaataca 76080 aaaaattagc caggcgtggt ggcgggcgcc tgtagtccca gctactcggg aggctgaggc 76140 aggagaatgg catcagccca ggagttggag cttgcagtga gccaagatcg cgccactgca 76200 ctccagcctg ggcgacagag cgagactccg tctcaaaaaa aaaaaaaaaa aaaaaaaaaa 76260 aaaaaaaaaa atttaagcat acaatttagg ctgcagtttc tcaaaatatt gtattaaaaa 76320 taaccaatta tatgctttta tagtcagtat aacgtatcca gttagtgtag aaattggcat 76380 2013203064 09 Apr 2013 68 of 771 ttgttgaaaa ctactacatg ttagtctttg atatacattc ttctactttt tggaccctga 76440 ttattaaaaa cacctttgaa tagggccatg atttacttta tatccatttt tatactacat 76500 agtggaagaa aattctgatt tgttatttcc tactatgata tgtaccgtgt ggcacatatc 76560 atataaatga tccaattcta cttgtagatg aattgaaaga aaggcttaaa aaagttctta 76620 gggtttgtgt gtgtggtttc actgtaaaac tatcattttt gtattgaact aacctcagta 76680 tacataaaat ctttatttgg cctggtatgt acgtatgcca ggaatctttg gcagacccta 76740 acacttacaa tacagatgag ccatgtgttt cacacttttt ttttaacaac cttcagaaat 76800 attctcttgt tcatcagagt gcttccccta agccaagcag tttcgatgat agccccagaa 76860 taactttgcc caagtctctc cataaatgta acttaggact ccaagtggtg tatttttata 76920 ctcttgcccc ataccaagta aatctcaaga tttattttaa gggagtggcc ttcactgctt 76980 aaagggccta gcatttaaga acagataaga tttttaatgg tgatcctaaa tgtttttttt 77040 taaaaaactt gcttgttttt ctcttgaaac taaatgtttt tattcacttc attttaagat 77100 atattgtaat caatccaaag tatggcttta tttttagtat aaacagtcaa atgaagctta 77160 gtcttgtggc attgtcagat ttataaccaa atattactga aactaatttt tttaagttca 77220 aaaacccaat ctagtagttt ctctcttatt ttcaactttt attttagatt ctaggggtac 77280 atgtacaggt ttgttactaa gatacattgt gtgatgccgg tgtttggagt atgattgaac 77340 ctttcatcta ggaagtaagc acagtaccta acaggtgctt tttaacctgt gcctcccttc 77400 ctctatcccc cctcttgtat ttcccagtgt ctgttcccat ctttatgtct atgtgtactc 77460 aatgtttagc tcccatttat aaatgagaac atggtatttg tttttctgca ttagttcatg 77520 taggatactg gccgcctgct acatccatgt tgctgcaaag gacgtgattt cattcttttt 77580 gtggccacat agtattccat ggcatataaa taccacattt tctttatcca gtccactgtt 77640 gatgggcacc tgggttggtt ccatgtcttt gctattgcaa accatgctgc agtgaacata 77700 tgggtacatg tgtctttttg atagaatgat ttatttttct ttgggtatat tcccagcaat 77760 aggattgcta ggttgaatgg tagttaaact cttaattctt tgaagaatct ccaaacttct 77820 ttccacagtg gtgtcattgt ggttttgact tgcatttctc tgatgattaa caatcagcat 77880 ttttccatat gtttgttggc cacacgtatg tctttttttg agaagtgtct gttcatgtcc 77940 tttgcccatt tttaatgggg ttgtttttgc ttgttaattt aagttccata taaactctgg 78000 atattagggc tttgtcagat gcatagtttg caaatatttt ctcccattct gtagattgtg 78060 atagtttctc ttgatttgca gaaactcttt agttaggtcc cattgtcaat ttttgttttt 78120 gttgcagttt cttttgggga ttagtcataa attctttccc aaggccaatg tcgagaaggt 78180 2013203064 09 Apr 2013 69 of 771 tatttcctag gttttcttct aggattttca tagtttgagg tcttacattt acatctttaa 78240 tccaccttac taatttttat atggcagtag gtaggggtcc agtttcattc ttctgcacat 78300 ggatagccag ttatcccagc accattaatg gaatagggag tcttttccct atggcttatt 78360 tttatcaact ttgtgtagat tacatggctg taggtgtgtg tctttatttc tggactctat 78420 tctgtaccat tgtgtgtggt ttttttttac cagtaccatg ctgtttcggt tactatagcc 78480 tgtagtatag tttgatttgg ggtaatgtga tgttgccaac tttgttcttt ttgcttagga 78540 ttgctttggc tatttggggc attttttggt tccataggaa ttttagaatg ctttttgcta 78600 attctgtgaa aaatgacatt gtagtttgat aggaatagtg ttgaatctat aaattgcttt 78660 gggtagtatg accattttaa ctatactgat tctaccagtc catgagcatg gaatgttatt 78720 ccatttgttt gtgtcatctt tgatttcttt cagcagtgtt ttgtagttct ccttgtaaaa 78780 attttaaact aacttagatg cattcctagg tattttactc tttttgtgac tgttacaaat 78840 gggattgcat tcttgatttg gctctcagct tgaacattac tggtgtatag aaatgctact 78900 gatttttgta cattgatttt aaatcctgaa cctttaccaa agttgtttat cagctccagg 78960 agccttttgg cagagtcttc agggttttct aggtatagaa tcataagtga aaagagatcg 79020 tttgattatt tattttccta tttggaagcc ttttatctct ttctcttacc tgattgttct 79080 gactaggatt tccagtacta tgttaaattg gaatggtgac attgggcatc cttgtcttat 79140 tgcattaagg ggaatgcttc cagcttttgc ccatttggta tgatgttggc tgttggtttg 79200 tcatacaggg ctctttatta ctttgaggta tgttccttca atacctagtt tggtgaaggt 79260 ttttatcatg aagagatgct ggattttatc gcaacttttt ctgcatctat tgagatgatc 79320 attatttttt ttgttatgtg gtgaatcaca tttattgatt tgcatatgtt gaacgagcct 79380 tgcatcccag aaataaagcc tacttgattg tggtgaatta actttttgat gtgcagctgg 79440 attcagtttg ctagtgtttt gttgaagatt tttgtatctg tgttcatcag ggatattggc 79500 ctgtagtttt gttgttgttg ttgtttctct accaggtttt ggtattagaa tgatgtttcc 79560 cttgtagaat aagttaggga tgaggccctc tttctagatt gcttttttag aatagtttta 79620 gtaggattag taccagctct tctttgtata tctggtagaa tttggctgtg aatccatctg 79680 gtcaagggct ttttttaatt ggtaggtttt ttattattga ttcaatttca gaactcgtta 79740 ttggtctgtt cagaatttca gtttcttcct ggttcaatct aggcaggttg tgtgtttcca 79800 tttccacata catacttact ccaaataatg gctttatata tacgggggtc agctgaaaac 79860 aaaaatgata ctttcatagt aaactccacc cgccccccca cccacataca cacacacata 79920 aaccctagat tttttaaagc ctttgttcca atttatccat ttcctctaga ttgtctactt 79980 2013203064 09 Apr 2013 70 of 771 tgtgtgcata gaggtgcttg taatagtgtg aagatctttt tcacttctgt ggaatctctt 80040 gtaatgtcat cttttacatt ttttattgtg cttatttggg tcttcactct ttttttcttt 80100 gttaatcttg ctagtggtct atcaatcttg tttatccttt caagtaacca acttttataa 80160 actaggtttt aagctaatta agatttctct actttcatta agaaggaagt agtgttacca 80220 cagactcatg aacacttctg tggagctcct gtattgactg ctaatcaact atatgctcca 80280 atgggtcagg aatttatata aagttgtatt aactaagttg ctttaaaata gtgattgctt 80340 aactaaatga ttcagttcag ttaactcctt cctgaagata ttttgaaaaa ttaattagta 80400 ttatttcttg ctctagtcag tacagcacag ttgggttcaa ttgtactttc tgagctgtat 80460 tgaaaaacat cagttttctc atttagaact atatataagt agtgagaaat taattacaaa 80520 ctgagtcata gaaaatgttt ttttttaatc ctccagcttg ttactctttc ttccttgttc 80580 taatgtggag taaagaaata tgcattccaa accatttaaa gttatgacta attgaggctg 80640 tcaaagtact gtttcagtgt attgatttgg cacatgtgtg ttctctttta cattgtcaac 80700 aaaagtacat tttatgattt tggatcaaga tttcactgag atacttctgg ttgtttaaag 80760 agtttcttta tgtattggtg tctttccttt ttaaaatttt atcactcctc tattaagttg 80820 tgatatccaa atttaaaata ttctaaaaac atgttctcct gcaagttgag gtaatgatag 80880 ttgttatgtg gtacttacta taatatatgc caggaactgt tctaagcatt ttacatattt 80940 aattctcaca acaaccctat gaggtaggga ctaatattgt cctcatttta cagaagggga 81000 aatgaagagt cagggagtaa cttgcacaga tatccagcta caacatggca gaaccaggac 81060 ttaaatccaa atatgctgat ttcaggtttc tgccctttag tcctatatca tactgtgcct 81120 ccaagagagc atggtaaact aattagcatg gttctatcat gattctgttt ctattttgaa 81180 ctattaataa aaatttttgc aattctcagt taccccattt agtatagaac acaataagaa 81240 tggaaccatt ctattctaac attgtacatt gagatatcgt tcccaccacc atatctgtcc 81300 tccatagact atatggtgtg tcattttaag gacagaggat ctaaaaatga tttttaaagg 81360 tgatttacat ttactcttcc ctttgcaaaa tggtttgcat ccctaataat ttagacaagt 81420 acatttcttc gtgatataaa ttacatttct tgcctttccc tggaattctg agtactttcc 81480 ctctgagaga acaatgtaat tcttatttat ttagtcacta aaataacttc aggagtatga 81540 ataagtctac taaaaagtct acaggatcca tgttgtagtt tgagtagatg gttccatacc 81600 aagtcaaggt aaaagataat ttatatataa tatgaaaatg gctgctttag gtttatagag 81660 taatcaatat aaatcttcct tataaaaggg aaatttccca cttataattt atgtaatgta 81720 aagtttttca tttcatcttc ccaaatgttt ttagtcccac gcagtattta tgttagtacc 81780 2013203064 09 Apr 2013 71 of 771 tatgtaaagg tgaaaagtga attttttcta ctggtagaac taatactatt tttagcatgt 81840 aatctgctgt catcttccta tctttataag tggctttgaa caagtgtaaa tagtgtaatt 81900 ctcttcatta tatatactac catgatttag attaatctta aaccacagtt tgtaatccgt 81960 tactccaagc ttagattttt ttttcagttt atagtaagag taatttgcct tatataacca 82020 atgaaattgt tgcatttaga gtgaaagtga gataaaaaaa taatttatag aagaatttac 82080 aaaagttatt tactcagatt gttttaacat accgttataa tactttgtat aaggaataac 82140 tctaatgaag tttctggcct atttgtaggc aaaattaatt gggaataggt tcctctggat 82200 cttttgcttt cagaaaaaaa aaagtttttt ctccttttcc atgtcacttt atcataattg 82260 ctaaataaaa tatttctccc atcttaatag ttttagaaag taaaaatact tcttgaataa 82320 actgtgtagc gcagaccttc ccattacagt tcatttctat gtattttttt aaatacccac 82380 agctcgaaaa acaaagaaaa aaataaaagg aattcagcag gccactacag gagtctcaca 82440 agaaacctct gaaaatcctg gtaacaaaac aatagttcct gcaacgttac cacaactcac 82500 ccctaccctg gtgtcactgt tggaggttat tgaacctgaa gtgttatatg caggatatga 82560 tagctctgtt ccagactcaa cttggaggat catgactacg ctcaacatgt taggagggcg 82620 gcaagtgatt gcagcagtga aatgggcaaa ggcaatacca ggtaagatgc aaaacataaa 82680 agagcaacta tataaacctt tgtgttttct tcagcaaaaa cactttggct tttatatcat 82740 cgtgagccca tggcttatct tgtttctctt agttctgggg actatgaagg ggagagtcag 82800 gtgaatacag gtgataggga gtttataata aaacatttac attactccct gcttttcaaa 82860 tcattatgca caggatggta atttcacata ggatgatgta atatcagaat tcaagttaca 82920 agactcactc aaaactcctt ttacactgaa gtttggggaa agaaaatgtt tttagttaat 82980 tccatttgtt ttccttcatt gtgccacttt taaaaatcag gttgtttgta agattggtaa 83040 acatcaagta tgttgattgt caaaatttgt actaaagtag aatgatttta acccttcact 83100 aaatgaaatg ctacacattg aatgtaattt taaagataat tttaaataaa agttacccta 83160 ttggaatttg gtgtggaatg gcagaggtca atgttagtgt cagctctgac tttaaagaca 83220 gggaattgac aagcctgtgt tcacgcaaat agttagggag agagcaagaa agtaacctga 83280 cctcctgtca tccttgtttt attaaggggg aaagaggtgt gaatagcagg gcaaatgttt 83340 tgcttaactc attgattaat acctcaagcc aagattcttt tctgtttttt aaaatcaata 83400 cataatagtt gtacatattt actgtacata tttatattta gggggtacat gtaataattt 83460 aataaaagca tacaacgtgt aaggatcaaa tcagagtaac tgggatatcc atcacctcaa 83520 acatttgttt ggggaacatt ccaaatcttc tcttttagct attttgaaat ataaagtaaa 83580 2013203064 09 Apr 2013 72 of 771 ttattgttaa ctatagtcat cctgttgtgc tactgaacac taaaacttat ttcttctaac 83640 tgtatttttg cacccgtcaa ccattcccgc ttcatcccca tcaccactat ctttcccggt 83700 cactggtaac cgccaagcca agaattttgg ctattttact atttagttca tgtttactta 83760 agcagacaga ggtgacaaaa ctggcttttt ttttttttac attaaaagct attaaaaagc 83820 acctaggggg ctgggtgcga tggctcacgc ctgtaatccc agcacttggg aagcccaggt 83880 gggtggatca gttgaggtca ggagttcgag accagcctgg ccagcatagc aaaaccccat 83940 ctctactaaa attacaaaaa ttagccgggc atggtggtat gaatctgtat tcctagctac 84000 ttgggaggct ggcactgaga atcacttgaa cccgggaggc ggaggttgca gtgagccgag 84060 atggcaccat tgcactccag cctgggtgac agagcaagac tttgtctcaa ttaaaaaaaa 84120 aaaaaaaaaa aaaaaacaca agagggtttg tgagtcttaa agtgtcagat gacagaagaa 84180 aactgtgtct acctagtatt taatttccat tttctgttag gggtgccctt gttttgacag 84240 ggctaattga tctcattgct ccttggcaat tcccacagag atgatcttct gaagagtgtt 84300 gcctcatacc tttatttctc ttaattcagg tttcaggaac ttacatctgg atgaccaaat 84360 gaccctactg cagtactcct ggatgtttct tatggcattt gctctggggt ggagatcata 84420 tagacaatca agtgcaaacc tgctgtgttt tgctcctgat ctgattatta atgagtaagt 84480 tgtatgtgtg tcattttccc tgtattcata gggtatcttt aaccagctga tgttttcctg 84540 attgactgct attgtgataa ttcaggactg aaacaatcct actaggtatc taggatctag 84600 gcaaactgga aatagagtta tgagtgcttg gggcaggaca agtgtaatgt aaagcaaatg 84660 tacatgtggc attattactg tcccaggaca tgtttgagga tatttaacag catatctgag 84720 gttagtaaag tctgtcgcaa gcaacaagga atcttactgt gatatcattt acataaccct 84780 attccagaaa gaaaaaggag catggtaaaa ctcatgtgga ttcagtgggg acaattgtag 84840 atgaggatat ctaggctgat ggggtgggac atatggaccc agacacaaga ggtatctctt 84900 tgcatggcaa ggctcaccca gtgtctgtgg tttaagaata tgggaacaaa tttgttttgt 84960 ttaactgaga gaagaccaag cctttaagat tttataaatc agctattctc ttatcctcta 85020 agcttattcc tgtgtctgcg aaatacttca ggtgtccatt tccccttacc tcattgcagt 85080 tgtttcctca ctcgttttct ccctccagtg taacgttcat catgttggct aatgtttgct 85140 tcctcaagca cagtctgact gcatcacata tctccccagt acacagattg tcttcagtat 85200 cttcccactg accctccagt acatattctg catgatttca gactttccag aatctgacct 85260 cacttcctct cccattgttt tccttcacac actcttcatt cccatccatc ctttccagca 85320 tactcttaga ctcttggtgt tcacatcacc agatacacag cagagaagtc acatcctagt 85380 2013203064 09 Apr 2013 73 of 771 tactctcact ttctaccttg tattactact tttcgtaccc ctagcttatt gctattagta 85440 caatgtaaac agggagttca cacacacata cccctggtct aagaagaata aaaaatgaag 85500 gagatttctg tttgtataga aaacagaagt caccttgact tttattgcca aaaagaggac 85560 tgttcaaact actgcatcac aatgtaacaa gattaggtag ttggatccaa ttttaaatta 85620 actggtaaat atatttagtt tctggggaaa ctgaagacat tattactcat cataatccta 85680 ccatgctgtt taaaaaatac catgttggca gtatttgttt tttagtcact ttctaatatg 85740 taatttgaag gcatttaagt ggaattaaaa gcataaacag atttgtatga aacaccaact 85800 tatcctggtt tataaaacta acctaattta gggtttttat tattagggca ttcagattta 85860 gctttaagca gtcacagcaa aatctaatca tgccacatac attccttaca taaagtggga 85920 tttataattt tttttcctca acagatttac attagtttca ttttcattaa gggatatgta 85980 cttcctattc ttgtgttctc atgctgctgc ctaaaagatg ggcagtcctc cacctttttc 86040 ttttcttttt tttttttttt tttttttgag acgagtctta ctctgtcacc caggctcaag 86100 tgcagtggtg tgatcttggc tcatggcaac ctctgcctcc agggttcaag tgattctctg 86160 cctcagcctc ccgaatagct gggattacag gcgcactcca ccacacttgg ctaatttttt 86220 gtatttttag tagagacggg gttttgccat attggccagg ctggtcttga actcctgacc 86280 tcaagtgatc cacccacttt ggcatcccaa agtgctggga ttacaggtgt gagccaccgc 86340 acccagccct ccaccctttt ttcttagccc actatgtttc catactgctc tggtgtctgt 86400 gacaggcaga tattgcatat cagaaagtat gcattcaagt tctgaccctc tatagagctg 86460 tcaaacagtc tctcatggtt gcccttaggt cagaacgttg tgggggaaaa aaaaattgtt 86520 gtttttacag ccaacaagaa tgagttttta cttattctac tacactataa ctttgttgaa 86580 attttcagtt atatgagtat aaccatgtac aagaaactaa aggaaaaaaa ggtgcctccc 86640 agaaaaggag tgctttacct actattaagg actagggagg tgcctcttcg gtaagagcag 86700 attttaaatt tgaagagcct ctgatcactt tggcagcata taagtcatgt ctaatttatt 86760 ttatataaag gaataaacca catattcagt agagaaaaat aataaccttt ctgttgttaa 86820 gtccaagacg actttctgtc agaaacttaa aaaaaaaaaa aaatcttgaa gcattttaaa 86880 agctgtgaac tgggcccagt ttcaggctct tagtgtcatt tcacaagtca ggaaacttta 86940 gagacctatt tgaaaatcat aggtatgtaa tgacttcaga atcataagca agaattggtt 87000 tagtaccttt agtttaaaga atattaaggc atatgcctgt cagaggcaga ttttgagcat 87060 cagaagtcta gaatcaagtt ctaggtctcg ccctctgcat aactgtgaac agtgtcacac 87120 atttttgtct ttaggatgga ctgctgtgaa aaaatttacc tttaaaaatc aagtgtgtag 87180 2013203064 09 Apr 2013 74 of 771 gacctaaaac tgtcgtctaa ttgaccgtat tcaaatgata aaccttgatt taaatgagca 87240 actagtaata agttctataa gaattctaac actttaatta aataataaaa taatacatgg 87300 catgcatgat agaaaataat atctccactg ttacattaga ttattcatta gtctatttaa 87360 acagccaaga tgcaggaagt ttaaggaaag ttctccaaaa ttctgatttt atagggaatt 87420 agcaataata ttattgcagt agttgttttt ctttatgagt tcatagtttt gcaaaacaaa 87480 acaaaaatgt gctttttggg gggaagtagc agtatttcta actaataccc tgctatttat 87540 ctttcacagg cagagaatga ctctaccctg catgtacgac caatgtaaac acatgctgta 87600 tgtttcctct gagttacaca ggcttcaggt atcttatgaa gagtatctct gtatgaaaac 87660 cttactgctt ctctcttcag gttggtagaa caccttttca ccttatgtca aaagcatgaa 87720 atatgaaggc ctagaaacaa aggttaattt atatacatag tactaataat tataccaagt 87780 ctactattat ttcctactag tcagatgatt tttatgaatg taaaatatta gaaaggcaca 87840 gtaagtgaca ccaagattaa taagacaaat aggtatggca gaaacagaga ggtatatgag 87900 ctgcataggg atctctgttg ataagaatct gtgtagactt ttttctcctt ccttcctttg 87960 atctttgatc atgggaagac atggaaaaag aaagctaact acagtgattt tgtctactac 88020 actgttattt ggttaaaaat tttagtttcc taatgagtat tagcatgtat gagaaattat 88080 gggagaaaaa ggcgcatcct agaaaaggtg tgcttaatta ctattgggga ttggttaaca 88140 tagcatggga gctggattgt cagagattca ttatctagaa aatggcaaca agagtttata 88200 aaacgaactt ctgtgagatt actttttagc tagcaaagac aaagatgtcc ttcagtaggt 88260 gaagtgataa actatgatac atccagatga tggaatacta ttgaggacta aaaagaaata 88320 agctgtcaag ccatgaaaac acatggaggg acgttaaatg catattacta agtgaaaaaa 88380 gctaatctga aagggctaca tactgtgtga ttctaactat ataacattcc ataaaaggca 88440 aaactgtgaa gacagcaaaa aaaaatcagc ggttgccagg gtttagaagg aagggaggga 88500 taaatgtgca gagcacagag gatttttagg gcagtgaaaa tacttcgtat gatactacaa 88560 tggtggaaac atgtcattat acatttatcc aaacccaaag aatgtccacc accaagagtg 88620 aaccctcaac tatggacttt gggtgatgat gtgtgggaca ggaggtatat gaaaaatctc 88680 tgtaccttcc tcccaatttt gctgtgaact taaaactgct ctaaaaaaag tcttttttaa 88740 aaaaagctct atgaactagt tggtattata aaccttaggc catttcaagt aaaaattaca 88800 tatcaatgtt tattaaatac tgagttaata gctgaatacc tctttcatat acaaataagt 88860 acatttgcaa ttttttaaaa agtcttaatt ccattagtaa ctgtggtttc atagttgcca 88920 aataactgta agctatggat gttgcacaag actgtgattt tatttaatca tttcatatct 88980 2013203064 09 Apr 2013 75 of 771 atttaaacat ttccaaagcg cacattcatc ttaatgtttt cacactattt ttgctcaaca 89040 aaaagttatt ttatgttaat ggatataaga agtattaata atatttcagt caaggcaaga 89100 gaacccgata aagatcattg ctagagacgt ttaatgttac ctgtagcggt acacttgtta 89160 aagaagtgat taagcagtta cataaaattc tgatcatagc tttgattgat accatgaagg 89220 tataattcag tgcctggata ctaacaactt tacttgttta aaaaaaaaaa aaaaagaatg 89280 gtttcaattg tatacatccc agactaattg agctatatga tttttttcat tgtaaataat 89340 atcacgagtt cttcttgtta aaaaataata gaatcataag gatggaaata tataccttaa 89400 gatatagact tctactatga tagactactg gaataggtat ataacctccc accaaaaatg 89460 ctagactaaa aaaattaaga actaagtgaa ggcaggaacc tacagagata agtggaactc 89520 aagccaactt gctctttgac ggcatttgta gaacctggta aattagtaag tttagtaagt 89580 tggggttttt ttaagtttat aatctttttt aaaatgattt caataggttt ttggggaaca 89640 ggtagtggta ggttacatga ataagttctt tagtggtgat ttctgggatt ttggtgcacc 89700 catcacccga gcagtgtaca ctgtacccaa tgtgtagtct ttcatccctc atcccctccc 89760 caaccctagt ccacaaagtc cataatatca ttctcatgcc tttgcatctt catagtttag 89820 ctcccactta gaagtgagaa catgcaatat ttggtttccc attcctgggt tacttcactt 89880 acaataatgg tttccagttc catccaggtt gctgcaaatg ccattatttt gttccttttt 89940 gtggctgagt agtattccat ggtatatata taccacattt tctttatcca ctcgttgatt 90000 gatgggcatt tggactggtt ctgtatattt agtaagttta aaaacaaggg atggaaatat 90060 aaatgcagtt gaaaaggcag tggatggatc taaaagcaga agaatacaat tgtttttaat 90120 gattgtgtat atgtttgtgt atataaacca caagggaaat ctgtaggtac tgaaaatcac 90180 aacaggaaaa tggcaacaaa gctatagaaa ctggaaaagc aatgactttt cttagatccc 90240 tcagagaatg gaggtcatag gacaaaccac cacttcaaaa tctagaagaa tagacaaata 90300 cagagaaaca gccaagatca gcttactggg aaaagatgcc actgaagcca ggaagactat 90360 ggcaatttgg gaaaagatgc cactgaagtc aggaagacta tggcaatttt gatgaattgc 90420 tggaggctga gtgaggacta gcttcagagt taaaaactcc cagggaccca gtcttagtgg 90480 gggtttcctg caatttcttg ggtttacccc acaaaatttc taacttccag aaactccaca 90540 aggttcttat ggtgaagatg caagaaaaat tccctccttt ttctggtagg agtagaggga 90600 aggtaaaatt tggaaatacg tagcagagtg ttcacaacaa aaggcctgcc ctgtaaggaa 90660 aactaattca acaggccctt atgtgacctg ggggaaaggc aaatagagga ttctagccct 90720 tccttagcct tcttgtctca tttctgaaag tcacagccca gggattcaga cccactaaaa 90780 2013203064 09 Apr 2013 76 of 771 aaaactgaga tttaatcata aagattaaaa aacaattccc ctccccctcc ccaacacctt 90840 accaccatat aaacagggct ccaggataaa ataacagtgg attacaactg agagagctgc 90900 aagacacaag ctgtttaagg agctcttagg aaacccaaaa acaacagaag aaaaagtaaa 90960 taaaaacaag gaaactagag gaaactgaag cctccagtac ctacaattat ggcaaacatt 91020 aaatacagcc cagctcctag ccagattagc atgaaacctc acactaaaag tctaattact 91080 tcagttttga tatatcaatc atgtccagct ttcagcaaaa aaactacaag gcatgctaaa 91140 aggcaagaaa aacccacggt ctgaagagac aaaacaagca tcagaagcag tcctcagata 91200 tgacacaaat atttcaatta tcagataggg aatttacaat acctatgatt agtaggttaa 91260 aggctccaat ggaaaaaagt agacaacatg caagaagtga tgtacgcaga gagatggaaa 91320 ctctaaaaat aaatgctaag gaatgctgta aggaaatgca gaatgatgtt gatgggctca 91380 tcagtagact gagcacagcc aagcaaagag tcagtgagct tgaagataga taggtcaaag 91440 gaaattcccc caaactcaaa tgcaatataa acatagtaga cattaatcca gctgtatcag 91500 taattacttt aaatttgaat gctctaagta caccaatcag ctattttttt aactaggagg 91560 tgaaaataaa gtttgccacc agatgctcac taaaaaatta ttagaggata tacttaggct 91620 aaagaaaagt aatcccagcc aggcgtggtg gctcacaccg gtaatcccaa cactttggga 91680 ggctgaggca ggcagatcac agagtcaaga gatcaagacc atcctggctt acgtggtaaa 91740 accccatctc tactagaaat acaaaactta gctgggggtg gtggtgcgcg cctgtagtcc 91800 cagctactca ggaggctgag gcaggagaat cacttgaacc tgggacgtag aggttgcaga 91860 gagccaagat agcaccactg cactccagcc tagtgacaga gggagactcc atcttagaaa 91920 aaaaataata aaagtaatcc catctttaag aaggactgaa gaataacaaa agtggtaaat 91980 aatatagata catttaaact gacatttact atgtatataa aataacaaca gtaacaattt 92040 ccttgagggc taaaaagtag aactaaagta agtttcaagg atgacaacta gaaatagggt 92100 atgcagggta tgcaaagtac caaaccattg ggggaagaga atacctaaga aaaacaatcc 92160 aaaagaatga aagacatgag aggagggaga aaaaaatgca taaacaaggg catgataaca 92220 ggaagtaaca gataaggtac attagtacag ctaaattcaa acacatcagt agtttagttt 92280 cattaaatat agagatgggg ccaggtgtag tggctcacac ctataatccc agcactttgg 92340 gaggctgtgg gcagatcact tgaggtcagg agttcgagac cagcctgacc aacatggcga 92400 aaccccgact ctactacaac tataaaaagc cgggtgtggt ggtgcatgcc tgttatccta 92460 gctactcggg aggctgaggc acaagaatca tttgaacctg ggagatggag gttgcagtga 92520 gccaagatcg tgccactctt ctccaaactg ggtgacagag ggacactgtc tcaaaaataa 92580 2013203064 09 Apr 2013 77 of 771 aataaatgta gagatggact gaatgctcca agctaatctg acaggatttt agaaataatc 92640 caaatttatg ctatttaaaa aaagctatat ctgaataaag atattgaaag gctgaagtaa 92700 aaggatctac tttgcatagt ataacccaag acatggccaa ctttttctgt aaagggccag 92760 atggtaaatg ttgttagctt tgcacagtct ctgtcacagc tactaaactc tgcccttgtg 92820 gcaggaacat agtcattgac ggtactcaaa tagaacaggc atggctgtgt tccaataaaa 92880 ctttatttac aaatacaggc tgcaagtagg atttggccca taggccaaag tttgctggcc 92940 cctatattga ccaaaacaaa accgaaggag ctacattatt accaagcaaa atagatgtta 93000 aggcaaaata ctccttaaag catttgttca ggaaaaataa ttgtaaatat atagtttcaa 93060 attacataat acaaaaattc atagaacaag aatacttaga taaatctagt aaaaataatg 93120 agattttact atacctttct tacaaattaa gcagacaaaa aaataaggat atggatgtac 93180 atttcatctc tcttgggtca atactgaggt gtgagatcac tgggacatag gttgagtgtg 93240 tgtttaaatt tatttttaaa attgccaaac ttttccgcaa ttgttaacat ttaccagaaa 93300 tgtatgagac ttcttaagat ccattctata tcctcctcag tacttggtac tgtcagcctc 93360 tttcatcgta ggtatactga tgattaaaaa tattaagcat cttttcatgg gcttattggc 93420 cacctatatt tcttatttgg tattgtgcct cttttaatct tttgcccatt ttttaactgg 93480 gttttaagaa ttgttcaaat attctcaatg tggccctttg ttaaatatat gttttgcatg 93540 ttttctttaa gtggattaca tttacagttt tcttaaaaaa atgtagagat gagcaaaagt 93600 gtataatttt gaagaaagct tcgtgtcttt gtttactaag aaagttttgc ttaatccagg 93660 gttaaaaaga ttttctacta tttgttttct tatagaaatt ctgtagtttc agctcacatg 93720 cttaagtata tgatgcaagg taagggacaa ggttcatttt cttccccaaa atccatatct 93780 ggttgctcca gaacttgact ctcttttccc tattgagtta cttggcaatt ttgtagaaaa 93840 tcagttgttt gtatatgtgt gggtctactt tcagactctt tttcttaccc aacgatctgt 93900 atttcttacc caatgatctg tatgcctata ttcatattga taacaccctg tcttgattac 93960 tgttgcatta cagtaaatct tgaaatttgg taatatgaat tctccaaatc tgttgttctt 94020 ttccaaactg ttgttttgga tattctagtt tccttgcatt tccacttcct tttttttttt 94080 tttttttgag atggagtctc actattgttg cccaggctgg agtgcagtgg catgatcttg 94140 gctcatcgca gcctcagcct ccccagcagt gggattgcag gcacccacca tcatgcttgg 94200 ctaatttttg tatttttagt agagacgggg tttcgccatg ttggccaggc tggtctcaaa 94260 ccctgacctc aggtgatcca cccacctcgg cctcccaaag tgctgggatt acaggcatga 94320 gccactgtgc ctggtcttcc acgtattttt taattagctt gacaatctct accaaaaagt 94380 2013203064 09 Apr 2013 78 of 771 cttttggggc tgggtgtggt agttcatgcc tgtaattcca ccactttgag aggccaaggc 94440 aggcagatcg cttaagccca ggagtttgag accagcctgg gcaaaatgtc gaaaccctgt 94500 cactacacaa aatagaaaaa attagccagg catggtagct tgtgcctgta gtcccagcta 94560 cccaggaggc tgaggaggga ggtcaaggct gcagtgagcc atgatcatgc cagtgcactc 94620 tagcctgggc aacagagtga gactctgtct caaaaacaca gtctgataga atttttatta 94680 ggatagcctt gaatctatag atccatttga aaataattaa catcttaaat ttccaatttc 94740 tggccgggcg ctatggctca cgcctgtaat tccagcacgt tgggaggccg aggtgggcag 94800 atcatcaagt caggagttcg agaccagcct gaccaacatg gtgaaaccct gtctctacta 94860 aaaatacaaa aaaattagcc aggcgtggtg gcacatgcct gtagtcccag ctactcagga 94920 ggctgaggca ggagaatcgc ttgaatctgg gaggcagagg ttgcagtaag ccgagattgt 94980 gccactgtac tccagcctgg gcaacagagt gaggctccgt ctccaaaaaa aaaaaaaaaa 95040 attccagttg ttgagaaaga ataggaattc cagctttgga ggagtgggga gaccatcaaa 95100 tcctctttcc aaaaatacta ctaaaatact actgagcaga gtatagttcc acaaatagtc 95160 ttctgtaaag agactcacag tacatatttg tctttgtagg ccatatagtc cctgttgcaa 95220 tttctcaatt ctacagctat aacaggaaag cagctatata cagtatgtga atgcttgtgt 95280 tctaatacaa atttatttgc aaaatcagga aaatggcttg aaatggttta agatctagtt 95340 ttctgactag atcatggtat ataatctttt ccatatatat tttgaatttg gtttgctaat 95400 attttgctga tcatttttat atctctcttt atgaaggatg ctgatctaca actttctttt 95460 cttgtgatat ctttttctgg ctttgctacc agggtagtac tagcctctta aaatgagttg 95520 agaagtattt tctgttttct taaagagttt atagagtatt gatcttattt attctttaaa 95580 tatttgatac atgttaccag tgaagccatc tgggtctgtg ttttctttca gggaagattt 95640 ttaattattt gcttatttgt tatatagatc tattcagaat ttatattttt ccttgacata 95700 gttttgtaat ttgtgtgttt ctatgaaatg agccattttg tctgagttgt ctaacttggg 95760 cataaagttg tttgtaatcc tttaagtttt gtaggatcca tagaggtgtc ccctccatta 95820 tagattttca taatttgtgc ctgatcatct ttttttcatg gtcagtctag ttaaaaattt 95880 atcaattttg ttggtcttta caaagaacca atttttagtt tcattgaaat ttttagtttc 95940 attgattttc tctttttgtt tcctatgtca ttgattatta tttcttcttt tctgcttgct 96000 tttcatttaa tttgttcctc tttttctagt ttaaggtaga agcttccatt gttagttgaa 96060 gaccttattt tcttatatag atgtttaaag ctatacattt tttgtatatt ttcattcatt 96120 tcattttcta atgtccttca tgattttttt cattgaccca tgtgtattgc ttaattttta 96180 2013203064 09 Apr 2013 79 of 771 tatatttggg gattttccat atctcttcct attcatttct aatttaattc cactgaggta 96240 ggaggtacat tgaaggactc taatattgaa tgactccaat aagtcttctg agactttttt 96300 aggcacttgc atatggtcta tcctgagtgt tccatgagtg cttgaaaaaa aacttactgt 96360 gctcttgtta agtagagttt tatgaacgtc agttaggtca agttgattga tagactaatt 96420 caagttttct gtatctttgc tgattttctg tctagttgtt ctagatccta caactttgtc 96480 tacatccttg ccagagcttg gtatggtttt tttattatcg ctatcctaga gagtatgtag 96540 ttgacccttg tgacttgcca tgcatttaat gactgcccat gttcatagca gcattattca 96600 taatagcaaa aaaaactttt atcatatgct tttgtgcctc aagatcatat atttttcgtt 96660 tttagtcact aatatggtat aatggtataa tatactgttt aatttctgag taattgacta 96720 gcctttcatt ccggggataa atcctatttg gttatgatat agtatccttt ttacatatag 96780 ctgaattcat tgtactaaaa ttttggtatt tttgcatcta aatccatgag ggatatattc 96840 tatagctttg gtgttatgat aatatggtat tatttctttc ttaaacgttt ggtaaaactc 96900 agcagtgaag ctgtcttggt ttgtttggag ccttttttgt agaaaggttt tcaagtacaa 96960 gttcatcaaa tgtttactga taatatgttt attcttgagt gagctttgtt ggtttacatc 97020 tttgaaggaa tttaactgtt tccttcaaat gttgaattta ttggtataaa gttaagttat 97080 tcataatatt cccataatat ccttctaatg gctccagtat ctctagtgtt attccctttc 97140 attcccgaca ttggtattta atatattctt gctttttttt ttttttttta atcagtctgg 97200 ctaaaagttt ttcagtttta ccaatgtttt catagaacca gcttggtctt gattttgttg 97260 ttgtttatgc atgttcttag ttattcgttt ctactcttta tcctttccat ttttcttgtg 97320 tttagggtag aagcatatat aattaattga gacctttctt ttctaatcaa agcttttaat 97380 gctgtaaatt ttctaagcac tgtcttcatt gcatcccaca cattttgata tgctgtgttt 97440 tcagtactag agatttttaa ttttatgata ccttatttaa tcatgatgcc ttatttaatc 97500 tatagcttat taaatgtcaa attctaaaca tttgggtttt tctccagata tgtttgttac 97560 tgacttctat tttaatctca tttttgtcag acagcattca ttgtatgact taatcctcct 97620 aaatgtattc agacttgttt tatgttctag attaatgttc tgtgtatact tgaaaagaat 97680 gcaagttctt gggtagactg tttcagaaat gtcagtcaaa tttaagtctt gtttattctt 97740 attgattctg agacaaaggt gtttataatg ttagatttgt ctgctatatc tctgacattg 97800 ccaaatatcc ccttggaggc aaaatctccc cctccctttt gagaaccact gatctatgta 97860 gccttttttc tgggactaat ttagccttgc ttctgagatg tggcccctag gtctctactg 97920 aatgcccggc atatttaatt agatctttct ttcctctatg gcctcaaggg atttcaccct 97980 2013203064 09 Apr 2013 80 of 771 aagtatgcac aaatttttat tcagccgaag actgtacaga tttctggagg cctttctttg 98040 tgtacctcct tcgtttccag tagtctgacc cataaattgt acagatttct ggaggccttt 98100 ctttgtgtac ctccttcgtt tccagtagtc tgacccataa attaaagctg ctttagcctc 98160 cccaaacttc aatctctttc tcctcaaccc agcaagattg ctagaccctg ggttcccttt 98220 cccttcactg cagtatgata attactttca agcacaaagg tttagaatta agatttctta 98280 ctcctgggct aggtatggct taccgtattt gtttctcttt tcctagggat cataatcatg 98340 tattgcttgt tgtccagttt tccagtagga ggggaattcc aggctgtact tacttcctgc 98400 agccaaaaga ggaagtaatg ttagtgattt caatattaaa acattaaaaa aaaatttaag 98460 atggatgaaa ttcttttata tgcatattga attgggcttc accatagtta tttttagaat 98520 taggactaac cggcagggaa aaaaactata cggcagggaa aaaaactata agccatcgct 98580 gttttacaat tttgcaataa ttagattttc tgtagtatag taatgtgtaa aattaaccca 98640 ttgttaatat agaatgccgt tatcactcct gattaagcgg tcttcatttt catgttaata 98700 ctgatgtctt gtaatgcttt ctggaatcaa acattttcat acatattcat tagtctaatt 98760 ctaatcataa tccaatgaaa aagagcagga aagatgctca aggaggttat attcaagtcc 98820 acatggcaag taagaaataa gactactcgg ctgggcatgg tgacttactg cctgaaatcc 98880 cagcactttg ggaggccaag gtgagcggaa ttgcttgaac ctgggaggcg gaagtggcag 98940 tgagctgaga tcatgccaat gcactccagc ctaggcaaca cagcaagact ctgtctcggg 99000 aaaaaaataa taataataag acttctagaa gctcctaaat ccatagcttt tcctctatac 99060 cagcatcttc taaaaatgtc agcagcagtg aagtttcagt ttgggaaata atgcatttcc 99120 cctctctgga gagtgcacag ttatatctcc aagaagtact gaaattcaga agtctgccta 99180 atatgtatta aacatttagc ttttctcaaa ctttgaccac caaatccttt gtctcgctct 99240 aactatagtt aacacagaat cagtgttccc aggagcacac tgtgaaaaat gtagcactct 99300 acaaaagtcc taatctccac aggattaagt gaaaccatga ttaaccctct gttccttgtc 99360 cttattagta ccattttctg aagagtaatg tatcccccca aaacttttat actagtttca 99420 ctaaccagaa tccatgtaca taaggaagga cagatatttg ctccctacta agacatatct 99480 attagctaca ttaaaaaaag tattgcatgc cgattttaaa gttataatta actggtgata 99540 tcacagatat tccaagatat aattgctgga ataaacactg ttgttgaagc cttctatcta 99600 tctcagtact agaattaaac tcaagtgcag aatggcagac aaagttaact aaaaatcact 99660 gtattatttc atttggtcct ccaaatagct ttgtgagcta aggaggagaa ggtgtatcat 99720 caccacttcc attttataga tgagaaatca agtgatttac tcaaggttaa gtcctccaat 99780 2013203064 09 Apr 2013 81 of 771 tctttgttat cctgcatttt ctcttggctg tagtttaatt aataatccta agaaaatgct 99840 tatattttag agtgcagtaa gagtacataa acaatgttaa atgcccatct tgcatgtata 99900 aaaagttata gcaagaaatc tggctgggaa tggtggctca cacctgtaat cctggcactt 99960 tgggaggccg aggcaggagg attgcttgag cccaggagtt taagaccagc ctgggcaaca 100020 tagggagatc ctgtctctac aaaaaaattt agccagacac agtggcttgt gtcctagcta 100080 ctcaggaggc tgaggtggga ggatcacttg agccaaggag gtcaaggctc cagtgagcta 100140 tgattatgcc actcagacat ggtggcttgt gcctacagtc ctagctactc aggaggctga 100200 ggtgggagga tcacttgagc caaggaggtc aaggctccag tgagctatga ttatgccact 100260 gcactccagc ctggatgaca cagtgagacc ctatctatct caaaaaaaaa aaaaaaagaa 100320 aagaaaagaa aaagaaaatc ctttaactga cttcatctta accttttagt tcctaaggat 100380 ggtctgaaga gccaagagct atttgatgaa attagaatga cctacatcaa agagctagga 100440 aaagccattg tcaagaggga aggaaactcc agccagaact ggcagcggtt ttatcaactg 100500 acaaaactct tggattctat gcatgaagta agtgtcaaac ataaagccaa atataagagt 100560 tttctgggac aaagtatgtt ttgattagtg aatataatta tataccagca gcgcccccac 100620 ccccgccccc agtttgtgga tgttggtgat agcttgagtt caacttatga acttcagttt 100680 tgtagacatt tttcctaagg ccaattatga aatatccttt cacctagtca tgtgtatata 100740 aaatcaccat gttattacag aatttagtaa cactgttttt aaaaagtatg attaatccat 100800 taaattagaa taatgcaccc ttcatatatt atggtactac agtgattcat gaaataattc 100860 tatataattc tacatacaat caaagaaata taaaatgtgt tttgtacgga agtgcttatt 100920 tttcatctgg ggaattccag tgagattggt atattctagg ccagataatt ttttcaaaat 100980 agaggacaac aaacatgaga tgttcccact gaccaatttg gaagcctgat cattaccata 101040 tcttctcttg caggtggttg aaaatctcct taactattgc ttccaaacat ttttggataa 101100 gaccatgagt attgaattcc ccgagatgtt agctgaaatc atcaccaatc agataccaaa 101160 atattcaaac ggaaatatca aaaaacttct gtttcatcaa aagtgactgc cttaataaga 101220 atggttgcct taaagaaagt cgaattaata gcttttattg tataaactat cagtttgtcc 101280 tgtagaggtt ttgttgtttt attttttatt gttttcatct gttgttttgt tttaaatacg 101340 cactacatgt ggtttataga gggccaagac ttggcaacag aagcagttga gtcgtcatca 101400 cttttcagtg atgggagagt agatggtgaa atttattagt taatatatcc cagaaattag 101460 aaaccttaat atgtggacgt aatctccaca gtcaaagaag gatggcacct aaaccaccag 101520 tgcccaaagt ctgtgtgatg aactttctct tcatactttt tttcacagtt ggctggatga 101580 2013203064 09 Apr 2013 82 of 771 aattttctag actttctgtt ggtgtatccc ccccctgtat agttaggata gcatttttga 101640 tttatgcatg gaaacctgaa aaaaagttta caagtgtata tcagaaaagg gaagttgtgc 101700 cttttatagc tattactgtc tggttttaac aatttccttt atatttagtg aactacgctt 101760 gctcattttt tcttacataa ttttttattc aagttattgt acagctgttt aagatgggca 101820 gctagttcgt agctttccca aataaactct aaacattaat caatcatctg tgtgaaaatg 101880 ggttggtgct tctaacctga tggcacttag ctatcagaag accacaaaaa ttgactcaaa 101940 tctccagtat tcttgtcaaa aaaaaaaaaa aaaaagctca tattttgtat atatctgctt 102000 cagtggagaa ttatataggt tgtgcaaatt aacagtccta actggtatag agcacctagt 102060 ccagtgacct gctgggtaaa ctgtggatga tggttgcaaa agactaattt aaaaaataac 102120 taccaagagg ccctgtctgt acctaacgcc ctatttttgc aatggctata tggcaagaaa 102180 gctggtaaac tatttgtctt tcaggacctt ttgaagtagt ttgtataact tcttaaaagt 102240 tgtgattcca gataaccagc tgtaacacag ctgagagact tttaatcaga caaagtaatt 102300 cctctcacta aactttaccc aaaaactaaa tctctaatat ggcaaaaatg gctagacacc 102360 cattttcaca ttcccatctg tcaccaattg gttaatcttt cctgatggta caggaaagct 102420 cagctactga tttttgtgat ttagaactgt atgtcagaca tccatgtttg taaaactaca 102480 catccctaat gtgtgccata gagtttaaca caagtcctgt gaatttcttc actgttgaaa 102540 attattttaa acaaaataga agctgtagta gccctttctg tgtgcacctt accaactttc 102600 tgtaaactca aaacttaaca tatttactaa gccacaagaa atttgatttc tattcaaggt 102660 ggccaaatta tttgtgtaat agaaaactga aaatctaata ttaaaaatat ggaacttcta 102720 atatattttt atatttagtt atagtttcag atatatatca tattggtatt cactaatctg 102780 ggaagggaag ggctactgca gctttacatg caatttatta aaatgattgt aaaatagctt 102840 gtatagtgta aaataagaat gatttttaga tgagattgtt ttatcatgac atgttatata 102900 ttttttgtag gggtcaaaga aatgctgatg gataacctat atgatttata gtttgtacat 102960 gcattcatac aggcagcgat ggtctcagaa accaaacagt ttgctctagg ggaagaggga 103020 gatggagact ggtcctgtgt gcagtgaagg ttgctgaggc tctgacccag tgagattaca 103080 gaggaagtta tcctctgcct cccattctga ccacccttct cattccaaca gtgagtctgt 103140 cagcgcaggt ttagtttact caatctcccc ttgcactaaa gtatgtaaag tatgtaaaca 103200 ggagacagga aggtggtgct tacatcctta aaggcaccat ctaatagcgg gttactttca 103260 catacagccc tcccccagca gttgaatgac aacagaagct tcagaagttt ggcaatagtt 103320 tgcatagagg taccagcaat atgtaaatag tgcagaatct cataggttgc caataataca 103380 2013203064 09 Apr 2013 83 of 771 ctaattcctt tctatcctac aacaagagtt tatttccaaa taaaatgagg acatgttttt 103440 gttttctttg aatgcttttt gaatgttatt tgttattttc agtattttgg agaaattatt 103500 taataaaaaa acaatcattt gctttttgaa tgctctctaa aagggaatgt aatattttaa 103560 gatggtgtgt aacccggctg gataaatttt tggtgcctaa gaaaactgct tgaatattct 103620 tatcaatgac agtgttaagt ttcaaaaaga gcttctaaaa cgtagattat cattccttta 103680 tagaatgtta tgtggttaaa accagaaagc acatctcaca cattaatctg attttcatcc 103740 caacaatctt ggcgctcaaa aaatagaact caatgagaaa aagaagatta tgtgcacttc 103800 gttgtcaata ataagtcaac tgatgctcat cgacaactat aggaggcttt tcattaaatg 103860 ggaaaagaag ctgtgccctt ttaggatacg tgggggaaaa gaaagtcatc ttaattatgt 103920 ttaattgtgg atttaagtgc tatatggtgg tgctgtttga aagcagattt atttcctatg 103980 tatgtgttat ctggccatcc caacccaaac tgttgaagtt tgtagtaact tcagtgagag 104040 ttggttactc acaacaaatc ctgaaaagta tttttagtgt ttgtaggtat tctgtgggat 104100 actatacaag cagaactgag gcacttagga cataacactt ttggggtata tatatccaaa 104160 tgcctaaaac tatgggagga aaccttggcc accccaaaag gaaaactaac atgatttgtg 104220 tctatgaagt gctggataat tagcatggga tgagctctgg gcatgccatg aaggaaagcc 104280 acgctccctt cagaattcag aggcagggag caattccagt ttcacctaag tctcataatt 104340 ttagttccct tttaaaaacc ctgaaaacta catcaccatg gaatgaaaaa tattgttata 104400 caatacattg atctgtcaaa cttccagaac catggtagcc ttcagtgaga tttccatctt 104460 ggctggtcac tccctgactg tagctgtagg tgaatgtgtt tttttgtgtg tgtgtctggt 104520 tttagtgtca gaagggaaat aaaagtgtaa ggaggacact ttaaaccctt tgggtggagt 104580 ttcgtaattt cccagactat tttcaagcaa cctggtccac ccaggattag tgaccaggtt 104640 ttcaggaaag gatttgcttc tctctagaaa atgtctgaaa ggattttatt ttctgatgaa 104700 aggctgtatg aaaataccct cctcaaataa cttgcttaac tacatataga ttcaagtgtg 104760 tcaatattct attttgtata ttaaatgcta tataatgggg acaaatctat attatactgt 104820 gtatggcatt attaagaagc tttttcatta ttttttatca cagtaatttt aaaatgtgta 104880 aaaattaaaa ccagtgactc ctgtttaaaa ataaaagttg tagtttttta ttcatgctga 104940 ataataatct gtagttaaaa aaaaagtgtc tttttaccta cgcagtgaaa tgtcagactg 105000 taaaaccttg tgtggaaatg tttaactttt attttttcat ttaaatttgc tgttctggta 105060 ttaccaaacc acacatttgt accgaattgg cagtaaatgt tagccattta cagcaatgcc 105120 aaatatggag aaacatcata ataaaaaaat ctgctttttc attatgtgac tccaacatgc 105180 2013203064 09 Apr 2013 84 of 771 ttttgtagaa cttgtacagt tccgattgtc caatctgatt tttgtttact gaaagtagag 105240 ttacccctgc ttcaggaacc ttaagataat atggtgggca tttaaatgtc agtgtggcaa 105300 tgttcgcctg ctaatatggc atagattcaa aataagctta accctggtgc caaagacctg 105360 aagattatcc catccatgcc tcaaatggtt gtgtgccaat tactgcaaag ggtactaagg 105420 gaaggagaaa ttcactcctg aggctgcttc aaatgtatgt ctttatcaca aaagatgaca 105480 ttttatgtaa gctaatgtta tctagtcaaa attcttagct tattttaaaa tcaactcttc 105540 aagaaaagga ataaacattt aatataaata tcatagcagt attgcacata gaatagaaag 105600 gtcgggcagg gtagtggaag tcagctattc tatacaatcc attcggtatt ttccaaaaca 105660 tttgatgttc aggccatatc caggaactgg atgacctaac aaacttctct gagtaccttt 105720 ttttccacaa gagatctcca tcactaagaa aaaaagcatt gtgatttaaa agccaaattt 105780 gccttatcca tcatcatgtg caccaagtat ttgctacctg cctactatat aatattgaag 105840 atacaacgtg aataagaaaa atactattgc taccctcaat cagagtatgt gattggaaaa 105900 gtgtataaca aacctttccc agtgtcttca ggtataatgc agagatacca gatacggcat 105960 caatgtgtat acacattatg gctgtaccat tcactttaag 106000 <210> 9 <211> 2034 <212> DNA <213> H. sapiens <400> 9 ggatctggca gcgccgcgaa gacgagcggt caccggcgcc cgacccgagc gcgcccagag 60 gacggcgggg agccaagccg acccccgagc agcgccgcgc gggccctgag gctcaaaggg 120 gcagcttcag gggaggacac cccactggcc aggacgcccc aggctctgct gctctgccac 180 tcagctgccc tcggaggagc gtacacacac accaggactg cattgcccca gtgtgcagcc 240 cctgccagat gtgggaggca gctagctgcc cagaggcatg cccccctgcc agccacagcg 300 acccctgctg ctgttgctgc tgctgctggc ctgccagcca caggtcccct ccgctcaggt 360 gatggacttc ctgtttgaga agtggaagct ctacggtgac cagtgtcacc acaacctgag 420 cctgctgccc cctcccacgg agctggtgtg caacagaacc ttcgacaagt attcctgctg 480 2013203064 09 Apr 2013 85 of 771 gccggacacc cccgccaata ccacggccaa catctcctgc ccctggtacc tgccttggca 540 ccacaaagtg caacaccgct tcgtgttcaa gagatgcggg cccgacggtc agtgggtgcg 600 tggaccccgg gggcagcctt ggcgtgatgc ctcccagtgc cagatggatg gcgaggagat 660 tgaggtccag aaggaggtgg ccaagatgta cagcagcttc caggtgatgt acacagtggg 720 ctacagcctg tccctggggg ccctgctcct cgccttggcc atcctggggg gcctcagcaa 780 gctgcactgc acccgcaatg ccatccacgc gaatctgttt gcgtccttcg tgctgaaagc 840 cagctccgtg ctggtcattg atgggctgct caggacccgc tacagccaga aaattggcga 900 cgacctcagt gtcagcacct ggctcagtga tggagcggtg gctggctgcc gtgtggccgc 960 ggtgttcatg caatatggca tcgtggccaa ctactgctgg ctgctggtgg agggcctgta 1020 cctgcacaac ctgctgggcc tggccaccct ccccgagagg agcttcttca gcctctacct 1080 gggcatcggc tggggtgccc ccatgctgtt cgtcgtcccc tgggcagtgg tcaagtgtct 1140 gttcgagaac gtccagtgct ggaccagcaa tgacaacatg ggcttctggt ggatcctgcg 1200 gttccccgtc ttcctggcca tcctgatcaa cttcttcatc ttcgtccgca tcgttcagct 1260 gctcgtggcc aagctgcggg cacggcagat gcaccacaca gactacaagt tccggctggc 1320 caagtccacg ctgaccctca tccctctgct gggcgtccac gaagtggtct ttgccttcgt 1380 gacggacgag cacgcccagg gcaccctgcg ctccgccaag ctcttcttcg acctcttcct 1440 cagctccttc cagggcctgc tggtggctgt cctctactgc ttcctcaaca aggaggtgca 1500 gtcggagctg cggcggcgtt ggcaccgctg gcgcctgggc aaagtgctat gggaggagcg 1560 gaacaccagc aaccacaggg cctcatcttc gcccggccac ggccctccca gcaaggagct 1620 gcagtttggg aggggtggtg gcagccagga ttcatctgcg gagaccccct tggctggtgg 1680 cctccctaga ttggctgaga gccccttctg aaccctgctg ggaccccagc tagggctgga 1740 ctctggcacc cagaggcgtc gctggacaac ccagaactgg acgcccagct gaggctgggg 1800 gcgggggagc caacagcagc ccccacctac cccccacccc cagtgtggct gtctgcgaga 1860 ttgggcctcc tctccctgca cctgccttgt ccctggtgca gaggtgagca gaggagtcca 1920 gggcgggagt gggggctgtg ccgtgaactg cgtgccagtg tccccacgta tgtcggcacg 1980 tcccatgtgc atggaaatgt cctccaacaa taaagagctc aagtggtcac cgtg 2034 <210> 10 <211> 2439 <212> DNA 2013203064 09 Apr 2013 86 of 771 <213> H. sapiens <400> 10 ctccgggaac gccagcgccg cggctgccgc ctctgctggg gtctaggctg tttctctcgc 60 gccaccactg gccgccggcc gcagctccag gtgtcctagc cgcccagcct cgacgccgtc 120 ccgggacccc tgtgctctgc gcgaagccct ggccccgggg gccggggcat gggccagggg 180 cgcggggtga agcggcttcc cgcggggccg tgactgggcg ggcttcagcc atgaagaccc 240 tcatagccgc ctactccggg gtcctgcgcg gcgagcgtca ggccgaggct gaccggagcc 300 agcgctctca cggaggacct gcgctgtcgc gcgaggggtc tgggagatgg ggcactggat 360 ccagcatcct ctccgccctc caggacctct tctctgtcac ctggctcaat aggtccaagg 420 tggaaaagca gctacaggtc atctcagtgc tccagtgggt cctgtccttc cttgtactgg 480 gagtggcctg cagtgccatc ctcatgtaca tattctgcac tgattgctgg ctcatcgctg 540 tgctctactt cacttggctg gtgtttgact ggaacacacc caagaaaggt ggcaggaggt 600 cacagtgggt ccgaaactgg gctgtgtggc gctactttcg agactacttt cccatccagc 660 tggtgaagac acacaacctg ctgaccacca ggaactatat ctttggatac cacccccatg 720 gtatcatggg cctgggtgcc ttctgcaact tcagcacaga ggccacagaa gtgagcaaga 780 agttcccagg catacggcct tacctggcta cactggcagg caacttccga atgcctgtgt 840 tgagggagta cctgatgtct ggaggtatct gccctgtcag ccgggacacc atagactatt 900 tgctttcaaa gaatgggagt ggcaatgcta tcatcatcgt ggtcgggggt gcggctgagt 960 ctctgagctc catgcctggc aagaatgcag tcaccctgcg gaaccgcaag ggctttgtga 1020 aactggccct gcgtcatgga gctgacctgg ttcccatcta ctcctttgga gagaatgaag 1080 tgtacaagca ggtgatcttc gaggagggct cctggggccg atgggtccag aagaagttcc 1140 agaaatacat tggtttcgcc ccatgcatct tccatggtcg aggcctcttc tcctccgaca 1200 cctgggggct ggtgccctac tccaagccca tcaccactgt tgtgggagag cccatcacca 1260 tccccaagct ggagcaccca acccagcaag acatcgacct gtaccacacc atgtacatgg 1320 aggccctggt gaagctcttc gacaagcaca agaccaagtt cggcctcccg gagactgagg 1380 tcctggaggt gaactgagcc agccttcggg gccaactccc tggaggaacc agctgcaaat 1440 cacttttttg ctctgtaaat ttggaagtgt catgggtgtc tgtgggttat ttaaaagaaa 1500 ttataacaat tttgctaaac cattacaatg ttaggtcttt tttaagaagg aaaaagtcag 1560 tatttcaagt tctttcactt ccagcttgcc ctgttctagg tggtggctaa atctgggcct 1620 2013203064 09 Apr 2013 87 of 771 aatctgggtg gctcagctaa cctctcttct tcccttcctg aagtgacaaa ggaaactcag 1680 tcttcttggg gaagaaggat tgccattagt gacttggacc agttagatga ttcacttttt 1740 gcccctaggg atgagaggcg aaagccactt ctcatacaag cccctttatt gccactaccc 1800 cacgctcgtc tagtcctgaa actgcaggac cagtttctct gccaagggga ggagttggag 1860 agcacagttg ccccgttgtg tgagggcagt agtaggcatc tggaatgctc cagtttgatc 1920 tcccttctgc cacccctacc tcacccctag tcactcatat cggagcctgg actggcctcc 1980 aggatgagga tgggggtggc aatgacaccc tgcaggggaa aggactgccc cccatgcacc 2040 attgcaggga ggatgccgcc accatgagct aggtggagta actggttttt cttgggtggc 2100 tgatgacatg gatgcagcac agactcagcc ttggcctgga gcacatgctt actggtggcc 2160 tcagtttacc ttccccagat cctagattct ggatgtgagg aagagatccc tcttcagaag 2220 gggcctggcc ttctgagcag cagattagtt ccaaagcagg tggcccccga acccaagcct 2280 cacttttctg tgccttcctg agggggttgg gccggggagg aaacccaacc ctctcctgtg 2340 tgttctgtta tctcttgatg agatcattgc accatgtcag acttttgtat atgccttgaa 2400 aataaatgaa agtgagaatc caaaaaaaaa aaaaaaaaa 2439 <210> 11 <211> 3318 <212> DNA <213> H. sapiens <400> 11 gtgatgcgta gttccggctg ccggttgaca tgaagaagca gcagcggcta gggcggcggt 60 agctgcaggg gtcggggatt gcagcgggcc tcggggctaa gagcgcgacg cggcctagag 120 cggcagacgg cgcagtgggc cgagaaggag gcgcagcagc cgccctggcc cgtcatggag 180 atggaaaagg agttcgagca gatcgacaag tccgggagct gggcggccat ttaccaggat 240 atccgacatg aagccagtga cttcccatgt agagtggcca agcttcctaa gaacaaaaac 300 cgaaataggt acagagacgt cagtcccttt gaccatagtc ggattaaact acatcaagaa 360 gataatgact atatcaacgc tagtttgata aaaatggaag aagcccaaag gagttacatt 420 cttacccagg gccctttgcc taacacatgc ggtcactttt gggagatggt gtgggagcag 480 aaaagcaggg gtgtcgtcat gctcaacaga gtgatggaga aaggttcgtt aaaatgcgca 540 2013203064 09 Apr 2013 88 of 771 caatactggc cacaaaaaga agaaaaagag atgatctttg aagacacaaa tttgaaatta 600 acattgatct ctgaagatat caagtcatat tatacagtgc gacagctaga attggaaaac 660 cttacaaccc aagaaactcg agagatctta catttccact ataccacatg gcctgacttt 720 ggagtccctg aatcaccagc ctcattcttg aactttcttt tcaaagtccg agagtcaggg 780 tcactcagcc cggagcacgg gcccgttgtg gtgcactgca gtgcaggcat cggcaggtct 840 ggaaccttct gtctggctga tacctgcctc ttgctgatgg acaagaggaa agacccttct 900 tccgttgata tcaagaaagt gctgttagaa atgaggaagt ttcggatggg gctgatccag 960 acagccgacc agctgcgctt ctcctacctg gctgtgatcg aaggtgccaa attcatcatg 1020 ggggactctt ccgtgcagga tcagtggaag gagctttccc acgaggacct ggagccccca 1080 cccgagcata tccccccacc tccccggcca cccaaacgaa tcctggagcc acacaatggg 1140 aaatgcaggg agttcttccc aaatcaccag tgggtgaagg aagagaccca ggaggataaa 1200 gactgcccca tcaaggaaga aaaaggaagc cccttaaatg ccgcacccta cggcatcgaa 1260 agcatgagtc aagacactga agttagaagt cgggtcgtgg ggggaagtct tcgaggtgcc 1320 caggctgcct ccccagccaa aggggagccg tcactgcccg agaaggacga ggaccatgca 1380 ctgagttact ggaagccctt cctggtcaac atgtgcgtgg ctacggtcct cacggccggc 1440 gcttacctct gctacaggtt cctgttcaac agcaacacat agcctgaccc tcctccactc 1500 cacctccacc cactgtccgc ctctgcccgc agagcccacg cccgactagc aggcatgccg 1560 cggtaggtaa gggccgccgg accgcgtaga gagccgggcc ccggacggac gttggttctg 1620 cactaaaacc catcttcccc ggatgtgtgt ctcacccctc atccttttac tttttgcccc 1680 ttccactttg agtaccaaat ccacaagcca ttttttgagg agagtgaaag agagtaccat 1740 gctggcggcg cagagggaag gggcctacac ccgtcttggg gctcgcccca cccagggctc 1800 cctcctggag catcccaggc gggcggcacg ccaacagccc cccccttgaa tctgcaggga 1860 gcaactctcc actccatatt tatttaaaca attttttccc caaaggcatc catagtgcac 1920 tagcattttc ttgaaccaat aatgtattaa aattttttga tgtcagcctt gcatcaaggg 1980 ctttatcaaa aagtacaata ataaatcctc aggtagtact gggaatggaa ggctttgcca 2040 tgggcctgct gcgtcagacc agtactggga aggaggacgg ttgtaagcag ttgttattta 2100 gtgatattgt gggtaacgtg agaagataga acaatgctat aatatataat gaacacgtgg 2160 gtatttaata agaaacatga tgtgagatta ctttgtcccg cttattctcc tccctgttat 2220 ctgctagatc tagttctcaa tcactgctcc cccgtgtgta ttagaatgca tgtaaggtct 2280 tcttgtgtcc tgatgaaaaa tatgtgcttg aaatgagaaa ctttgatctc tgcttactaa 2340 2013203064 09 Apr 2013 89 of 771 tgtgccccat gtccaagtcc aacctgcctg tgcatgacct gatcattaca tggctgtggt 2400 tcctaagcct gttgctgaag tcattgtcgc tcagcaatag ggtgcagttt tccaggaata 2460 ggcatttgcc taattcctgg catgacactc tagtgacttc ctggtgaggc ccagcctgtc 2520 ctggtacagc agggtcttgc tgtaactcag acattccaag ggtatgggaa gccatattca 2580 cacctcacgc tctggacatg atttagggaa gcagggacac cccccgcccc ccacctttgg 2640 gatcagcctc cgccattcca agtcaacact cttcttgagc agaccgtgat ttggaagaga 2700 ggcacctgct ggaaaccaca cttcttgaaa cagcctgggt gacggtcctt taggcagcct 2760 gccgccgtct ctgtcccggt tcaccttgcc gagagaggcg cgtctgcccc accctcaaac 2820 cctgtggggc ctgatggtgc tcacgactct tcctgcaaag ggaactgaag acctccacat 2880 taagtggctt tttaacatga aaaacacggc agctgtagct cccgagctac tctcttgcca 2940 gcattttcac attttgcctt tctcgtggta gaagccagta cagagaaatt ctgtggtggg 3000 aacattcgag gtgtcaccct gcagagctat ggtgaggtgt ggataaggct taggtgccag 3060 gctgtaagca ttctgagctg ggcttgttgt ttttaagtcc tgtatatgta tgtagtagtt 3120 tgggtgtgta tatatagtag catttcaaaa tggacgtact ggtttaacct cctatccttg 3180 gagagcagct ggctctccac cttgttacac attatgttag agaggtagcg agctgctctg 3240 ctatatgcct taagccaata tttactcatc aggtcattat tttttacaat ggccatggaa 3300 taaaccattt ttacaaaa 3318 <210> 12 <211> 78001 <212> DNA <213> H. sapiens <400> 12 cagattccgg gtctcatccc tagaccaaag atatctgaat catttggcga tgggtccagg 60 aacctgcatt attcaacaca cttcccaggt gaccgtaaat gtcaaaagac aaaattacaa 120 caaacttaaa catcttaatt ggcttcattc atgattctag aatcgggcaa gacttcattc 180 ctcaaaatag cacaagtgtc ccaatgagct gagcagagga ggttggtttt atagacagaa 240 aagggctgaa aaaagcagaa acaaagaaca aaaagcagat tggtcatttc aaagttactt 300 tccttgtaag gcaggaacag ggaaacagaa caagagagaa ataactgatt ggtcgcatcg 360 2013203064 09 Apr 2013 90 of 771 ggttacttca ggttactttt tgttgtaagg attaaagcaa agggaacttc attatgttga 420 ttaaaacggt ctgcttggga aatcagggtg tgtatctctc ttctgatttt gtgaaaggtt 480 atcagtctga tgatgtagaa ctttagcatg agtgactcca ttttgatttt tagtctagtc 540 tgttgagacc ctaatgccag aacttttttt gtttgtttgt ttcgctcttg ttgcccaggc 600 tggagtgcag tggagctatc ttggctcact gcaacctctg cctccagggt tcaagcgatt 660 ctcctgcctc agcctcccaa gtagctggga ttacaggcat gcgccaccac gcccggctaa 720 tttttttttt tttttttttt tttagcagaa accgagtttc accatgttgg tcaggctggt 780 ctcggactct tgacctcagg tgatccacct gcgtcggtct cccaaagtgc tgggattaca 840 ggtgtgagcc accacaccca gccctttttt ttcaagacag ggtctctctc tgccacccaa 900 ggtggagtgc agtggcgcca aaacagctca ctgcagcttc cacctcctgg gctcaggtga 960 tcttcctgcc tcagcctccc cagcagctgg gccccaccac accggctaat tttttaactt 1020 ttagtagtga cgaggtctga ttctgttacc caggctggtc tggaactcct ggcctcaaga 1080 catccgcctg cctctgcctc ccaaagtgct gggattacag atgtaagcca ccgcgcctgg 1140 gctcctatga tttttattta acataatgca ccatggaatt tgtgctctgc ttagttcagt 1200 ctgagcagga gttccttgat acttcgggaa acactgaaaa tcattccatc cccatccatt 1260 cattcctgca gcacccaagt ggaaattctg cgtttcagac agggacacta cccttagaga 1320 gcagtgggct tccccagcag cgtagtgaaa catgatactc ctgagtttca tgaaaaaagg 1380 gcagacatct ggccagagct gggaggcagg aaatagagca cggtgccctc ctcccatact 1440 ccagcttgga ttactgaggc tggggcccag gccctgcagg aaaggaggtg catgactact 1500 ttaaggccac tcactctgtg actcaacggg ccgggtcggg gctggaactc aatgccctcc 1560 cgggcctgga gagcccacgc gccgtgggcg gggctcccgg ggtcgcctag gcaacaggcg 1620 cgcgccgcgc ccgagcccag agccccaaag cggaggaggg aacgcgcgct attagatatc 1680 tcgcggtgct ggggccactt cccctagcac cgcccccggc tcctccccgc ggaagtgctt 1740 gtcgaaattc tcgatcgctg attggtcctt ctgcttcagg ggcggagccc ctggcaggcg 1800 tgatgcgtag ttccggctgc cggttgacat gaagaagcag cagcggctag ggcggcggta 1860 gctgcagggg tcggggattg cagcgggcct cggggctaag agcgcgacgc ggcctagagc 1920 ggcagacggc gcagtgggcc gagaaggagg cgcagcagcc gccctggccc gtcatggaga 1980 tggaaaagga gttcgagcag atcgacaagt ccgggagctg ggcggccatt taccaggtgc 2040 gggagcgccc cggagcgtgg cgggcccttc gcttaggccg cttgaacatc ccctcagacc 2100 tccaggcccc agactccctc tgggtcttgc cctctgcctc gctcctactg cttgaggatt 2160 2013203064 09 Apr 2013 91 of 771 cgatgggaca gcgacgcact gcgtcccccc accctttgtc cccggggcgg gcgtgtttct 2220 cgccgcagcg tcggagcccc cttcgatccc ccacctccct tctgttctcc agctcgggtg 2280 atctctcaag ccgggggacc gccggtctgt gctctcaacg cgaatccctc gcaccccgac 2340 cccgccccct gcctgtccac tctttgtccc ctggggtgat ttagcacccc cactatttcc 2400 ttttctggag tggaccacct cagactctct tcctttgtct ccctggggga aaaggttact 2460 ccccccgtcc ctccttcaca tttcctttcc cctagtctca gtgtgcgtcg agtcccagag 2520 atgacagtcc cctttcccct ttctgttcat tcatttattg gataggagtt ggcaagctta 2580 ttctgtgcta ggcaccgctt aggcattgga ggtggtgttt gctaatcagg acaggcaaga 2640 tcctagcctt agtggggcct agagtcgaat agggcaatca aacacaaaag caaataattt 2700 cagatagtga caggtgctgt gaagagaacg acttcctaac ggggtacagg gtgactgcat 2760 agaaggccgg ctgtcttaga gaaggggatc agggaaggcc tgtcaaagga ggagacattt 2820 gctttgtgag ctgaaccaag aggagcagaa agccgtgaga atatggggct aaagaacctt 2880 ctagccagga ggcctgcggt acccactcca ttggggccat gatattattc tttcaggcag 2940 ggactcagga aggttaacgt tttaaccctc tctaaaatag catctttcct caatgagcag 3000 cttagtcttt ggtcgtggca gagatgacct tgtcttagga gtcatctcct tgtgtgttaa 3060 aaagttagga aaggagggtt tctcatatat ctataaaaca agtagttaaa aacacaaaga 3120 gctcttcctt tcacaagcag ctgaataaga tacatactcc caattaaatg tcattgcggg 3180 ggttgttaag attaactaaa accacacttg cacagtatct taaataagcg atatacagaa 3240 tagagagatt ttgttacttg tgtaaaggga gacagcagat gattctgttt tcagcttata 3300 ggctcaaaag gcaaattgtg agatccatca gctgtagtat taaaatctat tttgagctcc 3360 gcttagaaag gaaaaaaggt ttaagcagtt ctttggtatg cttgactaac aaaagccttt 3420 ttttttggca gccttgattt tcatgtggat ttacatcaag cttatttgac aggattcttt 3480 ttatttggac tgtagtgtgt atattagttt ctgctagact aatatttcta accactgtaa 3540 tctatatact aataagtatg attgatcagt atataaaatt tgtatgccat atctggtctc 3600 tgaattagct gaatgaattc cataagggac tttgagactg tgtagacaaa ttttctgcat 3660 cagtttaatg cagtagagtc taaaatgtct ttaaatgaaa attgttggtc tgaagtgttg 3720 gagttgatta tgatacaccc catcacagtg gaagcattgt ggagagaagt cttttccact 3780 gaaattgact gagttgacaa caagaaatac gtattgtaac ttagttctta gttgaatttt 3840 atttcttaca attttaagcc agagtgggtt gacctgtcac ccaagcatgg ttaaaattgt 3900 attcagcatg caactagcat ggagtgtgtc agtcttcaat tcatttcctt cattgttctt 3960 2013203064 09 Apr 2013 92 of 771 aagtttttct gccacaatta aaccccacaa gttagtcaag gtgttgagat tttcactgct 4020 tcttaatgga ttgccacatt ccctgaggta gtttcttttg gtcttagaga attgtcaggg 4080 ccagcttttc tcacctccac tgtatggata tttttctttt ctaagatctt gaaatcagaa 4140 gcttttctcc taagtgtaaa agtagctctt tgtcatacaa ctgtagcgtt ttctgaaaca 4200 gagttcagat gaccttgagt ctaaagtggc taactttcca aggtgtgtat cgctttacca 4260 aaaccattat ttttcaagga ttcaaagaat gtgtttacaa ttgatagaaa atggaagttt 4320 aaaaaaatta atactttata gcatgttgaa atgagggcag ccttatacaa agtcatactt 4380 tgagcttgcc tagcctattg tgatcagaga ataatgtaat ttttgcttac aacttggtaa 4440 gcaggtcagt tattctaact tattttctga ttagaacaaa aagatgtaaa aacttgaaaa 4500 ctattgggaa aagaacaaag agtgaagagg acttttgagt gctgaggaat gtggcagctt 4560 ggaaaacaaa ctttttaggc agagattctt tgctaggtca gtttgataaa gtgagcataa 4620 ccgtattttt aatctttaat gctaatgaat agcatagatg ctaataagca tctaggtcta 4680 taaaaagtca gctttgatag tgtatataga tggctttaaa cattgttttc tagcatttaa 4740 acactttcaa atcatccggt tgcttgattg ggcctagctg tctaagagga gagaatgagc 4800 ccagatgagg aaaagagatt gattttactg agctagaatg agaggagaga gggttgagtg 4860 aatgaaaaga atagctcatg tgctcccctc catctgtagt ttaagagggg ttgggtccgg 4920 tgttttgctt gttttctcgt ctgtaaattc tttgattctc tgacaccact cactatattt 4980 cattgtgaat gatttgattg tttcagataa aggggactgc aataatacct tgtgacatga 5040 aggcaagatt tattcatgtt agaggcaggc tttgtaaaat gggccactct tccaattgac 5100 atttgttttt atagctgttt tcattatgaa atacaatcta atgcctgact aggttaaaac 5160 catgttgtaa caatagttca ctaaaattcc ttactgatat acagcttatg ttgttatatt 5220 ccaaaaagat gaatattaaa atttgccaat aatgtttatt taaatactat tttcttcaga 5280 ggaaaaaaaa ctattttatg caaaggagaa agatctatac actatgactc acttcactta 5340 aaaaaaaaaa gactaacgga aatgacatgg agagactggg aagttctagt catcttgagt 5400 gacccattag atctaaatgt tcttgtttag ccctggtttg agtgaactaa atttaggtgt 5460 ctgatcagta ctttggaaat ggtgtaaatg cctttgtaat tgtctggact gatattagat 5520 taactgggag cacaagtaga aatagtgaag gaaagaactt tttgctattg ttatttgaca 5580 tcactggcat atttatagga atactttggt gtttttggaa gtaagtaaac caaccagtgg 5640 ttctaaaaag tcagctgggg gataatggta atgccgctgt ttcttagctg caagttatct 5700 gccgttactt ctcctccatt ttgcatttta tcttgaatag ctcctcaaaa cctattaaaa 5760 2013203064 09 Apr 2013 93 of 771 tacctggtat tgaataatgt aattgaatgt gtactgaatt tcacagtgga aatgaataag 5820 aaatttcctg tggaggtttt ttgacttagc tactgaaata acggcctttt gttgtgtgat 5880 tctttccctt ttctctttgt taaagaaaac tgtcttgtga tcttgtagat tacagaatcc 5940 ttttggcaat ttctgttcct agcactgctt tttctttctt tctttctttt aaatagaaat 6000 ggggttttgc tgtgttgccc aggttggtct tgaactcctg gcttcaagcg atcctcccac 6060 cttggcctcc tgaagttggg attgcaggcg tgagcaggta ctttttctga ggcctgcctg 6120 agcctatata tattttgcac aatttggcat tcctccctac agtgtttatg ctgatttgtt 6180 tctggtaaca actaatactg gcaaatcggc tgggcatgtt actttatgct gcccatattc 6240 aggaaaattg gaattctagc tgggtcattg ttcccagatg atgtagtttg gcaccagcca 6300 ttccatgttc acattttgag tatccaggag ggctggggac tttggagtag ttggtgattc 6360 cctctgccac atttcactgg ttggtcacta tggcatcctt tccaccacac tagtagtcta 6420 ggttctcaga tgttgcttat gagcctgcaa tggtttctag tttcacactg cagaaatgag 6480 tgaagccggt tacccgttaa tatggtccca tcatcactag agtaattcat tgttctaaaa 6540 ccagatctga gtctctcact cctctgcaac tacttctgat tctttcataa cacttgtaaa 6600 gtccaaactc ctctttagca tggcagccag cttccagtcc ttccctccta tgtggcttcc 6660 attctagcca gacaagaaag ggcagcgttc tccaaactca tcctcgccct tcattcctct 6720 ataccattgc tgagcacttt gttgaggatg cctctcccgt tcaatctagc ttgcatcttc 6780 cagctcgaat gtgtgcttcc ttgcaccaga gttttgttcc gtcacctgtg tgttttcata 6840 caagctggca catatctctt ctaaagccct gctgtcattg tagctgcgtc tttacaaaca 6900 tttttttttt aaatttttat aaagtcaagg tctcactata ttgcccaggc tggtctcaaa 6960 ctcctgggct caagtgatcc tcctgccttg gcctcccaga gtgctgggat tataggtatg 7020 agacactgtg cccagctgta gctgctactt tatatcccag gtctatctcc aatggagccc 7080 aagcttcctg aggccacctg ttgtatcttt ctcattcatc ttgaagtcct ctgctcctgg 7140 cacagagtag gtacctaaca agagttggga ttgaattgat ggtcagtact ttgctagcct 7200 gatggtataa agatgtacaa aacatgttcc tggctcccac tctagggggg caatgatgga 7260 aacaaataga ttagcccaca ttagtaccaa tagtagaggt cactctggga gaaggccccc 7320 accacatttt gagtcatggc ctaatgaggt aatttagtat tgcctgctgc agtggctttg 7380 gaagaaaggc tggcattctt agccagtaga agctgatacc actgatttgt ttcacagaag 7440 ctttaaatat aacaataaat ttgtgcttgg cctacggtga actttacagg caacttggag 7500 gtaatatgtt tgtctctcta agaattgttg aattcctctt ccctcatccc tcctgactgg 7560 2013203064 09 Apr 2013 94 of 771 ttctcacaag cctagcgggc ctttgcatgt ggttggttca taaaatactt tttgattttg 7620 ggatataaaa tatagttctc cataaaataa cgactgttac caagtctttg attttttttt 7680 tcaaactata aatggtaatg acattctttg gcctttgatc agaccaccct taggggcaag 7740 agagtagttt catgttttgc tttttctagt gtcccctgtg tctgggtata gttgcagtct 7800 cagctgtcat actaacagtg ctgagtgagt cccttacttt ctttgggttt tggtttctcc 7860 cttgtaaaaa tgatcctgga ctaactgatc attaagttca ggtcaagtaa taaaaatcct 7920 taatgtactc acaaatacaa tttaatgttc ctgaataatc cttgtaaaaa ctgcagcagt 7980 tactcagttt tgtaaggtgt ggttgggtac tattaggctc aaaagtttat aggagctttg 8040 tgagtatagt taacaactca aaagaatggg gtgttttttc ccgaggggca tgaaatgttt 8100 ttgataaata gagttcattt gacttggtaa tgtggaaaat gagtagccct gacacgtacg 8160 ctatgctttt gcagtttttc tctcaagtag caattgggtg gcttttcctg taaaagatag 8220 aggaactgat tcttgagaat ttacgaaagc ttcaacccta actaggtatg caaagaatag 8280 ttgcccttta tgttgtaatt ttaggaagaa acctacatct ggtctaagtt tcatttgaat 8340 aatatgatag tttacacatc tgccatattt gagaagaaag tacctaagtc tccagcattt 8400 tagaaataat gctttacttt gtgtagaaat ggtctttaga gtttaatagc tgctgccctc 8460 tcctttttca aagcagcttg acataatcat gagtatcttg ctgacagctt gtaaattttg 8520 attgtatgaa aactgaaaat aagaccattt cacatggaag attccctcct gccctgaaac 8580 agccaaagaa aactgtagcc atcaaatcta ttgatctctg ggctttggta caagtcacac 8640 tactacaaat aaaataatac caagtactta taaatgattt tcagtccttt taaagtttat 8700 ttttttaata ttttttttga gatggggtct tgctgtgtcg tccaggctgg agtgcagtgg 8760 cacaatcttg gctcactgca acctccacct cctgggctca agtgatcctc ccacctcagg 8820 ctcccaagta gctgagacta caggcatgtg ccatcacgcc cagctaattt ttgtattttt 8880 ttggagtaga gatgggattt tgctgtgttg cccaggctgg tcttgaactc ctgggcttaa 8940 gccatctgtc tgcctcaggc tcccaaagtg ttgggattac aggtgtgagc cactgtgccc 9000 ggcccagccc tttttttaag agaaaaacgt atgacatcgt tcgatttact gagtgcttat 9060 ggttttacta aggcagtaag gttttatgga taccctatgg taattagata gaattagtgc 9120 tctgaagtca gctctgtaat atggactcag agtaaacatg gcaaagggac acttaaggtc 9180 tgcattttct ctgggaaata aacgtattct ttactactct gaatctagtg ctgggaaatt 9240 ctaaatcctt cttgaggatt aaccacttga agtaaagttt tgggtcccaa gtaggcttgt 9300 gtccctgtct ccttctcttt acttttcaga tgtttcttcc tagagactga ggtatatttt 9360 2013203064 09 Apr 2013 95 of 771 acttttacag atgaagaagg aagcctcggc tgtgtttgtg gcttttgtgg gtgagcaaca 9420 tcacttgcaa agataagatg agcatagcaa aactaggctt tcaaaataat ttttaaaaat 9480 ttcttagtga ttagaaaagg aaaactcttc ccttgtctct gttaagaaac gtttttcgac 9540 ttttttcctt tcttaatgga tcttttattg gcacttctct tccttttgca gaatcttact 9600 taaaagtcac tacgttacat tacagcaaac agcttagcta atttttatcc agatgggccc 9660 cggttacagg attgtacact attgcgaatt tcttacagga aagtgaacat caagtaatta 9720 ttccaaatag agttctctta agaacgtgag ttacttaaaa atgtctaagg atgaagtcac 9780 ttctgaatat aacttcactc aagagaacaa ataagcaaac tgcatttagc ataacatggt 9840 aaattagctt taactctcct tgatgtttga acatttgtcg ctgttaacta ctgtttcact 9900 tttcaaatag tcagggctta gtttgcttct gtaaggataa agggaaaata cgccttcact 9960 gagtcataaa tatttttgtg gctaactttt gcacagagaa aagaggcctc taagaaggta 10020 cccagtgaat ttttttttcg gggcagggag agaatatgtc attttttggt ttgttgttgt 10080 tgttgtcatt gttttgcttt gttgttttta ctctgaactg aactgtatct tgacagcact 10140 tttgaattaa gagcattact cttattgttc tctactacct ggacgccacc tccctgttgc 10200 catagtgtta aggatcatgc tccgaggtgg ggtgaggcag aatggggcca agatcagaaa 10260 gttacattaa gctacatcag gtttatacaa gcataaaacc aaatttttgg agcagtcccc 10320 agaatacaac ctggtttagc cacacctaaa ggttgctctt gaatattcct tgagaatcca 10380 catccctaga atgctgggtt tcaatgggcc ctttatgtac ctatcatggt gtcatttctg 10440 agcatttcta aatattcctt catgtcttac tgacagtttt tcttgaataa atcttaggaa 10500 tattagtgcc attatcagta ttttgtttgg tctgttcaca ccacaaataa ctacccaggt 10560 ctgctacttg cccctatttc tctacctgct aatgaaaatg cttttgaaag tttgagtaac 10620 agtattggag tgtgcacagt ggtattggta ggttctgtac tcatccttaa ccacttgttt 10680 tcatcctttg tgagcttgaa gtttctccaa aaaatttatc acaaaactta tcagacatag 10740 ttaatacact cagagagaga atcactgaaa aagtagatgt agtttaacaa acccagtgcc 10800 ttttttttac ccatgaatac atatttgtca actaaacctc attttgcaac ttgttccact 10860 actcgaatgg taacaaactt ttggtttccc aatagatttg gaagatgttg cttttgaaag 10920 taggaaatag atggctttag aagatggaag aatattttgt ttgaagtggg agcgtggtat 10980 gtccttagct gtctgtgaaa tgcagctgaa gatgggtgtg ggccttcatc tgcatttccc 11040 atcttcagtt tgaggaggta gttacccttc taaccactta agaactgcat ggtacatgct 11100 gttttattta cagggcaaaa ctgtgctccc gtagtttccc tggtgcttgc cttcacgtta 11160 2013203064 09 Apr 2013 96 of 771 acacagtgtc atcgtttggc agtgtttatg tgccagggtc catgttagaa ggaggaaagg 11220 tatagcgaag ttaaagggtg cagttggcct cccaccttta gttttgtaag tgcctttaaa 11280 gtttgatttt tgtaggttga tcataaggaa gtgataagta tgttaggtta tttgtggttt 11340 gagctaattt tagtctcttt ttacagcttg ctttgtatcc tttgccatta aaacatgctt 11400 tctagaaaga caacttttga atgtaggaca cagtctatat tctatacttg gctacatttc 11460 aaaaaatatt ttctcagtac tttggaagtt ggacagttgg aagcatagtg acagtattta 11520 aaaatctttg attccggccg ggcatggtgg ctcacgcctg taatcccagc actttgggag 11580 gccgaggtgg gtggatcact tgaggtccgg agttcaggac cagcctgacc aacatggtga 11640 aaccctgtct ctactaaaaa tacaaaatta gccgagcgtg gtggtacatg cctgtaatcc 11700 cagctactca ggaggctgag gcaggagaat cgcttgaatc tgggaggcgg aggttgcatt 11760 gagccgagat cataccattg cactacagcc tgggggacaa gagtgaaact ctgtctcaaa 11820 aaaaaaaaaa aaattaagtg atttctttgc tttgtgacac ttctactttt ccagcaagta 11880 aattatattc tttcatacag gtatgaaatt cttgttccaa gctagtggtt aaaaaggcac 11940 agttgatatt agaggatttg taaaagatta tgaccacgcc tgcaatgtac tgaagcaagg 12000 ctttgctggg ctgtgtatag gaaaccttcc ccagcctgtg cccttgcttg atagaacatt 12060 ttgctcctaa gggtaggtgc ctgtatctgt ctccagtact ggttagtttc acacagaaca 12120 gttgtgtttc agagctttag tctcaagctg ccctgctccc ctgaagcagc caccctgagc 12180 atgtgcactc acaggagggg acatgtgagg tcatggaaga agacgactca ggaagaagaa 12240 gacttgggtt tgggttctga ctctgccttt gactgttgtg ggattttgag gagttgcata 12300 caggatctgt aaaatgtagt cattagacta gactagacag ccatatagca ttacctagat 12360 gtaactttct acaaagacat ggtcacagga gaagaccaga gggtggggtg atctttctgg 12420 aaaaattggg gcttcatgcc ttactcatgc tagatatggt agcattatat ggctgtgcct 12480 gatcccccta atctaaaagt gggacagaac tttaaaattt catattaact caaattaaaa 12540 cttgaaaaaa acccattatt tccttaaaaa taataaaatg ccctgtgggg gcataagtca 12600 cattatattt taaaattcct gaatgccaca tggatgaatg tagttccttt tgaaattctt 12660 cttttgtcta aagaggaatg ttggattttg taattggact aaaaaatctt ccatttgaga 12720 gagaaacagt ctgctgcatg ttctaccctt gttcaggata aaacccacta atagctaaca 12780 tttattgaat tctgtgttgt gcctcaggca ctgtgcaaag tcctttacat gcaatgctgt 12840 ttattatata ctgtcaattg gtctataaca gcaggaaatg tttcaggagg acaatgaggt 12900 cccagaccct cagtcttctc ctgtgtcctg gattcagctt cacaatagca ctatggcagt 12960 2013203064 09 Apr 2013 97 of 771 gtggccactg cttcagcttc cacatacatg gctgtgaaga gagacagggg attgtgctaa 13020 gcctccccga tttattagga cataggagga gagagtttgt agtttttgac ctttgcctag 13080 ttttctaacc tctttcctag atgtcacaaa ttggccaccc acagtcatat tttgcttgct 13140 tcacgcaatg ctttttaaaa aagagaagag tttaatttgt gccattgttt ataaatgaat 13200 caggagaaat gacatgcaac tctggattct ggcctctctt gaaaaatctg aaaatcacac 13260 cgtctgagct tacactggca gtggtctgct ggactgaggg acacaactcc ttttggatgt 13320 acatgtgtgc gttgcagagt ttaccacagt cccacagtgg gtcacactgt ccttgtcggt 13380 gtacactacc tagcacttga gtttgcaacc cctaccccaa gctgagtttt ctcgtcaagc 13440 ttgatgttaa tgttatgtga tgcttggcct tgtaggtatt tggtatatta tcgttagata 13500 aaattgaagc aaagggctaa agggttggtg gcctgaggga gtgcccttga cagtaaagtc 13560 taggataaaa tcattggcca ggtactcctt cccttcccgc ccttcctctt ttctctttat 13620 cctcagcctc cttctgctat tttgaggaag ttagaagcca ccaccatttt ttcccacctc 13680 aggcaactga gtgtggctgt atttctgtcc catgttcagt tatttccagg aactattttt 13740 gatgaccaac ttgaagttac attgggtggg cctaatgggg gctgataaaa gaatgaggtg 13800 accaaatatg cttgcactga gacggctacg aagtaaggtt tttaatgact tgctttgtga 13860 cttggtcagg agtgatacca tttgtcatgt gtccaacttc atgactaaat ggttgctcta 13920 ccttatcctc atagctataa taaaataaaa taaatacata cattgcaggg aggaatgtat 13980 cttgttaaag gtctctccct tttagcaaca aaagtacata ttatgttgta gaacatgctt 14040 tttctttgat ccttcttgaa cacctattac tctatagagg tatgttgtgt atggcaaatt 14100 agaacaagca atagataagg atgattcttt accattataa cccagtcaag gtctttgtcc 14160 taagttttgt acctttctcc agagggaaag gtatttgtat ttatttattt atttttgagg 14220 cagagttttg ctcttgttgc ccaggctggg gtgcaatggc acgatctcag ctcactgtaa 14280 catccgcctc ccgagttcaa gtgattctcc tgcctcagcc tcccgagtag ctgggattac 14340 aggtgcctgc cacgatgccc ggctaatttt tttttttttt tttgtatttt tagtagagat 14400 ggggtttcat catgttggcc aggctggtct tgaactcctg acctcaggtg atccatccac 14460 ctcggcctcc caaagtgttg ggattacagg catcagccac tgcctccggc caggtatttg 14520 tatttttagt ctctatgcct taccgtctca gatcaggagg atttggtgat ttatcgaatg 14580 tgggggaagg ggaagaagag gaaacgggag gaatgttcca gattagggaa atagctagat 14640 ggaagatgca gcccctcatc aaggtgggga cacaggaaaa ggaacgtgtg caaagaagat 14700 ggtgatctgg ttgtgaccat gttgttagag gacgtccagg gaagcatctg gtaggtggtg 14760 2013203064 09 Apr 2013 98 of 771 gggtgtttaa atatagaaca ttcggagaat gctccgaagc ttcagagaac ccttcccaaa 14820 aggacaaaac cagctcagtg ttttagcact ccgggatcat atggcatgac agcatggctg 14880 ctttatactt ttttgtgtat gtgaaattaa aaccaaccac tcaggaccaa tttctctgaa 14940 gctttttgtc aatctttcat ttgcttttct cgtctagatt gtaagctcct tgcagccagt 15000 gtctgttgat tcagtcattc aaaaaataat acatgaacag ctactaggta ccaggctctg 15060 tgctgggcag ttgggatatg tggtgaggaa gacaaacttg gtccctgccc ttaggaagtt 15120 cagtagtcca gcagacaaag tggctgaata aagataatct cagttcacag tgataagagc 15180 tcttacaggc ctaggctcca ggtgctgtgg ggatgctcag gaaaaggtat ctaattggga 15240 ttgggagcag gcaaaacaaa taaaggatag tgtataaagg taatatctag ttgaagttct 15300 gaagggcaag gaggagtgag cctgtatatt ctctgagtct ctccctaatc tgggattgac 15360 ttcttgtccg tctctgttca tattaagtgt cacctaggct tgaaagggtg agatcatatt 15420 tcacttcctt cctctttggt cttaaccttt ctctgctacc ccctcacaca atgcatatgc 15480 attattctct tattgtatat atttttcctc tcttcctttt catgtttcct ctgccattac 15540 ttttaacctc gactgccata tggcctctaa acgcttccag aagggtagcc tagtggaggt 15600 tattccatca tggccttgag ctcatgcgac cagatagtga aggcatctgt gtaggtgtct 15660 tctccaggag ggtgatattt gtttcattgt aaattttgta gccctagaac accaacaaca 15720 gtgcacagta attagtaggc aggcagtaca ggattcattg aagtgaagtg ataactttta 15780 tccaagtatg tatgcagata atctttgatt tgtacaaaaa aaattatatt ttaatatgta 15840 aagatttttt aaaagaatct tcaagtttta gccttcccac taggaatata ttgaaaacat 15900 gtgcctagtt cactgacttg cagctgccac tatgagaata aaggtctcat ttagttgttg 15960 tgaattttaa gggatatttt caatgatgtt ggctggttta tcccattatg tggtcttttt 16020 tttttttttt tttttttttt gaggtggagt ctcgctctgt cacccaggct ggagtgcagt 16080 ggcgcaatct cgactcactg caacctccgc ctcccgggtt caagcgattc tgctgtctca 16140 gcctcctaag tagctgggat tacaggcgcc tgccactacg cccagctaat ttttggtatt 16200 tttggtagag aagggtttca ccatgttggt caggctggtc tcgaactcct gacctcatga 16260 tccactcact tcagcctccc aaagtgctgg gattacaggc gtgagccacc atgcccagcc 16320 tatgtgctct tattagcaat tctcagtaca cagatagctt tgagtgattc tttcaagtca 16380 agtaccttat taaaaaactc aagtgtactg ataattatct tacttttaaa tggctaagtg 16440 ataagactga atttttaggt actgtaacac ttcagattac agattctgat atttttatgg 16500 ttatttatat ttatttattt ttgagatgga gttttgctct tgctgcctag gctggagtgc 16560 2013203064 09 Apr 2013 99 of 771 aatggcacga tctcggctca ctgcaacctc cgcctcccag gttcaagcga ttctcctgcc 16620 tcagcctcct gagtagctgg gattacagtc acccgccact acagccggct aatttttgtt 16680 atttttaata gagacaatgt ttcaccatgt tggccagggt ggtctcgcac ttctgacctc 16740 tggcgatccg cccgcctcgg cctcccaaag tgctgggatt acaggcgtga gccaccgcac 16800 ctggcctggt tacttaaatt taaatacaaa aattatgttg attaattctg aatgatttcc 16860 tgattgctcc ccgtttacca ttcacacatt tattaaattc ttcgcttgcc atatagaagc 16920 agtctctctg ccatatatgc catatagata acagaactag ctgtctgcaa accactgaaa 16980 ttgtgaaaac atctcccctt ttttcctgtt tctaattcta gctatgagga ttatatacag 17040 aagtagtcct ggatttgatt tttttttttt tttgatgatt gttttttgat agttgttgac 17100 tacaaatcat ttaaacgtct gaaaggggaa aggttttcct taaaaatgga tgacaaagga 17160 gaataaaaag gtattttgac tatttttttg aatgatgagt tttttttttc tctttcttgt 17220 tttcttttgg agtcatttat gtgtcactga gtggatacca tggaacatgt ggcagaagta 17280 gatatatggg gtaaaagaac catagttcat aagctccttg acagaatcac tgaagtgtag 17340 ccgttatatg gccactgtcg cagggggagg cagcagtttt gaagaagggg atgagtaata 17400 atgagtgata aaaaggcatc ctggatagaa gaccaaactc tgcagaagac cccagtttga 17460 ttatgctttt gttttctgat ttgcggagga gagtgaaaat gcctgagggg tgcgggggag 17520 cacatagggt gtatgtgtgt gtgtgtgcgc gtgcagattc tctctttcac tgtatgtatt 17580 tgtatgcatg tatgtatctt aggacttaag ctttctagtc aataaattgc catagtgggg 17640 aattgcttaa ttgcttgcct tctgttgttg tatttaattt aattttattt ttaatgattt 17700 ttttggtggg gtacagggtc ttaactatgt tgtccaggct ggtcttgaac tcctaaactc 17760 aagtgatcct cccgcctcgg gctcccaaaa tgctgggatt acaggtgtga gccaccatgc 17820 ccagcttagt tgtattttaa atgggcctgt ttgcagcatt ccctactccc cttagtttac 17880 ctggctcaca acctgtcttt ccatatcaag gcttctgtca cccctggccc atgtcagtgc 17940 atttgggcag cccacccagc atcatcacct catgtcccag ggaacttcct gttcctctct 18000 tccagctatt tccttccctg gcagttgaga tagtctctac ctttgaccta ctgttaagct 18060 cagaccttct gctctctagt tacagcctct gtgctgccag attccctcgc tcagttgctt 18120 tctctagttt gggttttctc ctttattcag atttccagct gtttctctcc tccccccacc 18180 gcagcctcct cacttccctc cttatgcatc tgagactgtg gtcagtcact ttagatgctg 18240 cctctccact gtacttgtgt ccatcttctt acctaccacc tctagccctg gagcaggctc 18300 ttcccctgtc tttgtcttcc tgggcccagg ctcctaagcg ctgctggaaa aaaaatcccc 18360 2013203064 09 Apr 2013 100 of 771 cagtattgag cccctagaaa tccagtcttt aatcccaaat ctgtctcccc cagcatctgg 18420 ccatcagatc taaagcttac ctgccatcct ttccacctca tttctctcac aggggaaaag 18480 gagcctttgc tcctagagtc tgcgctcctg accccttccc atctcacctg ttcaaggcat 18540 cttgcaataa ggggttggtg actctcgagg aatggatccc aggccctccc tattatcatc 18600 ttatgtatgc cagttcaacg ttctcagctt cctccagccg agacggcccc tccagccact 18660 gctttatact ctccttctct ggttgaaatt tttgaagtaa ataggtcact ctgcccatcg 18720 ttcatcttcc agtcactctg tgtgtttatc ttccagggaa gtgaggctct atgctaccaa 18780 gccactgaaa taattttttt ttttttccag actgagtctt gctctgtcac ccaggctgga 18840 gtgcagtgcc gcagtcttgg ctcactgcaa cctctgcctc ccggcttcag gcgattctcc 18900 tgccccagcc tcctgagtag ctgggattac aggtgcctgt catcacgcct ggctaatttt 18960 ttgtattttt ggtagagatg gggcttcacc atgttggcca ggcttgttgg catgttgacc 19020 atgttggcca ggctagcctc aagtgatcca cccgtcagcc tcccaaagtg ctgagattac 19080 aggtgtgagc caccgcacct ggcctgaaat aattcttgac aagatctgct tccttgttac 19140 taatacagtg gatattttgc atcctaattt taatgcagtt cagtgtggta gacctgtatt 19200 tgcatattga atattccctt ccctgtttta ataactctat tttttccttt tcttttatat 19260 ctcctgcttc tctagctagt cctagacctt actcatcggt gtcttctctg tttgttcctc 19320 aacttgagga gttcctacag ggtttaccca atctgctgct ttcatttagc ccttttgttc 19380 tttttgagcc atctcattca ctcacccagg atgtagcatc ggcccttgaa ttcagtgtgc 19440 acacatacac tgtgcactat gggacagcct tcagaggcac tttgttcctg aaattgtggt 19500 ggtctttgcc tctcatggag ccttgcatat gctgtttcct ctgcctggaa tatcctacct 19560 tttacttaac tgattctcgt tcttctttcc agtcacattt tgtacatttc ttctgggaag 19620 ctttctctga tttccccttt ccacaggtcc aagttaactg ccttgtctag gtcctcccat 19680 ggccctctga aggcctcctt tcatagcacc atgtctgagt atactgtaat aacacgcatt 19740 gctctgtaat agcctgttta cttacctatt gccaagtaat ctatcaagtc ttataaaggg 19800 cggggctgct tttgttctag tcatttgtat ctcttagtac ccaatatagt gtttggcata 19860 tagaaaatac ccaacaaggc cagtcgcagt ggctcatacc tgtaatccga gcactttggt 19920 aggctgaggt gggcggatca cttgaggtca ggagtttgag accagcctgg ccaacatggt 19980 gaaaccctgt ctctactaaa aatacaaaaa ttagccaggc gtggtggcgg gtgcctgtag 20040 tcccagctac ttgggaggct gaggcaggag aatcacttga actggggagg tggaggttgc 20100 agtgagctga gatcactcca ctgcactcca gcctgggtga cagagtgaga ctccatctta 20160 2013203064 09 Apr 2013 101 of 771 aaaaaaaaaa agactccatc ttaaaaaaaa aaaaaaagaa aaaagaaaga aaatacccaa 20220 taagtagttc ctgaatgaat agatgagaat gctgtttaga aggttcatga attggaaacc 20280 gtgattgcta gggaggcttt gagttgatgg tattgtgttg aaccatgtgt tacccaggat 20340 caatttagat tttacacttt gttttctctg ttccttttta tagtaatttt ctgtatgtgg 20400 tgttttcccc ccatgagatt gtataccatt tctcagcgag aactgtgtgt aatgcttggt 20460 ggctccctca tggtgccttg catggaattg gacttcgttt cagtggatct gatcccagtt 20520 atgttaatgc tcgatggagc taagtcttat ctcgaagcag tccatgtctt catcagctgg 20580 ccctgcctcc atgccctgca cagaccatgc cactctggag aggtagtttc cctgtggctt 20640 attagtctta tgttccagtg tgctggccaa gtatgagaga catcagtggt atgagagagt 20700 ctctctcatt caaacttcgt aggttttgta gctgggactg accagtgctg acaggaaata 20760 gaggcattta ttaaaagcca gagatttttc aagttgcagg aagcaaagct cttgttagct 20820 atgattttgt ggtgggtttg gtagtccaat ataaaagtaa aaactggatg acaatgggag 20880 gagcatgctt gggtctccaa agttagatca tttttcctaa gtaatttgtc tttaaacttt 20940 tactggtttg gaatttcctg agattttgat cttgccagaa agtttatagc aaaagttctg 21000 agcagatgac acttttgcgt ctgaaaccaa atcattgttt ttgtttttaa cttttttctt 21060 aatatattat ccttagttca gccctgaaga ttattctgtt atttgtggat ctcaactttc 21120 cccccatctc ctggatcttt gtgaaatgaa tggtattaat tgaatagaga aggaagatat 21180 aaacataaac ttagtcaaaa acttgttctt gactaggcaa gttgggcttt atagctttga 21240 gctgatgaca tgtctattct tgtgaaaaag ggatttttag tgttggtttg gcttcttgtt 21300 atatttgatt tattattatt atcattatca ttatttttga gacagagtct tgctctgtcg 21360 cccaggctgg agtgcagtgg ctcaatctcg gctcagtgca acctccgcct cccaggttca 21420 agcgattctc gtgcctcagc ctctggagta gctgggatta caggcgggtg ccactacacc 21480 tggctaatat ttgtattttt agtagagaca ggtttcacca tgttggctag gctggtcttg 21540 aactcctgac ctcaggtgat ccacctgcct tggcctccca aagtgctggg attacaggcc 21600 ttagccactg tgcctggctg attttttttt tttttttttt tttaggtttg ttttaactgg 21660 aactttacgt gaatgtaatt gaatttagaa taaaagcact taatttcaca gtgtgcagtg 21720 aactttctgt tacttatttt aacagtaaaa ccccttgcag taaatgactt ggagcaaaga 21780 ttgctttttt aaaaaatgtt ttaatttgtt tttcttttct tgagatggag tcttgctctg 21840 tcaccaggct ggagtatggt ggcgcgatct tggctcactg cagcctcccc gcctcctagg 21900 ttcaagcgaa tctcctgcct cagcctcctg agtagctggg actacaggca catgccacca 21960 2013203064 09 Apr 2013 102 of 771 tgcccagcta atttttgtat ttttagtaga gacagggttt caccatgttg gtcaggatgg 22020 tcttgatctc ttgaccccgt gatccaccct cctcggcctc ccaaagtgct gggattacaa 22080 ctgctgggat tacaagtgct gggattacaa gcgtgagcca ccacgcctgg ccaatttttt 22140 tttttttttt ctttttgaga cagagtttca ctctgtcacc caggctggag tgcagtgtca 22200 cagtcaaaac tcactggcag ccttaacctc ctgggctcga atgatcctcc tgcctcagcc 22260 tcccaagtaa ctgagactac aggcatgtac cactgtgccc agctaattgt ttttttattt 22320 tttatttttt gtagggacag ggtctcgcta ttttgcccag gctagtctac aactcttggg 22380 ctcaagcagt cctcctgcct tgacctccca aaatgttggg attacaggga caagccactg 22440 cacctggcca aggattgttt tttaagtgaa ctgagaccca gccttattag tggtcccaga 22500 gcagacctgg gacctgaagg gaaccctttt cttctggtcc agcgtctttc ctctgatggg 22560 ctactttcct ggagcctttg attgcctgtc atcagagtaa ctgagtttga acagagtagg 22620 tagttcctct ccagaccacc acactcacca gctttcattc tgcttctctc gtttagactg 22680 tggttctgaa tcctcagttc tatttactga gtgtttttaa acataaaaat gccttttaat 22740 gagattgaag gccagaggtg ggacagttga ggacaaagta gaaataaaac cttcaaggcg 22800 gggttgttgg tgggagtctt tttttgtttg tttgtttttt gagactgagt ctcgctctgt 22860 cacccaggct ggagtgcagt ggcacaatct cagctcactg caacctccgc ctcccgagtt 22920 caagctattc tcctgcctca gcctccttag tagctgggat ttcaggctcc cgccaccatg 22980 cccagctaat ttttgtattt ttggtagaaa cggggtttca ccatgttggc caggctggtc 23040 tcaaactcct gacctcaggt gatctgtctg cctcagcctc ccaaagtgct gggattacag 23100 gcgtgagcca ctgtgcctgg cagggagtct tatagaagct gtcgtggaca atgtgggaag 23160 tagtgagcct ttgtattcca gtatgctggg ctccactgtg cttgctctgg cccccggtcg 23220 ctctctgtgt gttattgagt ccccatccac ggccatactc ttcgtcctgc ttctctcctt 23280 accatcctct ccccgctagt ggtaccacgg ctaccactag caattactga catgtgggat 23340 cttagggcta cttccctata aggctgcagg gcatgtggtg ttggctacgc gcatggtaac 23400 catggtagcc ctgtggttct ccacatgtgc gccttgtgac ctgggattgg ctgcagacta 23460 gtaataaact gcgtcttctg gtatggaatc tgtctgtagt tgtactttct acctctgtat 23520 ttaaggggag atctgtaacc taccaatgcc agttgaagag gatggatgat agagatgtta 23580 acaaacagct gaaaaactaa ctacaatggc ctgcaaaata gaacagcagg tttttgtggc 23640 aaaactttgt gtccatgagt ttgtttttta aatatcctca tataatctgt tttaaatcga 23700 gaggctttgg gtaaaagcca tggctagtct tacatgtcat ggagtaccta gcttgtgagg 23760 2013203064 09 Apr 2013 103 of 771 ttcacagttt attatttaca gagtgtcccc ttaaatcttc tttgggtcgg ttcagcgaat 23820 gttgctcaga tggacttttt tggctgacat agagtcaaaa tggtaatcaa gcatgaaagt 23880 acagacagtc cttaacgcac aaatgtgtca tgcttgaaaa gttggaaagt tggttctctg 23940 gagctctgat tgtattgtcc tgtagaatcc gtgttgtgaa tggtggttaa atcccaaatg 24000 agtccgtaga acctatataa tctgcaatat acctgcagta ttccaattaa tatgtaattc 24060 ccccatagaa ctatgttaat gatttgtatg tatggtattt aatattatac ataataatga 24120 ttgtatgaat aaaaaacatt ctgggctcca tgtggatgat ggggtgtgtg tgtgtgtctg 24180 tctatgtgtg ggtgggtgtg tgttcataga tcccttttcc tgcaatcctg gcactggaat 24240 tggttttatc atttccaatt aagtttcatt cccatgaatt ttggagtaca gactgggtcc 24300 aggtatgcag ggcatagatt agagccctga gaaataggat taggctggaa ttgctgggtt 24360 ggagatcagt agcttccagg aacacttttt gggcctggct gtcttcatta tccccttttg 24420 ttttctcctg gggtctgcag gtattgccct gttttgttcc tctaatatca cttttttttt 24480 ttttctgctt ttgaccaggg tttttgcctc tggtctacaa ctgaatatcc tatcagactc 24540 tcctgatttt gaaataaata tatagttttt ttgaggtgtt ctagcgaatt tctaaatcta 24600 aatgttgtgg cagagttatt acatactaat tttgctatga gaggttgtag aatcccagat 24660 gactaatctt gtaaaccata cacgcatttc catctaattc tccattgtat atcatgttgc 24720 agaaaataac agcctctaga gtttacattg cctcctttga ctatatttct tatttaagat 24780 tagttttcag ataagacctt ttcatggcag tacataactg tacagagggc ttccaacttg 24840 tcttgggagc tctcatctct gggagacatc acattaccca ctgccccctg ccccccgccc 24900 ccagcctgga tgcactcagc ctgtacccca tttctgtcct cagccaaaca ctgctgaaat 24960 gcaagagctt tcaattgcta gccagtgaag atgcagacta agggatttcc atgtagaagc 25020 ccgctctttt cagctggctc gtcgagagct ggaggcccct tgcttgttca catgaggctt 25080 tttgtccctg acttggtggc tgctgtttca cttctcagca gaaagggaca cccttgcccc 25140 cccccagaaa ggaagatttg atgtaccact tccgaaaggt tcagtcgggc atcactgtaa 25200 ccaagaagat aggtcaggtg aggctggagg tggaacaggg ctgctcgcta gaactccaga 25260 ttgttccaca agtgccttct ggcagagaat gatggaagct tccgtgattt ttttttctcc 25320 ttaatagtta tgagcacaga agaggagcag attgtctggc tatagaagct gtcttatttt 25380 ttatttttgt ttttgagatg gagtctttct ctcttgccca ggctaaagtg caatggcgcg 25440 atctcggctc actgcaacct ccgcctcccg agttcaagcg attctcctgc ctcagcctcc 25500 tgagtagctg ggaattacag gcatgcgcca ccatgccaga ctgatttttg tattagagac 25560 2013203064 09 Apr 2013 104 of 771 agggtttcac catgttggtc agtctggttt cgaactcctg acctcaagat ctgcccacct 25620 cagcctccca aagtgttggg attacaggtg ttagccactg cacccggccg aagctgtcat 25680 attaaatagc actttctgct tttagcaaat ttaatccaaa tgagacttta gattttcttg 25740 ctctgactta ccagcagttc cttgaaacac atttaattat ttttgccaga aaatcactca 25800 agcacttacg ccattttttt accgtgaaaa tatgctgcat tattttaaaa tatattagaa 25860 gtcagtaacc ataagatttt atatgttttc taatgtattc tgtaagcttt ctgctgcttt 25920 tgtttggaag gtgtattttg taacgtagag gactgcttta tctgcttgta agcttgattt 25980 ttgtttttac tgtaattttt ttttcttttg ctgtattgag aaatacattg agtaattata 26040 aagtcagtgg catgtttata agttaatatt tgtatctatt ccttagttac tctaactcaa 26100 aacctaaagt aatcttcaac tctaatttac tctgacatcc agttgactgc caagtcctcc 26160 aacttaatcc ttatcctttt ttttttaaag agatgcagtc ttgctttgtc acccaggctg 26220 gagtgcagtg gtgcaatcat agcttactgt aacctcaaat tcctgggctc aaatgatcct 26280 cccacgtcag cctctggagt agctggggct acaggctctt gctaccatgc ccagctaact 26340 ttttattttt attttttata gagacagagt ctcactgttg ctcaggctgg ccttgaactc 26400 ctgccttcag gcggaactcc tgccttcagg cggtcctcct gcattggcct cccaaagtgc 26460 tggaattaca ggcccaattt tattcttggg atgtatgtct gaaactcttt ccttcacttc 26520 cttcccaagc cttagttcag gcccttctca tctgtggtct tcaaagtcgc cttcagctgg 26580 ttcaggtcct tcctttctgc tgtatctttc atgggaggac atgttatgta tcactgtcct 26640 acttgaaaac ttccattccc cattgatgag ggtgttacct ccagattcct aacacaggtg 26700 ctgaaggcat gcctggataa aggcactccc ttgatctcct ggccaggtcc ccgtacacct 26760 gcagcgcatg ctccacattc tgtctttact gatgctgtgt cttctgcctg cggagccacc 26820 caccattcta ttcacagccc ctgcctcagc ggagcacgtg cctccctctt cctacactga 26880 gctgtccttt ctattgaatc ccctcttttt tgtagtatgg gaaatatttt attatgaata 26940 ctcttttctc tgttgcctcc gtgaccacgt taactttgcc ctaattcgcc ttaggactcc 27000 atctgcttag gggaaagtta ggatttggtt acagaaagca agctgctaga aagaacagtg 27060 tttagcttct gacaggcaaa ataggatttt gcaacatgct tttccttttt aatgcttaga 27120 cattttatat gaattaatat ttttatttgg ttgcttatac attactttct ttttagctag 27180 aatgtgaacc ctataggaac atggggattg cctttcacat ctttgtatcc tcagtaccta 27240 atgttcagtc accctgtggt cttgtgtcgt atatacattt agccttcctt aattaaacca 27300 tatgtactgg tccccgtccc ccacccccaa atagagagaa agaaattcct tgaatactac 27360 2013203064 09 Apr 2013 105 of 771 attgccagta tcaaaccaca ccttgatatc ctctggggaa agggaggtat cagttgaaaa 27420 gagaaaagag gttaaaatct aggcattaaa atgtgtaagg cttagatgct ggcaatttaa 27480 ggtatgtttt cctgaggtta attttgattg tgtgcaaatt ttacctcata tctaactgta 27540 ggatttagtc accacataag atgggatacc tccataaatc cttcagaaat gtttgtgaaa 27600 ttaaataaag ccttattgaa gactcagctc ttgagagtca tctacctacc taacagttat 27660 tcttgaacag aagagtctta cttttcccta taaggcagtg tgatagccat ctgtatattc 27720 atataattta tgttggcgct tacttcattt aaaaatgtat tccgtgaatg cagttgccag 27780 gcggtgtgct gatcagaaac gtgtaccaat ggcctctttt ataattataa gaggaagacc 27840 aacctgaaac agtcacacaa atgattaatt ttaattgtgg aggagtgctg ggaaagaaaa 27900 ataaaagatg caatgcaagt gtttacaaag gagctttgag cttgtttgaa gtggtccttg 27960 ggcacttaag caaggcttaa agaatgatgt gattagaagt ggcttagcaa ttctaaagaa 28020 cacagggaag gcgtgtggcc agaacattgg tccctagagc acatcgcctc ctgacatacc 28080 atttccttaa gttaatgttt taccactata cataggccct cccctttgtt tacccagatt 28140 tttttaattt taaggatgtt tttaataact tagaatcctg taatttgttg aacagtcctg 28200 tattcccttt acttatattc cttgagattt tataaaatat tttttacatg tcccaagtct 28260 tgattatatc tttttacctc ttgttaagaa atacttactt ttctattttt atgctatatt 28320 tcatgtttac tgtagaaaac aaaaaaagta aaatttttct ttattcctat cactgcagct 28380 tataagcact ctaaacattt tgatctatat tttgccaatc atatatttta gttaaaattg 28440 ttgttgacat aattgtagat tcctgtgcag ttgaaagaaa taatacagag ctgagcgcgg 28500 tggctcacgc ctgtaatccc agcactttgg gaggccgagg caggcagatc atgaggtcag 28560 gagtttgaga ccagactggc caacatggcg aaaccctgtc tctactaaaa atacaaaaat 28620 tagctgggtg tggtggcggg cacctgtaat cccagctagt tgggaggctg aggcaggaga 28680 atcgtttgaa ctccggaggc agaggttgca gtgagccgag atggtaccat tccactccag 28740 cctgggcaac aagagcaaga ctgcatctca aaaataataa taataataat aaataaactt 28800 taaaaataaa acagagagat cccatgtgcg ctttgcctag ttcccccatc cactgcccat 28860 aacattttgc agaactgcag tacagtatca caaccacaat actgacattg atacagtctg 28920 ctcatcttat tcatatttcc ccagtgttac tcgtatccac gtgtgtatgc attgtgtttt 28980 caatactctt ttattataaa gctgttttta atgtgattca attctaggtt gttttgttct 29040 gccctcaaaa agcattccct ctcctaatca tatctccgtc atacccttgt atgttttctt 29100 taaacctgtt ttaagaaagc agctacctgt aagagaaatg agattgaaaa cagaattgcc 29160 2013203064 09 Apr 2013 106 of 771 aatctgcttg tactttataa gcctgttgat tgtttagata cggtttagcc agtttatagt 29220 taccctgggt gctgaaaggt atgctggatg atacctaacc aacagagaac cattgaatgc 29280 cgttcaaaat ggactgaagc atcagcaatg tctgaaaaag gcctgacagt aatgtacatg 29340 tcaaatggcc cgtaatttaa gcagagtaga gtaagtagaa gaataaacat ggggaaagtt 29400 ccagcaacag aggaggcttt gagcttttgc tcttcatctt gagtggatgt tgttctcagg 29460 tggtaatagg ccatcgagct ttctccactg gctgcctctc tggggaacaa ataaccgaaa 29520 agatactcag caccctggtt ggtacatagg tggtcagttg atttatactt cctggttttc 29580 agtgttgctt gaattttcta aatggaaaca cagtaccttt ataatcagaa aacaatcccg 29640 agttttgatt tgagggtgtt gtaaaaagtt aaaaaaaaaa aaacagaaat gtgaaaagga 29700 agttgtgtta gagtatttgg agttgagaaa gcatgaaaag gacagaagag aagctggttg 29760 tcaggttgca tggggtagct acaagcacac tgaccagaaa gtcagctgga aaaaaaatgt 29820 agaaacagga gataaaacgg ccaaggggct atacaagcaa acagcaagga cctgagaaga 29880 aaaactagtt aggtgtgact gtcagagtga tgtgtacagt gtgatccttt ctgtgtaaaa 29940 acaagcagta agaattcgct gtttacgttt gcgtgtgttt ggagaagagt ggggaagagt 30000 aggcactgcc agactgtgaa cactggttag gttattgtta tatctttgta ttatatacac 30060 tggacatgtt atttgtataa tatgagaaga aattttataa atcattaaat cttttggcat 30120 ttaggaacat ttgtgttttc taatagttgc ttctatacta ttatctttat tatatgccct 30180 tcatcttctc agtgtttggc tgttgttgtg attccctttt gtgagcagtg ttgaagttag 30240 ctaatattca tttcttctcc cttctttcac cctcctccag agtctgattt gaagtattcc 30300 tagctgctac ctataaaagc aataagcaag attgttttac ttttcacaaa ctcgtcctgt 30360 tctgtgcctc tgcctcggac atagctgtag tatagagtgt tgtctccctt acatccttct 30420 atcttagacc tactagtaaa tattaatgct cactctaagt tcttctcaat tctttttttt 30480 tttttttttt ttttttttga gaaagagttt cgctcttgtt gcccaggctg gagtgcaacg 30540 gcacgatttc ggctcaccgc aacctccacc ttctgggttt aagcgactct cctgcctcag 30600 cctcctgagt agctgggatt acagtcacgt gccaccaccc ctggcaaatt ttgtattttt 30660 agtagagaca aggtttcttc catgttggcc aggctggtct caaactcccg acctcaggtg 30720 atccacctgc ctcagccttc caaagtgctg ggattccagg cgtgagccac cgcgcccagc 30780 ctcttctctc aattcttcct gaagctcttt ctgcactaga ttcctcagga agggcttgtg 30840 ggaacaatct tctgtgaatc aacagtacat attcataata gtttgtcagc agcctattat 30900 tttaaggcca tttggtctgt atataaaaat gtttggatca cattttcttt ctttaaggta 30960 2013203064 09 Apr 2013 107 of 771 aatatgttat tctgttgtct tctggtataa agcattgctg taaatgtttg acagtctaat 31020 tatcttttgc ttataagtga cttagggttt tttgtctatg tgcccaaagg attttttccc 31080 tctttctctc tttttttttt tttttttttt tttttaaaca gacaggatct caccctgttg 31140 cccaggcttt agtgcagtga ggcagtcaga gcttactgaa gttttgaact cctgggcttg 31200 aggaacaaag gattttttta accttttaat tcaaagtctc atcatttatg caaccatgtc 31260 ttggtgttgg ctgttttggg ttgttctccc tcaaaaatcc atgtgctctt tcaatatgta 31320 gttttaaatc tttttttttt aatttcagga aaatcttgaa ttagagtttt ccgtttttcg 31380 tctggtacat tgcttgggtt tccttcttca ggaactcagc ctgttatgtg tatgtttgat 31440 cttctttgcc tgtcgtctgt ttctttcact tcctctcact tttttaaact tcatttatta 31500 aaaaaaaatt tttttttcga gacagagttt cgctcttgtt gcccaggctg gagtgcaatg 31560 gcgtgatctc ggctcactgc aacctccgcc tcccaggttc aagtgattct cctgcctcag 31620 tctcccaagt agctgggatt acaggcatgc gccaccacgc ccagctaatt ttttgtattt 31680 ttagtagaga cagggtttct ccatgttggt caggctggtc ttgaactcct gacctcgtga 31740 tctgcccgcc tcagcctccc aaagtgctgg gattacaggc gtgagccact gtgcccagcc 31800 ttattaaaaa ttttaaaaac atacatttaa acttaacaga aaaattatga gagagaaggg 31860 ggtggtgcca ggctttttta aacaaccagc tcttacatga actcatagag tgataactca 31920 ttaccatgag gacggcatca agccgttcat gaaggatctg gccccgtgac ccagacacct 31980 cctactaggt ccatttttaa cattggggat cacatttcaa cgtgagattt ggagggggca 32040 aaactacaaa ccatgtcact cagggattgg aggagcaagt accacctata ctttggactc 32100 aggtagaaag gcaaaatatc caggaaataa gctgctaccg tccagggttc agcagaggtg 32160 cccatcagcc tgccaagtac tcaagagtcc agcctctagg gagctaatca tcatggtgag 32220 ctcttcgagg cacagggagc tgggaagaca gtgcttgcca cccctgcctg aatagtgttt 32280 gcacagagag ttctgttgtg tcttgattgg gtcctcctgc cactgggaat gctgtggatt 32340 atactaggtc tctatctggc ttgtttcagg gctccatgtg aaaaccttct tgatatccta 32400 gccatccacc tgctcagtcc ctagtttgca aggaggctgt ggggagccta gattctgtgt 32460 cagatagaat gtactacatt ccgtctcagg aatgtaccac atcagaaaac agtgcgacct 32520 gcaggagaag tagaggtgaa gaggcacatt cttccgagaa atgtttctct caacacccag 32580 cattccctgg atatcagcag gaaattactc actgctagaa aatgccccat gagccttctg 32640 ttaaggaggt caagggagag aacagagaaa gttctcaaag ttgacttggt cactggtact 32700 ttcttatgcg gttcttattt tgtttgccat cgtcatcatc atgctatgtc tattttctca 32760 2013203064 09 Apr 2013 108 of 771 atccaaatcc actgctttca ccttggttct ttctgaccgg tttggcacac tcattcagta 32820 aatccttatg gagagcccaa tgtctgcata attgtgctgt gctgatgacc aagctagacc 32880 tacgagtgtc ggctcctttg agatgtacgg gacagctctt ctgtcatctc ttctgggaag 32940 cctctccagg cttggtgaac agtggcaaga tgtttaacag ttgtacatgt gtcccatgtt 33000 cctttctaag agcctgggca aaccagaccc ggtcgcaggt catcgtagta tggcgtgagc 33060 ttcctctctc ctttctgacc ttttgtgtga tggcaagaac ctgcagagtg acacaagcag 33120 caggcttctg aggttgctct agcctcagaa tggccgtccc ttctccaccc tggccctcat 33180 tgctgaggtt tcctttgaag caacagtgcc ggaacagact aggggaagca gcttggacat 33240 agctgtatga tttattacca cccattgagg ccaaccaaag tcggcaagga gaggtagcag 33300 gtcagtggtg cctggaagct tcctctttcc tttgcaccag atgtgactgc tctgcaatta 33360 ctcctaaatt tgctactctc gtttttacta gccaaccttg atgtttttcc cttcttcctg 33420 tagaatagac ttcccctctg atcagtactt tctactcaac actatttgtg gccacagtgg 33480 gaactcattg aggacaggga ccatgacatt actacctgac ccatcaacac ttggcataac 33540 ttgaaatgca aggacaaaaa ttggctgcaa gtacaatgtg gtcttcactc tgaaggtgat 33600 ccttaaaact tggctttggc atcatattgc cttaatatac ctaggggatt gggtaaaacc 33660 agttacttta aaagagtttt acaattctgg ccttctagct atcttgtctt cttaaacaag 33720 agcacaagat gaatgtatct tagtgaaatt ttatatggtt tgctttgagt aatcttgcga 33780 agattgattt ttagcacagt aggaaagaca cattctaata gtgatttttt tccccgagtt 33840 tatgtactgc tgttgcatga aaatctgact agatttaatg ttcctaaagt tctttgttca 33900 tcctgatttt tgcaggtcct agggaaagct ttgttttcct cttaacctaa cttagatgtt 33960 gtcatttcat gagctttgga ggaagagtgt atagccaatt gtgtaatgtc tttaaaggat 34020 attatctctg caatagttgt ttataaggcc taagttattc atgtaataat agtggccccg 34080 gatctgtttc tagcaatagg tatatggatt ttggttccta tatagttgta gttgtggctt 34140 tgagatattg agcaagccct tttaagaaag gatttggcat ccctcagcct tcaaaagctt 34200 ctcaaaattg atcatatgtt attagcaaag gtttactgcc tgcttccatt gtatagacaa 34260 tttatttttt atgtattccg ttctaagaag gcagatgacc aaaagatctt gcatctgttg 34320 cccaaggctt gtgactagag aggaaagaga taagaatact tttttaaaat cccattttac 34380 taaatatgtt gaggaagtgg taagatatat taatttgttg agatttttct gttatgccta 34440 ttatatgaaa taggtactct gaacatggct tcttaattaa atatatttga taaaatacaa 34500 cttgcttccc ctggagttta gaagtcagat aactgccatg gagagctatg ctttctttgt 34560 2013203064 09 Apr 2013 109 of 771 tttaaagatc tgcttatgaa catgataaac aggaacaatt taatgttttc aatattttct 34620 tgtattttac tgcaagttta tacacaacat aaatatgggg gaagggggaa atgtttatac 34680 cagagccatc ctgcccattc tttccttaca gaaggacaaa ggagcagtat ttattttaac 34740 tacaaaaata ctattgtagg ttttaaaaat tccgtatatt ttgatatctt gtgttcctct 34800 tgacctttaa tttgctaaat agttgcaaag aatgaaggta acctgcatca tcttcttaaa 34860 aaccaactct atctaattat aatagtttgt ctatctctga aaaatagtga tgtgttcatt 34920 ctgaaatcag aactaccgga tgcagctgca ttttgttact atttgaattt cgggagaggg 34980 aggaggatgc agcctttcga gctgctgaaa tacacaaaca caaagaagac accaagcata 35040 gtagaactgt gttaagctga ccaagccaga agaagcacct attctcagca tagtatgaga 35100 cgtaaaggca atataatggg catagttgaa gatggtagaa ggaaaataga ctctgatggt 35160 ttaatgttaa atgctttttt taaaaaagtg gtattccaat atcgaagaag aagactttct 35220 acttttagaa gcaataaagg aaattgcaga ggaaagggtc aataggttgg aatacataaa 35280 aattaaaaac ttttaaactt tttttttttg agacagagtc tcactctgtc acccaggctg 35340 gagtgcaatg gtgcaatctc ggctcgctac aacctccgct tcctgagttc aagcaattct 35400 cctgcctcag cctcccgagt agctgggatt acaggcatgg gccaccactc ctggctaata 35460 tttgtatttt tagtagagac agggtttcac catgttgtcc aggctgatct caaactcctg 35520 acctcgtgat ccgcctgcct cggcctccca aagtgctggg attacaggca tgagccaccg 35580 cgcctggact aaattgtttc agtattaatt ttttttaaaa caagatctta ctgttgccca 35640 ggctgaagta cagtggccca atcatggcta actgcagcct tgacttctgg gcctcaaggg 35700 atcctcccac ctcagcgtcc cgagtagctg ggaccacaga catgtaccac cacacccagc 35760 tacttgtttt atttttattt ttgtagagat gaggtttcac catgttgccc aggctggtct 35820 cgaactcctg ggcccaagca atcctcctcc cttggcctcc caaagtgctg gtattacagg 35880 tgtaagccat tgcgccctgc ctgatttttt aaatgtgcaa acagataagt tggaaaagtg 35940 atttccaata aagataaaga gttgatggtt ttaaaatacg taaagagctt atatgaatga 36000 gaaaaacact aacattccaa aagattagaa ggcaaaggac agaaagaaac aaatcactat 36060 gtctgggaag ggacatgaag gagcaggttc ccactgggcc agcggggctc aaacccactg 36120 gggacgtccg agagactgca agggccatgc cttcacattg ccgtacctga gaagcaagga 36180 gctggggtat ttatctcttt cacactttgg gaggctgagg tgggcggatc acctgaggtc 36240 aggagttcga gactagcctg gccaacacag tgaaaccccg tctctactaa aactagaaat 36300 aattagctgg gtgtggtggc acacacctgt aatcccagct acttggaagg ctgaggcatg 36360 2013203064 09 Apr 2013 110 of 771 agaattgctt gagcccagga ggtagaggct gcagtgagca taaattgcac cactgcactc 36420 cagcctgggt gaaactctgt ctcaaaaagt aataataatc atgataaata aaataacatt 36480 agattgttag cagaagtagc cacaggtttc tcccacctct ctgcaagttg ctgagtgtga 36540 ttcccatcaa gaggtacaat gtctttttat ttttatttta tttattttat ttatattgcc 36600 tatgttgtct aggctggttc caaactcctg agctcaagtg atccttctac gtcagccccc 36660 caaagtgttg ggattacagg catcagccac tgcacctggc ccagatactt tttcttgagt 36720 aggaatttcg agtcaccctg aacattgcat gccttcgtag tggggaagac aataggaaac 36780 cacaggctgt aggctaaaat gggttgtgtt tcttgtaacg tcatgacaag gcataaccca 36840 tcttggcata gtaaatagta agcactcact gaactgatga ttttaaatct ttgctgttta 36900 ttcagcaata tcctaaatta gcgctatgtt agtggagttg catctccctc atggattagt 36960 ctgaaaaaga tgagaaatct gtatgtagac caagttatcc ttaaactgct cataatgtat 37020 gatgcacgtg gttttacgtg tacagcctgg taccattgtt cttaggcaca tttcagtgcc 37080 agaactctta atacccagga agaagcaaaa agaaagatgg aggtgcagct agaggttgtg 37140 gcctttgaac gattcattct gccttaataa gagtggtctg gctgagctcg gtggctcaca 37200 cctgtaatcc cagcactttg ggaggccaag gcaggcagat cgcttgagcc caggagttca 37260 agaccagccc aggcagcata gcgagacccc ccctcccccc gtctctacaa aaaaatagaa 37320 acaatgagcc aggcatggtg gaacgtagtg cgtggtgcct gtagtctcag ctacccagtt 37380 ggctgaggtg ggaggatcac ctgagcccta gaagtcgagg cttcagtgag cccttattgt 37440 gccactgcac tccactctag gtgacagagc gagacaggtc ctgtctcgaa aagaaagaag 37500 aagaattaaa aaaagtgatt agatcccttg tgtttgggac acttgttggc agcagggatg 37560 gtagcgttta tgagggttgc atgtaacatc gcctagctca gacatctgtt tgactgtctt 37620 cccccctgaa gcgcaggctc tgtgagggca ggtcttttgt ctttcttgtt aatcttcata 37680 tgcttagtgc ttgccacata gttgatgctc agtcgatatt tggatgaatt gaagggatta 37740 atgcattgaa tctgaacctt gctttcttaa tgcatatggg gagttctttg gaaagccaca 37800 cagaggagct tggttgcctg cttcctctct tccccagatt gtctttttat tgttgtggct 37860 tcactgaagc actctcactt caaataattt tgggcattgg tcgtatttta ttctttgttc 37920 cttcttcatc cttacccctc agatggtatg tagaaaagta cactacatct agaaagtact 37980 ttataaactc atttggttga taataataca tatgcctttt ccttggtcct ggtagcagaa 38040 tcttgtgcca ctcttggaat acaaacgaaa ttcttaacca aagccagttt cattttgatg 38100 ttctattttc ctcccattca cactccaaat tgtgcaccaa agtatcatcc tagttttgtg 38160 2013203064 09 Apr 2013 111 of 771 aggatggttc tccatacttc agggtaggag tatcatgtgg attcctatga tacctttctc 38220 cctgggacca tggagggcag cagctggtga ttgatagtct gattcccggt gaggaaagct 38280 gtgagccttc cacttgcaga tgtctgccaa ctacatgtgt ccttagtcaa ctgtaccact 38340 gtcctccggc aaacagcaga agcccagggc ctgaagttct taagctgtca ttatggaaag 38400 cagaaggtaa acaaaacaga agtgaaagta gatttaattt tttagactgt tctcttacag 38460 gaatggtttt gtggttctca gcattttaaa aaaaatagtg gttccaatat gttttattga 38520 catcaattac tgtaagtctg attcattttc tgcctattga tttctaccca aggtgaaatt 38580 catgacattt aacagaaagc ataagtgatt ttttaaaagc agacactatt agggacggta 38640 aaaataagat ttaaagtcgg gacacttgaa aaagcaattt ttataccttt ggtaacgatt 38700 ctattctgat tctttgtata aataatataa acaaaggctc tagaagctta ctataatgaa 38760 gttggtgtgc tgtttctaaa ttctggttta aggcccaaat tcattttatc tgcattaact 38820 tttttttttt tgagagtctc gctctgtcac ccaggctaga gtgcaatggt atgatctcgg 38880 ctcactgcaa cctctgcctc ccgggttcaa gcgattctcc tgcctcagcc tcccgagtag 38940 ctgggattat aggtgtgcgc caccacgccc ggctaatttt tgtattttta gtagagacgg 39000 ggtttcacta tgctggtcag gctggtctca aactcctgac cttgtgatcc gcctgcctcg 39060 gcctcccaaa gtgctgggat tacaggcgtg agccactgca cccggccgtg ttaaaatttt 39120 tcagtggtag accactatgt caatatgttg ctttcactga caacagtatt ttcttaaaga 39180 taggataccc catttctaga tgaatctcat tctagctgga aaataatttt tcagttctga 39240 aactacatca ggcctcaggg aatcaaaact agctattagc cacacacata taaagtggct 39300 ttgctttata aacgatttag ggtcaccatc aatgacaatg gtcccttttt attgtatttt 39360 taagagtttc ttatcttaaa tggctgcata actgtagagt tttaaaaaaa ttaagtaaat 39420 gaccatgtta atgctctatt aagcttccaa acaatattgt aatttacttt gaagattttt 39480 ttttattctc aacatcctgc agcttgaccg tttgcctccg tgtctcagtg ctgcttattt 39540 tgaggtgtgg actggagtcc atctgtcccc cttgcctctg aactgctccg ttttgtgttt 39600 cgtaattctt catgctgcat cctgggcgca tttctctgta gtagctttca atttgctcat 39660 gctttgactg ggcttagtct agcgtttatc ctatctctta aggtttttta aaaaattttc 39720 atgattattc atttatttcc aggatttctc atttcttcag tcacatctcc ttgttctggt 39780 tttacttctt cctgttttta ttcataacat cttttttata cacgattcct tcatgtattt 39840 ctaatcttaa gtatatttaa ttgcttattt gattcttttt tttttttatt gagacagggt 39900 cttactctgc caccaggccg gagtgcagtg acatagtcat agctcactgc agcctcaact 39960 2013203064 09 Apr 2013 112 of 771 acttggactc aagcgacctt cccacctcag cctcccaggt agctaggaat acaggtgtga 40020 gagccgccac acccagctga tttgtcttac tatgttgccc aggctggtct tgaattcctg 40080 ggctcatgtg atctgccctt cttggcctcc tgaagtgctg agattatagg tgtgaaccac 40140 tgcacctggc caagtatgtt tatttattta ttctaatttg agagggagtc tcgctctgtc 40200 gtgcccaggc tgtagtgcag tggcacaatc ccagctcact gcaacctctg cctcctgggt 40260 tcatgcgatt ctcttgcctc agcctcctga gtacctgggg ttacagttgc gtgccaccac 40320 acctagctaa tttttgtgtt tttagtacag gcggggtttt accctgttgg ccaggctggt 40380 cttgaacttg tgacctgaag tgatccgccc gccttggcct cccaaagtgc tgggattaca 40440 ggcatgagcc accacgcttg gcccaagtat gtttattttt aaagtcccca acaagctata 40500 caataaattg catatggaat ggatttttgt tctagttgat ttgttggtta tcatttgtag 40560 aactaactag ttgtcttctg tgtttgatac cttgcttcta ggtcattttg agttgggagc 40620 cttttgtttt gtttttattc tcatgctgtt tttgagccta gctgtgcctt tatggttttc 40680 tctaaattta attgaccatt gttttatatt tggagcagtg ggtgtacatc agagtgtgaa 40740 agcagcccca ccctctccac cagaaggtct ccatgccagt ttcacgaagc atttttcatg 40800 ccctcattcc tgcccttatc ccttgatttg tggggagttt gtaaagcagt tgattgtttt 40860 ttttccacgt agttttccaa gtgcacataa ttgttctgtt agtgacttgt agctccatta 40920 tctattaacc ttgccccaga ccactgtaca agcggaccca acgcttcctc cagctgtggc 40980 agggacagtt acttggtatc ctgctgcctt ttcaatgctg accagttttg ccccttcctc 41040 ccctcaaccc ctgtctttca ttcaactatc accaaaccaa aagattctgg tttgcttttt 41100 agtatgtgtt cttattcagt acatagtcat tttaaaattt aaaccaaaac agacttggta 41160 ctgattagct taattttaag ctttttcttt attattaaac agtgtagttt atcttagcat 41220 ttcatattaa gtatatgatt tatttcatat tgcttatatg aatgtacaca taaatataat 41280 aaaaatattt tcctaaggtt tttgtagtaa attatatcgt ttcattaact ttcatatata 41340 gcattgcttt tgacctggaa gacattgaac ctctgatgat ttgtatattc ctcggagtat 41400 actttgttac atagaaattt tctcatttat aatgagattt gtgattaaca aaatttgttc 41460 aacatgcatt actttgaaga tctggtttct aaaattttat gctagttacc ccaccccccc 41520 ttctatatat atctccctat tcagcgacta ctgcaagagt tccaggaaat gtacactgtg 41580 tgttcactta ctgcatttta aatcattgcc tttactatat ttctgcattt cccttcaatc 41640 tagctctgtc tgtacatttc tgaaagccag tagcttccct gaagaaccag gtaacaaccc 41700 gaacaatcaa attagataac catttgtaga atggaggttc cgggagatct tagaagatgt 41760 2013203064 09 Apr 2013 113 of 771 gatgggtgct aagggacttt gtagttccct gaagttccag tgagtaaaag gtacccttgg 41820 aattttttat tccttcagac ttttaaaaca gagatcactt tcaaaaatta ctctttctgc 41880 tttgaatcca tgttttagta actattttga cactgtttgg tcagaaggct gtgtgggtca 41940 actgcaaata aataaaataa atgtgatttc agtaatttcc attttgtaac aagtaattga 42000 gaaaatagga ttggatcaga tatttgctta tacacattcc ctttcaggag cacttctgtt 42060 ctataaagaa tgttggtata ttgttaagga cacttcaagc tttgggaacc tttgaagtat 42120 ccattgattc agttaacaaa attatgttga gtgcctaccc tgggcctggg cctgtgttag 42180 gaggggacac taagatgaga gtccaaagca cttcttctca gactcctggc tgctaatggg 42240 ttgctgcctc tacttcttca cttagcagat agctttaaaa tgagtaatgc attttaccat 42300 ggagcccgta agagacattc acccagttgt ggaccgagga gaagggtgtt aaacccagat 42360 tgtgatgttt cacttgatga agtgcttaat ataaacatgg aaatatttcc gcaaggataa 42420 actggctttt atgcctgtgt gttttcagga gaaatagaaa tctctaatca aatattgcca 42480 gcttttcacc caagtttgac tttttgccta attgagtttg ggaggtgtct gaataatgga 42540 taatgagctt tcctgaataa atataaaaat taattaactc caggctctaa ttcattctgt 42600 taccagagtt ttgtaagcat gttacccctt tgtgttcatt gggagatcat ctgttacctt 42660 cttaaatgag tggggaagga tgggaaatga ggaagagcta taaaaactat tcaggtgaag 42720 aaggtttctg cccctccttg ccccttttaa aatctccagc tcagcagatg ctttgtttaa 42780 acttgatcaa gtgcttgtga atcttcctag cctagctaaa tcataacttt ggaaggactt 42840 gcttttttct ctcatgacaa tggtttacca cagaaatgat tcagatcact ttgtgtgcct 42900 gatgcctatg taaaatgata cagtgaaatg gaaaccattt acctgtaagc tttgggcaca 42960 cccaagcctg cttcaggagc acatgatcag gcgtgcactc tgggagagcc gtacacattt 43020 gacatctatg atgtgtggcg ttttattcta tcacatttct gaaatctaca ctaagagaaa 43080 ggaggctctt aaaaaaccac tgaggtgtgg actgggggaa ggagagatcc gtaaagaacc 43140 tgtttgttac ctgttgatac tatttcccat tggtaaaatt tctaatttag tgtgatccag 43200 ccctgaaatg ctgaggcaca cactgaatga ctcctgacat ctttagtgtt tttgttcagg 43260 ggactcttct gggaatctgt ttcatggcaa gtttattatt cccttttggt ttggctcatc 43320 agtttaccca gcagtcatct taatcggttt taaaggcttt tattttattt tgttttctct 43380 gtggaaattt tacacattca gtagattaga agtagttatt taatctttgg ttagcataat 43440 aaaagatctt ctagggacat tttttgcttg cagtggaagg ctagttaaat gtgttcatta 43500 gtcatgaatc tgctttttct atagctgttg gaaacgtagc tcccctgtga tacagttgta 43560 2013203064 09 Apr 2013 114 of 771 gaatacagaa atctcgtttt gctgttacgg tacggtagtc tacttacttt cttccaaacc 43620 attaatgtta tagttacctt taattgcgta ggtcctatca cccctcaatt ttaagactct 43680 aagcctggca ttttatctta caaaatgaaa tataaagact tgtactcaga gtatgtgtgt 43740 gttttccata taccattcta aagtagagaa agatgaggga ttcgccagaa actgatttct 43800 aataaattat ccagaaactg accccttctc acctcttctg ttactgtcac tgtggtttca 43860 gccacagcat cctttgctgc attgttacct tagtttcctg actgtatcct tccttacacc 43920 attgatccct gcaatcccat ctgcgcgtag cagccagaag ggatccactt actgctgtga 43980 tcagaaatcc tcagccaggt gcagtggctc atgcctgtaa tctcagcact atgggaggct 44040 gagactggag aattatttga gcccaggagt ttgagaccag cctcaaactg ggtaatataa 44100 tgagacctca tctctacaaa caggaaaaaa aaaatttttt tttttttttt aactagccag 44160 gtatagtgct aatatacctg ttctgggatc cagcatgctc tccctgacct gcagcttcat 44220 ctccaccact ttgcccctca ctcccaccac aatggctttc ttctcttcct cagacatgcc 44280 gtgcgtcctc ctacctggaa tattcccctc caaacattcc catggctcac tccctcacct 44340 tcatcagatc tctgttccag tgtcactttt actggaaggt cttttgtgac catcctactt 44400 attataaaaa aataatctgc ccaaccttct ccttttattt cctctacttg atttttcaat 44460 ttagtactta tcagctgaca tatattttgt ctctctgtct ctctctgtct ctcatagaag 44520 gtaaattcta taaaggaagg aatttttatg tttggttctt tgctgtagct ccaatattca 44580 aaacagtgcc tgacacacag taggcccttt atatttgttg aataaatgtt gacactctga 44640 tatctaattt ttgtctggtg actaatacga aaactataga gtgataataa aagcattacc 44700 ttagtagact ggaaagggat gagcgctagg atgaactttc tgcctggcga tcttgctgaa 44760 tttaggaggc agattggggt tcaaaggagg ctgaaatggc taggatttgc agagcagggt 44820 actaaggatg agcaggctat gacagaaaga actccagaaa tctgcaaagg gatcaccttg 44880 agtctggctg gatacagtgt acactttgta gggtgtctct tcatgagctt ggataaagaa 44940 caactgttgg ggagtggata attcccagca ctcattcaag cttgcatcgg ccagaacgga 45000 gagagacaga cctctgtaat acgtaggata tttggtagaa acattcaacc gaaaaccatc 45060 agatatgcaa aaagtaataa taataagtaa acaatgtgat gcatagctag aagaaaaatc 45120 agacattaga agcaagccca gaaatgacag atgataaatt agcagataag gacattaaaa 45180 cagctattat aaataactta gcagatttaa agaaaaacaa cataatgagg ataatggaag 45240 aaaaacaacc gaataccatt tctaaagaag aaaaatacaa tatctgaaat gagaatttag 45300 ctggatagga ttaatagttt aggcactgca gaagaaaaaa acagcatcta tatgagaata 45360 2013203064 09 Apr 2013 115 of 771 tacccaaggg aagtacagag aggaaaaaaa tgtggattgg ggggtgcctc agtgacatat 45420 ggaacaatat taaacaagtc tgcccccaaa atacttgaag gaataaggtt caagtttttt 45480 ccaggtttaa tgaaaactat aagcctacag attcaagcat ttcaacaaac cttcagcaaa 45540 ataaacaaaa ccacagtagg cctggcacac tgtctcatgc ctgcaatccc agcactttgg 45600 gagcctgagt caggaggatt gcttgagatc tgcttgggca acatagccag accctgtctc 45660 tacaaaaaat aaaatgaaat aaattagctg gatgtggagg tccacacctg taactctagc 45720 tagcctggag gctaagaagg gaggattgcc tgagcccagt agttcaaggc tggagtgagc 45780 taggactgca tcactgcact ccagcctagg caacagcaag accacatctc tctctctctc 45840 tctctctctc tctcaaaagg cagtgaaata acgacttatt tggggaaaaa ataaaggcag 45900 agaatttgtt gccagcagac tagcataaaa aaaaggaagt ccttgaaaca gaagagaaat 45960 gataaaagat ggaaatttgg atatatacta aagaatgagg attgctaaaa gtgacataca 46020 tagataaata tgaaatatat ttttatttta aaatttattt aaagcaaaaa taaaaataca 46080 tcatatttat aacatagaaa taaaaaatgt atgataatag cataaaggat aagtggacaa 46140 atgctgttgt cgtatttttg gtaaaatgca ctattatttg aaagtagacc atcgtgaatt 46200 cgatgcatat tgtaaaccaa atagaacact aaaaaatgaa aataaagaga tatggctaat 46260 gtgccaatgg tggagataag atagatgcaa aaaaagaaaa acattcaaaa gaaggcagag 46320 acagaggaaa aaaggaccaa agatcaaatg agtcaaatag aaagcagcta aactagcaat 46380 atggcagatt taaatctagc catgtcaata gttatattaa atgtaaatgt tctaaatacc 46440 tgaattaaag gatgaagatt gtcagattag attgaaaaag catgacccaa ctacatgctg 46500 tctgtaagaa attagaaaaa gaacaaatta aatccaaagt aagaagaaag gaaatagagt 46560 agaagttagt gaagtataaa acaaagagca aagaaaatca attaaatgaa aagctggttc 46620 tttgtaaaga tcagtaaaat tgataaattt ctagctaaac tggccaagaa aaaagaaaag 46680 acatacaaat taacagtatc aggaagaaaa acagagaatt caaaggagtg taatgcaaac 46740 tttatgctag taaatgcaat aagttagatg gtatggaaaa aaatgtgaac aatacaaagc 46800 agactgtggt tgcctttggt ggcagtagcg gggtgggagt ggaaggttga attgactgga 46860 accagaagca caagtgaact ttttggggtg atggaaatgt tttgtatctt ggttgcattg 46920 atagttaaat ggttgtagac attgcttaaa actcactgaa cacttaagtg ggtatgtttt 46980 attatttgta aaatatacct caaaagcagt tttaaaaatg tattcaagta catacttaag 47040 atctttgcat tttactctga gtatacctta attttaaaat ctgtttttta aaaagtatta 47100 tgtagatacc ttttattttc ccaatgtctt tattaaatga catctccacg ttttgcttct 47160 2013203064 09 Apr 2013 116 of 771 tacctctatt tttttttttt tatttctctg tctctcaggc atgcacacac acacaccaaa 47220 aaaagtacat atgcataatc cttttggctg aataaaatca gttgcaactg ttatttcggc 47280 ccttatttgc tccgggtaaa tattcgttag ctgagtggtt tatctgtatc agatatttct 47340 tacatcttca tccagtcaca ccagctggac tgaccagatt gtttttcact tcaagggcag 47400 aatttgtact cactgctgaa tgcttccaaa tgatacgtag aataacaaat ttaagactta 47460 gatttttact ttttcaggtc tttttttttt tttctgtgct gtatagcatt tccctgaaag 47520 cttaatctca tctgtaagtg atgcagtgga tgtgttacta ttggattaat ttatttactc 47580 ttaggtaggt ttgtaatctg tcatcatgct gttgtttttt tgtgtgggtt tgtttttggt 47640 tttgagacag ggtctcactc tgctgcccag gctggagagg ctagagtgca gtgatgtgtt 47700 tatgggtcac tgcagattca atctcctggg ctcaagtgat cttcctgcct caaccccttg 47760 tgtagatgga agcacaggtg cacgccacca cacccggcta tttttttaaa tgtattgtag 47820 agacgaggca tcattttttt gcccaaggct gatcttgaac tcctgggctc aaacaatcct 47880 cccacctcgg ctcccaaagt gctgggatta cagatgtgaa ccaccactcg agctccatca 47940 ttctgttatt agttgttctc tagtatgagt caaaaactct tacctgccct tttacagttt 48000 tataaataag taagcagaat agcagaatgt ggacattttt taaatccaaa ttgaatatgc 48060 acatgactca aggagtcaaa tagtaccgta atcggtttat gataaaatcc agtggtttgg 48120 ctgggtgtcg tggctcacac ttgtaatccc agcaccttgg gaggctgagg caggtggatc 48180 acctgaagtc aggagtttga gaccagtctg acctacatgg tgaaactact aaaatacaaa 48240 attagctggg catggtggtg catgcctgta atcccagcta cttgggaggc tgaggcagga 48300 gaattgcttc aacccgggag gcagaggttg tggtgagccg atatcgcatt atttcagaac 48360 aattttccac aagatcagtg agtgctgtcc aatagacata taatacaacc cacatacatg 48420 actttacatt ttcttgtagc catagtagaa aaggtcaaaa gaagcagatg aaattaatag 48480 cctgggcaac aagagcaaaa ccccatcttt taaaaaataa aataaaatat ggtggtttgc 48540 tgtccccacc tcagaccatt tctctggtct ttctcattga ccaccactcc caatctttgt 48600 tctgctgatt gattacagct tgtatatatc tccatatttc taagcaaaat gtttatcttt 48660 tttaaattta taaattcttt ttattatttt tcagagacag ggtcttaact ctgtcgccca 48720 ggctggagta cagtggcacc atcgtagctc actgtagcct cgaactcctg ggctcaagca 48780 gtcttcctgc ctccgcctct caggtagctg agactacgct acaggcacat accaccatgc 48840 ccagctcaaa atgtttatct tttgatacat tattcgagac cattattaag gtggatgatt 48900 tagttttctt aaacagccat cccctttctt ttcctcccct ctgcttcacc gcccccattt 48960 2013203064 09 Apr 2013 117 of 771 tcccaatgtt ttaccttttg gttaaatcag tactcattgt ttacattatt tgcctctgca 49020 catagtcaca gatagtattg tactgtactg tactgtgttt cttttttaaa cattatttct 49080 gttgttaata attgactttt taattttttt cctattttgt tttttaaaga gatggggtct 49140 tactatattg cccaggctag agttcagtgg ctcttcgcgg gcatgatccc actgctgatc 49200 agtacaggaa tttccacctg ctccatttcc aacctggacc agttcacccc ttcttaggca 49260 acctggtggt cccccattcc cgggaggtca gcatattgat gccaaactta gtgcggacac 49320 ccgatcggca taacgcatgc agcccaggac tcctgggctc aagcagtcct cccgggctca 49380 agcagtcctc ccacctaagc ctcccgcgta gctgagacta cagacacttg ccaccacacc 49440 aggttaattt ttgtgttttt tgtagaggtg gggttttgcc atgttgtcca gactcatctc 49500 aaacttctca gctcaagtga gcctcctgcc tcagcttccc aagtagctgg gattatagac 49560 gcatgccacc acaccccatg ataattgcct ttttttttaa tttgcataat tttctttgta 49620 gcttttgcta atgttcccat atcttcttat agccttacag aatgattttc cacaagatca 49680 gtgagtgctg tccagtagac atataataca acccacatac atgattttac ctttttttgt 49740 agccatagta aaaaaggtca aaagaagcag atgaaattaa tagtatcttt tacttaaccc 49800 agttcattca aaatgttatt tcaataaatg gtcaatattt aaaatacttg agatattttg 49860 cttttattta tttcttttgt tactaagtct tcaaaatcca atgtgtattt tacacttaca 49920 gaacatctct ttttagactg gccacatgta gctcagggtt actgtattgg acagagtggt 49980 ttcagtttca agtttttcct tggagacatc ctacttgaaa tttccattct ccatgtatct 50040 gggtggttgg tctatagact tgccactcac agctgtcatc ttgagacttt ctttgctttt 50100 cttctctatt ggatattcag tttcctggat ttcaggtctt ctcattttcc tctagtagtt 50160 ttgttaggtc atggttggta tggcatggtt gggatagcgt gttcacacag ctatctcgtg 50220 agtcatactc ctccaatcca gcctgctcgc ttcccgtgtc tgtcatgtag ttgtcaccct 50280 gctatctctc cctccagttt ttgcagaaat ttcctttgtc ttcactcttg gtcttcctct 50340 cccatccccc atgtatccta tatctttctc tttcttggtt tatttcatca ctcaggtgga 50400 aaagatgctc cagtggatta ctgggaaaag ggggagcatg gatgataaag gtattgagac 50460 cttacacgtc agggaatttt tttttttttt tttttttgag acggagtttt gctcttgtcc 50520 aggttggagt gcagtggcgc caactcggct cactgcaacc tccacctcct gggttcaagt 50580 gattctcctg cctcagcctc ctgagtagct gggattacag gtgcccgcca ccacgcccag 50640 ctaatttttt gtatttttaa tagagacgag gtttcactgt gttggccagg ctggtcttga 50700 actcctactt caggcaatcc acccacctcg gaatgttttt attgtccctt ctcatttcat 50760 2013203064 09 Apr 2013 118 of 771 gactgctggg ctaggtatag aattccagaa tcattgttct tagaatctcg aaggcattgc 50820 ttcattgctg gccagctttc agtgttcttg caaagtctga agctgtgcta atcacctcat 50880 cctttgaaag tgaactgttt tttcttccca gaaacttaca gaacattctc tttgtccgca 50940 gaattctggg attgcaatta ctgtgcctta gaatgggtct gtttttatca ttatgaagag 51000 tactggatgg gtcgggaggt tttcttgaat tacttcttga tgttttcttt ccttgtattt 51060 ttttgtttgc taattttcta tttttttttc ttggtttact ttcttgggca gggggatttc 51120 ttctacttat atttgattct tcagttgagc ttgtcatttt tgctatcttg tttttaagtt 51180 tcgagagaca tctttgtttt atataacatt ctgttcttaa tacatagatg caagatcttt 51240 tctttctgag tatattaata tgtatttgaa atctttctat tctctgcagt ttgtttcccc 51300 caagggtttt tttttttttc tggtttttgt tttttgtttt tatgttagag actttcctgt 51360 tatatctggt catcagtggt acctgcatgt ggtggagagt aggggcttat tggagtatga 51420 gaaccttgag caggtgtaag gagcctgtca acactgcgct ggcctcaggg cctctaggga 51480 ggctgccagt tgtgcattct gaggatacct tttggttgtg ccttttgtct ggtcagatta 51540 tctagagatg ctctgcctcc tacctggagg agaagggtct agctgccagc ggtgtgagtg 51600 tctcttgggg aaaaggactc gagttcctgg tgtttggctt gtgtatggcc gcttacccca 51660 tttttggtgg agcgctcaca tcttccactg tgccaacagt cttgctgcag ttcatagacc 51720 ttctggttta catttttcca gaaagtatgt ctttagattt ctgcagaagt ctgaggagca 51780 tggaaggagc ttggggaatg agatggcaat ccaggtcttc ccagatggct ctacctttat 51840 cccctgcagg gaatcccact cctccttcct gactgggagc acagccagag ccttgggagg 51900 aatctggagt ggaaatctcg ggcggtctgg ctttcttact gttcacttgt aattttgctt 51960 tctcacaact gccaaccact aatcagcctg atttccagct tccagaattc tattgctgtt 52020 gtctgctctc ctattcccac cgtaggggat ggggctgtct tttttttttt ttttaatttt 52080 ggtaaaacat acaaaacata aagtgttcca ttttagccat ttttaggtac acagttcagt 52140 ggcagtaagt acattcacgt tgtgtgtatt tgttttttta gtaataaaca atataaaatt 52200 ttttaagtaa taaaacacaa ataaaagatt gtttaatgtg attatcgtgg aattttaggt 52260 gtgatcagga gccatggtgt agtcttctgt tgaaacaggg tgataggatt tgtttaccac 52320 ctcctaggaa agcagttgga tagtttgttg gcataaaagt acattttatc tatttttaat 52380 aatcgtagct ttatagaaat tgcagttgga actcccaggc ctggcattca aggctctctg 52440 agatctgggc tacccaccca tgtcctccag ccgtctgtcg cacctcctac tgcccactca 52500 ctgttcctgg catgagatgt gatctccagc ccccatgcct ttgctgtgca gggtgttcca 52560 2013203064 09 Apr 2013 119 of 771 gagtgaattg tccctcctgt ctgtctctct gccctcttcc tcgtctttcc atcttcctgc 52620 cccacatcac tgcctcctac ccaaggcctg tgctcattcc tcctcggttt tcccccatgg 52680 cctggtacat acctctgaat tatcaccttg catttcccat attgcccggc tctctttgat 52740 gtctgtttct ttgctgggtc ttcctcagtg tctgacggtc agttaaatgt ctttattctt 52800 ttttgtagga tatccgacat gaagccagtg acttcccatg tagagtggcc aagcttccta 52860 agaacaaaaa ccgaaatagg tacagagacg tcagtccctg taagtatcca cgtggccggt 52920 accagtcttg ctcttccttt gctgcaggcc tttttagtca agactccttt cgcctcaggg 52980 tttagtataa taataaatca atgtagcaga ggtttatgac gcgattgttt cctatagtaa 53040 aggcattaga gacttatagt aatagctcat ttttccacca ttatagaagg gctcaggttt 53100 cagtttctgg aaaattcagt gaagttcaaa gcacttttct taagctttga ctgtttttgt 53160 gatgaatcat tttcctacca gctgaagcag agtatagcag gcataataaa accttttctg 53220 gatgactcag cagcagcgtc attagggcat gagcactgtg ttccgctgta atgaagcccc 53280 gcacaggcat tcggggtggg cactgtcgtc ccctgcgctg aatatgcaag gcagctctgt 53340 ctggagtccc caccgcctcc acccccgcca acctcatcat ttttctccct ctttcctgct 53400 gttagttctt cctaggattg tcagtgtgcc tgctggcctg tggcagccct gtccgccttc 53460 tgagtgattg gctgtcagtc tgccggtagc tgaaaagtaa ataacttaac atgttagaat 53520 ttgcataaag taaggaaaac tggagctgag tacaggactt gaactgcgcc atctcctcta 53580 ggccacagag gcctttttga cccccttcca ggtctttaga cattgtcagg cagtgagggg 53640 tcgtagctgc cagtgtctcc atggtagcgt gctctgccag ggatgcagaa gattctccag 53700 tcattcctcc agtgggcact tcctgcaggt cctgtgccca tggctgggag tggtggctgt 53760 cattgttctc tgccagaagg gttagcagtg catcctgacc tgacttatgt ggcgcccaga 53820 ttcctggaag gggtctaaaa atggacctag acttggtgta gaacgtgtgc ctcttggcct 53880 gccaccatgg ttccctgcct ggttttgtgt gtcagctctg ccgcttaaga actgagtggc 53940 ttcgggcaag ttgttctctc tcataggagt gtgtgaagat gaagcaacat aagctgctta 54000 gcccagcgcc cagtacctca cgcagacata agtgctcagt aaatgttgtc tgtggtgggg 54060 atggttgtca ccaacatctg aagtgcactt ctaggtcatc aggtgacatg attggcgcca 54120 acacatggta ctcttgattt agcacatctc agctgaggca cctcattgat atttgtttaa 54180 aaacaaaaac aaaaaacctt ggtgattctg ctgtgaagtc ctggccagaa acctccagac 54240 cgctgatcaa cacgcaacag aaccatcacc gttcacctct ttgacatggt gccaggatac 54300 cctggatctc tagcttttgc tatagttgct ctaattaggg aataatcttg tctttaatat 54360 2013203064 09 Apr 2013 120 of 771 tcctttgcta cattttttaa catttcttat ctaaatggtt ttatgaatca gttttacaga 54420 gaaaaaaaac cagtatttaa aatattcttc caggggctgg tccaagtaca gtagtgttta 54480 caactatgtg atcacaacca gttacagatt tctttgttcc ttctccatcc ccactgcttt 54540 acttgactag ccaaaaaaaa aaaaaaaaaa agttattcca gggaaacaat tctccaactt 54600 tttcactccc aatctcactc ctcttatctt cctcccgtac tcctatcctc ctcccgtact 54660 cctatcctcc tcccctactc ctatcctcca gtagaaacag tcatttgctg tgaaggttat 54720 gggggagaat gagtcaaggt agaaggtcac ctgctgccca gctcacagtg ctgctggtga 54780 tgacagcagt ccacagttac aggcacttgc tgaacgaggg gctctgtata cacctcagct 54840 cattgactct tcccacaacc ctcttgtcac ctaccattta gcaaatgaaa aaaccaaggc 54900 tctgaggtga gttgtttgcc cagagtcacc cagtgctgtt tgaacccact cacataacca 54960 accaatacca ttatgtaatt tttgaggtct tttatctctg tgatccactt aaaaattatc 55020 caagtatctt tatttgtact aagcctccat aatgagaaac agtgttccag atggtggcta 55080 gttttcaaag acatctctct ttggaattct tctttagaac aaaaagcccc agaccactta 55140 tccccattca tatccccttt ggacctaggg agaaggtact atttataggt gatcacctga 55200 gtttattgtc ccttgtgctg tgccagaaat aaaggtcccc acctgctctt attagctcta 55260 ctaacaggat aaggaaagtg gccctcagag agctactgct tttgtgacaa acaaatgata 55320 caagaaaaaa aaagtggctt tttaatttta gtgacctggg gcaggacttc caaatgaaag 55380 tttatttcta aaaactaaaa ggtaaattta atatactttc agtgtttggg cttaaattct 55440 ctttcaagtg tctttgtgat atgctctgaa ttttaaaaat ttagaatcat tgaagttcat 55500 tatacttgaa ctttaaaaaa aaaaaacaaa aacctcgtat aaaggtcaag gtatgacttc 55560 atgctgctgt gtacttaggt catttaatct tcaaaccact ggatagaggt taggttgaag 55620 ttcgatctta aatcctacct actgtagctc attgtaccag caacagctgt agggactagg 55680 tggaattcat ggtgggtttt gttccctttt aaagattgaa gccaccatat tttctgccct 55740 ctaaaagttt atgtcagcca ggcatgggtg gctcacactt gtaatcccag cactttgggg 55800 aggctgaggt gggtggatca cttgaggcca ggagttcgag accagcctgg ccaacatggt 55860 gaaaccccat ctctactaaa aatagaaaaa ttaggtgagc atggtggcct gcgcctgtaa 55920 tcccagctac tcgggaggct gaggcaggag aaacatttga atccgggaga tggaggctgc 55980 agtgagctga gaacatgcca ctgcactcca gcctgggtga cagagtgaga ctcttgactc 56040 aaaaaaaaaa gttatgcatc agagaacaga tcctttgatg ccctcctctg ccctgaaagg 56100 tttttggggg agagtaataa gtatcacaac aagatatgac ctgagaacag atttcccaga 56160 2013203064 09 Apr 2013 121 of 771 taggacatga tccatgtttt aatatggctt actgctgttg cttcatagtg tgaagcttca 56220 gacacttctg aaaacccttt cagaaaatcc cagtcgcccc atactgatga ctaatctcaa 56280 ctaaaacagg gcttcagcca gtgtgaatgc cactaatgcc accaactcac ctttgctttt 56340 ctgtagggtg tgcacctgta tgtacacatt cagcttttcc gggattaacc tctgagttct 56400 ggtttgtctt tcagttgacc atagtcggat taaactacat caagaagata atgactatat 56460 caacgctagt ttgataaaaa tggaagaagc ccaaaggagt tacattctta cccaggtaag 56520 cagattgtct gaattttcta tttaatgtca atttaagagt ttgagagtgc tgttatccac 56580 acctcaaata aaatctgcca catcctttag aaggtcagga tttcagcata ccaaaaagca 56640 gcaaggaagg gggaaaaatc atccttcaaa ggttcagttt ggttataagg aacgctaatc 56700 ttttctggga agcataagat gacattgctg gaaatgagag cttatagaaa acaacattaa 56760 aatgccagag ttgcctgtgt ggtctgttgg cagagacagc agagccatgg ctggaggagg 56820 gtctgtacct gtgttgcttc cagaagtatt tgtcgtagag cacttgtgat ggcaaatcta 56880 agaacgttag cagtagacca ggaatctctg tccagagcca ttcagagtag ctcagcatgg 56940 ttctcattct ttggccagaa gaaaggcatc attggatcat gtgaacaagc atgaaaaatg 57000 acttaaaatt tctgttggct tttggcatct ttatggaaac aaaatcctga aagtggttta 57060 ataattgagc ctcttgtaaa acactcagtg gcatgtgacc aaaagggtat ctgggaaaga 57120 ggataaaaag agtttctttt taattaatct tctcaagtct taacttgtta cctgtaagtt 57180 ggtctaaaaa gactgggttt cttattttgt ttttcatcat aatttttgtt tctcattcca 57240 tgtcagcttt cagtcttata tggctttagg ccacagggcg attttgaaca tttgtaattt 57300 tgcttaataa ttaggaaatt aaaattctgg ggaagacaga atgctctatg aagaaaggct 57360 gctttgagca aggagctagg tcagggcgcg ttcaactgag gcctttcttc actgcctttt 57420 tgtcttgtcc cagttcctcc ccatttatga ctaaaatcag cccagatgct tctcgtcatc 57480 tgggatgcag agcatcagcc cagctgtgtt cagtcctatg gggccattga gtaagttctt 57540 ggtgcatgga tacagggcag gcctttacca ggccctgagc ccctggtcct cccagcacct 57600 ctggggtatt taggggaggc tgatggggga gggggttgat aaggcgggag atgtctgggg 57660 atgaggttga ggcaaaagtg acttcttgag gactttgctt tttggagaag tcaaatttcc 57720 tacttcttga tttcagccct tcaactctgg tatggagtca ggaagccctt taaatacctg 57780 ttgtcgggtg tatcatgtca agtgttgcat tagcaaatga ccatgtatcc ttgtgctact 57840 gtcctgccta ccccgcatcc tagcgcttcc ttgggacatg agaagctctg tctggtttgt 57900 gaggtggcac tggggatgtt gagaaactgt ttacacagtt tccctttgcc ctggggattt 57960 2013203064 09 Apr 2013 122 of 771 actaaaggag tcgaggcagc ctgaccccaa agcatcaccc ctggacacta tgaccgaaac 58020 atttccccag tgcccaaacc aagaacaccc ttcccatttt tttttcagtg gtgttcatta 58080 tgtaataata caagtctctc ttctcatttt ttaaaagtca gaagtacaga agagcagaga 58140 ataatgtcca aggggccctc cttcacctcc cccgtgcagt gtcagctaag tgtggtgcgt 58200 gtccttgcag atcttagggg attgtgatcc ttcagaccat tctaaactgg ggtggtgctg 58260 ggagttaggg aaggcatgaa gggagtagtg gagagctgca gtgactgggg tcttcatgcc 58320 agggtggaga atgcaaggcc caggtggcca gccatgtgcc acgggatttc tggctgccaa 58380 gagctgttta tctgttcact ggggagggaa gagttaaatg tggtctgctt ttctccgagt 58440 cccttcagca cagggagtgc tgacttgtct tgttcaggta gtaagttcaa gatgagctca 58500 ggaaagaaag tgagaggaca ctgagggcta gtggttgagc caagtgtgat gggacttaaa 58560 gggagaagat ttaaagaata aggagcttat gggccgggga cggtggctta cgcctgtaat 58620 cccagcactt tgggaggctg aagcaggtgg atcacttggg tcaggagttc gaggccagcc 58680 tggccaacat ggtgaaaccc cgtctctact aaaaatacag aaattagctg ggtgtggtag 58740 tgtgcacctg taatcccagc tacttgggag gctgagacag gagaatcgct tgagcccagg 58800 aggcagaggt tgcagtgagc caggattgcg cccctgtact ccagcctggg tgatggagcg 58860 agactctgcc tcaaaaaaaa ttaaaaaaaa ataaagaggt taggtgaaaa tagatgagaa 58920 tggaaaccat gagaagaagt gatgctggcc aaggacatga caggttctga tgtggaggtg 58980 ataggcaatg tctcttccag ccactgctaa taattgagac aaactcaagg cattcatacc 59040 ctgtgtccag taaacatctg tgcccattgc caggtgagct ggattgaaat gggccagctg 59100 ctcagcagac accctcatgc cccagtgact ctgttcccct tgggccacct cattgaccat 59160 ttatgtttct acatctccta agtttgttgg gccaaggatg gaggctgtct gccgtcaggg 59220 tcctcattgc tgatggtagg aatagttgct gatgtttcat tggatgttgc tgtattctag 59280 ggactgtgct aagtacttta tagaaatgaa catacttcat tttcacagtt ttatgaatag 59340 ggactattat tagtcaagta agcgatgggg aaactggggc agggagcgat gaagtgactt 59400 gcgcaaggtc acaagatgat gtgattggaa ccaagagaag tgttgtggtt ggccacgccc 59460 ccacactgcc tctcatctgc accaaggagt tttgtcccat agcccaaggg ccttggggac 59520 gaatctcagt ggaggccctt agcgggcctg cctgagccag aaagcagaat cggcattttt 59580 ctgtccttgg ttggcccagc cctgaactga gatgcggaaa tcgcctttcg ctgcctggta 59640 gaaaatggag ctgcagttac tgaccaccag gcagagagag gtgggtccct gtcccagcct 59700 cagccaccac tctgcctaag ctgtggggac tgagggcgct gtcgttagct gactgcagaa 59760 2013203064 09 Apr 2013 123 of 771 ggtgagcaca cgctgtagca tgttatgttt cagatgtcac atgttgtgtt attgtgtctt 59820 tgcagggccc tttgcctaac acatgcggtc acttttggga gatggtgtgg gagcagaaaa 59880 gcaggggtgt cgtcatgctc aacagagtga tggagaaagg ttcggtaagt ctcggcttca 59940 tttgctgtgt atgtgatcat gcataccact ccatatagtt accattttcg tccagatttt 60000 taaattattt ttcttgcctt tgtatttcct ttacgtagta tttttattta aaaaaattaa 60060 aacagcagca tataaatgca tgttggttgt caaccagtta atgaagtgaa taaaagggag 60120 gaggcggaag aactgcacgg acctcttcgc ccccgccttc tcctgtgtgg tgcgtgtggc 60180 gctccgccca cctgtgctgc ctgtgcggct ctcatcacag tgtggagttg tgtgtggagt 60240 tatggagacc tgcttttatc ttgaaaagca agttcttagt gcatcttcat ggtgtctgat 60300 tttttggctg gtgagagtgt ggctacctct gcggagctgt gggagcggct gactagatga 60360 gatttgcctc cattcagtac ctagactctt gccctgccac acctcttcgg agtgagcatt 60420 gacttcagga tgtgtgtcat tctaagttcc tgcaactttt caaacacccc tcgggctagc 60480 gtgtggctgc acggtgtcca tttgtgcagg ccaccactcc tcttgcatct gggtctagcc 60540 acctctcctt cttgacttac catagttcat tttgtaccat gctttcagaa tgagctttct 60600 caaatccaag tctcaccacg gttcttccca gctgaaaacc cttgtgcggt tccctttgcc 60660 tcacaggata atacatggtg tggcttacgg aaccctgcag gtctggccct aggcccctgg 60720 acacagacct ctcaccactc ttggaacttt agccaggaca aagttttctg tttttagttt 60780 cttaccatgt tctctgggcc gaggagtccc agtgcccacg ttcatcccac ttgcaggcac 60840 ccctggacgg ctgcccccag ctccccaact gcctgcattc tcccctgccc tcctcactct 60900 gttggaatag ctgagaatag ccgatttctg ggcagccggc ctcctgtgta gactgtcctg 60960 tgtagactgt cctgtgtaga ttgtctgtgt agactgtcct gtgtagattg tctgtgtaga 61020 ctgtcctgtg tagactgtcc atgtaaactg tcctgtgtag attgtctgtg tagactgtcc 61080 tgtgtagact gtcctgtgta gattgtctgt gtagactgtc tctgtagacc gtcgtgtata 61140 gactgtcctg tgtagactgt ctctgtagac cgtcgtgtat agactgtcct gtgtagactg 61200 tctctgtaga ccgtcctgtg tagattgtct gtgtagacca tcctgtgtag accatcccat 61260 ttagaccatc tgcctgtgca ggcgcaggcc agtgttcagc agggccacag gctcctcggc 61320 ctccctgccc tcgctgctcc ccaacactgc caaccctgct gcggggtcca ggaggagatg 61380 ggctgaggat cgtggagacc agcaggagcg tgtggcccag gagcagggaa ctgggtgtcc 61440 ttgggccttg ccaggtccag gctcagctag gacacggctc tcacagctgt cctggttgcc 61500 tccggccaca gaagaaggtg agggctccag agaggccacc tttccaaaaa aagcacagtc 61560 2013203064 09 Apr 2013 124 of 771 atggccctag aatgtaaaaa atccaagtgt taagaaggaa cacatcaaag gaaacttcag 61620 cagtgaaaac ttgaagcatt aaccacgaag cctctgcctc caccacacac aaagaaacgg 61680 ctttagttac tcgcagaaag tcttcctctt aggacagcgc gtgtttaaaa tcataggggt 61740 ttggtttgtt ttgttttggg gttggggttt tttgggggtt ttttaccctt gcctactttt 61800 taaaaaatga aagtgtttat ttgcccaaca ataacagaca gggagcttgc ctaagtgttc 61860 tgttgatgat ataatgtatc ttgtcttaga aaaaaacttt ttcagtgaaa ggtggttttt 61920 aaattttttc ttccctcctt agtagcttga ttagtaaaat gtgaagttac aaatgtgaag 61980 caaaccccca cccttcacca ctagtcagca attttgagta aagaaacaaa gcatcaggtg 62040 ctcacagcac acactgtctt agagggaagg ggaagcctgg tggcctgtgg aagccttcag 62100 catagctcca tctgcaggct tctgaccctc agcactactg acacttgggc tggatcattg 62160 tctgctaggg atccgggcag ggagtggctg tgctgggcgc tgtaggaagt ttagcagcat 62220 ctctggcctc tatccaccag atgccagtag caccccctcc ccagatgtgg cagtcagatg 62280 tgtttctgtc tagactccag actttgtcca acgtcccctg gtaggccaaa ttgcccccgg 62340 ttgagaacca ccgctctaga tggtattgag ggttgggaat tttaaatcaa gacatttatt 62400 cagaaattac cagatatagt agcatttgct tcttatttat ttctttgttg ctaagtgttt 62460 ggcaaaacct ctttgctgtg agcacaaggt ttgctttagc aattgttgtc acattacagc 62520 aaggagtggt gtccagcgct gtagttatgt atttgagcag tgtccagtgc tgtagttatg 62580 tgttccagcc tcaccaggcc ctgtgcttca ttgtctccca ctcaagactg accacaaatg 62640 gcccacagat ccactgtgac aacctttccc tttgggttac tgtggtggca tcgagaacat 62700 ggctggttgg ctttgctgta gtttactgtg ataactgtgc cagcagtccc tgctttcctt 62760 tgttaagtat cccattccac tggaggatta cttgggcgtg cagattggca tgaaaagcaa 62820 tgtatggttt gagattgtta aagtttcttt gggatcaaca ttttcaattc tgtatcagca 62880 ttatccctcc cagagggctg gctgggagaa atcatgagaa gttacagtat cttatttgct 62940 cagctaatct aattataaat gatccacaca gcttgtggta aaaccagctt ttggggagtt 63000 ttcatttaat gcatacttgt cttctgattt ccttccttca ccaaatagtg taggatgctc 63060 cctcttattt ttggcaaaca tgcctgttat cttttgggac cctgggcttc ctggaaacca 63120 gttatgcaga agatgattgt gtgtgttaga ctggggtcat ccagatggct agagttctca 63180 ctggttctgt ttaaggattg actttagaca cctcagtgta ggctgcacca tggcgtaagg 63240 gttgggattg ttgtttagaa gggggaagta agcaaggtga gtttaattgg ccattgcaga 63300 atctcacccg tatctccctc ctgaaatcct cactaaagct gccgtttgct ttcaggtgct 63360 2013203064 09 Apr 2013 125 of 771 ttcatgcaca agacactgca ttttgtatca cagggtccat ataattcatt tttctctcgt 63420 acttagttct ctgtgttaag aattacttac ttagttctct gtgttaataa tttttggcga 63480 aaccaaatta cccgtcacag ggttactgta gatgtctttc ataggttttc caaacaccac 63540 ttgcccactt gtttgggaag gccccaagga ctgtttaaca tctgccttca tggtggaaac 63600 agcaactatg agagatgcta gcatgttggc actgccatgt tcctctggta ccagcccaag 63660 ataggactca atttgaggcc tggtgaagta ctgtgttcta ataaaaatcc atctactttt 63720 catggccgta tatatcaatg taatagggta actggaaatg tgatcttgtg ccttttaaaa 63780 attttgtgtg tttaaaacaa aaatttctat tggaaatgac agagcatagc ttgttgctgt 63840 agacacctga gagtccttaa aaataaatat tgggttattg acacttagtt gcatgacaga 63900 attcctcact tgtacagttc caaagtctta gtctttaccc agattacaga gggttattaa 63960 gcattaggtt tggttttgaa agtgagtgct tgctgtctgg aggtgagctt taagactcgt 64020 ctgccctgct tatgagatga ggaagggtgg cctcttcctc ctgcatttct gttcttcgct 64080 tccttctctg tctgctcact ctgtggaatg cccaccccag cacgggtggg gtggaacctg 64140 tcagatcagt ctcttgtttc tggggtcttg aggcattata agatctagtt gttagaagtg 64200 tgggattaat tcatcttttc acattcttct aagttcctgc ttttagctgc cacacccact 64260 ttggctaagt gggggtcttg ccatgtaatt agcgcctcca tgccaagtgg cagaattgct 64320 tcaatggtga cagattgtcc ccattcaaga gttcactttt ggcaactcat cattgatcca 64380 ggaaggtgac atggatgaaa ctggctaaga cttcagacag gcttgtgtcc agactcttga 64440 gaaagctctg ttggcttctg gtctggcact gtgaagtttg ctgtgatgct ggcaccacaa 64500 cctggtgttt cctaatttgt ttctcccaca ttttgctttg gttttgtctt ttgggcagct 64560 tccagctcca gtagagcagg accaataggc atttgtggtt ctatattcac cctcctcacg 64620 tgcttcctgg ctcctcattg cccccagatg atgccacagg tccctgggcc tgctgccagt 64680 cgtctgtgat ctgggcctct gctggcccct tctccagctg ctcttttcag cctcttattt 64740 gcagtcactg cctaggaaat cctagtcatc cttcaaaacc tgcctcttgc acagagcttt 64800 ctctgatctc tcttttctgt aaccttggct gacctgaaac atttccctct tctgaattcc 64860 tgctgcatgt ccgtagcatt tccccctcag ccctccccca tagtccacct tgtcactgct 64920 gggcacagca gtgtcttctg acagacagct ggccctgaag tggttccctt cacccacacc 64980 atcctttgcc ccagaggagg tattgagtgg gtcagtgcac gtgaactgcc agtgtcattt 65040 gccaaagagc tgttgacaca cgctgacatt tcttttgctg aaaatcataa gggctttgag 65100 cttccctctg tccaggcaca tggtcaggct gacccggtag ctctgcccct gctgacctgc 65160 2013203064 09 Apr 2013 126 of 771 catttttgtc cacaacagtt atccatgagc agaaacattt gtgtaactga ggcagaaact 65220 tagttcaagt aaaatgtcac taaattcgag tcagtttttg tcttagaccc taaatgaaac 65280 caaattttca taaattttct tgttttaaag aaaaatttaa tgagctacat ttaaactgag 65340 aacatcagat agtgtctgag attatcaaaa tagaacatca aaagtatttt tctgaatgaa 65400 ctgaaccaaa ccagaatgaa agggcaagcc ctggggagcc tgtctccaag ccttctctga 65460 aagggagtct gtatttggtg ataactgctc agcctctcca aagggcctca cctgctgtct 65520 ctcccagttt tatttttaat tgcctgtgag ttttctgtgc agggtaaggc acctacattc 65580 tatgccagca gcctgatcag gtcctgggta atgtttgaaa tggctacaca gaggagtttc 65640 aaagcctttt gttcaatctg gcttcacctc gtagacggtg agaaagcgtc agagccctgc 65700 aggatcccgt tgccacgttt gaccggggag ccgatgggtt tggaagtctg agccctgtct 65760 gcacaacctg ccccggtcag cagcttcgtg cccccacccc catctcccca tgaggcaggc 65820 atctgtgctg accatggctt ccatgttcag aaacccccag gcctttgagt tatcatgaag 65880 cttgtgggat gtgctccaag cctcctgcca tagaaaaact gccatattgc tcacaataat 65940 tcactattat ttgtttcccc agttaaaatg cgcacaatac tggccacaaa aagaagaaaa 66000 agagatgatc tttgaagaca caaatttgaa attaacattg atctctgaag atatcaagtc 66060 atattataca gtgcgacagc tagaattgga aaaccttaca gtgagtatag cacacacttc 66120 agcacttcag gcggctactg gttcacatgc ctcttccttt atcccttggg tgatattacc 66180 taatgtcagt gttcctggct tttgtatacc ccgagcaaga tgtggtttgg gcactgtggt 66240 gagcggagct tacttgtgta cctaccaagt gcccagggag ggtggaggcc acagtgctct 66300 ctctgacctt taacaacagt taacaccagt tcttagggaa aggagagttt cttacccaaa 66360 agactggttc ctgcttgtgc agctgcagag ggactggagc ggcagcctgc aagtcccagt 66420 gaagcatgct gccttctttg tggtcctcag tcttcgagtc tgaagagagg gaagaagggg 66480 tataggggct cactccagtt tcatagctag tgaaagtttt ctgggccagg tcttgggttt 66540 ttttgttgtg ggaagagttt ataacaccag ctacttgctt ggtaaaagtt ggtcttggaa 66600 catggcaagg cattgtggca agcagcactg ccgctgaacg cgctgctcct ggggctttgg 66660 aataattccc ctggatccgt aacttggggg tgttcatgtc attctgggga acagtggagg 66720 gagtgcgcgg cagcacctgg gggcaccagt gaagagtggc cagccaccaa cctctagaac 66780 ctaactgggg tcgaatcctg gccccacctt actagctcat cacagtgtct ccgtttcctc 66840 ttctgtcaaa ctcaggtttt gcgagggttc tgggaggtcc tatacgggaa gggttagcag 66900 ttaccatggg tgtgtagcac gggctttatc tgaagggaag gtggagccgt agggagacca 66960 2013203064 09 Apr 2013 127 of 771 tgtggagtgg ggctccaggg ctgtgtgggt ggggagggat ctgcttctgg gttaccccat 67020 gcctcccctt ctcaagtact actttttaat catcatggct cctgccattc atttcatagt 67080 tgatgtaagc caggtgcggt ggctcacgtc tttaatccca gcacttgggg aggctgaggc 67140 caggaggatc actcgaggcc aggagttcaa gaccagcttg ggcaacatag tgagaccccc 67200 gtctctacaa aaaaacaaaa acagttagtc agacatcgtg gtgctcccct atagtccagc 67260 tactcaggag gctgaggcag gaggattgct tgtgcccggg agttcaaggc tgcagtgagc 67320 tatgcttgca ccactgcact ctagcctggg tgacagagca agaccctgtc tcaaaaataa 67380 ataaataaaa aaaatagtag aagtaagatc tagaatgtag cacaggttac caggacgtag 67440 gcaaggggtt cgggctgcct ggctcttgag gatggtagca gtgcagctga tgtgagtgct 67500 ttctgccctc tggtggtgac cgcgccggag tcaccagccc tgccatagcc ctgatggggc 67560 agagggttct gagtacggtg gatggaggtg ctttctggaa gattctcagg agtaacatgg 67620 gcagtgtgtt ggaatgtgct agaggattta tgcagtagcc ttttaaaaga atgcttttta 67680 gcatttgcaa gcctgacatt aagagtgact tctgggaaac tatttgcttg ttgagggaaa 67740 ctgaatttca acagagcaga agagctgtgc gctttttgct tggcagagtg aatacagcca 67800 gctcagaggt tttgatgtta ggatctgttt gctccaacag actttgtttt taaaaggctt 67860 ttctcagcca tagctgtctg ttctagcaca aggctggaat gagttccttg tgaaagaggt 67920 gagcaggtgt gagggagggt gtcagtgggc ggtaacccac accttcaagg attaaaggaa 67980 aacttgcatt tggcatgctt gcttcttatt caattttaaa atacatttta acggccgggc 68040 acggtggcta acacctgtaa tcccagcact ttgaggggct gaggtgggtg gttcacgagg 68100 ccaggggttc aagaccagcc tggccaagat ggtgaaaccc catctctact aaaaatacaa 68160 aaaaaaaaaa aattagccgg gcgtggtggc gggcacctgt aatcccagct actcgggagg 68220 ctgaggcaga gaattgcttg aacccaggag gcggaggttg cattgagccg agatcatgcc 68280 actgcattcc agcctgggcg gcagagcaag actctgtctc aaaataataa taataatttt 68340 ttaaaaatac attttaagtc cttttcttcc ccacctgcct ccacccacca aatagaagag 68400 gtatttcttc ttctttaatg tcattaaggt tatatggata ccattttcta gagaggaaag 68460 aatgatggaa ttgcctagtg tgagtctagc aattatccta acatacacaa atttctcctt 68520 gttctgtgcc aagatactgt atttaatatt taatgaacat taaatattat ttactagtgt 68580 atttaatggc tgaggcaggg ttaaatatgt attattttca tcccagcaga gttgggggag 68640 gtcctagtaa ctatgccatg agctctgtga gggtgaggtg gtgtctttgc ccccgcctcc 68700 ctggcacagt gactggcaca tgattggcat agtgtggaca ttcgtcaagt gaaggaaggc 68760 2013203064 09 Apr 2013 128 of 771 atcatgagca gatctctggc ctgaatcctt ctgccatcag ctgctcgcca ggtggccctg 68820 gcactgggcc acagggaaac tctccaggct ggtatggttc ctgtctgtgg ctgtcttccc 68880 gggcccatgt taggagactt tcacttccag agccctttcc ctctcagggc cttgcttacc 68940 aagtgactgg ttcccattta ctaggagctc ttaggtcatt gaagatgttg cgtactcccc 69000 ccagtgaggg ctgccttttg atcacagccg ccagaagcct caaggaagga gcagagctgg 69060 aaacagacgc caggccattg cttctgttcc tctggggcag acccagccac ggaagagaca 69120 ttctgggaca agggctgggg tccacctttc aaacgtgtct gcagcaggct ctcagcatgg 69180 actctctgcc tccaaacatc cacctcctca tcggaaaatg gatgggagtg cctgcctgga 69240 gcagctggtg ggagagcgca gcgccagcac gtaggacaca ctcggttcat gggctgatgc 69300 cgttcgcatt gactgcctct tcagctgggt gttgagccac accttggagt caccagtctt 69360 tggagaccaa gtctgctact tttttctcta aagtgacaat cctctgaaac ctccagatca 69420 tcttgaagcc cccgtctgaa agttgcccag agccagtgcc tcacctgctg ttccttgttc 69480 actttttcac gggaggcctt gcagggcttt atgacaagat tttatgggtg gctgcccagc 69540 atcattgtga ctcgtgagac agagagaaac cagttgtaac catgtagaca gtggaagtga 69600 tagggagaaa agaggtgagg ggactcttca atccgaaggg aaatgaagtc taagcaggcg 69660 caccctgcag gttcagtgtc aagcccaggg cctggcccca gggtgtggta tttgttgact 69720 gggtgtgtgg accctgggag aaagtctgag aatgaatgtt cctcttagag gtagagagtg 69780 gaaggtgact ctgtgtgtac ttggaattag tgatttctgt acagatgatt cttttagaat 69840 catcatgagt atttttctct ttcagaccca agaaactcga gagatcttac atttccacta 69900 taccacatgg cctgactttg gagtccctga atcaccagcc tcattcttga actttctttt 69960 caaagtccga gagtcagggt cactcagccc ggagcacggg cccgttgtgg tgcactgcag 70020 tgcaggcatc ggcaggtctg gaaccttctg tctggctgat acctgcctct tgctggtaag 70080 gaggccctcg cgggtgccct ggggagctcc tctacctgct ctgctgtgat gttttttcct 70140 aagtagaaac tgaagcgctc ctcttccaaa atacagagac tcactgtgtt agtctgtttt 70200 tgcgttacta ataaaggcgt acctgagact cggtaatttg taaagaaaag aggtttaact 70260 ggctcccggt tctgcaggct gtacaagcat ggcaccagca tctgctcggc tcctggggag 70320 gcctcaggga gcttccagtc atggtggaag gtgaagggga gcaggagcaa gagatggggg 70380 aggtcccaga ctcttaacca gctctcttgt gaatgcattg cctcagggag ggcaccaagc 70440 ctttcatgag ggacctgtcc ccctgaccca gacacctccc acccagcccc acctccaaca 70500 ctagggatca catttcagca tgagattggg aggggacaga catctaacgg tgttattaac 70560 2013203064 09 Apr 2013 129 of 771 gttgcccttg agaattggac ctggctgact tatatctcct ctctggcttt cagatggaca 70620 agaggaaaga cccttcttcc gttgatatca agaaagtgct gttagaaatg aggaagtttc 70680 ggatggggct gatccagaca gccgaccagc tgcgcttctc ctacctggct gtgatcgaag 70740 gtgccaaatt catcatgggg gactcttccg tgcaggtcag cattgccttt gtttgaatcc 70800 aggtgtgacc attttaactt ttttgtcttt gaaggaggct gtcagttgta aaagttcaaa 70860 caccgtctgg tgtcagggga aatagctacc cttcatgttt aaaatagcta gaaagttgtc 70920 aaaatgttca ccatgttgca ctttgtgcct ttgaagtgct cacatagaga gcattgatag 70980 gaagacgaga ctttattttc aaaagatttc atcttccaag tacatggctg cagccctgag 71040 aggccgagag cccctcgcca agccgtcacc tctgctcatg caaagggatt tcctgacaaa 71100 ccagccgaag tgaacactaa taggacttcc tcttgctgct ctttcaagga tcagtggaag 71160 gagctttccc acgaggacct ggagccccca cccgagcata tccccccacc tccccggcca 71220 cccaaacgaa tcctggagcc acacaatggg aaatgcaggg agttcttccc aaatcaccag 71280 tgggtgaagg aagagaccca ggaggataaa gactgcccca tcaaggaaga aaaaggaagc 71340 cccttaaatg ccgcacccta cggcatcgaa aggtaatatg attgggtccc agcttgttgg 71400 ggtgagggga aatgactttc tgttctagaa acacacgctg gtactgaaac cctgtggatg 71460 cagcctcctg ttggcaagca gcgcttccgc atccttgggg aacagggcgc gtggaccaca 71520 gccactccac tcctggctgc tggaggtccg gtattgggca cagggtggcc gcaggacatg 71580 agccacttct gtgggcttct agtgccacct tgtggtgctt gttggaatga ggggctcgga 71640 gccaccgagt agggtttttc tgccccccct gacgacagcg ccctccccca ggtttccgga 71700 cagtcctgaa atgtgatgtc caggcttgag tgccctcagt ccccacagtg gtcctttggg 71760 gaatgtaacc ttttttatgt ggtcttgatt aaatcccatt ttacttcctt gcaggttaac 71820 aaccattatt gagtacctat tgatatgtgt ggtgtactga gttaactaga acatgtcccc 71880 tggtctgtgt tctagaccat cttgctggga aaaaggcaga cccaaagcat attttggtgg 71940 gggcccatgg acagtgatgt gatagaggtg tccgctgagg tggtcaggga aggctgcttg 72000 cagtaggtgg ccgtgcacgg aaagtttgca gaatgagcag gtgttagttc cagctggaga 72060 tgactgccgg ctgtgccctt ggtacctgct ttctggaggg aagttttaag acgtgtgcat 72120 acttgaccca gcagttgtat acatggagaa atttactttg cagcaactct caaaacaagc 72180 gtgtaaagat gtgtataggt agttgtgttt gttgtggcat tgtttgtagt agtgaaaaat 72240 tagagacagg ccaatgatat aaccagggac ctgatcaatt atgttctctc ccggtgttgg 72300 gatattctgt agctcttaaa gaatgagatc tgggtgtact gatgtggcca gacattgcaa 72360 2013203064 09 Apr 2013 130 of 771 ttgcagtaca tgagaaggca aatcatacag tagtgtgtac accagtgagt cctccagcca 72420 gataaatcct cacagtgacc agtcgcccag gcaccttgtg aaccctaccc tgggtgtggg 72480 tgctatctga agtacctggg ggagggggtg acaagtggac ttcaggctga tgtgggccct 72540 ggcctggccc tccctccaag cagagggggc tggctcgctg gaaggttaac atcatccaac 72600 tctgtctaca cgtggcttgt tttttcctag aattcctgcc acaatagcag catccttgcc 72660 attcattttc tccaaagtga gtaacccatc tctgccctct gattcctcag catgagtcaa 72720 gacactgaag ttagaagtcg ggtcgtgggg ggaagtcttc gaggtgccca ggctgcctcc 72780 ccagccaaag gggagccgtc actgcccgag aaggacgagg accatgcact gagttactgg 72840 aagcccttcc tggtcaacat gtgcgtggct acggtcctca cggccggcgc ttacctctgc 72900 tacagggtat gtttccactg acagacgcgc tggcgagatg ctcgtgtgca gagagcactg 72960 gccgctagcc cgatggtagg attcagttct gtggtgcatc tgagccagtc tcagaagaaa 73020 cagatcaaag gtttttaaag tctggaactg tggaagggct aacaagagaa ttaaggatcg 73080 atgcactggg gttttaagga gccctctggt cccaagaata taagagtcta atctcagggc 73140 cttaacctat tcaggagtaa gtagagaaaa tgccaaatac gtctgtttct ctctctcttt 73200 ttttttttat tcctttgttt ttggaaaaaa atagagttac aacacattgt tgtttttaac 73260 ctttataaaa agcagctttt tgttatttct ggaacaaaaa aaaacaaagt aggcacttat 73320 gaaactttct cataccctta ggtgatgtaa tcagccatat aatttatatt tgatttccca 73380 gggaaggaat cccaaacttt tacgaatgta aactcccttg gagaagaggg ttaggacgct 73440 gttgcgctca agcccccctc agctgtgtgc acactgagcc aggacagggt ctttgagctt 73500 tcccactata agaagaacag caacaaaagg ccgtctagaa aaacagaacc tgcctctgct 73560 tctgctcagg gtgtccccgc tgggtttcca ttgtcctttc tccattgctc cctcctgtga 73620 cagccatctt gctcatgtac cagccctcat caccccatcc ccataaatgg gtgtcctcga 73680 ggcctctgcc tgggggtcag aggtcaccac agggtggcca ttggcatgtc aacccgctgt 73740 taattcagag aagtgggctc cacctcattg ggagaagtgc catttcagca gaaattcaca 73800 cgttagacgt gtgttgctgt taagtaaggg gaagagagag gactagcctc agagctctgg 73860 ccatggaaat gacctcctaa gactttttcg tggttttaaa tattttacct ctttccaggt 73920 ggcatctgag tacatcagat ggttttgcaa aatgcaaaca attttttcct tggggatgat 73980 ttttggggag agggggctac tgtaaaaaat aaaaccaaaa ccccctttgc tccctcggag 74040 gttgaagttg ccggggggtg tggccggggt catgcatgag gcgacagctc tgcaggtgcg 74100 ggtctgggct catctgaact gtttggtttc attccagttc ctgttcaaca gcaacacata 74160 2013203064 09 Apr 2013 131 of 771 gcctgaccct cctccactcc acctccaccc actgtccgcc tctgcccgca gagcccacgc 74220 ccgactagca ggcatgccgc ggtaggtaag ggccgccgga ccgcgtagag agccgggccc 74280 cggacggacg ttggttctgc actaaaaccc atcttccccg gatgtgtgtc tcacccctca 74340 tccttttact ttttgcccct tccactttga gtaccaaatc cacaagccat tttttgagga 74400 gagtgaaaga gagtaccatg ctggcggcgc agagggaagg ggcctacacc cgtcttgggg 74460 ctcgccccac ccagggctcc ctcctggagc atcccaggcg ggcggcacgc caacagcccc 74520 ccccttgaat ctgcagggag caactctcca ctccatattt atttaaacaa ttttttcccc 74580 aaaggcatcc atagtgcact agcattttct tgaaccaata atgtattaaa attttttgat 74640 gtcagccttg catcaagggc tttatcaaaa agtacaataa taaatcctca ggtagtactg 74700 ggaatggaag gctttgccat gggcctgctg cgtcagacca gtactgggaa ggaggacggt 74760 tgtaagcagt tgttatttag tgatattgtg ggtaacgtga gaagatagaa caatgctata 74820 atatataatg aacacgtggg tatttaataa gaaacatgat gtgagattac tttgtcccgc 74880 ttattctcct ccctgttatc tgctagatct agttctcaat cactgctccc ccgtgtgtat 74940 tagaatgcat gtaaggtctt cttgtgtcct gatgaaaaat atgtgcttga aatgagaaac 75000 tttgatctct gcttactaat gtgccccatg tccaagtcca acctgcctgt gcatgacctg 75060 atcattacat ggctgtggtt cctaagcctg ttgctgaagt cattgtcgct cagcaatagg 75120 gtgcagtttt ccaggaatag gcatttgcct aattcctggc atgacactct agtgacttcc 75180 tggtgaggcc cagcctgtcc tggtacagca gggtcttgct gtaactcaga cattccaagg 75240 gtatgggaag ccatattcac acctcacgct ctggacatga tttagggaag cagggacacc 75300 ccccgccccc cacctttggg atcagcctcc gccattccaa gtcaacactc ttcttgagca 75360 gaccgtgatt tggaagagag gcacctgctg gaaaccacac ttcttgaaac agcctgggtg 75420 acggtccttt aggcagcctg ccgccgtctc tgtcccggtt caccttgccg agagaggcgc 75480 gtctgcccca ccctcaaacc ctgtggggcc tgatggtgct cacgactctt cctgcaaagg 75540 gaactgaaga cctccacatt aagtggcttt ttaacatgaa aaacacggca gctgtagctc 75600 ccgagctact ctcttgccag cattttcaca ttttgccttt ctcgtggtag aagccagtac 75660 agagaaattc tgtggtggga acattcgagg tgtcaccctg cagagctatg gtgaggtgtg 75720 gataaggctt aggtgccagg ctgtaagcat tctgagctgg gcttgttgtt tttaagtcct 75780 gtatatgtat gtagtagttt gggtgtgtat atatagtagc atttcaaaat ggacgtactg 75840 gtttaacctc ctatccttgg agagcagctg gctctccacc ttgttacaca ttatgttaga 75900 gaggtagcga gctgctctgc tatatgcctt aagccaatat ttactcatca ggtcattatt 75960 2013203064 09 Apr 2013 132 of 771 ttttacaatg gccatggaat aaaccatttt tacaaaaata aaaacaaaaa aagcaaggtg 76020 ttttggtata ataccttttc aggtgtgtgt ggatacgtgg ctgcatgacc gggtgggtgg 76080 gggggagtgt ctcagggtct tctgtgacct cacagaactg tcagactgta cagttttcca 76140 acttgccata ttcatgatgg gtttgcattt tagctgcaac aataaaattt ttttctaaag 76200 aacatgaatt tggggtgctt cccatttttt tctttgctta atagagctaa accaggatga 76260 gtaactcctg tttctttcta tccctgctga tgtgaaacag atgttgtcaa tcagctgggg 76320 ttagagtttt ccacttctaa gaattaacct cagcatccct gcattgccag caccctcagg 76380 ctggagcgct ttccttgact gtgagcttgt tgaacacctt aggcctcagc ccatttcctt 76440 cccaaattga cgctttgcct gtgtagggcc ctcagataac ttaacaaact taccagtgtt 76500 gtttgaagaa cagtgttttg agttgtaatc tcaaaaccat atcccttacc caattacctg 76560 taagacacaa tggttaccac atctcagtac gtaaagtcca cttgatatag aattgactta 76620 gaaataagac agattagtat agtttttcat ttgtgtacaa aattaaacaa tgtaaattcc 76680 ccccaaagtg atttttttga ctttttgaag taattttgga cttgcaaaat gttgccaaaa 76740 tagtacgaag agttccccag taccctcgaa gtttcctcga ctgtttcaaa gctggctgca 76800 ggcccaggct catgagactg ggaagaggac aggctgtggt catgtggacc cacaggggcc 76860 tggggctgca gaagtcagtg tggcttccac catttcaggt ataaaaaagg gcatctaagc 76920 tttcaagaag agggaggatg ctctagggca gcggtcccca accttttctg gcaccaggaa 76980 ccggttccat ggaagacaat tttttcacag gcctgggggt ggtgagggat ggttttggga 77040 tagaaacttc cacctcagat catcaggcat cagattctca taaggagctt gcaacctgat 77100 ctcttgcaca cattcagttc acaatagggt tcacgctcct aagagaacct gatgctgcag 77160 ctgatctaac aggagatgga gctcaggtgg tcatgctcag tcgctcgcca ctcacctcct 77220 gccatgcagt ccagttccta acaggcctca gaccagtacc ggtctgtggc ctgggggttg 77280 aggacccctg ctctaggctg gtactgctga tgcttaaaaa gagagggttt gccagaaatc 77340 agatgggaca aaagggcaaa ggccgtgcca cagagtgccc atatagggga gagcacgcct 77400 ggagccttcg agagcatgca gagaagcctg gagactgcat ttaccggagc tgctgcctga 77460 ggccaccctc caagtgtccc cacagcgcac cacaagacca caggagtgac ctcctcactg 77520 gcaggtattt ggggaaacaa ctgctgtcta ctcttttggg taaaaagtga aacaccaata 77580 gtttaattga aatttcagaa aattgaacat atgaacaagg caaataaata ctaagtaagt 77640 taaaaacaca aaatatgtcc aggaagtatc gatgagaatg ttcaagttaa agttctccaa 77700 tgccattgct acagcaacct caaaccctag gttctctctg cactattaac acagacatct 77760 2013203064 09 Apr 2013 133 of 771 caggacatgg tttgcttttt tttaagactt aaataggaaa ctaatttttc tttctttaaa 77820 gcaattgcgt tcttcagtga actctttctt taggccagtt gatggcttct tagcagttta 77880 ttgacgagat cctagggtag cttccgaagc tgggttgatt gattgcattt gggtgcggat 77940 ggccaaagtg agtggcccta ctgcctgtgc tgctcagggc tcctgggctg atgtggtggc 78000 t 78001 <210> 13 <211> 2160 <212> DNA <213> Mus musculus <400> 13 ggcgccctgc tctcccggcg gggcggcgga gggggcgggc tggccggcgc acggtgatgt 60 ggcgggactc tttgtgcact gcggcaggat acgcgcttgg gcgtcgggac gcggctgcgc 120 tcagctctct cctctcggaa gctgcagcca tgatggaagt ttgagagttg agccgctgtg 180 aggccaggcc cggcgcaggc gagggagatg agagacggcg gcggccacgg cccagagccc 240 ctctcagcgc ctgtgagcag ccgcgggggc agcgccctcg gggagccggc cgggcggcgg 300 cggcggcagc ggcggcgggc ctcgcctcct cgtcgtctgt tctaaccggg cagcttctga 360 gcagcttcgg agagagacgg tggaagaagc cgtgggctcg agcgggagcc ggcgcaggct 420 cggcggctgc acctcccgct cctggagcgg gggggagaag cggcggcggc ggccgcggct 480 ccggggaggg ggtcggagtc gcctgtcacc attgccaggg ctgggaacgc cggagagttg 540 ctctctcccc ttctcctgcc tccaacacgg cggcggcggc ggcggcacgt ccagggaccc 600 gggccggtgt taagcctccc gtccgccgcc gccgcacccc ccctggcccg ggctccggag 660 gccgccggag gaggcagccg ctgcgaggat tatccgtctt ctccccattc cgctgcctcg 720 gctgccaggc ctctggctgc tgaggagaag caggcccagt ctctgcaacc atccagcagc 780 cgccgcagca gccattaccc ggctgcggtc cagggccaag cggcagcaga gcgaggggca 840 tcagcgaccg ccaagtccag agccatttcc atcctgcaga agaagcctcg ccaccagcag 900 cttctgccat ctctctcctc ctttttcttc agccacaggc tcccagacat gacagccatc 960 atcaaagaga tcgttagcag aaacaaaagg agatatcaag aggatggatt cgacttagac 1020 2013203064 09 Apr 2013 134 of 771 ttgacctata tttatccaaa tattattgct atgggatttc ctgcagaaag acttgaaggt 1080 gtatacagga acaatattga tgatgtagta aggtttttgg attcaaagca taaaaaccat 1140 tacaagatat acaatctatg tgctgagaga cattatgaca ccgccaaatt taactgcaga 1200 gttgcacagt atccttttga agaccataac ccaccacagc tagaacttat caaacccttc 1260 tgtgaagatc ttgaccaatg gctaagtgaa gatgacaatc atgttgcagc aattcactgt 1320 aaagctggaa agggacggac tggtgtaatg atttgtgcat atttattgca tcggggcaaa 1380 tttttaaagg cacaagaggc cctagatttt tatggggaag taaggaccag agacaaaaag 1440 ggagtcacaa ttcccagtca gaggcgctat gtatattatt atagctacct gctaaaaaat 1500 cacctggatt acagacccgt ggcactgctg tttcacaaga tgatgtttga aactattcca 1560 atgttcagtg gcggaacttg caatcctcag tttgtggtct gccagctaaa ggtgaagata 1620 tattcctcca attcaggacc cacgcggcgg gaggacaagt tcatgtactt tgagttccct 1680 cagccattgc ctgtgtgtgg tgatatcaaa gtagagttct tccacaaaca gaacaagatg 1740 ctcaaaaagg acaaaatgtt tcacttttgg gtaaatacgt tcttcatacc aggaccagag 1800 gaaacctcag aaaaagtgga aaatggaagt ctttgtgatc aggaaatcga tagcatttgc 1860 agtatagagc gtgcagataa tgacaaggag tatcttgtac tcaccctaac aaaaaacgat 1920 cttgacaaag caaacaaaga caaggccaac cgatacttct ctccaaattt taaggtgaaa 1980 ctatacttta caaaaacagt agaggagcca tcaaatccag aggctagcag ttcaacttct 2040 gtgactccag atgttagtga caatgaacct gatcattata gatattctga caccactgac 2100 tctgatccag agaatgaacc ttttgatgaa gatcagcatt cacaaattac aaaagtctga 2160 <210> 14 <211> 5572 <212> DNA <213> H. sapiens <400> 14 cctcccctcg cccggcgcgg tcccgtccgc ctctcgctcg cctcccgcct cccctcggtc 60 ttccgaggcg cccgggctcc cggcgcggcg gcggaggggg cgggcaggcc ggcgggcggt 120 gatgtggcgg gactctttat gcgctgcggc aggatacgcg ctcggcgctg ggacgcgact 180 2013203064 09 Apr 2013 135 of 771 gcgctcagtt ctctcctctc ggaagctgca gccatgatgg aagtttgaga gttgagccgc 240 tgtgaggcga ggccgggctc aggcgaggga gatgagagac ggcggcggcc gcggcccgga 300 gcccctctca gcgcctgtga gcagccgcgg gggcagcgcc ctcggggagc cggccggcct 360 gcggcggcgg cagcggcggc gtttctcgcc tcctcttcgt cttttctaac cgtgcagcct 420 cttcctcggc ttctcctgaa agggaaggtg gaagccgtgg gctcgggcgg gagccggctg 480 aggcgcggcg gcggcggcgg cacctcccgc tcctggagcg ggggggagaa gcggcggcgg 540 cggcggccgc ggcggctgca gctccaggga gggggtctga gtcgcctgtc accatttcca 600 gggctgggaa cgccggagag ttggtctctc cccttctact gcctccaaca cggcggcggc 660 ggcggcggca catccaggga cccgggccgg ttttaaacct cccgtccgcc gccgccgcac 720 cccccgtggc ccgggctccg gaggccgccg gcggaggcag ccgttcggag gattattcgt 780 cttctcccca ttccgctgcc gccgctgcca ggcctctggc tgctgaggag aagcaggccc 840 agtcgctgca accatccagc agccgccgca gcagccatta cccggctgcg gtccagagcc 900 aagcggcggc agagcgaggg gcatcagcta ccgccaagtc cagagccatt tccatcctgc 960 agaagaagcc ccgccaccag cagcttctgc catctctctc ctcctttttc ttcagccaca 1020 ggctcccaga catgacagcc atcatcaaag agatcgttag cagaaacaaa aggagatatc 1080 aagaggatgg attcgactta gacttgacct atatttatcc aaacattatt gctatgggat 1140 ttcctgcaga aagacttgaa ggcgtataca ggaacaatat tgatgatgta gtaaggtttt 1200 tggattcaaa gcataaaaac cattacaaga tatacaatct ttgtgctgaa agacattatg 1260 acaccgccaa atttaattgc agagttgcac aatatccttt tgaagaccat aacccaccac 1320 agctagaact tatcaaaccc ttttgtgaag atcttgacca atggctaagt gaagatgaca 1380 atcatgttgc agcaattcac tgtaaagctg gaaagggacg aactggtgta atgatatgtg 1440 catatttatt acatcggggc aaatttttaa aggcacaaga ggccctagat ttctatgggg 1500 aagtaaggac cagagacaaa aagggagtaa ctattcccag tcagaggcgc tatgtgtatt 1560 attatagcta cctgttaaag aatcatctgg attatagacc agtggcactg ttgtttcaca 1620 agatgatgtt tgaaactatt ccaatgttca gtggcggaac ttgcaatcct cagtttgtgg 1680 tctgccagct aaaggtgaag atatattcct ccaattcagg acccacacga cgggaagaca 1740 agttcatgta ctttgagttc cctcagccgt tacctgtgtg tggtgatatc aaagtagagt 1800 tcttccacaa acagaacaag atgctaaaaa aggacaaaat gtttcacttt tgggtaaata 1860 cattcttcat accaggacca gaggaaacct cagaaaaagt agaaaatgga agtctatgtg 1920 atcaagaaat cgatagcatt tgcagtatag agcgtgcaga taatgacaag gaatatctag 1980 2013203064 09 Apr 2013 136 of 771 tacttacttt aacaaaaaat gatcttgaca aagcaaataa agacaaagcc aaccgatact 2040 tttctccaaa ttttaaggtg aagctgtact tcacaaaaac agtagaggag ccgtcaaatc 2100 cagaggctag cagttcaact tctgtaacac cagatgttag tgacaatgaa cctgatcatt 2160 atagatattc tgacaccact gactctgatc cagagaatga accttttgat gaagatcagc 2220 atacacaaat tacaaaagtc tgaatttttt tttatcaaga gggataaaac accatgaaaa 2280 taaacttgaa taaactgaaa atggaccttt ttttttttaa tggcaatagg acattgtgtc 2340 agattaccag ttataggaac aattctcttt tcctgaccaa tcttgtttta ccctatacat 2400 ccacagggtt ttgacacttg ttgtccagtt gaaaaaaggt tgtgtagctg tgtcatgtat 2460 ataccttttt gtgtcaaaag gacatttaaa attcaattag gattaataaa gatggcactt 2520 tcccgtttta ttccagtttt ataaaaagtg gagacagact gatgtgtata cgtaggaatt 2580 ttttcctttt gtgttctgtc accaactgaa gtggctaaag agctttgtga tatactggtt 2640 cacatcctac ccctttgcac ttgtggcaac agataagttt gcagttggct aagagaggtt 2700 tccgaagggt tttgctacat tctaatgcat gtattcgggt taggggaatg gagggaatgc 2760 tcagaaagga aataatttta tgctggactc tggaccatat accatctcca gctatttaca 2820 cacacctttc tttagcatgc tacagttatt aatctggaca ttcgaggaat tggccgctgt 2880 cactgcttgt tgtttgcgca ttttttttta aagcatattg gtgctagaaa aggcagctaa 2940 aggaagtgaa tctgtattgg ggtacaggaa tgaaccttct gcaacatctt aagatccaca 3000 aatgaaggga tataaaaata atgtcatagg taagaaacac agcaacaatg acttaaccat 3060 ataaatgtgg aggctatcaa caaagaatgg gcttgaaaca ttataaaaat tgacaatgat 3120 ttattaaata tgttttctca attgtaacga cttctccatc tcctgtgtaa tcaaggccag 3180 tgctaaaatt cagatgctgt tagtacctac atcagtcaac aacttacact tattttacta 3240 gttttcaatc ataatacctg ctgtggatgc ttcatgtgct gcctgcaagc ttcttttttc 3300 tcattaaata taaaatattt tgtaatgctg cacagaaatt ttcaatttga gattctacag 3360 taagcgtttt ttttctttga agatttatga tgcacttatt caatagctgt cagccgttcc 3420 acccttttga ccttacacat tctattacaa tgaattttgc agttttgcac attttttaaa 3480 tgtcattaac tgttagggaa ttttacttga atactgaata catataatgt ttatattaaa 3540 aaggacattt gtgttaaaaa ggaaattaga gttgcagtaa actttcaatg ctgcacacaa 3600 aaaaaagaca tttgattttt cagtagaaat tgtcctacat gtgctttatt gatttgctat 3660 tgaaagaata gggttttttt tttttttttt tttttttttt ttaaatgtgc agtgttgaat 3720 catttcttca tagtgctccc ccgagttggg actagggctt caatttcact tcttaaaaaa 3780 2013203064 09 Apr 2013 137 of 771 aatcatcata tatttgatat gcccagactg catacgattt taagcggagt acaactacta 3840 ttgtaaagct aatgtgaaga tattattaaa aaggtttttt tttccagaaa tttggtgtct 3900 tcaaattata ccttcacctt gacatttgaa tatccagcca ttttgtttct taatggtata 3960 aaattccatt ttcaataact tattggtgct gaaattgttc actagctgtg gtctgaccta 4020 gttaatttac aaatacagat tgaataggac ctactagagc agcatttata gagtttgatg 4080 gcaaatagat taggcagaac ttcatctaaa atattcttag taaataatgt tgacacgttt 4140 tccatacctt gtcagtttca ttcaacaatt tttaaatttt taacaaagct cttaggattt 4200 acacatttat atttaaacat tgatatatag agtattgatt gattgctcat aagttaaatt 4260 ggtaaagtta gagacaacta ttctaacacc tcaccattga aatttatatg ccaccttgtc 4320 tttcataaaa gctgaaaatt gttacctaaa atgaaaatca acttcatgtt ttgaagatag 4380 ttataaatat tgttctttgt tacaatttcg ggcaccgcat attaaaacgt aactttattg 4440 ttccaatatg taacatggag ggccaggtca taaataatga cattataatg ggcttttgca 4500 ctgttattat ttttcctttg gaatgtgaag gtctgaatga gggttttgat tttgaatgtt 4560 tcaatgtttt tgagaagcct tgcttacatt ttatggtgta gtcattggaa atggaaaaat 4620 ggcattatat atattatata tataaatata tattatacat actctcctta ctttatttca 4680 gttaccatcc ccatagaatt tgacaagaat tgctatgact gaaaggtttt cgagtcctaa 4740 ttaaaacttt atttatggca gtattcataa ttagcctgaa atgcattctg taggtaatct 4800 ctgagtttct ggaatatttt cttagacttt ttggatgtgc agcagcttac atgtctgaag 4860 ttacttgaag gcatcacttt taagaaagct tacagttggg ccctgtacca tcccaagtcc 4920 tttgtagctc ctcttgaaca tgtttgccat acttttaaaa gggtagttga ataaatagca 4980 tcaccattct ttgctgtggc acaggttata aacttaagtg gagtttaccg gcagcatcaa 5040 atgtttcagc tttaaaaaat aaaagtaggg tacaagttta atgtttagtt ctagaaattt 5100 tgtgcaatat gttcataacg atggctgtgg ttgccacaaa gtgcctcgtt tacctttaaa 5160 tactgttaat gtgtcatgca tgcagatgga aggggtggaa ctgtgcacta aagtgggggc 5220 tttaactgta gtatttggca gagttgcctt ctacctgcca gttcaaaagt tcaacctgtt 5280 ttcatataga atatatatac taaaaaattt cagtctgtta aacagcctta ctctgattca 5340 gcctcttcag atactcttgt gctgtgcagc agtggctctg tgtgtaaatg ctatgcactg 5400 aggatacaca aaaataccaa tatgatgtgt acaggataat gcctcatccc aatcagatgt 5460 ccatttgtta ttgtgtttgt taacaaccct ttatctctta gtgttataaa ctccacttaa 5520 2013203064 09 Apr 2013 138 of 771 aactgattaa agtctcattc ttgtcaaaaa aaaaaaaaaa aaaaaaaaaa aa 5572 <210> 15 <211> 103886 <212> DNA <213> H. sapiens <400> 15 cccttgcagg gaccgtccct gcatttccct ctacactgag cagcgtggtc acctggtcct 60 tttcacctgt gcacaggtaa cctcagactc gagtcagtga cactgctcaa cgcacccatc 120 tcagctttca tcatcagtcc tccacccccg ccccacaaca gcctaccctg cctccggctg 180 ggtttctggg cagaggccga ggcttagctc gttatcctcg cctcgcgttg ctgcaaaagc 240 cgcagcaagt gcagctgcag gctggcggct gggaaccggc ccgagcaagc cccaggcagc 300 tacactgggc atgctcagta gagcctgcgg cttggggact ctgcgctcgc acccagagct 360 accgctctgc cccctcctac cgccccctgc cctgccctgc cctcccctcg cccggcgcgg 420 tcccgtccgc ctctcgctcg cctcccgcct cccctcggtc ttccgaggcg cccgggctcc 480 cggcgcggcg gcggaggggg cgggcaggcc ggcgggcggt gatgtggcgg gactctttat 540 gcgctgcggc aggatacgcg ctcggcgctg ggacgcgact gcgctcagtt ctctcctctc 600 ggaagctgca gccatgatgg aagtttgaga gttgagccgc tgtgaggcga ggccgggctc 660 aggcgaggga gatgagagac ggcggcggcc gcggcccgga gcccctctca gcgcctgtga 720 gcagccgcgg gggcagcgcc ctcggggagc cggccggcct gcggcggcgg cagcggcggc 780 gtttctcgcc tcctcttcgt cttttctaac cgtgcagcct cttcctcggc ttctcctgaa 840 agggaaggtg gaagccgtgg gctcgggcgg gagccggctg aggcgcggcg gcggcggcgg 900 cacctcccgc tcctggagcg ggggggagaa gcggcggcgg cggcggccgc ggcggctgca 960 gctccaggga gggggtctga gtcgcctgtc accatttcca gggctgggaa cgccggagag 1020 ttggtctctc cccttctact gcctccaaca cggcggcggc ggcggcggca catccaggga 1080 cccgggccgg ttttaaacct cccgtccgcc gccgccgcac cccccgtggc ccgggctccg 1140 gaggccgccg gcggaggcag ccgttcggag gattattcgt cttctcccca ttccgctgcc 1200 gccgctgcca ggcctctggc tgctgaggag aagcaggccc agtcgctgca accatccagc 1260 2013203064 09 Apr 2013 139 of 771 agccgccgca gcagccatta cccggctgcg gtccagagcc aagcggcggc agagcgaggg 1320 gcatcagcta ccgccaagtc cagagccatt tccatcctgc agaagaagcc ccgccaccag 1380 cagcttctgc catctctctc ctcctttttc ttcagccaca ggctcccaga catgacagcc 1440 atcatcaaag agatcgttag cagaaacaaa aggagatatc aagaggatgg attcgactta 1500 gacttgacct gtatccattt ctgcggctgc tcctctttac ctttctgtca ctctcttaga 1560 acgtgggagt agacggatgc gaaaatgtcc gtagtttggg tgactataac atttaaccct 1620 ggtcaggttg ctaggtcata tattttgtgt ttcctttctg tgtattcaac ctagggtgtg 1680 tttggctaga cggaactctt gcctggttgc aagtgtcaag ccaccgattg ctttcttagg 1740 ctatctatat ggtctcttcc tgagggctat tgtccgttaa tacagaatac agtacactgt 1800 tagtggatta gcgagctcgg taatccggtc tcctaaatga acaaaaaagt agacgctttt 1860 tgaggttgag catatttcga ttaaatcttg gcttaggccc tagatcaagg gtttagatca 1920 gaataaaatg aaaattagtg ttgcacgtac gcatattgca tcagaatctt gcagtgattg 1980 ttttagtttc ctgagttgca ttgatagatt cttttaaaat atgactgatt tgcataactt 2040 tagaagcaga atcattttca gtatatatgg tgcacattga gggcaaaaag tagttttgtt 2100 aatgtttaaa cttaagttac ctacaacttt gaactgtatg tagaagtttt gtagtttgaa 2160 gtcaatagtg ccataatata ccttataagg cgttcttact agatctttgt tatatttacc 2220 tttttctctc cctatggggt gatgtaggat agtgcttgaa atttgcactt cagtagcatt 2280 taatgttcag tgctcttgtc ataaacatag aatggatatt gagtagtttc tgatcccaga 2340 tggtaatgtg taggttcaag ggtattgtgt gtagcaagtg aagattgcag aaataaaact 2400 tcagttcatg cttgaaattt aagtattgtt gtgatgccag aattgctgct caccgttttt 2460 aggtttcagg tcctctgaca ccttttggta tcgttaattt tactgatttg tgtagaatgt 2520 cagttgtatt ttaccagcta atatctagaa atgctggcaa gaggggttta ctccagcttt 2580 agattgtagg tatgttagct tttttcatac agtgtattaa atttactgag tcagcttgct 2640 gaataagaca gaagcccaag aattttaaca gtgtgtagct ttagttgtct aaaagttagg 2700 ccttcgggct tcaaaagtta gtggtcatcg aaaagcatta atctttgcag tttcaggtac 2760 aacacattgg ttttgattag ggatggggat ggggccctct ttttgcagaa tggggaaagt 2820 attgacagga attgagagct attggtaggc cagtgtataa ggtatgtgaa aacagaatta 2880 agttattggt ctgaagtgac tgaagcattt aggctctatc aaggcctaaa atttggtaat 2940 atgagtttgg taatgcgaat tgtggcagtg gacaatattt agttaaaatt atgtaattgc 3000 ataagtacta gcacagtatt tttaataaaa gttatttctt agcaaatgtc agttgcattt 3060 2013203064 09 Apr 2013 140 of 771 tgtctaaagg tagagtgaca ctacagtgtc tatatgtcct gctaaaaatt gtggggaata 3120 ttttttttta agacagcgtt tatatcggga gaggttttat tccgttggat tatgttagct 3180 gcatataaat gtgcacagtt aattttgccc aagtttttgt tttgaaatga atgtaaaact 3240 tactgaagaa gtagcttccc aaaatttagt tttctgttaa gccaaaaata ttattttaaa 3300 agagtatttg caaattttga agttgacatt aattgagaat gttactaagg ctaaactgga 3360 cccgcttgcc cagaagataa ttatggaaaa attcttttgt gacttccaaa gcagtctact 3420 attagcatga attactgaca gtcatccaaa tatataggaa caaaaaatta aatgtttatg 3480 taactttgaa aaaaaagcct ttgaagaaaa taattgaatg ctgtctggga gacagatttc 3540 tttcagcact taaagtacat aacacactac ttttactttt cccacttgat tttaaattat 3600 cagggttatt aagaccttaa aattatttta ccaggttttt acatgtgagc tgtgacatga 3660 ctggcatttt ctttgatttc agcgtatgtt ggtctctaca catgaaattt gtgtgactta 3720 aaactttctc taaaactgta cttttagtta tgatatgcat agaaagcagt atcaaatatt 3780 gcgtcaaatg actaataaca cttaatttct agagttgtgg ttttattgag ccaaaagttg 3840 atatgaaaaa aagtcagtaa ggaaagtcag tgaagtgctt gcttttttga taattgcact 3900 cccaataatt ttgatattcc aacgtacttg gtttgcttgt tttcacgtta atgttttctg 3960 tttattggag tgggaaggca ttaaaattgt cattgaagac tttgtctttg acatgttgta 4020 gtatttattt cagtaactaa cctgtgaaaa gttaaattcc tttatgaaag tagtgattgg 4080 agtattttta tctgataaag aaagattaat aatgaagcca tttctccgag gaaaattgag 4140 gacaataatt cagttttaaa atattatcgc aaaattaaat tattctaaaa atttgttagt 4200 agggttatat gcttaatatt agtctgaaat atagtgctga atttgagact atagaaaaat 4260 taagtgtatt tagggtatgt ggaaacgtta ggcttctgtt gtatttttat tgtttggtag 4320 atttgcctct tttcaaataa atgttcacag ggaatacttt taacttgtag agagtacagt 4380 gactattgaa gttacctaaa ttacctcaag gtaagtgatt actgaaatta atcatgaggg 4440 ttttaaaaag tattctattc acaacattta ttttacattg ttttgtatct gctaagttat 4500 atttcctgaa aaacatgact ggaccaccta attgctgtat gataacttac aaacttcatt 4560 tttcatagtg cttattcaag tgtaaagcac aactgaaagg agtaatgtac agtttatatg 4620 aggaaaaagg aattttattg ctgccagtgt aaaagtttgc acagcagtat agtcatcaat 4680 gcagatttac attgcttata atatactaag taaatactaa atgattaaag ataataaaat 4740 atggtgaggt ataaccacct tcattttaaa cttagtttta gaagatagta aagaaagatt 4800 cctttattac ctttttagaa ttttattttt aataacatgg gaaaggcaac tggtgatatt 4860 2013203064 09 Apr 2013 141 of 771 ttaatttttg tatggaacag tgcatctgct ttctcatagc cacataaaat acataaactt 4920 cttagtgtta tgaaatggct tactttttgg aagtgaagaa gtcttcaatt cttattttct 4980 aatgttattt tgaaatttgc ctccatttgc tgtttgttca tttggtgata gcgcaacact 5040 taaaaaaata ttttaagccg cttctgaagt aatcacttca gtgactttta atggaggagt 5100 atttgttatg ggaaattcac ttcacaaagt tttaacatta attcacttga agtaaacgtg 5160 ctatttttaa attttcatct caatctttta agtaagacga aagcttagga aatcactttt 5220 attattgata ttgtgtgtga cttcagagtt tgtaaagaga attgtagaag tgttgcatgc 5280 atatgacaat tttctgctta attgaaatgt gaggcctctg ccatactaca aggatttagc 5340 ttccagaaaa tgtaatatta acatagctta agaaatgtat tttttttttt ctgtagaaac 5400 cgttgggtta aacaaacagt tcagaagttt tattacatgg aacccattag ttcttaatct 5460 tgttaccttt ttcttcattt tttctgttaa acttgatttt cacagtcagc attgaagaat 5520 tcatcttgtg gcctgaattc attaagaaaa gatgttagga tttgttctga agatagtgac 5580 ttaggaaatt tgtgagactg gggtcagtca gttctgtttt acaattgctt tctatttggt 5640 agctttgaaa ttaatttagt tgcttatcag agagaataat gttgaggtta gactaacctt 5700 aaattggtaa ggctttgctg agcaaactga taactgtaag tcttttatag ggtgcattac 5760 tgccacatat acgttcttcc ataggtggtt aaaagtatat tggtctgtgt ttggtgattc 5820 tctttgtaca tattgagtat atgcattcac taatgtaaaa taatttgcca agaaaggtga 5880 aattagtata ttgtacttga ctattcacct ttcccttagt tttttgaatt tttttcattg 5940 gttgcagagg aagtattagc aatttaattc ttttaaaata atttgcactg gaataaataa 6000 gtatcggcaa atataagaag agtaacataa tttaagggtg aattaatttt atttgggaag 6060 ttttagttct gtatagttaa ggcagattct tcatttgcaa cagttgacat tgggacatgt 6120 gtgaacatct tcaaggtatt aggacatctt caaggcatta ctttttggca gtgttgagaa 6180 tttttttttt tttttttttt ttttttgaga tggaatctcg ctctatcgcc cagtctgggg 6240 tgcagtggca ggatctcggc tcactggaac ctctgcctcc caggttcagg cgattctcct 6300 gcctgaacct cccaagcagc tgggattata ggtgcatgcc accacgccca gatagttttt 6360 gtacttttag tagagatggg gttttaccac cttggccagg ctggtctcaa actccagacc 6420 tcaagtgatc cgcctgcctc ggcctcccaa aatgctggga ttacaggcgt gagccactgc 6480 gcctggccag tgttgagaat attgagagat ggatattgta gctgtacctg ccatcaaaag 6540 aattttcttg acctccacat agtgtgaaaa agaagactgt ttacacatta tattttaagt 6600 aattatacac ataattatta tcagtactca ccacttcaaa tatgaacagt gaatctaacc 6660 2013203064 09 Apr 2013 142 of 771 agtgtttgat ttctctgtgt gtgtatgtgt atacaaagtt agcaaacctt ttatcttaat 6720 atttattaaa aaacgaattt ttgtttcttt aaagaaaaga ctaccttaga gaatattgtt 6780 ctatagtttt taaatatggt cagatctatt ttaaattatg ttaaaatttt gagtattacg 6840 tttatctata cttttaagca tatatacatt gtttcatttt agattttagg gaggcagtgt 6900 gggctctgga gccagactgc ttgttttgta atcctggatc ttccatttag tagctggatg 6960 actttgagta ggttatttag attttctcaa tctattttat ctgtaaaatg gggatgataa 7020 tggaacctac cgcatacgtt tatcttgaat agtaagtgag ataataataa gtaatttcat 7080 ttagcatagt acctgccaca ttgtaaatac ttaaatggta gctactgctc tgaaaaactg 7140 taatttcagg ttatgtatgt agggaaatta tttgtatttt catttatggt gtatgattgt 7200 aactgaattt cctcagtttg ggccatgtta ggattttgtt tcaagttata agtgttttta 7260 aaaataaggg tattccttta ggaagtctgg gtatgacatg tctgtgattt tgctggttca 7320 tcacaaatgg gaaataaatc tctgctaact caaactgttg accaaagtaa aattaattat 7380 gccaatcaaa aactatttgc tttaaaatat aaaaggcaaa aacttcctat tagcataatg 7440 aagtagaatt tttaaacttt gttataatct taaattttct ttagtgttga agataggtca 7500 acttaactat catacatttt tattcacata aagtaaactc tgcctcaaat gtaataaact 7560 taatatgagt tatgtaaact ttggtcaata gaggtatatt ttttagcatt tccttttgaa 7620 aatttcagcc ttttgaggga gtcttgcaac tgaatgtcaa gttacattta ttacaataaa 7680 atggacactt aatataatct gtaatgcatt aacataatat gggaactttt aaagtattca 7740 gtctctgtat tattgagtcc tatttccaca tttggccagg attctcaata tgatttaggc 7800 ccaagacgtg ggaagaaaga agtaaagaac taaaggattt ttttcttcat ttttttaatt 7860 gaatatgggg aaagatggaa taagcttatc tgtccagtaa aggccattat gtgtacatag 7920 ggattattat ttttcccccc cttgggctgt actgatttcc cagatgtacc acagcactct 7980 tagtagtgaa gcacttgact tctagtgagt ggattttttg tgtgtgtgtt ttatattgca 8040 gagtgaatac actctgtctg atactatgtg actttctgat tatgtgattt ttatgcattt 8100 tatgtgtttt gtaaactagc tgtatttttg gtccatgtct aggttgtaga attgaattgt 8160 gcattttggc atctgagcac agctgagttt tctaaatcaa tctctctcct tgcacctagt 8220 ttttgcttta gatcactacc taagacttac tgttgattta atattagagc acttaagcat 8280 agctttgact tttatttcct ttgatttttg tagattttca ggctgaagta caataaggtt 8340 ctctgttctt tactagtaat tgcaaagatt gtattctgtg aattttattt gtttaatact 8400 tttgatcttt tgaagaggat gtaattattt aaggtattat gaaatgcatt gtgatttgaa 8460 2013203064 09 Apr 2013 143 of 771 ttagatactc tttggagatg gagttttgct gttgttgccc aggctggagt gcaatggtgt 8520 gatctcggct caccacagcc tccgcctcct gggttcaagc aattctcttg ccgcagcctc 8580 ccaagtagct ggaattacag gcatgcgcca ccacgcccgg ctaattttat attttttttt 8640 tcagtagaga tggggggttt ctccatgttg gtcaggctgg cctcgaactc ttgacctcag 8700 gtaatctgcc tgtctcagcc tgctaaagtg ctgagattac aggcatgagc cactgcgccc 8760 ggcctcagat actcttttaa ttagatgcgt ttaaaaattt aacccaccat tgctggcatg 8820 aatagatgta tttttagagt gattcataaa tatcgtatac atgtttaaag ttacaaactt 8880 tttgcttatt tcaaaatgca ggattctttt ccatttaaaa ttccctctct ttgtgagact 8940 tctttttgag tattctggtt actctaaact gattggagat gaaattagat agaattgaaa 9000 actgtacttt taaaatgaaa ttttggggat gtcattaagc ttgatttttt aggttttttt 9060 tttagtgtgt attataaatt attttacact gattgtcagc gataaaatgg aatgcctggg 9120 attttttaaa atttatttta ttcattttta taaggtaaaa acagtgtttt gctaggctta 9180 atttgaccat gttgtaaaat ttattgtata ccttgaaaga atcatttatg aaagatactg 9240 aattagctaa tatatactct gtcttatgta gtttttgatt aacaatacac tttttaaatc 9300 attagctcat ttgattttgc aaagaagaac aggtaaccta agaggcagac agaacaggca 9360 ttacttttat ttttctttct tttttatttt atttatttat ttatttattt attttttgca 9420 gcttaggaat tgtagctcca gtggaatcag tatcttgtta atggctagtg aaagactgag 9480 tctgaagaag gatgcaggac ttttttggca cttggtgcag tatttttccc attatgttac 9540 atgagtggtt cttaaacttc agtgtgttag aacaacctga agggcttatt aagctatgga 9600 ttgcttactc caccctcaga gtttctgatt cagtaggtct ggattgggac ctgagaattt 9660 ttatttctta gaagttttca agtgatgctg atgctggtgc tctggggatc acactttgag 9720 gaccaccaat gaacattatc tcccaccaag caaaccctta acatgttata ctcctttagg 9780 ttattagaat ttatacatgc attatttcat ttgacctgta aactctaagt aactttgcat 9840 ggaaaatgtt atcctgattt tatagacgag atagtgagtt tagaaaggca gtatggtgga 9900 atggagcata gatttggagt tggctagacc taaagtccag attaaatctc tgctcaaggc 9960 tgggcgtggt ggctcatgcc tgtaatccca gtgctttggg aggccagcgt tggcagattg 10020 cttgagtctg gaagttcgag accagtctgg gcaacatagg cagaccctgt ctctacaaaa 10080 aaaaatacaa aaattagtcg ggtgttatag tgcgcattgg tagtcccagc tactgaggag 10140 gctgaggtgg gatcacctga gactgggact ttgaggctgc attgagctgt gattgggaca 10200 ctgtactcct gcctgggtga cagagtgaga ccctctctca aaaataaata aataaataca 10260 2013203064 09 Apr 2013 144 of 771 tccccgctca gccacttatc agttacgtag atacactgcc taaccttagt gaaccctgtt 10320 tcgacaactc caaaatggga gtaaaaatcc taaacttgta cagtggtttt ttagttttgt 10380 taaaagtaca ggtgaggttt ttttcagagt attggttgcc atctgagagt gatccccttt 10440 cacctcctct aggactttta gcattttctg gagacatttt ggtggtcaca gctggggtgg 10500 tagagtgtgc tattggctag gggcttgaag ccagtgatgc tgcttaacat cctatatggc 10560 acaagacccc tccccatcaa caaagaatta tctagcccaa aatgctgtgt aaaatgtctg 10620 gtatataata agtataatat ttgatgaaaa tcagtacctt tgcccccagg tgtgatattt 10680 aagaaggtca acttactaaa tcagtgatgg agttagtcct aacatctggg tgttctgact 10740 gctgctaggc cagtattctt tatatgataa taagaacttt gtccacagaa gatatcccta 10800 ataacaaaaa aggtttattt gaagaggact catgtgttct ttggctgatt gtgaaagtgt 10860 tgctttgaac ttctgttaga aaaggttgaa gatgttttcc gtaagtgttt ttaatactgt 10920 acgtagtatt cagaaggatg tttaattttt tttttaattt tgctagtagt ttttaaagta 10980 atcctttttc ctttaattat gtagttgttg aactgttggg agttactttt ctcttactat 11040 tttgttattt aatgtattct ttgaccttat gcttttttat tctaaagctg cttttattat 11100 agtcagatat gatgaagtta aatgtacaat gtaaaattgc aaatttccaa cgagctatac 11160 aaacttaaat atttctaagt aaagaaaata gggctgactc taaggttctt tgatccatgt 11220 gttgcattct tttctaggcc ctaaatttgc tatgccagcc tgttgaatta aagtgcttta 11280 tttatctaaa ttagaaactt gtattaaagt gaagttttag aaaaaaagaa acaaaatcgg 11340 aatggagttt taggttagcc cagagatggg aagatgccaa gaaggtagct ttagtggatt 11400 ctgaattttt tggttttgtt ttgtttttag ggcaggcaaa tgtaattaca aaagggttct 11460 aggaatagat tgctgtgatt ttttttctgt ttgcatgatt ttacagtttg ctttgcctct 11520 cacttttgaa tgcagaataa aatgtcaagg ccttattttt ttttaaattc ttaagaaatt 11580 taagatttga ctgttaattc cttttgaaat atgggatatt ttgagatacc aattatttaa 11640 gacaaatagg actcattgtt acaattcagt tgaataaggc ttatgatgtt tatttcagta 11700 tatgaatgaa aactatgtgc ttattgtact taagaaaatt tcttttatta aaaacatgac 11760 taaagagaat tttaaaaatc acccactgtc ctacttctct aaaacttaat gttttcatat 11820 tagcttccag ttttgttcat atgcatatac tttaaaacct agttcatggt gaacttaaga 11880 gggtgttctt tttaaaaaac aatttccatt gcactttgtc gttgccttaa ttaaatggtg 11940 aaatcatcag aaatatttat tttcctatac ttatacattt attaagcttg tttccatttt 12000 tttattttgt gattttttaa gtggatttaa gataacctaa acattagaga ggattttcat 12060 2013203064 09 Apr 2013 145 of 771 ggttttgatt catgaaatca taatgttata caaacctaac tgaagtgtta gagccttgaa 12120 gatttttccc ccgaattaca tatagtaact ctacttgtat ttaatactga aagcatattt 12180 tacttattta agtgagacaa agtaaaattt agctgaatac tttagatcta tcatttcctt 12240 ttcctgttgt aagaacatta cattgtgttg aaattaaagt ggatatagaa ggtaattaga 12300 ataaactgcc acatcatttt tatagtaaag tggtaataac actattgctt tctgtttttt 12360 taatcagaag gagtatgggc ttataatgat gttactgttc cctgaagcat attttgaatg 12420 atacggttta tatttgcaca gttgcccagg taatcattgt gatattaatt gatcaatttg 12480 ctatttattt gcgttttaaa tcagtactag tatttgtgct taaaaatttt gcatatgttt 12540 tatcagattt aatttttaag tgtcagatac taaaacaaat aaccttaact ttattaaatt 12600 ataatttttt atcatgaggt ggtattcatt tattcatata gttagaacaa aaaatattta 12660 aaatattgag gtagaaacaa attagtctct ttttaattaa aagccagatt acttgttaga 12720 gtaacatttt cccaaatgag gtaaaattgt tgcgactgtt aaacttaagg aaattttgat 12780 ctaggtgtgg tatatacctt cttgtggggt gctaatgaaa acagggatgg caaaaatatt 12840 ttgtttgtga gtgtatgcat ttatgctttt tgacaaccta agaaacactc ttacatctga 12900 gtatctttca tggactagct gtaggaaatc tatataaaat agcttagtat actgaaagta 12960 tgacatagtt ttacatatct agattgtggt tgtgattata tataatacta taaaatatgc 13020 taacgtgctg cttaataata ctatttggat tttttttaat actgaaaagg tcacacagat 13080 tgtgattatt gtgtagtgtc caagaactaa ggcctaccat ctgttactca aatgtatgaa 13140 aaagttaaga taatttagtg atataagtgg ttttgacacc actgtttttg gaataatcta 13200 attatgattt ttataaagac taatatcaaa ttttaaacgt ttgcaaaaat gaaacctaat 13260 agttatactg ttatttatat ttttctatta caatacagat actggctgag aactaaagat 13320 tgtgtaataa acgcctggcc ttcagtcatt tggttttttt tttccctcga ttgtttggat 13380 agttaactgg acatcatgtt ttaacttgag aaattaagtt atacaagatt ttgatatttt 13440 aaactagttt tcctaactgg ttgagatata taagaattta gtattacagg actcaatcag 13500 ggaactgatt taataagaat ttcttaaaaa tttgtttaaa tatttttcaa gttcttttct 13560 tcatcttcta caacttaatt cttgtctgta tgcaaatgag cttccccatt taaaattttg 13620 ctgttgcatt ttaggccact atagaagttg tttctttaat tttcactcac aagaatttgg 13680 tcttaccaaa ttgtgtaaat ctttaaaatt gtgtatttgg cttaatatta tagaatctga 13740 ttgatttaat ctaccttgtt tcatttagta tgttgacatt ttcttgagaa atttgttatg 13800 ccaaatgatt aacataataa tattttaagt ttagatatga ttttgaattt acattttcaa 13860 2013203064 09 Apr 2013 146 of 771 atgcaacttt gtgtctgtgg cctttttttt tttttttttt ttacgagaaa catcttgcca 13920 attttcagat taatctgtga ggaaagtaga ttggtttact agactcagtt tgtagacttt 13980 ggtgagaact gaattggagg ctatgaaaaa aatacctttt gggcctttct gaatagacat 14040 atatacataa attatatctc ttacattaag tgaggcacat atgtaggtga gatttttacc 14100 tgaatattaa aagtttaaaa gtcgttacct attctgttta cttaatagta tttaaagggt 14160 gtgagaggtg ttatgtgttt ctgtcccttg tttttattcc tatccctccc atctaactgt 14220 tggtactctt atcttcccag gtattaaact tgtatgtttt aaaagcttat ttacttgttg 14280 aaatggttaa cttaattagt tttttctttg aagtttcagc ctaaatattt tctgtttttt 14340 tatatgtcct ttaaatatga aaattctaca gctaatcata attagtaatt gtactttttc 14400 ccctattaca ataactggtt tcataataaa atggtatccc ttcaataaca agcatttata 14460 gtagtttatt aaaactaagg gtgttatcta ttcaaaccaa gcaatgcaga cttactgttg 14520 actctgttaa tatattttaa aattgcatat tactaaaatt taaaatatga ttttgactag 14580 tattttggtg tatgttattt tagatatttt gattatgcac tacttaagaa tgaattgtca 14640 agtatgatta taaagttgat ataatagtta accttcagtg ggaataggaa tcatttaata 14700 ttgttagata tttgtattat tagaacaatc tcctatgatt cttactaata tagtaatgaa 14760 tgacagacaa tatgttggct ttcatattta aaaattcaca tgcatttcta gtttatgttt 14820 ttcttcgact aaaattctgc agcacttagg caaagctatt tttaccagtt ggaaaaaaag 14880 taagtcattt ccaaccaatt ttcctggctt gtagtataga ataaagagac ttgattttat 14940 tacattaaag ccaaatataa aatgatgcaa tctagcacac acttgtttgg aacttttctc 15000 ttttaaatat tcagattaag aggacgttga aaggtaaatt tttttttttt tttgagacgg 15060 agtctagctc tgtcacccag gctggagtgc actggcacga tttcggctta ctgcaagctc 15120 tgcctcccag gttcatgcca ttctcctgcc tcagcctccc gagtagctgg gactacaggc 15180 gcctaccacg gtggcgcccg gctaattttt tgtattttta gtagagacgg ggtttcaccg 15240 tgttagccag gatggtctcg atctcctgac ctcgtgatct gcctgcctcg gcctcccaaa 15300 gtgctgggat tacaggtaaa ttttgattgt tattagcaac tataaaagtt ttgcagttgg 15360 cttattggaa aaagaaaacc tccttgccgg agacggagac gcatttgtat tagaactttg 15420 ttttctgagt accttaccta tagtaggttt caaatattgg tgaattagtt gatggttagg 15480 tctgcataat tactgcgtat ggaaattctg gaaccctatt ttttcaaaat gcagctaatg 15540 ttgagagaat atgcactaaa tattactaga tctttgtttt tcaagatgct gatatccctt 15600 aacatcttct gcactttacc tgtttgaata tcttttttgc tgtaaaaatt agtggcctta 15660 2013203064 09 Apr 2013 147 of 771 tgtctttctg cataattata gagtagccaa aacctgtttt aggttaatca cctctggcaa 15720 aataaatgat aaaagcatag cttttgtaag cagaatgata ttacagaagt taacttataa 15780 atctaagtgt attaaagaca cttaggaaat ttatgataat gctgggtcag cattacagtt 15840 ttaacttttt acagtttttc atatgctttt tttgtgattt tgctgtagaa aattaacagt 15900 tggcatttgg cttagttcaa gtataatgct gttgacaagt atatctgaca cgtcattgaa 15960 ctaataatat ttttgaaagc tgataggtaa gttatatcta ttttgtttca ttcgtcatta 16020 gtgatcggtc ttagatgttt ttagcgagag caaaactgta gaggaatgtg tgtctgtgtg 16080 tgtatatgtg tgtgtgtgtg tgtgtatttt aacagcagga gagttctgaa acaggaaacc 16140 agtcttatca tattcatcca gagacctagg aagaaggtaa ttgtttggta tactcgttaa 16200 aaccagttgg ttgggcaact taaattttta gaggatcaca gatgtaggct tgagcagttg 16260 taatagatga tttctttttt tttctttctt ttttcttttt tttttgagat agagtctctc 16320 tctgtcatcc aggctggagt gcggtggcgc gatcttggct tactgcaacc tctgcctccc 16380 aggttcaggc gtttctcctg tctcagcctc ctgagtagct gggattacag gcgcatgctg 16440 ccatgcccgg ctaatttttt gtattttagt agagacgggg tttcaccgtg ttccccaggc 16500 tggtctcgaa ctcctgagct caggcaatct acccacctcg gcctcccaaa gtgctgggat 16560 tacaggcgtg agccaccgtg tctggcgata gattatttca taattaacac ctgctatgaa 16620 gaaaaattga ttaaaatagt tgagaagtct agtacactct cagctaatat actaaattat 16680 actatggatt ttagagtatt gttaacatta tcagtgactt gatatcttcc tgaggttcta 16740 atttgcttaa ctttaaataa ttggggttca gatcaccttg attgttccct taaagattaa 16800 attttgtaaa actgtgtgta attttcctgt atctggtttg gatagcttta aaaatggttc 16860 ttaagtttaa tgagttcaac tgggaaaaaa gttagttcta ttttagatgt tgtgtcactg 16920 gaaattatgt ttccctgttt gttatatgca cattattaca aagttgtaat caatgttttc 16980 atactgttct ctggtctgtt tttttcacaa atacactttt tatttgtcgc caggtactta 17040 tttttaaagc tatagaggta atatttcatc aggtgagggt aactaccatg gtttgtttgc 17100 tatactgtgt tagggttatt ttcgtttttt ttttctttta taaactatag ttgtgaatat 17160 gtttatatag tttacttttg gtttattaga atatattgct agagtgggat tacaggatta 17220 aagagtgtac agtattttag tttttttttt ttttttacaa gttgcagatt tgttgccaaa 17280 tgaacgagtt tgtagtattg ctaacaagga gaagaattac tagcaagtct tgatgttact 17340 tttgaagagt gtgatgattg catttaggaa gatatctaaa cttctgtttc aaagcaaaaa 17400 gtatgtgcaa atttcttact catgacaaat tcatataata taaaaacatg aaagttgtga 17460 2013203064 09 Apr 2013 148 of 771 ggtcaggttg tttggagaag tagaaaactt cagtagagtt tatagatagg cagtcttcct 17520 ttctggtttg gcactgacag cagattaact agaaagtgtt agaaggaacc taaaatttat 17580 actaaagtca atttaagtta attaatatac cagaattcct tcttttacaa tttatttata 17640 aaaacaccat attgagttgc cttgtaatga gacatttaaa ctaaatttaa ataacagaat 17700 tcatgcacca tctaataaca accccttatt tacaattata gagtcctttg caattttata 17760 gatattttca tgtatcccat ttggtccttg aaacaattaa tgaagaagtt acagcaagtg 17820 gtattatcat tattttacag aagaacaaaa caaaaatata tgtggcccag agattgagtg 17880 atttacctga ggttataggc tttagattgc atagctggaa gtagaacctt gttcttctat 17940 attaaatgac aatattcatt aagtacttag cacaggattt ggtacctagt aaatatttaa 18000 atgttcctgt gttattcctg actattcctt ctttattctt aaaacgccat tttttgagca 18060 ctcttaatat ttatagttca aactttgtac ctatgtacct ttttctcttt agaaaataag 18120 atttcaggct gcattaattt gatctgtaca ggaatgatta tatgttttac atattgggac 18180 aaattgctct ttttttatat accttaagct ctagggtaca tgtgcacaac atacagattt 18240 gttacatatg tatacatgtg ccatgttagt gtgctgcacc cattaactca tcacttacat 18300 taggtatatc tcctaatgct atccctcccc cctccccata ccccatgaca ggccctggtg 18360 tgtgatgttc cccaccctgt gtccaagtgt tctcattgtt cagttcccac ctatgagtga 18420 gaacacgcgg tgtttggttt tctgtccttg cgatagtttg ctcagaatga tggtttctag 18480 cttcatccat gtccctacca aggacatgaa gctcatcctt ttttatggct gcatagtatt 18540 ccatggtgtc tatgtgtcac attttcttaa tccagtctat cattgatgga catttgggtt 18600 ggttccaagt ctttgctatt gtgaatagtg ctgcagtaaa catacatgtg catgtgtctt 18660 tatagcagca tgatttatac tcctttgggt atatacccag taatgggatt gctgggtcaa 18720 atggtatttc tagttctaga tcactgagga attgccacac tgacttgaac tagtttacag 18780 tcccaccaac agtgtaaaag tgttcctgtt tctccacatc ctctccagca cctgttgttt 18840 cctgactttt taatgatcac tattctaact ggtgtgagat ggtatctcat tgtggttttg 18900 atttgcattt ctctgatggc cagtgatgat gagcattttt tcatgtgtct gttcgctgca 18960 taaatgtatt cttttgagta gtgtctgttc atatccttcg cccacttttt gatggggttg 19020 tttgattttt tcttggaagt ttgtttaagt tctttgtaga ttctggatat tagccctttg 19080 tcagatgggt agattgtaaa agttttctcc cattctctag gttgcctgtt cactctcatg 19140 gtagtttctt ttgctgtgca gaagctcttt aggacaaatt gttcttaaat aatgaacagt 19200 tggcactttt tcaactggaa aattcaagga actgctcttt ctgctttctg ctcaatatga 19260 2013203064 09 Apr 2013 149 of 771 atcttcaatt tagaaatgag agtccatcat taacaattca acatagctta ttaataggaa 19320 aaaaaaacct agtaacaaat gtaaaatctt tgattaaatg agaaagtcat agaagttcat 19380 cagatttgta tttaaagcat gatttcatta gaaaagttga taataaggat ttaactgtga 19440 cataattgga aaatacttgt ttaaacttaa aattttgaaa agaaatgtaa atgtgatgta 19500 acttatgaat cagtggttga gtttcttttt tgctcacaag aaccctaact gtgtgttact 19560 tgaaagcact gatggaaatc agggaaaaag ctccagaagt tcctacgaaa taaaattaaa 19620 tgataaagtc ctggtatctg ctaacttgcc ttccattcct gttatctttt cttcttagtc 19680 tgacttcatt aattctttca ccctggctac tggtttagct cagtgtttta tgagccaggc 19740 agcttcagac tttgcttttg atgctctttg ttcattacct ctaaagctgt attatcactt 19800 tcattttatc attaatgttt catgtatatg ttatagtttc atattgttac tgcaactttt 19860 acttagctat aatttaaaaa atatctgtga tctgtggaaa taattattct atggcagaaa 19920 agtagttatt gcattttact ttataagttg tttaaggata agcataccta tatattaagc 19980 actacaaaga aacttttaca atggctttat ttttagcaaa ccatcatagt taaaataaga 20040 tttagtgtac atgtcaggaa cacagtctta tgaaataagg tttagggagc tatttttagt 20100 tactatatcc tacttgaaaa ttgtagttaa atttctagca tataccctat taatttagat 20160 gcaagtacag atttgagata aggtagatac attatttgga tgtcaactcg gaagttgttc 20220 aagaaaagat attttgttat ttagatgtaa cttggaacat atttctagtg tttcaagtca 20280 tgattgtatg cctagaacag gcaataaaaa tttacttagc tggtaaaaca gccacattat 20340 ttcaaatata gtttagttat attatggatt aaattgattt ttgtggacag actttagaac 20400 ttaattgcta ttaattacat tttttctttg ggacggtatt tgttctttgg tgagaaagga 20460 ttcttgtaac acctaaatca agactgtcca aacatggcat atgcagttta ccagtcaaaa 20520 caaactaatc acttaagatc tgtgtatttt gttttatttg aattatacct caattaaaac 20580 aaatttagca tgtttacaca aaggtggggg gaaactgtct aatatatctg agatctgttg 20640 gagctggggt gaccatccaa cttaggcaag atagctagta ccatgtatgc atttctttta 20700 cctttcttat tgtatataca gtaatcactg atattatgag aaaaagaact ttttaataat 20760 tcaggagata ttttatcgct agtatatatt gagtgcttat tatgtgcctt atatactttg 20820 gactcattta atcctcaaca caacaaccct atgtagttca tactagaatt attcccattt 20880 aaagatgggg aaagtgatgt ttagagaggc taagtgactt gcccatggcc aaagtattag 20940 aactgggatt tgaacacagg tagcctgatt cctaaataaa tgaccactaa cattaaaaag 21000 acataaacat agaggtgttt gttgcaatgt tagtcataat acctaaaaat tgtgaactag 21060 2013203064 09 Apr 2013 150 of 771 ttaaatgtcc aatagtagta aaatggttca ttaaccatgg tacacccatc aatataatgt 21120 tatattgtca tttaaaattg tattcccaag tttcgtatca ggaaaatata ataaattttt 21180 gaaaaatgta atgggatata ttgtatttat aatacagtaa tcactatgta accaacattt 21240 ttatttccat caaaaattag ttataaagaa atagaaatct aagaagttta atagatatta 21300 ccattgaaca ctagatttgt attagtatct tttatattta tctctctcat ttcctatatt 21360 ggccatgttt acttttaaaa tagtaaaagt cataagctct attttaaaaa taaatgttag 21420 tttattaacc caagaataat agctaactat aaattcatat ttgataaaat aaaaagatga 21480 cattcatcat aagggataca tacctgtgct agcatatggc atttttaaaa tcacatgagt 21540 aatttgtaat catcatagaa atattagaaa atacaaataa gcaaacacat actgaaaatt 21600 tagtgttccc aaatctaaaa cagagacact gtttttttct tttgggattg tattttagat 21660 atgttcttaa gttataataa agtaaatact taaaaggcaa attgatacat taaggatttc 21720 aaagagtaaa actttttgtt aagctttgat gttctttaga aagtttagat tattccacaa 21780 gtcactgtcg ttgaaagaaa agtagttaca gtggggtctt atgggataag gcattaccat 21840 ttgttcagtt gagagacagc tatcactatg ttttaagcat tgttcatata ttagctcatt 21900 taatcctcat agcaacctta tatgataggt acctttatta gccccattct gcttaggaag 21960 caacagaaag agtatgtatt ttgcctaagg ttgcacaata agttaagctg gggttccaat 22020 tctagcaagt tggttctaga gtgtatgtta ttaaccatta tgccgtagtg cctgcaagta 22080 gatctctaga tgtcagaaat actcatcttc ctctggttac ctggttgtta taaatcttta 22140 tgcttaatac ttatgtcatt atatgtaaat ttcgtattaa acactcaact tattcagaag 22200 aatatcaggt aagtgtaggt taaggctgtt ttctatcaga aatcattata tgtatatata 22260 ttcctcagtt cttatgttgt ttagtttttc taaaatgtca aattttataa tatatggaga 22320 agtataaatg tatattagaa agattttgtt tatttgtgta atttgtggca taagaaatat 22380 ttgcctcaag atttggtgct tgtttaggta gttgctggca ttacttttgg aaatgtcagt 22440 aaattttcat actgtcttgg aattttttca atttttacat tttattagta aatgtaatta 22500 caggttagta aatcacttat ttgaacctgt ttcctttgaa agttttatat ttttatttgg 22560 aaatagaaaa accttaattt cctctcgttg ggcagtatgg tgtcaaaagc ttgggctttg 22620 gagcttcgta tataatctgg gttcaaatta taacttacta gttactaact tgggcaaatt 22680 acccagtctt tttgactctc aatttctttg tctatgaaat gtaatactat ttaggattgt 22740 taggattaaa tgagaatata tttggcatac tgtctggtac atgatactta acaggtacta 22800 gttgtctaca tctttctaac ttaggatgga tgccgatgtc ttgggtaaca tctcaaactt 22860 2013203064 09 Apr 2013 151 of 771 tatcagtaag gaaggtgaga atctgaagaa aatgaaacct taaaaagatt gaattcctgg 22920 actccattta aaggagtaaa tagctcacga acaagacttg ctgctctgca aagtcttcca 22980 tgttgatcct ggtctttgac tccttatctg tctgattaaa ttgaattcgc tgccgtggca 23040 tccttaaagc tggaccttac tttgtcagtc ctgccttctc catgttgctt tgtgtgtaag 23100 cttcactgga ctgtttgctt tttgctgatt attttatgta tttccatatg tctactttag 23160 cctttgcttg gaatgttcta actgctcttg tttcttcctc tgtttactgg tttctgactt 23220 aactcttaag gattatctaa tatattacct acttggtgaa ggtttatctg tgtccccaca 23280 gaattaatcc ttccctcttt aactcttaag ctatcttatt ttttatctaa tcgggtcttt 23340 ggcacaatta taggtctgtg tgtctgtctt ccctaataga ataggaaagc cttgaggaca 23400 gtagtctttg cttacttagc cttatattct cagtgcccct tgtgcaaaac gttcaatata 23460 tgtttgaatg attatgtgaa tgaaggaggg ggccagctga atttacttta atgattatgt 23520 aacacccatt tatgtatagt tatagacttg tctgaaatga gttaaatcct ttgcaacgtt 23580 tgctgctatg ctttgaatgt ctcttacaaa actcatgttg aaatttaatt gccattgtaa 23640 tggtattaag agatggaacc tttaagaggt gattagataa tggtatctct atccttatga 23700 atggattaat gctgtttgaa tggtagtgga tgagttatct tgggagtttg gcctcctccg 23760 tctcacatgc ttccttacct tctgccatgt ggtaactcaa cacaaagatc cttgccagat 23820 gctgatgcca tgctcttgga cttcccagtc tccagaaccg tgagccaaat acatttctgt 23880 tcattctaaa ctacctgttt tgtggtattc tagtaaagca acataaaatt tactaagaaa 23940 actggtacca agagtgtgat tgttgccata acaaatacct gaaaatgttc aaatggcttg 24000 ggttctggct agagaaggat ggaagagttt ggatgaacag gctagaaaaa gcctgtattg 24060 ctgagaatag agcattaagg acaattctga tgaggattca gaagaagaga gctgtaggga 24120 aaatctggaa cttcttagag agttgtcatc agttggtaga actataagtg gtaaaggtct 24180 ttctgatgat atctcagaaa tgaagaacaa gatactggac actggagtaa aggccatcct 24240 tgttaaatag ttgcaaagaa cttggcgaaa ttatgttcat atcctaagac tttatggaat 24300 gcagaattta agagtgatga actaggatat gctgcagaag aaataactca gcagcagagc 24360 atttaggtta ctggatggct acttttaacc acttaaacta agctggggga agggaatgac 24420 ttgaagacag aatttataat taaaagagag gcagaatgga aatacttgga aaatttgcag 24480 cctggccata gtaaagaatg caaaaggtat gtttaggaga gcaaaccaag ggtgtggtcc 24540 aggaaccatt tgctgaagag attaatattc ctagaggaga cccaagggct atttatcaag 24600 acagtggaaa aagaccccag aggcattttg gagatctttg aggctgcctg ccccatcaca 24660 2013203064 09 Apr 2013 152 of 771 ggcccagagc tctaggaggg cagaatggtt tgtggctcag gtggtccttc acaagcttgc 24720 tgcccagggc tacctcagct ccccatattt caacccagtg ggccttggct gtcctaggtc 24780 tggttcagag gggcccaggt gtggcttagg ctactgctga gtactcaaat ggtaaacctt 24840 ggcagcgtct atatggtgct aattctgcag gctcacagga tgaaagagct gtgggagaca 24900 tggctaccac caccaggatt tcaaaggatg atggggatag tctgggagag acttgccaca 24960 ggcttggagc ctctgaaggg tggaaatgtg ggttggagtc actacagaga gtccctacta 25020 gggcattgca taatggagcc atggcagcag gcccaccacc aaagcttcag aactgtagag 25080 ctacaagtat acagtgccag cctgggagaa cttcaggctt gagaccctaa cctgtgaaag 25140 ctgcatgggc taagtacagc aaagccatgg aggtggggct tcccagggtc tattgggatg 25200 aaacgaatgt attttgtagg tgagaaggac atgagttttg aggcccaggg gcagaatgct 25260 atggtttggt tgtttccttc aaaactcatg ttgaaacttc attgccatgt ggcattatta 25320 tgaggtggaa cctttcagaa gtggttacat tataagggct ttgccttcat taatggatta 25380 atgccattat tgcaggtgtg ggttagttat ctctggagtt tggccccctt tttctctatc 25440 atgtgctcat gccctctttt gccatgtgat gccttctacc atgttatgat gcatccagaa 25500 gactctcacc acatgcagcc ccttgatctt agacttctca gcttctagaa ctgtgagtga 25560 aataaacttc ttttctttat aaattacccc gtctgtggta ttgtatagca gcagaaaata 25620 gacatcagcc tgaagttccc ccaggctggc attaaatact aattattaat tagtatttat 25680 agtgcaagga taaattcaag tttagccctg gttagaatga ccacatttca agggaggggc 25740 tttgtacttc tgtgcatatc tgtaaggata aaaatcttaa tactattctc actgaaatta 25800 atggtttagg ttaggtaagg ttgttagtgc taataattat ttcttttaat aaaatattct 25860 tagttgcgtt gttcaaaaaa catagatgat ttgaatttat attttttggc caaaatatat 25920 ttataatttt gagtaggaat tccagagtat tggtagctat aaccactttg ggttccctgc 25980 cattgcttct ggtgcctcat tttttctgac gtcttccatt ttcttacatt tgtcttctaa 26040 ggtggagtta agattactca gttaagatta tttcacttta ggcctctgct gtcttctgct 26100 ttttttttta aaatgaatgg atataatatc ccaatacatt ttgataattg aacaacagct 26160 acatttttaa gtgaggctac tttcttctaa ttttttaaat ttatttttct cagtttttaa 26220 aaaaaatgtc agattggcta agagttgggg cagctttctt atgtgagagt agtagatgac 26280 agcaaatatt tgtgatgtta aaatgataat cctaatagtt ttcttttaga atctttataa 26340 taaaaaccct ttgaggctga gggtgaattt gtatgttcct aaagtgacaa aaaatgttct 26400 tggggcatag taatttaaat cttagatgct tttattagta taattttttg gtagaaattt 26460 2013203064 09 Apr 2013 153 of 771 ggcattaaaa aatgcataca gagctttttc tacatacagg gcaagacagc attttgtcat 26520 ggcaattagt aaatagataa ttataaaaca tctaatttta agcaatttgt tacagaaacg 26580 atacaggtac attgtggcaa aaatagaaga tacaaaacaa gcaaatatga gaaaaaatat 26640 acatgccacc acctatatat gacttttagt actttataat cttttgtcta tatatgtcta 26700 tatggatata tacgtattct ttttatccaa atggtattac attgtacatt ctgttttgaa 26760 acctgccttt tttagtcatt tacatctact tttccatctc agtaactttt catcttgtgt 26820 aatgcccgga tcacattaaa atgtttccaa ttagctcaaa aatgtccttt atggctggtt 26880 tggctaaaac agtatccagg ccagcattgc acctatgaaa ttggctgtta ggaatcttgt 26940 atctttaaaa atcaagggca gcaacccatc ctcccgcttc ccccacctcc caccaccccc 27000 ccaccttttt tttttcttaa agatactggc ttgttgaaga gagaatgggt catgtcctac 27060 aaactgtctg aatttgtcca gtttgctgtc tcatagtgtc atttagcttg ttttatccta 27120 tgtatttcct gcaaattaaa atttgtatct gaatccttgg tggatttgag ttgaagatcc 27180 ttaaccatca tagatgatgc tgtgtccttt atattgcatg tcagaagtta catgatcttt 27240 acttgattca tgatgaggag atggccactg aaattggaca gtgacagtct tttctgccca 27300 ttgttcaatt atattcgtct ctttacatta gaaagtattt tgggtagtag tattttggtg 27360 ctgtaagaaa gttcattttc tcatcaacca ctcacctatt ggtttaacac catttgttga 27420 tctttgagta tatcagtaat ttcatcaggg tttgcaaaat aagactttaa attctattgt 27480 tttacattat taattgatgt tttttgataa ggtagaactt gtgaaatggg actatttgtt 27540 tgtctttaaa tacagtctct ataggaaaga caaaataaat acttaaatct cactctttac 27600 catttttcaa agtgaagaac tattccgtta accacctcaa aagatgataa ataaaaaggg 27660 tatttttagt tgtttcaact tttttttttt ttttgagatg gggtcttact ctgttgccca 27720 ggctggtgtg ctgtggtgca atcatggtac accgaagcct cagtctccct gggctcagat 27780 gattctccca cctcagcctg ggactaaagg tgtacaccac catggccagc caattttttt 27840 gtattttttg tagagatggg gttttgccat attgcccagc ctagcctcaa actcctgggc 27900 tgaaggaatc cacccatctc agcctcccaa agtgctagga ttacagacgt gaccaacaat 27960 atccggcctt aacttttttc ttttgagtgt ctttatagac tcaaggactt ttatttaatt 28020 cagggtgtta gtaccattta aatgttttct ttgatgctca gattatcaca gctagtcatt 28080 tggaccttta taccacctcc tatgtccatt tgatataggc cattaatctc tataagcctt 28140 cctccttctc ttggaatgaa aaggtatcct aggctcacct gtaccttccc tactccagac 28200 ctggcattaa gtctttttcc aaggagtttg gtacctttta gtttattatg atattagaga 28260 2013203064 09 Apr 2013 154 of 771 tgaaaatctg tgttctagga atgtttatta ctgctagagt gatgttgctt ttaggccatt 28320 tcagagaaaa gacctagaaa acagattttt acaaacatga attcatactg atatttttag 28380 ttttttacat gatttcttga ttttacaata ttatctgctt tcttaactta aaattatgaa 28440 ccttaaagtc attagcataa cttctttgct tatttctaca acataaagaa aatagtcctg 28500 gtgcggtggc tcacactgta atcccagcac tttgggagat tgaggcaggt ggattgcttg 28560 agctcaggag ttcaagacca acctgggcaa catgatgaaa ccttgtcttt acaaaaaatt 28620 agctgggcat ggtggcatgt gcttgtattc ccagctactc aggaggctga ggtgggagga 28680 tcacctgagc ccaggaggtc aaggctctag tgagccatga tcatgccacc acactccagc 28740 ctgggtgaca aagtgagacc ctgtttcagg gggaaaaaaa agataaaata gtttgaggag 28800 gctggatgta gtggctcatg catgtcatcc tggcactttg ggaggtcaag gtgggaggat 28860 ggcttgagcc caggagtttg agaccagcct gtgccacatc atgagacctg gtctctattt 28920 aaaaaaaaaa aaaaaagaaa atagtttgag gatatcaata atgatattac tagaatcagt 28980 aaaactacca aaagaagttt aaagtttctt cctagtgttt ttttgttctt agaatacttc 29040 ctaccaagaa gtgcagtaaa agtgcagtgt ccaaatagcc cttgtaacaa aacctttctc 29100 tttctcctgg gtgccaattt gacatttaat cagttttgtt tctagcagtg ttcaatttat 29160 tagattataa gtcttttttt tctttatatt attctaagat caaaaatata taaagatata 29220 cacaggagtc ctgctgctac ctgttcttgc tatgcttttc cccttttctt ccctttctct 29280 gtgaagcagc catttttatt agtttcttgt ttatcactca tgcatgcata tgtttattga 29340 ggatgttgac attcaagcaa atatatgggt taacattctt tttgtcatcc ctatacgaaa 29400 gatataccca gtatactcta ttgggtgggt ttttttcctt aaaatattca gtagatctct 29460 ccagttagca catagttatc ttatagatag aacatataca tataaccttt tcttaaacta 29520 tgctattaaa ataatagctt tcagtaactt gataattatt tttggattga aaatactact 29580 gaaatcaact caatcatgtg aaagctgcag aaagaaaaag acctagaaaa agggcattgg 29640 attaggtcaa ctttgaattt tatttggaag ataaatgagt ccagaagtga gtgggcagag 29700 attattggag ttggtcttga aatgaggcgt taggcagatt gactgggctg gtgtgaaagg 29760 tctgtcagaa aatcatgaga ttagattgag gtacctcaaa aaatgagagc tggtatgatg 29820 agtgggtaag aatcataaaa gcgtagagtg ttgatgattt ttatagttta taaatggttc 29880 ttgtgtgtag agttttgttt ttatgctagc tatagtctgt aacataattc actataatgg 29940 gcatgctaaa tatccatgac agttgaccct tgaacaacac agagggtagg ggcgcctacc 30000 cctgtgcagt tgaaaattca catgtaactt ttgactcccc aaaacttaat atttagccta 30060 2013203064 09 Apr 2013 155 of 771 tacttgacta gaagtcttac tgatgacata atgttcgtta atacatattt tatatatgtg 30120 tcagatagca tatttgtata ataaagtaag ctgcaggaaa aatattaaaa tcataaagaa 30180 gagaaaatat acttactatt cattaagtgg aagtggatcc tcataaaggt cttcatcctc 30240 actgccttca ctttgagtag gccgaggagt aggagagaga ggaaaggtca gacttgctgt 30300 ctcatgggtg gcagaggtag aagaaggtcc acatacaagt ggtccgacac agctcaaacc 30360 ggttttgttc attggccaac tgtagtttga ttgaaagtaa taataaatga agtttctgcc 30420 tcagttcagt attatcaagt catagatagc aagggctgga agaaacctta gtagtaatct 30480 ctttgagtct aattatcatg tagaatagga aattgcggtc tagaaaggtt aagtgacttg 30540 tccaaattac acaactagtt agagacatag ccagctctta aatctgactt ccagattttc 30600 actgtgtctt cttttttctg taacgtgttg ccttttttag ccatgaaaaa ttagaagttg 30660 aactcttgtc ttttcaggca ggtgtcaatt ttggggtttt gttttgattt ttggtttttg 30720 acataaagta ctttagttct gtgatgtata aaccgtgagt ttctgttttt ctcatatacc 30780 tgaatactgt ccatgtggaa gttacctttt atctttacca gtattaacac ataaatggtt 30840 atacataaat acattgacca ccttttatta ctccagctat agtggggaaa actttctttt 30900 cataactagc taatgtttta aaaagtattc ttttagtttg attgctgcat atttcagata 30960 tttctttcct taactaaagt actcagatat ttatccaaac attattgcta tgggatttcc 31020 tgcagaaaga cttgaaggcg tatacaggaa caatattgat gatgtagtaa ggtaagaatg 31080 ctttgatttt ctatttcaaa tattgatgtt tatattcatg ttgtgttttc atttagaaaa 31140 gatttctaag ccacagaaaa agatactttg tgatgtaaac tattattgta gtgctctata 31200 atcatttttt ggcttaccgt acctaatgga cttcaggggg atacagttca tttgataaga 31260 actgacctta tacattacat aatcaggtac ttatgtgata tcatttcctg gactccataa 31320 aatgctggtc accaggttta atacctggat tccattacag tgtgattttt gtcttatttc 31380 atagttgggg attaggctta aaatcctaga gtggatttat tcagttaaat ttattcacac 31440 taagatgtag atgactaata ctgtatattt ttatgtagac caaattttaa ggtaccactg 31500 tgcatatgta taccaactac ctgaagaagt atttggttgg tacaagagat atagaaagga 31560 atcgctgggt gtaccaaggc taatcagttt tataattttg cataattttc taactgcgat 31620 tatcatttag tttagaacaa tttatttctc aaggcccatg taaatattat ttttaaaata 31680 tacagtctta agaattcatg gcatatttta tgaaaggagg aattcatgtc tgatgtgcaa 31740 atagtcttaa gatattttct aatttcagag caaaaatata tatgtatgaa taaattaact 31800 gtaaattgtc agtaggaacc ttaagaattc gtggcgtatt ttatgaaagg aattcatgtc 31860 2013203064 09 Apr 2013 156 of 771 tgatgtgcaa atagtcttaa catatttgct aatttcagag caaaaatata tgtgtattaa 31920 taaatcaact gtaaattgtc agtaagaacc ttaatggctt taaaagttaa aatttcaggt 31980 caagcattgt ggtgtgctcc tgtagtccca gctacttggg aggctgaggt gggaggatca 32040 cttggcttga acccccaggt agagggtaga ggccagtctg ggtaacacag cgagaaccca 32100 tctcttaaaa aaaaagttta agttgtggat tatttccttt acactctttc attagtatct 32160 ttcctggaga ctttcaattt aaatacttgg tgcttatgac aattagatgt taaaatggat 32220 gggaaagtac tttgtaactt ataaagcatt atgcagatgt agactccttt tataatagtt 32280 gtgtaagtat ataagacaac ctacattctt catgagctag ccataagttt tagcaacttg 32340 ctttgaacca cggtagattt acaattttct gtagtattga gttgtgttca tttagaattt 32400 tgtaatattt atattgaaaa tcaaattttt gtacctacaa aaactacaaa aaaatccccc 32460 tagtttttat agtttctatt aaaattatag ctggtacata gggatgccag aaggactgtt 32520 taagaagctg aaaatagaga aatgaattta tcttctcata gttaggcagg gcacagtaga 32580 aggatgctta acattgcaag ctgatgggaa cagcaggttg atatagcttg tgataacact 32640 tctaaagaaa aagcaatgag ccatagaaaa aagaaaaaga tacattttga attaaggaag 32700 atggtgaatc tgggaagtga gcagtacagt caccagacgt gtatcctctc ctatggtaca 32760 gaagtgttta ttgggtctct ttatggcctg catgatatat cccacaagat gacctacttc 32820 acattatttt aattctgtat tcaactaagc actaattcaa cccagccaga ttagtactca 32880 taccaaaaaa gagtgaatac tctgaataga gggcaggttt tctgattatg gtgagaatat 32940 ctttgtggta aattaatctg gtgtgctagt ttttacgttg gtctcttctc agtgtcgtta 33000 gtcactgagg ctgattgatc atcttttagg ttactgataa agttcctgta cagctgattt 33060 tcagacctta gattgcaata acttcaccaa gaaaatactt cattgggaag cattttggtc 33120 cttccatttg attcataact cttaccttta tgcctctgaa ggaaaagatt tatacattca 33180 gcttgtaatt agtaatcaag actgaggttt agtctatcta gcttcacaat ctatctagtt 33240 tgttttgtct agccatatga tttcttcaaa tatgccattt cttaaaaaaa aatgttttat 33300 gtatcccgat taatatttag ccagtggttc ttttagccga tggatcttgt cacctcttat 33360 gatactatta atagcatgtc aacatgaaga attatctgct gaatataata gctatgctgt 33420 ccttgtttcc ttttgtctca ttcttttttg attgggggat aattggccaa taaagctttg 33480 atagcctcta ttgcccaggc ccctcctctt cttttatgag agaaaggatg aacagtgacc 33540 agaaataaag gtattgtttt tttctatcaa ctaaaatgga aataaataat tcctaagtaa 33600 tttgcctgtt aggattaaag tctccaagag aatggctgtg cctagtacct aagtgattaa 33660 2013203064 09 Apr 2013 157 of 771 tttccttgat tggttcacat tatattgagg atattagtaa tcagtagtga ttcctttttt 33720 ggttcaaaga tgatagtgtc acagtgaaaa atgtttttaa aatttttgta tacttaattt 33780 ttctgttaac gaaagtattt tcagttggat ttttgtttgc cctctctatt agaatgccca 33840 aagaatattt aaaattttcc ttttctctta tactgcatat ttttcctgtg atttttcccc 33900 aaacggaaaa tactctgcag agattagact ttgttattgt tgtactacat cattgctttg 33960 actaaaataa actcagattg caaatacctt caagcttaca ttgctcagta tttttttttt 34020 tttttttttt tgagacggag tctcactctt gtcgcccagg ctggagtgca gtggtgccat 34080 ctcagctcac tgcaacctct gcctcctggg ttcaagcgat tctcctgcct cagcctgcgg 34140 agcagctggg attatagatg cccgccccca cgcccagctg atttttgtat ttgtagtaga 34200 gatggggttt taccttgttg gccagtctgg tctcaaactc ctgacctcgg gtgatccatc 34260 tgtctcggcc tctggaatta caggtgtgag ccgccacgcc tggctaaatt gatcagtatt 34320 atttaacttt gagggatatg atttgttatg gaatgcgaag ttttatactt gaggtactca 34380 gagtcctttt gagacaaata tttaacttct ccttttgagg ttaccgccta cgattgggaa 34440 ttaatgtaaa aaataagcca aaagaaagtg agggaaaagt gaaccaagct gtaatttttt 34500 tactcttttt tattgttgtt gttattgttg ctgtttttta ctatcttgat tgcaacagtt 34560 tggcttatat atatagcatt tggaattgac agtaagaaag ccacatctca tagaagctaa 34620 ctattcccaa attgtttttt tcttcttttc ctcttactac tgctgttttc ctcctttctt 34680 gctgctaagc tcttgtcctg acatgctggt aatatgaaac agtgttttat tcagataatt 34740 gattattctg taatatgtat gttaatcttt tttattacac tttaagtaat agggtacata 34800 tgcacaactt acagattcgt tacatatgta tacatgtgcc gtgttggttt gctgcaccca 34860 ttaactcgtc atttacatta ggtatttctc ctaatgttat ccctctccca accccccacc 34920 ccaggacagg ccccggtgtg tgatgttccc cgccctgtgt ccaagtgttc tcgttgttca 34980 gttgccacct gtgagtgaga acatgcggtg tttggttttc tgtccttgcg atagtttgct 35040 cagaatgatg gtttccagct tcatctatgt ccctacaaag gacgtgaagc tcatcctttt 35100 ttatggctgc atactactcc gtggtgtata tgtgccacat tttcttaatc cagtcagtca 35160 ttgatggaca tttgggttgg ttctaattct ttgctattgt gaatagtgct gcagtaaaca 35220 tacgtatgca tgtgtcttta tagtagcatg atttataatc ctttggatat atacccagta 35280 atggaattgc tgggtcaaat ggtatttcta gttctagatc cctgaggaat tgccacactg 35340 tcttccacaa tggttgaact agtttacagt cccaccaaca gtgtaaaaat gttcctgttc 35400 ctccacatcc tctccagcac ctgttgtttc ctgacttttt aatgatcgcc attctaactg 35460 2013203064 09 Apr 2013 158 of 771 gtgtgagatg gtatctcatt gtggttttga tttgcatttc tctgatggcc agtgatgatg 35520 agcatttttt catgtgtctg ttggctgcat aaatgtctat aaatgtcttc ttttggaaag 35580 tgtctgttca tatcctttgc ccactttttg atggggttgt ttgatttttt tcctgtaaat 35640 ttgtttaagt tctttgtaga ttctggatat tagccatttg tcagatgggt agattgcaga 35700 aattttcttc cattctatag gttgcctgtc cactctgatg gtagtttctt ttgctgtgca 35760 gaagctcttt agtttaatta gatcccattt gactattttg gcttttgttg ccattgcttt 35820 tggtgtttta gtcatgaagt ccttgcccat gcctatgtcc tgaatggtat tgcctaggtt 35880 tgcttctagg gtttttatgg ttttaggtct acatttaagt ctttaacatt taagtcttta 35940 atccatcttg aattaatttt tgtataaggt gtaaggaaat gatccaattt cagctttcta 36000 catatgacta gccagttttc ccagcaccat ttattaacta gggaaccctt tccccatttc 36060 ctgtttttgt caggtttgtc aaagatcaga tggttgtaga tgtgtcatgt tatttctgag 36120 ggctctgttc tgttccattg gtctatatct ctgttttggt accagtacca tgctgttttg 36180 gttactgtag ccttgtagta tagtttgaag tcaggtagtg tgatgcctcc agcttttttc 36240 tttctgctta ggattgtctt ggcagtgcgg gctctttttt ggctccatat gaactttaaa 36300 gtagtttttt ccaattctgt gaagaaattt attggtagct tgatggggat ggcattgttt 36360 ctataaatta ccttgggcag tgtggccatt ttcacgatat tgattcttcc tacccatgag 36420 catggaatgt tcttccattt gtttgtgtca tcttttattt cgttgagcag tggtttgtag 36480 ttcttgaaca ggtccttcac atcccttgta agttggattc ctaggtattt tattctcttt 36540 gtagcagttg tgagtgggag ttcactcatg atttggctct ctgtctgtct gttattggtg 36600 tataagaatg cttgtgattt ttgcacattg attttgtatc ctgagacttt gctgaagttg 36660 cttatcagct gaaggagatt ttgggctgag acagtggggc tttctaaata tacaatcatg 36720 tcatctgcaa acagggacaa tttgacttcc tcttttccta attgaatacc ctttatttct 36780 ttctcttgcc tgattgccct ggccagaact tccaacactg tgttgaatag gagtggtgag 36840 agagggcgtc cctgtcttgt gccagttttc aaagggaatg cttccagttt ttgcccattc 36900 agtatgatac tggctgtggg tttgtcataa atagctctta ttattttgag atacgttcca 36960 tcaataccta atttattgag agtttttagc atgaagggct gttgaatttt gtcaaaggcc 37020 ttttctgcat ctattgagat aatcatgtgg ttttttgtct ttggttctct ttatgtgatg 37080 gattatgttt attgatttgc gtatgttgaa ccagccttgc atcacaggga tgaagccaac 37140 ttgatcttgg tggataagct ttttgatgtg ctgctggatt cggtttgcca atattttatt 37200 gaggattttt gcattgatgt tcatcagggg tgttggtcta aaattctctt tttttgttgt 37260 2013203064 09 Apr 2013 159 of 771 gtctctgcca ggctttggta tcgggatggt gctggcctcc taaaatgagt tagggaggat 37320 tccctctttt tctatgaatt ggaatagttt cagaaggaat ggtaccagct cgtcttttta 37380 cctctggtag aattcggctg tgaatctgtc tggtcctgga cttttttcgg ttggtaggct 37440 attaattatt gcctcaattt cagagcctgt tactggtcta ttcagggatt caacttcttc 37500 ctggtttagt cttgggaggg tgtatatgtc caggaattta tccatttctt ctagattttc 37560 tagtttattt gcatagaggt gtttatagta ttctctgatg gtagtttgta tttctgtggg 37620 atcagtggtg atatcccctt tatcattttt tattgcatct atttgattct tctctctttt 37680 cttccttatt agtcttgcta gcagtctatc aattttgttt tttaaaaaaa ccagctcctg 37740 gattcattga tttttttttt gaagggtttt ttgtgtccta tctccttcaa ttctgctctg 37800 atcttagtta tttcttgcct tctgctagct tttgaatttg tttgctcttg catctctagt 37860 tgttttaatt gtgatattag ggtgttgatt ttagatcttt cctgctttct cttgtgggca 37920 tttagtgcta taaatttccc tgtatacact gctttaaatg tgtcccagag attctggtac 37980 gttgtgtctt tgttctcatt ggtttcaaag aacatcttta tttctgcctt cattttgtta 38040 tttacccagt agtcattcag gagcaggttg atcagtttcc atgtagttgt gcagttttga 38100 gtgagtttct taatcctgag ttctaatttg attttactgt ggtctgagag acagtttgtt 38160 gtgattttta ttcttttaca tttgctgagg agtgagtgct ttacttccaa ctatgtggtc 38220 aattttggaa taagtgtgat gtggtgctga taagaatgta tattctgttg atttgggatg 38280 gagagttctg tagatgtcta ttaggtctgc ttggtgcaga gctgagttca aatcctggat 38340 atccttgtta accttctgtc tcgttgatct gtctcatatt gacagtgggg tgttaaaatc 38400 tcccgatatt aactgtgtgg gagtctaagt ctctttgtag gtcactcagg acttgcttta 38460 tgaatctagg tgctcctgta ttgggtgtat atatatttag gatagttagc tcttcttgtt 38520 gaattgatcc ctttaccatt atgtaatgcc cttctttgtc tcttttgatc tttgttggtt 38580 tacagtttgt tttattagag actaggattg caacccctgc tttttcttgc tttccatttg 38640 cttggtagat cttcctccat ccctttattt tgagcctgtg tgtgtgtctg catgtgagat 38700 acatctcctg aatacagcac actgatgggt cttgactctt tatccaattt gccagtcttt 38760 gtcttttaat tggggcattt accccattta catttaaggt taatattgtt atgtgtgaat 38820 ttgatcctgt cattgtgatg ttagctggtt attttgccca ttagttgatg tagtttcttc 38880 ctagcatcaa tggtctttac aatttggcat gtttttgcag tggctgatac cagttgttcc 38940 tttccatgtt tagtgcttcc ttcaggagct cttgtaaggc aggcctggta gtgacaaaat 39000 ctctcagcat ttgcttgtct gtaaaggttt ttatttctcc ttcccttatg aagcttagtt 39060 2013203064 09 Apr 2013 160 of 771 tggctggata tgaaattctg ggttgaaaat tcttttcttt aagaatgtag actattggcc 39120 cccactctct tctggcttgt agagtttcag cggagagatc tgctgttagt ctgatgggct 39180 tccctttgtg ggtaacccga cctttctctc tggctgccct ttacattttt tcctgcattt 39240 ccaccttggt gaatctaaca attatgtgtc ttggggttgc tcttctctag gagtatcttt 39300 gtggtggtct ctgtattccc tgaatttgaa tgttggcgtg ccttgctatg ttggggaagt 39360 tctcctggat aatatcctga agagtgtttt ccagcttggt tccattctcc ccgtcactgt 39420 caagtacacc aatcaaacgt agatttggtc ttttcacata gtcccatatt tcttggaggc 39480 tttgttcatt tctttttact gttttttctc taaacttctc ttcttgcttc atttcattca 39540 tttgatctgc aattactgat accctttctt ccacttgatc gaatcggctg ctgaagcttg 39600 tgcatgcgtc atgtagttct cgagccatga ttttcagctc catcaggtca tttatggtct 39660 tctgtacact gtttattcta gttagccatt tgtctaatct tttttcaagg tttttagctt 39720 ccttgcgatg ggtttgaaca tcctccttta gctcggagaa gtttgttact actgaccttc 39780 tgaagcctac ttctgtcaac tcgtcaaagt cattcttcat ccagctttgt tccattgctg 39840 gtgaggagct gtgatccttt ggaggagaag aggcactctg ggttttagaa ttttcagctt 39900 ttctgctctg ttttctcccc atctttgtgg ttttatctac ctttggtctt tgattatggt 39960 gacctacaga tggggttttg gtgtggatgt cctttttgtt aatgttgatg ctattccttt 40020 ctgtttgtta gttttccttc taacagtcag gtccctcagc tgtaggtctg ttggagtttg 40080 ctggaggtcc actccagaca ctgtctggat atcaccagtg gaggctgcag aacagcaaat 40140 attgcagaac agcaaatatt gctgccggag ccttcctctg gaagcttcgt cttgggggca 40200 cccggctgta tgaggtgtca gtcggcccct actgggaggt gtctcccagt taggctacaa 40260 gggggtcagg gacccacttg aggaggcagt ctgtccgttc tcagagctca aacactgtgc 40320 tggtagaact actgctctct tcagagctgt cagagaggga tgtttaagtc tgaggaagtt 40380 tctgctgcct tttgttcagc tatgccctgc ctccagaggt ggagtctaca gaggcaggca 40440 ggcctccttg agctgtggtg ggctccaccc agttggagct tcccaaccac tttacctact 40500 caagcctcag caatgatgga cgcccctccc ccagccaggc tgctgccttg aagttcaatt 40560 tggaactgct acgctagcag tgagcaaggc tctgtgggcg taggacctgc tgagccaggc 40620 acgggatata atctcctgtt gtgccatttg ctaagaccgt tggaaaagcg cagtatttgg 40680 gtggcagtgt cccaattttc ccggtatagt gtgtcacagc ttcccttggc ttggaaaggg 40740 acatcccccg accccttgtg cttcctgggt gaggcaatgc cccgccctgc ttcagctcac 40800 cctccgtggg ctgcacccac tttccaacca gtcccagtga gaagaaccag gtacctcagt 40860 2013203064 09 Apr 2013 161 of 771 tggaaatgca gaaatcacct gtcttccgcg tggatcatgc tgggagctgc agacaggagc 40920 tgttcctatt tgaccatctt ggaatgccac cttttttttt tttttttttt ttttaaggca 40980 gtttcttgct ctgtcaccca ggctggggtg cagaggcatg atcacggctc actgcaacct 41040 ctgccttctg ggctcaagtg atcctcccac ctcagcctcc caagttgctg ggaccacagc 41100 cacgcatcac caggcctggc taatttttgt gttttttgta gagatagggt ttcgctgtgt 41160 ttcccaggct ggtctcaaac tcctgcgctc aagcgatccg cctgcctcag cctcccaaag 41220 tgctgggatt acaggcatga gccactgcac ccggccaata tgtatgttaa tctcatccct 41280 caagctgata ctgaagtttt tcaatttatg ttatttggtg taaatctagg cagtctttaa 41340 caaaattggt gcttcatgtg tttaagaggc ataacttaag aattgtttgt ttcttataaa 41400 tcaggagaat ggaggtttaa tagaggtgaa ctgtctttct cactgcagaa cctttaatat 41460 gccactatgc attgtaaatc tcccaagagt gagattctag tatgatgctt ttcttttcct 41520 tttctgttct ttccctttcc ctctacctcc tttttctttt ctttgttggt ggcatgagtc 41580 ctatattata aggaaatgct tttagagtac agtcttctga tatatagtga tttttgaaaa 41640 agatttattt attgtcttgt tcactgtgag ctttttcccc catgtataag cagctgtgta 41700 atagattcaa gagcaccccc tcgccccttt ttttttgaga cagagtctcg ctcggtcact 41760 caggctggag tacggtggtg ctgtgatcat ggttcacctc gacttctggg ctccagcgat 41820 cctcccacct catcctctca agtagctggg accacaggcg tgtgtcaccg tacatggcta 41880 atttttctat ttttagtaga ggcagagttt cgccatgttt tccaggctgg tctcgaactc 41940 ctgaactcaa gcagtccacc tgtctcagcc tcccaaagtg ctgggattac aggcgtgagc 42000 ctccactccc agtctcaaat attcttttga aatatttgaa atatgttgat ctctcagtct 42060 ttcaacctta gttgtatgtt gattttcaat aaaaaggaag tatttgttgc cctaacatca 42120 gtattggcta ttcagtttaa aaaaggagtt aaagagatgt tatttatagg caggcttcaa 42180 aagaggaaag aatgatcagt ttcattctct gtttctagca tattctgact ccttctctca 42240 tattacctcg tttttcccac attttttctt taataaagtg aaattcacat aacagctaac 42300 cattttaacc acggaaagtg tacattccgt ggcatttatt accttcacag tgttacctct 42360 acctttatca agtttcaaaa cattttatca ccccaaaaga aagccctgtt cttattgggt 42420 gcctcttgct tttttttttt tttttttttt taaatcttga gacggggtct tggtttgttt 42480 cccaggttgt agtgcaatgg ggcgatctca tctcattgca acctctgcct cccgagttca 42540 agcaattctc ctgcctcagc ctcccgtagc tgggactaca ggcacgcgcc acatgcctgg 42600 ctaatttttg tatttttagt agaaacgtgg tttcaccatg ttggccaggc tagccttgaa 42660 2013203064 09 Apr 2013 162 of 771 ctcctgacct taggtaatct gcctgccttg gcctcccaaa gtgctgggat tataggcgtg 42720 agccaccgtt ctggccacct cctacttctt tcattagtct taattcctta gtggatttga 42780 cagtgtttat attatctaca ccaatgcatt tttttgtatg ttaataatag gagatattta 42840 ttgggcattt atttacatac ttatttgcat gtgtaactgt tgtatagcca gtttatgtat 42900 ataatcttac taaatctcta cagtaaatct atccccattt catagatggt ttaaaagaag 42960 ttaacttccc caagcattac ttttagtaag tagtgagact gaaggttgag ttctggtctg 43020 tcagattccg aagttgtttc cttaggaacc atattatctt gtgtacaact cttgggctaa 43080 tcttgttaat attctttatt tgacctcaca ctgttgattc ataccatgtt taaaattgaa 43140 atacattacc tatatttaaa aattgagacc tcacataaaa agctatattt ctagctgctt 43200 ttgaaatttc gaaggatctt ccaacacttg gctgacattc ctgcgtgaca aaaatcagct 43260 ggagctgtgt aatgtccgac ctgtctctgt caatgaacag attattcatt gtcatttctc 43320 atctgttttt gagattgtaa ctttgattct gtataactca tagaattagt agttagacct 43380 atatatgtta gttattacat tatttgtata tgtacagact gctttagaca atattgtagt 43440 gttatatgtt aattttatca attaaaatgt gctataggat cattgtagag atcttgtctc 43500 taattaacag gattcataaa gagaaaacaa aggagagaaa catccagatt gaaaagacct 43560 acatagtgcc aagcacaata aaagaaaccc tatactaggc aaattattat gaaatttgtt 43620 ttaggacacc agaaataaag ataatatcta aaaacttttt agaatcgcct aggagggatt 43680 aggaatatga atagcatcta acttgttggc agtagaattg aaggtagaag gtggtaaaac 43740 atcaccttga aagttctgca ttcagcctag aattctgtat ccagttaaac catcaatcaa 43800 gtgtgaaagt agggggaaaa actcaaggac taaaaaaatg tgctcatgaa gaacattttt 43860 tttggacatt acccagaaga tgtggttcaa caaaacaagg gaataaacca agaaaggaaa 43920 taaaagagct tcagtaaaca gagaatccca ctcagaagca acaaagaaga aagtcccagg 43980 atgacagctg tgacacaagc tgaaaagtta ccagttttgc ttggagcagg agattagaac 44040 ttccgggaaa ataatcaaat tgatagatgg atgttgaaat atttggagaa aaatgtaatg 44100 gattcttgca aaactgagca aattagaaaa aggaaacaat tattagcatt ggtggtttga 44160 gttaacccaa aattgtgatg ttgctatttt aggggaatta agataagtga aacacgtatg 44220 gaatactgct agttttgtaa gtctccttta ccatggcagg acatctgtag ttaataaatc 44280 tgtaagaagc agtattaaga ataatatttt aaaataccta attaaatagg aggaaaaaga 44340 atccgagtag ttgagggtga ttgcatctgg ggagaagcag gaataaaggt ttgaagataa 44400 atagggccag agatgagtaa ttttgttact gtgataatat attttatata tatgtgtatg 44460 2013203064 09 Apr 2013 163 of 771 tgtgtgcgtg tgtatatata tatatgagat atatctcata tatatgagat atatatgata 44520 tatatatgat atatatgata tatatatata aaacatacag ttcagtagca ttaacatcta 44580 gcattcagta catttacatt gttgtgcaat tgtcaccact gtccatctct agaacttttt 44640 cattatccca cactgacata ccacacccat taaataataa ctcctcattg ctcctcctgt 44700 tagtaccaac cattgttcta ctttcatctc tatgtatttg actattctag gtacctcgta 44760 taagcggaat cacgtgatat ctttttgtaa ctggcttatt tcactaacta tcttcgaggt 44820 tcatccatgt tgtagcagtt gttagcattt ccttcctttt aaaaggccga ataatattcc 44880 attgttatgt atataccata ttttgtttat ccatttattc atcaatagac acttttggct 44940 gttgtgaata atgctgctat gaatatgggt atgtaatacc tgtttgagta tctgctttca 45000 tttcttttgg atatgtaccc aaaagtgaga ttgctggatt gaatggtaat tctatattta 45060 aatttttgag aaaccaccat actgtttgat atactggctg cccaatttta cattaccacc 45120 agcaatacac tagggttccg aatttgccac atcctcacca tcgtgttgtt ttgtttatgt 45180 ttttttttaa taatagccat cctaatgggt gtgaagtctc attgtggttt taatttgcat 45240 tttcctaatg atcagcgata ttgaacattt gcacatgctt atttggtcat ttgtatatca 45300 gctttggagc aatgatgtct cttgaagcct tttgcccatt tatgaattga gtagtttggg 45360 atttttaaat tgtgttttag aagttctttg tatactctgg ctgggcacgg tggctcgtgc 45420 ctttgggagg ccgaggcagg tggatcacga ggttaggagt tcaagaccag actggctggt 45480 atagtgaaac cccatctcta ctaaaaatac aaaaattagc tggtgtggtc gggcgtgatg 45540 gtgcacacct gtagtcccag ctgttgggga ggctgaggca ggagacttgc ttgaacccgg 45600 aaggtggggg ggttgcagtg agacaggatt gtgccactgc actcagcctg ggtgacagag 45660 cgagactctg tctcaaaaaa aaagaaaaag aagttctttg tattctctga atattaatcc 45720 cttattggat atgttatttg caaatatttt ctcccataaa gaatgggtta ctttttcact 45780 ctgttgattg tttcctttgc tgtgcaggag ctatttagct tgaaaaaatc caacttgtct 45840 gttttctttt gttgcctgta cctttggtgt cacattcaag aaataattgc caaattcata 45900 ccatgaaact ttcccccatg ttttctcctg aaggttttta tagttttagc tctcacattt 45960 aggtgtttga tccattttga gttaaatttt gtatataatg ttatgtaaga gtccagcttc 46020 acacttttgg atgtgaatat ctagttttcc cagcattatt tgttgaaaag agtgtctttt 46080 tccccattga atagtcttgg cactcttgtt gaaaattatt tgacaataga tgcaagggtt 46140 tatttttggg ctctctcgac tattctgtta gactatatgt ttgttttttt atgtcaggac 46200 caccctaatt ttagtactgt agctttatag taaaatttga aaccaggaag tatatgtctt 46260 2013203064 09 Apr 2013 164 of 771 gtgtatttat ttacttattt tttgaaatag catctggctc tgttgcccag gctggagtgc 46320 agtggcacaa tcttagctca ctgcaacctc cacatctgag gttcaagcaa tcctcccacc 46380 tcagcctcct gagtagctgg gattgtagac acataccacc atgctcagct agtttttgta 46440 tttcttgtag agacagggtt ttgccatatt gcccaggtgg gtctcgaact cctgagccca 46500 agcagtctgc cctcctcagt gtcccaaagt gttgcgatta caggtatgag ccaccgtgca 46560 tggccccaac ttcttatatt tcaagatggt tttggccctt cagggccctt tgtgagtttt 46620 aggatggatt ttttttttaa cttttaagtt taggggtgca tgtgcaggtt tattacatag 46680 gtaaatttgt gtcaaggtgt tctgttgtat agattatttc atcacccagg tattaagcct 46740 agtacccatt agttattttt cctgagctcg cctcctccca cctggatttt tttttttatt 46800 tctaccagaa acattgttgg gattttggta gggattgtat tagtctgtag attgcattga 46860 atagtactga catcttaaca atattaagtc tttaaagcca tgaacaccag atgtctttcc 46920 atttatttac gtattctttc ttttctttca gcaatgtttt gtaattttca gtgtacaagt 46980 attttacctc cttggttaag ttaattccta agtattttat tcattctgat gatcttataa 47040 atctgttttc ttaatttcct ttcctaattg ttcattctta gggtatagaa acacaactga 47100 ttcttcgcac attaaatttg tgccctgctt cttcgcgggt ttgtttattc tttttttgtg 47160 tttgaaatcc ttgaggtttt ctgcatataa gattatatca tctgcaaatg agataatttt 47220 acttgttcct ttccaatttg agatgatttt tattcatttt cttaatgctc tctcatacat 47280 tcaatactat gttgaatgga agtggtgaaa gcaggcatcc tgtcttgttt ctgaccttat 47340 aggaaaagct ttcaattctt tgccattgac tatcatgtta gctatgggat tttttttttc 47400 cccccagata gagtctcgct gtgtcgccca ggctggagtg cagtggtgcg atctcggttc 47460 actgcaccct cctcctcccg ccaggttcaa gtgattctcc tgcttcagcc tcccaagtag 47520 ctgggattac aggtgtccac cactatgccc agctaatttt cgtattttta gtagaaacat 47580 ggtttcacca tgttggccaa gctggtctcg aactcttggc ctcaagtgat tcacctgcct 47640 cggcctccca tagtgctggg attatagtca gccaccatgc ctggccactg tgggattttt 47700 atatatggcc ttcattatgt tgtggtaatt tctttttatt cttagtttat tgagtgtttt 47760 tatcataaaa tcttgttgaa ttttttcaaa tattttttct gtgctagttg agatgaccat 47820 gtgatttgtt ttcttctttc tattaacatg atatattgtt tttcatatat tgagccattt 47880 ttgcatccca ggaataaatt ttacttggtc ttcgtgtata atccatttaa taagctgtgg 47940 aattcagttt gttggttctg tgttgaggac tttatatcaa tgttcctaag ggctactggt 48000 ctatagtttt cttttgtagt ttctttgact ttgctatcag ggcaatgctg gcctcattga 48060 2013203064 09 Apr 2013 165 of 771 atgtgttagg aagtgtttcc tcatccattt ttggcaaaac tttgggaaaa aacgatgttc 48120 tttaaatgtt tgatagaatt cacagataaa aaaatcacat ctagggcttt tgtctggaat 48180 ttttttattg ttattattga ttcagtcttg ttactagtta taggtctatt cagattttct 48240 ttttgtgtgt gtgattcagt attagtacat tttgtacttc tcgttatttc tccatttaat 48300 ctatattatc taatttgttg gcatacaatt gttcatagta ctgtcttctc ttttttttaa 48360 acttctgtgc agttgatact aatgtcccta cttttatttc agattttagt aatttgaatc 48420 ttctttatct taatacaggt aaagctgggt caattgttaa aattttttca aagaaccagt 48480 ttttggtttc attgattttt ctctgttatt tttctattat ttatatcctc tctaagcttt 48540 gttatttcct tcatcctgct agctttgggt ttattagttt gttctttttc tagttcctta 48600 agatttgaag ttggattatt gatttgagat cgttttcaat taaatgtgta caactacaaa 48660 tttccctctt aggactgctt ttgctgttct gtaatttttg gcatgttgtg tttttttgtt 48720 ttaatttatt tctaagtatt ttctaagttc ccttgtgatt tcttctgcgt ttaaccgtgt 48780 attttttaat ttccacagtt ggtgaatttt ctactttttc ttcagttatt gattttattg 48840 attttcagtg gcatcctgtt gtgatagaag atactttatt tggttccctg tttttttttt 48900 aaaacagagt gttgctctgt cacccaggct ggagtgcagt ggtgcgatct tggctcactg 48960 caacatccac ctcctgggtt cgagcaattc tcctggtctc agcctcccca gtaggtagga 49020 ttacaggcac atgccaccat gcccagctaa tttttgtatt tttagtagag acagggtttc 49080 gccatgttgg ccaggatgat ctcgaactcc tgacttcaag tgatccaccc gccttggcct 49140 cccgaagtgc taggattata ggcgttagcc accttgtctg gcccagatcc tctattttct 49200 tgcctatatt ctgactgggt gtttttgtcc attattgaga gtagggtatc gaagtgtcca 49260 gctgttattt cagaactgtc tgtttacctt caattctgtc aattttttgc ttcatataat 49320 tgggtggtct cttattaggc atgtaaatgt ttttgattat tatatcttct tgctatattg 49380 acacttattg atgtgtaata tcttttttgt ctcaaccttg ttttgattta gtttgtctaa 49440 tattaatgta gctacctgca ctctcatttg gttattactt gtatagaatg tctttttaca 49500 tcccttattt gtgtctttgg atctgaaatg agtctcttgt agacagcata tacaatctct 49560 tgtagattgt gtttttctta tacattctgt caaactctgc cttttgattg aagagtttta 49620 tcatttacaa ttaaagtaat tattgataag gatttaactg ctgccatttt gctgtttatt 49680 ttctatatgc cttacagctt ttttgtccct catttcctgc cttactggca cttgtgttta 49740 gttgatattt tgtggtgaag tgttttaatt tccttgttat ttccttttgt ttatattctg 49800 ctattttctg tgtgtgtgtg tgtgtggttg ccattggggg tcacatttaa tgccctaaag 49860 2013203064 09 Apr 2013 166 of 771 ttataacact gcaatttcaa tttataccaa tttactttca atagcataca aaaattcagc 49920 tcataagatt cagtccctgc tcccttccag ttattgatgt cataaaatta catttttatg 49980 tattgtgtgt ctaaaagcgt agactaataa ttgtttttta atgcagtagt gtcttaattt 50040 gtggaaaaca aaaagtggag ttgtaaacca atgttacaat aatgctagct ttggtaattg 50100 ctcatgtatt tatcatttct cagatcttta tttcttaata cagcttcaag ttactgtcta 50160 gtctcctttt atttcagcct gaaagactca cttcagcgtt tcttgcagga caggtctggt 50220 gataatgaac tctctcagat tttgttaatc tggaaatgtc ttaatgtctt catttttaag 50280 gacatttttg ctggatatag tattctcagt tgacaggtat ttgtgtttat ttgtttgttt 50340 cctttcagga ttttaaatat atcatcccac tgccttctgt ccttcaagag ttctgatgag 50400 aaatctgctg atattgagga tccctttgta tgttacaagt tgcttctctc attccatgtt 50460 caggattctc ttttttcata gtttgattat aatctatctc agtttttcct acttggatct 50520 ctgagttttt cctacttgga gttaattgag cttcttgaat atttatattc atgtctcatc 50580 aaatttggga agtttttgat taatatttct tcacataatc ttttttgccc cttttctctc 50640 tttttattct gggattccca gagtgtgtat gtgttggtcc acttgatgat ggtgttccac 50700 aggtgtctta ggctcttgtc ttcaattttc cttcagtttt ttttttctgt tcctcagaca 50760 cgtggtattt tcagctgttc tgccttccaa gtttactgat tcttctgcct gcccaaattg 50820 gcttttgaat tcctctagta aatttttatt tcagtttttg tacttttcag ctccagcatt 50880 tattttttga tttttttatg ttttctcttt attgatattt caattttgtt ttttgacatt 50940 atccatatct tcctttagct ttttgagcac ctttcaacat ttgttttaaa gtctatgtct 51000 agtaagtgtc tgccatctga tcttctcagg cacagtttct gttaatttat ttttttcctt 51060 ttggcctata cttaatgttt tgcttggggt agtttttttt tttggtatgc tttgtgattt 51120 ttgttgttgt tgtcaaaaac tggaatttga atcttaaaga gtggtaactt tggaaattag 51180 atttttctct tttctctaag atgtgctatt ttgtttggtt tttttatttg ttgtagagta 51240 tttctatgct gggtgtaatc ttaagatctt ctcggcctgt gtttttccct gggcatgtgt 51300 agtgactttc taaattgccc tatgtatgca gttcttttgc agtagtatcc tccttaaatg 51360 tttggctcct aaaaggcaaa ataaataaat aaataaataa aaattaaaaa ttaaaaataa 51420 atcaaagggg tgaaatagct ctggatcttt aaatccctgg agcaattttt tcagccaatg 51480 gcagttaaat aatgatagtc tgcctctgtg tcacattttg atcagaagca gcaattagca 51540 atcagaacac agattcctga tatttggagg gcaaggtctt tgttgccaac cttgactctt 51600 acaaactgtg tgcagggtgc tctgggaaca tgtgcatggt tgcctgcttt gagagtgggt 51660 2013203064 09 Apr 2013 167 of 771 gatgggtagc cgcgacggca caaagagctg aaattgactc aaactaactg atttaccatt 51720 caagtctttc cttagaaact gaaaacctga atagactcca gagttccaga atcacagatt 51780 ctgcttacag tcgtctaggt ggggagatgg gttcctggta cttctgattc tgccatcttt 51840 ctttgactaa tttttttttt ttgttcttga gatggagtct tactctgttg cccgcccagg 51900 ctggagtaca gtagcatgac ctcggctcac tgcaacctct gcctcccggg ttcaggcaat 51960 tctcctgcct cagcttccca agtagctgga attacaggcg tgcaccacca tgcctggcta 52020 attttttgta tttttagtag agacagggtt tcaccatgtt ggccaggcta gtctcgaact 52080 cctgacctca ggtgatcaac ccgcctcagc ctcccaaagt gctaggatta caggtgtgag 52140 ccactgcacc cagctcttag acaaattttt tattccaaac tttttttatt ttatcatttg 52200 aaaggtatat gtttattatt ttgtcaaaaa taattttaaa acgtattctt gaagcttatt 52260 tagatctgtt tcataggaac tgtgaagaaa gtaaagaatt taaaaaatga agacagattt 52320 tctcaccctg cttatgggtg cttctcgtgc tagccttttg caagtgtcgg gaagtgtaac 52380 ctgcaggagg catcagggct ttgggcctgc atggtctgag tgctgccctg tgagtttcag 52440 aaggcgcagc aacctgtata cctgaaagcc atctctgctg gggcaggtac ctagtgtccc 52500 cacctacctg ggtcgtagtc aggccctggg caagcctgct atgcttttcc ttccctaatc 52560 cctcaggggt gggatagaga gcacagtggc ctcccaggga ggtagaagct gctccagact 52620 aacaatcaga gctgccagtt cttaatcccc aagaccgcca gacttcacaa agacataccg 52680 aggtctgtgc tgtcagtgcc ccactactac actcccttaa gtagccccac attcttgtgc 52740 ttgtttcttt tttctgctct ctttccttgc ccaggtaaga ggtctgccca taagggatat 52800 tttgcagcat gtgaagcttt ttaaaaagtt aggcttattg aagtataatt tacacacaaa 52860 gtacaaaaaa aaaaagactg tgttctcaaa tctgtgagtc attaatgggt ttagatgttt 52920 atatattgaa attattggaa gtaaggtatg tttatattag aaagatttgt agtctagatt 52980 atccaagttt tgggagtatt acctctctgc ttttgtttat ctactttttt agtctctact 53040 ttccaagtat ctataggcaa attttcccat ttccctttgg aaagtgctgt tttcttgctt 53100 tttttccgcc tttccattgt gtcagactta taaggcaatc agccaactgt gggcatgaaa 53160 tccttgggag gaaagagaag gaagtgggag gggcagccat ggtgaatgtt tccctaagtt 53220 atagtcaagt tctttgagag aacataacct catccccttt ttaaactgtt gtaatacttt 53280 cttttaaata gattgtttat tctcctgcaa gtctcacagt tgttcacagt ggtaggtaag 53340 aaatcataaa gttcaaatat taaagggagc tcacaaaaga gcatggtttc accagccctc 53400 actaaaaaca aaattatggg aaaatgctgt aaaagaaacc agaattcttg gttgcaaatg 53460 2013203064 09 Apr 2013 168 of 771 atagaaagtg actctgattt acctaatcag aaaggaattt ttaaaaaagt attaggtagg 53520 tggaagctaa gggaagcaag acatggcccc aaggtttcaa caggagcaat ctgcttagga 53580 ctttgctgct tggacacttg gtgtaatagc tgctgccact atgcctcgaa actggtgact 53640 ctgctcatta actcacctcc tctggtgatc tctaggaata atctctgact ctcctgtacc 53700 ttgtcctcac taggattcgg tatccacggc aaaaagatct attaatagtt ggtatcaggc 53760 ctgtacatgt gttaagagaa agatgaggaa agaagtatct gcttctaatc tcttgaaatt 53820 atctccaaat tgaaatggta ttttggttgc ctaacagcct gaagatgaca aatatcccct 53880 acaaatttct cctattttac cctcttccta actatatctg taatttaaag tttcacatat 53940 tcttttgaaa attgttttca ttgtttaccc actttttaag aaaagcaaat gggaacatac 54000 taccactgtt tggccccttt caaaaatttt atatctgagg aatcttccat attgttgtgg 54060 acatctacct acctgattct tttattaact accttttatt tcattttatg atcatgctat 54120 cattaatagg cccctatgat gaatatataa gttgtttcca gttttttttt tgtcattgag 54180 aacagttcac atatgtatct tgttgtcttt tccaagtata tctttaaggc aaattcttag 54240 cagtggagtt gctaggtcca ttgcgtctat ggtttaaact agtgccttca aaaatggtat 54300 tttatatact cactgtttaa gagtgcttct tccttctatc cccactaact ttggcaaact 54360 gaatagtttc aaactttaac tttttatagc ttgttggcaa aaaatggtat cttgttattt 54420 gatcgtgttt ttttaattgt gaggtttagc gactttttga tgtattggtc ttatgtactt 54480 tctggtgtgt gtgtatgtat atactgaccc tattttcaac ttatttttct tttagtttgt 54540 ttgtattttc cttaatgatt ttcaggaaac caattttatt ctttcttcag acagttgtct 54600 aatgttctgc ttctcttgcc atttgaattt tgtgactaca aaattcagat gaaacaataa 54660 tagcataaag aacttggtgg gttatctttt gttttgcatt attgattgtt tattaagaaa 54720 tattctttaa aagtcacctt gcttaaatta gcaagtagga aatgctttca ataaagagaa 54780 ctgtcatgta cccactactc cttacttact gaatcatctt cttttggata gagaagataa 54840 aagtgaaaag ggaatttaag agttcctgcc tttttccttg tctttagcat tatatagctg 54900 tttaatgtgt gggagtctaa tttctttttt ctttcttgag acaaagtctc actctgttgc 54960 ccaggctgga gtgcagtggc acagtcttgg ctcactgcaa cctctgcctc ccaggttcaa 55020 gcaattctcc tgccttagcc tcctgagtag ctgggactac aggcatgtgc caccatgccc 55080 ggctaatttt tgtattttta gtagatatgg gacttcacca tgttggccag gctggtcttg 55140 aactcctgac ctctagtgat ctgcctgctt tggcctccca aagtgctggg attacaggca 55200 tgagccactg cacctggcct aattttttta ttgttctttt tggtgtgaac attctcccct 55260 2013203064 09 Apr 2013 169 of 771 cctccaagcc ttttgttttt actattttca tgttccttta tatgtgctgc tgttttgttt 55320 catctgtaat tatctctcat cccctttttt ggctattata atatatatat gtacgttttg 55380 aatctgagct ttgaaggtaa attcactgca gctgtgttgg ttgattttag ataatttgtg 55440 tatttcctcc tttgtctttt ttaaactgga gtcatttgta gttgtttata cagaatttta 55500 gtttttaaaa ccacaagtct ttcattatag gttgagttat gaattcatag cctgttattt 55560 aaatgaagct tttgaaatct gttttactga tctgtatcat atctaactac gccagtattt 55620 ccttccttgt ctgacgtgaa ctctaaaatt atgtgaacac tttctccctg tttcctggca 55680 tttccactca aacttgttcc tcattcttag ttagaaatat atccagaatt gtagtttctt 55740 tctaatctaa tgacagaagc aaattaatca agcatggcaa gaatttattg gaaaactgca 55800 tgtagttgaa aatatgttta gtatatattt tgacagctgt gaagtctcta atttttactg 55860 taccttttct ctgttccaat tttatgctct attctaagga tgtacccatt tctactacct 55920 gactagggag catgtgtatt gtatcccagc agattttttt tttcatagat agatatcctt 55980 tagatatctg ttatccagtg taggtagcca ctagccacat gtagctatca ttatgtttaa 56040 atgtaaataa aataaaataa atttactgag ttgtttttgc tagctacatt tcttgtgctc 56100 agtagctaca tgtggcttgt gattactgta ttaagacagc acagatacag aacattttca 56160 ttattgcaaa agttctgtta gacagtgctg ttctatacag tgtcattctg cctctcattc 56220 taaaaagttc taattcctga agttgatgta ctctttctgt tgctgtcctc tagcttaatc 56280 aaaataaatt tgagtctttt taaaggtagg ttgcatttta catactgata tttctaaatc 56340 agaggctatt tatattactt tttttatatt acttttaaaa attagcttta ttggagtata 56400 atttacatgc aataaaatct acccatttta aatgtacggt tcattgactt ttgagaaata 56460 cacacacaca cacacacaca cacacacctt cttgtaaaca cacaccttct tgtaaacaca 56520 acaaccaaga tttagaacac tcgctttatg aaaagtttcc ctcatgccca tttgtagtca 56580 gtccccaaac ctggtttcag gcaatctctg atctgctttc tatatgcttt gcctatacta 56640 ggattacata taaatacagt catatagcat gtattccttt ttgtgtctgg cttctttctt 56700 ttagtataat atttttgaaa tttatccctg ttgttactag tatcaataat ttgttctttt 56760 ttattgctga ctaatattac attgtatgga tatgacattt ctttattagt gtggtgggca 56820 tttgagttgt tttcagtttg ggtctgttat gaacaaagct gctgtaagca ttcatgtgca 56880 agacttttgt ggacatatat ttttgtttct gtttattcaa tacctttgag tagaattgtt 56940 gggtcacatg atgtagatca gttgaacaga gtagattcca gaaaagttca catacacatt 57000 tcttgacaaa ggtgctgaga ttattcatgg gaaaaggata atcttttaaa caaataatac 57060 2013203064 09 Apr 2013 170 of 771 tggaacaata gagaaaacaa agtgaacctt gacttttatg tcttatcata tacaaaaatt 57120 aatttgaagt ggattgttga cctaaatgta aaagtaaaat ttaaaaatat aaaacttcta 57180 gatgaaaaca taggagaaaa tctctgtgac ttttggttta aagatttctt agacagtaca 57240 tataaaatta actatataag gaaaaaatgg acaaatttga ctttatcaac attaaaaatt 57300 tctgctcatt gaaagactca aaatgaaaag gcaagcagtt ttggagaaaa tatttgcaat 57360 acatatatct gaaaaaggac ttgaatgtat aatatataca taaagatgct cttacaactt 57420 cataatgaga aaataacccc ataaagagaa gggcaggccg ggtgcagtgg ctcatgccta 57480 taatgccagc acttttggag gctgaggtgg gtgaattgct tgagcccagg agtttgagac 57540 cagcctgggc aacatggtga aacccagtct ctacaaaata aaaaaataca agaaattagc 57600 tgggcatgat ggcatgcacc tgtagtccta gctgtttggg aggctgaggt gggaggatag 57660 cttgagcctg ggaggcggag gctgcagtga gctgtgatcg caccgctgca cgcttgcctg 57720 agcaacacag tgagatcctg tctcaaaaca aacaaacaaa aaaaaaaaca aaaaatggaa 57780 acagaaattt tacaaaagaa gatatataga tggccagtag gcatatgaaa agatgtttaa 57840 aatcagtcat cagggaaatg aaaatttaaa cgtaatgaga tagctcatat ttactggaat 57900 ggctcaaaaa gggcttacag gaattggcaa agacatagat taactggaac tcttatgcat 57960 gttggttaga gcacaaaatg atatgatttc ttgggagaaa tatttggcag tttttaagat 58020 tatttttgat agccttctga atttcttagt gagttatagg tcagttctgc cactgtttct 58080 ttcttttctt tctttctttc tttccttcct tcccttcctt cccttccttg cctgtcttgc 58140 ctgccttcct tgccttgcct gccttgcctt cctttcttcc tttcttccct ttcttttctt 58200 tcttttcttt ttttttttaa aggagtctcg ttttgttgcc caggctggag tgcagtggca 58260 cgatcttggc tcactgcaac ctccacctcc cgggttcaag caattctccc tgcctcagct 58320 tccccaatag ctgggattac aggcgcgttc caccatactt ggctaatttt tttaattttg 58380 gcagaggcag ggtttcactg tgttggccag gctagtctcg aacacctgac ctcaagtgat 58440 ctgcccgcct tggcctccca gagtactggg attacaggtg tgagccactg cgcctggcct 58500 ggcactgttt atttcttttc cctccagttt tatacctatt tagagagatt agattttctt 58560 gagtactagg aatcactatt tttgagcaga attattcaaa actgttatta ttttttcttt 58620 aacttgaggc aatgtaggag aaagcagtac tgtgcaggtg aaagttacaa acaagaacat 58680 tttaaacaag atagttactt tccatgtatt ggatacgtaa cagaattaat tctaataacc 58740 atcctgaaga tggtcaggag gcattagtta agaattgaaa tgtttggagc ttgcctgtgt 58800 tgatgggatt aaggcaggga tgatttatgt gtaaatttat gcgttagtaa cagcagtaac 58860 2013203064 09 Apr 2013 171 of 771 cgctgtagtt acactagggt tctaagagca aatgttgatt aaacatgaat gtagcaggag 58920 tgataaggtt tggctctgtg tccccaccca aatctcatgt ggagttgtga tcctcagtgt 58980 tggaggaggg gcttggtagg aggtgattgg atcatgggag tggtttgtaa tggttttagc 59040 actatcaccc tagagctgtc tcgcgaaaga gttctcctga gatctgcttg tatataagtg 59100 tgtagcacct cccctctttg ctctctctct tcctcctact cctgccgcgg ggacgtgctt 59160 gctttccctt ggccttctgc catgattgta agtttcctga ggcctctgat taaacctttc 59220 ttcttctaaa agattaccca gtctcaggta gttctttata gcagtgtgag aatggactaa 59280 tacaagggga aatatatatg gttaccaaat agcgaattag ccatgggaaa aagtagcaaa 59340 taaataatta ttttactttt tcagatgcta atttttcttt tcgtttattt taggattggt 59400 gggagctgtc caatgtcctt aggctgtttt ccaaatgaga taccaaaagc tagttctcca 59460 tcgggtttct caggctgcta gaagcattca ttattatggt tgtcattact tcgagttctg 59520 ttgccgctat gcccacagta gtatttgtta cataacaggt gcttgataaa tatttgctaa 59580 atgaattttt ggaaaataca atctgccaca cctttcttct acagtttaca atcttctgtt 59640 gagatcatcc gatagatttt ttttcttaga tattgtactt ttgaggcctc aaattgctgt 59700 cttttgtatt ttctatgtct gcagagactt tccatctttc actcattgta ttcattgttt 59760 tttaacatct ttgtacatat ttatagtaac tgttttaaag tcactgtctg ttaattcaaa 59820 catctggttc atcttggagt ctgattctat tgcctgctct tttttctttg taataggtca 59880 tgtttttctg ctttgcctgt ctagtaaatt ttaatcgtat gttgaaatgt agggagtttg 59940 gattgttact tcctttaagg gtgctgagtt tcattttgtc aggcatttaa attgatagtt 60000 gatttagtat tgtcaggttt ggttctcttt gttaaagcag gcatttttca gatttgtctt 60060 ttgtcctagg gcatggtttt taacttcaag gttgcccttt ccaatgtctc agctaagtat 60120 ctggggtgtt ccatgaggtc tcttccactt tgcctaggcc agaactccag cttctcccag 60180 tattatattt cgttacctct ggcgtcatct ccgttatgct ttcagatcct gcgcatagac 60240 agcccagccc ccagccaagg acctgagatg aaatccatac aaaattctta gtcccttgct 60300 ccacaaactc caacagcctt agcagtctaa tctcttcctg tttacctcag tgaaatctgt 60360 gttccacttg agttccattt ccttctgtat cagagaagag ccaccatgct gaaagcaagg 60420 ggcactatgt ttctttgttc ttaaggatgg tagcctatct gcaacaactg tagtgtgata 60480 taaaaatata taatttatgt tgctgacagt tacaaatact gcttgcagta ctttgtaaca 60540 taatttttca gattcaagtt catatactct ttttttccac atcaccacac acatattttc 60600 agacttcctc ctcatccttc ttcttgccag tagttgtatt ataattcctg ccagtagtta 60660 2013203064 09 Apr 2013 172 of 771 cattataatt ttggttatat caatattgag tttttatggg attataacta gataaatgcc 60720 attcatagtt aagtgataga gtatattgtg acttttttcc tgcatgtttt attttttctg 60780 gacttcacag ttgtctctct tttttttaaa aaaattagtt ttcaatgttc ttagctttaa 60840 ttcataaact cacccctaat tgtataaatc tctcaacatg tttaagcaca tttggcatta 60900 tatcaatttt atcttttcca ggtgccttct aatctgtccc agtctggact aattgttctt 60960 cctggcttgc tgtatggctg tctactcaag atgtcccttc accatcattc tagggattcc 61020 cttttcctct cttgtgggtt agattcttca gttcttggag actgtcatct tctttcatgg 61080 tttcccactc ttgttttggc ggagcacatc tttagtaact tcctgacaaa gtgtatggtt 61140 tgagatttcg ctgattttaa aatgccctta ttatatagtc acacttgatt tatagtctgt 61200 cttggtatag aattctaggc tgagaagagt tttccctcaa aatcagaagg ttttgcccaa 61260 ttgtttttta gctgctagta ttgctgttaa aaaggataat gtcattttga ttctagattc 61320 ttttatgaaa cctgtttctt ctctggcagc ttttaggatc ttctgtttct ttggtattca 61380 gaaatttcat gagatatgtg tgcttctatt ttggtcttat tttcatctgt tttgccaggt 61440 actcatgcaa ctttccagtt tgaaaactca catccttcac ttttgagtat ttttcttgag 61500 ttatgtcttc ggtttcttct cagtgttctc tgtttctgga actcctaaaa tatatttaac 61560 atcctgaact cttagttttt gtttagtctt ctgattttca tttgtctttt tattctgtat 61620 attctgttaa ttcctcggct tcatggtctt ctagcccttc ttttgcctat cttatggggt 61680 tgaggattaa acagtttata tacctgaggt gcttaggata tgtctgtcat atagtaagtg 61740 cttgtgttag ctgtaattgt tgtttacttt cataactgtc ttgagggaaa ggtctttggt 61800 cttgattctt tgacttcttg gctgtacatg accttggacg agttatgtaa tctctttgag 61860 acctacctcc ctcttctgta tagtgttaat aagctctagc tctcagatgt ttgtgagggt 61920 cgaatggagt atatatgtga aaatgtttaa tacctttgta cagaattaat agttagtacg 61980 tggatctttc aaatatcaaa agttttcagt ttgatgggaa aatgatgtct gaattttcag 62040 ggttattttt aagagtactt gattatgact gtcttgtaaa tctctatgag ctaggtatac 62100 ttgcactaaa tgctaatgct ttttaaagaa gttatgtctt aatattcagt ctcattatgt 62160 taggttgaag atagaagatt atgaaaatat tctctgaaaa gctctggttt tacttcagat 62220 tgtataaatc tgtgtaatgt aataattatt taagaatgac atgattacta ctctaaaccc 62280 atagaagggg tatttgttgg attatttatt ttcacttaaa tggtatttga gattaggaaa 62340 aagaaaatct gtcttttggt ttttcttgat agtattaatg taatttcaaa tgttagctca 62400 tttttgttaa tggtggcttt ttgtttgttt gttttgtttt aaggtttttg gattcaaagc 62460 2013203064 09 Apr 2013 173 of 771 ataaaaacca ttacaagata tacaatctgt aagtatgttt tcttatttgt atgcttgcaa 62520 atatcttcta aaacaactat taagtgaaag ttatctgctt gttagagtga ggtagagtta 62580 aagatacatt ttaacagaat tgtattccta aaccgattaa gtcaagaagt ccaagagcat 62640 tgttagatca tttagaaagt gtagtgatga ggtaaaacat tgttggcaca gattcatgtt 62700 acttgatctg ctttaaatga cttggcatct agcccatatt tgagcccata accgtgtggt 62760 aatttgaagt gtaattcaca gtagagcttc tgttaaagca ctaatagcat cttccatgga 62820 ggtatacttc agagtgaata taattttgtt tatcctgtgt ctctagagct attgactgaa 62880 aaagctgtta gggcattctc taactgtaca tcacctaagt tatttaaaat tgctgaatta 62940 ggtggcttgt cttgtctagg acagagtttt aaggactgcc cacctgattg atagagctag 63000 ttgaccttat ctttaacttt ttgtttttct tttgactttg ggagtagaga tgtgaaaagg 63060 taaaaaggaa ggaaggaaga gaaaacttaa ctctttttgc ccatgaagac tgtttttcct 63120 tctcaaaata ttgactattt tctgatttgt aaaaatcggc acataaaacg tgttattttt 63180 tacttgactt ttatctttcc catgtgatat ctataaatta tagataggaa aaatttatct 63240 gtaatttagt gatctttcta gtgtgataaa acgtcagaag tactgagagt ggagtggaca 63300 ttgatattgt tactctcagt aagttttcac tgatttttct cagagtcatg aaggaacaaa 63360 cgtttgttaa gtccttatca cttattagat aacacaaaac atgttggggg ggtgtgtaca 63420 gaggtgagta agatgtagct cccattctca agtcgcttac attctaatgt aaaaggtaga 63480 caaagcatta cagaagaagt aactctgcta tagaaggttg caatgaagag aacattggaa 63540 acactaattt taccttataa agaaggtttc ataaaggaag gcaagtttga gctggggtga 63600 aaaggaccag taagggttga ctttcaagcc aaggagagga ggggaagtga tgttacaggc 63660 caaaggaatg gcattgtaag aagcttgttg gcataaaagt gtttagaata tggcagcgaa 63720 ttcattatca tcagattgtg gtgtctgtat gttgggggtg ggagagaatt gtggtggcaa 63780 taggcaacaa gataaaagaa agtaaaaggt gttatggaaa cttaatgggt ccagcttaca 63840 aatgatctat gcatttaggg gtctttctct tttcctgata aacctctcct acaaagagcc 63900 ttgttgcgga taccatagtg tttctttgga ggaaaataaa aactacaaag ctttgtattt 63960 tttgcacaac tggattcaga atataagtaa taaaaaagga caagaacttt caaaagctag 64020 aagccattaa actgagtcac ttcagggtta gactatcaga actggggatt tagaaagtct 64080 cagaatggaa atcgaaggac accaaagaca aattcggcct ttttcaaaat tttattctag 64140 tttaacatat tcaaagaaag ggaaggaaat tcttttcatt cctgtgtgta gtgacttcct 64200 gctttaagaa cttaggactt cagctgtact atcagtattg taggtcactt aacattatta 64260 2013203064 09 Apr 2013 174 of 771 tggttaaagt tggcattgga gagagcctag gaacctaact gcctgtttgt ttttatattt 64320 ccaaccattg gattcccaag ttaatgaagt ctgtttatta gttgagggta gctcttaatg 64380 catatatttt aatgcccctt ccccacatgg aatcataagc tttcagaact ggagagtacc 64440 tgaaagagat catttagtcc aaccttctca ttttacagat ggggaatctg aggcctagag 64500 aagttaagtg agttgaacaa ggtcacacag gtacatatgg tagccgacca tccactgttt 64560 atgccaatat tccctttacg ttttgctttt ttgcttgttc gttttaacct ctccaaattt 64620 tactgacttc agaagtttct agaactaagt tatagcatgt tttgagttct aatgtcactt 64680 tccgatcttc tttacctttt ttctacctct gtttgtattt ctggttctgg ttaagtgagt 64740 ctggtaagca gcaggtgttc tattttattt cttttatttt taggatagta ttacatgtga 64800 tatatatgtc tttgcaaaca tacataattt gaagatctta aaatatttgc actaggcata 64860 cccacattta atagtatgtt aaatctttta tagcaattat gatatacatg ggtgaagaag 64920 agttcctaat atggcctttc tgattaactg tatctgttta tatctgtgtt ttcttcaggc 64980 attcataaca ttaagcaaat tcaggtgtac tgttacttaa ttgaattaat cagtttgttt 65040 tgtacaagta tattttattt ttgttccttg ttgtataatc tggtaggaat ggggaagggg 65100 agatagtgaa taaagagatg tatacttctt gcctttgagg aatttaagtt ttcactgtat 65160 accaattttt taaaggtatt tactatattt cagtgcatat tttatttgac atactttatc 65220 attttgtggt aaacctttag ctttactaat tttcatctat taagttttct tttgtaagat 65280 ggtgatagct tcatcaaaga gagtaaagaa gagacctgcc tacctagctg attctatggc 65340 aaatctcact tctctggaag cttttcctgt taatcttatt ccttcagttt ctgcctcttg 65400 tttcataaaa actcattctt taaatgctta ttcatttctc ttgtctcata taaaccaata 65460 tgaggtactg gtatcttttg agttttagtt ataaggaagc ataaatggtt aaatttaaat 65520 ggctaaaccc catttgccat ttgtgtatct ttaattttag tttgttgaga gacttatcac 65580 taccaaacca caaagaattt aaaagaaact gtcagtaggt ataggtggaa ggagggcatt 65640 tatcagagat tttaatttaa gaagaaagtc ttcatcctta tcctaccaac ccccattccc 65700 tgagcatatt tatcattact agtcccagca tatttgctcc catatttcct atgcttacct 65760 gtgaagattt tcataacttt ttccttgctt tttactgtca ctgttggttc tgtgatttat 65820 gacagatact gctcttgtag gaatgctggc tttgactgaa atttgttact gcttttgtat 65880 ttaaaacttt ttttttatta taagtagaat tatggaacag tagtagaaaa agtttgactt 65940 ttgtaatcag agatactgag cttgagttct ggctctttca tttgtatact gttatttggg 66000 gcaagttttt taatgctctt aagtcttagc tttctcatat ataaaatgga gataataaca 66060 2013203064 09 Apr 2013 175 of 771 gttatcacgt gattgtgagg atgaaacaaa aaaaagtgga aactctttgt aaggtgtgtt 66120 catctggttg acacttagta gtcattactt ccactttccg tccatatagt cctcttaaca 66180 gtaatatttg agaggcattt ttattaaagc agtcttaagg agtgttcgtc aaaccacatg 66240 ttctgggatc ctgagaaagt aggggaagtt tagagaactg aagctgcaca aaactaatgt 66300 ttattttctg ttgtgttgtc ctgagaccag cttcttagat tgtgtttcct agtcctacat 66360 ctctgattcc ttataaaata ttccattatg aattcttcac tattgacaat ttctcccctt 66420 ttatcttaaa agtaccaaag aaagtgtaaa atgtgactgt cttgtcagtc ctctttttcc 66480 tgtttttcat gtcagtgggt atgaaattac tagcaaggat gcatatatgt gcatatgtca 66540 ttactaaatg cattttcttt ctagaaaaac tcaatatact aaattgtact aaaaaggaaa 66600 agcttgtttt gttttgagtg gtagtatgaa agttgtttta ttttaggtct gaccagttag 66660 aaaccaatgg attgtagttt atttataatt agttaaacct tcatgtgaat ttggttttga 66720 attaccttta aggtagagaa gaaactatat agatgttttt cagggtttct aaatgtacaa 66780 tacaggttca caatcactta tttgaaactc ttggggccaa gtatgtttcc attttcagaa 66840 attttagttt tcaaaaggta gcacagataa atatactttt acataaacac cccagtgggg 66900 tgtgggtcag tacctgaaat gaaatgtttt actcttcgct ctaagtgtat taaatattat 66960 gtacaatctt attacttcag atcaggattt gctgtagttg agtttgccat aaaacttaag 67020 agaaaatttt agatgttttg aacttttggg atattgaaat tgcaggttaa ggagctatgg 67080 acctttattt gttttaaaat gctaagagtt tattttaagt aatttttaaa aaatttgttt 67140 tgcatagtag ttggagttac cagggtactg ctaaccacac tgatatgtaa gatctctttc 67200 tgagcctttt attgtttgta aacatggcct gttaatcatt agaaagccag tacatactaa 67260 catatcactg ctattaagac aaatattagc atactctagt aatgacaagt cagcatttta 67320 ctattctgta ttgattttac ttattctttc attactctca tactgtaatt aaaacttgca 67380 atctgagaga ctgttgaaaa aggtgatcgt tggcttttca acagggagta aggtctggtt 67440 taaaaaaaaa ttagtaagca tttggccaag tagattaaca acattcagtt tttctttact 67500 gtccttatgc ttttactatt tttaacatat atctttttga agaatagttt gagaattatg 67560 tatgcttaac tatgagatac agatactatt gaaactagtc agttgtttat aggtacttgt 67620 aaaattaaaa atatattcca atagcatgca gatttttcat agaggaaatt tgaaagcatg 67680 gaagcacctg aatttacagt actctgtatt agtggcatca caagttttta agcaaatgta 67740 ttagctctaa ttgcatacac ttaatctttt aagctttggt tttattatta taatatgggg 67800 gtgataacag tatctactta atagaattct tgttattaca tgaaataatt aatgttaaac 67860 2013203064 09 Apr 2013 176 of 771 acagcataat atgtgtcaca ttataaagat tcaggcaatg tttgttagta ttagtacttt 67920 tttttcttcc taagtgcaaa agataacttt atatcacttt taaacttttc ttttagttgt 67980 gctgaaagac attatgacac cgccaaattt aattgcagag gtaggtatga atgtactgta 68040 ctatgttgta taacttaaac ccgatagact gtatcttact gtcataacaa taatgagtca 68100 tccagattat cgagtgagat acatatttaa gaattatctt taaaaatttc aaaaatttta 68160 attttactgt tgtgttttag gaaaaagtat tgcataaagc tattaatatt gtcaggaaga 68220 ctaaagtgca gcatagacta agaattagga aaattcctag actaaaaata gtataaggag 68280 agggtttacc tactatttga ggcagttggt ctaatagtaa gcaatcacag ggagaaagca 68340 gaactactta actcttctgt gttgaggaat gacataaaag gtaggaaagg atataacaaa 68400 tgttgataag aggagtctga tggatgagag gagggaactg ctttaaatga gtttctactt 68460 cagacataag ttaattctca gagcccacaa aaactttcac ttttatttgt gaaatacaac 68520 tcagttctca tggcttaaca ctttaaacca tgagaaaact gaagagttga gaagcttggc 68580 agatgctgct gtgatagtca aaaagaaagt gggtgccatg agctactatt gatgtatttg 68640 ccattgatcc ctcctgaaaa tctagaatgg actttcagac aaatggtttg aaaattctaa 68700 atcactaatg attgagattt agtataggtt tactaagaac gggttttttt tgtttttgtt 68760 tttggtggat ttaggctgtt gcttactaag caaagcaggc tttagttgag gtttatcttg 68820 ctttaaacag atatttaaca gattttcctg gaggtttttg tgtaccactg ggaaaatgaa 68880 gttaggcaga tgactaagtg aaagctgtcc tgctgactcc ttataatgat agtcattgtc 68940 taccagaaga tctctcctgt cacaccaaag gataattgat tatatcctgt accatattat 69000 gagtcacctg attggagata taagacatac ttctcacata tttagatgac acaggttagt 69060 acattgaata tcagccaggg tttttaagga tcttaataga gtggaactaa ggtagaaact 69120 attaagagca attaatagtg atatatctat agtcctgttt ctaaacaagt ttttttaaaa 69180 acctcaactc tgactatagt gaacagagaa gtcttggact cttacaattc atgtgagaag 69240 acctgaaact ttgataacaa ttatatacat tttgtgagta atttctttgg tgtatgcctt 69300 cacatatctc tggtatgtga cctatgctgc agtccattga gcatagattc ccagaatgta 69360 ttctcctgca gaaaatggag gaaaataata cttggcttcc ctaatgatta catgtgtata 69420 caacactaac atttgcaaga ccacctttaa ataacacact tagcattttt attttatgaa 69480 atgtaatatg tagttctttg catagtttat cctattagta atctattctg tctttggaat 69540 atgttttgtg atgatgaaat aaatactata aatagtatta ttccttttgc attgagagtc 69600 ctgacgaaat gtccatgtga cagttcattt tgggtttagc tctacctcta atatgtgacc 69660 2013203064 09 Apr 2013 177 of 771 tatgctacca gtccgtatag cgtaaattcc cagaatatat cctcctgaat aaaatggggg 69720 aaaataatac ctggcttcct taatgattat atttaagact tatcaagaga ctattttcta 69780 tttaacaatt agaaagttaa gcaatacatt atttttctct ggaatccagt gtttctttta 69840 aatacctgtt aagtttgtat gcaacatttc taaagttacc tacttgttaa ttaaaaattc 69900 aagagttttt ttttcttatt ctgaggttat ctttttacca cagttgcaca atatcctttt 69960 gaagaccata acccaccaca gctagaactt atcaaaccct tttgtgaaga tcttgaccaa 70020 tggctaagtg aagatgacaa tcatgttgca gcaattcact gtaaagctgg aaagggacga 70080 actggtgtaa tgatatgtgc atatttatta catcggggca aatttttaaa ggcacaagag 70140 gccctagatt tctatgggga agtaaggacc agagacaaaa aggtaagtta ttttttgatg 70200 tttttccttt cctcttcctg gatctgagaa tttattggaa aacagatttt gggtttcttt 70260 ttttccttca gttttattga ggtgtaattg acaagtaaaa attatatata aatacaatgt 70320 ataatatgat gttttgatgt atgtgtatat acattgtgaa atgattacta cagtcaaact 70380 acttaacata ttcatcacct cacataatta ttattctccc cccagggtga aagcatttaa 70440 gatctacaag ctacaatttt caattataca atgttattat taactatagt cactatgctg 70500 tccagtagag cttcagatct tgttcatctt gtgttcctcc ctccccaccc tcagtccctg 70560 gaaaacaggt tttaaagata gttgctaatc cttatttctt ctaaattttt aaatcagttg 70620 ctgcctcaat ttctatatga gaaatgactg attgatttca tttttctgtt cacgctacca 70680 ttttcatatc atactagcac atgttaccca ttaactgtat tgcagatttg gtctcacaaa 70740 attcttctaa aataacattt ttaaaaagca tattaatcaa aaataagctt tatatttctg 70800 aagcttgttt gagcatagaa tgcctttgga taaaatacca ttacctagta aagtgtgaac 70860 ttttataatc cataaaaatt attcttttat aagaatattc ataaatgtag ttagattaat 70920 agaagattct cgattctttg atcagaaaac taaggactat attgaaaaat cagtgacaaa 70980 tttaattctt atagtacatc tgaaagaaaa aagaaaactc ttgggagaac ttttacagtg 71040 atttaatttt gctgttgata tatttctttg ggtggtaagt atggcaaaac atgttaaaat 71100 ttaatgcaaa gagattttgt acatttttcc atctctaaga aggacaaagc ctaagcccct 71160 ccagatagat agaaaaactc atttagagag ttctccttca tgttaatcta atttcttctt 71220 aattcagctg taaaacagaa atagaatgat cgtattaatc atttaaagct gtgtaattgc 71280 atagattcct tgttccttta ccccctctta tatcttgttt cctatccttt gtgacttttt 71340 ttgcattata tataaggatg ccgaaatact gtttattgtt gatagtttac aaaattgaat 71400 cttacattag tgcataattt tggtgaatgt tgaagattat ggtagattgc cttacatttc 71460 2013203064 09 Apr 2013 178 of 771 tgcatattgt ttgcaccttg gaatgatagc actggcatga attatagagc tgaggatcta 71520 aagattttta ctttgattta tcccattatc atctgcaggg aaacaattgc ttttactgat 71580 taaaaatgca ggctgggcac agcggctcac gcctgtaatc ccagtacttt gggaggccga 71640 ggcgggcgga tcacaaggtc aagagatcga gaccatcctg gccaaccaac atggtgaaac 71700 ctcatctcta ctaaaaatac aaaaattagc tgggtgtggt ggcgcgtgcc tgtaatccca 71760 gctactcagg atgctgaggc aggagaatcg cttgaacccg ggaggtggag gttgcagtga 71820 gccgagactg tgccactgca ctccagcctg gtgatagagg gagactccat ctcaaaaaaa 71880 aaaaaaaatg cagtagcaaa agcgatggta gaaatttaaa acagagttga tgagcagcat 71940 atattttggt agtggaaaaa aaggtaaaaa attttttgta ataaaataga aaaattttgt 72000 aatgtggagg cgcagaacac tagatttaag ccagggggtc ttaaattgtg ttacattcct 72060 tttaaagtct gatggaaggt ataaatgttc tcccctcaaa aaatgtgcat agtgtacata 72120 aaattttgca gtttttatta cattgaaata tattctttta gacagaatgt aaaagaacct 72180 tcatgaaaac tatgtcactt ttttatgcaa aaaccagtgg ctactacatg agagcaatga 72240 ataaatctaa gtggtacaaa ttaaccaaaa ttaagcttta gttctgttca atactaaatt 72300 ttaatgaaaa gactgctatt taacttttaa aataacaagt tgaaactatg ctctttgact 72360 ttgactttgc aacttttata tgatctttga tatccaatca gtgttgactt tggtaaaaag 72420 tgctgaaaat gctattttac aaaagaaaga agagtaaatg gaatctgtag attctattgc 72480 ctgatgaaag tagacgtgtc aagaaataag aattctccaa ggctcttcag ataaattcat 72540 gtttcatcat tttctttgcc ttcaagttac tgagatcatt tttggcaaga tctgtatcat 72600 taatgctgtg ttaggaaaga aaagattatg actccacatt ttactttcaa ggttgaagag 72660 ttaaactgtt taaaaagagt gtatgttatc ctgtaaacag cagtatcagg ctgtagaatt 72720 tgtcttctga aagcagggaa cttatatata gcaaagaact tcatagtgct cccatttctt 72780 gacaaaacct ctcgagaagc tcttgattga aagtcttggc tttcatgaat ctggcagctt 72840 tcacaatagt ggatttttca tgacaaatca tcttacacag ggaattattc aagggttggc 72900 acttgaaaca gtagaatact ttcacaacaa gagataagat ttctttcagg attgatgaca 72960 gtcttgcacc ctagcgcata ctgatgaaga gagcagtggg tgaccatgac atggagagct 73020 tctgtcttta ccagtgcccc aatatcagat gtgttgtctg gcagtaaggt gtactgtctg 73080 cctacagaat actgaggttt cttcaggaga agttttttgg taaagaaact ttaccatttt 73140 gaaagtgtta atgttttctg aagcttccaa aaagattcca aaatgggaat gtttccttga 73200 ttgtgtcacc atgcttgcat ttgatgaaaa cttgtagccg gctatactga gaaatcatat 73260 2013203064 09 Apr 2013 179 of 771 ctgaagaaag gtggtacttc caatcttttt gtgacctact ttattattgt ttttttaatg 73320 tcagggtttt ttttggaatg gagaaaagta tttgatagag gtattgcaac agtcttattc 73380 ttcttcatgc tacaagtata tttgactctt tctaagatac ttgccttcac tgttcaactg 73440 tgtgactttt tgtttgttta gcattacaat caatatccta gtaggatgat ttaatcaatg 73500 atttttaatt ggaacaaata gtttttgtaa tggtctaggc ttttccaact taactgtgct 73560 ctcacatgtg gtctcttttt ctccctcttt cctccttctt atacactctc acccacacac 73620 atatgcatac ataccctgtc tgatgtatct gcttcttcag aatagttggc tgtgctctgc 73680 tgatgatgag aacttgccat ttaagaagga cttgggatag tccatgtcat catgttcagg 73740 gataaaagta aaacccaagg gcatttaaac tttattgtat tttattttct gtttccagtc 73800 caaattaaat ccaagagaag gctccataat caaaaagtaa ggacatattt taaatttgcc 73860 aatgggaaga tattctagtc attacagtct ggtaatacta tcaattctgt ttctcttcag 73920 aggtgagggg agactatttg atgaaatcgt aagtcctgta gggtgttgtg aaatagggcc 73980 agaatgaaag atagcaagaa tagtgttatg aaaataaaat gcaaagttta taatatcatg 74040 tggtaaaatg taatagtatt tacttcatca gtagaactgc tctagtagct gtatattctc 74100 catccttgca taggttggaa tatcccccaa gtgaaaagag attgatgggc taatagttaa 74160 tagaaaatgg agatctgtac atacagtgtt aagaatgtag atattaaaat tgttatattt 74220 agctgttaca taatattaag actcagagtt aagtaatttc actgaaattg attgcttttt 74280 gtgtcttgga gtcaaaataa ataactgaaa tctactatac ttggctcatg cttaattaat 74340 atacttagac catatttcgg atgaattatt cacagaatct aaaggagtat cctcgtgttc 74400 ttaccttctt tatccctgtg tttatttaaa aaggcaaaaa aaatggagca gatgctgttg 74460 gttgaccata ttttactgaa cagtagcatt tgtgtttagg ttgaaacagc attagaaaac 74520 tagatacgga ttaaagtcag tggtaggttt tttttttttt ttcttccagg aatgtttctt 74580 atagatgatc aaacaggcac aggaagggga agtgttgtga tcaatattat ccagttaata 74640 ttagcattca gaggaaaatt tgagtcctct gatacactgt taaatttctt tctatactat 74700 caagtccaca aatcctggaa ctgcaaaaga attttgagac tgttcaaaat aattaatctc 74760 tgtataggct caggctttcc tgcaaggtta tgaaatgctg ataaaattgg tcttattttg 74820 aaaggctcct cagcttatac ctttccttac aaatgcttcc ttacaaatgc taaagcattt 74880 aatgactcct gacttaaagg gaatttggac agattgaggt tgttggtctt ggaaatataa 74940 tactgcaggc ttctgtaaaa tacttgaaat gtaattgttt taaaactttc aaagatacca 75000 cttgtttgcc tgttggttag aatactggtg aaataatttt taatctttta tgaataacta 75060 2013203064 09 Apr 2013 180 of 771 atttcatcat aagaaaactt agctaagcat ggtaaagctg ttgttataca actgtggaat 75120 tcttcctgag gagtaactat cttataataa atgtagttga ttatctaaag tagttttatt 75180 cttggaatat ctcataatag gtttattctc ttcttgtcag tatttccttg tagattgagc 75240 ctgtggattt gcatttttgt aattgtgaat caccattata ggagatacat gcattttatc 75300 tacttttcag tttgtatggg gttaacttta ttagaattat ctttaatgtt attttgctta 75360 tatacttaat tttaattata gacaaacatt aagaagctgg agaaaattat gttctagtga 75420 catttatata gaagaagaat cttttttccc cctttctttt ttgaagggag atgaggcagt 75480 catattttgg taaagaattt gtagactttg cagaggtctc ttcaaaataa tctggctcag 75540 agtcttgaca tatcctcagc agacatggtg caaattagat ggcagagtgg tgggtacaag 75600 ttgaccataa aataacgcat taggttagta atgcccaaat aatactttgg gttttcagtg 75660 ttgcagagaa gtcagacaac tgatagttat tataaagaaa aatgttctga gagtgaggta 75720 accgcttaag ggaaggaagc ctccttctgt cttattcact aatttacaag aagataattg 75780 tgttacactt ccttaggagt cattcatttg tatatttgac acttttgctt tatgaacatg 75840 tgaagattat tcaaaagtaa gctgttggtg atttttttct tccaagaaag catgccacag 75900 ggcaacttct agggttggtt ctcatctagt cctgtgctcc acactatctg catctgcact 75960 taagtttcaa tattagataa ctcacatgtt taaactatga agaaagagtt aaaacatcct 76020 gagaatgcta gtaagtatgt atttttgaaa ggacttccaa aatttgagtt taaagaggta 76080 aactcctttt acatgacaaa gttacttaga aacactactg ctgtttccct ctcccttgcc 76140 ttctccctgt cccatgcata cccccagctg tgttccagaa tgatggcaca taaagtaaac 76200 attcatattt atttcccttt ttttgttttt tttttttttt ttttttgctt gtttgttttg 76260 tttttttgtt tgagacagtc tcactcaatc acccaggctg gagtgcagtg gcaacatctc 76320 agctcactgc aacctctacc tcctgagttc aagcgattct cctgcctcag cctcccgagc 76380 agctgggatt acaggcgcct gcccccacgc ctggctaatt tttgtatttt tagtagagat 76440 ggggtttcgc catgttggcc agactggtct tgaactcttg acctcaagtg atccgcccac 76500 ctcggcctcc caaagtgctg agattacagg catgagtcac tgtgcctggc ctcttatttt 76560 ttctttggtt aaacttttag ggaaaaagtt tgagctgctt ttaattttct ttttgttttt 76620 aaataaatta ttaaagtttc tctatgttag gaactcttgt gtacatgagt tcattgagct 76680 tattcttaat aaagacaaat cttctagaaa taatagttgt atctttaaat gatctcaagg 76740 aaaatgtttg gtttctctgg ggaatgaatt ttcatgacct aatcttaaat caggttattt 76800 tttctagcct gtttactaaa tttctacatg ttataaccta atgaaatttt cttacttcct 76860 2013203064 09 Apr 2013 181 of 771 ctttatttaa aacaaactat aattactgtc tttttaaaaa tcttccaatg tggcgttctt 76920 atttttctta acatttgaat tttcctgggc caaaccatgt tactatgata cacattattt 76980 aaggctgtta tataatacag taaaattgta gaactttcat accttgaagg atcttagcaa 77040 ttatttaatt caaacccatt ctaacataga tgataaaaca gatttgcagg gttgggcacg 77100 gtggctcata cctatattcc cagcactttg ggagactcaa gcgggaagat tgcttgagcc 77160 caggagttca agaccagctt gggcaacata gtgagaggct gtctctacaa aaaaatattt 77220 aaaaaatagc cgggcatggt gtcacgtgcc tgtagttcca gctgcttggg aggctgaggt 77280 gggaggattg ccagagcctg ggaggttgag gctgcagtga gccatgatca caccacagca 77340 ctctagccta gagcctccct gtgtggcagg ctctacactt cagataggca acagatcgag 77400 accttgtttc acaaaacgaa cagatctgca aagatcaacc tgtcctaagt catataatct 77460 ctttgtgtaa taataaaaac cccatcttct aaccttaaac ctggtatttt tttctacgaa 77520 actatgttct gcagtccaaa ttatttttct ttattatttt gaatcctaaa gtagaaatag 77580 aaacttagaa aaataaaaag caactccttt atgacatatg aggacttttt cagttttaaa 77640 taagaaaaac ccaactcaaa gtagcttaaa taaaaggaga cattttttga cttacataac 77700 ctaaaagctc tggcctggat ctaggtgctc aacagatctc aagagtatct ctcttattct 77760 ctctccctcc cttaccctcc tcctcttttc tctcttctgt atatatgtta ttttcaaaca 77820 ggctctcaca agtagtggca agatatagtt cctaatagct tcaggtttgc attctaccta 77880 ctttagcaac tatgatgaga agagagctac aatttgagca aaaatttgta gggtgagttc 77940 tgatttccct ggattgaggc acatgcctat tattcctgaa ccaaatattc tgtccaggga 78000 atggaattct ctggggcatg tatctaaagc tgaagtgtag agcctgccac acagggataa 78060 taatagtttt ccaaagaaaa atcaaggagg ggaaagaatg ttggaaagag aaaaaaatat 78120 cagttgtctg cttcacattt gttctcaata attagtttca tagaagtgaa atactgtgta 78180 acaccctaaa ctttagagat tcttcgtaga caggaaaaat aagaactcaa tgaagttgtg 78240 acttcattca aatcacgtag tttatataca tgctattagt aaaacccagg acagctgagt 78300 acaagtttta cccttatatt cacattgagg tccagatcct ggttttgaat gagataatta 78360 cgtgcagtcg gactgttttc tgatcctaaa aatagagaca ataatatcta tcttgtaaag 78420 ttatggtagt gttaaagata tataaaatgt tggcaagtac cttaatatac aataactact 78480 gctatatgtt gtcattgtaa taataatcat atttcttcct ttgttgaatt gctttcctgt 78540 agtaatctta ttgtgatcat cctgaaacat agatttccga gcttcaagca aacactatta 78600 tgttgaaaaa tctacattat ttctaagttt agcagtgcca gtggaaagtt tattgaaata 78660 2013203064 09 Apr 2013 182 of 771 gaaaattact tttttaactg aggagtgtag attgtgaatt cgtgattcat cttcttagga 78720 gatgatcgga atattgataa atattgatgc atagaatatg aacaaaacat tacatatctt 78780 gtgctgtgat attaaagtag tattctgttc tggtagtagt atggcagtat tttaggtctg 78840 aaagatgtac ataatctgta ctttgaagtc tgttttttaa gagattaatc acaagagatt 78900 tacataaaac aactaaggtt aaaaataaat ggtggattag agatacatca ggcaaatttc 78960 aatttcaaaa gcagatgaca gaatctcagt atcagggtag catttaaagc aaaaagcatt 79020 aaactggatc aaaaatgtca ttttacatca acacagggta cactccaggt aaagacttaa 79080 cagttatgaa cgaatgtgct aaacatcaaa atgtattaag taaaagctga aagaaatgaa 79140 gaataattgg tagaaaagca atgataggaa tccttaatgt acttcaaaag gcacgaagta 79200 agaaggtaca gtcatgtacc acataatgat gtttgagtca acacctgacc tggtatacga 79260 caatggtcct ataaaattat aatggagcta aaaagcttct atcacctagt gatgttgaag 79320 ccgttgcaat gcaatgtatc actcacatgt ttgtggtaat gctggtgtaa gcaaacttac 79380 tgtactgtca gttgtataaa agcatagcac agttatgttc agcacataat actttataat 79440 gataaacgaa tatgttacta gtttacgtgt ttacagtact attattttag catgtgcttc 79500 tgcttattaa aaaatgttaa ctataaaata atctttaggc agatcctaca ggaggtattc 79560 cagataaagg cattattgtc ataggagatg gcagctccat ggatgttatt gccccttaag 79620 accttccagt gggacaagat gtataggtgg aagacagtga tattgatgat cctgaccttg 79680 tagaggccaa ggctaaagta tgtatttatt agtttttaac aagagtttaa aaagtaaaaa 79740 aaaaaaataa atttaaaaat agaaaaaatc ttaataagga tacaaagaaa aaatgttttt 79800 gtgtagctgt gtaatatgtt tttgttttaa gttaaatgtt acaaaagagt cagagttaaa 79860 tttttttata tttataaagt gaaaaagtta taaaatgcta aggttaattt actgaagaaa 79920 gaaaaaattt ttaaacagat ttagagtagc atgtttataa aatctacagt agtttacagt 79980 aatatcctag gccttcacat taactcacca ctcacccact gactcaccca gagcagcttc 80040 caatcctgta agctccattc gtggtaagtg ccctatacag gtgtacaatt tttatatcct 80100 ttataccatt tttactgaac cttttctgtc ttttagatac acaaataaca ttgtgttaca 80160 gttgcctatg atattgaata cagtaactta ctgtacaagt ttgtagcata ggagctgtat 80220 catatagcct gggtgtgtag tgaactatac catctaggct tgtgtaagta tattttatga 80280 cacagtgatg aaatcatcca gatacagttt ctcttaagca acacataact gtatatatat 80340 atatataggt ggctttaata ataaaataat gaaatatatt tctttttttc tgtcattgac 80400 aaaacaatta ccagtcttac taattagatc aactgcaaaa caaaatctca ctcaaaaata 80460 2013203064 09 Apr 2013 183 of 771 aaaatatgta agtcccattc cttgattaca attcattaga actggagatt tttaaaaatg 80520 tttaaattta tatggaaata taaaatcatg ttttaaataa tttttgattc aatgaggaaa 80580 tgtaaattta gaactaaaga ttaataacta gagatttata aaggcaaaaa tgttaatgaa 80640 ttaggaaaca gtaaaccatt tgaactaatc taaatactga ttgcatgaaa atgccaataa 80700 aatcaataca tatttttaaa agccagtcaa ggataaaaga aaagagggaa actaaaagtg 80760 agacattaag tatgagaaag gagataaaac taaagtgtgg aggtgatgtt aaaaattata 80820 ttcaggtctg tgctaatcat tttggaaatt tcagtgagaa gtgggcaatt ttcagtgaat 80880 atatcattgt aaatgctttg aggagagaca aaatctgaat agaccctgca ataatgaaaa 80940 tgtctaggag ccctcaagaa atacctggtt taaattgcat ttcaggtggc tggttatcac 81000 accttgaagt atcaagtaat tatgttatct aaattggacc aggtgttaga aaaatatgtg 81060 agacttcaca ggtggctgct tatgtagccc ttatacctta atctgataaa ggtagcatat 81120 atttaaaaag agagaaaacc agaaggtaca atttagggaa aattaaatac ttctatttgg 81180 ccaaagtaag agtacattca agggaattgt gagaggtaag agtggaaaca gaggttggag 81240 ctgtattttt atgctgtgat tgaattacag tgtgtgataa atattgctct tatttgggta 81300 gattaccatt taacattttg aattaattgg taattggatt aatcttaact tttaaaaaac 81360 taatctgaga gtggtataaa ggatagatta cagaatggat aaagggtgat aaatcagttg 81420 gctatggcaa aattgcagga agaaactgaa ataggccaca gaaaactgaa actgacattt 81480 tgagtagtat ttcagaatca agatctggat tttggcaact gaatagatgc gtaggaatca 81540 aagatgagta tactaaatga acttaatcta tgatttgtct gtcattttat tgtgtaccat 81600 tagtgtgtat gcatgtatgt atgtgccagg tagttaatag gctgactgtg tctcttagct 81660 ccactctgct gcctgggcct ttgccatagt gctggagttc cctcacttct cttttctgta 81720 accctattat attactgctg tctctcagct gtgtttcatt cctcaagcag aaagaagatg 81780 ggaggatcat atagtagttg actagaagct gtggagtttg agtgctggga ttatatctag 81840 ttccattact tatgaagatt atatctagtt ccattacttc acctcatcta taaaatggtt 81900 taccaatagt acctacctta catggtttta tgagtattaa attatgtatt tctaaagaca 81960 tttagaacaa tacaaagaat atagtgtggg ctcaataagt gacgatggtg ttagttatta 82020 gaaggccatc gagtgctgga gaaaataatt gaatatcatt gatggaaata aaggaagttt 82080 tccacgttaa aaagcttcgg tttttggaaa tgtgtgtttt cagtatttct gagattacca 82140 ggtagaaatt ccagccagat gttggaattc tgcactggca gttgggaata aagtcatgtt 82200 aaaggagata agttttggag ttattgtgta aaattggtaa agcactggaa tagattggtt 82260 2013203064 09 Apr 2013 184 of 771 tgacagaggg gaaactcttt ttgagatagg cctatattta gggacaagag aagagacaac 82320 caataagggt tgaaagaaac cttgagagag taagtcctat gacagaagca gggaagtttc 82380 agaatgattg cagaaagatc agccaggctc ttcctgttct ccatcgtggt gcaggatcaa 82440 ggtgaaaagg ataaccccat gcaggaattt tgcatctgca ggctccgctt caacatctgt 82500 ttaggagaaa gtggagacag actgacctga gtaactaagg tcttggaaca gcttacaggt 82560 cagaaccagg tgttttccaa agctagatat actgttagcg cctttggcaa cagaagaaat 82620 gaaaagactg ttgtctgctg cacagttcga ggggccaagg cagacgaaat cctggagaat 82680 gatctaaagg tgcaggagtg tgagttaaga aaaaataact tctcagatac tggaaacttt 82740 ggttttggga cccaggaaca cattgatctg ggtatcagat atgacccaag cattgatgtc 82800 tacagcctgg acttctatgt ggtgctggaa aagccaggtt tcatcattgc aggtaagaag 82860 tgcgggacag gcttcattgg tgccaaatag aatcagcaaa gaggaggcca tgcgctggtt 82920 ccagcagaag tatgatggga tcatccttcc tggcaaataa attctcattt ctacccaaaa 82980 gggtaataaa aagttttcag tgaaatgttt aaaaaaaaaa taaaaaaaag atcagccagc 83040 agccaggatg ggattgtgaa aacagcagga aattagttgt tgacaaagca ttaatgacca 83100 ttaagaaatc agcctcggct gggcatggtg gctcatccct gtaatcgtaa cactttggga 83160 ggccaaggca gatttcttga gtccaggagt tgagaccagc ctaggcaaca tggcaaaacc 83220 ctcgttcctc cttaataaat aaataaatga ataaataaac aagcaagcaa gcagggcttg 83280 gtgttaggcg cctgtactcc tagctactcg ggaggctgag ggggttgaac ctgggaggca 83340 aaggttgcag tgagccaaga ttgcactact gcactccagc ctgggtgaca gagtgagacc 83400 atggcacccc cctccccttc aaaaagaaat cagcctcata atcaatttct ctggattaag 83460 gagtaagagc gtctcaagat ttgctgttta tagagaggga ggctaatagt ttgagagaga 83520 tacagaatct agggagagtg tgggtttttg gtctttcagt tgtttgccag ccttggataa 83580 agaatgaaga ttacttgagc atattattta gagacaagtg gagagaataa aggcacatgc 83640 cagataggag ataattaata aagcacttgt ccaaaataga aacttgttga acaggaagag 83700 acgtcaagta taaggagatt ttaagatggg agaagggaat tttgagtgtt tgtattggat 83760 gacctcaggg ttcccagtaa agcaggagct gaattcatcg aaggtgatgt gttggtcagg 83820 atcaagagag aggttgggag aacaaagtgc taaaatcgtt gtggtcaaga gtttaaaaag 83880 tgtataccag aagagttatt gagtgatagg ggtttgaaat aggcaaagct gtaggaaagg 83940 gggctggaag gaatattagg aggaacacta aatatacttc tgaggtctac ctcctggtct 84000 gtgaacataa aggagctgaa agagtaatgg ctgaagttct ttagtttagc taaagttttt 84060 2013203064 09 Apr 2013 185 of 771 tagctaaagc tagaattgtt gaaagttgta tttgaggaaa aaaagttaag gatacagttg 84120 accgttcgat aatgtagccc actgttgacc agaagcccta cccacaacat aaacaggcaa 84180 taacacatat tttgtatgtg tattatatag tatattctta acaataaagt aaactagaga 84240 aaagaacatg tatcaagaaa atcataagga agagaaaaca catttacagt actgtactgt 84300 atttattggt accatacatt tatgttgctg tttacaagat gaagcatctg tctgaaatgg 84360 ccagcagcta cagctgtacc tatctactgt acatatcaag caagtcactt tattcttata 84420 atgtctatga cttctttctt tgaaagcgct tccatcatca ctgttggcac ttcatatggg 84480 tctcatggtg ttaaggttta cggcattgca ctagacacaa tgaaaactac acaagagggc 84540 cgggcacggt ggctcacgcc tgtaatccca gcactttggg aggccgaggc gggcggatca 84600 tgaggtcagg agattgagac catcctggct aacacagtga aaccctgtct ctattaaaaa 84660 taaaaaaatt agccaggcat ggtggcacgt gcctgtaatc ccagctaatc gggaggctga 84720 ggcaggagaa tcgctttttc ccagaaggcg taggttgcag tgagccgaga tcgtgccact 84780 gcactccagc ctggatgata gagggagact ctgtcgcaaa aaaaaagaaa agaaaaagaa 84840 aagaaaagaa aaacacacaa gagccgtgag agagatagct tttgattgca atacacaatt 84900 tactggagag atgagctgat catacagaga tgattagtgt cacacagtgt tttaaacaga 84960 ttcttgcaac cctggagttc actgcagtag caacagaagt tagctatgag attttaacag 85020 tagtatagta tgtactacag ttaatattag gtagctatga tttaatgctg catctttgca 85080 tttgtttaca tttatcttga ctacaagtgg tattatgtct ggtcttaagg tttgtgtgca 85140 tatgttttga tgaattttaa ctttttataa taggtttgtg tatattttat ggcagtaaat 85200 gataaaacag actaatctac atatatttta tgtagtcatg acataaacct aactttttct 85260 taactttttg atatttctag tctatgtgtt tcatctgcag gttttttcaa attgttgaaa 85320 tctctgaaaa attttattga aaaaaaatcc atatatgtaa gtggacccac acatttcaaa 85380 cctgtgttca agggtcagct gtgtaaataa ttttcctcaa aattaaagtg gaaaaggaga 85440 gttactacta gtagaaagta gaactgtacc cttgggcagg ggtgtgtgtg tgtagttaaa 85500 gatcaattta acttaaaagg tcttggttag agaataaaaa ctggccctta ttagctttaa 85560 tttacatgaa aaatgaaaaa ttttaggcca ggcacagtgg ctcaggcctg taatccctta 85620 actttgggag accaagggga gtggatcact tgaggtcagg agttcaagac agcctggcca 85680 acatgctgac tcacccttcc ctactgaaaa tacaaaagtt agccaggcgc agtggccatc 85740 cctacagtgc tagctactcg ggaggctgag gcaggagaat tgcttgaacc cgggaggcaa 85800 ggttgcggtg agctgagatc gcaccactgc actccagact gggtgacaga gcgagactcc 85860 2013203064 09 Apr 2013 186 of 771 atctcaaaaa aaaaaaaaaa aaaaaaagat ttgaaaacag agtatttttt aatctgcaag 85920 agctttacag ccttttattc atatgtataa gcttttaaag atgactaaaa ttttagtgtg 85980 gactttccac tcattggaaa tcctatattg caggtgttaa ttcaatttta gtgagtgtgc 86040 atcatggctc agagagatag gactagaatg aggaggtcac attggagact ctgaaacaga 86100 tacatgtgag cctcccaact ttttaatatt tgttaatcta gaagtgttga attttgggtg 86160 ctgacaaggc agcaggtaga taagaattgc aaagttaaga aaatagactg taatattgat 86220 ggtaaactaa ttgattaaat tttaaaatgt acttttccat gtttttcttt gaattgtcag 86280 taattttgtt tcaactggta ttcatacata gattattcac ccaatgttga caactagtag 86340 atttatatat tttttatgtt gcctatcctt ttttgggtaa ggattaacag aatgtataat 86400 cacctacatt ataggtacac tactaatcac ttgctacttg aaaaaaccta aagctttgaa 86460 atctttttat tattgcacac aaacttatgc caaaaatgga gataaagaga aaaatgtcat 86520 ccactaaacc ccaacaaata atgttgacaa tgtggtctac tcgtagactc gcattgactt 86580 aattttttta aatcttattg catattttga ctagataata aatgcatatg gttaaaaaat 86640 tcacatggtt caaaaaagta cacctcccac tcatcttcca tgtgatattt cctttctgct 86700 tagcaattct gtatttatct tgctaaacat gaatgacagt tgtttgctga aattacatta 86760 aatgtgacgt aataaaatca ttgtaagttt acatttttta actttaataa tttttaatgt 86820 tttaatgaag agtatgaaga gtagtagtac tgctcttcaa agtactacta ctttacctta 86880 ccttttactg ttttgttaag aaaattaggc cgggcgcagt ggctcacgcc tgtaatccca 86940 gcactttggg aggccgagac gggcggatca cgaggtcagg agatcgagac catcctggct 87000 aacacggtga aaccccgtct ctactaaaaa tacaaaaatt agccgggcat ggtggtgcgc 87060 gcctgtagtc ccagctacac gggaggctga ggcaggagaa tggcgtgaac ccgggaggca 87120 gagcttgcag tgagccgaga tcgcaccact gcactccagc ctgggcgaca gagcgaaact 87180 ccgtctcaaa aaaaaaaaaa aaaaaaagaa aaaagaaaat tatatagaaa taaaattcca 87240 gctattccaa aactgcacct tgaatacagg tacagaattg ctaaaaccgt gtaccatttt 87300 gtagttttag catgcttttg tgtaactgca tctggtgttt gatcctcatg agagccctgt 87360 taaggaaggg tacatattat tgtcctcatt ttccttcgaa aacacatcag agtttgtatt 87420 ttgactgtca gcattcaaat acaagtcttt tatttataaa attttggtct ttatactgtg 87480 gctaaaaatc ttaaatcact tgtcatgatt tgaaatggtt tataccgatt ttttttgaca 87540 tttatacaca catacacata tttttaaatt gtctataata aaatcatgct catctttgaa 87600 aaaatattag gagtactaca gtggatacct acatacttgc tattcagcat acctggtttt 87660 2013203064 09 Apr 2013 187 of 771 ttgtttgttt tttgagacag tcttctctgt ggtccaggtt ggagtgcagt ggcacgatct 87720 cagctcattg caacctccgt ctcccaggct caagtgattg tcctgcctca gcctcccaag 87780 tagctgggac tgcaggtaca catcaccacg cccagctaat tttttgtatt tttggtagag 87840 acggggtttc accatgttgg ccaggctggt ctccaactcc tgacctcaag tgatcagccc 87900 acctcggcct cccagagtgc tgggattaca ggttgtgagc cactgcacct ggcctgtttt 87960 taaattcaca taaatatgtt ttatattttt cattagggag aagaaggttg tgtctacaat 88020 ttttaagaca ttggggagat ttagatgcca gtagtaactt aaaagagaaa taattgcaaa 88080 ttctttttcc tcttgagtat actttcattt aaggtacagt gttctgtaag ttacttttac 88140 cgttaaactt cttaatgttg cttattgttt gtcttacatt tttaggttgg atttttctta 88200 agtcacatgt ctaataaaaa aaacccttaa atacctcatt tattcgtctt cgttagtgaa 88260 tgcattgttg tacatattag atttttctct ttagataact cagcttcccc tattaagtgc 88320 cacatgtatt acaaaatttt atttatgttt tattgtttaa taaactcttg agaactagat 88380 acattttaat catttgtaat acttacattt tctaaaacac ttcatttttc cctggtttct 88440 tcaacaaaga gatgcatgta gtacaaggat agctttacct gtgttagaag attgtttcac 88500 acatttacat caactgcata gtcctgtttt tgttgggccc taatgccagc atcacttttt 88560 gctactgctg tttctgcctt aaaggcaata tgcctctgtc tagtttgctg attctgatac 88620 tctttcccct ggaaagtagg taatcaagtt tgtgaggagc tgtgtgttta aggagtccat 88680 aaatccttgt ggggagccct aggtgtatag agcatagctg tagggcagag gcctttgaca 88740 cttattctgg atatgcagtg gcctttgcct atggggttca tgggtcagag cgctgttgtg 88800 acctttgaat aaatgggttg ttatgataat tgttttaagg gaggagagtt attctgatat 88860 cctttgtatt gatattgctc ttatttatta ttgagctgga tttaagtatt aatcatttaa 88920 ggtcaaattt ctaatgtata tatgttctta aatggctacg acccagttac catagcaatt 88980 tagtgaaata actataatgg aacatttttt ttcaatttgg cttctctttt ttttctgtcc 89040 accagggagt aactattccc agtcagaggc gctatgtgta ttattatagc tacctgttaa 89100 agaatcatct ggattataga ccagtggcac tgttgtttca caagatgatg tttgaaacta 89160 ttccaatgtt cagtggcgga acttgcagta agtgcttgaa attctcatcc ttccatgtat 89220 tggaacagtt ttcttaacca tatctagaag tttacataaa aatttagaaa gaaatttacc 89280 acatttgaaa tttatgcagg agactatatt tctgaagcat ttgaacaaat taattagctt 89340 tgttgttcaa ctcattgggc taaagaagcc aaaagcaatg ggttttaatg tagtcgaagc 89400 caaattatat ttatgaaaga aatattctgt gttataacca ccaaatacag cccaattctg 89460 2013203064 09 Apr 2013 188 of 771 actagatgat ggaagaacct gtcccatcag aggtccagca tgaggtccag cagaggtcca 89520 ccagaggagt tcagcaattt gctgctctta gggcagggat caattcctta atatcttagg 89580 aagactaggt attgacagta atggtgacaa agcaatgaaa aggaaaggaa gaagtgataa 89640 gacgtggcag caagctgaag tatgatgagt aaagaatagg aatcaaagta tgtggagtgt 89700 tagagaaaac ctggatttag atccagattc tagtcctatc tctgtcatta atctattgcg 89760 taaccctgag catatcatct acctctcttt gagtttgctt gtcaataaaa tgaagagact 89820 ttgaaatctg agacttcctg gataagtact aaatacagat tatgtcactg atgtctgcct 89880 ctatttattt ctccctttta ccctaatctc tataagtcta cctcagtcat cctgatccta 89940 ttctacttct ctgatgttgt tgtcagatag gtgtgatcat cctcatcaga tcttttctgt 90000 attcttagag acagataact ttatcaaaga ccacagattt attagtatag catgttaaag 90060 tcttctaaag agtctcattg atgctctttt catctcagta caatttttaa aactgctgaa 90120 tgcaaggtac tgagctgttg gaagtgactg acagatgaat gtaacagatt catagagaag 90180 gaaaaaggaa gaaaaactca tgctcttcct atagtattga tatcagtgta agagccaaga 90240 gaaaggtata aagtatcatg cagatattaa gggaaagaaa acattcactt tagtaatctt 90300 tcctcatttt ctagtttcct cttatgtact atgatttaat actgtagtaa agttttaata 90360 aaatatgagc tatatgtaat taagtgggag gttgtggggc taggcacgag gctcacacgt 90420 gtaaccccag cactttggga ggctgaggca ggcggatcgc ttgatctcag gagttcgaga 90480 ccagcctgga caacaaggtg aaaccccatc tctactaaaa acacaaaaat tagctgggca 90540 tagtggcaca cacctgtagt cccagcttct tgggaggctg aggcaggaga atcgcttgaa 90600 tccaggaggc agaggttgca gttagccgag atcatgccac tgcactgcag cctggacatc 90660 ggagcaagac tttgtcttag aaataaataa ataaatataa aataaaataa atgggaagtt 90720 gtgtatataa attataaatg ctacattcag aaaagctttt gaaggttgtc agacagtttc 90780 ttaaaggaag ttcaccagtt ctttattgaa cattgaagaa aacatacagt ttagactggc 90840 attaaaactg aaagaagtgg ccagacgcag tggtagacgc agtggttcac gcctgtaatc 90900 ccagcacttt gggaggtcaa ggtggatgga tcacctgagg tcaggagttt gagatcaggc 90960 tggccgacat ggtgaaaccc tgtctctact aaaaatacaa aaattagcca ggcatggtga 91020 tgcgtgcctg tagtcccagc tacttgggag gctgaggcag gagaattgct tgaagccgaa 91080 ggtggaggtt gcagtgagcc gagattgcgt cattgcactc cagccagggc ggtaagagtg 91140 aggctccgtc ttaaaaaaaa aataagtaaa taaattaaaa actactgaaa gaagtattac 91200 aggcaatggg aaatagcttg agtggaagtg cagcagaagg aaaaagctgg acaagaatgt 91260 2013203064 09 Apr 2013 189 of 771 agtgtcagag aataggtatg gaacgtgtga gtgactgtta gaggatcttg aatggggata 91320 acagacttga tttcataaat actgagatgt catgataata cttgaggact aaaccatgtt 91380 ttaaggacag ttgtatgcaa agttgtaatc gcaagaggaa aaaatagtgg aaaagaaacc 91440 agtaataaaa cttgccttaa tgcaggtatg ctaagacaat caaatgggat ttcattaatt 91500 ttttatttgc catttatagc caaagatttt gtaaaagttt tgagcccagt caggtgaaat 91560 agtctcagaa agaaagaaaa gtgaatctga gacttggaga cattaatgtt gatattttgg 91620 ttttaaacgt gttttaaatc cggtaaaagt gagcttctca catgacaata ttcagtgggt 91680 acttgggagt atgggttcga atctaggtag gagatatatc gatattttgg gcatcatcag 91740 gaaagggaga gtagttaagc ctttcatata aataatggtg tggcgtttgg gcatgggaag 91800 tcttggagga aaggaagaaa aggagagggt gaggactgag ataagaatgg caacttgggt 91860 ttaggaagaa gaagaggaat caatgtagag aacagatagt gctgaaaaat acagcatctt 91920 ctgtagggat tggcagcttt ttcttgattt ttgtcttaat atttctaaga gatggaaaaa 91980 gctactatat tctagacatt taacagggtt aaaaatgtta ctaaaagatg atcaatgtgg 92040 ttttcattca agactataac aatatgtata tatccaagga aatttaattc tgacttaaaa 92100 aaattgtttt gcttgtatag atttagggac acaagtgtaa ttttgttaca tgcatagagt 92160 gtatagtttc aagtcagggc ttttaggttg tccatcatct gaataatata cattgtaccc 92220 attaagtaat ttctcatctt ctactcaccg tttcaagtct ccactattta tcattccatt 92280 ctttacattc tgattttcat ttactaggtg tattagtctg tttttgcatt gctttaaaga 92340 aatacctgag actgagtatt aaacaggttt aacctgtttt ctttatgaat tcttctttaa 92400 ttggctcatg gttctgcacg ctgtacagaa agcatagcag catctgcttc tggggaggcc 92460 tcaggaagcc tccaatcatg gctgaaggca aaaggggagc atggtgagaa tgggagcaag 92520 aaagagaagg agtggtgggg agaaggtgcc acccactttt aaatgccagc tcacttacca 92580 ccaagaggat ggcccaagcc attcatgtgg gatctgcccc catgattcaa gcttcttcca 92640 ccaggcccca cctctagcac tggggattac aattcaacct gagatttggg agggaaagat 92700 atccaaacta tatcactagg tctggatctt gttatttatt ttttggaaca tagtcatata 92760 tatccaagga tatatattgt agaagtccac agaaccatac taatattgga cttctgctta 92820 gttaggtctt atctatctga aacatgatat tcatattgca gagaagatta ttttctttag 92880 tgattgagga aatctttact acttatacat ttttaatata atactataat atttgaagat 92940 gcacatttta gatgtagttt aattgaaacc tggaaatact attaatttgc tttttaaagt 93000 cctaaaatca ggattatcag attctgaatt aatggagttt aaatcaaaaa gattacaagg 93060 2013203064 09 Apr 2013 190 of 771 cagtttttca gttttattct ggttaatttt atcacagctt tggaatccta ctttgtttat 93120 ttgcttcttg aagttagatt tcccagtgaa atttcagtat cacataaagt cttatgaaat 93180 ggctcattgc actttgaact ttgagtcaag gaagtgaaat ttattgatag attgttggtg 93240 taatatttat cctgtttgtg gtagcttttt tgaataataa gtgtcttaga agaccatgtt 93300 ggagtagcct gcatgctttt atcaaacata ttaattatgt gatggctgat actgctttag 93360 atattacata gaaatagtag taggtgttta ctaaactgga aatttcattt aacttggttt 93420 agctttgcct tgttctcagt cacattgata aaaatgtaag acttttgttt atcttttaga 93480 ataatgacac cttttggtgc tgagaatttt ttgttttata tatatatata tatatacgta 93540 atataaatac aaaatatatt taaatatgta taatatttct catacacttt atgtaacttt 93600 gtgttcctgt ttctctatta tcttggcatg ttttcttcaa atggcacttc ttaacctcct 93660 aaggttaata aatttctttg taatggactt ttgttttcta attcctcagc gtatgacaaa 93720 tgaattatac tttgtcaaat tatttaggta actttcagtt tttgaagtcc tgggatcata 93780 acattcatca gtctttaatt tctgtcatta aggtcattag ctataaatga atttatgagt 93840 agatttaaaa aataaaacat acaatccttc ccttaacaca ctttcccacc atttggttca 93900 actgctagtg taaaagcatg atgaattttg agaagttata ttttaccagt tactttattt 93960 tttaccagtt atttaaaaca gacatgagcc aaagccagaa tacttgttaa tgaaaatgag 94020 gtgttttgga ggaaaggaag gttgtgctgc agtttttact tgaaatctgt tacatttctt 94080 tacagaaatt tcaaatctct tgtttcctgt tatgatggtg gcattatata cctttaaaat 94140 gtgagctata ggaaaatgaa tgatggttaa ttttttaata aatatttaga cttgtgtttt 94200 tgaaattttt tataacattg ttataggttt tatcctcttt ctcttgtgaa catgtagtga 94260 tttgtatttt gtgatctttg ccgcatgcta gagacttaag aatactatag caaatatctg 94320 tcttctttac atttaaaaat ttttcgtgac tactccctgt tgatatctgt cttaaaagtt 94380 acttttgatg tagttcacaa atgtaccaga taattatttc atcgttttta atgcttaaag 94440 tttttatttg tattaggatt tttagtatga ttttaatgtt aaagttttga agttactctg 94500 ccactagaag tctaattttg ggacttacta ttcatgaaat aggaattgac ttttatataa 94560 gtaataggac cttattttga aggttcaaac tggagaaaat cttacattgt ttatattttt 94620 atttcattta tttcagttga tttgcttgag atcaagattg cagatacaga atccatattt 94680 cgtgtatatt gctgatatta atcattaaaa tcgtttttga cagtttgaca gttaaaggca 94740 tttcctgtga aataatactg gtatgtattt aaccatgcag atcctcagtt tgtggtctgc 94800 cagctaaagg tgaagatata ttcctccaat tcaggaccca cacgacggga agacaagttc 94860 2013203064 09 Apr 2013 191 of 771 atgtactttg agttccctca gccgttacct gtgtgtggtg atatcaaagt agagttcttc 94920 cacaaacaga acaagatgct aaaaaaggtt tgtactttac tttcattggg agaaatatcc 94980 aaaataagga cagattaaaa gctatatttt attttatgac atgtaaggaa ctataatttg 95040 ttttctatta gatctgcagg tgttttgctt actctggcat tggtgagaca ttataagggt 95100 aaataatcct gtttgaagga aaaggcctta tggcattgta acatgagagg aatttttctt 95160 aacaaggatg gttaactgag aagaaattag catgggacca atattttaaa aattttggtc 95220 tataggtaga aatgagatct gttctgtggt cttatgtagt gacacaaacc actttttctc 95280 cattttggct tatgtttctt tttctttcct tttttttttt tttccttttt gttagagaca 95340 gggtcttgtt ctattgccca ggctgagtag ctaagactac aagcatgtgc caccacaccc 95400 agctaatttt ttttattttt atttttgtag ggacagggtc tcactatgtt gcccaggctg 95460 gtctcaaact cctgggcaca agcagtcctc acgctttggc atcccaaaga gttggaatta 95520 caggtgtgcg ccatcatgcc tggccttaac gtttcttaag acttgattat tttctattta 95580 gcttctgtgg atttactgat taatttttta actaggagag aaatcagtat gaagaggaag 95640 taataaagaa tgaaaacatg gtatttaaat gtgcaggttt agaaagttaa tgaagtttga 95700 atttgattga tctgtattta gagaaggcaa cgtcttatta ttttaaaacc aactatccgc 95760 cctgtgcggt ggctcacgcc tgtaattcca gcactttggg aggctgaggt gggcagatca 95820 gctgaggtca ggagttcgag accagcctgg ccaacatggt taaaccccat ctctactaaa 95880 aatacaaaaa aattagccgg gtgtggtggc aggcgcctgt tttcccagct actcaggagg 95940 cttgaggcag gataattgct gaacccgaga ggcggaggtt gcagtaagcc aagaatgcac 96000 cattgtactc cagcctgggc aacaagagtg aaactccatc tcaaaaaaaa agaaaaaaaa 96060 aacaacaact atcttcattt aaaatattaa atgtgaatat ttaaagtgag actaaggtgc 96120 aacattttta gatagtaatg aagaaaagga ctaactttgt agtgttgctg ccttgttaaa 96180 catactagat agcatattgc caatctttaa acattctcaa tgataggatt tatttacttt 96240 ttctgatttt tagcttttct tttgaaagaa aataagagga agtttcattt actgcaaaat 96300 tttaaatgct gctttgatgt atcagtagag atataatttt cctttatcca gaatccaagt 96360 agctggaaaa aaaaatcaaa atatgctgaa cttttttttt tttagccaga aacccatttc 96420 ctatcgtctg tacaaataaa agttaaatat atctcaataa cttagaaaaa ttattttttg 96480 ataatccagg aagtattagc aactgtttta aaattaagat aactagtaag ttttatttag 96540 ctttcaaaaa taggcatcta catcatcatc tctgcatacc tttaggaatt tcctaattct 96600 tatttccctt catctgtact ttaacacatg caaaattgaa ggttagatta aatatttatg 96660 2013203064 09 Apr 2013 192 of 771 atttatttgt ttatccttga ctacataaat ttccatttta ttgattttcc ctgccttatt 96720 taagaatatg ctatgattaa aacacaaaaa attttagtat aacccatata tatatagaat 96780 tcaccttttt gttatttaaa tattattggc ttattttctt ctaagtaaaa tacaattact 96840 ggctaaaata attgaaataa gcaaaaaaaa aattttaaag accttgtata caagattact 96900 ttgccaggta ctgttaaaag atgcaatgac atttaagacg taacatcctt aaggatctta 96960 ttttctgggg gataaaaaac tttaagataa attagaataa aagatttaaa tggcatttta 97020 aggtaccagg taccagataa gatgtcacaa ggctgtatat cattaattgc caaatgattt 97080 atacaggcca gatttctttg ttggtcaata gaggtttaaa gtgatgaact tctgttgtgt 97140 ttttttatta agaaggtatt atcttattag taagaagtga ttttttttaa gaacaagcat 97200 tttataacat caaaagaaat cagtagtact ctttcctacc ccctcatatt tattctgaaa 97260 gtattcaagc attatattgt catgtaagaa actggagctt ctcatgtttg tattgctgta 97320 gaagtaaaca tgtatttgcc atgcgtcatc agggaagttg cactcaccgt ccaagaactt 97380 ttgttaaagt aaatcttgga ataggtagct catttgaaat gtagaaaaaa ttaaatccat 97440 atctgaattt tgtttatatg tatgtacacg taaactaaaa acgtatttaa agctagtatt 97500 agatgagaaa agaggttttt ttacttaaaa ttttaaggca aaagtagttt atcttagatc 97560 ttgtgagatt gtatttttgg tttaaaattt gagaatttga gtgaagaaaa atcatgtgaa 97620 tgaaaatgca acagataact cagattgcct tataatagtc tttgtgttta cctttattca 97680 gaatatcaaa tgatagttta ttttgttgac tttttgcaaa tgtttaacat aggtgacaga 97740 ttttcttttt taaaaaaata aaacatcatt aattaaatat gtcatttcat ttctttttct 97800 tttctttttt ttttttttta ggacaaaatg tttcactttt gggtaaatac attcttcata 97860 ccaggaccag aggaaacctc agaaaaagta gaaaatggaa gtctatgtga tcaagaaatc 97920 gatagcattt gcagtataga gcgtgcagat aatgacaagg aatatctagt acttacttta 97980 acaaaaaatg atcttgacaa agcaaataaa gacaaagcca accgatactt ttctccaaat 98040 tttaaggtca gttaaattaa acattttgtg ggggttgttg acttgtatgt atgtgatgtg 98100 tgtttaattc taggagtaca gctgatgaag aacttgcttg acaagttttt aacttatgta 98160 ttatttcgaa gcagtgttta cgtagcagta acatgaaagt ttctaataaa atacccaatg 98220 tacacagcgt caaaaaagct gcatttttcc ttttcctaat tcttcgttgt ttgctgaaat 98280 ctggggcaaa ggtgcgggag ggggctaaat gactgggata tgaagtagga atgggagagg 98340 aaagaaatag atgggaactc agtcatttgg gaatgattca tatggaatgt ttttactgct 98400 tccactcctg tctgccttcc aatttattct caatccctca gagtgatctt aaaaatagac 98460 2013203064 09 Apr 2013 193 of 771 ttgattgtgt cacttctgtt tacactttat aaggaccttg tgtttttttt tttaccatga 98520 cctacaaggc ccagcataat ttagcacagg gctacctcct acatcagcac tagtcacctt 98580 ctctccttgt ttcttgagat tcagtcatac tggtctttct tcagttcttc aaaatgctaa 98640 gcttctgcct cttctagtct ttccagttat tttccttctc cctgtacctt ttcatctcag 98700 ccttttcccc tgaccttcca tagctatctt catatttcca gccttagctt caatctcata 98760 ttctctgaag tcctttgatt gtcctcccgt tattcttttt ttaaaaatcc tatttcctta 98820 tattgtatct tagaattatt tggtttgttt catttttgcc tatgtgtgat atatgtattt 98880 ctacataggt atatatatct acttatagac aagaattctt cagattaaaa aaatctgatt 98940 tgtaaacatt cccaagtggt tgtttaccat ttttttcttc ccccttccta tttcttattc 99000 tacctgattt tcccctgttc attcaccaca ctcgtttctt tctctttttt actctctctt 99060 aatttttcat tcaattttta taacatgtaa taaatctaac tgtagcgtct gagtattaag 99120 aatattgcta gtaatacttc acctgtaatc ccagcacttt gggaggctaa ggcaggcgga 99180 tcacttgagg cccaggagtt taagaccagc cggccaatat ggcgaaaccc tatctgcact 99240 acaaatacaa aaattagctg ggcatggtgt cgcacacctg taatcccagc tacttgggag 99300 gctgaggcac aagaattgct tgagcctgtg agatggaggt tgcagtgagc cgagatcaca 99360 ccagtgcacg tgcacttcag cctgggcaac agagcaagac tctgtcttaa aaaaaaaaaa 99420 aaaaaaaaaa tatatacaca cacacacaca cacacacaca cacacacaca ctattactac 99480 caatatacat acatatatgt atgtatgtat gtatgtatat tggtagtaat agtaatactt 99540 gggcccctgc acgttttaag tgaaaataga tctaatatta aatgtcttta gcccttaaat 99600 tttttttaag tgttcagaag tttcccttta aaaaaatttt taatatataa taattgtaca 99660 tatttatggg atacagagtg atattttcat gtatgcagtg tgtgatgatc aaatcaggat 99720 aattagcata tggatcacct caaacatttg tcatttcttt gtgttaggaa cattcaaaat 99780 tctgtcttct agctatttga aaatatacag taaattattg ttgactagtt acagttctat 99840 agaacactat aatttattcc tcctgtgtgt aattttttat cttttaacca acatctccct 99900 atcctcccct cccactccct ttcccggcct ctaataacca cactcttatg agctcaactt 99960 ttttagcttc catatatgag tgagaacata cggtatttat ctttctgtac ctgacttatt 100020 ttacttaaca tcatgtcctc cgggctagac attctcttta gaatccacag gtttcctttc 100080 ttttctctaa atctgcattt tgctcagcca ttaactttta aaatgtcttt ttccctttag 100140 ttttattgtt ttctatttta atattgcaag atgttttata tttgtgatta caaataaaaa 100200 ctccattatt agtaaacaaa tacaatgtca tatagtagta agtgctataa aaaatagaca 100260 2013203064 09 Apr 2013 194 of 771 ggatagaaag taatcttggt ttgtatgttt tttgtttttt agcaaagatg attagagaag 100320 gcccaaccaa gcagataaca tttaagcaga ggcctaaatc atataagtga gttatacaaa 100380 tatctgggaa aagagttaag agtacagatg caaaagccct tagacaagag aatgagcttg 100440 gtatatctga agagtggata agtcattttg actgaaacag agtggacaag aaaaccagtc 100500 caagtgtaaa gacactagtg tgtgttcagc ataggaagga tgtaatctga attttgtgtt 100560 taatattccc tgtgttcatg ctttcaaaat acagatgagt gaggaaagta gggagaaggg 100620 gtaataaagg aagctgagag atcagttaag aggtacttga atagtttagt aaagatgaga 100680 gaagatgttt gcttcttgtt gcccctcact gcttagaata gtggcagtga agggtaacaa 100740 gaagctgtca gattaactta aagagtttac tgatgcagtg gatgttggtt gtaagagaag 100800 aattgataat gactcttgga taatagggga gggaggggct gtcaatataa tataatgaag 100860 aagggatttg aagtcatttc tgatttaaat ctcacatcca ctacctactt ttaatagata 100920 tgtagccttt aacaagttcc ctaacctttc tgggccttag ctacctcccc ttggaaatgg 100980 aaatacctaa catgtaaggt tgttttgaca gttattttca ctaggcatgt aaaggcactt 101040 gactctctgt tatagaccac tgtattatgt taatgtccct ctccttcctc cctttaggta 101100 aagtttttag ggctaataaa tcccaaatat caatgttgat cagtagtttg tgtttgtgta 101160 gtgttgttta tatcaaaaac tacattgaag ccgggcacag tggttcacgc ctaaaatcgc 101220 aacactttgg gaggccaagg tgggcctccc accttgaact aaggagtttg agaccagcct 101280 gggcaacatg gtgaaatccc atctctacaa aaaatataaa agctagctgg gtgtggtggc 101340 atgcacctgt agtcctagct acttgggagg ctgaggttga tcctgggagt ttgagcctgc 101400 agtgagctgt gaagatgcca ctgcactcta gtctgggtga cagagcaaga ccctgtctca 101460 aaaacacaca cacacacaca cacacacaca aagaaataca ttgatttttc acataggtag 101520 taagagaaac attctttttg aactcagctg tttgtgaatt gaattttgta attcaaatgc 101580 tatattatgt aaactattga tgactttcaa tctgcattta ttttgtataa ttatttagtt 101640 aatatttgcc acttatattc cttaaaaaat aaaattgagg ttgggcgtgg tggctcacac 101700 ttgtaatccc agcactttgg gaggctgagg caggcagatt gcctgagctc aggagtttga 101760 gatcagcctg ggcaacatca tgaaccccat ttctactaaa atacaaaaaa ttatctgggc 101820 atggtggtgt acacctgtag ccctagctgt ttgggaggct aaggcacgag aattgcttga 101880 acccgggagg cagaggttgc agtgagccaa gatcatgcca ctgcactcca gcttggcaac 101940 agagcaagac tcttgtctcc agaaataaaa ataaataaat tgtattaaca tcctgatagt 102000 ttatctgttt agtacctagc aagaaagaaa atgttgaaca tcttaagaag agggtcattt 102060 2013203064 09 Apr 2013 195 of 771 aaaaggcctc ttaaagatca tgtttgttac agtgcttaaa aattaatatg ttcatctgca 102120 aaatggaata aaaaatctgt taaaaatata tttcactaaa tagtttaaga tgagtcatat 102180 ttgtgggttt tcattttaaa ttttctttct ctaggtgaag ctgtacttca caaaaacagt 102240 agaggagccg tcaaatccag aggctagcag ttcaacttct gtaacaccag atgttagtga 102300 caatgaacct gatcattata gatattctga caccactgac tctgatccag agaatgaacc 102360 ttttgatgaa gatcagcata cacaaattac aaaagtctga attttttttt atcaagaggg 102420 ataaaacacc atgaaaataa acttgaataa actgaaaatg gacctttttt tttttaatgg 102480 caataggaca ttgtgtcaga ttaccagtta taggaacaat tctcttttcc tgaccaatct 102540 tgttttaccc tatacatcca cagggttttg acacttgttg tccagttgaa aaaaggttgt 102600 gtagctgtgt catgtatata cctttttgtg tcaaaaggac atttaaaatt caattaggat 102660 taataaagat ggcactttcc cgttttattc cagttttata aaaagtggag acagactgat 102720 gtgtatacgt aggaattttt tccttttgtg ttctgtcacc aactgaagtg gctaaagagc 102780 tttgtgatat actggttcac atcctacccc tttgcacttg tggcaacaga taagtttgca 102840 gttggctaag agaggtttcc gaagggtttt gctacattct aatgcatgta ttcgggttag 102900 gggaatggag ggaatgctca gaaaggaaat aattttatgc tggactctgg accatatacc 102960 atctccagct atttacacac acctttcttt agcatgctac agttattaat ctggacattc 103020 gaggaattgg ccgctgtcac tgcttgttgt ttgcgcattt ttttttaaag catattggtg 103080 ctagaaaagg cagctaaagg aagtgaatct gtattggggt acaggaatga accttctgca 103140 acatcttaag atccacaaat gaagggatat aaaaataatg tcataggtaa gaaacacagc 103200 aacaatgact taaccatata aatgtggagg ctatcaacaa agaatgggct tgaaacatta 103260 taaaaattga caatgattta ttaaatatgt tttctcaatt gtaacgactt ctccatctcc 103320 tgtgtaatca aggccagtgc taaaattcag atgctgttag tacctacatc agtcaacaac 103380 ttacacttat tttactagtt ttcaatcata atacctgctg tggatgcttc atgtgctgcc 103440 tgcaagcttc ttttttctca ttaaatataa aatattttgt aatgctgcac agaaattttc 103500 aatttgagat tctacagtaa gcgttttttt tctttgaaga tttatgatgc acttattcaa 103560 tagctgtcag ccgttccacc cttttgacct tacacattct attacaatga attttgcagt 103620 tttgcacatt ttttaaatgt cattaactgt tagggaattt tacttgaata ctgaatacat 103680 ataatgttta tattaaaaag gacatttgtg ttaaaaagga aattagagtt gcagtaaact 103740 ttcaatgctg cacacaaaaa aaagacattt gatttttcag tagaaattgt cctacatgtg 103800 ctttattgat ttgctattga aagaataggg tttttttttt tttttttttt ttttttttta 103860 2013203064 09 Apr 2013 196 of 771 aatgtgcagt gttgaatcat ttcttc 103886 <210> 16 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 16 ccggaggtgc ttgaat 16 <210> 17 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 17 cggaggtgct tgaa 14 <210> 18 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 197 of 771 <220> <223> Synthetic Oligonucleotide <400> 18 gaagccatac acctct 16 <210> 19 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 19 aagccataca cctc 14 <210> 20 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 20 gttgaagcca tacacc 16 <210> 21 <211> 14 2013203064 09 Apr 2013 198 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 21 ttgaagccat acac 14 <210> 22 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 22 cctcagggtt gaagcc 16 <210> 23 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 23 ctcagggttg aagc 14 2013203064 09 Apr 2013 199 of 771 <210> 24 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 24 tttgccctca gggttg 16 <210> 25 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 25 ttgccctcag ggtt 14 <210> 26 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 200 of 771 <400> 26 agttcttggt tttctt 16 <210> 27 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 27 gttcttggtt ttct 14 <210> 28 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 28 cctcttgatg ttcagg 16 <210> 29 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 201 of 771 <220> <223> Synthetic Oligonucleotide <400> 29 ctcttgatgt tcag 14 <210> 30 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 30 atgcccctct tgatgt 16 <210> 31 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 31 tgcccctctt gatg 14 <210> 32 2013203064 09 Apr 2013 202 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 32 tgccacattg ccct 14 <210> 33 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 33 ttgccacatt gccc 14 <210> 34 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 34 2013203064 09 Apr 2013 203 of 771 gttgccacat tgcc 14 <210> 35 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 35 tgttgccaca ttgc 14 <210> 36 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 36 ctgttgccac attg 14 <210> 37 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 204 of 771 <223> Synthetic Oligonucleotide <400> 37 tctgttgcca catt 14 <210> 38 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 38 ttctgttgcc acat 14 <210> 39 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 39 tttctgttgc caca 14 <210> 40 <211> 14 <212> DNA 2013203064 09 Apr 2013 205 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 40 atttctgttg ccac 14 <210> 41 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 41 gtaggagaaa ggcagg 16 <210> 42 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 42 taggagaaag gcag 14 2013203064 09 Apr 2013 206 of 771 <210> 43 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 43 ggcttgtaaa gtgatg 16 <210> 44 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 44 gcttgtaaag tgat 14 <210> 45 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 207 of 771 <400> 45 ccactggagg atgtga 16 <210> 46 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 46 cactggagga tgtg 14 <210> 47 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 47 tttcagcatg ctttct 16 <210> 48 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 208 of 771 <220> <223> Synthetic Oligonucleotide <400> 48 ttcagcatgc tttc 14 <210> 49 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 49 catatttgtc acaaac 16 <210> 50 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 50 atatttgtca caaa 14 <210> 51 <211> 16 2013203064 09 Apr 2013 209 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 51 atgcccatat ttgtca 16 <210> 52 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 52 tgcccatatt tgtc 14 <210> 53 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 53 ttttggtggt agagac 16 2013203064 09 Apr 2013 210 of 771 <210> 54 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 54 tttggtggta gaga 14 <210> 55 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 55 tctgcttcgc acct 14 <210> 56 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 211 of 771 <400> 56 gtctgcttcg cacc 14 <210> 57 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 57 agtctgcttc gcac 14 <210> 58 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 58 cagtctgctt cgca 14 <210> 59 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 212 of 771 <220> <223> Synthetic Oligonucleotide <400> 59 tcagtctgct tcgc 14 <210> 60 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 60 ctcagtctgc ttcg 14 <210> 61 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 61 cctcagtctg cttc 14 <210> 62 2013203064 09 Apr 2013 213 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 62 gcctcagtct gctt 14 <210> 63 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 63 agcctcagtc tgct 14 <210> 64 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 64 2013203064 09 Apr 2013 214 of 771 aactctgagg attgtt 16 <210> 65 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 65 actctgagga ttgt 14 <210> 66 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 66 tcattaactc tgagga 16 <210> 67 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 215 of 771 <223> Synthetic Oligonucleotide <400> 67 cattaactct gagg 14 <210> 68 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 68 attcatcatt aactct 16 <210> 69 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 69 ttcatcatta actc 14 <210> 70 <211> 16 <212> DNA 2013203064 09 Apr 2013 216 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 70 ttgttctgaa tgtcca 16 <210> 71 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 71 actg 4 <210> 72 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 72 actg 4 2013203064 09 Apr 2013 217 of 771 <210> 73 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 73 tgttctgaat gtcc 14 <210> 74 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 74 cagatgagtc catttg 16 <210> 75 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 218 of 771 <400> 75 agatgagtcc attt 14 <210> 76 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 76 atccacaggg aaattg 16 <210> 77 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 77 tccacaggga aatt 14 <210> 78 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 219 of 771 <220> <223> Synthetic Oligonucleotide <400> 78 cagttgtaca agttgc 16 <210> 79 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 79 agttgtacaa gttg 14 <210> 80 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 80 cacagagtca gccttc 16 <210> 81 <211> 14 2013203064 09 Apr 2013 220 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 81 acagagtcag cctt 14 <210> 82 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 82 ggtcaaccac agagtc 16 <210> 83 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 83 gtcaaccaca gagt 14 2013203064 09 Apr 2013 221 of 771 <210> 84 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 84 cagccacatg cagc 14 <210> 85 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 85 ccagccacat gcag 14 <210> 86 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 222 of 771 <400> 86 accagccaca tgca 14 <210> 87 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 87 taccagccac atgc 14 <210> 88 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 88 ttaccagcca catg 14 <210> 89 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 223 of 771 <220> <223> Synthetic Oligonucleotide <400> 89 gttaccagcc acat 14 <210> 90 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 90 ggttaccagc caca 14 <210> 91 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 91 aggttaccag ccac 14 <210> 92 2013203064 09 Apr 2013 224 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 92 taggttacca gcca 14 <210> 93 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 93 aggttctgct ttcaac 16 <210> 94 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 94 2013203064 09 Apr 2013 225 of 771 ggttctgctt tcaa 14 <210> 95 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 95 tactgatcaa attgta 16 <210> 96 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 96 actgatcaaa ttgt 14 <210> 97 <211> 16 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 226 of 771 <223> Synthetic Oligonucleotide <400> 97 tttttcttgt atctgg 16 <210> 98 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 98 ttttcttgta tctg 14 <210> 99 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 99 atccattaaa acctgg 16 <210> 100 <211> 14 <212> DNA 2013203064 09 Apr 2013 227 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 100 tccattaaaa cctg 14 <210> 101 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 101 atattgctct gcaaag 16 <210> 102 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 102 tattgctctg caaa 14 2013203064 09 Apr 2013 228 of 771 <210> 103 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 103 actg 4 <210> 104 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 104 atattgctct gcaa 14 <210> 105 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 229 of 771 <400> 105 aatattgctc tgca 14 <210> 106 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 106 gaatattgct ctgc 14 <210> 107 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 107 agaatattgc tctg 14 <210> 108 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 230 of 771 <220> <223> Synthetic Oligonucleotide <400> 108 tagaatattg ctct 14 <210> 109 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 109 atagaatatt gctc 14 <210> 110 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 110 gatagaatat tgct 14 <210> 111 <211> 14 2013203064 09 Apr 2013 231 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 111 ggatagaata ttgc 14 <210> 112 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 112 atggaatcct caaatc 16 <210> 113 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 113 tggaatcctc aaat 14 2013203064 09 Apr 2013 232 of 771 <210> 114 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 114 gaattctggt atgtga 16 <210> 115 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 115 aattctggta tgtg 14 <210> 116 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 233 of 771 <400> 116 agctggaatt ctggta 16 <210> 117 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 117 gctggaattc tggt 14 <210> 118 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 118 tgaaaatcaa aattga 16 <210> 119 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 234 of 771 <220> <223> Synthetic Oligonucleotide <400> 119 gaaaatcaaa attg 14 <210> 120 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 120 aaacagtgca tagtta 16 <210> 121 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 121 aacagtgcat agtt 14 <210> 122 2013203064 09 Apr 2013 235 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 122 ttcaggaatt gttaaa 16 <210> 123 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 123 tcaggaattg ttaa 14 <210> 124 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 124 2013203064 09 Apr 2013 236 of 771 ttttgtttca ttatag 16 <210> 125 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 125 tttgtttcat tata 14 <210> 126 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 126 gatgacactt gattta 16 <210> 127 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 237 of 771 <223> Synthetic Oligonucleotide <400> 127 atgacacttg attt 14 <210> 128 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 128 gtgtgatgac acttga 16 <210> 129 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 129 tgtgatgaca cttg 14 <210> 130 <211> 16 <212> DNA 2013203064 09 Apr 2013 238 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 130 tattcagtgt gatgac 16 <210> 131 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 131 attcagtgtg atga 14 <210> 132 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 132 attggtattc agtgtg 16 2013203064 09 Apr 2013 239 of 771 <210> 133 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 133 ttggtattca gtgt 14 <210> 134 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 134 cctctagctg taag 14 <210> 135 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 240 of 771 <400> 135 ccctctagct gtaa 14 <210> 136 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 136 gccctctagc tgta 14 <210> 137 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 137 ggccctctag ctgt 14 <210> 138 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 241 of 771 <220> <223> Synthetic Oligonucleotide <400> 138 aggccctcta gctg 14 <210> 139 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 139 gaggccctct agct 14 <210> 140 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 140 agaggccctc tagc 14 <210> 141 <211> 14 2013203064 09 Apr 2013 242 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 141 aagaggccct ctag 14 <210> 142 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 142 aaagaggccc tcta 14 <210> 143 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 143 gaatggacag gtcaat 16 2013203064 09 Apr 2013 243 of 771 <210> 144 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 144 aatggacagg tcaa 14 <210> 145 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 145 gttttgaatg gacagg 16 <210> 146 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 244 of 771 <400> 146 ttttgaatgg acag 14 <210> 147 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 147 tggtagtttt gaatgg 16 <210> 148 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 148 ggtagttttg aatg 14 <210> 149 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 245 of 771 <220> <223> Synthetic Oligonucleotide <400> 149 tcactgtatg gttt 14 <210> 150 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 150 ctcactgtat ggtt 14 <210> 151 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 151 gctcactgta tggt 14 <210> 152 2013203064 09 Apr 2013 246 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 152 ggctcactgt atgg 14 <210> 153 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 153 tggctcactg tatg 14 <210> 154 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 154 2013203064 09 Apr 2013 247 of 771 ctggctcact gtat 14 <210> 155 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 155 gctggctcac tgta 14 <210> 156 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 156 ggctggctca ctgt 14 <210> 157 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 248 of 771 <223> Synthetic Oligonucleotide <400> 157 aggctggctc actg 14 <210> 158 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 158 caggtccagt tcat 14 <210> 159 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 159 gcaggtccag ttca 14 <210> 160 <211> 14 <212> DNA 2013203064 09 Apr 2013 249 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 160 tgcaggtcca gttc 14 <210> 161 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 161 gtgcaggtcc agtt 14 <210> 162 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 162 ggtgcaggtc cagt 14 2013203064 09 Apr 2013 250 of 771 <210> 163 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 163 tggtgcaggt ccag 14 <210> 164 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 164 ttggtgcagg tcca 14 <210> 165 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 251 of 771 <400> 165 tttggtgcag gtcc 14 <210> 166 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 166 ctttggtgca ggtc 14 <210> 167 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 167 taactcagat cctg 14 <210> 168 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 252 of 771 <220> <223> Synthetic Oligonucleotide <400> 168 ataactcaga tcct 14 <210> 169 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 169 aataactcag atcc 14 <210> 170 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 170 aaataactca gatc 14 <210> 171 <211> 14 2013203064 09 Apr 2013 253 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 171 aaaataactc agat 14 <210> 172 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 172 caaaataact caga 14 <210> 173 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 173 gcaaaataac tcag 14 2013203064 09 Apr 2013 254 of 771 <210> 174 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 174 agcaaaataa ctca 14 <210> 175 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 175 tagcaaaata actc 14 <210> 176 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 255 of 771 <400> 176 cagggcctgg agag 14 <210> 177 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 177 tctgaagtcc atgatc 16 <210> 178 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 178 ctgaagtcca tgat 14 <210> 179 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 256 of 771 <220> <223> Synthetic Oligonucleotide <400> 179 tgggcatgat tccatt 16 <210> 180 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 180 gggcatgatt ccat 14 <210> 181 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 181 tggagcccac gtgc 14 <210> 182 2013203064 09 Apr 2013 257 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 182 ttgaagttga gggctg 16 <210> 183 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 183 tgaagttgag ggct 14 <210> 184 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 184 2013203064 09 Apr 2013 258 of 771 accagtatta attttg 16 <210> 185 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 185 ccagtattaa tttt 14 <210> 186 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 186 gtgttctttg aagcgg 16 <210> 187 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 259 of 771 <223> Synthetic Oligonucleotide <400> 187 tgttctttga agcg 14 <210> 188 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 188 agttactttg gtgt 14 <210> 189 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 189 tggtacatgg aagtct 16 <210> 190 <211> 14 <212> DNA 2013203064 09 Apr 2013 260 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 190 ggtacatgga agtc 14 <210> 191 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 191 actg 4 <210> 192 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 192 actg 4 2013203064 09 Apr 2013 261 of 771 <210> 193 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 193 actg 4 <210> 194 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 194 actg 4 <210> 195 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 262 of 771 <400> 195 actg 4 <210> 196 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 196 actg 4 <210> 197 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 197 actg 4 <210> 198 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 263 of 771 <220> <223> Synthetic Oligonucleotide <400> 198 actg 4 <210> 199 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 199 actg 4 <210> 200 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 200 tccatgccat atgt 14 <210> 201 <211> 16 2013203064 09 Apr 2013 264 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 201 ccctgaagaa gtccat 16 <210> 202 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 202 cctgaagaag tcca 14 <210> 203 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 203 gcccagttcc atgacc 16 2013203064 09 Apr 2013 265 of 771 <210> 204 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 204 cccagttcca tgac 14 <210> 205 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 205 ttgaggaagc cagatt 16 <210> 206 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 266 of 771 <400> 206 tgaggaagcc agat 14 <210> 207 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 207 tggatgcagt aatctc 16 <210> 208 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 208 ggatgcagta atct 14 <210> 209 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 267 of 771 <220> <223> Synthetic Oligonucleotide <400> 209 tataaagtcc agcatt 16 <210> 210 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 210 ataaagtcca gcat 14 <210> 211 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 211 aagttcctgc ttgaag 16 <210> 212 2013203064 09 Apr 2013 268 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 212 agttcctgct tgaa 14 <210> 213 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 213 aatggtgaag tact 14 <210> 214 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 214 2013203064 09 Apr 2013 269 of 771 tgtcagcagg at 12 <210> 215 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 215 cagcaggaaa ta 12 <210> 216 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 216 ccagcaggaa at 12 <210> 217 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 270 of 771 <223> Synthetic Oligonucleotide <400> 217 accagcagga aa 12 <210> 218 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 218 gaccagcagg aa 12 <210> 219 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 219 tgaccagcag ga 12 <210> 220 <211> 4 <212> DNA 2013203064 09 Apr 2013 271 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 220 actg 4 <210> 221 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 221 atgaccagca gg 12 <210> 222 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 222 aatgaccagc ag 12 2013203064 09 Apr 2013 272 of 771 <210> 223 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 223 caatgaccag ca 12 <210> 224 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 224 ccaatgacca gc 12 <210> 225 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 273 of 771 <400> 225 accacaagcc aa 12 <210> 226 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 226 tagccgccca ca 12 <210> 227 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 227 actg 4 <210> 228 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 274 of 771 <220> <223> Synthetic Oligonucleotide <400> 228 ccggccacca ca 12 <210> 229 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 229 accggccacc ac 12 <210> 230 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 230 gatgttgctg gc 12 <210> 231 <211> 4 2013203064 09 Apr 2013 275 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 231 actg 4 <210> 232 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 232 cgatgttgct gg 12 <210> 233 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 233 ccgatgttgc tg 12 2013203064 09 Apr 2013 276 of 771 <210> 234 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 234 gccgatgttg ct 12 <210> 235 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 235 tgccgatgtt gc 12 <210> 236 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 277 of 771 <400> 236 ctgccgatgt tg 12 <210> 237 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 237 caggcccaca aa 12 <210> 238 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 238 ccaggcccac aa 12 <210> 239 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 278 of 771 <220> <223> Synthetic Oligonucleotide <400> 239 gccaggccca ca 12 <210> 240 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 240 ccaagccact tg 12 <210> 241 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 241 agagcgcatt cc 12 <210> 242 2013203064 09 Apr 2013 279 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 242 acaggtagag gc 12 <210> 243 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 243 agatcttggt ga 12 <210> 244 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 244 2013203064 09 Apr 2013 280 of 771 actg 4 <210> 245 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 245 tgttccagcc cag 13 <210> 246 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 246 tgttccagcc ca 12 <210> 247 <211> 4 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 281 of 771 <223> Synthetic Oligonucleotide <400> 247 actg 4 <210> 248 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 248 actg 4 <210> 249 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 249 actg 4 <210> 250 <211> 4 <212> DNA 2013203064 09 Apr 2013 282 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 250 actg 4 <210> 251 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 251 atgttccagc cc 12 <210> 252 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 252 tggtgatgcc ca 12 2013203064 09 Apr 2013 283 of 771 <210> 253 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 253 atggtgatgc cc 12 <210> 254 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 254 catggtgatg cc 12 <210> 255 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 284 of 771 <400> 255 actg 4 <210> 256 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 256 tcatggtgat gc 12 <210> 257 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 257 atcatggtga tg 12 <210> 258 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 285 of 771 <220> <223> Synthetic Oligonucleotide <400> 258 ccctcctgtc ac 12 <210> 259 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 259 gccctcctgt ca 12 <210> 260 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 260 agccctcctg tc 12 <210> 261 <211> 12 2013203064 09 Apr 2013 286 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 261 cagccctcct gt 12 <210> 262 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 262 ccagccctcc tg 12 <210> 263 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 263 gccagccctc ct 12 2013203064 09 Apr 2013 287 of 771 <210> 264 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 264 gacgaaggtc tg 12 <210> 265 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 265 gtatttgtcg aa 12 <210> 266 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 288 of 771 <400> 266 ggacaccgtc ag 12 <210> 267 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 267 cagcttcagg ta 12 <210> 268 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 268 catgaccatg ag 12 <210> 269 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 289 of 771 <220> <223> Synthetic Oligonucleotide <400> 269 gcatgaccat ga 12 <210> 270 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 270 ggcatgacca tg 12 <210> 271 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 271 tggcatgacc at 12 <210> 272 2013203064 09 Apr 2013 290 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 272 ctggcatgac ca 12 <210> 273 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 273 actg 4 <210> 274 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 274 2013203064 09 Apr 2013 291 of 771 cctggcatga cc 12 <210> 275 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 275 gcagcccacc tc 12 <210> 276 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 276 agcagcccac ct 12 <210> 277 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 292 of 771 <223> Synthetic Oligonucleotide <400> 277 gagcagccca cc 12 <210> 278 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 278 catgagcttc ac 12 <210> 279 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 279 gcatgagctt ca 12 <210> 280 <211> 13 <212> DNA 2013203064 09 Apr 2013 293 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 280 ggcatgagct tca 13 <210> 281 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 281 ggcatgagct tc 12 <210> 282 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 282 actg 4 2013203064 09 Apr 2013 294 of 771 <210> 283 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 283 gggcatgagc tt 12 <210> 284 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 284 cagcatgagt cc 12 <210> 285 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 295 of 771 <400> 285 ccagcatgag tc 12 <210> 286 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 286 actg 4 <210> 287 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 287 gccagcatga gt 12 <210> 288 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 296 of 771 <220> <223> Synthetic Oligonucleotide <400> 288 ccatggtgaa ga 12 <210> 289 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 289 cacagctgcc cg 12 <210> 290 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 290 acacagctgc cc 12 <210> 291 <211> 12 2013203064 09 Apr 2013 297 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 291 cacacagctg cc 12 <210> 292 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 292 gcacacagct gcc 13 <210> 293 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 293 gcacacagct gc 12 2013203064 09 Apr 2013 298 of 771 <210> 294 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 294 actg 4 <210> 295 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 295 gccggagact ga 12 <210> 296 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 299 of 771 <400> 296 attgaggttg ac 12 <210> 297 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 297 cattgaggtt ga 12 <210> 298 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 298 gcattgaggt tg 12 <210> 299 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 300 of 771 <220> <223> Synthetic Oligonucleotide <400> 299 ggcattgagg tt 12 <210> 300 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 300 gggcattgag gt 12 <210> 301 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 301 actg 4 <210> 302 2013203064 09 Apr 2013 301 of 771 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 302 actg 4 <210> 303 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 303 actg 4 <210> 304 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 304 2013203064 09 Apr 2013 302 of 771 actg 4 <210> 305 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 305 actg 4 <210> 306 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 306 actg 4 <210> 307 <211> 4 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 303 of 771 <223> Synthetic Oligonucleotide <400> 307 actg 4 <210> 308 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 308 actg 4 <210> 309 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 309 actg 4 <210> 310 <211> 4 <212> DNA 2013203064 09 Apr 2013 304 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 310 actg 4 <210> 311 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 311 actg 4 <210> 312 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 312 actg 4 2013203064 09 Apr 2013 305 of 771 <210> 313 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 313 actg 4 <210> 314 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 314 actg 4 <210> 315 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 306 of 771 <400> 315 actg 4 <210> 316 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 316 actg 4 <210> 317 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 317 actg 4 <210> 318 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 307 of 771 <220> <223> Synthetic Oligonucleotide <400> 318 actg 4 <210> 319 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 319 actg 4 <210> 320 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 320 actg 4 <210> 321 <211> 4 2013203064 09 Apr 2013 308 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 321 actg 4 <210> 322 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 322 actg 4 <210> 323 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 323 actg 4 2013203064 09 Apr 2013 309 of 771 <210> 324 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 324 actg 4 <210> 325 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 325 actg 4 <210> 326 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 310 of 771 <400> 326 actg 4 <210> 327 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 327 actg 4 <210> 328 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 328 actg 4 <210> 329 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 311 of 771 <220> <223> Synthetic Oligonucleotide <400> 329 atggggcaac ttca 14 <210> 330 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 330 catggggcaa cttc 14 <210> 331 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 331 acatggggca actt 14 <210> 332 2013203064 09 Apr 2013 312 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 332 gggatgctct gggc 14 <210> 333 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 333 cgctccaggt tcca 14 <210> 334 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 334 2013203064 09 Apr 2013 313 of 771 gatacacctc cacc 14 <210> 335 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 335 agatacacct ccac 14 <210> 336 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 336 gagatacacc tcca 14 <210> 337 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 314 of 771 <223> Synthetic Oligonucleotide <400> 337 gcctgtctgt ggaa 14 <210> 338 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 338 ctgtcacact tgct 14 <210> 339 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 339 cggccgctga ccac 14 <210> 340 <211> 14 <212> DNA 2013203064 09 Apr 2013 315 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 340 ccggccgctg acca 14 <210> 341 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 341 cccggccgct gacc 14 <210> 342 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 342 tcccggccgc tgac 14 2013203064 09 Apr 2013 316 of 771 <210> 343 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 343 atcccggccg ctga 14 <210> 344 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 344 catcccggcc gctg 14 <210> 345 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 317 of 771 <400> 345 gcatcccggc cgct 14 <210> 346 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 346 gtgcccttcc cttg 14 <210> 347 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 347 atgagggtgc cgct 14 <210> 348 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 318 of 771 <220> <223> Synthetic Oligonucleotide <400> 348 tatgagggtg ccgc 14 <210> 349 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 349 ctatgagggt gccg 14 <210> 350 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 350 cctatgaggg tgcc 14 <210> 351 <211> 14 2013203064 09 Apr 2013 319 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 351 cgaataaact ccag 14 <210> 352 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 352 ccgaataaac tcca 14 <210> 353 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 353 tccgaataaa ctcc 14 2013203064 09 Apr 2013 320 of 771 <210> 354 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 354 ttccgaataa actc 14 <210> 355 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 355 gccaggggca gcag 14 <210> 356 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 321 of 771 <400> 356 gagtagaggc aggc 14 <210> 357 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 357 ccccaaagtc ccca 14 <210> 358 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 358 tccccaaagt cccc 14 <210> 359 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 322 of 771 <220> <223> Synthetic Oligonucleotide <400> 359 gtccccaaag tccc 14 <210> 360 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 360 acgtgggcag cagc 14 <210> 361 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 361 cacgtgggca gcag 14 <210> 362 2013203064 09 Apr 2013 323 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 362 ccacgtgggc agca 14 <210> 363 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 363 gccacgtggg cagc 14 <210> 364 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 364 2013203064 09 Apr 2013 324 of 771 cagggaacca ggcc 14 <210> 365 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 365 tcagggaacc aggc 14 <210> 366 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 366 ctcagggaac cagg 14 <210> 367 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 325 of 771 <223> Synthetic Oligonucleotide <400> 367 cctcagggaa ccag 14 <210> 368 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 368 tcctcaggga acca 14 <210> 369 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 369 gtcctcaggg aacc 14 <210> 370 <211> 14 <212> DNA 2013203064 09 Apr 2013 326 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 370 ggtcctcagg gaac 14 <210> 371 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 371 tggtcctcag ggaa 14 <210> 372 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 372 ctggtcctca ggga 14 2013203064 09 Apr 2013 327 of 771 <210> 373 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 373 gctggtcctc aggg 14 <210> 374 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 374 gtgctggggg gcag 14 <210> 375 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 328 of 771 <400> 375 ggtgctgggg ggca 14 <210> 376 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 376 gggtgctggg gggc 14 <210> 377 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 377 tgggtgctgg gggg 14 <210> 378 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 329 of 771 <220> <223> Synthetic Oligonucleotide <400> 378 gagcagctca gcag 14 <210> 379 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 379 ggagcagctc agca 14 <210> 380 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 380 tggagcagct cagc 14 <210> 381 <211> 14 2013203064 09 Apr 2013 330 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 381 ctggagcagc tcag 14 <210> 382 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 382 ccctcacccc caaa 14 <210> 383 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 383 accctcaccc ccaa 14 2013203064 09 Apr 2013 331 of 771 <210> 384 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 384 caccctcacc ccca 14 <210> 385 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 385 acaccctcac cccc 14 <210> 386 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 332 of 771 <400> 386 gacaccctca cccc 14 <210> 387 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 387 agacaccctc accc 14 <210> 388 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 388 tagacaccct cacc 14 <210> 389 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 333 of 771 <220> <223> Synthetic Oligonucleotide <400> 389 tggcagcagg aagc 14 <210> 390 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 390 atggcagcag gaag 14 <210> 391 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 391 catggcagca ggaa 14 <210> 392 2013203064 09 Apr 2013 334 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 392 gcatggcagc agga 14 <210> 393 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 393 ggcagcagat ggca 14 <210> 394 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 394 2013203064 09 Apr 2013 335 of 771 cggcagcaga tggc 14 <210> 395 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 395 ccggcagcag atgg 14 <210> 396 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 396 tccggcagca gatg 14 <210> 397 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 336 of 771 <223> Synthetic Oligonucleotide <400> 397 ctccggcagc agat 14 <210> 398 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 398 gctccggcag caga 14 <210> 399 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 399 ggctccggca gcag 14 <210> 400 <211> 14 <212> DNA 2013203064 09 Apr 2013 337 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 400 cggctccggc agca 14 <210> 401 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 401 ccggctccgg cagc 14 <210> 402 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 402 gccggctccg gcag 14 2013203064 09 Apr 2013 338 of 771 <210> 403 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 403 agttacaaaa gcaa 14 <210> 404 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 404 actg 4 <210> 405 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 339 of 771 <400> 405 actg 4 <210> 406 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 406 gtcgcccttc agcacg 16 <210> 407 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 407 tcgcccttca gcac 14 <210> 408 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 340 of 771 <220> <223> Synthetic Oligonucleotide <400> 408 cgcccttcag ca 12 <210> 409 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 409 actctggacc caaacc 16 <210> 410 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 410 ctctggaccc aaac 14 <210> 411 <211> 16 2013203064 09 Apr 2013 341 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 411 ccatttcagg agacct 16 <210> 412 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 412 catttcagga gacc 14 <210> 413 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 413 tttgggaggt ggtc 14 2013203064 09 Apr 2013 342 of 771 <210> 414 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 414 cacaccaggc agag 14 <210> 415 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 415 ctttacagct tcca 14 <210> 416 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 343 of 771 <400> 416 cactaccttc cact 14 <210> 417 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 417 aacacacact acct 14 <210> 418 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 418 ctcttcaaaa caca 14 <210> 419 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 344 of 771 <220> <223> Synthetic Oligonucleotide <400> 419 gtaattgtgc tgtc 14 <210> 420 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 420 tttttcttcg aatt 14 <210> 421 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 421 cattttcgat agcg 14 <210> 422 2013203064 09 Apr 2013 345 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 422 accttccagg ttca 14 <210> 423 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 423 ataggaagca taaa 14 <210> 424 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 424 2013203064 09 Apr 2013 346 of 771 tcttttaaag aaga 14 <210> 425 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 425 aaggatattt taaa 14 <210> 426 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 426 actg 4 <210> 427 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 347 of 771 <223> Synthetic Oligonucleotide <400> 427 gaacaaaaat taaa 14 <210> 428 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 428 ttccacagat ctgt 14 <210> 429 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 429 tttataaagt aaag 14 <210> 430 <211> 4 <212> DNA 2013203064 09 Apr 2013 348 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 430 actg 4 <210> 431 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 431 actg 4 <210> 432 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 432 actg 4 2013203064 09 Apr 2013 349 of 771 <210> 433 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 433 tactgtgaga aata 14 <210> 434 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 434 actg 4 <210> 435 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 350 of 771 <400> 435 ttccagcttg aaga 14 <210> 436 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 436 gatcagttct catg 14 <210> 437 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 437 actg 4 <210> 438 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 351 of 771 <220> <223> Synthetic Oligonucleotide <400> 438 actg 4 <210> 439 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 439 ttatcaatga tgca 14 <210> 440 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 440 gcatgctgga cagt 14 <210> 441 <211> 4 2013203064 09 Apr 2013 352 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 441 actg 4 <210> 442 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 442 actg 4 <210> 443 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 443 ttgcacctga acta 14 2013203064 09 Apr 2013 353 of 771 <210> 444 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 444 cagaatatat ttct 14 <210> 445 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 445 actg 4 <210> 446 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 354 of 771 <400> 446 actg 4 <210> 447 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 447 actg 4 <210> 448 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 448 actg 4 <210> 449 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 355 of 771 <220> <223> Synthetic Oligonucleotide <400> 449 actg 4 <210> 450 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 450 ataagagatt aaaa 14 <210> 451 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 451 tcccccttct catt 14 <210> 452 2013203064 09 Apr 2013 356 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 452 gggcattgtt aaaa 14 <210> 453 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 453 actg 4 <210> 454 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 454 2013203064 09 Apr 2013 357 of 771 actg 4 <210> 455 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 455 agaactcaca tctg 14 <210> 456 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 456 gagctggacg gagg 14 <210> 457 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 358 of 771 <223> Synthetic Oligonucleotide <400> 457 aagcttcatc ggag 14 <210> 458 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 458 ataatggcat cccg 14 <210> 459 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 459 actg 4 <210> 460 <211> 14 <212> DNA 2013203064 09 Apr 2013 359 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 460 tgctgtccta taag 14 <210> 461 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 461 cacaaaggta attg 14 <210> 462 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 462 atcatttctt ccag 14 2013203064 09 Apr 2013 360 of 771 <210> 463 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 463 actg 4 <210> 464 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 464 actg 4 <210> 465 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 361 of 771 <400> 465 actg 4 <210> 466 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 466 ccattacctt ccag 14 <210> 467 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 467 gcataaacag ggtt 14 <210> 468 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 362 of 771 <220> <223> Synthetic Oligonucleotide <400> 468 actg 4 <210> 469 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 469 actg 4 <210> 470 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 470 actg 4 <210> 471 <211> 4 2013203064 09 Apr 2013 363 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 471 actg 4 <210> 472 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 472 tatgaaagga atgt 14 <210> 473 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 473 actg 4 2013203064 09 Apr 2013 364 of 771 <210> 474 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 474 ttccttaagc ttcc 14 <210> 475 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 475 actg 4 <210> 476 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 365 of 771 <400> 476 actg 4 <210> 477 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 477 actg 4 <210> 478 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 478 actg 4 <210> 479 <211> 4 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 366 of 771 <220> <223> Synthetic Oligonucleotide <400> 479 actg 4 <210> 480 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 480 actg 4 <210> 481 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 481 actg 4 <210> 482 2013203064 09 Apr 2013 367 of 771 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 482 actg 4 <210> 483 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 483 actg 4 <210> 484 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 484 2013203064 09 Apr 2013 368 of 771 actg 4 <210> 485 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 485 gaacagttaa acat 14 <210> 486 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 486 tagagcttcc acttct 16 <210> 487 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 369 of 771 <223> Synthetic Oligonucleotide <400> 487 gagcttccac ttct 14 <210> 488 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 488 tgttggccgt ggta 14 <210> 489 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 489 atgttggccg tggt 14 <210> 490 <211> 14 <212> DNA 2013203064 09 Apr 2013 370 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 490 gatgttggcc gtgg 14 <210> 491 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 491 agatgttggc cgtg 14 <210> 492 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 492 gagatgttgg ccgt 14 2013203064 09 Apr 2013 371 of 771 <210> 493 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 493 ggagatgttg gccg 14 <210> 494 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 494 aggagatgtt ggcc 14 <210> 495 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 372 of 771 <400> 495 caggagatgt tggc 14 <210> 496 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 496 gcaggagatg ttgg 14 <210> 497 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 497 ggcaggagat gttg 14 <210> 498 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 373 of 771 <220> <223> Synthetic Oligonucleotide <400> 498 gtggtgccaa ggca 14 <210> 499 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 499 tgtggtgcca aggc 14 <210> 500 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 500 ttgtggtgcc aagg 14 <210> 501 <211> 14 2013203064 09 Apr 2013 374 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 501 tttgtggtgc caag 14 <210> 502 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 502 ctttgtggtg ccaa 14 <210> 503 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 503 actttgtggt gcca 14 2013203064 09 Apr 2013 375 of 771 <210> 504 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 504 cactttgtgg tgcc 14 <210> 505 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 505 gcactttgtg gtgc 14 <210> 506 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 376 of 771 <400> 506 tgcactttgt ggtg 14 <210> 507 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 507 ttgcactttg tggt 14 <210> 508 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 508 cggtgttgca cttt 14 <210> 509 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 377 of 771 <220> <223> Synthetic Oligonucleotide <400> 509 gcggtgttgc actt 14 <210> 510 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 510 agcggtgttg cact 14 <210> 511 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 511 aagcggtgtt gcac 14 <210> 512 2013203064 09 Apr 2013 378 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 512 gaagcggtgt tgca 14 <210> 513 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 513 cgaagcggtg ttgc 14 <210> 514 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 514 2013203064 09 Apr 2013 379 of 771 acgaagcggt gttg 14 <210> 515 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 515 cacgaagcgg tgtt 14 <210> 516 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 516 acacgaagcg gtgt 14 <210> 517 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 380 of 771 <223> Synthetic Oligonucleotide <400> 517 aacacgaagc ggtg 14 <210> 518 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 518 gctgctgtac atct 14 <210> 519 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 519 actg 4 <210> 520 <211> 14 <212> DNA 2013203064 09 Apr 2013 381 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 520 agctgctgta catc 14 <210> 521 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 521 aagctgctgt acat 14 <210> 522 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 522 gaagctgctg taca 14 2013203064 09 Apr 2013 382 of 771 <210> 523 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 523 ggaagctgct gtac 14 <210> 524 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 524 tggaagctgc tgta 14 <210> 525 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 383 of 771 <400> 525 ctggaagctg ctgt 14 <210> 526 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 526 cctggaagct gctg 14 <210> 527 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 527 acctggaagc tgct 14 <210> 528 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 384 of 771 <220> <223> Synthetic Oligonucleotide <400> 528 cacctggaag ctgc 14 <210> 529 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 529 tcacctggaa gctg 14 <210> 530 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 530 atcacctgga agct 14 <210> 531 <211> 14 2013203064 09 Apr 2013 385 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 531 catcacctgg aagc 14 <210> 532 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 532 acatcacctg gaag 14 <210> 533 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 533 tacatcacct ggaa 14 2013203064 09 Apr 2013 386 of 771 <210> 534 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 534 gtacatcacc tgga 14 <210> 535 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 535 tgtacatcac ctgg 14 <210> 536 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 387 of 771 <400> 536 gtgtacatca cctg 14 <210> 537 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 537 tagcgggtcc tgag 14 <210> 538 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 538 gtagcgggtc ctga 14 <210> 539 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 388 of 771 <220> <223> Synthetic Oligonucleotide <400> 539 tgtagcgggt cctg 14 <210> 540 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 540 ctgtagcggg tcct 14 <210> 541 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 541 gctgtagcgg gtcc 14 <210> 542 2013203064 09 Apr 2013 389 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 542 ggctgtagcg ggtc 14 <210> 543 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 543 tggctgtagc gggt 14 <210> 544 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 544 2013203064 09 Apr 2013 390 of 771 ctggctgtag cggg 14 <210> 545 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 545 tctggctgta gcgg 14 <210> 546 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 546 ttctggctgt agcg 14 <210> 547 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 391 of 771 <223> Synthetic Oligonucleotide <400> 547 tgaacaccgc ggcc 14 <210> 548 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 548 atgaacaccg cggc 14 <210> 549 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 549 catgaacacc gcgg 14 <210> 550 <211> 14 <212> DNA 2013203064 09 Apr 2013 392 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 550 gcatgaacac cgcg 14 <210> 551 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 551 tgcatgaaca ccgc 14 <210> 552 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 552 ttgcatgaac accg 14 2013203064 09 Apr 2013 393 of 771 <210> 553 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 553 attgcatgaa cacc 14 <210> 554 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 554 tattgcatga acac 14 <210> 555 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 394 of 771 <400> 555 atattgcatg aaca 14 <210> 556 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 556 catattgcat gaac 14 <210> 557 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 557 aggttgtgca ggta 14 <210> 558 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 395 of 771 <220> <223> Synthetic Oligonucleotide <400> 558 caggttgtgc aggt 14 <210> 559 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 559 gcaggttgtg cagg 14 <210> 560 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 560 agcaggttgt gcag 14 <210> 561 <211> 14 2013203064 09 Apr 2013 396 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 561 cagcaggttg tgca 14 <210> 562 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 562 ccagcaggtt gtgc 14 <210> 563 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 563 cccagcaggt tgtg 14 2013203064 09 Apr 2013 397 of 771 <210> 564 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 564 gcccagcagg ttgt 14 <210> 565 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 565 ggcccagcag gttg 14 <210> 566 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 398 of 771 <400> 566 aggcccagca ggtt 14 <210> 567 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 567 tgtcattgct ggtcca 16 <210> 568 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 568 tcattgctgg tcca 14 <210> 569 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 399 of 771 <220> <223> Synthetic Oligonucleotide <400> 569 tggccagccg gaactt 16 <210> 570 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 570 gccagccgga actt 14 <210> 571 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 571 gggatgaggg tcagcg 16 <210> 572 2013203064 09 Apr 2013 400 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 572 gatgagggtc agcg 14 <210> 573 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 573 aaggcaaaga ccac 14 <210> 574 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 574 2013203064 09 Apr 2013 401 of 771 ggagcgcagg gtgc 14 <210> 575 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 575 tgcacctcct tgtt 14 <210> 576 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 576 cagcagaccc tgga 14 <210> 577 <211> 16 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 402 of 771 <223> Synthetic Oligonucleotide <400> 577 acatctggca gaggtt 16 <210> 578 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 578 atctggcaga ggtt 14 <210> 579 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 579 caggccagca ggagta 16 <210> 580 <211> 14 <212> DNA 2013203064 09 Apr 2013 403 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 580 ggccagcagg agta 14 <210> 581 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 581 ctcaaacaaa aagtcc 16 <210> 582 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 582 caaacaaaaa gtcc 14 2013203064 09 Apr 2013 404 of 771 <210> 583 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 583 gtggtgacat tggtca 16 <210> 584 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 584 ggtgacattg gtca 14 <210> 585 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 405 of 771 <400> 585 actg 4 <210> 586 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 586 actg 4 <210> 587 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 587 ttggcagtgg tgtt 14 <210> 588 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 406 of 771 <220> <223> Synthetic Oligonucleotide <400> 588 atgttggcag tggt 14 <210> 589 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 589 aggaaatgtt ggcagt 16 <210> 590 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 590 gaaatgttgg cagt 14 <210> 591 <211> 14 2013203064 09 Apr 2013 407 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 591 caggaaatgt tggc 14 <210> 592 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 592 gggcaggaaa tgtt 14 <210> 593 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 593 aaggtaggta ccag 14 2013203064 09 Apr 2013 408 of 771 <210> 594 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 594 accaaggtag gtac 14 <210> 595 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 595 ctttgtggca ccaa 14 <210> 596 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 409 of 771 <400> 596 gcactttgtg gcac 14 <210> 597 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 597 tgcactttgt ggca 14 <210> 598 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 598 gctgcacttt gtgg 14 <210> 599 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 410 of 771 <220> <223> Synthetic Oligonucleotide <400> 599 ggtgctgcac tttg 14 <210> 600 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 600 ggcggtgctg cact 14 <210> 601 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 601 tgaacactag gcgg 14 <210> 602 2013203064 09 Apr 2013 411 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 602 tcttgaacac tagg 14 <210> 603 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 603 cacctcttga acacta 16 <210> 604 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 604 2013203064 09 Apr 2013 412 of 771 cctcttgaac acta 14 <210> 605 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 605 acctcttgaa cact 14 <210> 606 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 606 cacacctctt gaac 14 <210> 607 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 413 of 771 <223> Synthetic Oligonucleotide <400> 607 cctcgaaccc actg 14 <210> 608 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 608 cttctggacc tcgatc 16 <210> 609 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 609 tctggacctc gatc 14 <210> 610 <211> 16 <212> DNA 2013203064 09 Apr 2013 414 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 610 ctgctataca tcttgg 16 <210> 611 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 611 gctatacatc ttgg 14 <210> 612 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 612 cacggtgtac atcacc 16 2013203064 09 Apr 2013 415 of 771 <210> 613 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 613 cggtgtacat cacc 14 <210> 614 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 614 ggacagactg tagccc 16 <210> 615 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 416 of 771 <400> 615 acagactgta gccc 14 <210> 616 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 616 gtcatcgcca atcttc 16 <210> 617 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 617 catcgccaat cttc 14 <210> 618 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 417 of 771 <220> <223> Synthetic Oligonucleotide <400> 618 tcacactgag gtcatc 16 <210> 619 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 619 acactgaggt catc 14 <210> 620 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 620 cgccccgtca ctga 14 <210> 621 <211> 16 2013203064 09 Apr 2013 418 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 621 ccagcaacca gcaata 16 <210> 622 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 622 agcaaccagc aata 14 <210> 623 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 623 caggctgtac aggtac 16 2013203064 09 Apr 2013 419 of 771 <210> 624 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 624 ggctgtacag gtac 14 <210> 625 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 625 gaagctcctc tcagag 16 <210> 626 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 420 of 771 <400> 626 agctcctctc agag 14 <210> 627 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 627 cccagccaat gcccag 16 <210> 628 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 628 cagccaatgc ccag 14 <210> 629 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 421 of 771 <220> <223> Synthetic Oligonucleotide <400> 629 tcaaacagac acttga 16 <210> 630 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 630 aaacagacac ttga 14 <210> 631 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 631 agcactgaac attctc 16 <210> 632 2013203064 09 Apr 2013 422 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 632 cactgaacat tctc 14 <210> 633 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 633 ggatccacca gaatcc 16 <210> 634 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 634 2013203064 09 Apr 2013 423 of 771 atccaccaga atcc 14 <210> 635 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 635 tgatcagtaa ggcc 14 <210> 636 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 636 ggacaaagat gaaaaa 16 <210> 637 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 424 of 771 <223> Synthetic Oligonucleotide <400> 637 acaaagatga aaaa 14 <210> 638 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 638 ggcacgcagc ttggcc 16 <210> 639 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 639 cacgcagctt ggcc 14 <210> 640 <211> 16 <212> DNA 2013203064 09 Apr 2013 425 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 640 tggaccccca gcagag 16 <210> 641 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 641 gacccccagc agag 14 <210> 642 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 642 caaaggcaaa gacc 14 2013203064 09 Apr 2013 426 of 771 <210> 643 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 643 tcacaaaggc aaag 14 <210> 644 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 644 cagtcacaaa ggca 14 <210> 645 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 427 of 771 <400> 645 cgtcagtcac aaag 14 <210> 646 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 646 gctcgtcagt caca 14 <210> 647 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 647 catgctcgtc agtc 14 <210> 648 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 428 of 771 <220> <223> Synthetic Oligonucleotide <400> 648 gggcatgctc gtca 14 <210> 649 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 649 actg 4 <210> 650 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 650 actg 4 <210> 651 <211> 4 2013203064 09 Apr 2013 429 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 651 actg 4 <210> 652 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 652 actg 4 <210> 653 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 653 actg 4 2013203064 09 Apr 2013 430 of 771 <210> 654 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 654 cttgggcatg ctcg 14 <210> 655 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 655 actg 4 <210> 656 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 431 of 771 <400> 656 actg 4 <210> 657 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 657 tgccttgggc atgc 14 <210> 658 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 658 gggtgccttg ggca 14 <210> 659 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 432 of 771 <220> <223> Synthetic Oligonucleotide <400> 659 gcagggtgcc ttgg 14 <210> 660 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 660 agcgcagggt gcct 14 <210> 661 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 661 gtggagcgca gggtgc 16 <210> 662 2013203064 09 Apr 2013 433 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 662 tggagcgcag ggtg 14 <210> 663 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 663 tggtggagcg cagg 14 <210> 664 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 664 2013203064 09 Apr 2013 434 of 771 gcttggtgga gcgc 14 <210> 665 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 665 agagcttggt ggag 14 <210> 666 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 666 aaaagagctt ggtgga 16 <210> 667 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 435 of 771 <223> Synthetic Oligonucleotide <400> 667 aagagcttgg tgga 14 <210> 668 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 668 aaaagagctt ggtg 14 <210> 669 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 669 caaaaaagag cttg 14 <210> 670 <211> 16 <212> DNA 2013203064 09 Apr 2013 436 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 670 aaggagctga ggaaca 16 <210> 671 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 671 ggagctgagg aaca 14 <210> 672 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 672 gcagaccctg gaagga 16 2013203064 09 Apr 2013 437 of 771 <210> 673 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 673 agaccctgga agga 14 <210> 674 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 674 accagcagac cctgga 16 <210> 675 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 438 of 771 <400> 675 actg 4 <210> 676 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 676 cagtagagaa cagcca 16 <210> 677 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 677 gtagagaaca gcca 14 <210> 678 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 439 of 771 <220> <223> Synthetic Oligonucleotide <400> 678 tgttgaggaa acagta 16 <210> 679 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 679 ttgaggaaac agta 14 <210> 680 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 680 cctgcacctc cttgtt 16 <210> 681 <211> 14 2013203064 09 Apr 2013 440 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 681 atgagggtct tcat 14 <210> 682 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 682 accccggagt aggc 14 <210> 683 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 683 cccggagtag gc 12 2013203064 09 Apr 2013 441 of 771 <210> 684 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 684 caggaccccg gagtag 16 <210> 685 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 685 gcaggacccc ggagta 16 <210> 686 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 442 of 771 <400> 686 aggaccccgg agta 14 <210> 687 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 687 caggaccccg gagt 14 <210> 688 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 688 cagacccctc gc 12 <210> 689 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 443 of 771 <220> <223> Synthetic Oligonucleotide <400> 689 agaggatgct gg 12 <210> 690 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 690 gagccaggtg acagag 16 <210> 691 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 691 agccaggtga caga 14 <210> 692 2013203064 09 Apr 2013 444 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 692 tgagccaggt ga 12 <210> 693 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 693 ttttccacct tgga 14 <210> 694 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 694 2013203064 09 Apr 2013 445 of 771 ctgcaggcca ct 12 <210> 695 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 695 tcaccagctg gatggg 16 <210> 696 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 696 ttcaccagct ggatgg 16 <210> 697 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 446 of 771 <223> Synthetic Oligonucleotide <400> 697 caccagctgg atgg 14 <210> 698 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 698 tcaccagctg gatg 14 <210> 699 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 699 tcaccagctg ga 12 <210> 700 <211> 16 <212> DNA 2013203064 09 Apr 2013 447 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 700 tgtcttcacc agctgg 16 <210> 701 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 701 gtcttcacca gctg 14 <210> 702 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 702 gtgtgtcttc accagc 16 2013203064 09 Apr 2013 448 of 771 <210> 703 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 703 tgtgtcttca ccag 14 <210> 704 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 704 ttgtgtgtct tcacca 16 <210> 705 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 449 of 771 <400> 705 tgtgtgtctt cacc 14 <210> 706 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 706 aggttgtgtg tcttca 16 <210> 707 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 707 ggttgtgtgt cttc 14 <210> 708 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 450 of 771 <220> <223> Synthetic Oligonucleotide <400> 708 gcaggttgtg tgtctt 16 <210> 709 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 709 caggttgtgt gtct 14 <210> 710 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 710 tcagcaggtt gtgtgt 16 <210> 711 <211> 14 2013203064 09 Apr 2013 451 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 711 cagcaggttg tgtg 14 <210> 712 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 712 ggtcagcagg ttgtgt 16 <210> 713 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 713 tggtcagcag gttgtg 16 2013203064 09 Apr 2013 452 of 771 <210> 714 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 714 gtcagcaggt tgtg 14 <210> 715 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 715 ggtcagcagg ttgt 14 <210> 716 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 453 of 771 <400> 716 ctggtggtca gcaggt 16 <210> 717 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 717 tggtggtcag cagg 14 <210> 718 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 718 ctggtggtca gc 12 <210> 719 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 454 of 771 <220> <223> Synthetic Oligonucleotide <400> 719 agttcctggt ggtcag 16 <210> 720 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 720 gttcctggtg gtca 14 <210> 721 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 721 tatagttcct ggtggt 16 <210> 722 2013203064 09 Apr 2013 455 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 722 atagttcctg gtgg 14 <210> 723 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 723 gatatagttc ctggtg 16 <210> 724 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 724 2013203064 09 Apr 2013 456 of 771 atatagttcc tggt 14 <210> 725 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 725 ccaaagatat agttcc 16 <210> 726 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 726 tccaaagata tagttc 16 <210> 727 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 457 of 771 <223> Synthetic Oligonucleotide <400> 727 caaagatata gttc 14 <210> 728 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 728 ccaaagatat agtt 14 <210> 729 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 729 ccaggcccat ga 12 <210> 730 <211> 16 <212> DNA 2013203064 09 Apr 2013 458 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 730 ggcacccagg cccatg 16 <210> 731 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 731 gcacccaggc ccat 14 <210> 732 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 732 cagaaggcac ccaggc 16 2013203064 09 Apr 2013 459 of 771 <210> 733 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 733 agaaggcacc cagg 14 <210> 734 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 734 ccagacatca gg 12 <210> 735 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 460 of 771 <400> 735 gacagggcag at 12 <210> 736 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 736 tgacagggca ga 12 <210> 737 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 737 ccactcccat tc 12 <210> 738 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 461 of 771 <220> <223> Synthetic Oligonucleotide <400> 738 gccaggcatg gagctc 16 <210> 739 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 739 ccaggcatgg agct 14 <210> 740 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 740 ccaggcatgg ag 12 <210> 741 <211> 12 2013203064 09 Apr 2013 462 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 741 cagggtgact gc 12 <210> 742 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 742 gttccgcagg gtgact 16 <210> 743 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 743 ttccgcaggg tgac 14 2013203064 09 Apr 2013 463 of 771 <210> 744 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 744 gcggttccgc agggtg 16 <210> 745 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 745 cggttccgca gggt 14 <210> 746 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 464 of 771 <400> 746 tcggccccag gagccc 16 <210> 747 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 747 cggccccagg agcc 14 <210> 748 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 748 ccatcggccc caggag 16 <210> 749 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 465 of 771 <220> <223> Synthetic Oligonucleotide <400> 749 catcggcccc agga 14 <210> 750 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 750 gacccatcgg ccccag 16 <210> 751 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 751 acccatcggc ccca 14 <210> 752 2013203064 09 Apr 2013 466 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 752 ttctggaccc atcggc 16 <210> 753 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 753 ggacccatcg gc 12 <210> 754 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 754 2013203064 09 Apr 2013 467 of 771 tctggaccca tcgg 14 <210> 755 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 755 caccagcccc caggtg 16 <210> 756 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 756 accagccccc aggt 14 <210> 757 <211> 16 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 468 of 771 <223> Synthetic Oligonucleotide <400> 757 tagggcacca gccccc 16 <210> 758 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 758 agggcaccag cccc 14 <210> 759 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 759 tggagtaggg caccag 16 <210> 760 <211> 14 <212> DNA 2013203064 09 Apr 2013 469 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 760 ggagtagggc acca 14 <210> 761 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 761 cttggagtag gg 12 <210> 762 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 762 tgatgggctt ggagta 16 2013203064 09 Apr 2013 470 of 771 <210> 763 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 763 gatgggcttg gagt 14 <210> 764 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 764 tgtggtacag gtcgat 16 <210> 765 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 471 of 771 <400> 765 gtggtacagg tcga 14 <210> 766 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 766 ggtacaggtc ga 12 <210> 767 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 767 ggtgtggtac aggtcg 16 <210> 768 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 472 of 771 <220> <223> Synthetic Oligonucleotide <400> 768 gtgtggtaca ggtc 14 <210> 769 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 769 catggtgtgg tacagg 16 <210> 770 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 770 atggtgtggt acag 14 <210> 771 <211> 16 2013203064 09 Apr 2013 473 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 771 tacatggtgt ggtaca 16 <210> 772 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 772 acatggtgtg gtac 14 <210> 773 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 773 atgtacatgg tgtggt 16 2013203064 09 Apr 2013 474 of 771 <210> 774 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 774 tgtacatggt gtgg 14 <210> 775 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 775 gcctccatgt ac 12 <210> 776 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 475 of 771 <400> 776 agcttcacca gg 12 <210> 777 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 777 gttcacctcc ag 12 <210> 778 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 778 catgccccag ccgccg 16 <210> 779 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 476 of 771 <220> <223> Synthetic Oligonucleotide <400> 779 atgccccagc cgcc 14 <210> 780 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 780 gatgagggtc ttcatg 16 <210> 781 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 781 gaccccggag taggca 16 <210> 782 2013203064 09 Apr 2013 477 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 782 atgctggagc cagtgc 16 <210> 783 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 783 tgctggagcc agtg 14 <210> 784 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 784 2013203064 09 Apr 2013 478 of 771 gtcttggagg gccg 14 <210> 785 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 785 cccaggtgtc agag 14 <210> 786 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 786 ttttccacct tggatc 16 <210> 787 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 479 of 771 <223> Synthetic Oligonucleotide <400> 787 tttccacctt ggat 14 <210> 788 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 788 tttttccacc ttggat 16 <210> 789 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 789 aggtgttttt ccacct 16 <210> 790 <211> 14 <212> DNA 2013203064 09 Apr 2013 480 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 790 ggtgtttttc cacc 14 <210> 791 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 791 ccaggaagga taggac 16 <210> 792 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 792 caggaaggat agga 14 2013203064 09 Apr 2013 481 of 771 <210> 793 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 793 tgacactgca ggccac 16 <210> 794 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 794 gacactgcag gcca 14 <210> 795 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 482 of 771 <400> 795 acatgaggat gacact 16 <210> 796 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 796 catgaggatg acac 14 <210> 797 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 797 gcagaaggtg tacatg 16 <210> 798 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 483 of 771 <220> <223> Synthetic Oligonucleotide <400> 798 cagaaggtgt acat 14 <210> 799 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 799 gcagtcagtg cagaag 16 <210> 800 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 800 cagtcagtgc agaa 14 <210> 801 <211> 16 2013203064 09 Apr 2013 484 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 801 acacggccca gtttcg 16 <210> 802 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 802 cacggcccag tttc 14 <210> 803 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 803 ggcccatgat gccatg 16 2013203064 09 Apr 2013 485 of 771 <210> 804 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 804 gcccatgatg ccat 14 <210> 805 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 805 tacagaaggc acccag 16 <210> 806 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 486 of 771 <400> 806 acagaaggca ccca 14 <210> 807 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 807 gaagttgcca gccaat 16 <210> 808 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 808 aagttgccag ccaa 14 <210> 809 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 487 of 771 <220> <223> Synthetic Oligonucleotide <400> 809 cagggcagat cctt 14 <210> 810 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 810 caagtagtct atggtg 16 <210> 811 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 811 aagtagtcta tggt 14 <210> 812 2013203064 09 Apr 2013 488 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 812 tggaaagcaa gtagtc 16 <210> 813 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 813 ggaaagcaag tagt 14 <210> 814 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 814 2013203064 09 Apr 2013 489 of 771 ggccagcttt acaaag 16 <210> 815 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 815 gccagcttta caaa 14 <210> 816 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 816 cgcagggcca gctt 14 <210> 817 <211> 16 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 490 of 771 <223> Synthetic Oligonucleotide <400> 817 aaaggaatag gtggga 16 <210> 818 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 818 aaggaatagg tggg 14 <210> 819 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 819 gcgaaaccaa tatact 16 <210> 820 <211> 14 <212> DNA 2013203064 09 Apr 2013 491 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 820 cgaaaccaat atac 14 <210> 821 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 821 ccccaggtgt cagagg 16 <210> 822 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 822 actg 4 2013203064 09 Apr 2013 492 of 771 <210> 823 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 823 gattgtcaaa gagctt 16 <210> 824 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 824 attgtcaaag agct 14 <210> 825 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 493 of 771 <400> 825 ttggtcttgt gattgt 16 <210> 826 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 826 tggtcttgtg attg 14 <210> 827 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 827 aaggccgaat ttggtc 16 <210> 828 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 494 of 771 <220> <223> Synthetic Oligonucleotide <400> 828 aggccgaatt tggt 14 <210> 829 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 829 aatccgactg tg 12 <210> 830 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 830 aatttaatcc ga 12 <210> 831 <211> 14 2013203064 09 Apr 2013 495 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 831 accttcgatc acag 14 <210> 832 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 832 actgatcctg ca 12 <210> 833 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 833 actgtggtca aa 12 2013203064 09 Apr 2013 496 of 771 <210> 834 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 834 agccgcccag tt 12 <210> 835 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 835 agccttgtcg at 12 <210> 836 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 497 of 771 <400> 836 agttcccagc ct 12 <210> 837 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 837 atccgactgt gg 12 <210> 838 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 838 atcctgcact ga 12 <210> 839 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 498 of 771 <220> <223> Synthetic Oligonucleotide <400> 839 atttaatccg ac 12 <210> 840 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 840 caatttaatc cg 12 <210> 841 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 841 cactgacgag tc 12 <210> 842 2013203064 09 Apr 2013 499 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 842 cactgatcct gc 12 <210> 843 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 843 cagccttgtc ga 12 <210> 844 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 844 2013203064 09 Apr 2013 500 of 771 cagttcccag cc 12 <210> 845 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 845 ccactgatcc tg 12 <210> 846 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 846 ccagccttgt cg 12 <210> 847 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 501 of 771 <223> Synthetic Oligonucleotide <400> 847 ccagttccca gc 12 <210> 848 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 848 cccagccttg tc 12 <210> 849 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 849 cccagttccc ag 12 <210> 850 <211> 12 <212> DNA 2013203064 09 Apr 2013 502 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 850 ccgcccagtt cc 12 <210> 851 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 851 cctgcactga cg 12 <210> 852 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 852 ccttggaatg tctg 14 2013203064 09 Apr 2013 503 of 771 <210> 853 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 853 ccttgtcgat ct 12 <210> 854 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 854 cgactgtggt ca 12 <210> 855 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 504 of 771 <400> 855 cgcccagttc cc 12 <210> 856 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 856 ctgatcctgc ac 12 <210> 857 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 857 ctgcactgac ga 12 <210> 858 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 505 of 771 <220> <223> Synthetic Oligonucleotide <400> 858 ctgtggtcaa aa 12 <210> 859 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 859 cttgtcgatc tc 12 <210> 860 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 860 gatcctgcac tg 12 <210> 861 <211> 12 2013203064 09 Apr 2013 506 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 861 gcaatttaat cc 12 <210> 862 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 862 gcactgacga gt 12 <210> 863 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 863 gcccagttcc ca 12 2013203064 09 Apr 2013 507 of 771 <210> 864 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 864 gccgcccagt tc 12 <210> 865 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 865 gccttgtcga tc 12 <210> 866 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 508 of 771 <400> 866 ggtcaaaagg gc 12 <210> 867 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 867 ggtcatgcac aggc 14 <210> 868 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 868 gtcgatctcc tc 12 <210> 869 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 509 of 771 <220> <223> Synthetic Oligonucleotide <400> 869 gtggtcaaaa gg 12 <210> 870 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 870 gttcccagcc tt 12 <210> 871 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 871 taatccgact gt 12 <210> 872 2013203064 09 Apr 2013 510 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 872 tattccatgg ccat 14 <210> 873 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 873 tcaggtcatg caca 14 <210> 874 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 874 2013203064 09 Apr 2013 511 of 771 tcccagcctt gt 12 <210> 875 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 875 tccgactgtg gt 12 <210> 876 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 876 tcctgcactg ac 12 <210> 877 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 512 of 771 <223> Synthetic Oligonucleotide <400> 877 tcgatctcct cg 12 <210> 878 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 878 tgatcctgca ct 12 <210> 879 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 879 tgcaatttaa tc 12 <210> 880 <211> 12 <212> DNA 2013203064 09 Apr 2013 513 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 880 tgcactgacg ag 12 <210> 881 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 881 tggtcaaaag gg 12 <210> 882 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 882 tgtcgatctc ct 12 2013203064 09 Apr 2013 514 of 771 <210> 883 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 883 tgtggtcaaa ag 12 <210> 884 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 884 ttaatccgac tg 12 <210> 885 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 515 of 771 <400> 885 ttcccagcct tg 12 <210> 886 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 886 ttgtcgatct cc 12 <210> 887 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 887 tttaatccga ct 12 <210> 888 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 516 of 771 <220> <223> Synthetic Oligonucleotide <400> 888 gactgtggtc aa 12 <210> 889 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 889 ccgactgtgg tc 12 <210> 890 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 890 cccagtgggt ttga 14 <210> 891 <211> 12 2013203064 09 Apr 2013 517 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 891 ttcttgatgt cc 12 <210> 892 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 892 gactccaaag tc 12 <210> 893 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 893 tcctgcactg acgagt 16 2013203064 09 Apr 2013 518 of 771 <210> 894 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 894 cactgatcct gcactg 16 <210> 895 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 895 cttccactga tcctta 16 <210> 896 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 519 of 771 <400> 896 gaaagctcct tccact 16 <210> 897 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 897 ggcagtcttt atcc 14 <210> 898 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 898 ctggtaaata gc 12 <210> 899 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 520 of 771 <220> <223> Synthetic Oligonucleotide <400> 899 ctacctgagg attt 14 <210> 900 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 900 cccagtacta cctg 14 <210> 901 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 901 tgttccctct ac 12 <210> 902 2013203064 09 Apr 2013 521 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 902 tattcctgga aaac 14 <210> 903 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 903 caagaagtgt ggtt 14 <210> 904 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 904 2013203064 09 Apr 2013 522 of 771 gtgaaaatgc tggc 14 <210> 905 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 905 aggaggttaa acca 14 <210> 906 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 906 tggatgattg gc 12 <210> 907 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 523 of 771 <223> Synthetic Oligonucleotide <400> 907 caaaaggatc cc 12 <210> 908 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 908 atgtcaaccg gc 12 <210> 909 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 909 tcagccagac ag 12 <210> 910 <211> 14 <212> DNA 2013203064 09 Apr 2013 524 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 910 taagtgtccc tttg 14 <210> 911 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 911 ctaaatttag ttca 14 <210> 912 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 912 gactacattt taca 14 2013203064 09 Apr 2013 525 of 771 <210> 913 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 913 cagtaaggaa tttt 14 <210> 914 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 914 tgtgtccctc agtc 14 <210> 915 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 526 of 771 <400> 915 ccgttggacc cc 12 <210> 916 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 916 gacagcttct ataa 14 <210> 917 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 917 agtgactgac caca 14 <210> 918 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 527 of 771 <220> <223> Synthetic Oligonucleotide <400> 918 gtagcataga gcct 14 <210> 919 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 919 cagatcttgt caag 14 <210> 920 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 920 gtaagaggca gg 12 <210> 921 <211> 12 2013203064 09 Apr 2013 528 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 921 ccatggcggg ac 12 <210> 922 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 922 gcttacgatt gt 12 <210> 923 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 923 ccagcacact ggaa 14 2013203064 09 Apr 2013 529 of 771 <210> 924 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 924 gtcagtccca gcta 14 <210> 925 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 925 ttagtatgac agct 14 <210> 926 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 530 of 771 <400> 926 tcagtgtagg aaga 14 <210> 927 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 927 tgaatataca gatg 14 <210> 928 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 928 cccgccacca cc 12 <210> 929 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 531 of 771 <220> <223> Synthetic Oligonucleotide <400> 929 ttgttccctc ta 12 <210> 930 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 930 tctacctgag tcca 14 <210> 931 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 931 aacatcaagc ttga 14 <210> 932 2013203064 09 Apr 2013 532 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 932 gatcaccttc agag 14 <210> 933 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 933 tgaacacatc acta 14 <210> 934 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 934 2013203064 09 Apr 2013 533 of 771 tttcctcttg tc 12 <210> 935 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 935 taattgatgt caat 14 <210> 936 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 936 agtaattgat gtca 14 <210> 937 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 534 of 771 <223> Synthetic Oligonucleotide <400> 937 acagtaattg atgt 14 <210> 938 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 938 ttacagtaat tgat 14 <210> 939 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 939 acttacagta attg 14 <210> 940 <211> 14 <212> DNA 2013203064 09 Apr 2013 535 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 940 agacttacag taat 14 <210> 941 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 941 tcagacttac agta 14 <210> 942 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 942 aatcagactt acag 14 2013203064 09 Apr 2013 536 of 771 <210> 943 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 943 tgaatcagac ttac 14 <210> 944 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 944 aatgaatcag actt 14 <210> 945 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 537 of 771 <400> 945 tgcaggatgt tgag 14 <210> 946 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 946 ctggtcagca ttga 14 <210> 947 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 947 caaagtccct tagc 14 <210> 948 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 538 of 771 <220> <223> Synthetic Oligonucleotide <400> 948 atttctctta cagg 14 <210> 949 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 949 ttaacgagcc tt 12 <210> 950 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 950 cgacacggga ac 12 <210> 951 <211> 12 2013203064 09 Apr 2013 539 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 951 caagtaggat gt 12 <210> 952 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 952 gttccctttg cagg 14 <210> 953 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 953 attagccata tctc 14 2013203064 09 Apr 2013 540 of 771 <210> 954 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 954 agcattcagc agtg 14 <210> 955 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 955 ttccctctac ac 12 <210> 956 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 541 of 771 <400> 956 tccctctaca cc 12 <210> 957 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 957 ctacaggaca atac 14 <210> 958 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 958 aactgggtta agta 14 <210> 959 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 542 of 771 <220> <223> Synthetic Oligonucleotide <400> 959 tgaacacgct atcc 14 <210> 960 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 960 tttccacttg ggtg 14 <210> 961 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 961 tctacaccag gt 12 <210> 962 2013203064 09 Apr 2013 543 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 962 gaaagctcct tcca 14 <210> 963 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 963 aggtaggaga ag 12 <210> 964 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 964 2013203064 09 Apr 2013 544 of 771 acccagtcag gg 12 <210> 965 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 965 atgtcattaa ac 12 <210> 966 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 966 gaggtgggaa aa 12 <210> 967 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 545 of 771 <223> Synthetic Oligonucleotide <400> 967 tttcctagga ggtg 14 <210> 968 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 968 gttcttagga ag 12 <210> 969 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 969 ctctacacca gg 12 <210> 970 <211> 14 <212> DNA 2013203064 09 Apr 2013 546 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 970 tgtttttaca caga 14 <210> 971 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 971 tggcttcatg tc 12 <210> 972 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 972 ttgttcttag gaag 14 2013203064 09 Apr 2013 547 of 771 <210> 973 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 973 tacaccaggt ca 12 <210> 974 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 974 tgagctacag tagg 14 <210> 975 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 548 of 771 <400> 975 ggctgacatt ca 12 <210> 976 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 976 tggtcaactg aaag 14 <210> 977 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 977 tagtcattat ct 12 <210> 978 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 549 of 771 <220> <223> Synthetic Oligonucleotide <400> 978 ccatttttat ca 12 <210> 979 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 979 gggcttcttc catt 14 <210> 980 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 980 ggtgtggata acag 14 <210> 981 <211> 14 2013203064 09 Apr 2013 550 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 981 tcataactat taag 14 <210> 982 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 982 cctctacacc ag 12 <210> 983 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 983 cagcttaggc agag 14 2013203064 09 Apr 2013 551 of 771 <210> 984 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 984 tcattcccca ct 12 <210> 985 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 985 ctcccacacc at 12 <210> 986 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 552 of 771 <400> 986 ttctgctccc ac 12 <210> 987 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 987 cagagaaggt ct 12 <210> 988 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 988 gtatgcactg ct 12 <210> 989 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 553 of 771 <220> <223> Synthetic Oligonucleotide <400> 989 caatgaagca cagg 14 <210> 990 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 990 tcccaaacaa at 12 <210> 991 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 991 attcttaaca caga 14 <210> 992 2013203064 09 Apr 2013 554 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 992 cgggtactat gg 12 <210> 993 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 993 ctacaccagg tc 12 <210> 994 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 994 2013203064 09 Apr 2013 555 of 771 tatagctcct ct 12 <210> 995 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 995 catttagggt ctaa 14 <210> 996 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 996 atcttcagag at 12 <210> 997 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 556 of 771 <223> Synthetic Oligonucleotide <400> 997 ttgatatagt ca 12 <210> 998 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 998 taatatgact tg 12 <210> 999 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 999 agccgcctga agtg 14 <210> 1000 <211> 12 <212> DNA 2013203064 09 Apr 2013 557 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1000 ccccagcagc gg 12 <210> 1001 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1001 tccttccact ga 12 <210> 1002 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1002 cggtttttgt tc 12 2013203064 09 Apr 2013 558 of 771 <210> 1003 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1003 taaatcctct agca 14 <210> 1004 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1004 gttccctcta ca 12 <210> 1005 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 559 of 771 <400> 1005 acaccatctc cc 12 <210> 1006 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1006 gctccttcca ct 12 <210> 1007 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1007 cactgatcct gcac 14 <210> 1008 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 560 of 771 <220> <223> Synthetic Oligonucleotide <400> 1008 tcggactttg aa 12 <210> 1009 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1009 tcggactttg aaaa 14 <210> 1010 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1010 atcagccaga caga 14 <210> 1011 <211> 14 2013203064 09 Apr 2013 561 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1011 catcagcaag aggc 14 <210> 1012 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1012 ttgttcttag ga 12 <210> 1013 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1013 gccagacaga ag 12 2013203064 09 Apr 2013 562 of 771 <210> 1014 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1014 ttgtcgatct gc 12 <210> 1015 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1015 ggagaagcgc agct 14 <210> 1016 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 563 of 771 <400> 1016 ggagaagcgc ag 12 <210> 1017 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1017 ctgcactgac gagt 14 <210> 1018 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1018 ctgcaacatg at 12 <210> 1019 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 564 of 771 <220> <223> Synthetic Oligonucleotide <400> 1019 ctgatcctta gaag 14 <210> 1020 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1020 ccttccactg atcctg 16 <210> 1021 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1021 ctccttccac tg 12 <210> 1022 2013203064 09 Apr 2013 565 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1022 tgcagccatg tact 14 <210> 1023 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1023 cgtttgggtg gc 12 <210> 1024 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1024 2013203064 09 Apr 2013 566 of 771 tccactgatc ctgc 14 <210> 1025 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1025 ttccactgat cctg 14 <210> 1026 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1026 tccactgatc ct 12 <210> 1027 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 567 of 771 <223> Synthetic Oligonucleotide <400> 1027 cttccactga tcct 14 <210> 1028 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1028 tccttccact gatcct 16 <210> 1029 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1029 ttccactgat cc 12 <210> 1030 <211> 16 <212> DNA 2013203064 09 Apr 2013 568 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1030 ctccttccac tgatcc 16 <210> 1031 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1031 tccttccact gatc 14 <210> 1032 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1032 gctccttcca ctgatc 16 2013203064 09 Apr 2013 569 of 771 <210> 1033 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1033 gctccttcca ctga 14 <210> 1034 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1034 aagctccttc cactga 16 <210> 1035 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 570 of 771 <400> 1035 aagctccttc cact 14 <210> 1036 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1036 agctccttcc ac 12 <210> 1037 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1037 gggaaagctc cttcca 16 <210> 1038 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 571 of 771 <220> <223> Synthetic Oligonucleotide <400> 1038 ttgcaatgtc tggc 14 <210> 1039 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1039 gatttatctg gctg 14 <210> 1040 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1040 aagggccctg gg 12 <210> 1041 <211> 12 2013203064 09 Apr 2013 572 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1041 aacttcagtg tc 12 <210> 1042 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1042 agggcttcca gt 12 <210> 1043 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1043 aggaagggct tc 12 2013203064 09 Apr 2013 573 of 771 <210> 1044 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1044 ccttccactg at 12 <210> 1045 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1045 ggaaacatac cctg 14 <210> 1046 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 574 of 771 <400> 1046 ccttccactg atcc 14 <210> 1047 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1047 cttccactga tc 12 <210> 1048 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1048 gaataggtta aggc 14 <210> 1049 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 575 of 771 <220> <223> Synthetic Oligonucleotide <400> 1049 aacaatgtgt tgta 14 <210> 1050 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1050 ccctctacac ca 12 <210> 1051 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1051 gcacacagct gagg 14 <210> 1052 2013203064 09 Apr 2013 576 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1052 gtgcacacag ctga 14 <210> 1053 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1053 cagtgtgcac acag 14 <210> 1054 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1054 2013203064 09 Apr 2013 577 of 771 ctcagtgtgc acac 14 <210> 1055 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1055 cacccactgg tg 12 <210> 1056 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1056 catttccatg gcca 14 <210> 1057 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 578 of 771 <223> Synthetic Oligonucleotide <400> 1057 accaaacagt tcag 14 <210> 1058 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1058 ttgaccagga ag 12 <210> 1059 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1059 caggccatgt gg 12 <210> 1060 <211> 14 <212> DNA 2013203064 09 Apr 2013 579 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1060 agtcaggcca tgtg 14 <210> 1061 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1061 gcgcgagccc ga 12 <210> 1062 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1062 tgtgaggctc ca 12 2013203064 09 Apr 2013 580 of 771 <210> 1063 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1063 ccctgaaggt tc 12 <210> 1064 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1064 tttgataaag ccct 14 <210> 1065 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 581 of 771 <400> 1065 caagaagacc ttac 14 <210> 1066 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1066 tgcacaggca ggtt 14 <210> 1067 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1067 acagccaggt ag 12 <210> 1068 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 582 of 771 <220> <223> Synthetic Oligonucleotide <400> 1068 tggaaaactg cacc 14 <210> 1069 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1069 tgggtggccg gg 12 <210> 1070 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1070 gggcttcttc ca 12 <210> 1071 <211> 12 2013203064 09 Apr 2013 583 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1071 gctgacatct cg 12 <210> 1072 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1072 cagcctggca ccta 14 <210> 1073 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1073 taaaaacaac aa 12 2013203064 09 Apr 2013 584 of 771 <210> 1074 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1074 tttataaaac tg 12 <210> 1075 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1075 actg 4 <210> 1076 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 585 of 771 <400> 1076 agtaaatatt ggct 14 <210> 1077 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1077 gttgagcatg ac 12 <210> 1078 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1078 gtgcgctccc at 12 <210> 1079 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 586 of 771 <220> <223> Synthetic Oligonucleotide <400> 1079 tcctgcactg acga 14 <210> 1080 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1080 gatcctgcac tgacga 16 <210> 1081 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1081 gatcctgcac tgac 14 <210> 1082 2013203064 09 Apr 2013 587 of 771 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1082 ctgatcctgc actgac 16 <210> 1083 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1083 tccactgatc ctgcac 16 <210> 1084 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1084 2013203064 09 Apr 2013 588 of 771 cgcgagatat ctaa 14 <210> 1085 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1085 cgcacctggt aaat 14 <210> 1086 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1086 gttcaagcgg ccta 14 <210> 1087 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 589 of 771 <223> Synthetic Oligonucleotide <400> 1087 ccctttacac aagt 14 <210> 1088 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1088 ctcaaaatag attt 14 <210> 1089 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1089 cacatgagct attc 14 <210> 1090 <211> 14 <212> DNA 2013203064 09 Apr 2013 590 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1090 gtgaagtgag tcat 14 <210> 1091 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1091 ggtcactcaa gatg 14 <210> 1092 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1092 ggactcactc agca 14 2013203064 09 Apr 2013 591 of 771 <210> 1093 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1093 tcagggctac tcat 14 <210> 1094 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1094 cagcactaga ttca 14 <210> 1095 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 592 of 771 <400> 1095 tagcttaatg taac 14 <210> 1096 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1096 ttgtgacatc tagg 14 <210> 1097 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1097 gtgcctagca caga 14 <210> 1098 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 593 of 771 <220> <223> Synthetic Oligonucleotide <400> 1098 cagcctacca gt 12 <210> 1099 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1099 acatgtcagt aatt 14 <210> 1100 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1100 ctcatggaca caaa 14 <210> 1101 <211> 14 2013203064 09 Apr 2013 594 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1101 ggaagttttc aagt 14 <210> 1102 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1102 gaatctggag gtaa 14 <210> 1103 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1103 agccccttgg ccgt 14 2013203064 09 Apr 2013 595 of 771 <210> 1104 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1104 gaatacttca aatc 14 <210> 1105 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1105 ctgatcctgc actg 14 <210> 1106 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 596 of 771 <400> 1106 tttgaggagc tatt 14 <210> 1107 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1107 ttgttgttcc ct 12 <210> 1108 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1108 gagttgttgt tc 12 <210> 1109 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 597 of 771 <220> <223> Synthetic Oligonucleotide <400> 1109 cgagttgttg tt 12 <210> 1110 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1110 gcgctaggcc gc 12 <210> 1111 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1111 gttgttgttc cc 12 <210> 1112 2013203064 09 Apr 2013 598 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1112 agttgttgtt cc 12 <210> 1113 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1113 ctcaccttca tg 12 <210> 1114 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1114 2013203064 09 Apr 2013 599 of 771 cttagaaggc agca 14 <210> 1115 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1115 gttgttccct ct 12 <210> 1116 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1116 ccaactccaa ct 12 <210> 1117 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 600 of 771 <223> Synthetic Oligonucleotide <400> 1117 gatctctcga gt 12 <210> 1118 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1118 aatgcaggat ct 12 <210> 1119 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1119 ctcggacttt ga 12 <210> 1120 <211> 12 <212> DNA 2013203064 09 Apr 2013 601 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1120 tgactctcgg ac 12 <210> 1121 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1121 cttgtccatc ag 12 <210> 1122 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1122 gggtctttcc tc 12 2013203064 09 Apr 2013 602 of 771 <210> 1123 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1123 cactgatcct tagaag 16 <210> 1124 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1124 cactgatcct taga 14 <210> 1125 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 603 of 771 <400> 1125 tccactgatc cttaga 16 <210> 1126 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1126 cttccactga tcctgc 16 <210> 1127 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1127 tccactgatc ctta 14 <210> 1128 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 604 of 771 <220> <223> Synthetic Oligonucleotide <400> 1128 cagtggacca ca 12 <210> 1129 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1129 tgcgagttgt tg 12 <210> 1130 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1130 aaagtcaggc ca 12 <210> 1131 <211> 14 2013203064 09 Apr 2013 605 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1131 taacttcagt gtct 14 <210> 1132 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1132 gaagggcttc cagt 14 <210> 1133 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1133 tgaccaggaa gggc 14 2013203064 09 Apr 2013 606 of 771 <210> 1134 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1134 aggccctgag atta 14 <210> 1135 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1135 ggttaaggcc ctga 14 <210> 1136 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 607 of 771 <400> 1136 ggaatgtctg agtt 14 <210> 1137 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1137 taatgacctg atga 14 <210> 1138 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1138 tgaagttaat tc 12 <210> 1139 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 608 of 771 <220> <223> Synthetic Oligonucleotide <400> 1139 gaaattgagg aa 12 <210> 1140 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1140 gtattcaagt aa 12 <210> 1141 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1141 acaattatgg ca 12 <210> 1142 2013203064 09 Apr 2013 609 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1142 cagtttattc aa 12 <210> 1143 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1143 gaagctgctg gt 12 <210> 1144 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1144 2013203064 09 Apr 2013 610 of 771 gtgaaacatt tt 12 <210> 1145 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1145 aaaagtgaaa catt 14 <210> 1146 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1146 ttcttaaagg tg 12 <210> 1147 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 611 of 771 <223> Synthetic Oligonucleotide <400> 1147 gcacaaattt tc 12 <210> 1148 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1148 gtttagtgca ca 12 <210> 1149 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1149 tctggatcag ag 12 <210> 1150 <211> 12 <212> DNA 2013203064 09 Apr 2013 612 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1150 tgctgcacat cc 12 <210> 1151 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1151 tctgactggg aa 12 <210> 1152 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1152 acaaagagtc cc 12 2013203064 09 Apr 2013 613 of 771 <210> 1153 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1153 agagagctga gc 12 <210> 1154 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1154 tggcctcaca gc 12 <210> 1155 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 614 of 771 <400> 1155 ggaccgcagc cg 12 <210> 1156 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1156 gttagaacag ac 12 <210> 1157 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1157 cctgaaactg ca 12 <210> 1158 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 615 of 771 <220> <223> Synthetic Oligonucleotide <400> 1158 tgctcacagg cg 12 <210> 1159 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1159 agagagcaac tc 12 <210> 1160 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1160 atggctgctg cg 12 <210> 1161 <211> 12 2013203064 09 Apr 2013 616 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1161 catggctgca gc 12 <210> 1162 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1162 cttggccctg gacc 14 <210> 1163 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1163 gctagcctct gga 13 2013203064 09 Apr 2013 617 of 771 <210> 1164 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1164 tggccctgga cc 12 <210> 1165 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1165 tttctgcagg aa 12 <210> 1166 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 618 of 771 <400> 1166 tacaggtcaa gtct 14 <210> 1167 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1167 acaggtcaag tc 12 <210> 1168 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1168 ttggataaat atct 14 <210> 1169 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 619 of 771 <220> <223> Synthetic Oligonucleotide <400> 1169 tggataaata tc 12 <210> 1170 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1170 ttctgcagga tg 12 <210> 1171 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1171 caccttcaag tc 12 <210> 1172 2013203064 09 Apr 2013 620 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1172 catagattgt at 12 <210> 1173 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1173 gtcagaatat ct 12 <210> 1174 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1174 2013203064 09 Apr 2013 621 of 771 tctgcagtta aa 12 <210> 1175 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1175 atcttgtgaa ac 12 <210> 1176 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1176 tcatcaaaag gt 12 <210> 1177 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 622 of 771 <223> Synthetic Oligonucleotide <400> 1177 ctttgtcaag at 12 <210> 1178 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1178 tatgcacaaa tc 12 <210> 1179 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1179 taatccaggt ga 12 <210> 1180 <211> 12 <212> DNA 2013203064 09 Apr 2013 623 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1180 cacacaggca at 12 <210> 1181 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1181 ttgagcatct tg 12 <210> 1182 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1182 cattttgtcc tttt 14 2013203064 09 Apr 2013 624 of 771 <210> 1183 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1183 gatttcctga tc 12 <210> 1184 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1184 ctggatttga tggct 15 <210> 1185 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 625 of 771 <400> 1185 tctggatttg atggc 15 <210> 1186 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1186 tggacttggc gg 12 <210> 1187 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1187 ctctggattt gatgg 15 <210> 1188 <211> 15 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 626 of 771 <220> <223> Synthetic Oligonucleotide <400> 1188 cctctggatt tgatg 15 <210> 1189 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1189 gcctctggat ttgat 15 <210> 1190 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1190 tttagcctct ggattt 16 <210> 1191 <211> 16 2013203064 09 Apr 2013 627 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1191 tctagcctct ggattt 16 <210> 1192 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1192 agtagttgta ct 12 <210> 1193 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1193 tctggagtca ca 12 2013203064 09 Apr 2013 628 of 771 <210> 1194 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1194 gtcataatgt ct 12 <210> 1195 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1195 gtgtcataat gtct 14 <210> 1196 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 629 of 771 <400> 1196 cttcaaaagg at 12 <210> 1197 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1197 gtcttcaaaa gg 12 <210> 1198 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1198 atcctcttga ta 12 <210> 1199 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 630 of 771 <220> <223> Synthetic Oligonucleotide <400> 1199 gtgcctttaa aa 12 <210> 1200 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1200 tgtcataatg tc 12 <210> 1201 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1201 caatctgaca ca 12 <210> 1202 2013203064 09 Apr 2013 631 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1202 aatattgttc ct 12 <210> 1203 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1203 gtcaggagaa ga 12 <210> 1204 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1204 2013203064 09 Apr 2013 632 of 771 tgtcaaaacc ac 12 <210> 1205 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1205 gtcctattgc ca 12 <210> 1206 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1206 aggtatatac at 12 <210> 1207 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 633 of 771 <223> Synthetic Oligonucleotide <400> 1207 cagctggtga ca 12 <210> 1208 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1208 ttcacttagc ca 12 <210> 1209 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1209 aaccctgcag aa 12 <210> 1210 <211> 12 <212> DNA 2013203064 09 Apr 2013 634 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1210 tgtcaaaacc ct 12 <210> 1211 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1211 gtgtcaaaac cc 12 <210> 1212 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1212 atggtccaga gccc 14 2013203064 09 Apr 2013 635 of 771 <210> 1213 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1213 tggtccagag cc 12 <210> 1214 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1214 tgggttatgg tc 12 <210> 1215 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 636 of 771 <400> 1215 caaagaatgg tg 12 <210> 1216 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1216 gtttagcatg ct 12 <210> 1217 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1217 tgcctttaaa aa 12 <210> 1218 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 637 of 771 <220> <223> Synthetic Oligonucleotide <400> 1218 accaatatgc tc 12 <210> 1219 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1219 caccaataag tt 12 <210> 1220 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1220 cctttagctg gc 12 <210> 1221 <211> 12 2013203064 09 Apr 2013 638 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1221 gttgaaagcc tc 12 <210> 1222 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1222 tttgatgatg gc 12 <210> 1223 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1223 tcattgtcaa at 12 2013203064 09 Apr 2013 639 of 771 <210> 1224 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1224 ttacaactga ga 12 <210> 1225 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1225 agatggagca gt 12 <210> 1226 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 640 of 771 <400> 1226 cttagcactg gcct 14 <210> 1227 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1227 agagtatctg aa 12 <210> 1228 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1228 actgatgtag gg 12 <210> 1229 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 641 of 771 <220> <223> Synthetic Oligonucleotide <400> 1229 ccacagtagg ta 12 <210> 1230 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1230 ctggcagcca gcac 14 <210> 1231 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1231 tggcagccag ca 12 <210> 1232 2013203064 09 Apr 2013 642 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1232 gcatcatcaa tc 12 <210> 1233 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1233 aaatcattgt ca 12 <210> 1234 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1234 2013203064 09 Apr 2013 643 of 771 gcaaaactca tt 12 <210> 1235 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1235 tgtgcaactc tgca 14 <210> 1236 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1236 gtgcaactct gc 12 <210> 1237 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 644 of 771 <223> Synthetic Oligonucleotide <400> 1237 aatattcatg ta 12 <210> 1238 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1238 ggattgcaag tt 12 <210> 1239 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1239 ataaagcatc tg 12 <210> 1240 <211> 12 <212> DNA 2013203064 09 Apr 2013 645 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1240 ccactgaaca tt 12 <210> 1241 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1241 gaagccctaa tc 12 <210> 1242 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1242 taaattgtat gc 12 2013203064 09 Apr 2013 646 of 771 <210> 1243 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1243 aagatcttca ca 12 <210> 1244 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1244 caagatcttc ac 12 <210> 1245 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 647 of 771 <400> 1245 atgtcaaggt ca 12 <210> 1246 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1246 ataatggctg ga 12 <210> 1247 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1247 agcaccaata tgct 14 <210> 1248 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 648 of 771 <220> <223> Synthetic Oligonucleotide <400> 1248 gcaccaatat gc 12 <210> 1249 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1249 tggcagacca ca 12 <210> 1250 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1250 tcctatgcaa tc 12 <210> 1251 <211> 12 2013203064 09 Apr 2013 649 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1251 tataaatgct tc 12 <210> 1252 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1252 gtcaaattct at 12 <210> 1253 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1253 ttcaggctaa tc 12 2013203064 09 Apr 2013 650 of 771 <210> 1254 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1254 ctgatgaggt at 12 <210> 1255 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1255 ggtgtcagaa ta 12 <210> 1256 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 651 of 771 <400> 1256 tttgaaagac ac 12 <210> 1257 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1257 actg 4 <210> 1258 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1258 tgcaacagcc ca 12 <210> 1259 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 652 of 771 <220> <223> Synthetic Oligonucleotide <400> 1259 aaagagtccc gcca 14 <210> 1260 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1260 aagagtcccg cc 12 <210> 1261 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1261 tccgagagga gaga 14 <210> 1262 2013203064 09 Apr 2013 653 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1262 ccgagaggag ag 12 <210> 1263 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1263 tcatggctgc agct 14 <210> 1264 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1264 2013203064 09 Apr 2013 654 of 771 acagcggctc aact 14 <210> 1265 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1265 cagcggctca ac 12 <210> 1266 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1266 ggtgacaggc gact 14 <210> 1267 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 655 of 771 <223> Synthetic Oligonucleotide <400> 1267 gtgacaggcg ac 12 <210> 1268 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1268 atggtgacag gc 12 <210> 1269 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1269 agaggcctgg ca 12 <210> 1270 <211> 12 <212> DNA 2013203064 09 Apr 2013 656 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1270 ctggatggtt gc 12 <210> 1271 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1271 aatggctgct gcgg 14 <210> 1272 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1272 ccgggtaatg gc 12 2013203064 09 Apr 2013 657 of 771 <210> 1273 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1273 tggaccgcag ccgg 14 <210> 1274 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1274 tgatgcccct cgct 14 <210> 1275 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 658 of 771 <400> 1275 gatgcccctc gc 12 <210> 1276 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1276 ctggacttgg cggt 14 <210> 1277 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1277 ggaaatggct ctgg 14 <210> 1278 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 659 of 771 <220> <223> Synthetic Oligonucleotide <400> 1278 gaaatggctc tg 12 <210> 1279 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1279 agaagctgct ggtg 14 <210> 1280 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1280 gatggcagaa gc 12 <210> 1281 <211> 14 2013203064 09 Apr 2013 660 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1281 agagagatgg caga 14 <210> 1282 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1282 gagagatggc ag 12 <210> 1283 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1283 gtggctgaag aaaa 14 2013203064 09 Apr 2013 661 of 771 <210> 1284 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1284 tggctgaaga aa 12 <210> 1285 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1285 atgtctggga gcct 14 <210> 1286 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 662 of 771 <400> 1286 tgtctgggag cc 12 <210> 1287 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1287 atgatggctg tcat 14 <210> 1288 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1288 tgatgatggc tg 12 <210> 1289 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 663 of 771 <220> <223> Synthetic Oligonucleotide <400> 1289 ctttgatgat ggct 14 <210> 1290 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1290 acgatctctt tgat 14 <210> 1291 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1291 tgtttctgct aacg 14 <210> 1292 2013203064 09 Apr 2013 664 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1292 gtttctgcta ac 12 <210> 1293 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1293 tttgtttctg ctaa 14 <210> 1294 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1294 2013203064 09 Apr 2013 665 of 771 cttgatatct cctt 14 <210> 1295 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1295 catcctcttg atat 14 <210> 1296 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1296 aatccatcct cttg 14 <210> 1297 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 666 of 771 <223> Synthetic Oligonucleotide <400> 1297 gaatccatcc tc 12 <210> 1298 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1298 gtctaagtcg aatc 14 <210> 1299 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1299 caagtctaag tc 12 <210> 1300 <211> 12 <212> DNA 2013203064 09 Apr 2013 667 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1300 aggtcaagtc ta 12 <210> 1301 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1301 cgcagaaatg gata 14 <210> 1302 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1302 gcagaaatgg at 12 2013203064 09 Apr 2013 668 of 771 <210> 1303 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1303 ttcgcatccg tcta 14 <210> 1304 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1304 tcgcatccgt ct 12 <210> 1305 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 669 of 771 <400> 1305 ccctaggttg aata 14 <210> 1306 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1306 cctaggttga at 12 <210> 1307 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1307 gttatgcaaa tcag 14 <210> 1308 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 670 of 771 <220> <223> Synthetic Oligonucleotide <400> 1308 ttatgcaaat ca 12 <210> 1309 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1309 tgactcagta aatt 14 <210> 1310 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1310 gactcagtaa at 12 <210> 1311 <211> 14 2013203064 09 Apr 2013 671 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1311 ttaaaattct tggg 14 <210> 1312 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1312 taaaattctt gg 12 <210> 1313 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1313 cctaactttt agac 14 2013203064 09 Apr 2013 672 of 771 <210> 1314 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1314 ctaactttta ga 12 <210> 1315 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1315 acctgaaact gcaa 14 <210> 1316 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 673 of 771 <400> 1316 gtgtcaaaac cact 14 <210> 1317 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1317 cctattccca ctga 14 <210> 1318 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1318 ctattcccac tg 12 <210> 1319 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 674 of 771 <220> <223> Synthetic Oligonucleotide <400> 1319 cccatagcaa taat 14 <210> 1320 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1320 ccatagcaat aa 12 <210> 1321 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1321 atcccatagc aa 12 <210> 1322 2013203064 09 Apr 2013 675 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1322 tctgcaggaa atcc 14 <210> 1323 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1323 ctgcaggaaa tc 12 <210> 1324 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1324 2013203064 09 Apr 2013 676 of 771 ttctgcagga aatc 14 <210> 1325 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1325 ccttcaagtc tttc 14 <210> 1326 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1326 ttgttcctgt atac 14 <210> 1327 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 677 of 771 <223> Synthetic Oligonucleotide <400> 1327 caatattgtt cctg 14 <210> 1328 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1328 caatattgtt cc 12 <210> 1329 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1329 acatcatcaa tatt 14 <210> 1330 <211> 14 <212> DNA 2013203064 09 Apr 2013 678 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1330 ctttgaatcc aaaa 14 <210> 1331 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1331 tttgaatcca aa 12 <210> 1332 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1332 tatgctttga atcc 14 2013203064 09 Apr 2013 679 of 771 <210> 1333 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1333 ttgtaatggt tttt 14 <210> 1334 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1334 atcttgtaat gg 12 <210> 1335 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 680 of 771 <400> 1335 agattgtata tctt 14 <210> 1336 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1336 cggtgtcata atgt 14 <210> 1337 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1337 aaatttggcg gtgt 14 <210> 1338 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 681 of 771 <220> <223> Synthetic Oligonucleotide <400> 1338 ttaaatttgg cggt 14 <210> 1339 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1339 taaatttggc gg 12 <210> 1340 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1340 tcttcaaaag gata 14 <210> 1341 <211> 12 2013203064 09 Apr 2013 682 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1341 tggtcttcaa aa 12 <210> 1342 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1342 gtgggttatg gtct 14 <210> 1343 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1343 aagttctagc tgtg 14 2013203064 09 Apr 2013 683 of 771 <210> 1344 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1344 ataagttcta gc 12 <210> 1345 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1345 aagggtttga taag 14 <210> 1346 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 684 of 771 <400> 1346 tcaagatctt caca 14 <210> 1347 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1347 agccattggt caag 14 <210> 1348 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1348 tcttcactta gcca 14 <210> 1349 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 685 of 771 <220> <223> Synthetic Oligonucleotide <400> 1349 tgctgcaaca tgat 14 <210> 1350 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1350 gctgcaacat ga 12 <210> 1351 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1351 ttacagtgaa ttgc 14 <210> 1352 2013203064 09 Apr 2013 686 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1352 ccagctttac ag 12 <210> 1353 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1353 cattacacca gt 12 <210> 1354 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1354 2013203064 09 Apr 2013 687 of 771 atcattacac cagt 14 <210> 1355 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1355 tcattacacc ag 12 <210> 1356 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1356 aataaatatg caca 14 <210> 1357 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 688 of 771 <223> Synthetic Oligonucleotide <400> 1357 tgtgccttta aaaa 14 <210> 1358 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1358 ttgtgccttt aaaa 14 <210> 1359 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1359 gggcctcttg tgcc 14 <210> 1360 <211> 14 <212> DNA 2013203064 09 Apr 2013 689 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1360 ccttacttcc ccat 14 <210> 1361 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1361 ctctggtcct tact 14 <210> 1362 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1362 gtctctggtc cttact 16 2013203064 09 Apr 2013 690 of 771 <210> 1363 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1363 tctctggtcc ttac 14 <210> 1364 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1364 cctctgactg ggaa 14 <210> 1365 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 691 of 771 <400> 1365 catagcgcct ctga 14 <210> 1366 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1366 caggtagcta taat 14 <210> 1367 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1367 caggtagcta ta 12 <210> 1368 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 692 of 771 <220> <223> Synthetic Oligonucleotide <400> 1368 tcatcttgtg aaac 14 <210> 1369 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1369 catcttgtga aa 12 <210> 1370 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1370 gtttcaaaca tcat 14 <210> 1371 <211> 14 2013203064 09 Apr 2013 693 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1371 tagtttcaaa catc 14 <210> 1372 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1372 agtttcaaac at 12 <210> 1373 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1373 gaatagtttc aa 12 2013203064 09 Apr 2013 694 of 771 <210> 1374 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1374 cattggaata gttt 14 <210> 1375 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1375 cactgaacat tgga 14 <210> 1376 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 695 of 771 <400> 1376 actgaacatt gg 12 <210> 1377 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1377 ccgccactga acat 14 <210> 1378 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1378 cagaccacaa actg 14 <210> 1379 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 696 of 771 <220> <223> Synthetic Oligonucleotide <400> 1379 agaccacaaa ct 12 <210> 1380 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1380 ctggcagacc acaa 14 <210> 1381 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1381 agctggcaga ccac 14 <210> 1382 2013203064 09 Apr 2013 697 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1382 acctttagct ggca 14 <210> 1383 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1383 tcttcacctt tagc 14 <210> 1384 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1384 2013203064 09 Apr 2013 698 of 771 tcaaagtaca tg 12 <210> 1385 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1385 gaactcaaag taca 14 <210> 1386 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1386 ggaactcaaa gt 12 <210> 1387 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 699 of 771 <223> Synthetic Oligonucleotide <400> 1387 agggaactca aagt 14 <210> 1388 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1388 gggaactcaa ag 12 <210> 1389 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1389 gctgagggaa ctca 14 <210> 1390 <211> 14 <212> DNA 2013203064 09 Apr 2013 700 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1390 tcaccacaca cagg 14 <210> 1391 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1391 gaactctact ttga 14 <210> 1392 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1392 gaagaactct ac 12 2013203064 09 Apr 2013 701 of 771 <210> 1393 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1393 gtggaagaac tcta 14 <210> 1394 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1394 tggaagaact ct 12 <210> 1395 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 702 of 771 <400> 1395 tgtttgtgga agaa 14 <210> 1396 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1396 catcttgttc tgtt 14 <210> 1397 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1397 agtgaaacat tttg 14 <210> 1398 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 703 of 771 <220> <223> Synthetic Oligonucleotide <400> 1398 ttacccaaaa gt 12 <210> 1399 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1399 tatttaccca aaag 14 <210> 1400 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1400 gtatttaccc aaaa 14 <210> 1401 <211> 12 2013203064 09 Apr 2013 704 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1401 tatttaccca aa 12 <210> 1402 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1402 tcctggtatg aaga 14 <210> 1403 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1403 cctggtatga ag 12 2013203064 09 Apr 2013 705 of 771 <210> 1404 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1404 ggtcctggta tg 12 <210> 1405 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1405 ttcctctggt cctg 14 <210> 1406 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 706 of 771 <400> 1406 aggtttcctc tggt 14 <210> 1407 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1407 ggtttcctct gg 12 <210> 1408 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1408 ttttctgagg tttc 14 <210> 1409 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 707 of 771 <220> <223> Synthetic Oligonucleotide <400> 1409 agacttccat tttc 14 <210> 1410 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1410 agacttccat tt 12 <210> 1411 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1411 caaatgctat cgat 14 <210> 1412 2013203064 09 Apr 2013 708 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1412 gcacgctcta tact 14 <210> 1413 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1413 cacgctctat ac 12 <210> 1414 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1414 2013203064 09 Apr 2013 709 of 771 tccttgtcat tatc 14 <210> 1415 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1415 gctttgtcaa gatc 14 <210> 1416 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1416 tgctttgtca agat 14 <210> 1417 <211> 14 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 710 of 771 <223> Synthetic Oligonucleotide <400> 1417 aagtatcggt tggc 14 <210> 1418 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1418 agtatcggtt gg 12 <210> 1419 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1419 ttaaaatttg gaga 14 <210> 1420 <211> 14 <212> DNA 2013203064 09 Apr 2013 711 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1420 ccttaaaatt tgga 14 <210> 1421 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1421 cttaaaattt gg 12 <210> 1422 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1422 tctactgttt ttgt 14 2013203064 09 Apr 2013 712 of 771 <210> 1423 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1423 ggctcctcta ctgt 14 <210> 1424 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1424 agcctctgga tttga 15 <210> 1425 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 713 of 771 <400> 1425 agcctctgga tttg 14 <210> 1426 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1426 tagcctctgg atttg 15 <210> 1427 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1427 tagcctctgg attt 14 <210> 1428 <211> 16 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 714 of 771 <220> <223> Synthetic Oligonucleotide <400> 1428 gctagcctct ggattt 16 <210> 1429 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1429 ctagcctctg gattt 15 <210> 1430 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1430 gctagcctct ggatt 15 <210> 1431 <211> 14 2013203064 09 Apr 2013 715 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1431 ctagcctctg gatt 14 <210> 1432 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1432 tagcctctgg att 13 <210> 1433 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1433 tgctagcctc tggat 15 2013203064 09 Apr 2013 716 of 771 <210> 1434 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1434 tagcctctgg at 12 <210> 1435 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1435 ctgctagcct ctgga 15 <210> 1436 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 717 of 771 <400> 1436 actgctagcc tctgg 15 <210> 1437 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1437 aactgctagc ctctg 15 <210> 1438 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1438 gaactgctag cctct 15 <210> 1439 <211> 15 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 718 of 771 <220> <223> Synthetic Oligonucleotide <400> 1439 tgaactgcta gcctc 15 <210> 1440 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1440 ttgaactgct agcct 15 <210> 1441 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1441 tgaactgcta gcct 14 <210> 1442 2013203064 09 Apr 2013 719 of 771 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1442 agttgaactg ctag 14 <210> 1443 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1443 gttgaactgc ta 12 <210> 1444 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1444 2013203064 09 Apr 2013 720 of 771 gaagttgaac tg 12 <210> 1445 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1445 acagaagttg aact 14 <210> 1446 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1446 tcattgtcac taac 14 <210> 1447 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 721 of 771 <223> Synthetic Oligonucleotide <400> 1447 cattgtcact aa 12 <210> 1448 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1448 tcaggttcat tg 12 <210> 1449 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1449 atgatcaggt tcat 14 <210> 1450 <211> 14 <212> DNA 2013203064 09 Apr 2013 722 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1450 tataatgatc aggt 14 <210> 1451 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1451 ataatgatca gg 12 <210> 1452 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1452 tggtgtcaga atat 14 2013203064 09 Apr 2013 723 of 771 <210> 1453 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1453 tcagtggtgt caga 14 <210> 1454 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1454 ctctggatca gagt 14 <210> 1455 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 724 of 771 <400> 1455 aaggttcatt ctct 14 <210> 1456 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1456 ttcatcaaaa ggtt 14 <210> 1457 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1457 cttcatcaaa aggt 14 <210> 1458 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 725 of 771 <220> <223> Synthetic Oligonucleotide <400> 1458 cttcatcaaa ag 12 <210> 1459 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1459 atgctgatct tcat 14 <210> 1460 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1460 ttttgtaatt tgtg 14 <210> 1461 <211> 14 2013203064 09 Apr 2013 726 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1461 tcagactttt gtaa 14 <210> 1462 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1462 tgtcctattg ccat 14 <210> 1463 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1463 tctgacacaa tgtc 14 2013203064 09 Apr 2013 727 of 771 <210> 1464 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1464 ctgacacaat gt 12 <210> 1465 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1465 tgttcctata actg 14 <210> 1466 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 728 of 771 <400> 1466 gttcctataa ct 12 <210> 1467 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1467 aagattggtc agga 14 <210> 1468 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1468 agattggtca gg 12 <210> 1469 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 729 of 771 <220> <223> Synthetic Oligonucleotide <400> 1469 gtgtcaaaac cctg 14 <210> 1470 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1470 agctacacaa cc 12 <210> 1471 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1471 cacagctaca caac 14 <210> 1472 2013203064 09 Apr 2013 730 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1472 acagctacac aa 12 <210> 1473 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1473 tatatacatg acac 14 <210> 1474 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1474 2013203064 09 Apr 2013 731 of 771 atatacatga ca 12 <210> 1475 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1475 aattttaaat gtcc 14 <210> 1476 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1476 attttaaatg tc 12 <210> 1477 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 732 of 771 <223> Synthetic Oligonucleotide <400> 1477 tcctaattga at 12 <210> 1478 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1478 aaagtgccat ct 12 <210> 1479 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1479 tttataaaac tgga 14 <210> 1480 <211> 12 <212> DNA 2013203064 09 Apr 2013 733 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1480 ttataaaact gg 12 <210> 1481 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1481 tgcaaactta tctg 14 <210> 1482 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1482 gcaaacttat ct 12 2013203064 09 Apr 2013 734 of 771 <210> 1483 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1483 agccaactgc aa 12 <210> 1484 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1484 cttagccaac tgca 14 <210> 1485 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 735 of 771 <400> 1485 ttagccaact gc 12 <210> 1486 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1486 taaatcattg tcaa 14 <210> 1487 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1487 gcactggcct tgat 14 <210> 1488 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 736 of 771 <220> <223> Synthetic Oligonucleotide <400> 1488 cactggcctt ga 12 <210> 1489 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1489 ttagcactgg cc 12 <210> 1490 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1490 tgtgtaaggt ca 12 <210> 1491 <211> 12 2013203064 09 Apr 2013 737 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1491 gttaatgaca tt 12 <210> 1492 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1492 gacaatttct ac 12 <210> 1493 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1493 aacactgcac at 12 2013203064 09 Apr 2013 738 of 771 <210> 1494 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1494 taggtcaagt ctaa 14 <210> 1495 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1495 tataggtcaa gtct 14 <210> 1496 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 739 of 771 <400> 1496 tttggataaa tata 14 <210> 1497 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1497 tgggacttca cacc 14 <210> 1498 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1498 accacagcta gt 12 <210> 1499 <211> 12 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 740 of 771 <220> <223> Synthetic Oligonucleotide <400> 1499 gggacttcac ac 12 <210> 1500 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1500 ccaaaaacct tact 14 <210> 1501 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1501 gtggcaacca ca 12 <210> 1502 2013203064 09 Apr 2013 741 of 771 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1502 aaggcttaaa gt 12 <210> 1503 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1503 aggacttggg at 12 <210> 1504 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1504 2013203064 09 Apr 2013 742 of 771 gggaatcaga gc 12 <210> 1505 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1505 atttgatgct gc 12 <210> 1506 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1506 ttccaatgac ta 12 <210> 1507 <211> 12 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 743 of 771 <223> Synthetic Oligonucleotide <400> 1507 atcaacagct gc 12 <210> 1508 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1508 gattgcaagt tccg 14 <210> 1509 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1509 tgcttggaag ga 12 <210> 1510 <211> 14 <212> DNA 2013203064 09 Apr 2013 744 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1510 ctgctgcaca tcca 14 <210> 1511 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1511 cacattaaca gt 12 <210> 1512 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1512 agttgaaatt tc 12 2013203064 09 Apr 2013 745 of 771 <210> 1513 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1513 accctcattc ag 12 <210> 1514 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1514 agaatgagac tt 12 <210> 1515 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 746 of 771 <400> 1515 gtaaatccta ag 12 <210> 1516 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1516 taaatatagg tc 12 <210> 1517 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1517 aatgccttat ta 12 <210> 1518 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 747 of 771 <220> <223> Synthetic Oligonucleotide <400> 1518 caccttaaaa tttg 14 <210> 1519 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1519 gtgtacagat tt 12 <210> 1520 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1520 ctttcagtca ta 12 <210> 1521 <211> 12 2013203064 09 Apr 2013 748 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1521 gggcatatca aa 12 <210> 1522 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1522 tgaggcatta tc 12 <210> 1523 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1523 actg 4 2013203064 09 Apr 2013 749 of 771 <210> 1524 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1524 cgtgggctcc agcattcta 19 <210> 1525 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1525 agtcatttct gcctttgcgt c 21 <210> 1526 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Probe 2013203064 09 Apr 2013 750 of 771 <400> 1526 ccaatggtcg ggcactgctc aa 22 <210> 1527 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1527 gaaaatagac ttcctgaata actatgcatt 30 <210> 1528 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1528 actcgcttgc cagcttgc 18 <210> 1529 <211> 23 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 751 of 771 <220> <223> Probe <400> 1529 tttctgagtc cccgtgccca aca 23 <210> 1530 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1530 tgagccttgc caccttctct 20 <210> 1531 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1531 gcgcacccca gccaa 15 <210> 1532 2013203064 09 Apr 2013 752 of 771 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Probe <400> 1532 agaggagctt cttttccctc tacctgggc 29 <210> 1533 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1533 atttcctgcc cctggtacct 20 <210> 1534 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1534 2013203064 09 Apr 2013 753 of 771 cgggcccaca cctcttg 17 <210> 1535 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Probe <400> 1535 ccacaaagtg cagcaccgcc tagtgt 26 <210> 1536 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1536 gccacaggct cccagacat 19 <210> 1537 <211> 25 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 754 of 771 <223> Primer <400> 1537 tccatcctct tgatatctcc ttttg 25 <210> 1538 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Probe <400> 1538 acagccatca tcaaagagat cgttagcaga a 31 <210> 1539 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 1539 atgacaatca tgttgcagca attc 24 <210> 1540 <211> 25 <212> DNA 2013203064 09 Apr 2013 755 of 771 <213> Artificial Sequence <220> <223> Primer <400> 1540 cgatgcaata aatatgcaca aatca 25 <210> 1541 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> Probe <400> 1541 ctgtaaagct ggaaagggac ggactggt 28 <210> 1542 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1542 gtgtgcacac agct 14 2013203064 09 Apr 2013 756 of 771 <210> 1543 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1543 cagcctgggc ac 12 <210> 1544 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1544 tgctcgaact cctt 14 <210> 1545 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 757 of 771 <400> 1545 gaagtcactg gctt 14 <210> 1546 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1546 gggaagtcac tggc 14 <210> 1547 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1547 gttaggcaaa gggc 14 <210> 1548 <211> 14 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 758 of 771 <220> <223> Synthetic Oligonucleotide <400> 1548 gggctgagtg accc 14 <210> 1549 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1549 atgctagtgc acta 14 <210> 1550 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1550 agctcgctac ctct 14 <210> 1551 <211> 14 2013203064 09 Apr 2013 759 of 771 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1551 gaggtatccc atct 14 <210> 1552 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1552 ggcaacttca acct 14 <210> 1553 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1553 gaagtagcca ccaactgtgc 20 2013203064 09 Apr 2013 760 of 771 <210> 1554 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1554 tagccaccaa ct 12 <210> 1555 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1555 actg 4 <210> 1556 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide 2013203064 09 Apr 2013 761 of 771 <400> 1556 actg 4 <210> 1557 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1557 agccaccaac 10 <210> 1558 <211> 8 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1558 gccaccaa 8 <210> 1559 <211> 13 <212> DNA <213> Artificial Sequence 2013203064 09 Apr 2013 762 of 771 <220> <223> Synthetic Oligonucleotide <400> 1559 tagccaccaa ctg 13 <210> 1560 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1560 taccgaacac ct 12 <210> 1561 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1561 gtccctgaag atgtcaatgc 20 <210> 1562 2013203064 09 Apr 2013 763 of 771 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1562 tgcactttgt ggtaccaagg 20 <210> 1563 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1563 gcttctccat cata 14 <210> 1564 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1564 2013203064 09 Apr 2013 764 of 771 tgtcttgctg cttt 14 <210> 1565 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1565 actg 4 <210> 1566 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1566 actg 4 <210> 1567 <211> 4 <212> DNA <213> Artificial Sequence <220> 2013203064 09 Apr 2013 765 of 771 <223> Synthetic Oligonucleotide <400> 1567 actg 4 <210> 1568 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1568 atggcttctc catcatatcc 20 <210> 1569 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1569 cttgggcatg ctcgtcagtc 20 <210> 1570 <211> 20 <212> DNA 2013203064 09 Apr 2013 766 of 771 <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1570 ccttccctga aggttcctcc 20 <210> 1571 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1571 ctgctagcct ctggatttga 20 <210> 1572 <211> 4 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1572 actg 4 2013203064 09 Apr 2013 767 of 771 <210> 1573 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1573 gaatatctat aatg 14 <210> 1574 <211> 12 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Oligonucleotide <400> 1574 gtaagcaagg ct 12 <210> 1575 <211> 2254 <212> DNA <213> Rattus norvegicus <400> 1575 agagaatgga gggacacgta gaggaaggct ctgaacttgg ggagcagaag gtcctgattg 60 ataatcctgc tgacattctg gtcattgccg cgtatttcct gctggtcatt ggtgttggct 120 2013203064 09 Apr 2013 768 of 771 tgtggtctat gttcagaacc aatagaggca cagttggtgg ctacttcttg gcaggacgga 180 gcatggtgtg gtggccggtt ggagcctctc tgttcgccag caacatcggc agcggtcatt 240 ttgtgggcct ggcggggact ggtgcagcaa gtggcttggc cgtggctgga tttgagtgga 300 atgcgctctt tgtggtgttg ctcctcggct ggctcttcgt gcctgtgtat ctgaccgccg 360 gagtgattac catgcctcag tacctccgca agcgctttgg tgggcgccgt attcgcctct 420 acctgtccgt gctctcgctt tttttgtaca ttttcaccaa gatctcggtg gatatgttct 480 ccggagcagt attcattcaa caggccctgg gctggaacat ttacgcttct gtcatcgcac 540 tcttgggcat caccatgatt tatactgtga caggagggct ggcggcactg atgtacacag 600 acactgtgca gaccttcgtc attcttgccg gggccttcat cctcactggt tatgctttcc 660 atgaagtggg cgggtactca ggtctcttcg acaaatacct gggagcagtg acttcactga 720 cggtgtccaa ggatccagct gttggcaaca tctccagcac ctgctatcag ccgaggcccg 780 actcctatca cctgctgcgt gaccctgtga caggagggct gccgtggcct gcgctgcttc 840 tggggcttac cattgtctca ggctggcact ggtgcagtga ccaggtaatt gtgcagcgct 900 gcctggctgg aaagaatctg actcacatca aggctggatg catcctgtgt ggttacctga 960 agctgatgcc catgttcctc atggtcatgc caggcatgat tagccgcatt ctttacccag 1020 atgaggtggc ctgtgtggta cctgaggtgt gtaagcgggt gtgtggcact gaggtgggct 1080 gctctaacat cgcctaccca cggcttgttg tgaagctcat gcccaatggt ctgcgtggac 1140 tcatgctggc agtcatgctg gccgccctca tgtcttctct agcgtccatc tttaacagca 1200 gcagcacact cttcaccatg gatatctaca cacgcctgcg gcctcgggcg ggtgataggg 1260 agctgctgct ggttggaagg ctttgggtgg tgttcattgt ggcagtgtcc gtggcttggc 1320 tgccagtggt gcaggcagca cagggcggcc agctcttcga ttacattcag tctgtctcca 1380 gctacctggc gcctccagtg tccgctgtct ttgtgctggc actctttgtg ccccgtgtta 1440 atgagaaggg tgctttctgg ggactcattg ggggcctgct gatgggccta gctcgtctca 1500 tacccgagtt cttctttggc acgggcagct gtgtgcgacc ctctgcatgc ccagccatct 1560 tctgccgggt acactacctc tacttcgcca tcattctctt cttctgctcc ggcttcctca 1620 cactcgcaat ctcccggtgc accgcaccca tccctcagaa gcatctccac cgcctggttt 1680 tcagtctccg gcacagcaag gaggagcggg aggatctgga tgctgaagag ttagagggtc 1740 cagcccctcc tcctgtgcag aacgggtgcc aggaatgtgc aatggggatt gaagaggtcc 1800 agtccccagc tccaggcctg ctccgccagt gcttgctctg gttctgtggg atgagcaaga 1860 gtgggtcagg gagtcctcca cccactaccg aggaggtggc tgcaaccacc aggcggctag 1920 2013203064 09 Apr 2013 769 of 771 aggacatcag tgaggatccc agctgggccc gagtagtcaa cctcaatgcc ctgctcatga 1980 tgactgtggc tgtgttcctc tggggctttt atgcataaag tcaagtgtgt tggttaccat 2040 gagttgcaac cagggcatgt ctgagcctca tgaaaagtga gggtgaagaa cttgtagtgg 2100 atcccagaaa agggcaaaaa tacggcagga aggaactggt tcccttcctc tttacctggg 2160 gtccagtcca tttgattggt tgtcacttcc cacaagatgg tggccaattt gtcatagatg 2220 tttgcctatg caaaaataaa gctgcccttc taac 2254 <210> 1576 <211> 3300 <212> DNA <213> Mus musculus <400> 1576 tacatcaatg gaatttaaat agagtcgtca tataataagg gaaacaatgt cccaactgga 60 catcacatgg taccaaacaa aagacccagt accaggaatg agttaccatc ttatgaagtc 120 attaaccata gagagctaat ggtagcctca atcattacaa aagctgttgc caaggttact 180 gggtgctctc ataccctgat ggtaagaccc tatggctgaa gatggaactt attgatatcc 240 ttgaacattg agaaattgag ctgtgtgact agaagcttca ccccatcgac gatggtcaca 300 gtgctgcaaa gtgctatgtt caggaggaag gtatccagcc gcctccctca gccacactct 360 gagactcaca ccagagacct gctcaaaggg catgcccact ggcccacaaa tattatggga 420 gcaactgacc actttttggg ggtgtattta aggtccactt catgaaatgg gacccatccc 480 tgacactgct aaaatgcctg agaacctgaa actagataga gcaagggctc taggggaaag 540 ctcactccag ttattctaag ggcacagggt tatgacgcct aatgacatat cgctggctac 600 atcccttggc cagcacatca ctgaaacctc accagaggag cttcttggag tagaaggtga 660 ttaacagaac tgtccgtgac tggatgactt gcagagagtg agagacttgg gagcactcag 720 acttcaatgg gatgcttgta tctcacccct ctgctaaaga tgcaggttct atacaggagg 780 tgcaaagatt gtaagagtca gagttggagg ttgtcttcag gaaagcagag ttttgcagac 840 acaacaaagc tgatgaaaat ctgaactcac agacagtgat agcatgcaca agacagatat 900 ctgaactcac agaccgtgat aacatggcac aaagacctgc acaaagttcg aaccaaataa 960 aatctgagca tggaaaatga ggtgtgggca caaagtccca ctcctaagta agaaactact 1020 2013203064 09 Apr 2013 770 of 771 tgcagttgac agctactagg agagagaaat gggttttctt caatggagag acactgggtg 1080 tatcaactgc accccaaggc aggccacacg ctcaggaaga gttggccaac acaaaacaca 1140 ctccgtgttt ggttttctgt ttgcttgggt ttgtttttgt gcttttattc ttccttcctt 1200 tctttctttg tttctttgtt tctctctctc tttctctctt tttctctctc cctcctcctc 1260 ttcttctttc ttctttttct tcttcttctt cttcttcttc tttttcttct tcttcttctt 1320 ctttttcttc ttcttcttct tcttcttctt cttcttcttc ttcttcttct tcttcttctt 1380 cttcttcttc ttcttcttct tctgatcaga gaggggaggg gatctgggaa aagtttgggg 1440 agaggaaaga atttgcccaa aatatattgc ataaaaactt tttaaaaata aatttaaaac 1500 aatttttagg atagagcaaa gagaaagtag aaaatatttg ggttgggaag ggcaggagaa 1560 tgagggaaat gtgatttttt tctccctagg ttttgtatgg cagaagtcag ggcatggcat 1620 gcgtgacagt caggctgagg aacatgtatg tcctgctgac tgtcaggggg tgctatggag 1680 gacttgtgcg gaggacactg tcagagttgg attcggacct tcctaatcaa agttagaggg 1740 tgtattttca gagaacgcag gaaggaactt tgcttggaac actgggtata ggatggatcc 1800 taaacccagg aaggagtgct cttgaattcc aaatggtcca gcgccccagg accagccttc 1860 ggccttgata gatcctgatt cagataaata aagctggaga aggaggctga gacctggggg 1920 acttgtcggg tcagtgctcc tgaggtaacc attaatcctt cccccagggg aatccaggga 1980 ctagcccctt gagggacaga tggtggagag aatggagcaa cacgtagagg caggctctga 2040 acttggggag cagaaggtcc tgattgataa tcctgctgac attctggtta tcgctgccta 2100 tttcctgctg gtcattggtg ttggcttgtg ggtgagacat tgaggggggt tggataggga 2160 aatgcttctg gggcttgagg gtaaagattt agggagacct cagagaggag tgggagaaaa 2220 gggtgcttgg atataatgag ggagaaacct agatttagta ggcaagccaa ttttaattct 2280 ttgtcttcgt accttctgga ttgtgcaaaa gagactgggg gtatcaatag gttttttttt 2340 aattcaagtg ttctaacaag tgctctaaga gatgtatcag ttcccacgtc tgtattatgg 2400 ctgagcagca gcctatattt aaggtcacca ggcaagttag gctgaatcta ggcatatcta 2460 ggttccagta gttgcgctag gattagggcc tgggttgttc tgagtgtcgg ggaaggttgg 2520 gggtaaggag gtgcagtctg gggagtccag ggctggttaa tcttcagcct gaaacaaggc 2580 tgaggaatgt gttgaggaag ctaaggaagt ccaaagatgt gccccaatcc cagtttcccc 2640 ccacttctgt ttcccagtct atgttcagaa ccaatagagg cacagttggt ggctacttcc 2700 tggcaggacg gaacatggtg tggtggccgg tgagaggggc tgggggatgg gatgggaggg 2760 accctggagg agcaccctac ctcaccccca tttctggcca cccaggttgg agcctctctg 2820 2013203064 09 Apr 2013 771 of 771 ttcgccagca acatcggcag cggtcatttt gtgggcctgg cagggactgg tgcagcaagt 2880 ggcttggcgg tggctggatt tgagtggaat gtgaggtctt cttttctata ataatccacc 2940 ccagtggaaa ctcctggaaa gatcacaact tggggaagct cctggcgtgg ggatatgaac 3000 aagttgggac agcacagttt gctgagggtg ggtgggtgtt aggttgggct gggagcaagg 3060 atcgcgtgct agcttacagc agtagggttc aggcaggtcc tgctcctgac tttctgtata 3120 cgccagcatc agtcctcgtg ggccttgacc actctgaaat ggggccggca cctcactgat 3180 gaagtacctg tctccatgtt ctttgatgct gtagtctgtg agcaactcta ggctgaactg 3240 aagttctttg caaaaacaag gatgggttgg aaagatgagg gtttgagcct tcctgtaaga 3300 2013203064 09 Apr 2013